nct_id,title,official_title,status,why_stopped,phase,study_type,enrollment,conditions,drug_names,intervention_types,primary_outcomes,start_date,completion_date,sponsor,sponsor_type
NCT02713035,Behavioral Self-Help Intervention for Pediatric Atopic Dermatitis and Eczema Patients,Behavioral Self-Help Intervention for Pediatric Atopic Dermatitis and Eczema Patients,TERMINATED,moved to new institution,NA,INTERVENTIONAL,10,"Dermatitis, Atopic, Eczema",,BEHAVIORAL,"SCORAD - Scoring Atopic Dermatitis - change at follow-up 1-4 months later, Index of Itching Intensity and Scratching Activity - change at follow-up 1-4 months later, Acceptability and Feasibility Questionnaire- to assess at follow-up 1-4 months later",2016-03,2017-07,University of Mississippi Medical Center,OTHER
NCT03929640,Management Of Pain After Cesarean Trial,Management Of Pain After Cesarean Trial,TERMINATED,"Lead co-I left institution in 2020 and enrollment was suspended. Study was kept open in hopes of finding a replacement/meeting enrollment goal, but a new lead was not found. Study is now officially closed.",PHASE3,INTERVENTIONAL,49,"Pain, Postoperative, Opioid Use","Acetaminophen, Placebo, Ibuprofen","DRUG, DRUG, DRUG",Pain Score,2019-08-05,2020-03-26,Milton S. Hershey Medical Center,OTHER
NCT05066789,CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 4,Comparison of Polymer-Free Cobalt-Chromium Thin Drug-Coated Stents With Biodegradable Polymer Ultrathin Sirolimus-Eluting Stents and Prasugrel Monotherapy With Conventional 12-Month Dual Antiplatelet Therapy,TERMINATED,Ending early registration due to low registration status and lack of research,PHASE4,INTERVENTIONAL,100,Coronary Artery Disease,Duration of DAPT,"DEVICE, DRUG","Stent Comparison Study: target-lesion failure (TLF), Antiplatelet Comparison Study: net adverse clinical events (NACE)",2022-01-17,2024-03-22,Samsung Medical Center,OTHER
NCT02788591,Confocal Endomicroscopy for Non-Erosive Reflux Disease Detection,Confocal Endomicroscopy for Non-Erosive Reflux Disease Detection (CENERDD),TERMINATED,lack of accrual,NA,INTERVENTIONAL,5,"Non-erosive Reflux Disease, Gastroesophageal Reflux","Proton Pump Inhibitor (PPI) Therapy, Sucralfate","DRUG, DRUG",Evaluate non erosive reflux disease (NERD) Symptoms.,2015-08,2021-06,LCMC Health,OTHER
NCT00947791,Treatment Study of Bipolar Depression,Intravenous Ketamine in Treatment-Resistant Bipolar Depression,TERMINATED,Change in available resources for study procedures,PHASE4,INTERVENTIONAL,1,Bipolar Disorder,"ketamine, midazolam","DRUG, DRUG",Montgomery-Asberg Depression Rating Scale (MADRS),2009-07,2009-10,Icahn School of Medicine at Mount Sinai,OTHER
NCT01406197,Uterine Electrical Activity Before and After Progesterone Treatment for Preterm Labor,Uterine Abdominal Electromyography Measurements Before and After Progesterone Treatments for Preterm Labor,WITHDRAWN,Investigator left organization prior to study initiation,NA,INTERVENTIONAL,0,Preterm Labor,"Experimental: Vaginal progesterone, Experimental: Topical progesterone, Experimental: Intramuscular progesterone","DRUG, DRUG, DRUG",Inhibition of uterine electromyographic (EMG) activity by various formulations of progesterone.,2011-07,2013-10,"St. Joseph's Hospital and Medical Center, Phoenix",OTHER
NCT02428010,Twelve Transcatheter Mitral Valve Replacement (TMVR) Pilot Study,"Evaluation of Safety and Performance of the Twelve Transcatheter Mitral Valve Replacement System in Patients With Severe, Symptomatic Mitral Regurgitation",TERMINATED,Site has not reliably responded Medtronic team since the transition from sponsor Twelve. No data entry completed since February 2018. Last study subject passed final study visit window. No data is expected to be entered.,NA,INTERVENTIONAL,3,Mitral Valve Insufficiency,,DEVICE,Adverse Events,2014-09,2021-04,Medtronic Cardiovascular,INDUSTRY
NCT01842113,Quality of Life and Nutritional Improvements in Cirrhotic Patients,Quality of Life and Nutritional Improvements in Cirrhotic Patients Following Hepatic Encephalopathy Using Rifaximin.,TERMINATED,PI Initiated study - PI left facility,PHASE4,INTERVENTIONAL,4,"Liver Cirrhosis, Hepatic Encephalopathy, Portal Hypertension","Rifaximin, Lactulose, Lactulose Placebo, Rifaximin Placebo","DRUG, DRUG, DRUG, DRUG","Outcomes of Change in Quality of Life Assessment Between the Two Groups, Nutritional Improvement Between the Two Groups",2013-04,,Tampa General Hospital,OTHER
NCT02893982,High Dose Rate Brachyablation of Primary Liver Lesions,A Phase I Therapeutic Dose Escalation Study Using Percutaneous Image-Guided Navigation for High Dose Rate Brachyablation of Primary Liver Lesions,TERMINATED,Study was closed due to poor accrual,PHASE1,INTERVENTIONAL,1,Liver Cancer,,RADIATION,"dosimetric coverage of liver lesions, maximum tolerated dose",2017-11-09,2020-03-16,University of Texas Southwestern Medical Center,OTHER
NCT01519882,Sleep Efficiency Assessed by Polysomnography (PSG Sleep Lab Testing) in Advanced Parkinson's Disease,"A Multi-Centre, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Effects of Rotigotine on Sleep Efficiency in Patients With Advanced Parkinson's Disease.",TERMINATED,"Due to major recruitment issues, a decision was made to terminate this trial",PHASE4,INTERVENTIONAL,1,Advanced Idiopathic Parkinson's Disease,,"OTHER, OTHER",Percentage Change From Baseline in Sleep Efficiency Index (SEI) to Week 4 of the Maintenance Period,2012-03,2013-01,UCB Pharma SA,INDUSTRY
NCT05521880,Anchoring Sequential Intermittent Long Acting Antimicrobials With Medication for Opioid Use Disorder (MOUD) for Invasive Infections Related to Opioid Use,Anchoring Intermittent Long Acting Antimicrobials to Medication for Opioid Use Disorder Treatment to Facilitate Structured Transitions of Care for People Who Use Drugs Admitted to the Hospital With Invasive Infections,TERMINATED,The study was not able to enroll adequate participants within predetermined timelines,PHASE4,INTERVENTIONAL,2,"Substance Use Disorders, Infection, Soft Tissue, Bacteremia, Osteomyelitis Acute, Septic Arthritis",Oritavancin,DRUG,"Frequency of clinically assessed cure, completion (no need for further parenteral antimicrobial therapy) or transition to suppressive antimicrobial therapy at 12 weeks for patients discharged to home with long acting agents and MOUD",2024-07-15,2025-05-23,"University of Maryland, Baltimore",OTHER
NCT00622570,Comparison of Effectiveness of Pentobarbital and Thiopental in Patients With Refractory Intracranial Hypertension,Comparison of Effectiveness of Pentobarbital and Thiopental in Patients With Refractory Intracranial Hypertension.,TERMINATED,Slowly recruitment rate. Intermediate analysis,PHASE3,INTERVENTIONAL,44,Traumatic Brain Injury,"Pentobarbital, thiopental","DRUG, DRUG",Intracranial pressure control,2002-05,2007-12,Hospital Universitari Son Dureta,OTHER
NCT03278873,Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNGA3,"Long-term Follow-up Study of Participants Following an Open Label, Multi-centre, Phase I/II Dose Escalation Trial of a Recombinant Adeno-associated Virus Vector (AAV2/8-hCARp.hCNGB3 and AAV2/8-hG1.7p.coCNGA3) for Gene Therapy of Adults and Children With Achromatopsia Owing to Defects in CNGB3 or CNGA3",TERMINATED,Strategic decision to not further develop AAV8-hCARp.hCNGB3 and AAV8-hG1.7p.coCNGA3. The decision is not due to safety concerns.,,OBSERVATIONAL,34,Achromatopsia,Prior exposure to AAV-CNGA3 or AAV-CNGB3,BIOLOGICAL,Incidence of Adverse Events Related to the Treatment,2017-06-29,2024-04-04,MeiraGTx UK II Ltd,INDUSTRY
NCT00299273,High Fat - High Protein Diet in the Treatment of Obesity,Exploratory Feasibility Study: High Fat/Protein Diet in the Treatment of Obesity,TERMINATED,PI left institution,NA,INTERVENTIONAL,8,Obesity,,BEHAVIORAL,Visceral adipose tissue,2006-03,2014-12,Rockefeller University,OTHER
NCT02037373,Evaluation of the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation,Post-Marketing Requirement Study to Evaluate the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation With Special Emphasis on Hyperfibrinolysis.,TERMINATED,FDA released requirement to complete study,,OBSERVATIONAL,43,"Coagulopathy, Endstage Liver Disease","Octaplas™, Plasma","BIOLOGICAL, BIOLOGICAL","To assess the incidence of hyperfibinolysis in patients undergoing OLT receiving octaplas™ versus regular plasma (e.g., fresh frozen plasma (FFP) and other FDA and American Association of Blood Banks (AABB) approved plasma products).",2015-08,2018-02,Octapharma,INDUSTRY
NCT01700569,Phase-1 Study of Folinic Acid to Modulate MGMT Gene in Glioblastoma,"Phase I Study of Escalated Pharmacologic Dose, of Oral Folinic Acid in Combination With Temozolomide, According to Stupp R. Regimen, in Patients With Operated Grade-IV Astocytoma and a Non-methylated Gene Status of MGMT.",TERMINATED,changing the standard of care,PHASE1,INTERVENTIONAL,24,"Grade IV Astrocytoma, Glioblastoma","Temozolomide, folinic acid at pharmacological dose is the escalated drug","DRUG, DRUG, RADIATION",Maximal Tolerated Dose,2013-01,2021-04-16,Institut Cancerologie de l'Ouest,OTHER
NCT05363605,A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours,"A Phase 1/2 Study of [225Ac]-FPI-1966, [111In]-FPI-1967, and Vofatamab in Participants With FGFR3-expressing Advanced, Inoperable, Metastatic and/or Recurrent Solid Tumours",TERMINATED,Fusion announced that it is discontinuing this study as part of a portfolio prioritization and assessment; Fusion no longer plans to pursue development of FPI-1966.,"PHASE1, PHASE2",INTERVENTIONAL,6,"Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma, Bladder Carcinoma, Susceptible FGFR3 Genetic Alterations, FGFR3, FGFR3 Overexpression, FGFR3 Receptor, FGFR3 Protein Overexpression, Ovarian Cancer, Colorectal Cancer, Breast Cancer, Liver Cancer, Lung Cancer, Gastric Cancer","[225Ac]-FPI-1966, [111In]-FPI-1967, vofatamab","DRUG, DRUG, BIOLOGICAL","Phase 1: Phase 1: Incidence of AEs to evaluate safety and tolerability of [225Ac]-FPI-1966, [111In]-FPI-1967, and vofatamab., Phase 1: Maximum tolerated dose (MTD) of [225Ac]-FPI-1966, Phase 1: Radiation dose of [111In]-FPI-1967 and [225Ac]-FPI-1966 (whole body, organs, and selected regions of interest), Phase 1: Effect of pre-dose administration of vofatamab on the radiation dosimetry of [111In]-FPI-1967 and [225Ac]-FPI-1966., Phase 2: Objective response rate (ORR) (sum of complete and partial response) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.",2022-04-20,2023-09-08,Fusion Pharmaceuticals Inc.,INDUSTRY
NCT04990466,Phase 2b/3 Trial of VSV-ΔG SARS-CoV-2 Vaccine (BRILIFE) Against Approved Comparator Vaccine.,"A Phase IIb/3 Randomized, Multi-Center, Placebo-Controlled Noninferiority Study to Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine (IIBR-100) in Adults Compared to an Approved COVID-19 Vaccine",WITHDRAWN,Production of the BriLife vaccine was halted by government sponsor,"PHASE2, PHASE3",INTERVENTIONAL,0,COVID-19,"IIBR-100, Active Comparator","DRUG, DRUG",Prevention of Serology-confirmed SARS-CoV-2 infection,2021-09-30,2022-02-28,"NeuroRx, Inc.",INDUSTRY
NCT03638466,Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With ADHD,Exploratory Neuroimaging Study to Evaluate the Effect on Brain Activity of SPN-810 for Impulsive Aggression (IA) in Patients With Attention-Deficit/Hyperactivity Disorder (ADHD) in Conjunction With Standard ADHD Treatment,TERMINATED,Financial decision,PHASE2,INTERVENTIONAL,7,"Attention Deficit Hyperactivity Disorder (ADHD), Impulsive Aggression","SPN-810, Placebo","DIAGNOSTIC_TEST, DIAGNOSTIC_TEST, BEHAVIORAL, DRUG, DRUG","Aggression-related Change in the Whole Brain in BOLD (Blood Oxygenation Level-dependent) Signal fMRI Contrast in Response to the PSAP Task, Provocation Event - Related Change in the Whole Brain in BOLD Signal fMRI Contrast in Response to the PSAP Task, Effect of SPN-810 on the Aggressions Score",2019-05-30,2019-11-07,"Supernus Pharmaceuticals, Inc.",INDUSTRY
NCT01865240,Renal Denervation for Resistant Hypertension,Renal Denervation for Resistant Hypertension,TERMINATED,No new participants enrolled. Protocol has been superseded,PHASE4,INTERVENTIONAL,5,Hypertension,,DEVICE,blood pressure control,2012-02,2013-10,Baker Heart and Diabetes Institute,OTHER
NCT03688789,Hématologie Adulte Prevalence of Adrenal Insufficiency Post-chemotherapy Adrenocorticotropia in Adult Hematology,Prevalence of Adrenal Insufficiency Post-chemotherapy Adrenocorticotropia in Adult Hematology,WITHDRAWN,Investigator leaving the hospital,NA,INTERVENTIONAL,0,Haematological Malignancy,,OTHER,Cortisol at T0 and T30 mins less than 550 nmol / L after ACTH 250 μG achieved during the last chemotherapy session,2019-01-01,2022-12-01,Rennes University Hospital,OTHER
NCT04835168,Safety and Pharmacokinetics of Orodispersible BT-11 in Active Eosinophilic Esophagitis,"A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate Safety and Pharmacokinetics of Orodispersible BT-11 in Active Eosinophilic Esophagitis",WITHDRAWN,The closure of the study is driven by the decision to redesign the study protocol for future studies.,PHASE1,INTERVENTIONAL,0,Eosinophilic Esophagitis,"BT-11 low, BT-11 high, Placebo","DRUG, DRUG, DRUG",Incidence and severity of AEs,2022-01-30,2022-06-30,NImmune Biopharma,INDUSTRY
NCT01597791,Combined Spinal Epidural Urinary Retention,Do Women Receiving Low Dose Combined Spinal Epidural for Labor Analgesia Exhibit Less Bacteriuria Using a Urinary Retention Protocol Versus Routine Urinary Catheter Placement?,TERMINATED,Change in procedure.US technically challenging.,NA,INTERVENTIONAL,56,"Anesthesia, Pain, Urinary Retention",,"DEVICE, OTHER",Number of Participants With Positive Urine Culture,2012-03-22,2016-12-01,Northwestern University,OTHER
NCT02053597,TRIal evalUating the Menstrual and Ovarian Function of Young Breast Cancer Patients Treated With a cycloPHosphamide-free Regimen,A Phase II TRIal evalUating the Menstrual and Ovarian Function of Young Breast Cancer Patients Treated With a cycloPHosphamide-free Regimen Composed of Doxorubicin and Paclitaxel,WITHDRAWN,due to evolving scientific knowledge in the field that would make the questions being addressed in the trial less relevant,PHASE2,INTERVENTIONAL,0,Breast Cancer,"Doxorubicin, paclitaxel","DRUG, DRUG","Change from baseline in ovarian function, Change from baseline in menstrual function",2014-10,2015-07,Jules Bordet Institute,OTHER
NCT03399097,"Characterizing the Intestinal Hormonal Secretion in Non-obese, Obese and Non-obese Patients After Bariatric Surgery","Characterizing the Intestinal Hormonal Secretion in Non-obese, Obese and Non-obese Patients After Bariatric Surgery",WITHDRAWN,change sites,,OBSERVATIONAL,0,Obesity,,,"Characterization the composition of enteroendocrine cells in the obese, non-obese and non-obese post-bariatric surgery.",2018-12,2020-07-16,Dr. Ofir Harnoy MD,OTHER_GOV
NCT05987813,Transcutaneous Electric Nerve Stimulation (TENS) for Vagal Modulation,A Pilot Study of Auricular Microstimulation to Determine if it Improves Vagal Modulation,TERMINATED,the ear clip is uncomfortable and compliance is down as a result. The team is working with manufacturer to develop new ear clip that will be used in a new protocol.,NA,INTERVENTIONAL,8,Functional Gastrointestinal Disorders,,DEVICE,"Change in High-frequency Heart Rate Variability (hfHRV) at 4 Weeks, Rate of Compliance With Daily TENS Usage",2023-10-18,2024-06-04,Virginia Commonwealth University,OTHER
NCT04009460,A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Solid Tumors,"An Open-label, Multicenter, Dose-escalation and Cohort Expansion Phase 1 Clinical Study of ES101 in Patients With Advanced Solid Tumors",TERMINATED,Sponsor's clinical development strategy adjustment,PHASE1,INTERVENTIONAL,22,"Solid Tumors, Neoplasms, Malignant Tumor",ES101,DRUG,"Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of of ES101, Frequency of adverse events of ES101, Severity of adverse events of ES101",2019-06-28,2022-04-22,"Elpiscience Biopharma, Ltd.",INDUSTRY
NCT02906020,"A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of Venglustat (GZ/SAR402671) in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation","Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GZ/SAR402671 in Patients With Early-stage Parkinson's Disease Carrying a GBA Mutation or Other Pre-specified Variant",TERMINATED,"The topline results of the 52-week double-blind placebo-controlled period were analyzed. The study did not meet the primary or secondary endpoints. Based on these results, the decision was made to halt the long-term follow-up period of the study",PHASE2,INTERVENTIONAL,273,Parkinson's Disease,"venglustat GZ/SAR402671, Placebo","DRUG, DRUG","Part 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), and Treatment-Emergent Serious Adverse Events (TESAEs), Part 1: Number of Participants With Abnormal Physical Examination Findings, Part 1: Number of Participants With Abnormal Neurological Examination Findings, Part 1: Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematology, Part 1: Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Liver Function Parameters, Part 1: Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Renal Parameters, Part 1: Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Metabolic Parameters, Part 1: Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Electrolytes Parameters, Part 1: Number of Participants With Potentially Clinically Significant Vital Signs Abnormalities, Part 1: Number of Participants With Potentially Clinically Significant Ophthalmological Abnormalities, Part 1: Number of Participants With Potentially Clinically Significant Electrocardiogram Abnormalities, Part 2: Change From Baseline to Week 52 in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II+III Total Score",2016-12-15,2021-05-27,"Genzyme, a Sanofi Company",INDUSTRY
NCT04575610,IRAK4 Inhibition in Treatment of COVID-19 With ARDS (I-RAMIC),Investigation of IRAK4 Inhibition to Mitigate the Impact of COVID-19 in Severe SARS-CoV-2 (I-RAMIC),TERMINATED,Study terminated due to lack of enrollment reflecting the decrease in number of COVID infections. There were no safety and/or efficacy concerns involved in the decision to stop enrollment.,PHASE2,INTERVENTIONAL,7,COVID-19,"PF-06650833, Placebo","DRUG, DRUG",All-cause mortality at Day 29,2020-11-27,2021-10-06,Yale University,OTHER
NCT03243760,Dose Escalating Study of CCI15106 Inhalation Capsules in Healthy Subjects and Moderate Chronic Obstructive Pulmonary Disease (COPD) Patients,"A Double-blind (Sponsor Unblind), Randomized, Placebo-controlled, Single and Repeat Escalating Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of CCI15106 Capsules for Inhalation in Healthy Subjects and Patients With Moderate Chronic Obstructive Pulmonary Disease (COPD)",TERMINATED,The trial is terminated before investigation of repeat escalating doses as these will be conducted with the new formulation instead.,PHASE1,INTERVENTIONAL,60,"Pulmonary Disease, Chronic Obstructive","CCI15106 7.5 mg capsule, Placebo, Placebo-2","DRUG, DRUG, DRUG","Part 1: Number of participants with adverse events (AE), Part 2: Number of participants with AE, Part 3: Number of participants with AE, Part 1: Number of subjects with abnormal clinical hematology test findings, Part 2: Number of subjects with abnormal clinical hematology test findings, Part 3: Number of subjects with abnormal clinical hematology test findings, Part 1: Number of subjects with abnormal clinical chemistry test findings, Part 2: Number of subjects with abnormal clinical chemistry test findings, Part 3: Number of subjects with abnormal clinical chemistry test findings, Part 1: Number of subjects with abnormal urine analysis test findings, Part 2: Number of subjects with abnormal urine analysis test findings, Part 3: Number of subjects with abnormal urine analysis test findings, Part 1: Number of subjects with abnormal findings of body temperature, Part 2: Number of subjects with abnormal findings of body temperature, Part 3: Number of subjects with abnormal findings of body temperature, Part 1: Number of subjects with abnormal blood pressure values, Part 2: Number of subjects with abnormal blood pressure values, Part 3: Number of subjects with abnormal blood pressure values, Part 1: Number of subjects with abnormal pulse rate values, Part 2: Number of subjects with abnormal pulse rate values, Part 3: Number of subjects with abnormal pulse rate values, Part 1: Number of subjects with abnormal respiratory rate values, Part 2: Number of subjects with abnormal respiratory rate values, Part 3: Number of subjects with abnormal respiratory rate values, Part 1: Number of subjects with abnormal electrocardiogram (ECG) findings, Part 2: Number of subjects with abnormal ECG findings, Part 3: Number of subjects with abnormal ECG findings, Part 1: Number of subjects with abnormal Telemetry findings, Part 2: Number of subjects with abnormal telemetry findings, Part 3: Number of subjects with abnormal telemetry findings, Part 1: Number of subjects with abnormal spirometry findings, Part 2: Number of subjects with abnormal spirometry findings, Part 3: Number of subjects with abnormal spirometry findings, Part 1: Area under the curve (AUC) from time zero to infinity (AUC[0-inf] following single dose administration of CCI15106, Part 3: AUC[0-inf] following single dose administration of CCI15106, Part 1: AUC from time zero to the time of last quantifiable concentration (AUC[0-last]) following single dose administration of CCI15106, Part 3: AUC[0-last] following single dose administration of CCI15106, Part 1: Maximum plasma concentration (Cmax) following single dose administration of CCI15106, Part 2: Cmax following repeat dose administration of CCI15106, Part 3: Cmax following single dose administration of CCI15106, Part 1: time of maximum concentration (Tmax) following single dose administration of CCI15106, Part 2: Tmax following repeat dose administration of CCI15106, Part 3: Tmax following single dose administration of CCI15106, Part 1: Elimination half life (T1/2) following single dose administration of CCI15106, Part 3: T1/2 following single dose administration of CCI15106, Part 1: Clearance (CL/F) following single dose administration of CCI15106, part 3: CL/F following single dose administration of CCI15106, Part 2: AUC from time zero to end of dosing interval (AUC[0-tau]) following repeat dose administration of CCI15106",2016-02-10,2016-08-20,GlaxoSmithKline,INDUSTRY
NCT04367623,Motor Conditioning to Enhance the Effect of Physical Therapy,Exploring Brain Computer Interface Controlled Functional Electrical Stimulation as a Motor Conditioning Strategy Prior to Physical Practice in People With Subacute Spinal Cord Injury,TERMINATED,"Delays in approval process, COVID restrictions, staffing shortages",NA,INTERVENTIONAL,10,Spinal Cord Injuries,,OTHER,"Changes in Spinal Cord Independence measure (range 0 to 100, max 100), Change in the hand range of motion (range 0 to 90 degress, max 90 degress), Changes in the Manual muscle test (range 0 to 5, max 5), Change in grip strength (range 0 to 80 N, max 80 N)",2020-12-09,2022-09-01,NHS Greater Glasgow and Clyde,OTHER
NCT01313923,Evaluating Sirolimus to Treat Autoimmune Blistering Dermatosis Pemphigus,Evaluation of Sirolimus for the Treatment of the Autoimmune Blistering Dermatosis Pemphigus,TERMINATED,Lack of funding,EARLY_PHASE1,INTERVENTIONAL,3,Pemphigus,Sirolimus (formerly known as Rapamycin),DRUG,Improvement of ABSIS Score While Reducing Steroid Dosage,2011-02,2014-10,"University of California, Irvine",OTHER
NCT04846946,"HIV Prevention and PrEP Intervention for SGM Adolescents and Parents: ""Hey, Friend""","Conducting the Preparation Phase of a Multiphase Optimization Strategy (MOST) to Develop a Modular HIV Prevention and PrEP Intervention for Sexual and Gender Minority Adolescents and Parents: ""Hey, Friend""",WITHDRAWN,Opted to not conduct this study; revised to a more condensed study.,NA,INTERVENTIONAL,0,HIV Infections,,BEHAVIORAL,"HIV Knowledge, SGM Related Stigma, HIV Testing Behaviors",2022-01-01,2022-04-25,University of Alabama at Birmingham,OTHER
NCT05627388,Feasibility Study of At-Home EEG Monitoring for Hypersomnia,Feasibility Study of Utilizing At-Home Electroencephalography Monitoring for Diagnosing and Treatment Monitoring of Hypersomnia,WITHDRAWN,Study was never started. The research protocol was redeveloped and submitted as a new study therefore we would like to close this study.,NA,INTERVENTIONAL,0,"Hypersomnia, Narcolepsy",,OTHER,"Measuring sleep and wake events for the evaluation of hypersomnia disorders, Performance of the automatic scoring of the Dreem 3 compared to the consensus of 5 certified sleep scorers realized on the polysomnography, during PSG and MSLT, Measuring Treatment Efficacy with At-home EEG Monitoring (Dreem 3 System)",2023-02,2024-04-01,Kaiser Permanente,OTHER
NCT00965003,MRI Laryngeal Imaging With a Surface Coil,High Resolution MRI in the Evaluation of Laryngeal Neoplasia,TERMINATED,Absence of key personnel to conduct study,EARLY_PHASE1,INTERVENTIONAL,3,"Laryngeal Neoplasms, Head and Neck Cancers, Larynx Cancer",,PROCEDURE,Tumor stage as determined by HRMRI.,2009-07,2010-01,Stanford University,OTHER
NCT02782403,"Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia","Alternating or Combined Therapy With Axitinib and Bosutinib for Patients With Chronic Myeloid Leukemia in Chronic, Accelerated, or Blastic Phases",TERMINATED,Terminated per PI's request at the time of CR. Study was closed due to low/slow accrual due to other competing studies.,PHASE1,INTERVENTIONAL,4,"Accelerated Phase Chronic Myelogenous Leukemia (CML), Blast Phase Chronic Myelogenous Leukemia (CML), Chronic Phase Phase Chronic Myelogenous Leukemia (CML), Philadelphia Chromosome Positive (Ph+) Phase Chronic Myelogenous Leukemia (CML)","Axitinib, Bosutinib","DRUG, DRUG, OTHER","Rate of major cytogenetic response (MCyR) among patients with chronic myeloid leukemia, chronic phase status post (s/p) failure of/intolerance to >= 3 tyrosine kinase inhibitors treated with alternating axitinib and bosutinib (Chronic Phase Cohort), Maximum tolerated doses of the combination of axitinib and bosutinib among patients with chronic myeloid leukemia (CML)-advanced phase (AP) or -blast phase (BP) (AP patients must have received >= 1 prior TKI) (Advanced phase cohort - Phase I Portion), Complete hematologic response (CHR) rate to the combination of axitinib and bosutinib among patients with CML-AP or -BP (AP patients must have received >= 1 prior TKI) (Advanced phase cohort - Phase II Portion)",2017-03-20,2019-11-11,M.D. Anderson Cancer Center,OTHER
NCT03337061,A Trial of Mindfulness Meditation for Chronic Insomnia,A Trial of Mindfulness Meditation for Chronic Insomnia,WITHDRAWN,Study never started - halted by funder,NA,INTERVENTIONAL,0,Insomnia,,OTHER,"Change in Insomnia Severity (Insomnia Severity Index), Change in Actigraphy determined wake time (TWT)",2018-05-01,2018-08-01,Guy's and St Thomas' NHS Foundation Trust,OTHER
NCT04407442,"Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab",Phase II Study of Daratumumab in Combination With Azacitidine and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated With Daratumumab,TERMINATED,Slow enrollment and change in sponsor direction,PHASE2,INTERVENTIONAL,5,"Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma","Azacitidine, Daratumumab, Dexamethasone","DRUG, BIOLOGICAL, DRUG",Overall Response Rate (ORR),2020-11-30,2023-04-30,"University of California, San Francisco",OTHER
NCT03372941,Hospital Avoidance Strategies for ABSSSI,Hospital Avoidance Strategies for Treatment of Acute Bacterial Skin and Skin Structure Infection (ABSSSI),TERMINATED,Funding and recruitment limited by pandemic,PHASE4,INTERVENTIONAL,11,Skin Infection,Dalbavancin,DRUG,Healthcare Utilization Related to ABSSSI,2019-03-04,2021-10-14,Washington University School of Medicine,OTHER
NCT06895941,Predictive Value of PET/CT for Efficacy of Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer,Predictive Value of PET/CT for Efficacy of Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer,WITHDRAWN,Unable to support implementation.,,OBSERVATIONAL,0,"Lung Cancer (NSCLC), Neoadjuvant Immunotherapy",,DIAGNOSTIC_TEST,FAPI PET/CT predicts efficacy,2025-04-30,2027-04-01,"Shanghai Pulmonary Hospital, Shanghai, China",OTHER
NCT04860466,A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma,"A Phase 1, Multicenter, Open-label, Dose Finding Study of CC-96673 in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma",TERMINATED,Business objectives have changed.,PHASE1,INTERVENTIONAL,9,"Lymphoma, Non-Hodgkin",CC-96673,DRUG,"Incidence of Adverse Events (AEs), Dose-limiting toxicity (DLT), Maximum tolerated dose (MTD)",2022-01-20,2024-07-31,Celgene,INDUSTRY
NCT02673866,Study to Evaluate the Efficacy and Safety of DS-1971a for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP),A Randomized Double-Blind Placebo and Active Controlled Parallel Group Study to Evaluate the Efficacy and Safety of DS-1971a for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP),WITHDRAWN,reassessment of phase 2 study indication,PHASE2,INTERVENTIONAL,0,"Neuropathic Pain, Diabetes","DS-1971a, placebo, pregabalin","DRUG, DRUG, DRUG",Change in weekly Average Daily Pain Score (ADPS),2016-02,2017-02,Daiichi Sankyo,INDUSTRY
NCT00216008,"Pharmacogenomic Study of Docetaxel and Cisplatin, Followed by Docetaxel, Cisplatin and Irradiation.","Phase II Pharmacogenomic Study of Neoadjuvant Pre-irradiation Docetaxel and Cisplatin, Followed by Neoadjuvant Concomitant Docetaxel, Cisplatin and Irradiation, Followed by Surgery (CD-CDR-S) in Adult Patients With Operable Adenocarcinomas of the Esophagus or Gastroesophageal Junction",TERMINATED,IRB Closure,PHASE2,INTERVENTIONAL,42,"Esophageal Adenocarcinomas, Adenocarcinomas of the Gastroesophageal Junction","docetaxel, cisplatin","DRUG, DRUG, PROCEDURE, PROCEDURE",response rate,2005-07,2007-02,H. Lee Moffitt Cancer Center and Research Institute,OTHER
NCT00459225,Iron Prophylaxis for Anemia in Infants With Cyanotic Congenital Heart Disease,Iron Prophylaxis for Anemia in Infants With Cyanotic Congenital Heart Disease: An Open Label Trial,WITHDRAWN,Difficulty recruiting subjects,NA,INTERVENTIONAL,0,Anemia,Iron (ferrous sulfate),DRUG,"Complete blood count, Iron study labs (ferritin, Total Iron Binding Capacity, and Iron lab) 72 hours prior to discharge following neonatal surgery, Hemoglobin and Hematocrit at pre-Glenn catheterization, Complete Blood count, Iron study labs, and Reticulocyte count at pre-glenn screening",2007-04,2013-06,Emory University,OTHER
NCT03808740,Orthostatic Intolerance After Bariatric Surgery,Orthostatic Intolerance After Bariatric Surgery,TERMINATED,"Due to COVID-19 pandemic, recruitment was stopped. All the weight loss surgeries were stopped.. Weight Loss clinic (VWL) was closed for IN person visits. We could not recruit any participant for Non surgical weight loss category.",PHASE1,INTERVENTIONAL,10,Orthostatic Intolerance,"Atomoxetine, Placebo","DRUG, DRUG","Blood Pressure Measurements During Orthostatic Challenge With a Head up Tilt (HUT at 60 Degrees) Before and After Bariatric Surgery: at 2 Timepoints: After 10% Weight Loss and After 3 Months, Cardiac Output During Orthostatic Challenge With a Head up Tilt (HUT at 60 Degrees) Before and After Bariatric Surgery: at 2 Timepoints: After 10% Weight Loss and After 3 Months, Stroke Volume Measurements During Orthostatic Challenge With a Head up Tilt (HUT at 60 Degrees) Before and After Bariatric Surgery: at 2 Timepoints: After 10% Weight Loss and After 3 Months, Calculated Total Peripheral Resistance During Orthostatic Challenge With a Head up Tilt (HUT at 60 Degrees) Before and After Bariatric Surgery: at 2 Timepoints: After 10% Weight Loss and After 3 Months",2018-07-01,2021-05-31,Vanderbilt University Medical Center,OTHER
NCT00441168,"Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma","A Phase 2, Multicentre, Randomised, Open-Label, Parallel Group Study to Evaluate the Safety and Efficacy of Velcade When Added to Adriamycin-Dexamethasone Treatment Versus Vincristine-Adriamycin-Dexamethasone Standard Treatment in Subjects With Multiple Myeloma Who Are Refractory to or Have Relapsed After Primary Therapy for Multiple Myeloma",TERMINATED,TRIAL STOPPED due to a change in standard of care and the required patient numbers could no longer be achieved,PHASE2,INTERVENTIONAL,30,Multiple Myeloma,"adriamycin, bortezomib, dexamethasone, vincristine","DRUG, DRUG, DRUG, DRUG","Best Confirmed Disease Response, Best Reported Disease Response",2006-12,2008-01,Janssen-Cilag International NV,INDUSTRY
NCT00624468,Atacicept in Subjects With Optic Neuritis,"A Two-arm, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Evaluate Safety and Tolerability and to Explore the Neuroprotective Effect of Atacicept as Assessed by Optical Coherence Tomography (OCT) in Subjects With Optic Neuritis (ON) as Clinically Isolated Syndrome (CIS) Over a 36-week Treatment Course",TERMINATED,EMD Serono voluntarily decided to terminate this trial after observing increased MS disease activity in trial 28063 ATAMS \[Please refer to ATAMS\],PHASE2,INTERVENTIONAL,34,Optic Neuritis,"Atacicept, Placebo matched to atacicept","DRUG, DRUG",Change From Baseline in Retinal Nerve Fiber Layer (RNFL) Thickness in the Affected Eye at Last Observed Value (LOV),2008-06,2011-01,EMD Serono,INDUSTRY
NCT01062191,Altrazeal Range of Motion Study Comparing With Typical Carboxymethyl,Flexible Hydrogel Nanoparticle Wound Dressing Allows Greater Joint Range of Motion Compared to Typical Sodium Carboxymethylcellulose Dressing,TERMINATED,Lack of enrollment,NA,INTERVENTIONAL,3,Burn,,"DEVICE, DEVICE",Range of motion in burned joints with dressing in place as compared to control,2007-05,2008-10,ULURU Inc.,INDUSTRY
NCT03843918,A Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate Cancer,A Phase I/II Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate Cancer,TERMINATED,"This is phase I/II study, phase I study completed, phase II study started and enrolled 1 patient. Company strategy consideration to terminated phase 2 study finally.","PHASE1, PHASE2",INTERVENTIONAL,33,Prostate Cancer Metastatic,LAE001,DRUG,"Incidence of DLT (Phase I), Number of Participants With Adverse Events as a Measure of Safety and Tolerability",2019-04-05,2023-10-09,Laekna Limited,INDUSTRY
NCT05156190,The Impact of Bright Classroom on Myopia,Cluster-randomized Trial of a Novel Bright Classroom and Artificial Light Renovation in the Prevention of Myopia Among Chinese School-going Children,WITHDRAWN,Approval for buiding the classroom has not been obtained.,NA,INTERVENTIONAL,0,Myopia,,OTHER,three-year cumulative incidence of myopia,2023-06-01,2023-12-30,"Queen's University, Belfast",OTHER
NCT01313390,"Everolimus and Docetaxel in Treating Patients With Recurrent, Locally Advanced, or Metastatic Head and Neck Cancer",DORA: A Phase I and Randomized Phase II Study of Docetaxel and RAD001 (Everolimus) in Advanced/Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,TERMINATED,Lack of recruitment,"PHASE1, PHASE2",INTERVENTIONAL,4,Head and Neck Cancer,"docetaxel, everolimus","DRUG, DRUG, OTHER, OTHER","Maximum-tolerated dose and recommended phase II dose of everolimus in combination with docetaxel (phase I), Safety and tolerability of the combination of everolimus and docetaxel, Response using RECIST criteria (phase II)",2009-06,2011-04,"University College, London",OTHER
NCT04645797,A Dose Escalation Study of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions,"A Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics/ Pharmacodynamics of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions",TERMINATED,Study terminated prematurely due to internal corporate decision,PHASE1,INTERVENTIONAL,11,Advanced Colorectal Carcinoma,APR003,DRUG,"Determine the Number of Patients With Dose Limiting Toxicities (DLTs), Maximum Concentration (Cmax) of APR003, Time-to-maximum Concentration (Tmax) of APR003, Area Under the Curve (AUC) From Time Zero to 24 hr (AUC0-24) of APR003, AUC From Time Zero to Time Infinity (AUC0-ꝏ) of APR003, AUC Over the Dosing Interval (AUClast) of APR003, Elimination Half-life (T1/2) of APR003, Apparent Volume of Distribution at Steady State After Administration (Vss/F) of APR003, Apparent Total Plasma Clearance (CL/F) of APR003",2021-01-19,2022-05-07,"Apros Therapeutics, Inc",INDUSTRY
NCT01048060,Consent for Obtaining Additional Bone Marrow Specimens at Time of Diagnostic Bone Marrow Procedure,Consent for Obtaining Additional Bone Marrow Specimens at the Time of a Diagnostic Bone Marrow Procedure,TERMINATED,Business Decision,,OBSERVATIONAL,334,"Brain Cancer, Cancer",,PROCEDURE,Cancer Research in Future,2002-02,2016-08,Stanford University,OTHER
NCT03750760,Early Alirocumab to Reduce LDL-C in Myocardial Infarction,Early Alirocumab to Reduce LDL-C in Myocardial Infarction,WITHDRAWN,Changes in funding decision,PHASE4,INTERVENTIONAL,0,"Myocardial Infarction, Dyslipidemias","Alirocumab, Atorvastatin 80mg, Ezetimibe 10mg","DRUG, DRUG, DRUG",Percentage change in LDL-C in enhanced care group verses standard of care group at 2 weeks after randomisation,2020-01,2021-12,Imperial College London,OTHER
NCT04617860,Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease,"A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120102 in Patients With Huntington's Disease",TERMINATED,Lack of efficacy,"PHASE1, PHASE2",INTERVENTIONAL,36,Huntington Disease,WVE-120102,DRUG,"Safety: Number of Patients With Treatment-emergent Adverse Events (TEAEs), Safety: Number of Patients With a Severe TEAE, Safety: Number of Patients With Serious TEAEs, Safety and Tolerability: Number of Patients Who Withdraw Due to TEAEs",2019-09-24,2021-04-29,Wave Life Sciences Ltd.,INDUSTRY
NCT00322582,The Genetic Basis for Familial Cardiomyopathy in Patients With Idiopathic Cardiomyopathy,Open Labeled of the Study the Genetic Basis for Familial Cardiomyopathy in Patients With Idiopathic,TERMINATED,no financial resources were available to complete the study,,OBSERVATIONAL,41,Cardiomyopathy,,,,2007-05,2009-02,Carmel Medical Center,OTHER
NCT01343823,Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema,Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema,TERMINATED,Interim analysis suggested a trend favoring ecallantide; observed response rate to placebo was substantially higher than described in medical literature.,PHASE2,INTERVENTIONAL,79,ACE Inhibitor Induced Angioedema,"ecallantide 60 mg, ecallantide 30 mg, ecallantide 10 mg, placebo, placebo match for 30 mg ecallantide arm, placebo match for 10 mg ecallantide arm","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG",Safety and Efficacy of Ecallantide,2011-06-01,2012-06-01,Shire,INDUSTRY
NCT02170480,Pin Size Influence the Incidence of Knee Pain,Does Pin Size Influence the Incidence of Knee Pain in Patients Undergoing Temporary Skeletal Traction?,TERMINATED,PI is moving to another university; resident researcher does not wish to continue study with another PI.,,OBSERVATIONAL,9,Pain,,,"2000 IKDC Subjective Knee Evaluation form, and pin site Visual Analog Pain Scale (VAS)",2013-04,2016-04,University of Utah,OTHER
NCT02949479,Dissociation Investigation Study in Sex Offenders,Dissociative Experience During the Offence in Sex Offenders : Clinical and Prognosis Correlates,TERMINATED,"STUDY INVESTIGATORS HAVE LEFT THE INSTITUTION, THE DEPARTMENT NO LONGER HAS TIME TO INCLUDE",NA,INTERVENTIONAL,30,Sex Offenses,,BEHAVIORAL,"point prevalence of clinical dissociation during the offence, assessed with the use of clinical examination (narrative and DSM-5 criteria)",2017-03-29,2021-12-10,Hôpital le Vinatier,OTHER
NCT01560962,Efficacy of Over the Counter (OTC) Povidone-Ioldine 5% for Treatment of Acute or Chronic Blepharitis,Efficacy of Over the Counter (OTC) Povidone-Ioldine 5% for Treatment of Acute or Chronic Blepharitis,TERMINATED,research staffs unable to continue.,NA,INTERVENTIONAL,100,Blepharitis,"povidone iodine, Azithromycin, tobramycin-dexmethasone","DRUG, OTHER, DRUG, DRUG, OTHER",meibomian gland plugging,2012-01,2012-12,Southern California Institute for Research and Education,OTHER
NCT02122146,A Study Of PF-06664178 In Patients With Advanced Solid Tumors,"A Phase 1, Dose Escalation Study Of Pf-06664178 In Patients With Locally Advanced Or Metastatic Solid Tumors",TERMINATED,The study was prematurely discontinued due to a business-related decision on 09-FEB-2016. The decision to terminate the trial was based on the overall results.,PHASE1,INTERVENTIONAL,31,Neoplasms,"PF-06664178, PF-06664178","DRUG, DRUG","First Cycle Dose Limiting Toxicities (DLTs) In Order to Determine the Maximum Tolerated Dose(MTD), Number of Patients With All-Causality Treatment-Emergent Adverse Events(TEAEs) [Part 2 & 3], Number of Participants With Laboratory Abnormalities [Part 2 & 3]",2014-08,2016-06,Pfizer,INDUSTRY
NCT04336046,Ultrasound Guided Bilateral Erector Spinae Block as Analgesia for Adolescent Idiopathic Scoliosis Correction,Ultrasound Guided Bilateral Erector Spinae Block as Analgesia for Adolescent Idiopathic Scoliosis Correction,SUSPENDED,busy,NA,INTERVENTIONAL,40,"Erector Spinae Block, Analgesia, Scoliosis Idiopathic","normal saline, Bupivacaine","PROCEDURE, PROCEDURE, DRUG, DRUG",postoperative morphine consumption,2025-12-31,2026-02-27,Tanta University,OTHER
NCT03283046,Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma,Phase 1 Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma,WITHDRAWN,Similar to another study.,PHASE1,INTERVENTIONAL,0,"Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic, Multiple Myeloma","Nivolumab, Lenalidomide, Dexamethasone, Ipilimumab","DRUG, DRUG, DRUG, DRUG","Maximum Tolerated Dose (MTD) of Nivolumab and Ipilimumab with Dexamethasone and Lenalidomide (NILd) in Participants with Newly Diagnosed Multiple Myeloma, Adverse Events (AE) of Nivolumab and Ipilimumab with Dexamethasone and Lenalidomide (NILd) in Participants with Newly Diagnosed Multiple Myeloma",2017-10,2020-10,M.D. Anderson Cancer Center,OTHER
NCT06093503,Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein,"Phase 3, Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Combined With Osimertinib vs Platinum-Based Chemotherapy in Subjects With c-Met Overexpressing (OE) EGFR Mutant, Locally Advanced/Metastatic Non-Squamous NSCLC After a First Progression on Prior Third Generation EGFR TKi Treatment",WITHDRAWN,Strategic considerations,PHASE3,INTERVENTIONAL,0,Non-Small Cell Lung Cancer,"Telisotuzumab Vedotin, Osimertinib, Cisplatin, Carboplatin, Pemetrexed","DRUG, DRUG, DRUG, DRUG, DRUG",PFS in the Population of Participants with no Central Nervous System (CNS) Metastases at Baseline,2024-05-31,2028-04-11,AbbVie,INDUSTRY
NCT05747027,Prospective Randomized Controlled Trial of Obstructed Defecation Surgery,Prospective Randomized Controlled Trial Comparing Transvaginal Rectopexy and Ventral Mesh Rectopexy for Obstructed Defecation in Pelvic Organ Prolapse (PROD Trial),TERMINATED,Due to low recruitment rate,NA,INTERVENTIONAL,15,"Obstructed Defecation, Pelvic Organ Prolapse",,"PROCEDURE, PROCEDURE",Degree of Rectal Hypermobility Measured Via Ultrasound,2024-05-16,2025-05-30,Endeavor Health,OTHER
NCT03100370,Effects of Combined Spinal Direct Current Stimulation on Upper Limb Recovery in Acquired Brain Injury,Effects of Combined Spinal Direct Current Stimulation on Upper Limb Recovery in Acquired Brain Injury (ABI),TERMINATED,Study halted prematurely due to COVID-19 pandemic.,NA,INTERVENTIONAL,9,Acquired Brain Injury,,"DEVICE, DEVICE, DEVICE, DEVICE","Fugl-Meyer Arm (FMA) Motor Score, Fugl-Meyer Arm (FMA) Motor Score, Fugl-Meyer Arm (FMA) Motor Score",2016-05,2019-12-17,"The University of Texas Health Science Center, Houston",OTHER
NCT06597773,Online Patient Navigation Program for Patients With Breast Cancer,Online Patient Navigation Program for Timely Access to Supportive Care Services Among Patients With Breast Cancer,WITHDRAWN,It was not possible to develop and implement the intervention due to lack of funding.,NA,INTERVENTIONAL,0,"Breast Cancer, Supportive Care in Cancer, Patient Navigation",,"OTHER, OTHER",Access to supportive care services,2025-09-21,2025-09-23,Medicos e Investigadores en la Lucha contra el Cancer de Mama,OTHER
NCT03944369,VITORA: Clinical Study to Evaluate the Effect of KB109 on the Gut Microbiome in Subjects Whose Gastrointestinal Tracts Are Colonized With Multiple Drug-resistant Organisms,"A Randomized, Open-Label, Prospective, Parallel Group, 2-Part Clinical Food Study to Assess the Safety, Tolerability, and Effect of KB109 on the Gut Microbiome in Subjects Whose Gastrointesinal Tracts Are Colonized With Multiple Drug-resistant Organisms",TERMINATED,COVID-19 pandemic,NA,INTERVENTIONAL,3,"Vancomycin-Resistant Enterococcus, Extended-Spectrum Beta Lactamase-Producing Enterobacteriaceae, or Carbapenem-Resistant Enterobacteriaceae Colonized Subjects",,"OTHER, OTHER","Incidence of product-related treatment-emergent adverse events (TEAEs), Incidence of serious adverse events (SAEs), Change in Bristol Stool Scale (BSS) through the collection of daily patient questionnaires.",2019-06-27,2020-06-16,Kaleido Biosciences,INDUSTRY
NCT04688541,A Study to Determine User Acceptability and Laboratory Data Regarding Use of a Novel Indwelling Urinary Catheter: the Optitip Study,A Preliminary Randomised Crossover Study to Determine User Acceptability and Laboratory Data Regarding Use of a Novel Indwelling Urinary Catheter: the Optitip Study,WITHDRAWN,"Consequence of COVID-19 pandemic all staff working on this study were moved elsewhere and never returned to complete this work. Full RCT 'CADET' looking into Optitip use now taking place, so this pilot work is no longer required.",NA,INTERVENTIONAL,0,Urologic Diseases,,"DEVICE, DEVICE",Number of blockage - accumulation of biofilm,2020-04-01,2020-04-01,University of Southampton,OTHER
NCT04365582,OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome,A Randomized Trial of Efficacy and Safety of an Early OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome: a Strategy to Prevent Hospitalization,WITHDRAWN,The PI decided.,PHASE3,INTERVENTIONAL,0,COVID,"Azithromycin, Hydroxychloroquine, Lopinavir 200Mg/Ritonavir 50Mg Tab","DRUG, DRUG, DRUG",Hospital admission,2020-05-07,2021-04-19,Fondation Hôpital Saint-Joseph,OTHER
NCT06498024,Blood Glucose Response of Novel Wild Rice Enhanced Food Products (Trial 2),Assessing the Blood Glucose Response of Novel Wild Rice Enhanced Food Products (ABWE) Study,WITHDRAWN,"The wild rice cereal development was stopped, so the trial was also withdrawn prior to starting.",NA,INTERVENTIONAL,0,Blood Glucose,,"OTHER, OTHER, OTHER, OTHER, OTHER, OTHER",The effects of different wild rice products compared to products currently on the market on glycaemic control.,2025-09-01,2026-09-01,Dylan MacKay,OTHER
NCT00714259,Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies,UAB 0775 Phase II Trial of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation Protocol From HLA Matched Related Donors for The Treatment of Patients With Low Grade B Cell Malignancies,TERMINATED,Accrual goals could not be met within a timely manner,"PHASE2, PHASE3",INTERVENTIONAL,5,"Multiple Myeloma, CLL / SLL, Non Hodgkin's Lymphoma, Waldenstroms, Mantle Cell Lymphoma",Fludarabine,"DRUG, RADIATION, OTHER","Progressive Free Survival Post Transplant, Progressive Free Survival Post Transplant, Progressive Free Survival Post Transplant, Progression Free Survival Post Transplant",2008-07,2013-02,University of Alabama at Birmingham,OTHER
NCT04329923,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),TERMINATED,Cohort 1: slow accrual Cohort 2: Other studies showed no benefit Cohort 3: Study met pre-specificied futility analysis at planned second interim analysis,PHASE2,INTERVENTIONAL,173,COVID-19,"Hydroxychloroquine Sulfate 400 mg twice a day, Hydroxychloroquine Sulfate 600 mg twice a day, Hydroxychloroquine Sulfate 600 mg once a day, Placebo oral tablet","DRUG, DRUG, DRUG, DRUG","Time to Release From Quarantine Time, Time to Hospital Discharge, Number of Health Care Workers Who Developed SARS-COV-2 Infection",2020-04-09,2020-11-13,"Ravi Amaravadi, MD",OTHER
NCT03580746,Comparison of Ponseti Method Versus Older Treatments in Talipes Equinovarus Through Gait Analysis and Clinical Results,Comparison of Ponseti Method Versus Older Treatments in Talipes Equinovarus Through Gait Analysis and Clinical Results,WITHDRAWN,Resident working on this study left our department,,OBSERVATIONAL,0,Clubfoot,,"PROCEDURE, PROCEDURE",Clinical results,2014-09,2015-08,Universitaire Ziekenhuizen KU Leuven,OTHER
NCT04372979,Efficacy of Convalescent Plasma Therapy in the Early Care of COVID-19 Patients.,Evaluation Of Efficacy Of COVID-19 Convalescent Plasma Versus Standard Plasma In The Early Care Of COVID-19 Patients Hospitalized Outside Intensive Care Units.,TERMINATED,Reluctance of patients and physicians in this transfusion study setting. Blood products have expired. New variants have appeared since the plasma collection period. Some recent publications question the effectiveness of transfusion.,PHASE3,INTERVENTIONAL,18,COVID-19,"Transfusion of SARS-CoV-2 Convalescent Plasma., Transfusion of standard Plasma.","DRUG, DRUG",Survival time without needs of a ventilator.,2020-09-14,2021-06-01,Direction Centrale du Service de Santé des Armées,OTHER
NCT02710396,Genetic Predictors of Benefit to Pembrolizumab,Identifying Genetic Predictors of Durable Clinical Benefit to Pembrolizumab in Advanced Non-small Cell Lung Cancer (NSCLC) Alone and in Combination With Chemotherapy.,TERMINATED,Frontline pembrolizumab approved in NSCLC as monotherapy and in combination with chemotherapy representing a new standard of care.,PHASE2,INTERVENTIONAL,19,"Carcinoma, Non-Small-Cell Lung","Pembrolizumab, Carboplatin, Nab-paclitaxel, Pemetrexed","DRUG, DRUG, DRUG, DRUG",Number of Subjects With NSCLC Who Achieved DCB,2016-05-31,2021-03-10,Columbia University,OTHER
NCT02408562,Study on Tolerability of Repeat i.c.v. Administration of sNN0031 Infusion Solution in Patients With PD,"A Phase 1, Multicentre, Randomised, Double-blind Study to Assess Safety and Tolerability of Repeated Intracerebroventricular Administration of sNN0031 Infusion Solution to Patients With Parkinson's Disease",TERMINATED,Issues with development and supply of infusion system for delivery of IMP. Prolonged approval process for the clinical study sNN0031-004.,"PHASE1, PHASE2",INTERVENTIONAL,1,Parkinson's Disease,,"OTHER, OTHER",Tolerability of sNN0031 [Number of Adverse Events (AE) and Serious Adverse Events (SAE) occurring in each group over the study duration],2015-01,2015-10,Newron Sweden AB,INDUSTRY
NCT02904746,Intervention to Increase Treatment Engagement Among Individuals Referred for Post-Crisis Mental Health Services,"A Brief, Trauma-Informed Intervention to Increase Treatment Engagement Among Individuals Referred for Post-Crisis Mental Health Services",WITHDRAWN,Unable to successfully recruit participants using current study design.,NA,INTERVENTIONAL,0,Mental Health Crisis,,BEHAVIORAL,Attendance status to Information Class,2016-10,2016-11,University of Manitoba,OTHER
NCT03712046,Comparison of FDG PET and Bone Scintigraphy/Labelled Leukocyte/Gallium Scintigraphy in Diabetic Foot Osteomyelitis,Comparaison Entre la Performance du 18F-FDG PET/CT et de la Scintigraphie Osseuse/Gallium ou de la Scintigraphie Osseuse/Globules Blancs marqués /Souffre colloïdal Dans le Diagnostic d'Une ostéomyélite du Pied ou de la Cheville,TERMINATED,Poor patient recruitment,NA,INTERVENTIONAL,2,Diabetic Foot Infection,,DIAGNOSTIC_TEST,Diagnostic accuracy of 18F-FDG PET-CT for the diagnosis of diabetic foot osteomyelitis,2019-01-15,2019-11-10,Centre hospitalier de l'Université de Montréal (CHUM),OTHER
NCT02599727,"Effects of Isometric Exercises on Balance, Heart Rate, Pulse Ox and Blood Pressure","Effects of Isometric Exercises on Balance, Heart Rate, Pulse Ox and Blood Pressure",WITHDRAWN,Logistics reason at the data collection site,NA,INTERVENTIONAL,0,"Exercise, Isometric",,"OTHER, OTHER",Changes in Heart Rate,2015-11,2017-01,Carrick Institute for Graduate Studies,OTHER
NCT03514927,High-Intensity Focused Ultrasound in Treating Participants With Intermediate and High-risk Prostate Cancer,Translation of High-intensity Focused Ultrasound (HIFU) or Treatment of Intermediate and High-Risk Prostate Cancer,WITHDRAWN,No funding,NA,INTERVENTIONAL,0,"Prostate Cancer Stage I AJCC V6, Prostate Cancer Stage II, Prostate Cancer Stage III",,"PROCEDURE, DEVICE, OTHER, PROCEDURE, PROCEDURE",Mean percentage of viable clinically-significant prostate cancer (Gleason pattern 4 or 5) after high-intensity focused ultrasound (HIFU) treatment,2019-07-01,2022-07-01,University of Southern California,OTHER
NCT00604461,"Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)","Phase I/II Trial of Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)",TERMINATED,Slow Accrual,"PHASE1, PHASE2",INTERVENTIONAL,13,Mesothelioma,"Carboplatin, Bevacizumab and Pemetrexed",DRUG,Number of Participants With Partial Response (PR) of Target Lesions,2007-10,2011-01,H. Lee Moffitt Cancer Center and Research Institute,OTHER
NCT00418470,Prolonging the Duration of Peripheral Venous Catheters in Cystic Fibrosis People,Prolonging the Duration on Site of Short Peripheral Venous Catheters Used to Administer Intravenous Antibiotics in Cystic Fibrosis Adults. Randomized Controlled Trial on the Effect of Different Concentrations of Antibiotic in Normal Saline,TERMINATED,impossibility to find volunteers,PHASE4,INTERVENTIONAL,60,"Cystic Fibrosis, Phlebitis",,"PROCEDURE, PROCEDURE","The irritation level of the first vein that is cannulated for the course assessed each day. The assessment will be done utilizing the ""Phlebitis Scale"" of the Standard of Practice of the Intravenous Nurses Society (Journal of Intravenous Nursing 2000;, The number of days that the first short peripheral venous catheter used for the treatment course stays in situ before removal",2007-03,2011-08,University of Florence,OTHER
NCT01076270,Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies,A Pilot Study of Combined Plerixafor + Filgrastim for Mobilization of Peripheral Blood Stem Cells From Normal Donors,TERMINATED,Funding withdrawal,NA,INTERVENTIONAL,1,"Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Atypical Chronic Myeloid Leukemia, BCR-ABL Negative, Blastic Phase Chronic Myelogenous Leukemia, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Splenic Marginal Zone Lymphoma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma","plerixafor, filgrastim","DRUG, BIOLOGICAL, PROCEDURE, PROCEDURE",Successful Collection of Stem Cells,2010-06,2011-02,Fred Hutchinson Cancer Center,OTHER
NCT04050969,Bariatric Atrial Restoration of Sinus Rhythm,Bariatric Atrial Restoration of Sinus Rhythm,TERMINATED,Difficult enrollment,NA,INTERVENTIONAL,1,"Atrial Fibrillation, Morbid Obesity",,"PROCEDURE, PROCEDURE",Time to first recurrence of AF following a 3-month blanking period after the ablation.,2020-10-01,2022-07-01,Stanford University,OTHER
NCT01023269,Efficacy Study of Pudendal Neuromodulation for the Treatment of Neurogenic Overactive Bladder,"Phase IV, Multi-center, Randomized, Cross-over Study to Demonstrate the Efficacy of Pudendal Neuromodulation for the Treatment of Neurogenic Overactive Bladder",TERMINATED,difficulty in the enrolment,NA,INTERVENTIONAL,17,"Neurogenic Overactive Bladder, Urinary Incontinence, Detrusor Overactivity",,DEVICE,Functional Bladder Capacity,2009-12,2012-06,MedtronicNeuro,INDUSTRY
NCT06493383,Lotrafilcon B Plano Cosmetic Contact Lenses Study,Lotrafilcon B Plano Cosmetic Contact Lenses Post-Market Clinical Follow-Up Study,WITHDRAWN,Information to be gathered in survey format instead of a clinical investigation.,NA,INTERVENTIONAL,0,Cosmetic Appearance,,DEVICE,"Incidence of corneal infiltrative events, Incidence of microbial keratitis",2025-01,2026-05,Alcon Research,INDUSTRY
NCT00774241,PRIMADOS Study:A Study of Avastin (Bevacizumab) Plus Docetaxel for First Line Treatment of Patients With Metastatic Breast Cancer,An Open Label Study of the Effect of First Line Combination Treatment With Avastin and Docetaxel on Disease Response in Patients With Metastatic Breast Cancer,WITHDRAWN,Study was put on hold then out of Medical Plan therefore cancelled,PHASE4,INTERVENTIONAL,0,Breast Cancer,"bevacizumab [Avastin], docetaxel","DRUG, DRUG","Response rate, median progression free survival, overall survival",2010-01,2013-11,Hoffmann-La Roche,INDUSTRY
NCT03877094,e-Nature VR: Evaluation of the Impact of Virtual Reality During Breast Biopsy,"e-Nature VR: Evaluation of the Impact of Virtual Reality on the Perception of Pain, Discomfort, Stress and Well-being During Breast Biopsy",TERMINATED,"Due to restrictions imposed by the COVID-19 pandemic and difficulty of partcipants' adhesion, we chose to stop the data collection and suspend the project.",NA,INTERVENTIONAL,24,"Pain, Breast Pain",,BEHAVIORAL,"The Connectedness to Nature Scale, Evaluation of Discomfort and well-being, Visual Analogic Scale for Pain",2019-07-31,2022-04-23,Hospital Israelita Albert Einstein,OTHER
NCT01493154,Safety Study of HPV DNA Vaccine to Treat Head and Neck Cancer Patients,A Phase I Clinical Trial Assessing the Safety and Feasibility of Administration of pNGVL4a-CRT/E7(Detox) DNA Vaccine Using the Intramuscular TriGridTM Delivery System in Combination With Cyclophosphamide in HPV-16 Associated Head and Neck Cancer Patients,TERMINATED,Study Funding Terminated,PHASE1,INTERVENTIONAL,2,Head and Neck Cancer,"DNA Vaccine, Cyclophosphamide","BIOLOGICAL, DRUG",Number of participants with adverse events after administration of pNGVL4a-CRT/E7 (detox) DNA vaccine using the intramuscular TriGridTM Delivery System (TDS-IM) in combination with cyclophosphamide,2012-04,2015-10,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,OTHER
NCT01766505,The Study to Evaluate Efficacy and Safety of Candesartan vs Losartan in Hypertension With Heart Failure (HONOR),"Randomized, Open-label, Phase 4 Study to Evaluate Efficacy and Safety of Candesartan and Losartan in the Patients With Hypertension and Heart Failure.",TERMINATED,lack of the subjects,PHASE4,INTERVENTIONAL,32,Hypertension,"Candemore tablet, Cozzar tablet","DRUG, DRUG",change from baseline average sitting DBP(diastolic blood pressure)at 16 weeks,2012-06,2014-03,Chong Kun Dang Pharmaceutical,INDUSTRY
NCT04250805,Trial Evaluating the Efficacy of the Combination of ROpivacaine With Reference XYlocaine in the Evaluation of Pain During the Installation of Percutaneous Radiological GASTrostomy,Trial Evaluating the Efficacy of the Combination of ROpivacaine With Reference XYlocaine in the Evaluation of Pain During the Installation of Percutaneous Radiological GASTrostomy,TERMINATED,Difficulties in recruiting patients,PHASE2,INTERVENTIONAL,17,"Cancer, Feeding Disorders","Lidocaine, Ropivacaine","DRUG, DRUG",Level of Pain,2020-10-27,2024-01-23,Centre Hospitalier Universitaire de Saint Etienne,OTHER
NCT05708066,Aromatherapy With Lavender as Anxiolysis Prior to Cataracts Surgery,Aromatherapy With Lavender as Anxiolysis Prior to Cataracts Surgery,WITHDRAWN,Never approved by the Albert Einstein College of Medicine IRB,NA,INTERVENTIONAL,0,"Aromatherapy, Anxiety",,"OTHER, OTHER",Effect of lavender aromatherapy on anxiolysis,2024-01,2024-10,Montefiore Medical Center,OTHER
NCT04342156,Safety And Efficacy Of Hydroxychloroquine For At Risk Population (SHARP) Against COVID-19,Safety And Efficacy Of Hydroxychloroquine For At Risk Population (SHARP) Against COVID-19- A Cluster Randomized Controlled Trial (SHARP COVID-19 RCT),WITHDRAWN,The number of patients with COVID-19 in Singapore was coming down for the community and the concerns about the potential side effects particularly when the baseline ECG and serum electrolytes was not proposed.,PHASE3,INTERVENTIONAL,0,"Coronavirus Infection, Hydroxychloroquine Adverse Reaction",Hydroxychloroquine Sulfate 200 milligram (mg) Tab,DRUG,positive serology or reverse transcriptase (RT-PCR) for COVID-19 up until day 28.,2020-04,2020-10,Tan Tock Seng Hospital,OTHER
NCT01148056,Intensity Modulated Radiation Therapy (IMRT) for Patients With Rectal Cancer,A Phase II Study of Neoadjuvant Short Course Intensity Modulated Radiation Therapy (IMRT) for Patients With Rectal Cancer: An Analysis of Quality of Life and Biomarkers of Response,TERMINATED,The study was closed to enrollment due to slow accrual.,PHASE2,INTERVENTIONAL,2,Rectal Cancer,,RADIATION,Bowel Quality of Life,2010-03,2014-04,Massachusetts General Hospital,OTHER
NCT05722522,Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy,"A Randomized, Parallel-group, 24 Week, Double-blind, Placebo-controlled, Multicenter Phase 3 Study to Assess the Efficacy and Safety of Secukinumab Compared to Placebo in Adult Patients With Active Rotator Cuff Tendinopathy",TERMINATED,Project discontinued to prioritize other key programs in portfolio,PHASE3,INTERVENTIONAL,33,Rotator Cuff Tendinopathy,"Secukinumab, Placebo","DRUG, DRUG",Change From Baseline in the Western Ontario Rotator Cuff Index (WORC) Physical Symptom Domain (PSD) Score at Week 16,2023-08-10,2024-12-13,Novartis Pharmaceuticals,INDUSTRY
NCT03095222,Exploring the Safety and Efficacy of Low-dose Ketamine Infusions for Pain Control in Acute Burn Injury,Exploring the Safety and Efficacy of Low-dose Ketamine Infusions for Pain Control in Acute Burn Injury,WITHDRAWN,The study never screened or enrolled any subjects due to stalled recruitment efforts.,PHASE4,INTERVENTIONAL,0,Pain,"Ketamine, Opioids","DRUG, DRUG",Change in pain severity,2017-04-01,2018-05-24,University of Kansas Medical Center,OTHER
NCT04199351,Single and Multiple Ascending Dose Study of AMG 171 in Subjects With Obesity,"A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 171 in Subjects With Obesity",TERMINATED,Amgen determined the totality of the data does not support continuation of AMG 171 development program for treatment of Obesity. No safety concerns identified.,PHASE1,INTERVENTIONAL,60,Obesity,"AMG 171, Placebo","DRUG, DRUG",Number of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs),2019-12-13,2021-09-10,Amgen,INDUSTRY
NCT01239368,Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma,Rapamycin-Resistant T Cell Therapy of Multiple Myeloma: Relapse Prevention and Relapse Therapy,TERMINATED,Terminated due to insufficient accrual.,"PHASE1, PHASE2",INTERVENTIONAL,34,"Myeloma, Plasma-Cell, Myeloma-Multiple, Myelomatosis","Rapamycin-Generated Autologous Th1/Tc1 Cells (modified primary human T cells), Th1/Tc1 Rapa Cell Therapy","PROCEDURE, BIOLOGICAL, BIOLOGICAL","Number of Patients With an Adverse Event Attributable to the Investigational Therapy, Number of Participants With Progression Free Survival in Cohort A Th1 (Type 1 T Helper Cells)/Tc1 (T Cytotoxic Cells, Type 1) Rapa Prevention of Relapse, Number of Patients Who Developed a Partial Response (PR)+Complete Response (CR) in Cohort B at Any Time Point Post Therapy With PR/CR Being Maintained Until Study Completed",2010-11-10,2017-08-16,National Cancer Institute (NCI),NIH
NCT03566290,Study to Assess Long-Term Safety/Tolerability of Enobosarm (GTx 024) in Stress Urinary Incontinence,"Phase 2, Open-Label Extension Study to Assess Long-Term Safety and Tolerability of Enobosarm (GTx 024) in Postmenopausal Women With Stress Urinary Incontinence",WITHDRAWN,Development of investigational product was halted.,PHASE2,INTERVENTIONAL,0,Stress Urinary Incontinence,GTx-024,DRUG,"Safety of GTx-024, adverse events, Safety of GTx-024, liver function test, Safety of GTx-024, lipid panel, Safety of GTx-024, sex-hormone binding globulin levels, Safety of GTx-024, testosterone levels, Safety of GTx-024, endometrial stripe thickness, Safety of GTx-024, weight",2018-06-28,2018-09-21,GTx,INDUSTRY
NCT03303690,AS: Ankle Spacer for Talar Osteochondral Defects,"A Prospective Trial on the Clinical Efficacy of the Ankle Spacer for the Surgical Treatment of Large, Multiple, Cystic and Secondary or Tertiary Osteochondral Defects of the Talus",TERMINATED,Arthrex stopped manufacturing the device,NA,INTERVENTIONAL,2,Osteochondral Defect of Talus,,PROCEDURE,NRS during walking/weightbearing,2017-12-05,2020-03-11,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),OTHER
NCT04248010,Mechanistic Clinical Trial of Individualized tDCS for Hallucinations in Schizophrenia,Mechanistic Clinical Trial of Individualized tDCS for Hallucinations in Schizophrenia,WITHDRAWN,Modifications in methodology had to be made that make the current registration invalid.,NA,INTERVENTIONAL,0,Schizophrenia and Related Disorders,,"DEVICE, DEVICE",The Auditory Hallucination Rating Scale (AHRS),2022-12,2025-06-01,Columbia University,OTHER
NCT04028713,Dose Tapering Study of Adalimumab in Psoriasis,A Non-inferiority Study on Dose Reduction of Adalimumab in Psoriasis Patients,TERMINATED,Too slow inclusion rate.,PHASE4,INTERVENTIONAL,19,Psoriasis Vulgaris,Dose reduction,"PROCEDURE, PROCEDURE, DRUG",Clinical response,2021-02-16,2022-03-22,"University Hospital, Ghent",OTHER
NCT04433013,A Randomized Controlled Trial Assessing the Efficacy of Lianhua Qingwen as an Adjuvant Treatment in Patients With Mild Symptoms of COVID-19,A Randomized Controlled Trial Assessing the Efficacy of Lianhua Qingwen as an Adjuvant Treatment in Patients With Mild Symptoms of COVID-19,WITHDRAWN,"Unable to find suitable site Principal Investigator. This study did not start and was withdrawn as of Aug 2020 (have updated as of Sept 2020, please proceed to update the status of study withdrawal accordingly)",PHASE3,INTERVENTIONAL,0,COVID-19,"Lianhua Qingwen, Placebo","DRUG, DRUG",Proportion of participants who test negative for COVID-19,2020-07,2021-02,Nanyang Technological University,OTHER
NCT01292213,A Study to Identify and Characterise Bacteria Causing Chronic Cough Among Children in United Kingdom,Identification and Characterisation of Bacteria Causing Chronic Cough Among Children in the United Kingdom,TERMINATED,• Long delay due to challenges with sample analysis at local labs; • Low recruitment of case and control subjects; • Constant staff turn-over in the sites.,,OBSERVATIONAL,19,"Infections, Respiratory Tract",,"PROCEDURE, PROCEDURE, PROCEDURE, PROCEDURE, PROCEDURE, OTHER","Occurrence of Haemophilus influenzae, in the absence of co-infection with other bacteria, in the lower airways of cases and controls",2012-05,2013-02,GlaxoSmithKline,INDUSTRY
NCT02574624,Vitreous Surgery With Intraocular Assistance,Vitreous Surgery With Intraocular Assistance (VISIA),TERMINATED,Difficulty in finding patients with complex retinal pathology to enroll in this study.,NA,INTERVENTIONAL,5,"Traction Retinal Detachments, Rhegmatogenous Retinal Detachments, Dislocated Intraocular Lens",,PROCEDURE,The primary outcome measure is recording of adverse events directly related to VISIA and adverse events unrelated to VISIA.,2015-11,2017-09,Johns Hopkins University,OTHER
NCT03065959,A Study to Assess the Anti-fatigability Effect of CK-2127107 in Elderly Male and Female Subjects With Limitations in Mobility,A Phase 1b Study to Assess the Anti-fatigability Effect of CK-2127107 in Elderly Male and Female Subjects With Limitations in Mobility,TERMINATED,Lack of efficacy determined at interim analysis,PHASE1,INTERVENTIONAL,42,Mobility Limitation,"reldesemtiv, Placebo","DRUG, DRUG",Change from period baseline in sum of the peak torque of 120 contractions,2017-06-28,2018-10-10,"Astellas Pharma Global Development, Inc.",INDUSTRY
NCT03791580,Reducing High-Risk Geriatric Polypharmacy Via EHR Nudges: Pilot Phase,Reducing High-Risk Geriatric Polypharmacy Via EHR Nudges: Pilot Phase,WITHDRAWN,NIA funded the first phase of the R21. The clinical trial never began as the R33 was not supported.,NA,INTERVENTIONAL,0,"Fall, Congestive Heart Failure, Chronic Kidney Failure, Adverse Drug Event",,"BEHAVIORAL, BEHAVIORAL","High-risk polypharmacy criterion: Fall condition-drug interaction, High-risk polypharmacy criterion: Fall drug-drug interaction, High-risk polypharmacy criterion: CKD-glyburide/glimepiride interaction, High-risk polypharmacy criterion: CKD-NSAID interaction, High-risk polypharmacy criterion: CHF-NSAID interaction, High-risk polypharmacy criterion: CHF-non-dihydropyridine calcium channel blocker interaction, High-risk polypharmacy criterion: CHF-thiazolidinedione interaction",2019-02-01,2019-09-01,RAND,OTHER
NCT01284179,Home Hypnotherapy for Refractory Functional Chest Pain: A Pilot Study,Home Hypnotherapy for Refractory Functional Chest Pain: A Pilot Study,TERMINATED,Unable to enroll,NA,INTERVENTIONAL,8,Functional Chest Pain,,"BEHAVIORAL, BEHAVIORAL",Global change in chest pain at the 12 weeks,2011-02,2015-12,"University of North Carolina, Chapel Hill",OTHER
NCT02516696,BiRd vs. Rd as Initial Therapy in Multiple Myeloma,Lenalidomide and Dexamethasone (Rd) Versus Clarithromycin [Biaxin®] / Lenalidomide [Revlimid®] / Dexamethasone (BiRd) as Initial Therapy in Multiple Myeloma,TERMINATED,low enrollment,PHASE3,INTERVENTIONAL,12,Multiple Myeloma,"Clarithromycin, Lenalidomide, Dexamethasone","DRUG, DRUG, DRUG",Survival Duration Without Disease Progression,2016-02,2022-07-22,Weill Medical College of Cornell University,OTHER
NCT03194646,Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids,"An Open-label, Parallel-group, Randomized, Multicenter Study to Assess the Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids Versus Standard of Care",TERMINATED,"Due to a change in the development program, the study was closed prematurely.",PHASE3,INTERVENTIONAL,1272,Uterine Fibroids,"Vilaprisan (BAY1002670), Vilaprisan (BAY1002670), Vilaprisan (BAY1002670), Vilaprisan (BAY1002670), Vilaprisan (BAY1002670), Vilaprisan (BAY1002670)","DRUG, DRUG, DRUG, OTHER, DRUG, DRUG, DRUG",Percentage Change in Bone Mineral Density (BMD) of Lumbar Spine,2017-06-30,2024-07-11,Bayer,INDUSTRY
NCT01072227,Study to Identify and Characterize the Bacteria Causing Acute Otitis Media Episodes in Young Children in Taiwan,Identification and Characterization of the Bacteria Causing Acute Otitis Media (AOM) Episodes in Young Children in Taiwan,TERMINATED,The study was terminated for logistic reasons,,OBSERVATIONAL,10,Acute Otitis Media,,PROCEDURE,"Proportion of H. influenzae, S. pneumoniae and other bacterial pathogens",2010-07,2011-04,GlaxoSmithKline,INDUSTRY
NCT04354727,A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy,Phase Ib/II Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy,WITHDRAWN,Sponsor decision,"PHASE1, PHASE2",INTERVENTIONAL,0,Myelofibrosis,"APG-1252, Ruxolitinib","DRUG, DRUG","Dose-limiting toxicity (DLT) rate at each dose level, Spleen Volume Measurement Reduction",2020-12-15,2023-06-15,Ascentage Pharma Group Inc.,INDUSTRY
NCT05405842,Transauricular Vagal Nerve Stimulation; Functional Dyspepsia and Gastroparesis,"Effects of Transauricular Vagal Nerve Stimulation on Electrogastrography (EGG) and Heart Rate Variability (HRV) in Healthy Subjects, Functional Dyspepsia, and Gastroparesis",WITHDRAWN,"There were equipment issues with the vendor that could not be resolved; therefore, enrollment was never opened.",NA,INTERVENTIONAL,0,"Gastroparesis, Functional Dyspepsia, Healthy, Digestive System Disease, Gastroenterology",,DEVICE,Establish EGG/HRV parameters and effects following taVNS,2024-01,2025-09,Stanford University,OTHER
NCT02262169,DLBS2411 Treatment for Ulcer Healing in Non-Bleeding Peptic Ulcers,DLBS2411 Treatment for Ulcer Healing in Non-Bleeding Peptic Ulcers,TERMINATED,This study was terminated due to internal technical issues at study site,PHASE3,INTERVENTIONAL,32,Non-Bleeding Peptic Ulcers,"Omeprazole, Placebo caplet of DLBS2411, DLBS2411, Placebo capsule of Omeprazole","DRUG, DRUG, DRUG, DRUG",Endoscopic ulcer healing rate,2014-10,2019-03,Dexa Medica Group,INDUSTRY
NCT03399435,A Study in Healthy Male Volunteers to Investigate the Safety and Tolerability of a Single Dose of Neosaxitoxin Alone and in Combination With Bupivacaine (With and Without Epinephrine) for Brachial Plexus Blockade,"An Exploratory Phase I Randomized, Single-site, Double-blind, Active-controlled, Parallel-group, Single-administration, Dose-escalation Trial to Investigate the Safety and Tolerability of Neosaxitoxin Alone and in Combination With Bupivacaine (With and Without Epinephrine), in Perineural Administrations for Brachial Plexus Blockade in Healthy Subjects",TERMINATED,The sponsor decided to stop further dosing of healthy volunteers after reviewing the obtained efficacy data. The decision is not related to any safety concern.,PHASE1,INTERVENTIONAL,242,"Anesthesia, Anesthesia, Local, Analgesia","Bupivacaine low (C3), Bupivacaine high (C4), Neosaxitoxin (T3)","COMBINATION_PRODUCT, COMBINATION_PRODUCT, COMBINATION_PRODUCT, COMBINATION_PRODUCT, DRUG, DRUG, DRUG, COMBINATION_PRODUCT, COMBINATION_PRODUCT, COMBINATION_PRODUCT","Occurrence of dose limiting events (DLEs) in all parts of the trial., Occurrence of other adverse events (AEs) leading to premature termination of dose escalation in Part A and Part B.",2018-01-30,2018-09-21,Grünenthal GmbH,INDUSTRY
NCT00076635,An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPF,An Open-Label Study of the Safety of Subcutaneous Recombinant Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis,TERMINATED,program discontinued based on GIPF-007 results,PHASE3,INTERVENTIONAL,91,"Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis, Lung Disease",Interferon gamma-1b,DRUG,"All adverse events up to the end of study, Survival status at end of study, Serum antibodies to Interferon gamma-1b after the last injection.",2003-11,2007-04,InterMune,INDUSTRY
NCT00208325,PFC Sigma Fixed and Mobile Knee Study,Clinical Evaluation of the P.F.C. Sigma (Fixed Bearing) and P.F.C. Sigma RP (Mobile Bearing) Total Knee Systems,TERMINATED,The study was terminated at the point the primary endpoint and early milestones were reached and because long term outcomes were available from other sources,PHASE4,INTERVENTIONAL,754,"Osteoarthritis, Knee",,"DEVICE, DEVICE","To Compare Range of Motion Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm, To Compare Range of Motion Between Sigma RP and Sigma Fixed Treatment Groups in PCL Retaining Arm, To Compare the Change in Range of Motion From Pre-op to 1 Year Between Sigma RP and Sigma Fixed Treatment Groups in PCL Sacrificing Arm, To Compare the Change in Range of Motion From Pre-op to 1 Year Between Sigma RP and Sigma Fixed Treatment Groups in PCL Retaining Arm",2000-05,2010-09,DePuy International,INDUSTRY
NCT01447589,Radical Lung Radiotherapy Plus Nelfinavir,"A Phase I Dose Escalation Study of the HIV Protease Inhibitor, Nelfinavir, Given Concomitantly With Radical Radiotherapy (RT) for the Treatment of Non-Small Cell Lung Cancer (NSCLC)",WITHDRAWN,"failed to recruit, no suitable patients","PHASE1, PHASE2",INTERVENTIONAL,0,Lung Cancer,nelfinavir,"DRUG, RADIATION",maximum tolerated dose,2012-02,2012-10,Oxford University Hospitals NHS Trust,OTHER
NCT04926168,6 Months Adjuvant Temozolomide (TMZ) vs No Adjuvant TMZ in Newly Diagnosed MGMT Methylated Glioblastoma (GBM),Randomized Pilot Study of Six Months Adjuvant Temozolomide (TMZ) vs No Adjuvant TMZ in Patients With Newly Diagnosed MGMT Methylated Glioblastoma (GBM) Following Standard Concurrent Radiation and TMZ,WITHDRAWN,lack of funds,,OBSERVATIONAL,0,MGMT-Methylated Glioblastoma,,"OTHER, OTHER",Overall Survival,2023-03-01,2026-12-31,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,OTHER
NCT02673697,Perceval Sutureless Implant Versus Standard-Aortic Valve Replacement,Perceval Sutureless Implant Versus Standard-Aortic Valve Replacement A Controlled Randomized Trial in the Surgical Treatment of Aortic Valve Disease,TERMINATED,Sponsor Decision,NA,INTERVENTIONAL,914,"Aortic Valve Disease, Aortic Stenosis",,"DEVICE, DEVICE",Proportion of Participants With Freedom From Major Adverse Cardiac and Cerebrovascular Events (MACCE),2016-03-22,2020-07-31,Corcym S.r.l,INDUSTRY
NCT04021797,Autonomic Mechanisms of Sleep-dependent Memory Consolidation,Autonomic Mechanisms of Sleep-dependent Memory Consolidation,TERMINATED,Study stopped due to COVID-19,NA,INTERVENTIONAL,12,"Memory, Sleep",,DEVICE,Change in memory between sham and active stimulation,2019-10-15,2020-03-15,"University of California, San Francisco",OTHER
NCT04913610,"Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection","A Phase-II, Randomised, Double-blind, Parallel-group, Proof-of-concept Trial to Investigate ABBV-4083 Given for 7 or 14 Days or in Combination With Albendazole in Subjects With Onchocerca Volvulus Infection, Comprising: Part 1 to Investigate Safety, Tolerability, Efficacy for Dose-Ranging and Pharmacokinetics; Part 2 to Investigate Efficacy of Selected Doses, Safety, Tolerability and Pharmacokinetics",TERMINATED,Strategic considerations,PHASE2,INTERVENTIONAL,153,Onchocerciasis,"ABBV-4083, Placebo for ABBV-4083, Albendazole, Placebo for Albendazole","DRUG, DRUG, DRUG, DRUG",Part 1: Percentage of Live Female Adult Worms Without Wolbachia at Month 6 as Assessed By Immunohistology of Nodules,2021-05-22,2023-08-29,AbbVie,INDUSTRY
NCT01939210,Meditation-Based Breathing Training in Improving Target Motion Management and Reducing Distress in Patients With Abdominal or Lung Cancer Undergoing Radiation Therapy,Influence of Meditation-Based Breathing Training on Target Motion Management and Distress During Radiation for Abdominal and Lung Malignancies,TERMINATED,lack of funding to hire a dedicated study interventionist,NA,INTERVENTIONAL,17,"Anxiety, Depression, Digestive System Neoplasm, Lung Neoplasm, Pain, Post-Traumatic Stress Disorder, Psychological Impact of Cancer",,"OTHER, OTHER, OTHER","Change in duty cycle, defined as the fraction of the time of the breathing cycle that the beam is on, before and after breath coaching, Changes in gate width, Changes in the length of the end expiration or end inspiration defined as when the breathing trace or internal motion change direction",2010-02,2015-12-02,Albert Einstein College of Medicine,OTHER
NCT01500382,A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004),A Placebo and Active-Comparator Controlled Multiple-Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of MK-4618 in Patients With Overactive Bladder,TERMINATED,This study was terminated early due to insufficient recruitment.,PHASE1,INTERVENTIONAL,4,"Overactive Bladder, Overactive Urinary Bladder","Vibegron, Tolterodine ER, Prophylactic Antibiotic","DRUG, DRUG, OTHER, OTHER, DRUG","Fold-change From Baseline in Maximum Cystometric Capacity Post-dose on Day 7, Number of Participants Who Experienced an Adverse Event (AE), Number of Participants Who Discontinued Use of Study Drug Due to an AE",2012-02-27,2013-01-02,Merck Sharp & Dohme LLC,INDUSTRY
NCT02109224,Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection,Phase I and Pharmacokinetic Study of Ibrutinib in HIV-Infected Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Multiple Myeloma,TERMINATED,Inadequate accrual rate,PHASE1,INTERVENTIONAL,72,"Adult B Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Cutaneous B-Cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, HIV Infection, Intraocular Lymphoma, Multicentric Angiofollicular Lymphoid Hyperplasia, Nodal Marginal Zone Lymphoma, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Plasma Cell Myeloma, Small Intestinal Lymphoma, Splenic Marginal Zone Lymphoma, Testicular Lymphoma, Waldenstrom Macroglobulinemia",Ibrutinib,"DRUG, OTHER, OTHER","Incidence of toxicities assessed using National Cancer Institute (NCI) CTCAE version 4.0, MTD of ibrutinib defined as the dose level in which no more than 1 out of 6 patients experiences a dose limiting toxicity assessed using NCI CTCAE version 4.0",2014-09,2015-07,National Cancer Institute (NCI),NIH
NCT00133679,Chronic Sildenafil for Severe Diaphragmatic Hernia,Chronic Sildenafil for Severe Diaphragmatic Hernia,TERMINATED,"Change in clinical practice allowing chronic therapy at 6 weeks of age, incompatible with possibility of placebo beyond 6 weeks of age on study protocol",PHASE4,INTERVENTIONAL,9,"Hernia, Diaphragmatic, Hypertension, Pulmonary, Hypoplasia, Pulmonary","sildenafil, Placebo","DRUG, DRUG",Estimated Systolic Pulmonary Arterial Pressure at Final Echocardiogram,2006-02,2013-10,"University of California, San Francisco",OTHER
NCT03854396,Clinical Trial on the Preventive Effect of Intravaginal Prasterone on Recurrent Urinary Tract Infections in Postmenopausal Women,"A Randomized, Double-blind, Placebo-controlled Trial on the Preventive Effect of Intravaginal Prasterone (DHEA, Intrarosa®) on Recurrent Urinary Tract Infections in Women With Genitourinary Syndrome of Menopause",WITHDRAWN,due to termination of ISR by PI with agreement by grant sponsor,PHASE3,INTERVENTIONAL,0,"Recurrent Urinary Tract Infection, Postmenopause, Postmenopausal Syndrome, Postmenopausal Symptoms, Menopause","Prasterone, Placebo","DRUG, DRUG","Incidence of urinary tract infections (UTIs), Incidence of urinary tract infections (UTIs)",2020-05,2021-02,"Olivia Cardenas-Trowers, M.D.",OTHER
NCT01953562,Positioning and the Spontaneous Breathing Test in Neonates,Evaluation of the Influence of Positioning and Time Duration on the Spontaneous Breathing Test in Neonates,WITHDRAWN,This protocol was closed and will be redesigned and submitted as a new protocol.,,OBSERVATIONAL,0,"Spontaneous Breathing Test, Infants, NICU",,,Effect of prone vs supine positioning on whether an infant receives a passing score on the SBT test,2013-10,2014-07,Christiana Care Health Services,OTHER
NCT03994146,Remifentanil Tapering and Post-adenotonsillectomy Pain in Children,"Remifentanil Tapering and Post-adenotonsillectomy Pain in Children: a Randomised, Placebo Controlled, Double Blind Study",TERMINATED,Recruitment rate was not compatible with study completion,PHASE4,INTERVENTIONAL,6,"Child, Only, Pain, Tonsillectomy, Remifentanil","Remifentanil, Sodium Chloride 9mg/mL","DRUG, DRUG",Intravenous fentanyl consumption in the perioperative period (mcg/kg).,2020-01-16,2023-08-18,"University Hospital, Akershus",OTHER
NCT05028946,A Study of Oral Foralumab in Participants With Moderate to Severely Active Crohn's Disease,"A Phase IB Multiple Ascending Dose Study of Safety and Tolerability of Orally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, in Subjects With Moderate to Severely Active Crohn's Disease",WITHDRAWN,For business reasons,PHASE1,INTERVENTIONAL,0,Crohn's Disease,Foralumab,DRUG,Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs),2022-05-01,2023-11-07,Tiziana Life Sciences LTD,INDUSTRY
NCT00090961,"S0229, Pulmonary Rehabilitation Education w/wo Exercise Training in Improving Physical Function in Patients Who Are Undergoing Chemo & RT for Locally Advanced Lung Cancer",A Randomized Trial Assessing the Effects of Exercise on Patients With Locally Advanced Lung Cancer Undergoing Curative Intent Combined Modality Therapy,TERMINATED,Closed early due to poor accrual.,NA,INTERVENTIONAL,2,"Lung Cancer, Pulmonary Complications",,"OTHER, OTHER",Exercise tolerance,2004-09,2008-10,SWOG Cancer Research Network,NETWORK
NCT04203186,A Clinical Trial to Evaluate Plasmodium Falciparum 7G8 and NF54 Challenge Strains (PfSPZ) in a Head-to-head Comparative Study - (ECG-CHMI),"A Phase 1 Clinical Trial To Evaluate The Safety and Infectivity Of Direct Venus Inoculation of Aseptic, Purified, Cryopreserved Plasmodium Falciparum 7G8 And NF54 Challenge Strains (PfSPZ) in a Head-To-Head Comparative Study",WITHDRAWN,Funding was lost due to the COVID19 Pandemic,NA,INTERVENTIONAL,0,Plasmodium Falciparum,atovaquone-proguanil,DRUG,"Difference in the pre-patent period, Difference in the total number of malaria events",2020-03,2021-09,U.S. Army Medical Research and Development Command,FED
NCT03854370,Vaginal Prep Solutions to Reduce Bacteria Colony Counts in Patients Having a Vaginal Surgery,A Randomized Trial of Vaginal Prep Solutions to Reduce Bacteria Colony Counts in Patients Having a Vaginal Surgery,TERMINATED,COVID impact on recruitment; challenges with enrollment,NA,INTERVENTIONAL,35,"Surgical Site Infection, Vaginal Surgery",,"OTHER, OTHER, OTHER, OTHER","Vaginal Colony Counts (Anaerobic), Vaginal Colony Counts (Aerobic)",2019-06-21,2024-01-01,Wright State University,OTHER
NCT02463669,The Use of Point-of-Care Ultrasound in the Diagnosis of Acute Infectious Mononucleosis in the Emergency Department,The Use of Point-of-Care Ultrasound in the Diagnosis of Acute Infectious Mononucleosis in the Emergency Department,TERMINATED,COVID pandemic,,OBSERVATIONAL,200,"Infectious Mononucleosis, Splenomegaly",,DEVICE,Presence of splenomegaly (maximal splenic cranio-caudal length) on point-of-care ultrasound,2016-04,2020-10-04,Jewish General Hospital,OTHER
NCT04912141,Prevention of Acute Kidney Injury in Patients With NSTEMI,"Conestat Alfa (a Recombinant Human C1 Esterase Inhibitor) for the Prevention of Acute Kidney Injury After Non-ST Elevation Myocardial Infarction: a Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 2, Dose-finding Study",TERMINATED,Lower than expected study enrolment rate. New strategic considerations.,PHASE2,INTERVENTIONAL,29,Non-ST Elevation Myocardial Infarction (NSTEMI),conestat alfa or placebo,DRUG,Urinary NGAL,2021-04-21,2023-04-28,Pharming Technologies B.V.,INDUSTRY
NCT03812341,"SINGLE PATIENT EXPANDED ACCESS OF A PROSPECTIVE, MULTICENTER CLINICAL TRIAL DESIGNED TO EVALUATE THE SAFETY AND PROBABLE BENEFIT OF THE KERAKLEAR NON-PENETRATING KERATOPROSTHESIS IN SUBJECTS WITH CORNEAL OPACITY WITH POOR PROGNOSIS FOR CORNEAL TRANSPLANT","SINGLE PATIENT EXPANDED ACCESS OF A PROSPECTIVE, MULTICENTER CLINICAL TRIAL DESIGNED TO EVALUATE THE SAFETY AND PROBABLE BENEFIT OF THE KERAKLEAR NON-PENETRATING KERATOPROSTHESIS IN SUBJECTS WITH CORNEAL OPACITY WITH POOR PROGNOSIS FOR CORNEAL TRANSPLANT",WITHDRAWN,No enrollment,NA,INTERVENTIONAL,0,CORNEAL OPACITY WITH POOR PROGNOSIS FOR CORNEAL TRANSPLANT,,OTHER,"1.Improvement in BCDVA compared to baseline [ Time Frame: Baseline, Month 1, Month 2, Month 3, Month 4, Month 6, Month 9 and Month 12 ]",2018-08-10,2019-08-09,"University of California, Irvine",OTHER
NCT03443154,VF Test for Prediction of Extremely PTB After Cerclage,"Vaginal Fluid (VF) Test VF-Test™ for Prediction of Extremely Preterm Birth After Exam-Indicated Cerclage Protocol for Prospective, Multicenter, Cohort Clinical Trial",WITHDRAWN,Industry sponsor withdrew financial support as well as the testing equipment.,,OBSERVATIONAL,0,"Preterm Birth, Infection",,DIAGNOSTIC_TEST,Rate of very preterm birth (PTB),2018-06,2018-06-01,Pediatrix,OTHER
NCT01673425,Evaluating Immune Response to Seasonal FluMist in Healthy Adults,Evaluating Immune Response to Seasonal FluMist in Healthy Adults,TERMINATED,Low accrual(4 completed subjects over 2 months)\& inconclusive nasal wash assays.,NA,INTERVENTIONAL,5,Influenza,Live Attenuated Influenza Vaccine,DRUG,IgA Antibody Titers,2012-09,2012-12,National Center for Occupational Health and Infection Control,FED
NCT03399825,Optical Coherence Tomography Angiography (OCT-A) in Children (≥ 6 <14 Years of Age),Investigation of Vascular Pathology in Eye Diseases Using Optical Coherence Tomography Angiography (OCT-A) in Children (≥ 6 <14 Years of Age),WITHDRAWN,administrative hurdles,,OBSERVATIONAL,0,"Retinopathy of Prematurity, Diabetic Retinopathy",,DEVICE,Evaluation of the sensitivity and specificity of OCTA,2018-01,2018-03-01,"Insel Gruppe AG, University Hospital Bern",OTHER
NCT02068625,Rasagiline (Azilect) - Neuroprotection for Macula-off Retinal Detachment,Rasagiline (Azilect) - Neuroprotection for Macula-off Retinal Detachment,TERMINATED,Persisting recruitment difficulties,PHASE4,INTERVENTIONAL,23,Retinal Detachment,"Rasagiline, Placebo","DRUG, DRUG",ETDRS Visual Acuity,2010-09,2018-12-31,"Insel Gruppe AG, University Hospital Bern",OTHER
NCT03468140,Pilot Trial of Eculizumab Therapy to Reduce Preservation Injury in Human Macrosteatotic Liver Transplantation,A Matched Intervention Pilot Trial of Eculizumab Therapy to Reduce Preservation Injury in Human Macrosteatotic Liver Transplantation,WITHDRAWN,Unable to recruit due to COVID 19,EARLY_PHASE1,INTERVENTIONAL,0,End Stage Liver Disease,Eculizumab,"DRUG, OTHER",Degree of Hepatocellular Injury,2021-10-01,2023-12-31,Yale University,OTHER
NCT01806740,DCE-MRI Using Dotarem® in Evaluation of Therapeutic Response to Sorafenib in Patients With Advanced Stage HCC,Phase IV Study of DCE-MRI Using Dotarem® in Evaluation of Therapeutic Response to Sorafenib in Patients With Advanced Stage HCC,TERMINATED,The planned number of enrolled patients was not reached.,PHASE4,INTERVENTIONAL,37,Hepatocellular Carcinoma,Gadoterate meglumine,DRUG,Correlation Coefficient Between DCE-MRI Perfusion Parameters and the Response of Target Lesions to Sorafenib,2013-05-09,2015-10-12,Guerbet,INDUSTRY
NCT01012440,Role of Positron Emission Mammography (PEM) Flex Solo II Positron Emission Tomography (PET) Scanner in Evaluating Neoadjuvant Chemotherapy Response in Patients With Breast Cancer,Role of PEM Flex Solo II PET Scanner in Evaluating Neoadjuvant Chemotherapy Response in Patients With Breast Cancer,TERMINATED,Poor accrual,NA,INTERVENTIONAL,5,Breast Cancer,,"DEVICE, DEVICE",Reduction in Tumor Size,2009-11,2012-05,University of Chicago,OTHER
NCT04468789,Evaluation of Six-month HIV Treatment Dispensing in South Africa,Evaluation of the National Department of Health's Six-month Antiretroviral Treatment Dispensing Demonstration Pilot in Primary Health Care Clinics in the Context of the COVID-19 Pandemic and Response in South Africa,WITHDRAWN,The South African government decided not to implement the pilot project for which this protocol was the evaluation. It was not approved by the IRB and never started.,,OBSERVATIONAL,0,HIV,,OTHER,"Uptake of 6MMD, Retention in care, Viral suppression",2020-11,2022-12,Boston University,OTHER
NCT04061590,Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer,A Phase 2 Study of Neoadjuvant Pembrolizumab-Based Combination Immunotherapy in the Treatment of Early Stage Non-Small Cell Lung Cancer,WITHDRAWN,Low Accrual,PHASE2,INTERVENTIONAL,0,"Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8","Cisplatin, Pembrolizumab, Pemetrexed, Pemetrexed Disodium","DRUG, BIOLOGICAL, DRUG, DRUG, PROCEDURE",Proportion of patients with a >= 2-fold increase in the number of tumor-infiltrating immune cells (TIICs) in post- versus (vs.) pre-pembrolizumab treatment tumor specimens,2020-05-29,2023-08-31,"University of California, San Francisco",OTHER
NCT01426113,A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paediatric Patients With Glaucoma,,TERMINATED,Study terminated due to corporate decision.,PHASE3,INTERVENTIONAL,6,Glaucoma,"bimatoprost ophthalmic solution formulation A, timolol ophthalmic solution, bimatoprost vehicle","DRUG, DRUG, DRUG",Change From Baseline in Intraocular Pressure (IOP) in the Study Eye,2011-09,2014-10,Allergan,INDUSTRY
NCT03966313,Perioperative Modification of Hemostasis During Ventricular Assist Device Implantation,Perioperative Modification of Hemostasis During Ventricular Assist Device Implantation,TERMINATED,"Due to inclusion difficulties following the evolution of surgical indications, which were clearly restricted, making patient inclusion too complex.",,OBSERVATIONAL,26,End-stage Heart Failure,,DEVICE,Von Willebrand Factor activity,2019-06-21,2024-04-13,"University Hospital, Strasbourg, France",OTHER
NCT02216760,Using Ripple Mapping to Guide Substrate Ablation of Scar Related Ventricular Tachycardia.,Determining the Pathophysiological Role of Slow Conduction Channels Identified by Ripple Mapping of the Ventricular Scar.,WITHDRAWN,Terminated prior to randomised phase,NA,INTERVENTIONAL,0,"Monomorphic Ventricular Tachycardia, Myocardial Infarction, Dilated Cardiomyopathy",,"DEVICE, DEVICE",Time to first appropriate ICD therapy,2014-08,2018-08,Imperial College London,OTHER
NCT03361124,Oxytocin Dosing at Planned Cesarean Section and Anemia,Oxytocin Dosing at Planned Cesarean Section and Postpartum Anemia: A Comparison of Two Protocols,WITHDRAWN,Investigator no longer interested in proceeding with study,PHASE4,INTERVENTIONAL,0,"Blood Loss Anemia, Uterine Atony With Hemorrhage",Oxytocin,DRUG,Blood loss in postpartum period defined by grams/hour,2019-03-01,2020-03-01,Milton S. Hershey Medical Center,OTHER
NCT04093323,"Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma","A Phase II Study of Type-1 Polarized Dendritic Cell (aDC1) -Based Treatment in Combination With Tumor-Selective Chemokine Modulation (CKM: Interferon Alpha 2b, Rintatolimod and Celecoxib) in Melanoma Patients With Primary PD-1/PD-L1 Resistance",TERMINATED,Funding completed,PHASE2,INTERVENTIONAL,1,"HLA-A2 Positive Cells Present, Refractory Melanoma","Alpha-type-1 Polarized Dendritic Cells, Celecoxib, PD-1 Ligand Inhibitor, PD1 Inhibitor, Recombinant Interferon Alfa-2b, Rintatolimod","BIOLOGICAL, DRUG, DRUG, DRUG, BIOLOGICAL, DRUG",Objective response rate (ORR),2024-11-13,2025-06-19,Roswell Park Cancer Institute,OTHER
NCT04398680,A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function,A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants With Relapsed or Refractory Multiple Myeloma Who Have Normal and Varying Degrees of Impaired Hepatic Function (DREAMM 13),WITHDRAWN,Sponsor Decision,PHASE1,INTERVENTIONAL,0,Multiple Myeloma,Belantamab mafodotin,DRUG,"Part 1 and Part 2: Maximum observed plasma concentration (Cmax) of Belantamab Mafodotin, Part 1 and Part 2: Time to Cmax (Tmax) of Belantamab Mafodotin, Part 1 and Part 2: Concentration at the end of infusion (C-EOI), Part 1 and Part 2: Predose plasma concentration (Ctrough) of Belantamab Mafodotin, Part 1 and Part 2: Area under the plasma concentration-time curve (from zero to the end of dosing interval), Part 1 and Part 2: Last time point where the concentration is above the limit of quantification (Tlast) of Belantamab Mafodotin, Part 1 and Part 2: Cmax of total monoclonal antibody (mAb), Part 1 and Part 2: Tmax of total mAb, Part 1 and Part 2: C-EOI of total mAB, Part 1 and Part 2: Ctrough of total mAb, Part 1 and Part 2: Area under the plasma concentration-time curve (from zero to the end of dosing interval)of total mAb, Part 1 and Part 2: Tlast of total mAb, Part 1 and Part 2: Cmax of Cys Monomethyl Auristatin F (cys-mcMMAF), Part 1 and Part 2: Tmax of cys-mcMMAF, Part 1 and Part 2: C-EOI of cys-mcMMAF, Part 1 and Part 2: AUC(0-168 hours) of cys-mcMMAF, Part 1 and Part 2: tlast of cys-mcMMAF",2021-04-20,2025-11-04,GlaxoSmithKline,INDUSTRY
NCT06739980,The ENABLE Study: Safety and Efficacy Study of INZ-701 in Patients With ENPP1 Deficiency,"The ENABLE Study: An Open-Label, Long-Term Safety and Efficacy Study of INZ-701 in Patients With Ectonucleotide Pyrophosphatase/ Phosphodiesterase 1 (ENPP1) Deficiency",WITHDRAWN,Study was not initiated as it is no longer consistent with the Sponsor's development plans.,PHASE2,INTERVENTIONAL,0,"Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy 1",INZ-701,DRUG,Change from Baseline in Plasma Inorganic Pyrophosphate (PPi) concentration through Week 52,2025-01-31,2028-03-31,Inozyme Pharma,INDUSTRY
NCT02665962,Evaluating the Effect of Perioperative Caloric Restriction Program on Perioperative Outcomes in Patients With Obesity and Endometrial Cancer,Evaluating the Effect of Perioperative Caloric Restriction Program on Perioperative Outcomes in Patients With Obesity and Endometrial Cancer,TERMINATED,Poor enrollment,NA,INTERVENTIONAL,8,"Obese, Endometrial Cancer",,OTHER,Number of completed perioperative caloric restriction program in obese newly diagnosed endometrial cancer patients,2015-07,2018-07,Abramson Cancer Center at Penn Medicine,OTHER
NCT01230788,Rituximab for Patients With Relapsed Acute Lymphoblastic Leukemia,A Trial of Rituximab Combined With Prednisone/Ifosfamide/Etoposide for Relapsed Acute Lymphoblastic Leukemia (ALL),TERMINATED,Lack of enrollment,NA,INTERVENTIONAL,1,"Leukemia, Acute Lymphoblastic Leukemia, ALL",rituximab,DRUG,"4 Month Event Free Survival (EFS), Toxicities of Rituximab, Remission Induction Rate",2010-09,2012-10,Emory University,OTHER
NCT02885727,"Durvalumab Plus ""Booster"" RT for Metastatic Adenocarcinoma Pancreas Cancer Post Chemotherapy (GCC 1598)","Phase II Trial of in Situ Tumor Vaccination Using Durvalumab and ""Booster"" Radiation Therapy in Patients With Metastatic Adenocarcinoma of the Pancreas Who Have Progressed Through First-line Chemotherapy",WITHDRAWN,Funding issues caused the study to not be opened the at local IRB,PHASE2,INTERVENTIONAL,0,Metastatic Pancreas Cancer,Durvalumab,"DRUG, RADIATION",Improvement in median Progression Free Survival using the combination of RT and durvalumab.,2017-07,2022-12,"University of Maryland, Baltimore",OTHER
NCT04103827,Qoos Use Sustaining Health Among patIents hOspitalized in Geriatric mediciNe (QUSHION),Usability Assessment of a Device to Promote Physical Activity for Old Patients Hospitalized,WITHDRAWN,no patient included after 6 month of enrollement,,OBSERVATIONAL,0,"Old Age, Usability, Satisfaction",,OTHER,"Usability of the device ""Le Qoos""",2019-09-16,2020-10-05,"University Hospital, Angers",OTHER_GOV
NCT00699842,A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients,A Phase I/II Optimal Dose Study of Lenalidomide in the Non-5q- LOW and INT-1 Risk MDS Patients,TERMINATED,Administratively terminated per FDA recommendation,"PHASE1, PHASE2",INTERVENTIONAL,8,"Myelodysplastic Syndrome, MDS, Low to Intermediate-1 MDS, Non-deletion 5q",Lenalidomide,DRUG,"Determine CR, PR, and Rate of Stable Disease in MDS Patients",2008-07,2012-05,Sidney Kimmel Cancer Center at Thomas Jefferson University,OTHER
NCT01842542,Efficacy and Safety Study of NeuroStar TMS Therapy in Patients With Major Depressive Disorder With Postpartum Onset,An Open-Label Study to Evaluate the Efficacy and Safety of the Neuronetics NeuroStar TMS Therapy System in Patients With Major Depressive Disorder (MDD) With Postpartum Onset.,TERMINATED,Slow enrollment,NA,INTERVENTIONAL,25,"Depression, Postpartum",,DEVICE,Mean Change in EPDS Score From Baseline to End of Acute (EOA) Treatment,2013-12,2015-08,Neuronetics,OTHER
NCT03160742,Pilot Study of a Non-Invasive Central Venous Pressure Monitoring System in Children,Pilot Study of a Non-Invasive Central Venous Pressure Monitoring System in Children,TERMINATED,Study device is incorrect size for pediatric patients,,OBSERVATIONAL,1,Central Venous Pressure,,DEVICE,Accuracy of Mespere VENUS 2000CVP,2018-04-25,2018-09-14,Boston Children's Hospital,OTHER
NCT05148442,"A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Myeloid Tumor","A Phase Ia/Ib Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Myeloid Tumor",TERMINATED,Due to the company's development strategy adjustment\],PHASE1,INTERVENTIONAL,1,Myeloid Tumor,IBI322,DRUG,Number of treatment related AEs,2021-12-28,2023-08-29,Innovent Biologics (Suzhou) Co. Ltd.,INDUSTRY
NCT03915886,A Study of JNJ-64530440 in Healthy Japanese Male Participants,"A Double-blind, Placebo-controlled, Randomized, Single Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-64530440 in Healthy Japanese Male Subjects",TERMINATED,Stopped due to a strategic decision.,PHASE1,INTERVENTIONAL,16,Healthy,"JNJ-0440, Placebo","DRUG, DRUG","Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability, Maximum Observed Plasma Analyte Concentration (Cmax) of JNJ-0440, Actual Sampling Time to Reach the Maximum Observed Plasma Analyte Concentration (Tmax) of JNJ-0440, Area Under the Plasma Concentration-time Curve from Time Zero to 24 Hours Postdose (AUC [0- 24h]) of JNJ-0440, Area Under the Plasma Concentration-time Curve from Time Zero to Last Quantifiable Concentration Time (AUC [0- Last]) of JNJ-0440, Area Under the Plasma Concentration-time Curve from Time Zero to Infinite Time (AUC [0-infinity]) of JNJ-0440, Apparent Terminal Elimination Rate Constant (Lambda[z]) of JNJ-0440, Apparent Terminal Elimination Half-Life (t1/2) of JNJ-0440, Apparent Volume of Distribution (Vdz/F), Apparent Total Clearance (CL/F), Amount of JNJ-0440 Excreted in Urine within the Time Interval x to y (Ae[x-y]), Cumulative Urinary Recovery (Ae[0-x]), Total Cumulative Urinary Recovery (Ae[total]), Percentage of JNJ-0440 Excreted in Urine (Ae%dose[0-x]), Percentage of JNJ-0440 Excreted in Urine (Ae%dose[total]), Renal Clearance (CLr) of JNJ-0440",2019-04-15,2019-07-17,Janssen Pharmaceutical K.K.,INDUSTRY
NCT04976686,Low Carbohydrate Small Intestine Study,Studying the Impact of a Low Carbohydrate Diet on the Small Intestinal Microbiota,TERMINATED,Halted after intervention group completed. Control group with only 3 participants,NA,INTERVENTIONAL,13,"Diet, Healthy",,OTHER,Assessment of microbiota profile by 16S sequencing before and after diet modification for significant differences,2021-11-17,2024-11-30,"Insel Gruppe AG, University Hospital Bern",OTHER
NCT00570908,Brain Mets - Capecitabine Plus Sunitinib and WBRT,"A Phase 2 Trial of Capecitabine Concomitantly With Whole Brain Radiotherapy(WBRT) Followed by Capecitabine and Sunitinib for Central Nervous System, (CNS) Metastases in Breast Cancer",TERMINATED,Due to poor accrual this study is being closed to accrual,PHASE2,INTERVENTIONAL,12,Breast Cancer,"sunitinib, capecitabine","DRUG, DRUG, RADIATION",Progression Free Survival,2009-02,2013-09,Baylor Breast Care Center,OTHER
NCT00243308,Serp-1 for the Treatment of Acute Coronary Syndrome,"A Phase 2, Multicentre, Double-Blind, Placebo-Controlled, Dose Escalating Trial of the Safety, Pharmacokinetics, and Biological Activity of 3 Consecutive Daily Doses of Serp-1 When Added to Conventional Therapy in Patients With Acute Coronary Syndromes (Non ST-Elevation Myocardial Infarction and/or Unstable Angina)",TERMINATED,Third dose group not recruited due to slow enrollment.,PHASE2,INTERVENTIONAL,72,"Unstable Angina, Coronary Atherosclerosis, Coronary Restenosis",Serine proteinase-1 (Serp-1),DRUG,Safety (Adverse events collected until 6 months post-dose),2005-10,2008-12,Viron Therapeutics Inc,INDUSTRY
NCT05053308,Proportional Dose of Sublingual Fentanyl Tablet Based on Daily Opioid Requirement,"Proportional Dose of Sublingual Fentanyl Tablet Based on Daily Opioid Requirement Versus Intravenous PCA for Breakthrough Cancer Pain: A Prospective, Randomized, Open Label, Non Inferiority Trial",WITHDRAWN,The supply of IP is disrupted,NA,INTERVENTIONAL,0,"Cancer Pain, Breakthrough Pain","Intravenous Infusion, Sublingual Tablet","DRUG, DRUG",Change in 11-point scale NRS pain score,2022-12-01,2023-12-31,Seoul National University,OTHER
NCT03872440,PDX Models From EGFR Mutant Tumors,ALCMI-012 A Prospective Biospecimen Collection Study From Patients With EGFR Mutant Tumors,WITHDRAWN,Did not meet the expected enrollment rate.,,OBSERVATIONAL,0,Non Small Cell Lung Cancer,,,The primary objective is to develop a unique cohort of PDX models from EGFR mutant cancers as a resource to the research community.,2018-11-14,2020-01-06,Addario Lung Cancer Medical Institute,OTHER
NCT00384150,Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL),"A Phase III, Open-Label, Multicenter, Single-Arm, Retreatment Study of Galiximab in Combination With Rituximab for Subjects With Relapsed, Follicular Non-Hodgkin's Lymphoma Who Previously Responded on Study 114-NH-301",TERMINATED,Enrollment challenges due to changes in standards of care resulted in premature termination. No safety or efficacy events factored into this action.,PHASE3,INTERVENTIONAL,16,"Lymphoma, Non-Hodgkin's",galiximab in combination with rituximab,DRUG,"Safety measures include: adverse event rates, clinical laboratory results, development of anti-galiximab and human anti-chimeric antibodies",2007-11,2010-01,Biogen,INDUSTRY
NCT03914989,Sensory Enrichment for Older Adults,Sensory Enrichment for Older Adults,TERMINATED,Unable to complete full enrollment due to Covid pandemic.,NA,INTERVENTIONAL,110,Cognitive Function,,OTHER,Evaluation of behavioral pattern separation ability,2019-03-08,2021-06-30,"University of California, Irvine",OTHER
NCT06113289,A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid Leukemia,A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid Leukemia,WITHDRAWN,PI Request,"PHASE1, PHASE2",INTERVENTIONAL,0,Acute Myeloid Leukemia,"ASTX727, ASTX029-01","DRUG, DRUG",Primary Outcome Measure,2024-02-08,2025-03-06,M.D. Anderson Cancer Center,OTHER
NCT03637491,"A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors","A PHASE 1B/2 STUDY TO EVALUATE SAFETY AND CLINICAL ACTIVITY OF COMBINATIONS OF AVELUMAB, BINIMETINIB AND TALAZOPARIB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC RAS-MUTANT SOLID TUMORS",TERMINATED,Available clinical data has shown limited anti-tumor activity and reaching target study drug dose levels may not be feasible.,"PHASE1, PHASE2",INTERVENTIONAL,36,Pancreatic Cancer,"Avelumab, Binimetinib, Talazoparib","DRUG, DRUG, DRUG","Number of Participants With Dose Limiting Toxicities (DLTs) During the Primary DLT Evaluation Period (Cycle 1) in Phase 1b, Phase 2: Confirmed Objective Response (OR) Based on Investigator Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.",2018-08-15,2021-02-02,Pfizer,INDUSTRY
NCT00626197,A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG),"A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of Ocrelizumab in Patients With WHO or ISN Class III or IV Nephritis Due to Systemic Lupus Erythematosus",TERMINATED,Study was terminated due to an imbalance of serious and opportunistic infections in the ocrelizumab treated patients versus the placebo arm.,PHASE3,INTERVENTIONAL,381,"Lupus Nephritis, Systemic Lupus Erythematosus","Corticosteroids, Cyclophosphamide, Mycophenolate Mofetil, Ocrelizumab, Placebo, Azathioprine","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Number of Participants Who Achieved Complete Renal Response (CRR), Percentage of Participants Who Achieved Overall Response",2008-02-15,2013-10-28,"Genentech, Inc.",INDUSTRY
NCT04495010,Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants,"A Phase 2, Randomized Study of Neoadjuvant Nivolumab Plus Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab Plus Ipilimumab Followed by Either Adjuvant Nivolumab or Postsurgical Observation Depending on Pathologic Response Compared With Adjuvant Nivolumab in Treatment-Naive Patients With Resectable Clinically Detectable Stage III Melanoma",WITHDRAWN,Business objectives have changed,PHASE2,INTERVENTIONAL,0,Melanoma,"Nivolumab, Ipilimumab","BIOLOGICAL, BIOLOGICAL",Event-free survival (EFS),2021-03-31,2027-10-23,Bristol-Myers Squibb,INDUSTRY
NCT01371110,Intravenous Ketamine in the Treatment of Obsessive-Compulsive Disorder,Intravenous Ketamine in the Treatment of Obsessive-Compulsive Disorder,TERMINATED,no funding,"PHASE1, PHASE2",INTERVENTIONAL,3,Obsessive Compulsive Disorder,"Ketamine, Midazolam","DRUG, DRUG",Change in Yale-Brown Obsessive Compulsive Scale (Y-BOCCS) Rating OCD Symptom Severity From Baseline to 24-hours After Ketamine Administration,2012-06,2015-06,Wayne Goodman MD,OTHER
NCT00765960,Evaluation of Outcomes Using the Amo Advanced CustomVue Ilasik Procedure,Evaluation of Outcomes Using the Amo Advanced CustomVue Ilasik Procedure,WITHDRAWN,Prinicipal Investigator separating employment from University.,,OBSERVATIONAL,0,"Myopia, Hyperopia",,,"Comparisons and statistical analysis will be done to determine if any statistical differences exist between preoperative and postoperative visits, and assess the efficacy, predictability and safety of the Advanced CustomVue™ iLASIK procedure.",2008-09,2009-10,Medical University of South Carolina,OTHER
NCT01633060,"A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi","A Phase III Randomized, Double Blind, Placebo Controlled Study of BKM120 With Fulvestrant, in Postmenopausal Women With Hormone Receptor-positive HER2-negative AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTOR Inhibitor Based Treatment",TERMINATED,"Novartis decided not to pursue further development of buparlisib program (assessment of moderate PFS benefit with know, but manageable, buparlisib profile).",PHASE3,INTERVENTIONAL,432,Metastatic Breast Cancer,"Fulvestrant, BKM120, BKM120 matching placebo","DRUG, DRUG, DRUG",Progression Free Survival (PFS) Based on Local Investigator Assessment - Full Analysis Set (FAS),2012-10-03,2017-09-21,Novartis Pharmaceuticals,INDUSTRY
NCT02198820,Practice Survey on Femoral Neck Fractures and the Incidence of Type of Anesthesia on Patient Outcome,Practice Survey on Femoral Neck Fractures and the Incidence of Type of Anesthesia on Patient Outcome in the Saint-Luc Bouge Hospital,WITHDRAWN,lack of investigators,,OBSERVATIONAL,0,Femoral Neck Fractures,"General Anesthesia, Loco Regional Anesthesia","DRUG, DRUG",Preoperative assessment,2014-10,2015-09,Astes,OTHER
NCT05252923,Endothelial Protection in Convalescent COVID-19 Patients,"Endothelial Protection in Convalescent COVID-19 Patients. The Effect of Sulodexide on Serum Levels of Biomarkers for Endothelial Dysfunction. A Pilot Prospective, Randomized, Open-label, Investigator-initiated Trial.",TERMINATED,Lack of the eligible patients,PHASE4,INTERVENTIONAL,2,"Endothelial Dysfunction, Inflammation, Thrombosis, COVID-19",Sulodexide,DRUG,Serum level of soluble Thrombomodulin,2022-04-01,2022-12-31,Pirogov Russian National Research Medical University,OTHER
NCT00637780,Study To Determine The Pharmacokinetics Of Sulfasalazine In Children With Juvenile Idiopathic Arthritis,An Open Label Non-randomized Study To Characterize The Steady State Pharmacokinetics Of Sulfasalazine Delayed Release Tablets In Children With Juvenile Idiopathic Arthritis,TERMINATED,Study terminated on 13 April 2016 for business reasons. No safety and/or efficacy concerns contributed to the termination of the study,PHASE4,INTERVENTIONAL,2,"Arthritis, Juvenile Rheumatoid",Sulfasalazine,DRUG,"Sulfasalazine Steady State Maximum Plasma Concentration (Cmax) and Predose Concentration (Cmin), Sulfasalazine Time for Cmax (Tmax) at Steady State, Sulfasalazine Area Under the Concentration-time Profile From Time 0 to Time Tau, the Dosing Interval (AUCtau) at Steady State, Sulfapyridine Steady State Cmax and Cmin, Sulfapyridine Tmax at Steady State, Sulfapyridine AUCtau at Steady State, 5-aminosalicylic Acid (5-ASA) Steady State Cmax and Cmin, 5-aminosalicylic Acid (5-ASA) Tmax at Steady State, 5-aminosalicylic Acid (5-ASA) AUCtau at Steady State",2010-06,2014-01,Pfizer,INDUSTRY
NCT03498196,A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer,A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer (BL-AIR: Bladder Cancer-Avelumab for Invasive Resectable Disease),TERMINATED,The sponsor of this study has terminated the study due to poor enrollment.,"PHASE1, PHASE2",INTERVENTIONAL,1,"Bladder Cancer, Metastatic Bladder Cancer, Invasive Bladder Cancer",Avelumab,DRUG,Change in T Cell Subpopulations,2018-12-14,2019-12-09,Baylor College of Medicine,OTHER
NCT05167396,REtinal and VIsual Cortical Response in Early PSYchosis,REtinal and VIsual Cortical Response in Early PSYchosis,TERMINATED,Malfunctions of the Retinaute® but no adverse effects on participants. Study interrupted for BioSerenity to make technical corrections. Long immobilization of the device and conditions for reusing it not adapted to the continuation of the study.,NA,INTERVENTIONAL,34,"Prodromal Schizophrenia, Psychotic Episode, Prodromal Symptoms, Healthy Controls",,"DEVICE, DEVICE, DEVICE","N95 wave, a wave, b wave, P100 wave",2022-01-26,2023-07-20,Centre Psychothérapique de Nancy,OTHER
NCT02428062,Target Hemodynamics and Brain Injury During General Anesthesia in the Elderly,Effect of Target Intraoperative Blood Pressure on the Incidence of Post-operative Cognitive Dysfunction in Patients Aged 75 and Older Undergoing General Anesthesia for Non-cardiac Surgery: an International Multicenter Randomized Controlled Trial,SUSPENDED,Pending Pilot study results evaluation,"PHASE2, PHASE3",INTERVENTIONAL,1812,Post-operative Cognitive Dysfunction,"Phenylephrine, Intravenous fluids, Ephedrine, Epinephrine, Norepinephrine, Dopamine","PROCEDURE, DRUG, DRUG, PROCEDURE, PROCEDURE, DRUG, DRUG, DRUG, DRUG",Post-operative cognitive dysfunction (POCD) at 3 months,2014-10,2019-12,"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico",OTHER
NCT00257946,Type of Material in Repair of Congenital Diaphragmatic Hernia,Prospective Randomized Trial Comparing Type of Material in Repair of Congenital Diaphragmatic Hernia,TERMINATED,poor accrual,PHASE3,INTERVENTIONAL,50,Congenital Diaphragmatic Hernia,,"PROCEDURE, PROCEDURE",Recurrence of Diaphragmatic Hernia,2005-12,2007-08,Children's Mercy Hospital Kansas City,OTHER
NCT03863288,Dose Response Relationship of Oxytocin on Irritability in Youths,Dose-Response Relationship and Pharmacokinetics of Intranasal Oxytocin on Neural Impact in Youth With High Levels of Irritability,TERMINATED,Per DSMB's recommendation,"PHASE1, PHASE2",INTERVENTIONAL,60,Irritable Mood,"Oxytocin Intranasal Spray 8 International Unit (8IU), Oxytocin intranasal spray 24 International Unit (24IU), Oxytocin intranasal spray 48 International Unit (48IU), Oxytocin intranasal spray 80 International Unit (80IU), Placebo","PROCEDURE, DRUG, DRUG, DRUG, DRUG, DRUG","Blood Oxygen Level Dependent (BOLD) response within rostro-medial prefrontal cortex ( rmPFC) region of interest to emotional stimuli during the Affective Stroop (AS) at approximately 50 minutes after intranasal administration of OXT., Plasma concentrations of OXT at 10, 20, 30, 40, and 50 minutes post intranasal OXT administration, and immediately post-fMRI scanning.",2022-02-18,2024-02-27,University of Nebraska,OTHER
NCT03159988,Angiotensin (1-7) Treatment to Improve Cognitive Functioning in Heart Failure Patients,Angiotensin (1-7) Treatment to Improve Cognitive Functioning in Heart Failure Patients,SUSPENDED,Study Suspended. Slow enrollment.,PHASE2,INTERVENTIONAL,6,"Chronic Heart Failure, Cognitive Impairment",Angiotensin-(1-7),"DRUG, BEHAVIORAL",Changes in performance on the Memory Intentions Test (MIST),2016-04,2026-06-01,University of Arizona,OTHER
NCT00215527,Intrathecal Enzyme Replacement Therapy for Spinal Cord Compression in Mucopolysaccharidosis (MPS) I,A Study of Intrathecal Enzyme Replacement Therapy for Spinal Cord Compression in Mucopolysaccharidosis I,TERMINATED,Due to slow enrolment.,PHASE1,INTERVENTIONAL,4,"Mucopolysaccharidosis I, Lysosomal Storage Diseases, Spinal Cord Compression",laronidase,DRUG,safety of intrathecal enzyme treatment by blood and spinal fluid tests each month,2005-11,2011-10,"Patricia I. Dickson, M.D.",INDIV
NCT02255461,"Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors","Phase I Study of CDK 4-6 Inhibitor PD-0332991 (Palbociclib; IBRANCE) in Children With Recurrent, Progressive or Refractory Central Nervous System Tumors",TERMINATED,Data for the primary objectives is complete and the MTD identified in Stratum II.,PHASE1,INTERVENTIONAL,35,"Childhood Choroid Plexus Tumor, Childhood Ependymoblastoma, Childhood Grade III Meningioma, Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Childhood Medulloepithelioma, Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Anaplastic Oligoastrocytoma, Recurrent Childhood Anaplastic Oligodendroglioma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Giant Cell Glioblastoma, Recurrent Childhood Glioblastoma, Recurrent Childhood Gliomatosis Cerebri, Recurrent Childhood Gliosarcoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor",palbociclib isethionate,"DRUG, OTHER, OTHER","Maximum Tolerated Dose (MTD) of Palbociclib in Stratum I, Maximum Tolerated Dose (MTD) of Palbociclib in Stratum II, Number of Patients Who Experienced Dose Limiting Toxicities (DLTs), Single Dose Apparent Volume of Central Compartment (Vc/F), Single Dose Elimination Rate Constant (Ke), Single Dose Half-life (t1/2), Single Dose Apparent Oral Clearance (CL/F), Single Dose Area Under the Plasma Concentration Time Curve (AUC), Steady State Apparent Volume of Central Compartment (Vc/F), Steady State Elimination Rate Constant (Ke), Steady State Half-life (t1/2), Steady State Apparent Oral Clearance (CL/F), Steady State Area Under the Plasma Concentration Time Curve (AUC)",2014-12-08,2019-02-25,Pediatric Brain Tumor Consortium,NETWORK
NCT04388761,Feasibility and Safety of Allogeneic Adipose Mesenchymal Stem Cells (aMSCs) Delivery Into Kidney Allografts Procured From Deceased Donors With High Kidney Donor Profile Index (KDPI),Feasibility and Safety of Allogeneic Adipose Mesenchymal Stem Cells (aMSCs) Delivery Into Kidney Allografts Procured From Deceased Donors With High Kidney Donor Profile Index (KDPI),WITHDRAWN,Challenges in recruiting participants.,PHASE1,INTERVENTIONAL,0,Ischemia Reperfusion Injury,Allogeneic adipose derived mesenchymal stem cells,DRUG,Serious Adverse Events (SAEs),2020-09,2024-02,Tambi Jarmi,OTHER
NCT05672342,Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors,A Pilot Study to Evaluate the Benefits of Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy,WITHDRAWN,withdrawn,EARLY_PHASE1,INTERVENTIONAL,0,"Breast Carcinoma, Chemotherapy-Induced Peripheral Neuropathy, Colon Carcinoma","Cannabidiol, Delta-8-Tetrahydrocannabinol, Placebo Administration","DRUG, DRUG, DRUG, OTHER",Difference in Functional Assessment of Cancer Therapy/Gynecologic Oncology Group (FACT/GOG)-Neurotoxicity (Ntx) subscale scores,2024-07-06,2025-10-31,City of Hope Medical Center,OTHER
NCT06586086,The Effect of Anxiety on Pain-pressure Threshold in a Healthy Population,The Effect of Anxiety on Pain-pressure Threshold in a Healthy Population,SUSPENDED,On hold pending challenges in scheduling for PI,,OBSERVATIONAL,60,Healthy,,,Pain-Pressure Threshold,2024-10-29,2026-10-01,Philadelphia College of Osteopathic Medicine,OTHER
NCT01583686,CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer,Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-mesothelin Gene Engineered Lymphocytes,TERMINATED,Study terminated due to slow/insufficient accrual.,"PHASE1, PHASE2",INTERVENTIONAL,15,"Cervical Cancer, Pancreatic Cancer, Ovarian Cancer, Mesothelioma, Lung Cancer","Fludarabine, Anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL), Cyclophosphamide, Aldesleukin","DRUG, BIOLOGICAL, DRUG, DRUG","Number of Patients With Objective Tumor Regression, Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0)",2012-05-04,2018-12-17,National Cancer Institute (NCI),NIH
NCT02667535,"PK, PD and Safety Comparative Trial of Isosorbide Mononitrate Gel in Healthy Participants and With Anal Fissure","Pharmacokinetics, Pharmacodynamics and Safety Comparative Trial of Isosorbide Mononitrate Gel in Participants With Anal Fissure and Healthy Volunteers.",WITHDRAWN,Study has been cancelled and it has not been initiated.,PHASE1,INTERVENTIONAL,0,Anal Fissure,Isosorbide Mononitrate,DRUG,"Pharmacokinetics, area under the curve time zero - last (AUC t0-last), Pharmacokinetics, area under the curve time zero - infinite (AUC t0-inf), Pharmacokinetics, constant of elimination (Ke), Pharmacokinetics, half-life (t1/2)",2017-07,2017-11,Biolab Sanus Farmaceutica,INDUSTRY
NCT03812835,A Study of Adverse Events and Suspected Adverse Drug Reactions of Patients Under Treatment of Apixaban for Venous Thomboembolism (VTE) Treatment,A PHASE IV NON-INTERVENTIONAL STUDY. REGISTRY OF ADVERSE EVENTS (AES)/SUSPECTED ADVERSE DRUG REACTIONS (SADRS) OF ADULT PATIENTS UNDER TREATMENT OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM (PE); PREVENTION OF RECURRENT DVT AND PE WITH ELICUIS REGISTERED (APIXABAN),WITHDRAWN,Company decision to not conduct study and was cancelled prior to any enrollment.,,OBSERVATIONAL,0,"Thrombosis, Deep Vein, Pulmonary Embolism",,,"The number, type and incidence of adverse events/suspected adverse drug reactions in patients treated with apixaban, according to therapeutic indications approved in Mexico.",2021-08-23,2023-08-23,Pfizer,INDUSTRY
NCT02357225,A Pilot Study of Pyridostigmine in Pompe Disease,Evaluation of Respiratory and Skeletal Muscle Functions in Response to Acetylcholinesterase Inhibitors in Pompe Disease,TERMINATED,The drug was ineffective in improving function in Pompe's disease,EARLY_PHASE1,INTERVENTIONAL,2,Pompe Disease,Pyridostigmine Bromide,DRUG,"Change in skeletal muscle function (6 Minute Walk Test)(QMT), Change in respiratory function (maximal inspiratory pressure, maximal expiratory pressure, and vital capacity), Change in quality of life [short form 36 (SF-36)], Evaluate the acute effects of pyridostigmine on neuromuscular junction transmission (Single-fiber EMG)",2015-08,2018-01-01,University of Florida,OTHER
NCT04844008,Do Nanobubbles Improve Joint Hypoxia?,An Investigation of Whether Orally Delivered Nanobubbles Have a Physiological Effect on Joint Hypoxia?,WITHDRAWN,Changes in treatment pathway made recruitment unfeasible,NA,INTERVENTIONAL,0,"Rheumatoid Arthritis, Psoriatic Arthritis",,DIETARY_SUPPLEMENT,Change in Synovial fluid pO2,2021-10-05,2022-05-17,University of Oxford,OTHER
NCT03465540,"Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies","A Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies",TERMINATED,Strategic decisions,PHASE1,INTERVENTIONAL,24,"Multiple Myeloma, Acute Myeloid Leukemia, Non-Hodgkins Lymphoma, Myelodysplastic Syndrome, AML, MDS, NHL","AMG 397, Dexamethasone, Azacitidine","DRUG, DRUG, DRUG","Number of Participants Who Experienced a Dose-limiting Toxicity (DLT), Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)",2018-08-17,2019-07-25,Amgen,INDUSTRY
NCT04200989,Novel Treatment for Patients With Peanut Allergy: Intralymphatic Immunotherapy,Intra-lymphatic Immunotherapy for the Management of Peanut Allergy,WITHDRAWN,Lack of funding,"PHASE1, PHASE2",INTERVENTIONAL,0,Food Allergy Peanut,Peanut allergen,BIOLOGICAL,Peanut tolerance,2021-03-01,2021-12-31,Scripps Health,OTHER
NCT04837989,Effectiveness of the Diabetes Body Project Among Females With Type 1 Diabetes,Diabetes Body Project: Effectiveness of a Virtually Delivered Eating Disorder Prevention Program Among Young Females With Type 1 Diabetes,TERMINATED,Data will be written up as a pilot RCT study and experiences and results will inform the start of a multi-site trial,NA,INTERVENTIONAL,58,"Feeding and Eating Disorders, Diabetes Mellitus, Type 1, Body Image",,"BEHAVIORAL, BEHAVIORAL","The Ideal-Body Stereotype Scale-Revised (IBSS-R), The Body Parts Scale, Dietary restraint, The Diabetes Eating Problem Survey - Revised, Social attitudes towards appearance questionnaire (SATAQ) 4R, Social Comparison Scale",2021-02-01,2022-07-31,Oslo University Hospital,OTHER
NCT02686489,Humidity Therapy for Spontaneously Breathing Tracheostomy Patients,Large Volume Nebulizers Versus Heated Humidity in Spontaneously Breathing Tracheostomy Patients,TERMINATED,Unable to enroll enough subjects to answer the research questions,NA,INTERVENTIONAL,8,Respiratory Failure,,"OTHER, OTHER",Clinical pulmonary infection score (CPIS),2017-03-24,2018-08-11,Rush University Medical Center,OTHER
NCT05879718,A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.,"A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE CLINICAL EFFECT, PHARMACODYNAMIC, PHARMACOKINETIC AND SAFETY PROFILE OF PF 06823859 IN ADULT PARTICIPANTS WITH ACTIVE CLE OR SLE WITH CUTANEOUS MANIFESTATIONS",TERMINATED,Pfizer has made an internal business decision to not continue this study. This decision was not due to safety concerns or clinical effect reasons or requests from any regulatory authorities.,PHASE2,INTERVENTIONAL,8,"Lupus Erythematosus, Systemic, Lupus Erythematosus, Cutaneous","Placebo, PF-06823859","DRUG, DRUG",Change from baseline in type 1 IFN GS score in lesional skin at Week 12,2023-07-07,2025-11-18,Pfizer,INDUSTRY
NCT05216510,Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens,"A Dose Finding Study for the Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens in Uninfected Healthy Subjects, COVID-19 Convalescent Subjects, and COVID-19 Vaccinated Subjects",TERMINATED,Lack of efficacy,PHASE1,INTERVENTIONAL,9,Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2,"TNX-2110, TNX-2120, TNX-2130, CANDIN, Diluent","BIOLOGICAL, BIOLOGICAL, BIOLOGICAL, BIOLOGICAL, BIOLOGICAL",Assessment of Delayed-type Hypersensitivity Reactions,2022-01-07,2022-09-17,"Tonix Pharmaceuticals, Inc.",INDUSTRY
NCT04169360,Safety and Preliminary Efficacy of ANS-6637 to Reduce Drug Craving and Harm in People With Opioid Use Disorder,Safety and Preliminary Efficacy of ANS-6637 to Reduce Drug Craving and Harm in People With Opioid Use Disorder,WITHDRAWN,"The FDA determined that there is not adequate safety information to continue clinical investigations using ANS-6637 and Amygdala Neurosciences, the product company of ANS-6637, is no longer pursuing research with this compound.",PHASE2,INTERVENTIONAL,0,Opioid-use Disorder,"ANS-6637, Placebo oral tablet","DRUG, DRUG","Number of Grade 3-4 events, Grade 2 Significant event",2021-01,2021-01-12,"University of Maryland, Baltimore",OTHER
NCT00849524,"Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)",A Phase II Study of Repeat Intranodal Injections of Adenovirus-CD 154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma,TERMINATED,drug supply became unavailable,PHASE2,INTERVENTIONAL,6,"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma",ISF35,BIOLOGICAL,Determine and Monitor Clinical and Biological Responses in Patients Treated With Repeat Intranodal Injections of Ad-ISF35.,2009-01,2014-07,"Januario Castro, M.D.",OTHER
NCT02035124,Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel,Cabazitaxel With BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer Following Treatment With Docetaxel: Phase II Study With Safety Lead-in Cohort,WITHDRAWN,Study withdrawn due to slow accrual. No patients were enrolled.,PHASE2,INTERVENTIONAL,0,Advanced Prostate Cancer,"BKM 120, Cabazitaxel","DRUG, DRUG","Number of Subjects with Serious and Non-Serious Adverse Events, Progression Free Survival (PFS)",2014-04,2015-01,"SCRI Development Innovations, LLC",OTHER
NCT01352923,Study of Polymorphisms in pear1 Gene Link to Platelet Activation and Signaling Pathway Variations,Study of Polymorphisms in pear1 Gene Link to Platelet Activation and Signaling Pathway Variations,WITHDRAWN,no resources,,OBSERVATIONAL,0,Platelet Function,,OTHER,,2011-05,2012-05,Universitaire Ziekenhuizen KU Leuven,OTHER
NCT02482623,The Dementia Symptom Management at Home Program,The Dementia Symptom Management at Home Program: A Bundled Interprofessional Intervention to Improve Dementia Patient-Caregiver Dyad Quality of Care and Quality of Life Through Home Healthcare.,WITHDRAWN,Loss of study site,NA,INTERVENTIONAL,0,Dementia,,BEHAVIORAL,"Person With Dementia Quality of Life, Caregiver Quality of Life",2017-08-01,2018-03-01,New York University,OTHER
NCT05606159,Bacillus Velezensis DSM 33864 for Reduction of the Risk of Recurrent Clostridioides Difficile Infections,"A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Tolerability and Effect of Bacillus Velezensis DSM 33864 on the Reduction of Risk of Recurrent Clostridioides Difficile Infection (rCDI) in Adults With a History of rCDI",WITHDRAWN,Research Project closed,NA,INTERVENTIONAL,0,Clostridium Difficile Infection Recurrence,,"DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",C. difficile colonization,2023-11,2024-12,Novozymes A/S,INDUSTRY
NCT02867280,Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection,A Prospective Multicenter Non-randomized Controlled Study of Sorafenib (Nexavar) Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection,TERMINATED,Midterm analysis showed negative results.,PHASE3,INTERVENTIONAL,154,"Hepatocellular Carcinoma, Recurrence",Sorafenib,DRUG,Recurrence free survival,2016-06-01,2020-01-31,Sun Yat-sen University,OTHER
NCT00083980,Kava Kava for the Treatment of Generalized Anxiety Disorder (GAD),KAVA KAVA in Generalized Anxiety: A Double-Blind Trial,TERMINATED,European reports of liver toxicity from kava meant that the study had to stop,PHASE2,INTERVENTIONAL,16,Anxiety Disorders,"Venlafaxine ER, Sugar pill, Kava","DRUG, DRUG, DRUG",Hamilton Anxiety Scale,2002-06,2004-08,National Center for Complementary and Integrative Health (NCCIH),NIH
NCT00311896,Efficacy & Safety of Prophylaxis With Bemiparin in Cancer Patients With a Central Venous Catheter (BECAT),"Multicentric, Randomized, Placebo Controlled and Double-blind Study to Evaluate the Efficacy and Safety of Antithrombotic Prophylaxis With Bemiparin (3,500 UI/Day) in Cancer Patients With a Central Venous Catheter (CVC)(BECAT)",TERMINATED,Sponsor stopped due to difficulties to recruit 402 patients required by protocol,PHASE3,INTERVENTIONAL,402,"Cancer, Thrombosis","Bemiparin, Placebo","DRUG, DRUG","Clinical or symptomatic CVC-DVT verified objectively (Doppler ultrasonography or phlebography)., Subclinical or asymptomatic CVC-DVT confirmed by elective bilateral Doppler ultrasonography performed 45±5 days after randomization.",2005-07,2010-12,"Clinica Universidad de Navarra, Universidad de Navarra",OTHER
NCT00926627,Safety and Efficacy Study of Bosentan in Progressive Pulmonary Sarcoidosis,"A Prospective Randomized, Double Blind, Placebo-controlled, Safety and Efficacy Study of Bosentan as add-on Therapy in Progressive Pulmonary Sarcoidosis",TERMINATED,Not enough patients with the specified criteria could not,PHASE2,INTERVENTIONAL,32,"Sarcoidosis, Pulmonary Hypertension","bosentan, placebo","DRUG, DRUG","Treatment efficacy is assessed by a composite clinical score, including six parameters: Pulmonary function test (FVC and DLCO), Blood gas analysis (AaDO2), HRCT (Oberstein score), 6 minute walk test (6-MWD), Dyspnoea (ATS dyspnea scale)",2009-04,2010-03,Daniel Doberer,OTHER
NCT03845127,Randomized Evaluation and Verification of Ventricular Enhancement,Randomized Evaluation and Verification of Ventricular Enhancement: The REVIVE-HF Study,WITHDRAWN,Lack of enrollment,NA,INTERVENTIONAL,0,"Ischemic Cardiomyopathy, Heart Failure",GDMT,"DEVICE, DRUG",6 Minute Walking Distance,2020-01-01,2024-12-31,BioVentrix,INDUSTRY
NCT04756427,Sodium Citrate 4% Locking Solution for Children Requiring Home Parenteral Nutrition,Sodium Citrate 4% Locking Solution for Children Requiring Home Parenteral Nutrition,TERMINATED,Subject recruitment was challenging,PHASE4,INTERVENTIONAL,1,CLABSI - Central Line Associated Bloodstream Infection,Sodium Citrate 4% Inj Syringe 3Ml,DRUG,Central Line-associated Bloodstream Infection (CLABSI) Rate,2022-03-28,2023-11-28,Johns Hopkins University,OTHER
NCT00578188,Chlamydia Trachomatis Persistence in the Female Gastrointestinal Tract,Chlamydia Trachomatis Persistence in the Female Gastrointestinal Tract,WITHDRAWN,Study redesigned and re-submitted to UAMS IRB under different study title and IRB number.,,OBSERVATIONAL,0,Chlamydia Infection,,,,2006-02,2008-01,Arkansas Children's Hospital Research Institute,OTHER
NCT01723488,"A Phase 0, Open Label, Multi-Center, Exploratory and Safety Study of [F-18]T808","A Phase 0, Open Label, Non-Randomized, Multi-Center, Exploratory and Safety Study of [F-18]T808",TERMINATED,Study was terminated in anticipation of transfer of ownership to Avid Radiopharmaceuticals.,EARLY_PHASE1,INTERVENTIONAL,12,Alzheimers Disease,,RADIATION,To monitor and assess the safety of IV administration of [F-18]T808,2012-07,2013-03,Avid Radiopharmaceuticals,INDUSTRY
NCT04496986,Dysphagia in Cardiac Surgical Patients_,"Mechanisms, Predictors and Clinical Markers of Dysphagia in Cardiac Surgical Patients",WITHDRAWN,This study was replaced by a new study given recent funding by the NIH.,,OBSERVATIONAL,0,Cardiovascular Diseases,,"DIAGNOSTIC_TEST, DIAGNOSTIC_TEST, OTHER, OTHER, OTHER, DIAGNOSTIC_TEST","Penetration Aspiration Scale, Penetration Aspiration Scale",2022-05,2026-12-31,University of Florida,OTHER
NCT00954486,Erythropoietin Alfa in Elderly Subjects With Unexplained Anemia,"An Open-Label, Single-Arm Pilot Study of the Efficacy of Erythropoietin Alfa in Improving Peak Oxygen Consumption in Elderly Subjects With Unexplained Anemia",WITHDRAWN,Difficulty in identifying interested subjects.,NA,INTERVENTIONAL,0,Anemia,Epoetin alfa,DRUG,Change in hemoglobin (Hb) levels,2008-12,2011-02,Stanford University,OTHER
NCT00981370,Clinical Importance of Treating Iron Overload in Sickle Cell Disease,Clinical Importance of Treating Iron Overload in Sickle Cell Disease,TERMINATED,"1 consented patient never started on study drug, lost to follow up",PHASE3,INTERVENTIONAL,1,"Anemia, Sickle Cell, Transfusion Hemosiderosis",deferasirox,DRUG,"To Determine if Red Cell Survival as Assessed by Hemoglobin Level, Reticulocyte Count, Lactic Acid Dehydrogenase, and Plasma Hemoglobin in Sickle Cell Patients is Related to the Degree of Iron Overload",2009-04,2010-12,Children's Hospital Los Angeles,OTHER
NCT02950935,Progesterone in Threatened Abortion,"Prospective, Double-blind, Randomised, Placebo Controlled, Phase III Clinical Study Assessing the Efficacy of Natural Progesterone 25 mg/Bid Administered Subcutaneously in the Maintenance of Early Pregnancy in Women With Symptoms of Threatened Abortion",TERMINATED,Difficulty in recruitment,PHASE3,INTERVENTIONAL,4,Threatened Abortion in First Trimester,"Progesterone, Placebo","DRUG, DRUG",Ongoing pregnancy rate at 12 weeks of gestation,2017-04-04,2018-05-02,IBSA Institut Biochimique SA,INDUSTRY
NCT01886625,Single-port Thoracoscopic Sympathicotomy in Complex Regional Pain Syndrome Type I (CRPS),"Single-port Thoracoscopic Sympathicotomy for Treatment of Complex Regional Pain Syndrome Type I, a Feasibility Study.",WITHDRAWN,No local inclusions,NA,INTERVENTIONAL,0,Complex Regional Pain Syndrome Type I of the Upper Limb,,PROCEDURE,Change in perceived pain measured in Visual Analogue Scale,2015-08,2017-02,University of Groningen,OTHER
NCT05584540,UNTIRE: Cancer-related Fatigue With Digital Treatment,The UNTIRE App Trial: The Feasibility of Using the Untire App for the Colorectal Cancer Patient to Manage Their Cancer Related Fatigue,WITHDRAWN,loss of funding,NA,INTERVENTIONAL,0,"Colorectal Cancer, Fatigue",,BEHAVIORAL,Enrollment Rate,2025-01-30,2026-01-30,Dana-Farber Cancer Institute,OTHER
NCT04374474,Anosmia Rehabilitation in Patients Post Coronavirus Disease (COVID 19),Olfactory Retraining Therapy and Budesonide Nasal Rinse for Anosmia Treatment in Patients Post-CoVID 19. A Randomized Controlled Trial,WITHDRAWN,Study withdrawn before any enrollment (site's research goals adjustments).,PHASE4,INTERVENTIONAL,0,Olfactory Disorder,corticosteroid nasal irrigation,"OTHER, DRUG, OTHER, OTHER","Change from Baseline Snap and Sniff Threshold Test at 3 months, Change from baseline Smell Identification Test (SIT) at 3 months, Change from Baseline Snap and Sniff Threshold Test at 6 months, Change from baseline Smell Identification Test (SIT) at 6 months",2021-01-10,2022-03-10,London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's,OTHER
NCT02907918,Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer,A Phase II Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab as Neoadjuvant Treatment of Stage II-III ER+ HER2+ Breast Cancer (PALTAN),TERMINATED,Futility,PHASE2,INTERVENTIONAL,26,"Breast Cancer, Cancer of Breast, Breast Carcinoma","Palbociclib, Letrozole, Trastuzumab, Goserelin","DRUG, DRUG, BIOLOGICAL, DRUG, PROCEDURE, PROCEDURE, PROCEDURE, PROCEDURE, GENETIC, PROCEDURE",Number of Participants With Pathologic Complete Response (pCR),2017-06-30,2020-09-23,Washington University School of Medicine,OTHER
NCT02777190,A Comparison of Oral Misoprostol and Vaginal Misoprostol for Cervical Ripening and Induction of Labor,A Comparison of Oral Misoprostol and Vaginal Misoprostol for Cervical Ripening and Induction of Labor,TERMINATED,Insufficient research staff to recruit and complete study,PHASE4,INTERVENTIONAL,34,"Labor; Forced or Induced, Affecting Fetus or Newborn, Pregnancy",Misoprostol,DRUG,Time to Active Labor,2017-11-01,2019-04-23,Milton S. Hershey Medical Center,OTHER
NCT02910297,The Pharmacokinetics of Cannabidiol (CBD) and Its Effects in Children With Severe Epilepsy,The Pharmacokinetics of Cannabidiol (CBD) and Its Effects in Children With Severe Epilepsy,WITHDRAWN,unable to recruit enough subjects on CBD,,OBSERVATIONAL,0,"Dravet Syndrome, Lennox Gastaut Syndrome",,,Reduction in seizures,2016-09,2017-12-31,Gillette Children's Specialty Healthcare,OTHER
NCT02247960,Antibiotic Prophylaxis for Urinary Catheter Removal After Radical Prostatectomy,Antibiotic Prophylaxis for Urinary Catheter Removal After Radical Prostatectomy,TERMINATED,Interim analysis determined that the study should be concluded for futility.,NA,INTERVENTIONAL,175,"Prostate Cancer, Urinary Tract Infection, Clostridium Difficile",Ciprofloxacin,DRUG,Number of Participants With a Positive Urinary Tract Infection,2014-07,2016-05,University of Rochester,OTHER
NCT03085420,Cardiac Arrhythmias and Dysfunction in the Pediatric Burn Patient,Cardiac Arrhythmias and Dysfunction in the Pediatric Burn Patient,TERMINATED,Participating site withdrew prior to any enrollment and lead site with slow enrollment. Not expected to meet enrollment goals.,NA,INTERVENTIONAL,10,Cardiac Dysfunction,,DIAGNOSTIC_TEST,Frequency of cardiac dysfunction in pediatric burn patients,2017-05-03,2018-10-21,Shriners Hospitals for Children,OTHER
NCT01952860,Hatha Yoga in Lung Cancer Couples,A Feasibility Study of Hatha Yoga in Couples Coping With Lung Cancer,TERMINATED,Requested by PI during yearly Continuing Review,NA,INTERVENTIONAL,30,Lung Cancer,,"OTHER, BEHAVIORAL","Feasibility of Yoga Program in Lung Cancer Participants Receiving Radiation determined by attendance, Feasibility of Yoga Program in Lung Cancer Participants Receiving Radiation determined by questionnaire responses.",2013-09-23,2019-09-17,M.D. Anderson Cancer Center,OTHER
NCT02660359,Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2,"A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis",TERMINATED,Slow recruitment of patients,PHASE3,INTERVENTIONAL,258,"Urinary Incontinence, Overactive Bladder","Botulinum toxin type A, Botulinum toxin type A, Placebo, Placebo","BIOLOGICAL, BIOLOGICAL, DRUG, DRUG",Mean Change From Baseline in Weekly Number of UI Episodes at Week 6 of DBPC Cycle,2016-07-08,2019-07-04,Ipsen,INDUSTRY
NCT02827279,Study of the Visual Perception During Emotional States on Subjects With an Intrusive Disorder of the Development,Study of the Strategies of Visual Perception of Social Scenes During Emotional States Induced to Subjects With an Intrusive Disorder of the Development: Pilot Study,TERMINATED,end of inclusion period,NA,INTERVENTIONAL,46,Autism Spectrum Disorder,,OTHER,Ratio corresponding to the relative change in visual orientation,2013-03-04,2017-04-03,"University Hospital, Montpellier",OTHER
NCT05068479,Safety & Efficacy of the Laser Scleral Microporation Procedure,Evaluation of the Safety & Efficacy of the Laser Scleral Microporation Procedure to Restore Visual Function and Range of Accommodation,TERMINATED,Study terminated early to pursue Gen II laser advancements,NA,INTERVENTIONAL,38,Presbyopia,,DEVICE,Binocular Uncorrected Near Visual Acuity (UNVA) @40cm,2021-04-29,2023-03-29,"ACE Vision Group, Inc.",INDUSTRY
NCT04844346,Plant Stanol Esters and COVID-19 Vaccination Response,The Effect of Plant Stanol Ester Consumption on the Vaccination Response to a COVID-19 Vaccine,TERMINATED,Recruitment was dependent on finding participants that had to receive an initial COVID-19 vaccination and we were unable to find new participants anymore.,NA,INTERVENTIONAL,48,Overweight and Obesity,COVID-19 vaccine,"DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, BIOLOGICAL",Vaccine specific antibody titers,2021-04-22,2022-01-11,Maastricht University Medical Center,OTHER
NCT00034788,A Study on the Efficacy and Safety of Long-Term Treatment and Re-Treatment of Lower Extremity Diabetic Ulcers With REGRANEX,A Multicenter Clinical Evaluation of the Efficacy and Safety of REGRANEX Gel in the Long-Term Treatment and Re-Treatment of Lower Extremity Diabetic Ulcers,TERMINATED,Slow recruitment; Study did not address safety concern raised by European Medicines Agency,PHASE3,INTERVENTIONAL,84,"Foot Ulcer, Diabetic Foot, Skin Ulcer, Diabetic Neuropathies",Becaplermin,DRUG,Time to complete ulcer healing.,2000-12,2004-02,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INDUSTRY
NCT03264742,Ghrelintrial With Patients With Stroke,Longitudinal Trial to Investigate a Neuroprotective Effect of Ghrelin After Acute Ischemic Stroke,TERMINATED,recruitment too low,,OBSERVATIONAL,6,"DEMMMI, Nine-Hole-PEG-Test, mRS, Stroke, Acute",,OTHER,De Morton Mobility Index (DEMMI),2017-04-01,2019-02-28,Kantonsspital Winterthur KSW,OTHER
NCT00768742,Safety and Effectiveness Study of RF Ablation of Uterine Fibroids to Reduce Menstrual Bleeding: the Fibroid Ablation Study,Clinical Study to Assess the Safety and Effectiveness of VizAblate(tm) Intrauterine Ultrasound-guided RF Ablation (IUUSgRFA) of Submucosal and Intramural Uterine Fibroids on the Reduction of Pictorial Blood Loss Assessment Scores,WITHDRAWN,study revised and reinitiated under another protocol,NA,INTERVENTIONAL,0,"Leiomyoma, Uterine Fibroids, Menorrhagia",,DEVICE,Menstrual bleeding as measured by the Pictorial Blood Loss Assessment Chart (PBLAC),2008-09,2010-11,Gynesonics,INDUSTRY
NCT02920242,A Study Comparing Two Rifaximin Tablets in Patients With Travelers' Diarrhea.,"A Randomized, Double-blind, Parallel Group, Placebo-controlled, Multi-center, Therapeutic Equivalence Study to Compare Rifaximin 200 mg Tablets (Sandoz GmbH) to Xifaxan® 200 mg Tablets (Salix Pharmaceuticals, Inc.) and Placebo in Patients With Travelers' Diarrhea",TERMINATED,Terminated due to low enrollment,PHASE3,INTERVENTIONAL,28,Travelers' Diarrhea,"Rifaximin (Sandoz GmbH) tablet, Rifaximin (Xifaxan), Placebo","DRUG, DRUG, DRUG",Clinical Cure Rate,2016-12-15,2017-05-23,Sandoz,INDUSTRY
NCT04296942,"BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)","A Phase 1b Trial of Sequential Combinations of BN-Brachyury, Entinostat, Ado-trastuzuamb Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)",TERMINATED,"One participant was accrued, and the study was stopped due to new safety data from the company for M7824 and slow accrual.",PHASE1,INTERVENTIONAL,1,"Breast Cancer, Triple Negative Breast Cancer, HER2+ Breast Cancer, Hormone Receptor Negative Breast Cancer, Metastatic Breast Cancer","Brachyury-TRICOM, Entinostat, M7824, Ado-trastuzumab emtansine","BIOLOGICAL, DRUG, BIOLOGICAL, BIOLOGICAL","Overall Response (Partial Response + Complete Response) for Participants With Triple Negative Breast Cancer (TNBC), Overall Response (Partial Response + Complete Response) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2) + Breast Cancer (BC), Number of Participants Experiencing at Least One Grade 3 to 5 Adverse Events for Each of the Three Combinations of Agents",2021-05-04,2021-10-22,National Cancer Institute (NCI),NIH
NCT05607342,Pilot of Osanetant to Reduce Testosterone in Men With Adenocarcinoma of the Prostate,Pilot of Osanetant to Reduce Testosterone in Men With Adenocarcinoma of the Prostate (PORT-MAP),TERMINATED,Development of the drug program has been discontinued,EARLY_PHASE1,INTERVENTIONAL,1,Prostate Adenocarcinoma,Osanetant,DRUG,To evaluate the effect of Osanetant on the testosterone levels.,2023-01-03,2023-11-06,University of Kansas Medical Center,OTHER
NCT03949842,Legend: TRELEGY Real World Chronic Obstructive Pulmonary Disease (COPD) Effectiveness Study,A Comparison of the Clinical Effectiveness of Inhaled Triple Therapy (Fluticasone Furoate / Umeclidinium Bromide / Vilanterol) in a Single Inhaler (TRELEGY™ ELLIPTA™) With Inhaled Non-ELLIPTA™ Multiple Inhaler Triple Therapies in COPD Patients in the US Within a Usual Care Setting in a Prospective Pre-Post Study,WITHDRAWN,The decision to end the study was based on a change in GSK strategy. No subjects were enrolled into the study.,PHASE4,INTERVENTIONAL,0,"Pulmonary Disease, Chronic Obstructive","Inhaled corticosteroids/long-acting beta2-adrenergic/long-acting muscarinic receptor antagonists, Fluticasone furoate/umeclidinium/vilanterol","DRUG, DRUG","Annualized rate of moderate, severe COPD exacerbations",2019-06-27,2022-11-30,GlaxoSmithKline,INDUSTRY
NCT01123161,The Intravascular Cooling in the Treatment of Stroke 2/3 Trial,Phase 2/3 Study of Intravenous Thrombolysis and Hypothermia for Acute Treatment of Ischemic Stroke,TERMINATED,The ICTuS 2 portion of the trial has been halted and data will be analyzed.,"PHASE2, PHASE3",INTERVENTIONAL,120,"Stroke, Acute",Group1: IV t-PA and normothermia,"DEVICE, DRUG","The Primary Outcome is the Proportion of Patients Achieving a Favorable Outcome Defined as Modified Rankin Scale Score of 0 or 1, Assessed 90 Days After Treatment., Incidence of Any Intracranial Hemorrhage (ICH) Within 48 Hours of Stroke Onset, Incidence of Any Symptomatic Intracranial Hemorrhage (sICH) Within 48 Hours of Stroke Onset, Incidence of Pneumonia, 90 Day Mortality",2010-06,2015-05,"University of California, San Diego",OTHER
NCT00297635,Telemetric Glucose Data Acquisition During Initiation of Insulin Pump Therapy,,WITHDRAWN,Decided not to participate in study per Leslie Padron-Massaro,PHASE2,INTERVENTIONAL,0,"Diabetes Mellitus, Type 1, Diabetes Mellitus, Insulin-Dependent",,"DEVICE, DEVICE","Regulation of blood glucose excursions, measured by hemoglobin A1c at the end of the 3 month study period and again after an additional 3 month follow-up period, Magnitude of glucose excursions and fluctuations as indicated by the standard deviation between glucose tests to indicate relative glucose control and the mean daily glucose value over the 3 month period following the initiation of pump therapy",2006-03,2007-12,Thomas Jefferson University,OTHER
NCT05129735,An Exploratory Investigation to Assess Changes in Quality of Life for Individuals With Type 2 Diabetes After Taking a Meal-replacement Shake.,An Exploratory Investigation to Assess Changes in Quality of Life for Individuals With Type 2 Diabetes After Taking a Meal-replacement Shake.,WITHDRAWN,Sponsor withdrawn,NA,INTERVENTIONAL,0,"Diabetes Mellitus, Type 2",,DIETARY_SUPPLEMENT,Improvement of quality of life score from baseline to 12-weeks,2022-09-15,2022-12-30,"Teatis, Inc",INDUSTRY
NCT04159935,Investigating iLux Efficacy in Contact Lens Wearers With Evaporative Dry Eye Disease,Investigating iLux Efficacy in Contact Lens Wearers With Evaporative Dry Eye Disease,TERMINATED,Cancelled due to COVID-19,PHASE4,INTERVENTIONAL,28,Dry Eye,,DEVICE,Mean Change in the Standard Patient Evaluation of Eye Dryness (SPEED) Questionnaire Score From Baseline to 1 Month,2019-11-15,2020-04-14,University of Waterloo,OTHER
NCT00946517,Impaired Family Dynamics Leads to Non Compliance in Type I Diabetes,Impaired Family Dynamics Leads to Non Compliance in Type I Diabetes,TERMINATED,PI left the institution,,OBSERVATIONAL,20,Type 1 Diabetes,,OTHER,Parenting styles,2009-07,2010-05,Nationwide Children's Hospital,OTHER
NCT01644240,"A Phase 1, Multiple Intravenous Dose Study to Examine Safety, Tolerability, and PK of Intravenous TD-8954, a 5-HT4 Receptor Agonist, in Healthy Subjects","A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Intravenous Dose Study to Examine the Safety, Tolerability, and Pharmacokinetics of Intravenous TD-8954, a 5-HT4 Receptor Agonist, in Healthy Subjects",TERMINATED,For business reasons,PHASE1,INTERVENTIONAL,16,Gastrointestinal Motility Disorder,"TD-8954, Placebo - saline","DRUG, DRUG","Cmax, Tmax, t½, AUC0-24, AUC0-∞, AUCtau, Plasma Vz, Plasma CL, Cmax, Tmax, t½, AUC0-24, AUC0-∞, AUCtau, Vss, CLss",2012-09,2012-12,Theravance Biopharma,INDUSTRY
NCT02846740,Cranial Electric Stimulation to Modify Suicide Risk Factors in Psychiatric Inpatients.,Cranial Electric Stimulation to Modify Suicide Risk Factors in Psychiatric Inpatients,TERMINATED,No finding at halfway point of the study,NA,INTERVENTIONAL,30,"Suicide, Depression, Anxiety, Insomnia, Agitation",,"DEVICE, BEHAVIORAL","Change From Baseline in the Modifiable Suicide Risk Factors (MSRF's) Global Score, Adverse Effects and Safety",2017-03-01,2018-01-22,"University of Maryland, Baltimore",OTHER
NCT00284440,Choroidal Blood Flow Response to Hand-grip Test in Progressive Glaucoma,Relationship Between Visual Field Progression in Glaucoma and Choroidal Blood Flow Response to the Hand-grip Test,WITHDRAWN,enrollment problems,,OBSERVATIONAL,0,Primary Open Angle Glaucoma,,,,2006-03,2011-06,"University Hospital, Basel, Switzerland",OTHER
NCT03888989,Response to Influenza Vaccine During Pregnancy,Response to Influenza Vaccine During Pregnancy,TERMINATED,Enrollment was not complete given logistical concerns that arose during the COVID-19 pandemic,PHASE1,INTERVENTIONAL,2,Influenza,Quadrivalent inactivated influenza vaccine (IIV),BIOLOGICAL,"Plasma HAI Titer at Day 7 (Year 1), Number of Participants With Related Adverse Events (Year 1), Number of Participants With Related Adverse Events (Year 2), Plasma HAI Titer at Day 7 (Year 2)",2019-09-30,2023-12-31,Stanford University,OTHER
NCT00048750,Comparative Study of Micafungin (FK463) Versus Placebo as Prophylactic Antifungal Therapy in the ICU,"A Phase 3, Randomized,Double-Blind, Comparative Study of Micafungin (FK463) Versus Placebo as Preemptive Prophylactic Antifungal Therapy in Patients in the Intensive Care Unit",TERMINATED,Inadequate enrollment,PHASE3,INTERVENTIONAL,104,Invasive Fungal Infections,"Micafungin, Placebo","DRUG, DRUG","Assessment of the incidence of a proven or probable invasive fungal infection, catheter tip fungal infection, or deep incisional surgical site infection during the study",2003-01,2003-06,Astellas Pharma Inc,INDUSTRY
NCT02940691,Scale-up of Treatment of Hepatitis C Infection Among People Who Inject Drugs,"A Phase IV, Open-label, Single Arm, Multicentre Trial of Grazoprevir/Elbasvir for Genotype 1 or 4 in People With Chronic Hepatitis C Virus Infection and Recent Injecting Drug Use or Receiving Opioid Substitution Therapy",TERMINATED,Poor recruitment due to new treatments becoming available.,PHASE4,INTERVENTIONAL,32,Hepatitis C,Grazoprevir/elbasvir,DRUG,Undetectable HCV RNA at 12 Weeks Post End of Treatment (SVR12),2017-05-01,2018-11-01,Kirby Institute,OTHER_GOV
NCT02677220,Implantation With the Nucleus CI532 Cochlear Implant in Adults,Implantation With the Nucleus CI532 Cochlear Implant in Adults,TERMINATED,No enrolled subjects,NA,INTERVENTIONAL,1,Hearing Loss,,DEVICE,AzBio Sentence Recognition in Noise,2016-05-11,2017-08-23,Cochlear,INDUSTRY
NCT07052682,A Study to Evaluate How Ontamalimab Works and Assess Its Safety and Tolerability in People With Nonalcoholic Steatohepatitis With Fibrosis Stages 1 to 4,"A Multicenter, Single-arm, Open-label, Phase 1b Study to Explore the Mechanism of Action and Evaluate the Safety of Ontamalimab in Participants With Nonalcoholic Steatohepatitis With Fibrosis Stage 1 Through 4",TERMINATED,Study was terminated early by the sponsor due to a strategic shift and reprioritization of clinical programs within Takeda.,PHASE1,INTERVENTIONAL,11,Steatohepatitis,Ontamalimab,DRUG,"Number of Participants With Treatment-emergent Adverse Events (TEAEs), Number of Participants With Clinically Significant Abnormalities in Clinical Laboratory Values, Number of Participants With Clinically Significant Abnormalities in 12-lead Electrocardiogram (ECGs) Findings, Number of Participants With Clinically Significant Abnormalities in Vital Signs, Number of Participants With Clinically Significant Abnormalities in Body Weight",2023-01-18,2024-12-30,Takeda,INDUSTRY
NCT02412124,Peer-to-Peer Support Program in Improving Quality of Life Outcomes in Patients With Gynecologic Cancer and Their Caregivers,Quality of Life Outcomes From a Peer-to-Peer Support Program for Women With Gynecologic Cancer,TERMINATED,Feasibility issues,NA,INTERVENTIONAL,3,"Cervical Carcinoma, Ovarian Carcinoma, Uterine Corpus Cancer, Vaginal Carcinoma, Vulvar Carcinoma",,"PROCEDURE, OTHER, OTHER","Change in quality of life benefits for patients, as assessed by the FACT-G, Satisfaction of patients with the timing, content, and format of the program, as assessed by the W2W Patient Survey, Satisfaction of mentors with the timing, content, and format of the program, as assessed by the W2W Volunteer/Mentor Survey, Satisfaction of patients' family caregivers with the timing, content, and format of the program, Benefits for patients' family caregivers after participating in the program, as assessed by the Modified Caregiver Strain Index",2015-07,2018-04,City of Hope Medical Center,OTHER
NCT04487262,Timing for Removal of Chest Tubes in Adult Cardiac Surgery,Timing for Removal of Chest Tubes in Adult Cardiac Surgery,TERMINATED,Safety interim analysis,NA,INTERVENTIONAL,515,"Heart Surgery, Chest Tube, Effusion Pleural, Pain, Postoperative",,PROCEDURE,Rate of postoperative pleural and/or pericardial effusion,2020-09-01,2021-10-31,Aarhus University Hospital Skejby,OTHER
NCT01597596,A Noninferiority Study of Alglucosidase Alfa Manufactured at the 160 L and 4000 L Scales in Treatment Naïve Patients With Infantile-Onset Pompe Disease,"A Phase 3/4, Prospective, Multinational, Open-label, Noninferiority Study of Alglucosidase Alfa Manufactured at the 160 L and 4000 L Scales in Treatment Naïve Patients With Infantile-Onset Pompe Disease",TERMINATED,Study was stopped due to approved label expansion of alglucosidase alfa.,PHASE4,INTERVENTIONAL,4,"Pompe Disease (Infantile-Onset), Glycogen Storage Disease Type II (GSD II), Glycogenosis 2, Acid Maltase Deficiency","alglucosidase alfa, alglucosidase alfa","BIOLOGICAL, BIOLOGICAL",Change From Baseline in Cardiac Function at Week 52,2012-08,2014-12,"Genzyme, a Sanofi Company",INDUSTRY
NCT05423496,KidneyCare Immuno-optimization in Renal Allografts (KIRA),KidneyCare Immuno-optimization in Renal Allografts,WITHDRAWN,Business decision based on clinical utility considerations,NA,INTERVENTIONAL,0,"Kidney Transplant, Immunosuppression, Allograft","steroid, MMF","DIAGNOSTIC_TEST, DRUG, DRUG","Estimated glomerular filtration rate (eGFR) at 12 months, non-inferiority, Estimated glomerular filtration rate (eGFR) at 24 months, non-inferiority, Interstitial fibrosis/tubular atrophy (IF/TA) quantified by Banff Working Group biopsy grade(s) at 12-months post-transplant, Interstitial fibrosis/tubular atrophy (IF/TA) quantified by Banff Working Group biopsy grade(s) at 24-months post-transplant, Transplant glomerulopathy (TG) at 12-months post-transplant, quantified by biopsy-based histopathology grade(s), Transplant glomerulopathy (TG) at 24-months post-transplant, quantified by biopsy-based histopathology grade(s), Total number of biopsies performed post-transplant, including both surveillance and clinically indicated biopsies, Number of clinically indicated biopsies planned and performed in the first 12- months post- transplant, Number of clinically indicated biopsies planned and performed in the 24-months post- transplant",2022-08,2023-02-23,CareDx,INDUSTRY
NCT04105062,"LS301 Uptake in Tumors of Patients Undergoing Liver, Pancreas, or Gastric Surgery","Evaluation of LS301 Uptake in Tumors of Patients Undergoing Liver, Pancreas, or Gastric Surgery",WITHDRAWN,One of the investigators is leaving the University.,"PHASE1, PHASE2",INTERVENTIONAL,0,"Pancreatic Cancer, Liver Cancer, Gastric Cancer, Gastrointestinal Stromal Cancer, Metastatic Cancer",LS301,"DRUG, DEVICE","Phase I only: Safety of LS301 as measured by incidence of related adverse events per patient, Phase I only: Optimal imaging dose of LS301, Phase II only: Ability of LS301 to predict presence of positive margins",2021-12-31,2023-12-31,Washington University School of Medicine,OTHER
NCT03371862,Liraglutide on Decreasing Parenteral Support in Short Bowel Patients (SLIPS),"Pilot Study of the GLP-1 Agonist, Liraglutide, on Decreasing Parenteral Support Requirements in Short Bowel Patients.",WITHDRAWN,No participants recruited. Not able to recruit due to COVID 19.,PHASE2,INTERVENTIONAL,0,Short Bowel Syndrome,Liraglutide Pen Injector [Victoza],DRUG,Improvement in parenteral support,2017-10-20,2020-09-30,Imperial College London,OTHER
NCT04423588,Dexlansoprazole Absorption and Marginal Ulceration After Gastric Bypass,"Prospective, Monocentric Study of Dexlansoprazole Absorption Preoperative and 6 and 12 Months After Proximal Roux-en-Y Gastric Bypass Surgery and of the Incidence of Marginal Ulcers 6 and 12 Months After Surgery",WITHDRAWN,No participants enrolled.,PHASE4,INTERVENTIONAL,0,Bariatric Surgery,,"DIAGNOSTIC_TEST, DIAGNOSTIC_TEST","Change of dexlansoprazole Serum concentration, Change of dexlansoprazole Serum concentration",2022-01-01,2022-09-30,Spital Limmattal Schlieren,OTHER
NCT05016661,Extension Study of ABP-20001 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 for Migraine Prevention,"A Randomized, Multicenter, Dose-Blinded, Phase 2 Extension Study of ABP-450 (prabotulinumtoxinA) Purified Neurotoxin Complex for the Prevention of Migraine Headache",TERMINATED,Study was terminated due to the analysis of the data not meeting the intended primary endpoint and key secondary endpoints.,PHASE2,INTERVENTIONAL,466,Migraine,ABP-450,DRUG,"Incidence of Treatment Emergent Adverse Events, Change in Monthly Migraine Days",2021-10-19,2024-08-30,"AEON Biopharma, Inc.",INDUSTRY
NCT01714986,Psychological Variables and Hyperglycemia in Diabetes Mellitus,"Psychological Impact, Metabolic Control, Biological Stress Markers in Diabetes: Intervention With Affect School and Basal Body Awareness",WITHDRAWN,Not active,NA,INTERVENTIONAL,0,"Diabetes Mellitus, Depression, Alexithymia, Anxiety",,"BEHAVIORAL, BEHAVIORAL","Intervention with Affect School with Script Analysis and Basic Basal Awareness Therapy in patients with diabetes, psychological symptoms and high HbA1c",2009-03,2024-12,Lund University,OTHER
NCT03239470,Polyclonal Regulatory T Cells (PolyTregs) for Pemphigus,"A Phase I, Open-Label, Multicenter Trial Exploring the Safety and Tolerability of Autologous Polyclonal Regulatory T Cell Therapy in Adults With Active Pemphigus (APG01)",TERMINATED,"Lack of recruitment, ongoing and new feasibility issues, and the impact of the coronavirus infectious disease 19 (COVID-19) pandemic",PHASE1,INTERVENTIONAL,5,"Pemphigus Foliaceus, Pemphigus Vulgaris","Cohort 1: 1.0 x 10^8 PolyTregs, Cohort 2: 2.5x10^8 PolyTregs","BIOLOGICAL, BIOLOGICAL",Number of Significant Adverse Events Through Week 52,2017-10-10,2023-01-09,National Institute of Allergy and Infectious Diseases (NIAID),NIH
NCT02952573,Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement,"A Phase II Open Label, Multicenter, Trial of JNJ-42756493 In Combination With Dexamethasone For The Treatment Of FGFR3 Wild-type Or Mutation Positive Relapsed and/or Refractory Multiple Myeloma",TERMINATED,Low patient accrual,PHASE2,INTERVENTIONAL,20,"Multiple Myeloma, Relapsed/Refractory","JNJ-42756493, Dexamethasone","DRUG, DRUG","Objective response rate (ORR), Minimal response rate, Stable disease rate",2017-06-13,2018-11-13,"University Health Network, Toronto",OTHER
NCT02959073,"Evaluation of a New Self-assessed, Home-based Symptom Score in Cat Allergic Patients","Evaluation of a New Self-assessed, Home-based Symptom Score in Cat Allergic Patients",TERMINATED,Company's strategic reasons,,OBSERVATIONAL,10,Cat Allergy,,OTHER,"Duration of provocation test under 2 different conditions, Number of score Points resulting from symptom record, fel d 1 concentration in cat dander, fel d 1 concentration in the air",2016-09,2017-02,University of Zurich,OTHER
NCT03090269,Methylphenidate for Cocaine Dependence,Pilot Study to Evaluate the Benefits and the Risks of Methylphenidate for the Treatment of Cocaine Dependence,WITHDRAWN,feasibility reasons.,PHASE2,INTERVENTIONAL,0,Substance-Related Disorders,Methylphenidate Pill,DRUG,Cocaine use,2018-06-01,2019-03-30,"ANRS, Emerging Infectious Diseases",OTHER_GOV
NCT06840769,A Clinical Trial to Assess Safety and Pharmacokinetics of Fosnetupitant 235 mg and Metabolites in Healthy Volunteers,"A Phase I, Open Label, Single Dose, Two Parts Study in Male and Female Healthy Subjects to Assess the Safety and Pharmacokinetics of Fosnetupitant 235 mg Administered as IV Bolus and of Derived Netupitant and Netupitant Metabolites",TERMINATED,Sponsor's decision,PHASE1,INTERVENTIONAL,50,Healthy Volunteers,"Fosnetupitant 235 mg solution, Akynzeo solution","DRUG, DRUG","Study Part A: Number of Treatment-emergent Adverse Events, Study Part A: Number of Subjects With Treatment-emergent Adverse Events, Study Part A: Type of Treatment-emergent Adverse Events",2023-06-17,2023-10-23,Helsinn Healthcare SA,INDUSTRY
NCT04582669,Optimizing Intralesional Triamcinolone Dosing for Hidradenitis Suppurativa,Optimizing Intralesional Triamcinolone Dosing for Hidradenitis Suppurativa,TERMINATED,This study was administratively closed.,PHASE4,INTERVENTIONAL,11,Hidradenitis Suppurativa,"Intralesional Triamcinolone 10 mg/mL, Intralesional Triamcinolone 20 mg/mL, Intralesional Triamcinolone 40 mg/mL, Placebo","DRUG, DRUG, DRUG, DRUG",Change From Baseline in Numeric Rating Scale (NRS),2022-01-24,2022-10-12,Montefiore Medical Center,OTHER
NCT04086069,Sit-to-stand Trainer in Patients After Lower Limb Amputation,Effect of Sit-to-stand Trainer in Patients With Unilateral Lower Limb Amputation on the Ability of Independent Standing up,WITHDRAWN,Main clinician cancelled collaboration for personal reasons.,NA,INTERVENTIONAL,0,Lower Limb Amputation,,DEVICE,Change in 30-Second Chair Stand Test,2019-02-06,2020-08-30,"University Rehabilitation Institute, Republic of Slovenia",OTHER
NCT02847078,Smart Phone Application in the Secondary Clinical Prevention Management for Chinese Patients,Effects of a Smart Phone Application in the Secondary Clinical Prevention Management for Chinese Patients After Coronary Intervention Treatment: a Randomized Controlled Trial,TERMINATED,Insufficient enrollment of patients,NA,INTERVENTIONAL,86,Coronary Disease,,"DEVICE, DEVICE",Change in quality of life,2016-09-20,2017-05-01,First Affiliated Hospital Xi'an Jiaotong University,OTHER
NCT03576885,Inhaled Nitric Oxide for Pulmonary Hypertension and Bronchopulmonary Dysplasia,Treatment of Delayed Pulmonary Transition in Extremely Preterm Infants & Bronchopulmonary Dysplasia,TERMINATED,based on DSMB recommendation at interim analysis,"PHASE1, PHASE2",INTERVENTIONAL,32,"Pulmonary Hypertension, Bronchopulmonary Dysplasia","inhaled nitric oxide, Placebo","DRUG, DRUG","Death, Bronchopulmonary (BPD) Dysplasia (Yes/no)",2019-07-15,2023-10-09,AdventHealth,OTHER
NCT03173885,Investigating the Cryopreserved Blastocyst's ImplantatiOn Potential After Genetic Screening,"An RCT Evaluating the Implantation Potential of Vitrified Embryos Screened by Next Generation Sequencing Following Trophectoderm Biopsy, Versus Vitrified Unscreened Embryos in Good Prognosis Patients Undergoing IVF",TERMINATED,Due to the slow recruitment of patients,NA,INTERVENTIONAL,56,"Infertility, Preimplantation Genetic Screening",,DIAGNOSTIC_TEST,Clinical pregnancy,2017-05-18,2020-02-05,"University Hospital, Ghent",OTHER
NCT04857008,BNT001 Digital Therapeutic Feasibility Pilot Study,"Phase II Pilot Study Evaluating the Feasibility of Delivery and Evaluation of BNT001, a Digital Cognitive-Behavioral Stress Management (CBSM) Software Application for Treatment of Anxiety and Depressive Symptoms in Veterans With Cancer",TERMINATED,recruitment challenges,NA,INTERVENTIONAL,17,Cancer,,DEVICE,"Identification of promoters and barriers to clinical implementation, To measure changes in pre and post cancer-related distress in patient participants.",2021-10-08,2022-08-05,Blue Note Therapeutics,INDUSTRY
NCT04625543,Neoadjuvant Immunotherapy to ESCC,"Neoadjuvant Immunotherapy Combined With Neoadjuvant Chemotherapy for Locally Advanced Esophageal Cancer: an Open Label, Randomized Control, Phase II Trial",WITHDRAWN,insufficient money,PHASE2,INTERVENTIONAL,0,Esophagus SCC,"Sintilimab Injection plus Paclitaxel and Cisplatin, Paclitaxel and Cisplatin","DRUG, DRUG",Major Pathological Response (MPR) rate,2020-12,2023-09,Qilu Hospital of Shandong University,OTHER
NCT01134315,Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to 16 With Chronic Kidney Disease Stage 5 Receiving Peritoneal Dialysis Within Current Clinical Practice,"A Prospective, Multicenter Study to Evaluate the Safety of Paricalcitol Capsules as Determined by Hypercalcemia in Pediatric Patients Ages 0 to 16 With Chronic Kidney Disease (CKD) Stage 5 Receiving Peritoneal Dialysis (PD) Within Current Clinical Practice",TERMINATED,Terminated after FDA agreement.,,OBSERVATIONAL,61,"Secondary Hyperparathyroidism, End-Stage Renal Disease","Paricalcitol, Calcitriol","DRUG, DRUG",Percentage of Participants With at Least One Incidence of Hypercalcemia,2010-06,2012-05,"AbbVie (prior sponsor, Abbott)",INDUSTRY
NCT00511576,Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors,"A Phase 1, Open-Label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of MGCD0103 (MG-0103) in Combination With Docetaxel (Taxotere®) in Subjects With Advanced Solid Malignancies",TERMINATED,Celgene terminated its collaboration agreement with MethylGene for the development of MGCD0103. All Celgene-sponsored trials with MGCD0103 will be closed.,PHASE1,INTERVENTIONAL,54,"Breast Cancer, Lung Cancer, Pulmonary Cancer, Non-Small-Cell Lung Carcinoma, Prostate Cancer, Prostatic Cancer, Gastric Cancer, Stomach Cancer",MGCD0103 & Docetaxel,DRUG,"To determine the maximum tolerated dose (MTD), dose limiting toxicities (DLTs), and safety profile of escalating doses of orally administered MGCD0103 in combination with two fixed doses (60 mg/m2 and 75 mg/m2) of IV docetaxel., To assess the plasma pharmacokinetics (PK) of MGCD0103 (and/or its metabolites) and IV docetaxel administered in combination., To evaluate potential pharmacodynamic (PD) effects of orally administered MGCD0103 in combination with IV docetaxel., To determine the overall tumor response of orally administered MGCD0103 in combination with IV docetaxel according to Response Evaluation Criteria in Solid Tumors (RECIST) methodology.",2007-08,2009-03,Mirati Therapeutics Inc.,INDUSTRY
NCT03933176,Absence of Liner Following the Selective Caries Removal (ALFSCaRe),Is the Use of a Glass Ionomer Liner Necessary After Selective Carious Tissue Removal?,WITHDRAWN,COVID-19 pandemic,NA,INTERVENTIONAL,0,"Caries; Dentin, Dental Restoration Failure of Marginal Integrity",,PROCEDURE,Longevity of restoration,2019-06-30,2024-09,Universidade Federal de Sergipe,OTHER
NCT03911076,"Phase II Study of Treatment for HPV16+ ASC-US, ASC-H and LSIL","A Randomized Double-Blind, Placebo-controlled Phase II Trial With Safety Run-In of Intramuscular pNGVL4a-Sig/E7(Detox)/HSP70 and TA-CIN for the Treatment of Patients With HPV16+ Atypical Squamous Cells of Undetermined Significance (ASC-US) or Cannot Exclude High Grade SIL (ASC-H) Cytology or Low-grade Squamous Intraepithelial Lesion (LSIL)",TERMINATED,Slow recruitment/funding,PHASE2,INTERVENTIONAL,16,"ASC-US, ASC-H, LSIL",PVX-2,"BIOLOGICAL, OTHER","Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v5.0, Percent of patients that have cleared HPV16 at Month 6",2019-05-22,2022-06-08,"PapiVax Biotech, Inc.",OTHER
NCT03832517,Single and Multiple Dose Escalation Trial of an Intravenous Antibiotic RC-01,"A Phase 1, Double-Blind, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RC-01 for Injection in Healthy Adult Subjects",TERMINATED,safety,PHASE1,INTERVENTIONAL,8,Safety,"Single intravenous doses of RC-01, Single intravenous doses of placebo, Multiple intravenous doses of RC-01, Multiple intravenous doses of placebo","DRUG, DRUG, DRUG, DRUG",Number of participants with a treatment-related adverse event collected over the duration of the study,2019-04-14,2019-05-08,"Recida Therapeutics, Inc.",INDUSTRY
NCT00539617,Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery,"A Single-Arm, Phase II Study of Tarceva Plus FOLFOX6 in Patients With Unresectable or Metastatic Cancer of Esophagus or Gastroesophageal Junction",TERMINATED,For slow accrual,PHASE2,INTERVENTIONAL,7,Esophageal Cancer,"Erlotinib, 5-fluorouracil, Leucovorin, Oxaliplatin","DRUG, DRUG, DRUG, DRUG",Progression Free Survival (PFS),2007-10-05,2011-05-12,"University of California, San Francisco",OTHER
NCT05417217,The Effect of Continued Mechanical Ventilation on the Occurrence of Myocardial Ischemia,The Effect of Continued Mechanical Ventilation on the Occurrence of Myocardial Ischemia in Patients Undergoing Totally Endoscopic Coronary Artery Bypass Grafting,TERMINATED,"After the passing of the principal investigator, the clinical trial could not be continued.",NA,INTERVENTIONAL,165,"Cardiovascular Diseases, Coronary Artery Disease, Myocardial Ischemia, Hypoxia",,"PROCEDURE, PROCEDURE","The influence of continued mechanical ventilation on the release of cardiac troponin T (cTn-T), The influence of continued mechanical ventilation on the release of creatine kinase-myocardial band (CK-MB), The influence of continued mechanical ventilation on the release of heart-type fatty acid-binding protein (hFABP), The influence of continued mechanical ventilation on lipid peroxidation, The influence of continued mechanical ventilation on the redox balance, The influence of continued mechanical ventilation on the partial pressure of oxygen (pO2), The influence of continued mechanical ventilation on the partial pressure of carbon dioxide (pCO2), The influence of continued mechanical ventilation on the pH, The influence of continued mechanical ventilation on lactate",2022-10-17,2024-11-09,Jessa Hospital,OTHER
NCT04445389,"Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults","A Phase 1/2a, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, and Immunogenicity of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Subjects",TERMINATED,The sponsor decided to change the investigational product for a strategic reason.,"PHASE1, PHASE2",INTERVENTIONAL,60,SARS-CoV-2,"GX-19, Saline","DRUG, DRUG","Incidence of solicited adverse events, Incidence of unsolicited adverse events, Incidence of serious adverse events",2020-06-17,2020-12-17,"Genexine, Inc.",INDUSTRY
NCT02955368,Clinical Trial to Evaluate the Efficacy and Safety of DP-R212,"A Multi-center, Randomized, Double-blind, Parallel-group Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R212 Fixed Dose Combination in Patients With Dyslipidemia and Hypertension",WITHDRAWN,Canceled,PHASE3,INTERVENTIONAL,0,"Hypertension, Hypercholesterolemia","DP-R212, C1-R212, C2-R212","DRUG, DRUG, DRUG","Percent change of LDL-Cholesterol, Change of mean seated Systolic Blood Pressure",2017-02,2017-08,Alvogen Korea,INDUSTRY
NCT04732468,COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA,"Phase 1b Open-Label Study of the Safety, Reactogenicity, and Immunogenicity of Subcutaneously and Orally Administered Prophylactic Vaccination With 2nd Generation (E1/E2B/E3-Deleted) Adenoviral COVID-19 in Normal Healthy Volunteers",TERMINATED,The study was terminated early due to low enrollment.,PHASE1,INTERVENTIONAL,28,Covid19,"hAd5-S-Fusion+N-ETSD (Suspension for injection), hAd5-SFusion+ N-ETSD (Oral capsule)","BIOLOGICAL, DRUG","Incidence of Solicited Local Reactogenicity AEs, Incidence of Solicited Systemic Treatment-Related Reactogenicity AEs, Incidence of Unsolicited AEs, Incidence of Unsolicited Treatment-Related AEs, Incidence of Unsolicited AEs, Incidence of Unsolicited Treatment-Related AEs, Incidence of MAAEs, Incidence of Serious AEs",2021-02-24,2023-01-09,"ImmunityBio, Inc.",INDUSTRY
NCT00623168,Ribavirin for Hemorrhagic Fever With Renal Syndrome,"A Phase 2 Treatment Protocol of Intravenous Ribavirin in Adult Subjects With Hemorrhagic Fever With Renal Syndrome (HFRS) in the 121st Combat Support Hospital (Seoul, Korea)",WITHDRAWN,This was an expanded access treatment protocol that did not enroll any subjects due to no infections requiring treatment.,PHASE2,INTERVENTIONAL,0,Hemorrhagic Fever With Renal Syndrome,Ribavirin,DRUG,"Number clinical events that occur with HFRS including oliguria, dialysis requirement, cardiac arrhythmias, and severe hemorrhage, Number of mortalities",2008-02,2019-12,U.S. Army Medical Research and Development Command,FED
NCT04726618,Development of Hardware and Software for Pulmonary Magnetic Resonance Imaging Using Inhaled Tracer Gases,Development of Hardware and Software for Pulmonary Magnetic Resonance Imaging Using Inhaled Tracer Gases,TERMINATED,Funding constraints,,OBSERVATIONAL,24,Healthy Volunteers,Hyperpolarized 129-xenon gas and Perfluoropropane gas,DRUG,"The primary objective of this study is to develop the necessary imaging sequences, reconstruction algorithms, and hardware to acquire high quality lung images using HP 129Xe, 19F MRI, and conventional 1H MRI.",2022-03-01,2024-04-09,The Hospital for Sick Children,OTHER
NCT02107118,Stem Cells for the Improvement of Erectile and Cardiac Function in Aging Men,H-34570: PHASE I Study: The Use of Autologous Adipose Tissue-Derived Mesenchymal Stem Cell (AdMSC) for the Improvement of Erectile and Cardiac Function in Aging Men,WITHDRAWN,Contract issues,PHASE1,INTERVENTIONAL,0,"Erectile Dysfunction, Cardiac Disease",ARM 1: AdMSC: adipose stem cells,"BIOLOGICAL, OTHER",Improvements in IIEF scores of greater than 2,2015-05,2022-02,Baylor College of Medicine,OTHER
NCT00877318,Cardiac Rehabilitation of Heart Failure Patients by Telemedicine,Cardiac Rehabilitation of Heart Failure Patients by Telemedicine: a Randomized Multicenter Study.,TERMINATED,insufficient recruitment,PHASE4,INTERVENTIONAL,64,Heart Failure,,DEVICE,Variation of VO2 peak at 3 months in comparison to VO2 peak at hospital discharge,2009-03,2012-12,"University Hospital, Caen",OTHER
NCT01386710,Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma,Phase I/II Trial Of Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory Glioblastoma Multiforme And Anaplastic Astrocytoma,SUSPENDED,PI left previous institution study will reopen at new institution.,"PHASE1, PHASE2",INTERVENTIONAL,54,"Glioblastoma Multiforme, Anaplastic Astrocytoma","Bevacizumab and Carboplatin, Bevacizumab and Carboplatin","DRUG, DRUG","Composite overall response rate, Six-month progression-free survival (PFS) and overall survival (OS)",2011-09,2027-12,Northwell Health,OTHER
NCT02227160,Group Interventions for Suicidal African Americans,Group Interventions for Suicidal African Americans,WITHDRAWN,This study never started enrolling participants due to lack of grant funding.,NA,INTERVENTIONAL,0,"Depression, Mental Illness, Suicide, Suicidal Ideation",,"BEHAVIORAL, BEHAVIORAL",Change in scores on Beck Scale for Suicidal Ideation,2016-05,2017-05,Emory University,OTHER
NCT02844582,Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer,A Selective Frontline Cabazitaxel Therapeutic Pathway for Castration-Resistant Prostate Cancer With Integrated Biomarkers,TERMINATED,Poor accrual of subjects onto study,PHASE2,INTERVENTIONAL,2,"Hormone-Resistant Prostate Cancer, Stage IV Prostate Adenocarcinoma","Cabazitaxel, Prednisone","DRUG, DRUG","PSA Response Rate, Defined as >= 50% Decline in PSA From Baseline Maintained for at Least 3 Weeks and Measured by the Same Laboratory, and Without Evidence of Other Disease Progression Documented at Time of Confirmatory Values",2017-12-20,2019-06-04,"University of California, Davis",OTHER
NCT04320082,Alteration of Blood-Brain-Barrier Permeability at Loss of Consciousness in Delirious Patients Recorded With Direct-Current Electroencephalography (ACDC),Alteration of Blood-Brain-Barrier Permeability at Loss of Consciousness in Delirious Patients Recorded With Direct-Current Electroencephalography (ACDC),TERMINATED,The study staff has left the clinic.,,OBSERVATIONAL,24,Delirium,,,1. DC-Shift (µV/sec) in the perioperative DC-EEG.,2020-08-10,2021-11-11,"Charite University, Berlin, Germany",OTHER
NCT00447226,"Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists","A Phase II, Placebo Controlled, Double-Blind, Randomized, Discontinuation Study of Lapatinib Administered Orally to Subjects With ErbB2 Positive Ovarian, Gastric/Esophageal Adenocarcinoma, Uterine Serous Papillary, or Bladder Cancer",TERMINATED,The study had failed to meet the primary objective of tumor response rate at 12 weeks from first dose.,PHASE2,INTERVENTIONAL,32,Cancer,Oral lapatinib tablets or placebo tablets,DRUG,"Number of Participants With the Indicated Tumor Response at 12 Weeks From First Dose, Percentage of Participants Who Remained Progression-free 12 Weeks After Randomization",2007-05,2009-09,GlaxoSmithKline,INDUSTRY
NCT03926143,A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies,"An Open-label, Multicenter Rollover Study to Provide Continued Treatment With Anetumab Ravtansine for Participants With Solid Tumors Who Were Enrolled in Previous Bayer-sponsored Studies",TERMINATED,"Due to strategic company decisions, the development of anetumab ravtansine was stopped.",PHASE2,INTERVENTIONAL,9,Solid Tumors,BAY94-9343 (Anetumab ravtansine),DRUG,"Number of Participants With TEAEs, TESAEs and Drug-related TEAEs and TESAEs",2019-06-03,2022-05-18,Bayer,INDUSTRY
NCT04812743,Colorectal Health Research Champions,Colorectal Health Research Champions,TERMINATED,End of grant funding,NA,INTERVENTIONAL,91,"Cancer of Colon, Cancer of Rectum",,BEHAVIORAL,"Increase in participants knowledge and intentions related to colorectal cancer screening., Increase in knowledge and intentions related to biospecimen donation and clinical trial participation.",2020-01-10,2023-05-15,Virginia Commonwealth University,OTHER
NCT00203385,Maintenance Phase Treatment With Divalproex for Post Traumatic Stress Disorder,Maintenance Phase Treatment With Divalproex for Post Traumatic Stress Disorder,TERMINATED,Funding expired,PHASE4,INTERVENTIONAL,20,PTSD,Divalproex,DRUG,Clinician Administered PTSD Scale (CAPS),2003-05,2005-03,Tuscaloosa Research & Education Advancement Corporation,OTHER
NCT02999243,Development of an HIV Self-testing Intervention,Development of an HIV Self-testing Intervention to Reduce HIV Risks Among MSM: Taking the Guess Out of Seroguessing,TERMINATED,"IRB expired, PI no longer at institution.",NA,INTERVENTIONAL,27,HIV Serosorting,,"BEHAVIORAL, BEHAVIORAL",Change in participants' HIV testing uptake,2017-08-15,2018-05-21,"University of California, San Francisco",OTHER
NCT00287443,Metabolic Abnormalities in Hispanic Children With Cystic Fibrosis,,WITHDRAWN,PI no longer with the University,NA,INTERVENTIONAL,0,Cystic Fibrosis,,"PROCEDURE, PROCEDURE, PROCEDURE, PROCEDURE, PROCEDURE, PROCEDURE",,2006-02-02,2006-02-02,University of Texas Southwestern Medical Center,OTHER
NCT00308789,A Trial of Infant Flow Biphasic Nasal Continuous Airway Pressure (NCPAP) Versus Infant Flow NCPAP for the Facilitation of Extubation in Infants </= 1250 Grams,Infant Flow Biphasic NCPAP Versus Infant Flow NCPAP for the Facilitation of Successful Extubation in Infants </= 1250 Grams: A Randomized Controlled Trial,TERMINATED,Poor enrollment,PHASE2,INTERVENTIONAL,136,"Infant, Premature, Diseases, Bronchopulmonary Dysplasia, Apnea of Prematurity",,"PROCEDURE, PROCEDURE",The rate of successful extubation with either mode of NCPAP,2006-04,2009-12,"Mount Sinai Hospital, Canada",OTHER
NCT04826250,The Effect of Timing of Antihypertensive Medication on Diurnal Fluctuations in Blood Pressure Using a Wearable Sensor With Continuous Monitoring,The Effect of Timing of Antihypertensive Medication on Diurnal Fluctuations in Blood Pressure Using a Wearable Sensor With Continuous Monitoring,WITHDRAWN,Preliminary data was not sufficient to support the study aim,NA,INTERVENTIONAL,0,Hypertension,,PROCEDURE,"Nighttime blood pressure, Nighttime blood pressure, Nighttime blood pressure, morning blood pressure, morning blood pressure, morning blood pressure",2021-01-01,2022-06-01,Tel Aviv University,OTHER
NCT02042950,A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma,A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma,TERMINATED,Terminated due to poor accrual,PHASE2,INTERVENTIONAL,6,Lymphoma,Carfilzomib,DRUG,Overall Response Rate of Carfilzomib,2014-07-14,2017-12-20,M.D. Anderson Cancer Center,OTHER
NCT03987750,Safinamide for Levodopa-induced Dyskinesia (PD-LID),"A Phase 3, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of 2 Doses of Safinamide Compared to Placebo in the Treatment of LID in PD Patients With Motor Fluctuations",WITHDRAWN,drug development plan has been updated,PHASE3,INTERVENTIONAL,0,"Dyskinesia, Drug-Induced, Parkinson Disease","Safinamide Methanesulfonate 150mg, Safinamide Methanesulfonate 100mg, Safinamide Methanesulfonate matching placebo","DRUG, DRUG, DRUG",Assess the effect of two doses of safinamide on reducing levodopa-induced dyskinesia,2019-10,2021-05,Zambon SpA,INDUSTRY
NCT04657250,mHealth for Smoking Cessation in Public Housing,mHealth for Smoking Cessation in Public Housing,WITHDRAWN,COVID-19,NA,INTERVENTIONAL,0,Smoking Cessation,,"BEHAVIORAL, BEHAVIORAL",Proportion of participants making a quit attempt,2020-10-26,2022-07-31,George Washington University,OTHER
NCT00291850,Phase II Trial of Dose-dense Paclitaxel and Cisplatin as Neo-adjuvant Chemotherapy for Operable Stage II and IIA NSCLC,Phase II Trial of Dose-dense Paclitaxel and Cisplatin as Neo-adjuvant Chemotherapy for Operable Stage II and IIA Non-Small Cell Lung Cancer,TERMINATED,no patient recruitment,PHASE2,INTERVENTIONAL,50,Non-Small Cell Lung Cancer,"Paclitaxel, Cisplatin, Pegfilgrastim",DRUG,the evaluation of the clinical response rate of neo-adjuvant chemotherapy with dose-dense therapy of paclitaxel and cisplatin(PC) with peg-filgrastim in patients with operable NSCLC,2005-06,,Central European Cooperative Oncology Group,OTHER
NCT02309450,"Pilot Study to Assess Efficacy and Safety of a Triple Therapy With Asunaprevir, Daclatasvir, and BMS-791325 in HCV Genotype 4-infected Patients After Failure of Pegylated Interferon-Ribavirin Regimen","Pilot Study to Assess Efficacy and Safety of a Triple Therapy With Asunaprevir, Daclatasvir and BMS-791325 in HCV Genotype 4-infected Patients After Failure of Pegylated Interferon-Ribavirin Regimen",WITHDRAWN,BMS decision,PHASE2,INTERVENTIONAL,0,Hepatitis C Virus Genotype 4 Infection,".Asunaprevir, Daclatasvir and BMS - 791325",DRUG,HCV sustained virological response rate,2014-12,2016-08,"ANRS, Emerging Infectious Diseases",OTHER_GOV
NCT03764774,A Study of LY3463251 in Healthy Participants,"A Randomized, Placebo-Controlled, Subject- and Investigator-Blind, Single and Multiple Dose, Safety, Tolerability, and Pharmacokinetics Study of LY3463251 in Healthy and Overweight Healthy Subjects",TERMINATED,Trial was terminated due to an insufficient benefit/tolerability ratio,PHASE1,INTERVENTIONAL,118,Healthy,"LY3463251, Placebo","DRUG, DRUG","Number of Participants With One or More Adverse Event(s) (AEs), All Causalities",2018-12-06,2020-12-07,Eli Lilly and Company,INDUSTRY
NCT04123574,A Pilot Study of BXCL701 in Patients With Pancreatic Cancer,"A Pilot Proof of Mechanism Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases (DPPs), in Patients With Pancreatic Cancer",WITHDRAWN,No longer relevant to field,EARLY_PHASE1,INTERVENTIONAL,0,"Cancer of Pancreas, Cancer of the Pancreas, Neoplasms, Pancreatic, Pancreas Cancer, Pancreatic Cancer",Talabostat Mesylate,DRUG,To characterize the quantitative and qualitative effects of BXCL701 on relevant immune effector cytokines and various immunological effector cells that are consistent with its known mechanism of action.,2019-10-15,2021-12-06,BioXcel Therapeutics Inc,INDUSTRY
NCT04786574,A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD),"A Phase 3b Multicenter Open-label Trial of the Safety, Tolerability, and Efficacy of Tolvaptan in Infants and Children 28 Days to Less Than 12 Weeks of Age With Autosomal Recessive Polycystic Kidney Disease (ARPKD)",WITHDRAWN,Study stopped before enrolling any participants.,PHASE3,INTERVENTIONAL,0,Autosomal Recessive Polycystic Kidney Disease (ARPKD),Tolvaptan (OPC-41061),DRUG,The percentage of subjects that will have Renal Replacement Therapy (RRT) by 1 year of age.,2022-07-01,2025-12-10,"Otsuka Pharmaceutical Development & Commercialization, Inc.",INDUSTRY
NCT01253590,Cardiac Monitoring of Post-Operative Cancer Patients Experiencing Atrial Fibrillation,Feasibility of Remote Cardiac Monitoring of Post-Operative Cancer Patients Experiencing Atrial Fibrillation,TERMINATED,Lack of accrual,,OBSERVATIONAL,5,"Post-Operative Cancer Patients Experiencing Atrial, Fibrillation",,BEHAVIORAL,Assess the feasibility and acceptance of continuous remote cardiac monitoring,2010-12,2011-11,Memorial Sloan Kettering Cancer Center,OTHER
NCT06417697,A Phase 1b Study to Evaluate the Safety of XEN-101,"A Phase 1b, Randomized, Double-Blind, Parallel, Placebo-Controlled Study to Evaluate the Effects of XEN-101 on Safety, Tolerability, and Pharmacodynamics in Subjects with Obesity",TERMINATED,Study not stopped for safety reasons. Data were reviewed after the first 23 patients had completed scheduled dosing and there was no signal of efficacy for change in body weight. This clinical trial has been determined to be futile.,PHASE1,INTERVENTIONAL,33,Obesity,"XEN-101, Placebo","DRUG, DRUG","Incidence of treatment emergent adverse events (safety and tolerability), Effect on body weight",2024-05-24,2024-09-09,Xeno Biosciences,INDUSTRY
NCT00420797,A Study to Evaluate Topical Phenylephrine Gel in the Management of Faecal Incontinence,"A Double-blind, Randomised, Placebo-controlled Study to Evaluate Topical 10% Phenylephrine Gel in the Management of Ileal Pouch Anal Anastomosis (IPAA)-Related Faecal Incontinence",WITHDRAWN,"Terminated, new protocol to be developed",PHASE3,INTERVENTIONAL,0,Faecal Incontinence,10% Phenylephrine hydrochloride gel,DRUG,The primary efficacy variable will be the change from baseline to the end of study in the faecal incontinence score (St Mark's),2007-02,2007-11,S.L.A. Pharma AG,INDUSTRY
NCT01291797,Use of AEEG as Predictor of Long-term Motor Outcome in Neonates With Congenital Heart Disease,Use of AEEG as Predictor of Long-term Motor Outcome in Neonates With Congenital Heart Disease,TERMINATED,due to inability to recruit sufficient sample size in reasonable time frame.,,OBSERVATIONAL,4,Congenital Heart Disease,,,Abnormal sleep wake cycles on AEEG,2010-07,2011-06,Icahn School of Medicine at Mount Sinai,OTHER
NCT00670410,Autologous Transplant Followed by Allogeneic Transplant for High Risk Neuroblastoma,A Pilot Study of Sequential Autologous Stem Cell Transplantation and Immunotherapy With Reduced Intensity Allogeneic Stem Cell Transplant for High Risk Neuroblastoma,TERMINATED,Poor accrual,PHASE1,INTERVENTIONAL,15,Neuroblastoma,"Busulfan, Thymoglobulin, Fludarabine","PROCEDURE, PROCEDURE, DRUG, DRUG, DRUG","Rate of engraftment following NAT/AlloSCT from either a related donor or umbilical cord donor., Progression Free Survival (PFS) in patients with high-risk neuroblastoma receiving sequential MAT/AutoSCT and NAT/AlloSCT., Overall Survival (OS) in patient with high-risk neuroblastoma receiving sequential MAT/AutoSCT and NAT/AlloSCT.",2003-11,2010-12,Columbia University,OTHER
NCT03371420,PET Imaging of Subjects Using 124I-PU-AD,PET Imaging of Subjects Using 124I-PU-AD: A Pilot Study,TERMINATED,Company has ceased operations,EARLY_PHASE1,INTERVENTIONAL,5,"Lymphoma, Solid Malignancy, Alzheimer Disease, Myeloma",PU-AD,"DRUG, DEVICE, OTHER","Pharmacokinetic profile of 124I-PU-AD: area under the curve (AUC), Pharmacokinetic profile of 124I-PU-AD: maximum plasma concentration (Cmax), Pharmacokinetic profile of 124I-PU-AD: trough plasma concentration (Cmin), Pharmacokinetic profile of 124I-PU-AD: plasma half-life (T1/2), Pharmacokinetic profile of 124I-PU-AD: time to maximum plasma concentration (Tmax)",2016-04,2019-06-10,"Samus Therapeutics, Inc.",INDUSTRY
NCT04554420,Promoting Youth Mental Health in Inequitable Contexts: Applying Participatory Action Research,Promoting Youth Mental Health in Inequitable Contexts: Applying Participatory Action Research,WITHDRAWN,"Given recruitment challenges for youth focus groups, we are currently finalizing the creation of the intervention based on the focus groups. We plan to submit for new grant funding to implement a different intervention at a future date.",NA,INTERVENTIONAL,0,"Youth Participatory Action Research, Youth Mental Health, Health Equity",,BEHAVIORAL,"Critical Consciousness Scale - Assessing change from pre-intervention to immediately post-intervention, Research Self-Efficacy - Assessing change from pre-intervention to immediately post-intervention, Multigroup Ethnic Identity Measure - Assessing change from pre-intervention to immediately post-intervention, Revised Child Anxiety and Depression Scale-Short Version - Assessing change from pre-intervention to immediately post-intervention, Adolescent Distress-Eustress Scale - Assessing change from pre-intervention to immediately post-intervention, Child and Youth Resilience Measure-28 - Assessing change from pre-intervention to immediately post-intervention",2024-02,2024-06,Charles Drew University of Medicine and Science,OTHER
NCT00878124,How Dose Coenzyme Q10 Supplementation During Infertility Treatment Effects Pregnancy Outcome,The Influence of Concomitant Co Enzyme Q10 Use on Pregnancy Outcome in Intrauterine Insemination,TERMINATED,Very low recruitment rate,NA,INTERVENTIONAL,100,Poor Ovarian Response,,"DIETARY_SUPPLEMENT, OTHER",Pregnancy rate,2009-06,,University of Toronto,OTHER
NCT00735124,Post-Operative Pain Scores and Analgesic Requirements After Elective Inguinal Herniorrhaphy,An Investigation of Post-Operative Pain Scores and Analgesic Requirements After Ambulatory Inguinal Herniorrhaphy With Pre-Operative Gabapentin Therapy,TERMINATED,Changes to surgical practices led to the loss of eligible patients,"PHASE2, PHASE3",INTERVENTIONAL,5,"Pain, Analgesia, Hernia, Inguinal",Gabapentin,"DRUG, OTHER",Post operative pain is reduced when single pre-operative oral dose of Gabapentine is given to the patient before the Inguinal Herniorrhaphy,2008-11-06,2009-09,University of Oklahoma,OTHER
NCT06348524,Ferumoxytol-enhanced Magnetic Resonance Imaging,Ferumoxytol-enhanced Magnetic Resonance Imaging,TERMINATED,new IRB not available,PHASE3,INTERVENTIONAL,36,Coronary Artery Disease,Ferumoxytol injection,DRUG,Detect the absence of ≥50% stenosis in the coronary artery tree,2015-01-01,2022-12-30,Transmed Solutions,OTHER
NCT05403723,Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC,"A Phase 1b Trial of Adaptive Stereotactic Body Radiotherapy in Combination With Durvalumab (MEDI4736), Platinum, and Etoposide in Extensive Stage Small Cell Lung Cancer",SUSPENDED,PI changed institution. Not yet approved at current location.,PHASE1,INTERVENTIONAL,50,Extensive-stage Small-cell Lung Cancer,"Durvalumab 50 MG/1 ML Intravenous Solution, Etoposide Injection, Cisplatin, Carboplatin","DRUG, DRUG, DRUG, DRUG, DEVICE",Incidence of treatment-related adverse events (AEs),2025-12-31,2027-08,Taofeek Owonikoko,OTHER
NCT03160508,Trochanter Fixation Nail Advanced (TFNA) Weight Bearing,A Prospective Study to Investigate Postoperative Real Life Weight Bearing Measured in Patients Treated With a Trochanter Fixation Nail Advanced (TFNA),TERMINATED,PCI decision due to technical issues,,OBSERVATIONAL,16,Femur Fracture,,PROCEDURE,Weight bearing,2017-10-20,2020-11-30,AO Innovation Translation Center,OTHER
NCT02591108,Train of Four Motor Point Stimulation and Monitoring,Quantitative Assessment of Train of Four Device for Patients Receiving Neuromuscular Blockade,WITHDRAWN,No Funding,NA,INTERVENTIONAL,0,Observation of Neuromuscular Block,,"DEVICE, DEVICE",Quantitative Amplitude of Force in the Neuromuscular Block Aid compared to the Qualitative Standard of Care Observations,2018-01-01,2019-11,University of Minnesota,OTHER
NCT01922908,Mesenchymal Stromal Cells for Ischemic Stroke,SAfety of Mesenchymal Stromal Cells for Ischemic Stroke,WITHDRAWN,Plan to change the trial design,"PHASE1, PHASE2",INTERVENTIONAL,0,Ischemic Stroke,"MSC Infusion, Placebo Comparator","BIOLOGICAL, BIOLOGICAL",maximum tolerated dose (MTD) of IV MSCs,2016-12,2018-12,Sean Savitz,OTHER
NCT00270725,Impact of Anti-HIV Treatment on Labor Productivity and Costs in South Africa,The Effectiveness of Antiretroviral Therapy in Reducing the Costs of HIV/AIDS,WITHDRAWN,"Enrollment never initiated, study withdrawn.",,OBSERVATIONAL,0,HIV Infections,,,,2005-07-01,2005-07-01,Boston University,OTHER
NCT01770717,Assessment of the Potential for Pressure Ulcer Formation,Assessment of the Potential for Pressure Ulcer Formation Using a New Optical Imaging Technology: Spatial Frequency Domain Imaging,WITHDRAWN,Not NIH defined clinical trial study.,,OBSERVATIONAL,0,Pressure Ulcer Not Visible,,OTHER,Formation of Pressure Ulcer,2012-08,2018-08,"University of California, Irvine",OTHER
NCT03392740,Prophylactic Lisinopril to Prevent Anthracycline Cardiomyopathy.,Prophylactic Lisinopril to Prevent Anthracycline Induced Left Ventricular Systolic Dysfunction (PLAID) Study.,WITHDRAWN,PI Andrew Hinojos Left Institution (Genesys) prior to Ascension Acquiring record,PHASE4,INTERVENTIONAL,0,"Cardiomyopathy Due to Drug, Heart Failure, Systolic","Lisinopril, Placebo Oral Tablet","DRUG, DRUG",Change in strain rate from baseline,2018-03-15,2018-12-15,Ascension Health,INDUSTRY
NCT00961168,Work of Breathing and Mechanical Ventilation in Acute Lung Injury,Prospective Study on the Effects of Artificial Breathing Patterns on Work of Breathing in Patients With Acute Lung Injury.,WITHDRAWN,Budgetary restrictions,NA,INTERVENTIONAL,0,Acute Lung Injury,,"OTHER, OTHER",proinflammatory cytokine expression in plasma,2009-09,2013-09,"University of California, San Francisco",OTHER
NCT00690118,Study of Pioglitazone in Patients With Amyotrophic Lateral Sclerosis,"Efficacy, Safety and Tolerability Study of 45 mg Pioglitazone in Patients With Amyotrophic Lateral Sclerosis (ALS) Receiving Standard Therapy (Riluzole)",TERMINATED,The interim analysis showed no tendency in favour of the verum group. Therefore it was decided to stop the study prematurely.,PHASE2,INTERVENTIONAL,219,Amyotrophic Lateral Sclerosis,"pioglitazone, placebo","DRUG, DRUG",Survival in patients with ALS treated with pioglitazone compared to placebo,2008-05,2010-06,University of Ulm,OTHER
NCT03720418,"Study of OXB-102 (AXO-Lenti-PD) in Patients With Bilateral, Idiopathic Parkinson's Disease",A Phase I/II Safety and Dose Evaluation Study of OXB-102 (AXO-Lenti-PD) in Patients With Bilateral Idiopathic Parkinson's Disease (SUNRISE-PD),TERMINATED,"As a result of termination of development of OXB-102-01, it is no longer possible for Sio to either commence or to continue any related clinical trials.","PHASE1, PHASE2",INTERVENTIONAL,6,Parkinson Disease,OXB-102,"DRUG, OTHER","Safety of OXB-102 as measured by incidence of treatment emergent adverse events and serious adverse events, Safety of OXB-102 as measured by changes in clinical laboratory analysis, Safety of OXB-102 as measured by changes in vital signs, Safety of OXB-102 as measured by changes in brain MRI findings, Safety of OXB-102 as measured by changes in physical examination",2018-10-17,2022-04-12,Sio Gene Therapies,INDUSTRY
NCT03191890,"Post Market Surveillance & Post Market Clinical Follow up, International, Medical Registry to Confirm the Safety and the Performance of the Anecova Intra Uterine Culture Device","Observational, Non-Interventional, Prospective, Post Market Surveillance & Post Market Clinical Follow up, International, Medical Registry to Confirm the Safety and the Performance of the Anecova Intra Uterine Culture Device for Participants With Subfertility Issue Undergoing Assisted Reproductive Medical Treatment in Routine Clinical Practice",WITHDRAWN,Sponsor stopped the study due to poor enrollment,,OBSERVATIONAL,0,"Infertility, Reproductive Sterility",,,Fertilization rate,2017-06-15,2018-03-31,Anecova SA,INDUSTRY
NCT06703190,Estimated Vaccine Effectiveness and Durability of Pfizer/BioNTech 2024-2025 COVID-19 Vaccine,Estimated Vaccine Effectiveness (VE) and Durability of Pfizer/BioNTech 2024-2025 COVID-19 (Coronavirus Disease 2019) Vaccine,TERMINATED,This secondary data analysis of symptomatic CVS MinuteClinics patients testing for SARS-CoV-2 was terminated due to incomplete data on KP.2 vaccination status (exposure). Termination was not based on any safety concerns or regulatory requirements.,,OBSERVATIONAL,1,COVID-19,"Pfizer-BioNTech BNT162b2 COVID-19 Vaccinated, Not vaccinated with 2024-2025 formulated COVID-19 vaccine","BIOLOGICAL, BIOLOGICAL","Number of Pfizer/BioNTech 2024-2025 formulation vaccinated patients who test positive for SARS-CoV-2 ≥14 days after receipt of vaccine, Number of COVID-19 2024-2025 formulation unvaccinated patients who test positive for SARS-CoV-2, Number of Pfizer/BioNTech 2024-2025 formulation vaccinated patients who test negative for SARS-CoV-2 ≥14 days after receipt of vaccine, Number of COVID-19 2024-2025 formulation unvaccinated patients who test negative for SARS-CoV-2",2024-11-25,2025-06-06,Pfizer,INDUSTRY
NCT01482897,Efficacy of corticoïd Infiltration Via Sacro-coccygien Hiatus in Discal Sciatica,Open Randomized Study on the Efficacy of corticoïd Infiltration Versus Physiological Solution Infiltration Versus Feigning of Infiltration Via Sacro-coccygien Hiatus Versus Natural Evolution in Discal Sciatica,TERMINATED,"Enrolment stopped on December 01, 2014 since after 3 years, only 13 patients were included (instead of 274) (Date of last visit last patient : October 3, 2013).",PHASE3,INTERVENTIONAL,13,Discal Sciatica,"Prednisolone acetate, sham procedure, comparator : physiological solution","DRUG, DRUG, DRUG",difference between the mean leg pain during the latest 24 hours preceding the infiltration and that preceding the visit S4,2011-12,2014-12,Nantes University Hospital,OTHER
NCT02424513,A Study of Positron Emission Tomography (PET) With [89]Zr-Df-IAb2M in Patients With High-risk Prostate Cancer,A Phase 2 Study of Positron Emission Tomography (PET) With [89]Zr-Df-IAb2M in Patients With High-risk Prostate Cancer,WITHDRAWN,Clinical trial was postponed as a result of restructured business priorities.,PHASE2,INTERVENTIONAL,0,Prostate Cancer,,RADIATION,"Sensitivity of [89]Zr-Df-IAb2M PET/CT for the detection of extraprostatic sites of prostate cancer as confirmed by biopsy and/or surgically resected tissue., Specificity of [89]Zr-Df-IAb2M PET/CT for the detection of extraprostatic sites of prostate cancer as confirmed by biopsy and/or surgically resected tissue., Positive Predicted Value of [89]Zr-Df-IAb2M PET/CT for the detection of extraprostatic sites of prostate cancer as confirmed by biopsy and/or surgically resected tissue., Negative Predicted Value of [89]Zr-Df-IAb2M PET/CT for the detection of extraprostatic sites of prostate cancer as confirmed by biopsy and/or surgically resected tissue., Accuracy of [89]Zr-Df-IAb2M PET/CT for the detection of extraprostatic sites of prostate cancer as confirmed by biopsy and/or surgically resected tissue.",2015-03,2016-03,"ImaginAb, Inc.",INDUSTRY
NCT00390013,To Evaluate if the Medication Gabapentin Lessens Vulvar Pain,"Vulvar Pain: Treatment Trial Using Gabapentin-placebo in a Cross-over Design, Pilot Study.",TERMINATED,poor recruitment,NA,INTERVENTIONAL,9,"Vulvar Pain Symptoms, Vulvodynia (Chronic Vulvar Pain)","Gabapentin, Placebo oral capsule","DRUG, DRUG",Change From Baseline in Vulvar Pain,2007-01,2008-03,Colleen Stockdale,OTHER
NCT05932667,"Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer","Milademetan and Fulvestrant in GATA3-mutant, ER-positive, HER2-negative Advanced or Metastatic Breast Cancer Patients: a Multicenter Phase II Trial",TERMINATED,Financial partner providing study drug could no longer support the trial,PHASE2,INTERVENTIONAL,1,Advanced or Metastatic Breast Cancer,Milademetan,"DRUG, BEHAVIORAL",Response per RECIST 1.1,2023-10-12,2023-11-30,Institut Curie,OTHER
NCT02895100,Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative Colitis,"A Phase 2b Randomised, Double-blind, Placebo-controlled, Parallel, Adaptive 2-Stage, Multi-Centre Study to Evaluate the Safety and Efficacy of Oral PTG-100 Induction in Subjects With Moderate to Severe Active Ulcerative Colitis",TERMINATED,Data Monitoring Committee discontinued the trial due to futility-based outcome,PHASE2,INTERVENTIONAL,98,Ulcerative Colitis,"PTG-100, Placebo","DRUG, DRUG",Proportion of Subjects Receiving PTG-100 With Clinical Remission at Week 12 Compared With Placebo,2016-12,2018-03-26,"Protagonist Therapeutics, Inc.",INDUSTRY
NCT00603200,Effect of Large Volume Paracentesis on Fatigue in Cirrhosis,The Effect of Large Volume Paracentesis on Fatigue in Cirrhosis,WITHDRAWN,Principal Investigator left institution,,OBSERVATIONAL,0,"Ascites, Fatigue, Cirrhosis",,,"Improvement in Fatigue symptomatology, as defined by fatigue questionnairre",2008-01,2009-12,Weill Medical College of Cornell University,OTHER
NCT03019107,Breath Synchronized Abdominal Muscle Stimulation to Facilitate Ventilator Weaning: a Pilot Study,Breath Synchronized Abdominal Muscle Stimulation to Facilitate Ventilator Weaning: a Pilot,TERMINATED,Unable to meet enrollment goal,,INTERVENTIONAL,2,"Electric Stimulation, Respiration, Artificial, Ventilator Weaning",,"DEVICE, DEVICE","Change in Maximum Expiratory Pressure From Baseline to Extubation, Change in Maximum Inspiratory Pressure From Baseline to Extubation",2017-02-22,2017-04-06,Liberate Medical,INDUSTRY
NCT04166734,Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma,Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma,TERMINATED,Study terminated due to slow recruitment and insufficient further funding.,PHASE1,INTERVENTIONAL,3,Advanced Malignant Pleural Mesothelioma,Pembrolizumab,"DRUG, RADIATION","Toxicity rate, stated as the number of patients who have had a Dose Limiting Toxicity calculated along with an exact binomial 95% confidence interval. All toxicities will be graded by CTCAE v5.0, tabulated by type, grade and dose level.",2021-01-26,2023-07-25,Royal Marsden NHS Foundation Trust,OTHER
NCT04581564,Rhythm-based Intervention in Aphasia,Investigating the Neural Mechanisms Underlying Language Recovery Through Rhythm Therapy,TERMINATED,Suspension of IRB (Institutional Review Board) Approval,NA,INTERVENTIONAL,4,Aphasia,,"BEHAVIORAL, BEHAVIORAL","Aphasia Spoken Word Assessment, Western Aphasia Battery (WAB) Test",2021-08-06,2024-02-28,The University of Texas at Dallas,OTHER
NCT01876264,Crohn's Extent of Resection Trial,Crohn's Extent of Resection Trial (CERT): A Randomised Controlled Trial Comparing Anastomotic Disease Recurrence Following 2cm Versus 10cm Resection Margins for Patients With Ileocolic Crohn's Disease,WITHDRAWN,Study abandoned,NA,INTERVENTIONAL,0,"Crohn's Disease, Recurrence",,"PROCEDURE, PROCEDURE",Endoscopic recurrence,2013-06,2013-06,Oxford University Hospitals NHS Trust,OTHER
NCT01130909,"A Blinded, Four-Way Crossover in Healthy Subjects to Assess EEG After Administration of Ketamine, Placebo and AZD6765","A Phase I, Randomized, Double-Blind, Four-way Cross-over Study in Healthy Subjects to Assess Quantitative Electroencephalography (qEEG) Parameters After the Administration of Ketamine, Two Doses of AZD6765 and Placebo",TERMINATED,The benefit of halting the study to analyze the available data outweighs the benefit of delaying the analysis to include data from remaining treatment periods,PHASE1,INTERVENTIONAL,36,Healthy,"AZD6765, AZD6765, Ketamine, Placebo","DRUG, DRUG, DRUG, DRUG",qEEG assessed through the gamma bands,2010-05,2011-01,AstraZeneca,INDUSTRY
NCT02960399,Assessment of Immunogenicity of Zostavax® in Patients With Antibody Deficiency 60 Years of Age and Older,Assessment of Immunogenicity of Zostavax® in Patients With Antibody Deficiency 60 Years of Age and Older,TERMINATED,PI has terminated the study at this time.,NA,INTERVENTIONAL,2,"Common Variable Immune Deficiency, Specific Antibody Deficiency, X-linked Agammaglobulinemia",Zostavax®,BIOLOGICAL,Determine in vitro changes in T cell proliferation preceding and following vaccination with Zostavax® by measurement of lymphocyte proliferation in response to VZV antigen.,2015-12,2017-12,University of South Florida,OTHER
NCT01642563,Italian Platelet Technology Assessment Study,"A Multi-center, Single-blind, Randomized, Parallel, Non Inferiority Study to Separately Investigate the Effect of Standard Platelets Versus Platelets Prepared With Two Commercial Procedures of Pathogen Reduction Technologies (PRT) on Bleeding Incidence and Severity in Thrombocytopenic Recipients",TERMINATED,Patient enrolment below planned schedule,PHASE3,INTERVENTIONAL,456,"Leukemia, Lymphoma",,"PROCEDURE, PROCEDURE",Incidence of bleeding of grade 2 or greater in recipients of PRT platelets versus incidence in recipients of control (standard) platelets,2010-10,2015-03,Centro Nazionale Sangue,OTHER_GOV
NCT02944721,"Genetic, Neurophysiological and Psychological Predictive Factors of Chronic Neuropathic Pain After Surgery for Breast Cancer","Genetic, Neurophysiological and Psychological Predictive Factors of Chronic Neuropathic Pain After Surgery for Breast Cancer",WITHDRAWN,change of sponsor,NA,INTERVENTIONAL,0,Breast Cancer,,"GENETIC, OTHER, OTHER, OTHER",Correlation coefficient between patients profile and type of pain,2016-11,2021-04,Hopital Foch,OTHER
NCT02075021,Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma,Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma,TERMINATED,PI left the institution,"PHASE1, PHASE2",INTERVENTIONAL,3,Relapsed or Refractory Multiple Myeloma,"Lenalidomide, nab-paclitaxel","DRUG, DRUG",Maximum Tolerated Dose (Phase I),2014-03,2015-11,NYU Langone Health,OTHER
NCT00742014,The Assessment of Right Ventricular Contractility in Response to Sildenafil,The Assessment of Right Ventricular Contractility in Response to Sildenafil in Pediatric Patients With Pulmonary Arterial Hypertension,TERMINATED,absorption of oral sildenafil not consistent,PHASE3,INTERVENTIONAL,10,Hypertension,Sildenafil,DRUG,Increase (% change) in endsystolic elastance of the right ventricle from baseline (in comparison to change in endsystolic elastance after inhaled NO),2008-08,2011-08,The Hospital for Sick Children,OTHER
NCT04712006,A Study of JNJ-64304500 Following Subcutaneous Injection in Healthy Chinese Adult Participants,"Phase 1, Open-label, Single Dose Study to Investigate the Pharmacokinetics, Safety, and Tolerability of JNJ-64304500 Following Subcutaneous Injection in Healthy Chinese Adult Participants",WITHDRAWN,Sponsor Decision.,PHASE1,INTERVENTIONAL,0,Healthy,JNJ-64304500,DRUG,Serum Concentration of JNJ-64304500,2021-05-30,2021-10-30,"Janssen Research & Development, LLC",INDUSTRY
NCT05193604,A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic Carcinoma,Phase I Clinical Trial to Evaluate the Tolerability and Safety of TQB2858 Injection in Subjects With Metastatic Pancreatic Cancer,TERMINATED,Terminated due to the adjustment of sponsor's development strategies and pipeline.,PHASE1,INTERVENTIONAL,29,Pancreatic Carcinoma,"TQB2858 injection, Anlotinib Hydrochloride Capsule, Gemcitabine hydrochloride for injection, Paclitaxel for injection (albumin bound)","DRUG, DRUG, DRUG, DRUG","Dose limiting toxicity (DLT), Recommended phase II dose (RP2D), Overall response rate (ORR)",2022-03-24,2023-11-27,"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.",INDUSTRY
NCT00500084,Phase III ALTU-135 CP Safety Trial,An Open-Label Clinical Study Evaluating the Long Term Safety of ALTU-135 in the Treatment of Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis or Pancreatectomy,TERMINATED,Sponsor decision.,PHASE3,INTERVENTIONAL,39,Exocrine Pancreatic Insufficiency,Liprotamase,DRUG,Number of participants with an adverse event,2007-12,2009-03,Anthera Pharmaceuticals,INDUSTRY
NCT00416884,"Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML","Fludarabine, Campath, TBI T-Cell Deplete NMSCT With Post-Transplant T-Cell Infusions for CML Failing Imatinib Therapy With Imatinib (STI571)",TERMINATED,Low enrollment,PHASE2,INTERVENTIONAL,1,Leukemia,"Campath, Fludarabine","DRUG, DRUG, RADIATION, OTHER",Number of Participants With Treatment-related Mortality,2003-05,2008-03,OHSU Knight Cancer Institute,OTHER
NCT04024384,Daratumumab as Maintenance After Peripheral Blood Stem Cell Transplantation From HLA-identical or Haploidentical Family Donor in the Treatment of Refractory or Relapsed Multiple Myeloma: a Phase 2 Trial,Daratumumab as Maintenance After Peripheral Blood Stem Cell Transplantation From HLA-identical or Haploidentical Family Donor in the Treatment of Refractory or Relapsed Multiple Myeloma: a Phase 2 Trial,WITHDRAWN,Promotor decision,PHASE2,INTERVENTIONAL,0,Multiple Myeloma,Daratumumab,DRUG,safety and efficacy of Daratumumab assessed by free survival,2019-07,2024-07,Assistance Publique - Hôpitaux de Paris,OTHER
NCT03265249,BRIDGE Device for Post-operative Pain Control,Auricular Percutaneous Electrical Nerve Field Stimulation (PENFS) Using the BRIDGE Device for Post-Operative Pain Control in Patients Undergoing Liver Transplantation,TERMINATED,slow enrollment,NA,INTERVENTIONAL,27,"Liver Failure, Liver Diseases, Alcoholic, Liver Diseases, Pain, Postoperative, Transplant; Failure, Liver, Liver Cirrhosis, Biliary",,DEVICE,Opioid Usage After Surgery as Measured by Total Milligrams of Morphine or Equivalent (MEQ),2018-02-12,2020-04-03,Duke University,OTHER
NCT02659449,Assessing the Impact of Different Compression of the Hand Versus Free Hand on the Implementation of the Precision Grip,Assessing the Impact of Different Compression of the Hand (Made to Measure Gloves / Compression Bandaging) Versus Free Hand on the Implementation of the Precision Grip,TERMINATED,No inclusion,,OBSERVATIONAL,3,Burned Hands,,"DEVICE, DEVICE, OTHER","Box and Block test, Purdue Pegboard test, Jamar's Test",2016-06-23,2016-12,Hôpital Léon Bérard,OTHER
NCT02080949,Phase I Dose Escalation in Patients With 1-3 Unresectable Brain Metastases,Study Phase I Dose Escalation With Hypofractionated Stereotactic Radiotherapy in Patients With 1-3 Unresectable Brain Metastases,WITHDRAWN,Low rate of recruitment.,PHASE1,INTERVENTIONAL,0,Brain Metastases,,RADIATION,Maximum Tolerance Dose,2011-01,2011-10,Barretos Cancer Hospital,OTHER
NCT00332826,Inhaled Technosphere Insulin in Subjects With Diabetes Mellitus and Asthma,"A Phase 3, 12-month Treatment, Multicenter, Randomized, Open-Label, Parallel Group Clinical Trial Comparing Prandial Subcutaneous Insulin With Prandial Inhaled Technosphere Insulin in Subjects With Diabetes Mellitus and Asthma",TERMINATED,Non-safety related business decision to combine special population protocols,PHASE3,INTERVENTIONAL,3,"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Asthma",Technosphere Insulin,DRUG,The primary safety outcome will be measurements of post bronchodilator FEV1 throughout the treatment period,2006-06,2007-10,Mannkind Corporation,INDUSTRY
NCT03935555,"Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib","Phase 1b Study of PU-H71 for the Treatment of Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Treated With Ruxolitinib",TERMINATED,Samus Therapeutics company closure,PHASE1,INTERVENTIONAL,11,"Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)",PU-H71,DRUG,"Assess Safety, Tolerability and Pharmacokinetics of PU-H71, Assess Safety, Tolerability and Pharmacokinetics of PU-H71, Assess Safety, Tolerability and Pharmacokinetics of PU-H71, Assess Safety, Tolerability and Pharmacokinetics of PU-H71, Assess Safety, Tolerability and Pharmacokinetics of PU-H71, Assess Safety, Tolerability and Pharmacokinetics of PU-H71, Assess Safety and Tolerability of PU-H71, Assess Safety and Tolerability of PU-H71, Assess Safety and Tolerability of PU-H71, Assess Safety and Tolerability of PU-H71, Assess treatment response of PU H71, Assess treatment response of PU H71",2019-08-12,2022-11-04,"Samus Therapeutics, Inc.",INDUSTRY
NCT00481585,The Biology of Claudin 3 in Primary Human Mammary Epithelial Cell Culture,The Biology of Claudin 3 in Primary Human Mammary Epithelial Cell Culture,TERMINATED,"study team failed to complete timely reviews, study suspended",,OBSERVATIONAL,13,Breast Cancer,,,Cell line data study,2007-05,,Hackensack Meridian Health,OTHER
NCT04148443,Impact of Preoxygenation Time on End-tidal Oxygen Concentration and on Hypoxic Events Occurring After Intubation in the Intensive Care Unit.,Impact of Preoxygenation Time on End-tidal Oxygen Concentration and on Hypoxic Events Occurring After Intubation in the Intensive Care Unit.,WITHDRAWN,"No inclusion after the 2 years of approval of the human subject review, even after 2 years of prorogation",NA,INTERVENTIONAL,0,"Preoxygenation, Intubation, Intensive Care Unit",,"OTHER, OTHER",Percentage of patients who reach an EtO2 of 90%,2023-12,2024-12,Centre Hospitalier Régional d'Orléans,OTHER
NCT04853108,Remote Monitoring of COVID-19 Positive Outpatients,"Using Telemedicine, Remote Physiologic Monitoring, and Mobile Self-reported Symptom Surveys to Improve Care for COVID-19 Patients",TERMINATED,The study terminated early due to end of funding.,,OBSERVATIONAL,300,Covid19,,OTHER,Identify Parameters Associated with Adverse Outcomes,2021-06-25,2023-04-01,Emory University,OTHER
NCT00764608,Study of the Human Skin Microbiome,Study of the Human Skin Microbiome,WITHDRAWN,"No Participants enrolled, per PI discretion",,OBSERVATIONAL,0,Healthy,,,Numerous organisms live on and in healthy human skin. This study seeks to survey the diversity of this complex ecosystem by collecting samples from approximately 1000 individuals in order to determine the type of organisms living on their skin.,2008-06,2009-02,Southwest Regional Wound Care Center,OTHER
NCT00528008,A Comparison of Surgical Preparations and Wound Infection Rates for Elective Cesarean Sections,Povidone-iodine vs. Chlorhexidine Gluconate - A Comparison of Surgical Preparations and Wound Infection Rates for Elective Cesarean Sections,TERMINATED,Study was stopped following interim analysis.,PHASE3,INTERVENTIONAL,268,Wound Infection,,"OTHER, OTHER",to determine the rate of wound infection using two standard wound preparations: povidone-iodine and chlorhexidine gluconate,2007-12,2010-02,Memorial University of Newfoundland,OTHER
NCT03479125,Post-Treatment Follow-up Study for Liver Disease Subjects With or Without Cirrhosis After Receiving Emricasan or Placebo,Protocol IDN-6556-18 - A Post Treatment Follow-up Study for Liver Disease Subjects With or Without Liver Cirrhosis After Receiving Emricasan or Placebo,TERMINATED,Sponsor has discontinued the development of emricasan,,OBSERVATIONAL,40,"Liver Diseases, Liver Fibrosis, Liver Cirrhosis, NASH Fibrosis, Decompensated Non-Alcoholic Steatohepatitis Cirrhosis, Orthotopic Liver Transplantation",,DIAGNOSTIC_TEST,Adjusted event rate for hepatocellular carcinoma.,2018-02-27,2019-09-30,Conatus Pharmaceuticals Inc.,INDUSTRY
NCT00929825,Therapies for Salivary Flux Stimulation in Patients Transplanted With Hematopoietic Stem Cells,Effects of Mechanical and Electrical Sialogogues in Stimulation of the Flow and Biochemical Composition of Saliva in Patients Transplanted With Hematopoietic Stem Cells,WITHDRAWN,The Hospital had the Unit of Stem cells Tranplantion suspended,PHASE1,INTERVENTIONAL,0,Mucositis,,"DEVICE, PROCEDURE",Salivary flux,2008-02,2011-08,Federal University of Minas Gerais,OTHER
NCT03737617,Immunoglobulin Replacement Therapy for Immunoglobulin G Subclass 2 Deficient Patients With Bronchiectasis,Immunoglobulin Replacement Therapy for Immunoglobulin G Subclass 2 Deficient Patients With Bronchiectasis- A Proof of Concept Study,WITHDRAWN,Cant obtain IMP,PHASE4,INTERVENTIONAL,0,"Bronchiectasis, Immunoglobulin Subclass Deficiency",Cuvitru 20 % Injectable Solution,DRUG,"Change in sputum bacterial load, Proportion with bacterial load >=10(6) colony forming units/ml",2022-08-05,2024-12-01,University of Edinburgh,OTHER
NCT03511417,The Effectiveness of Over the Counter Hearing Products for Middle-Aged Adults,Aging and Speech Perception in Complex Listening Environments,WITHDRAWN,Due to the delay in establishing FDA regulations for over-the-counter hearing aids,NA,INTERVENTIONAL,0,"Hearing Loss, Functional",,DEVICE,"Speech Perception, Cognitive Load, Localization Ability, Self-Perceived Listening Effort",2018-10-16,2020-01-17,"University of Massachusetts, Amherst",OTHER
NCT04436250,ESKETamine for FIBromyalgia Treatment,Intravenous Infusions of S-KETAMINE in Fibromyalgia Syndromes: an Exploratory Study.,TERMINATED,Lack of recruitment.,NA,INTERVENTIONAL,23,Fibromyalgia,"Active comparator, S-Ketamine Low dose, S-Ketamine High dose","DRUG, DRUG, DRUG","The primary outcome is twofold, aiming on one side pain relief and on the other the improvement of the patient's functional status",2020-10-10,2024-09-30,Grand Hôpital de Charleroi,OTHER
NCT01716650,A Pilot Study to Evaluate the Contribution of the Saphenous Nerve in Ankle Pain of Patients With Degenerative Joint Disease of the Ankle,A Pilot Study to Evaluate the Contribution of the Saphenous Nerve in Ankle Pain of Patients With Degenerative Joint Disease of the Ankle,TERMINATED,no available participants,,OBSERVATIONAL,4,Degenerative Joint Disease of the Ankle,,,Ankle pain,2012-10,2016-09,Mayo Clinic,OTHER
NCT01721174,Endoscopic Biliary Radiofrequency Ablation of Malignant Distal Common Bile Duct Strictures,A Randomized Controlled Trial of Endoscopic Biliary Radiofrequency Ablation of Malignant Distal Common Bile Duct Strictures.,TERMINATED,Poor recruitment,NA,INTERVENTIONAL,42,"Pancreatic Cancer, Cholangiocarcinoma",,"PROCEDURE, PROCEDURE",Stent patency rate,2012-11,2017-12,Chinese University of Hong Kong,OTHER
NCT02212574,Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt Positive Medulloblastoma,Pilot Study Assessing the Feasibility of a Surgery and Chemotherapy-Only Approach in the Upfront Therapy of Children With Wnt Positive Standard Risk Medulloblastoma,TERMINATED,Participant relapses led to abrupt stop of study.,EARLY_PHASE1,INTERVENTIONAL,6,Medulloblastoma,"Lomustine, Vincristine, Cisplatin, Cyclophosphamide, Mesna, Vincristine","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG",Progression Free Survival,2017-04-04,2018-11-09,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,OTHER
NCT03782818,Olaparib for PAH: a Multicenter Clinical Trial,Olaparib for Pulmonary Arterial Hypertension: a Multicenter Clinical Trial,TERMINATED,"The recruitment was stopped on October 31st 2024 due to limited recruitment within the last year, as well as the end of funding (Spring 2025).","PHASE1, PHASE2",INTERVENTIONAL,17,Pulmonary Arterial Hypertension,Olaparib,DRUG,Occurrence of treatment-emergent AEs at week 24,2019-11-20,2024-10-31,Laval University,OTHER
NCT01006018,DPP-4 Inhibition and TZD for DM Prevention,DPP-4 Inhibition and Thiazolidinedione for Diabetes Mellitus Prevention (DInT DM Study),TERMINATED,Unanticipated delays due to sterilization/stabilization testing of GLP-1.,NA,INTERVENTIONAL,3,Prediabetic State,"Sitagliptin + Pioglitazone PLACEBO, Sitagliptin + Pioglitazone, PLACEBO","DRUG, DRUG, DRUG",Insulin Secretion,2011-07,2011-12,Emory University,OTHER
NCT01545518,IVIG Treatment for Refractory Immune-Related Adult Epilepsy,IVIG Treatment for Refractory Immune-Related Adult Epilepsy,TERMINATED,"Futility criteria, unable for Phase 2 of study, \& phase 1 was terminated.",PHASE2,INTERVENTIONAL,20,"Epilepsy, Cryptogenic, Epilepsy, Partial, Seizure Disorder, Autoimmune Diseases, Nervous System, Limbic Encephalitis",IVIG,DRUG,Immune Abnormalities,2011-11,2013-08,Emory University,OTHER
NCT04476797,Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLC,"GRECO-1: Phase I/II, Randomized, Placebo-Controlled Study of Stereotactic Body Radiation Therapy (SBRT) and GC4711 for Centrally Located or Large, Node-Negative Non-Small Cell Lung Cancer (NSCLC)",TERMINATED,Development GC4711 was halted after the lead study in pancreatic cancer was stopped early due to meeting the requirements of a futility analysis,"PHASE1, PHASE2",INTERVENTIONAL,47,"SBRT, NSCLC, Non-metastatic","GC4711 +SBRT, Placebo +SBRT","DRUG, DRUG",Percent of Patients With a Complete Response or Partial In-field Tumor Response Based on the RECIST 1.1 Criteria Through 6 Months Following SBRT.,2020-10-18,2023-11-28,"Galera Therapeutics, Inc.",INDUSTRY
NCT05915897,Whole Blood Biospecimen Collection for Subjects With Chronic Granulomatous Disease (CGD),Whole Blood Biospecimen Collection for Subjects With Chronic Granulomatous Disease (CGD),TERMINATED,Unable to recruit subjects due to disease rarity,,OBSERVATIONAL,6,Chronic Granulomatous Disease,,DIAGNOSTIC_TEST,Participants have been diagnosed with Chronic Granulomatous Disease (CGD),2023-05-23,2024-03-25,Sanguine Biosciences,INDUSTRY
NCT04515797,QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir,QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir,TERMINATED,Unable to meet enrollment goal prior to drug expiration,PHASE4,INTERVENTIONAL,2,"Kidney Failure, Hepatitis C, Kidney Disease, Chronic",Glecaprevir and Pibrentasvir,DRUG,Number of Participants With Undetectable Blood HCV RNA Level,2021-05-01,2023-08-31,Massachusetts General Hospital,OTHER
NCT02277210,Follicular Flushing in Patients With Suboptimal Responses,Effect of Follicular Flushing on the Ongoing Pregnancy Rate in Patients Who Developed Four or Fewer Follicles of 14mm Following Standard Ovarian Stimulation for In-vitro Fertilization Treatment - A Randomized Controlled Trial.,TERMINATED,poor recruitment,NA,INTERVENTIONAL,4,Infertility,,OTHER,ongoing pregnancy rate,2014-10,2018-06-02,The University of Hong Kong,OTHER
NCT01700010,Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer,Phase II Trial of Lapatinib and Weekly Paclitaxel for Advanced Platinum Refractory Urothelial Cancer,WITHDRAWN,Funding issues.,PHASE2,INTERVENTIONAL,0,"Urothelial Cancer, Bladder Cancer",Lapatinib and Paclitaxel,DRUG,Progression free,2012-11,2019-01,University of Michigan Rogel Cancer Center,OTHER
NCT03998410,Evaluation of the Diagnostic Value of the TPD System in Determining ADHF Causing Acute Dyspnea,Evaluation of the Diagnostic Value of the TPD System in Determining ADHF Causing Acute Dyspnea,TERMINATED,due to the pandemic,NA,INTERVENTIONAL,130,ADHF,,DEVICE,Accuracy of diagnosis,2019-09-15,2021-07-01,Echosense Ltd.,INDUSTRY
NCT05114213,MR-Guided Adaptive SBRT of Primary Tumor for Pain Control in Metastatic PDAC,"MR-Guided Adaptive Stereotactic Body Radiotherapy (SBRT) of Primary Tumor for Pain Control in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - a Randomized, Controlled Clinical Study",TERMINATED,"Low accrual, close out in November 2025",PHASE2,INTERVENTIONAL,9,Pancreatic Cancer,SOC chemotherapy,"RADIATION, DRUG",Mean cumulative pain index,2021-12-15,2025-11-11,Ludwig-Maximilians - University of Munich,OTHER
NCT05558813,Natural History of Duchenne Muscular Dystrophy Cardiomyopathy (DMD-CMP),Prospective Cardiac Magnetic Resonance Imaging Study in Duchenne Muscular Dystrophy (DMD-CMP),WITHDRAWN,Cancellation of financing by the financier.,NA,INTERVENTIONAL,0,Duchenne Muscular Dystrophy,Blood assays,"DIAGNOSTIC_TEST, BIOLOGICAL",Late gadolinium enhancement burden on cardiac MRI,2024-11,2029-04,Assistance Publique - Hôpitaux de Paris,OTHER
NCT02992860,Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED THERAPY,Single Agent JNJ-56022473 in MDS and AML Patients Failing Hypomethylating Agent Based Therapy,TERMINATED,"Enrollement was stopped due to a recommendation by the IDMC/FDA for a parallel clinical trial with TALA, where potentielly no efficancy could be determined.",PHASE2,INTERVENTIONAL,25,"Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)",JNJ-56022473,"DRUG, PROCEDURE, OTHER, OTHER, PROCEDURE, GENETIC, PROCEDURE, PROCEDURE, PROCEDURE",Overall hematological response rate,2016-07,2018-10,GWT-TUD GmbH,OTHER
NCT03284060,Social Cognition Training and Cognitive Remediation,Social Cognition Training and Cognitive Remediation : a New Tool for 22q11.2 Deletion Syndrome,TERMINATED,inclusion difficulties,NA,INTERVENTIONAL,3,22q11.2 Deletion Syndrome,,BEHAVIORAL,"The primary endpoint is the variation in sub-scores of specific baselines, obtained before and after cognitive remediation intervention:",2017-10-11,2019-05-21,Hôpital le Vinatier,OTHER
NCT03246685,Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SD,"A Multicenter, Open-label, Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv Squamous Cell Carcinoma of H&N (SCCHN) Who Failed Pembro Monotherapy or Experiencing SD Following Completion of 4 to 8 Cycles of Pembro Monotherapy",TERMINATED,"Due to enrollment challenges resulting in changing treatment patterns, the study has been terminated. No patients remain on study.",PHASE2,INTERVENTIONAL,1,Squamous Cell Carcinoma of the Head and Neck,"Imprime PGG, Pembrolizumab","BIOLOGICAL, DRUG",Overall Response Rate (ORR) to Imprime PGG + pembrolizumab using RECIST v1.1 criteria,2017-11-08,2018-04-13,"HiberCell, Inc.",INDUSTRY
NCT02293408,Natural History Study to Characterise the Course of Disease Progression in Participants With Mucopolysaccharidosis Type IIIB,A Prospective Cross-Sectional and Longitudinal Study With Additional Retrospective Chart Review to Evaluate Clinical and Biochemical Characteristics and Disease Progression in Patients With Mucopolysaccharidosis Type IIIB,TERMINATED,The Sponsor's decision to terminate the SBC-103 program was reached after review of the data from all interventional clinical studies of SBC-103.,,OBSERVATIONAL,30,MPS IIIB (Sanfilippo B Syndrome),,,"Collection And Analysis Of Clinical Characteristics Of MPS IIIB, Longitudinal Analysis Of The Course Of Disease Progression In Participants With MPS IIIB",2014-09-14,2017-07-11,"Alexion Pharmaceuticals, Inc.",INDUSTRY
NCT01650285,Cabazitaxel and Radiation For Patients With Prostate Cancer,Cabazitaxel and Radiation For Patients With Pathologically Determined Stage 3 Prostate Cancer and/or Patients With PSA Elevation (>0.1- < 2.0 ng/mL) Following Radical Prostatectomy,TERMINATED,slow recruitment and lost funding,PHASE2,INTERVENTIONAL,5,Prostate Cancer,Cabazitaxel,DRUG,Maximum Tolerated Dose of Cabazitaxel With Concurrent Adjuvant Radiation,2013-01,2014-07,Brown University,OTHER
NCT01318915,Research Study of ATG and Rituximab in Renal Transplantation,"Immunosuppression With Antithymocyte Globulin, Rituximab, Tacrolimus, Mycophenolate Mofetil and Sirolimus, Followed by Withdrawal of Immunosuppression, in Living-donor Renal Transplant Recipients",TERMINATED,The stopping rule for incidence of acute rejection was met.,EARLY_PHASE1,INTERVENTIONAL,10,Renal Transplant Recipients,"ATG, Rituximab, Tacrolimus, Sirolimus, MMF","DRUG, DRUG, DRUG, DRUG, DRUG",Percent of Participants Successfully Withdrawn From Immunosuppression and Remained Off Immunosuppression for at Least 52 Weeks,2011-07-25,2017-08-25,National Institute of Allergy and Infectious Diseases (NIAID),NIH
NCT02840825,Biochip for HCMV Detection in Breast Milk,Biochip for HCMV Detection in Breast Milk From Lactating Women of Preterm Infants Less Than 33 Weeks,TERMINATED,Technical issues with microchip,,OBSERVATIONAL,2,"Cytomegalovirus Infections, Breast Feeding, Premature Birth of Newborn",,,optical detection of HCMV specifically captured on the biochip with respect to the reference (PCR) technique.,2016-03-08,2021-09-29,Centre Hospitalier Universitaire de Besancon,OTHER
NCT03115476,A Trial to Compare the Incidence of Squamous Cell Carcinoma (SCC) and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp,"Incidence of Squamous Cell Carcinoma and Other Skin Neoplasia in Subjects With Actinic Keratosis Treated With Ingenol Disoxate Gel 0.018% or 0.037%, or Vehicle Gel",TERMINATED,Study halted prematurely and will not resume; participants are no longer being examined.,PHASE3,INTERVENTIONAL,563,"Actinic Keratosis, Squamous Cell Carcinoma","ingenol disoxate gel 0.018%, ingenol disoxate gel 0.037%","DRUG, DRUG, OTHER",Time to First Squamous Cell Carcinoma (SCC) in the Treatment Area,2017-06-16,2018-03-12,LEO Pharma,INDUSTRY
NCT04194476,Performance Study of Nova StatStrip® Blood Glucose Monitoring Test System on Neonatal Capillary Blood,Performance Study of Nova StatStrip® Blood Glucose Monitoring Test System on Neonatal Capillary Blood,SUSPENDED,The protocol needs to be further developed.,NA,INTERVENTIONAL,120,Healthy and Unhealthy Neonates,,DIAGNOSTIC_TEST,"blood glucose level measured by StatStrip blood glucose meter, plasma glucose level measured by a laboratory biochemistry analyzer",2025-01-01,2025-03-30,Nova Biomedical,INDUSTRY
NCT01650740,Study of Placebo Without Deception Versus Standard Antidepressant for Major Depressive Disorder,A Randomized Trial of Sequenced Treatment Using Placebo Without Deception Followed by Open-Label Antidepressant Versus Immediate Open-Label Antidepressant Treatment for Major Depressive Disorder,TERMINATED,Poor recruitment results.,NA,INTERVENTIONAL,1,Major Depressive Disorder,"Duloxetine, placebo","DRUG, DRUG, OTHER",>= 50% improvement in Montgomery-Asberg Depression Rating Scale (MADRS) Scores (MADRS Response),2012-08,2014-11,Sunnybrook Health Sciences Centre,OTHER
NCT04091191,Evaluation of a Nutraceutical for Endometriosis Pain Relief,"A Single Center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Tolerability of a Specialized Nutraceutical for Endometriosis",TERMINATED,Insufficient recruitment,NA,INTERVENTIONAL,5,Endometriosis,,DIETARY_SUPPLEMENT,Pain relief,2021-10-13,2022-12-16,Metagenics Europe,INDUSTRY
NCT00447291,Safety & Efficacy of Omega-3 Fish Oil in Overweight Children & Adolescents,"Evaluation of the Safety and Efficacy of Omega-3 Fish Oil Dietary Supplementation in Biometric Measurement, Lipid Profile, Serum Markers for Inflammation, and Insulin Resistance in Overweight Children and Adolescents",TERMINATED,"Zone Labs, Inc discontinue utilizing their fish oil supplement and frozen foods",PHASE3,INTERVENTIONAL,60,"Overweight, Obesity",Supplement: Omega-3 Fish Oil,"DRUG, BEHAVIORAL",To compare effects between Omega 3 fish oil and placebo,2006-12,2010-07,Children's Heart Center,INDUSTRY
NCT01133574,This is a Single Ascending Dose Tolerance Study,"A Double-Blind, Randomized, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of SLV354 After Oral Dose Administration in Healthy Adult Male Subjects",TERMINATED,"Part A completed successfully 22 July 2010, Part B will be separate PET study",PHASE1,INTERVENTIONAL,47,Cognition Disorders,"SLV354 capsules, SLV354 capsules, SLV354 capsules, SLV354 capsules, SLV354 capsules, SLV354 capsules, SLV354 capsules, SLV354 capsules, Placebo capsules, SLV354 capsules, SLV354 capsules, SLV354 capsules, SLV354 capsules, Placebo capsules","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Safety and tolerability assessments including adverse events, clinical laboratory tests, ECG and vital signs (Part A), Safety and tolerability assessments including adverse events, clinical laboratory tests, ECG and vital signs (Part B)",2010-02,2010-07,Abbott,INDUSTRY
NCT04248491,Emsella Chair Versus Sham for the Treatment of Chronic Pelvic Pain,"A Single-Blind, Randomized Study of the BTL Emsella Chair Versus Sham for the Treatment of Chronic Pelvic Pain",TERMINATED,Due to low enrollment and lack of efficiency,NA,INTERVENTIONAL,11,Pelvic Pain,,DEVICE,The Change in Subject-reported Pain and Discomfort as Measured by the Visual Analog Scale (VAS),2020-07-13,2023-07-13,Corewell Health East,OTHER
NCT04878874,Effects of Magnetic Tape Over Hip Flexion in Patients With Low Back Pain.,Effects of Magnetic Tape Over Hip Flexion in Patients With Low Back Pain.,WITHDRAWN,Logistics and infrastructure problems,NA,INTERVENTIONAL,0,Low Back Pain,,"DEVICE, DEVICE",Hip flexion,2021-06-22,2021-06-22,Francisco Selva,OTHER
NCT00971074,Study of Viscosupplementation for the Treatment of Knee Pain After Menisectomy,The Use of Viscosupplementation for the Treatment of Patients With Persistent Non-mechanical Pain Status-post Partial Menisectomy,WITHDRAWN,Patients did not meet inclusion criteria.,NA,INTERVENTIONAL,0,Arthralgia,Hylan G-F 20,"DRUG, OTHER",VAS pain scale,2009-12,2011-12,Grant Jones,OTHER
NCT00278018,Peritumoral Injection of Immature Dendritic Cells to Irradiated Skin Metastases of Solid Tumors,Peritumoral Injection of Immature Dendritic Cels to Irradiated Metastases of Solid Tumors,TERMINATED,Because there were no responses,"PHASE1, PHASE2",INTERVENTIONAL,20,"Cancer of Skin, Solid Tumors",,PROCEDURE,"Complete evaluation of untreated lesions with physical examination and appropriate X-rays and/or scans will be performed four to six weeks after the last DC injection., Immunological evaluation will be performed two weeks after the last DC injection.",2005-12,2008-12,Hadassah Medical Organization,OTHER
NCT04192318,Evaluating Outcomes for Youth Receiving Hospital-based Violence Prevention With and Without a Community-level Initiative,Evaluating Outcomes for Youth Receiving Hospital-based Violence Prevention With and Without a Community-level Initiative,TERMINATED,"Due to COVID, enrollment and data collection was shut down. Project was funded by training grant which ended before COVID restrictions were sufficiently lifted to resume enrollment.",NA,INTERVENTIONAL,2,Violence in Adolescence,,"BEHAVIORAL, OTHER, OTHER","Change in youth violence - self report, Change in youth violence - caregiver report, Change in youth dating violence, Change in youth sexual violence",2020-02-10,2020-02-10,Virginia Commonwealth University,OTHER
NCT00248118,Efficacy and Safety of Bupropion for Treatment of Adolescent Smoking,Neurocognitive and Affective Correlates of Tobacco Dependence in Adolescent Smokers and Efficacy and Safety of Bupropion for Treatment of Adolescent Smoking,TERMINATED,PI left NIH,"PHASE2, PHASE3",INTERVENTIONAL,72,Tobacco Dependence,Bupropion,DRUG,"Bupropion will be safe and tolerable, increase cessation rates, and reduce smoke and nicotine exposure",2005-01,2008-05,National Institute on Drug Abuse (NIDA),NIH
NCT03074318,Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery,A Phase I/II Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma,TERMINATED,Terminated due to PI leaving institution,"PHASE1, PHASE2",INTERVENTIONAL,35,"Metastatic Leiomyosarcoma, Metastatic Liposarcoma, Unresectable Leiomyosarcoma, Unresectable Liposarcoma","Avelumab, Trabectedin","DRUG, DRUG","Incidence of Adverse Events, Overall Response Rate (ORR)",2017-09-28,2020-11-15,Fred Hutchinson Cancer Center,OTHER
NCT01916590,Effectiveness of Continuous Femoral Nerve Block Versus Single Shot Femoral Nerve Block for Pain Control,Effectiveness of Continuous Femoral Nerve Block Versus Single Shot Femoral Nerve Block for Pain Control After Anterior Cruciate Ligament Reconstruction With Patellar Tendon Graft or Allograft,TERMINATED,lack of patients,NA,INTERVENTIONAL,7,Post-operative Pain,"Bupivicaine, placebo","DRUG, DRUG",Pain Scores Will be Collected for 48 Hours After ACL Reconstruction,2011-07,2014-05,"University of Colorado, Denver",OTHER
NCT00230490,Open-label Treatment Extension Study for Patients Who Complete Study RNA200103-201,Open-label Treatment Extension Study for Patients Who Complete Study RNA200103-201,TERMINATED,Adverse findings from nonclinical carcinogenicity studies.,PHASE2,INTERVENTIONAL,150,"Hepatitis B, Chronic","pradefovir mesylate, adefovir dipivoxyl","DRUG, DRUG","- Safety: Clinical examinations of laboratory tests, - Efficacy: Change in viral load over time",2005-06,2007-05,"Bausch Health Americas, Inc.",INDUSTRY
NCT05639790,The Effectiveness of Using E-Cigarettes for Smoking Cessation and Decreasing Risk of Diseases Among Heavy Smokers,The Effectiveness of Using E-Cigarettes as Harm Reduction Strategy for Smoking Cessation and Decreasing Risk of Diseases Among Heavy Smokers: an Open-label Randomized Controlled Trial,WITHDRAWN,Due to issues arised from the collaboration contract between sponsor and research site,NA,INTERVENTIONAL,0,Smoking Cessation,,"COMBINATION_PRODUCT, OTHER",7-day point prevalence abstinence,2023-11-01,2024-08-01,Shenzhen Smoore Technology Limited,INDUSTRY
NCT03136497,A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma,Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL),TERMINATED,Lack of enrollment,PHASE1,INTERVENTIONAL,10,"Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma","400mg ABT-199, Ibrutinib, Rituximab, 800mg ABT-199","DRUG, DRUG, DRUG, DRUG",Maximum Tolerated Dose (MTD),2017-09-05,2020-11-09,Hackensack Meridian Health,OTHER
NCT00748410,Study to Evaluate the Pharmacodynamics of SB-656933 in Patients With Ulcerative Colitis,"An Open Label, 7-day Repeat Dose Study to Evaluate the Pharmacodynamics of SB-656933-AAA in Patients With Ulcerative Colitis.",TERMINATED,SB-656933 is no longer being developed for ulcerative colitis.,PHASE2,INTERVENTIONAL,3,"Colitis, Ulcerative",SB-656933,DRUG,Change From Baseline at 1 and 7 Days Treatment With Daily Dose of SB-656933-AAA in 99m(Technetium-hexamethyl Derivative of Propylene Amine Oxide)Tc-HMPAO Leukocyte Single Photon Emission Computerized Tomography (SPECT) Scintigraphic Activity Scores (SAS),2009-01-22,2009-12-12,GlaxoSmithKline,INDUSTRY
NCT06127810,MRI Gadopiclenol Enhanced Imaging of CNS Tumors,A Pilot Study of Gadopiclenol for Imaging Central Nervous System (CNS) Tumors at Point of Care Magnetic Resonance Imaging (MRI),WITHDRAWN,The sponsor backed out of the trial.,,OBSERVATIONAL,0,Image,Gadopiclenol,"DEVICE, DRUG",Visibility of lesions,2024-12-30,2024-12-30,Medical University of South Carolina,OTHER
NCT03187210,Brentuximab Vedotin and BeEAM High-dose Chemotherapy in Lymphomas,"Brentuximab Vedotin and BeEAM High-dose Chemotherapy (B-BeEAM) With Autologous Stem Cell Transplantation for CD30+ Lymphomas, a Phase I/II Study",SUSPENDED,low accrual,"PHASE1, PHASE2",INTERVENTIONAL,20,Lymphoma,"Brentuximab Vedotin, BeEAM Regimen","DRUG, DRUG","Phase 1: Dose finding, Phase 2: Disease free survival at 12 months",2018-09-01,2025-04-30,"Insel Gruppe AG, University Hospital Bern",OTHER
NCT04455035,DynaCleft® Effects on Soft Tissues and on Quality of Life for Incomplete Unilateral Cleft Lip Infants,DynaCleft® Effects on Soft Tissues and on Quality of Life for Incomplete Unilateral Cleft Lip Infants,TERMINATED,PI left institution,NA,INTERVENTIONAL,24,Cleft Lip and Palate,,"OTHER, DEVICE","Changes in Soft Tissue as Indicated by Width of the Cleft Lip Measured From Extraoral Clinical Photographs, Changes in Soft Tissue as Indicated by Columellar Angle Measured From Extraoral Clinical Photographs, Changes in Soft Tissue as Indicated by Nostril Height Measured From Extraoral Clinical Photographs, Changes in Soft Tissue as Indicated by Nostril Width Measured From Extraoral Clinical Photographs",2020-09-21,2021-04-06,"The University of Texas Health Science Center, Houston",OTHER
NCT00843115,Observational Study Of Donepezil In Routine Clinical Practice,Ecological Perspective On The Efficacy And Tolerability Of Donepezil In A Routine Clinical Practice: A Patient Centered Observational Study,TERMINATED,See Detailed Description.,,OBSERVATIONAL,370,Alzheimer's Disease,,OTHER,"All Subjects Improved/Stabilized or Worsened for Cognitive Activation in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment, All Subjects Improved/Stabilized or Worsened for Attention in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment, All Subjects Improved/Stabilized or Worsened for Repetitiveness in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment, All Subjects Improved/Stabilized or Worsened for Remembering in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment, All Subjects Improved/Stabilized or Worsened for Temporal Orientation in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment, All Subjects Improved/Stabilized or Worsened for Asphasia in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment, All Subjects Improved/Stabilized or Worsened for Spatial Orientation in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment, All Subjects Improved/Stabilized or Worsened for Judgment in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment, All Subjects Improved/Stabilized or Worsened for Insight in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment, All Subjects Improved/Stabilized or Worsened for Leisure in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment, All Subjects Improved/Stabilized or Worsened for Domestic Activities in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment, All Subjects Improved/Stabilized or Worsened for Hygiene in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment, All Subjects Improved/Stabilized or Worsened for Dressing in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment, All Subjects Improved/Stabilized or Worsened for Telephoning in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment, All Subjects Improved/Stabilized or Worsened for Agitation in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment, All Subjects Improved/Stabilized or Worsened for Mood in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment, All Subjects Improved/Stabilized or Worsened for Anxiety in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment, All Subjects Improved/Stabilized or Worsened for Delusions in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment, All Subjects Improved/Stabilized or Worsened for Apathy in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment, All Subjects Improved/Stabilized or Worsened for Caregiver in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment, All Subjects Improved/Stabilized or Worsened for Severity in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment",2007-02,2008-04,Pfizer,INDUSTRY
NCT04355676,Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19,"A Phase 2 Randomized, Open-Label, Multicenter Study to Evaluate the Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Patients With Moderate or Severe COVID-19",WITHDRAWN,No participants enrolled,PHASE2,INTERVENTIONAL,0,Coronavirus Infection,Selinexor,DRUG,Percentage of Participants with at Least a 2 Point Improvement in the Ordinal Scale,2020-04-30,2020-08-30,Karyopharm Therapeutics Inc,INDUSTRY
NCT03762317,Clonidine as Adjunct to Morphine for Neonatal Abstinence Syndrome,Clonidine as Adjunct to Morphine in the Management of Term and Near Term Infants With Neonatal Abstinence Syndrome,TERMINATED,Study was initially suspended due to IND application and later terminated due to the difficulty of obtaining consent during COVID period,PHASE4,INTERVENTIONAL,10,Neonatal Abstinence Syndrome,"Clonidine, Placebo","DRUG, DRUG",Duration of Pharmacotherapy for NAS,2018-04-30,2018-12-12,"Hennepin County Medical Center, Minneapolis",OTHER
NCT04464317,Dysphagia and Vocal Cord Injury Following Cardiac Surgery,Vocal Cord Impairment and Dysphagia in Cardiac Surgery,WITHDRAWN,"Observational only, no subjects enrolled",,OBSERVATIONAL,0,"Dysphagia, Cardiovascular Diseases",,,Incidence of vocal fold mobility impairment (VFMI) and dysphagia in postoperative cardiovascular patients,2020-08-05,2023-06-13,University of Florida,OTHER
NCT02068417,Pilot Study of the Treatment of Erectile Dysfunction (ED) With Extracorporeal Shockwave Therapy (ESWT),"A Prospective, Randomised, Blinded, Placebo-controlled Pilot Study of the Treatment of Erectile Dysfunction With Extracorporeal Shockwave Therapy (ESWT)",TERMINATED,It has been decided to improve the inclusion criteria for better study outcome,PHASE3,INTERVENTIONAL,40,Erectile Dysfunction,,DEVICE,Effects of erection problems on the sex life (International Index of Erectile Function (IIEF) Questionnaire),2011-10,2014-02,Storz Medical AG,INDUSTRY
NCT06072040,Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia,"A Phase 1/2, Multi-Center, Open-Label, Single-Arm Safety, Tolerability, and Efficacy Study of an Auricle and Wedge Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia",TERMINATED,Business reasons,"PHASE1, PHASE2",INTERVENTIONAL,3,Microtia,,COMBINATION_PRODUCT,"Incidence of Treatment-Emergent Adverse Events, Appearance/Efficacy of the AUR-201 Implant",2024-01-26,2025-11-14,"Auregen Biotherapeutics, SA",INDUSTRY
NCT02196389,Comparison Between 4 Different Nasal Dilators,Comparison Between 4 Different Nasal Dilators: Objective vs Subjective Parameters,TERMINATED,"No contract, no costs",PHASE4,INTERVENTIONAL,100,Incompetence of Nasal Valve,,"DEVICE, DEVICE, DEVICE, DEVICE",Peak Nasal Inflammatory Flow,2014-01,2018-08-18,Universitaire Ziekenhuizen KU Leuven,OTHER
NCT06041568,A Study of Imvotamab in Severe Systemic Lupus Erythematosus,"A Phase 1b, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Imvotamab in Participants With Severe Systemic Lupus Erythematosus Who Have Failed Standard Therapies",TERMINATED,Company Decision.,PHASE1,INTERVENTIONAL,17,"Systemic Lupus Erythematosus, Lupus Erythematosus",Imvotamab,DRUG,Safety and tolerability of imvotamab,2023-08-15,2025-01-27,"IGM Biosciences, Inc.",INDUSTRY
NCT06219174,Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO),Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC,SUSPENDED,Drugs unavailable,"PHASE1, PHASE2",INTERVENTIONAL,45,"Non Small Cell Lung Cancer, Lung Cancer","Pembrolizumab, Difluoromethylornithine","DRUG, DRUG","Phase I- Maximum Tolerated Dose (MTD), Phase II- Objective Response Rate (ORR)",2024-08-07,2029-08,H. Lee Moffitt Cancer Center and Research Institute,OTHER
NCT04078074,Occlusal Stabilization Splints and Sleep Disordered Breathing,Occlusal Stabilization Splints and Sleep Disordered Breathing,WITHDRAWN,Lack of funds,NA,INTERVENTIONAL,0,Sleep Bruxism,,"DEVICE, DEVICE, DEVICE","Change in peripheral capillary oxygen saturation (SpO2) as measured by the MediByte device, Change in pulse as measured by the MediByte device, Change in airflow as measured by the MediByte device, Change in chest plethysmography as measured by the MediByte device, Change in abdomen plethysmography as measured by the MediByte device, Change in masticatory muscle activity as measured by the MediByte device",2022-07-01,2023-07-01,"The University of Texas Health Science Center, Houston",OTHER
NCT03791918,Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria,Lenvatinib Plus Programmed Cell Death Protein-1 (PD-1) Antibody Versus Transarterial Chemoembolization for Intermediate-stage Hepatocellular Carcinoma Beyond Up-to-seven Criteria,WITHDRAWN,No participants enrolled,PHASE3,INTERVENTIONAL,0,Hepatocellular Carcinoma,"Lenvatinib, PD-1 antibody, TACE Drug Protocol","DRUG, DRUG, PROCEDURE, DRUG",Overall survival,2019-01-01,2022-01-01,Sun Yat-sen University,OTHER
NCT04481490,A Study to Objectively Measure Physical Activity and Sedentary Behavior During Cardiac Rehabilitation,Objective Measure of Physical Activity and Sedentary Behavior During Cardiac Rehabilitation: Are Patients Achieving Recommendations/Guidelines,WITHDRAWN,Stopped due to lack of personnel and funding support,,OBSERVATIONAL,0,"Cardiac Disease, Myocardial Infarction, Cardiac Valve Disease, Coronary Artery Disease",,,"Change in minutes spent in moderate-vigorous physical activity, measured by accelerometry",2022-01,2023-12,Mayo Clinic,OTHER
NCT06285097,A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors,"A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTITUMOR ACTIVITY OF PF-07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS",TERMINATED,The trial was terminated for strategic business reasons; the decision was not based on any safety and/or efficacy concerns.,PHASE1,INTERVENTIONAL,9,"Neoplasms, Non-small-cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Urothelial Carcinoma, Colorectal Carcinoma, Ovarian Carcinoma","PF-07820435, Sasanlimab","DRUG, BIOLOGICAL","Number of patients with dose limiting toxicities (DLTs) in dose escalation (Part 1A and Part 1B), Number of patients with adverse events (AEs), Number of patients with clinically significant lab abnormalities, Objective response rate (ORR) in Part 2 Expansion",2024-02-08,2025-02-13,Pfizer,INDUSTRY
NCT00934297,Visualization Tool for Investigation of Breast Lesions,Evaluation of a New Multi-modality Visualization Tool for Investigation of Breast Lesions,TERMINATED,The study was terminated as the PI left the institution.,,OBSERVATIONAL,10,Breast Lesions,,,"Target identification success: this outcome measure is a 'yes/no' outcome, indicating whether or not an MRI-detected lesion could be successfully visualized using US-guidance in the supplemental US exam",2009-07,2011-07,Sunnybrook Health Sciences Centre,OTHER
NCT04797897,Study to Evaluate the Safety and Effectiveness of REAL INTELLIGENCE™ CORI™ in Unicondylar Knee Arthroplasty (UKA) Procedures,"A Prospective, Multi-center, Randomized Controlled Study to Evaluate the Safety and Effectiveness of REAL INTELLIGENCE™ CORI™ in Unicondylar Knee Arthroplasty (UKA) Procedures",TERMINATED,The Study terminated prematurely due to very low patient enrollment in the study.,NA,INTERVENTIONAL,4,"Non-inflammatory Degenerative Joint Disease, Osteoarthritis, Avascular Necrosis, Requires Correction of Functional Deformity, Fracture, Knee",,"DEVICE, DEVICE",Post-operative Leg Alignment,2022-02-12,2024-02-16,"Smith & Nephew, Inc.",INDUSTRY
NCT00497471,RCT Iron Supplementation and Malaria Chemoprophylaxis for Prevention of Severe Anemia and Malaria in Tanzanian Infants,The Prevention of Anaemia and Malaria in Infants in an Area of Intense and Perennial Malaria Transmission,TERMINATED,Follow-up end in 1999,NA,INTERVENTIONAL,832,"Malaria, Anemia","Deltaprim (3.125 mg pyrimethamine plus 25 mg dapsone), iron (2 mg/kg/daily)","DRUG, DRUG","Clinical Malaria, Severe Anemia (PCV < 25%)",1995-02,1999-07,Hospital Clinic of Barcelona,OTHER
NCT01189864,Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas,Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas,TERMINATED,Terminated to initiate FDA IND-cleared study protocol,,OBSERVATIONAL,3493,"Keratoconus, Ectasia, Degeneration","Ciprofloxicin or Vigamox or other., Nonsteroidal (Acular, Acuvail, Voltaren Xibrom, etc), Steroid (FML, Pred Forte, Flarex, etc.)","DRUG, DRUG, DRUG",Increase the biomechanical and biochemical stability of the cornea by inducing additional cross-links within,2010-02-01,2017-02-03,Cxlusa,INDUSTRY
NCT03396809,Punctal Plugs and Iodine Related Discomfort,The Use of Punctal Plugs in Reducing Iodine Related Ocular Surface Discomfort,WITHDRAWN,PI left the institution. There are no publications for this research \& this is not Applicable Clinical Trial.,NA,INTERVENTIONAL,0,Dry Eye Syndromes,,DEVICE,Reduction in OSDI scores,2017-07-26,2018-12-07,University of New Mexico,OTHER
NCT04035109,Anakinra as a Rescue Treatment for Allergic Inflammation,Anakinra as a Rescue Treatment for Nasal Allergen Challenge-induced Airway Inflammation,WITHDRAWN,Study stopped due to COVID-19 pandemic.,"PHASE1, PHASE2",INTERVENTIONAL,0,"Asthma, Allergic","Anakinra, Preservative-free 0.9% sodium chloride (Placebo), House dust mite allergen, Cat hair allergen","DRUG, DRUG, BIOLOGICAL, BIOLOGICAL",Change in eosinophils per milliliter of Nasal Lavage Fluid (NLF),2019-12-16,2023-10,"University of North Carolina, Chapel Hill",OTHER
NCT04124809,Truth or Dare; Artificial Blastocoel Collapse Using Laser Before Blastocyst's Vitrification Versus Non-laser Usage,Truth or Dare; Artificial Blastocoel Collapse of Human Blastocysts Before Vitrification,TERMINATED,no fund for recruitment,NA,INTERVENTIONAL,10,Blastocyst Disintegration,,DEVICE,"survival rate, survival rate",2019-01-05,2021-10-01,Benha University,OTHER
NCT04458909,Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer,"An Open-Label, Phase III Study of Platinum-Gemcitabine With or Without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma",TERMINATED,External information,PHASE3,INTERVENTIONAL,15,"Metastatic Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Metastatic Nasopharyngeal Nonkeratinizing Carcinoma, Metastatic Nasopharyngeal Undifferentiated Carcinoma, Nasopharyngeal Nonkeratinizing Carcinoma, Recurrent Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Recurrent Nasopharyngeal Undifferentiated Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8, Stage IVA Nasopharyngeal Carcinoma AJCC v8, Stage IVB Nasopharyngeal Carcinoma AJCC v8","Carboplatin, Cisplatin, Gemcitabine, Nivolumab","DRUG, DRUG, DRUG, BIOLOGICAL, OTHER",Overall Survival (OS),2020-12-09,2023-08-15,National Cancer Institute (NCI),NIH
NCT00977132,Efficacy and Tolerability of the Combination of Valproic Acid and Lenalidomide in the Treatment of Patients With Myelodysplastic Syndrome,Phase II Study for the Determination of Efficacy and Tolerability of the Combination of Valproic Acid and Lenalidomide in the Treatment of Patients With Myelodysplastic Syndrome With Favorable Risk Profile,TERMINATED,delayed recruitment,PHASE2,INTERVENTIONAL,23,Myelodysplastic Syndrome MDS,"Valproic aicd, Lenalidomide","DRUG, DRUG",hematologic success,2009-10,2014-05,"Heinrich-Heine University, Duesseldorf",OTHER
NCT01742793,"An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)","An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)",TERMINATED,"The study was terminated due to withdrawal of institutional support, Phase II never began.",PHASE1,INTERVENTIONAL,12,"Hodgkin's Lymphoma, Mature T-cell Lymphoma, Multiple Myeloma",lenalidomide (Revlimid) and romidepsin (Istodax),DRUG,"Overall Rate of Clinical Response (Complete Response + Partial Response), Overall Rate of Clinical Response (Complete Response + Partial Response)",2012-10,2016-08,Yale University,OTHER
NCT01335204,Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer,Phase Ib/IIa Study of Cabazitaxel Plus Bavituximab for Patients With Castration-resistant Prostate Cancer Previously Treated With Chemotherapy,TERMINATED,lack of funding,"PHASE1, PHASE2",INTERVENTIONAL,4,"Prostate Cancer, Prostatic Neoplasms",Cabazitaxel plus bavituximab,DRUG,Probability of Progression-free Survival at Day 85,2011-06,2013-03,Medical University of South Carolina,OTHER
NCT06780033,A Study to Evaluate ART101 in Adult Participants With Hypertension,"A Phase 1, Randomized, Double-blind, Placebo Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ART101 in Adult Participants With Hypertension.",TERMINATED,At Sponsor's Request,PHASE1,INTERVENTIONAL,1,Hypertension,ART-101 - SAD,"DRUG, OTHER","Assess safety of ART101 by the incidence of adverse events, adverse events of special interest and SAEs, Number of participants with abnormal laboratory values and/or adverse events that are related to treatment, Change in pharmacodynamics of ART101 by noting change from baseline of serum angiotensinogen.",2025-03-17,2025-04-30,"Arnatar Therapeutics, Inc.",INDUSTRY
NCT03550352,Cannabinoids in PLWHIV on Effective ART,"Cannabinoids in People Living With HIV on Effective Antiretroviral Therapy: A Pilot Study to Assess Safety, Tolerability and Effect on Immune Activation",TERMINATED,expiration of study product; end of study product availability,PHASE2,INTERVENTIONAL,10,HIV Infections,"TN-TC11M2 oral capsules (THC 2.5 mg/CBD 2.5 mg), TN-C200M2 oral capsules (CBD 200 mg)","DRUG, DRUG",WHO toxicity scale,2021-08-20,2022-05-31,McGill University Health Centre/Research Institute of the McGill University Health Centre,OTHER
NCT03418649,Eplerenone as a Supplement to Epidural Steroid Injections,"Epidural Steroid Injection With Supplemental Oral Eplerenone for Low Back Pain: A Prospective, Double Blind Randomized Trial",WITHDRAWN,Unable to recruit subjects,PHASE4,INTERVENTIONAL,0,"Degenerative Intervertebral Discs, Sciatic Radiculopathy, Low Back Pain","Eplerenone 50 Mg Tab, Placebo Oral Tablet","DRUG, DRUG",change in Oswestry Low Back Pain Disability Questionnaire at 12 months,2023-06,2026-06,University of Cincinnati,OTHER
NCT00470249,Carboplatin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Breast Cancer,A Phase II Study of Carboplatin in Combination With Gemcitabine as a Dose Dense Schedule in Patients With Locally Advanced or Metastatic Breast Cancer That Are Resistant to Anthracyclines & Taxanes,TERMINATED,Due to difficulty in recruitment,PHASE2,INTERVENTIONAL,5,Breast Cancer,"Carboplatin, Gemcitabine Hydrochloride","DRUG, DRUG",Overall response rate (complete or partial response),2006-07-15,2008-11-03,University of Southampton,OTHER
NCT02025049,DP-b99 in the Treatment of Acute High-risk Pancreatitis,Pilot Trial of Intravenous DP-b99 in the Treatment of First-ever Episode of Non-obstructive Acute High-risk Pancreatitis,TERMINATED,Slow recruitment,PHASE2,INTERVENTIONAL,10,Pancreatitis,"DP-b99, Placebo","DRUG, DRUG",C-reactive protein serum concentration,2013-12,2015-05,D-Pharm Ltd.,INDUSTRY
NCT03003949,"The Menopause Transition: Estrogen Variability, Stress Reactivity and Mood","The Menopause Transition: Estrogen Variability, HPA Axis and Affective Symptoms",TERMINATED,In-person visit restrictions due to COVID-19,PHASE4,INTERVENTIONAL,82,"Perimenopausal Disorder, Stress, Emotional","Estradiol Patch, 0.1 Mg/24 Hours Weekly Transdermal Film, Extended Release, Placebo Patch, Progesterone Capsule, Placebo Oral Capsule","DRUG, DRUG, DRUG, DRUG","Change Over Time in the Anxiety Score From State-Trait Anxiety Inventory, Change Over Time in Anhedonia Score From Snaith-Hamilton Pleasure Scale",2017-01-24,2020-05-10,"University of North Carolina, Chapel Hill",OTHER
NCT03519126,Electrostimulation in the Treatment of Idiopathic Overactive Bladder,Efficacy of Vaginal and Transcutaneous Electrostimulation of the Posterior Tibial Nerve in the Treatment of Overactive Bladder,TERMINATED,Due to the covid-19 pandemic,NA,INTERVENTIONAL,67,"Urinary Bladder, Overactive",,OTHER,Change from baseline miccional emergency at 6 weeks after starting treatment and at 1 month after the end of treatment.,2016-04-19,2020-03-30,Janaina Mayer de Oliveira Nunes,OTHER
NCT02743078,Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma,Phase II Trial Of Optune® Plus Bevacizumab In Bevacizumab-Refractory Recurrent Glioblastoma,TERMINATED,Treatment now available commercially,PHASE2,INTERVENTIONAL,3,"Glioblastoma, Glioma, Gliosarcoma",Bevacizumab,"DRUG, DEVICE",Overall Survival at 6 Months,2017-05-09,2019-10-15,"RTOG Foundation, Inc.",OTHER
NCT06752135,Node Positive Cervical Cancer Treated by Neoadjuvant Chemotherapy Plus Radical Surgery: a Single Center Experience,Node Positive Cervical Cancer Treated by Neoadjuvant Chemotherapy Plus Radical Surgery: a Single Center Experience,TERMINATED,Retrospectively data collection complited,,OBSERVATIONAL,97,Cervical Carcinoma,neoadjuvant chemotherapy (cisplatin or carboplatin plus paclitaxel),"PROCEDURE, DIAGNOSTIC_TEST, DRUG, PROCEDURE, RADIATION","Progression-Free Survival (PFS) in Patients with Cervical Cancer After NACT + Radical Surgery, Overall Survival (OS) in Patients with Cervical Cancer After NACT + Radical Surgery",2024-04-10,2024-12-06,Azienda Policlinico Umberto I,OTHER
NCT04395378,Use of Dexcom G6 in Commercial Pilots With Insulin Treated Diabetes,The Use of the Dexcom G6 in Commercial Pilots With Insulin Dependent Diabetes (DEXFLY),SUSPENDED,COVID-19 policy of the University of Surrey,,OBSERVATIONAL,30,Type 1 Diabetes,,DEVICE,Glucose concentration (mmol/L),2019-12-05,2022-12-02,University of Surrey,OTHER
NCT03743935,Use of Cardiac MRI in Early Stages of STEMI to Predict Left Ventricular Function Recovery and ICD Implantation,Primary Prevention ICD Implantation in STEMI With Severe Left Ventricular Dysfunction : Input of Early Cardiac MRI in Order to Predict Left Ventricular Recovery,TERMINATED,Recruitment difficulties,NA,INTERVENTIONAL,12,"Acute STEMI, Severe Left Ventricular Systolic Dysfunction (Disorder)",,OTHER,"Mesure of zones of delayed myocardial transmural enhancement and no-reflow, Mesure of ejection fraction and regional wall motion and thickening, Mesure of extracellular volume",2019-01-07,2021-02-22,"University Hospital, Montpellier",OTHER
NCT03955835,Acandis Credo Intracranial Stent for Unsuccessful Recanalization After Thrombectomy (ACUTE),Acandis Credo Intracranial Stent for Unsuccessful Recanalization After Thrombectomy (ACUTE),TERMINATED,CREDO stent is now CE-marked for rescue stenting (new indication).,NA,INTERVENTIONAL,27,"Acute Ischemic Stroke, Intracranial Stenosis",,DEVICE,"Co-Primary Technical Efficacy Endpoint, Co-Primary Clinical Efficacy Endpoint, Primary Safety Endpoints",2019-08-09,2021-09-22,Acandis GmbH,INDUSTRY
NCT00003535,Antineoplaston Therapy in Treating Children With Recurrent or Refractory High-Grade Glioma,Phase II Study of Antineoplastons A10 and AS2-1 in Children With High Grade Glioma,TERMINATED,Slow accrual,PHASE2,INTERVENTIONAL,9,High Grade Glioma,Antineoplaston therapy (Atengenal + Astugenal),DRUG,Number of Participants With Objective Response,1994-04,1998-01,Burzynski Research Institute,OTHER
NCT01188408,Efficacy and Safety Study of LE-DT to Treat Metastatic Castrate Resistant Prostate Cancer,"A Multicenter, Open-Label, Phase II Study of LE-DT for Efficacy and Safety in Patients With Metastatic Castrate Resistant Prostate Cancer",WITHDRAWN,Study shut-down in 12/2010 when NeoPharm merged with Insys.,PHASE2,INTERVENTIONAL,0,Prostate Cancer,Liposome Entrapped Docetaxel (LE-DT),DRUG,Assessment of serum PSA,2010-06,2011-09,INSYS Therapeutics Inc,INDUSTRY
NCT04909008,Exercise Training to Improve Cardiopulmonary Hemodynamics in Heart Failure Patients,Exercise Training to Improve Pulmonary Haemodynamic and Right Ventricular Function in Heart Failure Patients With Pulmonary Hypertension,SUSPENDED,Lack of recruitment,NA,INTERVENTIONAL,40,"Heart Failure, Pulmonary Hypertension",,OTHER,Maximal oxygen uptake (VO2max) measured in mL/kg/min,2024-01-01,2026-12-01,Mayo Clinic,OTHER
NCT00005808,Photodynamic Therapy Using Lutetium Texaphyrin in Treating Patients With Cervical Intraepithelial Neoplasia,Phase I Study Photodynamic Therapy Using Lutrin (Lutetium Texaphyrin) in the Treatment of Patients With Cervical Intraepithelial Neoplasia,TERMINATED,Administratively complete.,PHASE1,INTERVENTIONAL,54,"Cervical Cancer, Cervical Intraepithelial Neoplasia Grade 2, Cervical Intraepithelial Neoplasia Grade 3","motexafin lutetium, photodynamic therapy","DRUG, DRUG, PROCEDURE, OTHER","Optimal dosage with the least toxicity of lutetium texaphyrin (Part 1), Maximal differential in Lutrin tissue levels between normal and dysplastic cells (Part 1), Percentage of tissue demonstrating PDT related effects (apoptosis/ necrosis) for normal versus abnormal epithelium at each total fluence for each LEEP cone biopsy specimen",2000-12,,National Cancer Institute (NCI),NIH
NCT00514917,"A Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Participants With a Rising Prostate Specific Antigen (PSA)","A Randomized, Open Label, Multicenter, Phase III, 2-Arm Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Subjects With a Rising PSA Following Definitive Local Therapy",TERMINATED,"Company decision to discontinue the study, not due to any safety or efficacy concerns",PHASE3,INTERVENTIONAL,413,Prostatic Neoplasms,"Docetaxel, Leuprolide, Bicalutamide","DRUG, DRUG, DRUG","Median Progression-Free Survival (PFS) in Intent-to-treat (ITT) Population, Progression-Free Survival (PFS) Rate at Month 36 in ITT Population, Median Progression-Free Survival (PFS) in Testosterone Specific Evaluable Population, Progression-Free Survival (PFS) Rate at Month 36 in Testosterone Specific Evaluable Population",2007-07,2012-09,Sanofi,INDUSTRY
NCT02046317,Trial of Ultrasound Guided Femoral Nerve Block on Isolated Femur Fracture Using Echo Friendly Needles,Trial of Ultrasound Guided Femoral Nerve Block on Isolated Femur Fracture Using Echo Friendly Needles,TERMINATED,"No further enrolled patients, Primary researcher left the institution",PHASE4,INTERVENTIONAL,12,Pain,Femoral Nerve Block,"DRUG, DEVICE, DEVICE, DEVICE","Patient Pain Level, Patient Pain Level",2011-05,2016-11,"The University of Texas Health Science Center, Houston",OTHER
NCT03735589,"Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",A Phase I/IIa Safety and Immunologic Efficacy Trial of Intraperitoneal Induction of CTLs Combined With Alpha-Dendritic Cell Vaccine for Primary Ovarian Cancer,WITHDRAWN,new study to be created,"PHASE1, PHASE2",INTERVENTIONAL,0,"Stage II Fallopian Tube Cancer AJCC v8, Stage II Ovarian Cancer AJCC v8, Stage II Primary Peritoneal Cancer AJCC v8, Stage IIA Fallopian Tube Cancer AJCC v8, Stage IIA Ovarian Cancer AJCC v8, Stage IIA Primary Peritoneal Cancer AJCC v8, Stage IIB Fallopian Tube Cancer AJCC v8, Stage IIB Ovarian Cancer AJCC v8, Stage IIB Primary Peritoneal Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IIIA Fallopian Tube Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Primary Peritoneal Cancer AJCC v8, Stage IIIA1 Fallopian Tube Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Fallopian Tube Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Fallopian Tube Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Primary Peritoneal Cancer AJCC v8, Stage IIIC Fallopian Tube Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8","Alpha-type-1 Polarized Dendritic Cells, Autologous Natural Killer Cell-like CTLs","BIOLOGICAL, BIOLOGICAL","Incidence of adverse events as assessed by Cancer Therapy Evaluation Program (CTEP) version 4 of the Common Terminology Criteria for Adverse Events (CTCAE), Dose-limiting toxicities (DLT) assessed by CTCAE version 5, Change in immune response, Persistence of nCTLs after their adoptive transfer",2023-12-15,2025-12-01,Roswell Park Cancer Institute,OTHER
NCT00514189,Feasibility Study of Acute Myelogenous Leukemia mRNA Plus Lysate Loaded Dendritic Cell Vaccines,Feasibility Study of Acute Myelogenous Leukemia mRNA Plus Lysate Loaded Dendritic Cell Vaccines,TERMINATED,Terminated early due to slow accrual.,PHASE1,INTERVENTIONAL,2,Leukemia,Autologous Dendritic Cells,BIOLOGICAL,Time to Adverse Event (AE),2007-07,2009-12,M.D. Anderson Cancer Center,OTHER
NCT05399368,An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis,A Phase 2 Study to Evaluate the Efficacy and Safety of RPT193 as Monotherapy in Adults With Moderate-to-Severe Atopic Dermatitis,TERMINATED,Study on clinical hold by FDA,PHASE2,INTERVENTIONAL,229,Atopic Dermatitis,RPT193,"DRUG, OTHER","Clinical efficacy, Safety as measured by adverse events",2022-06-07,2024-05-24,"RAPT Therapeutics, Inc.",INDUSTRY
NCT02655068,Phase III Trial of PET/CT vs. CTSurveilance for Head and Neck Cancer,"Efficacy of Monitoring Strategies Following Definitive Therapy for Locally Advanced Head and Neck Cancer: A Randomized, Phase III Trial of PET/CT vs. CT Surveillance",TERMINATED,due to non-feasibility,PHASE3,INTERVENTIONAL,38,"Carcinoma, Squamous Cell of Head and Neck",,"OTHER, OTHER","Which type of surveillance following definitive therapy for HNC is superior, PET/CT or CT surveillance",2012-05,2016-09-30,University of Pittsburgh,OTHER
NCT04679350,Efficacy and Safety of hzVSFv13 in Patients With COVID-19 Pneumonia,"A Multi Center, Randomized, Double-blind, Parallel Design, Phase 2 Study to Evaluate the Efficacy and Safety of hzVSFv13 Compared to Standard of Care After Intravenous(IV) Administration With Add-on Standard of Care in COVID-19 Moderate to Severe Patients",TERMINATED,A new study combining Phase III clinical trials has been planned.,PHASE2,INTERVENTIONAL,1,COVID-19,"hzVSF-v13, Placebo (Normal saline solution)","DRUG, DRUG",Changes from baseline in the clinical improvement score on an 8-point scale at Day 21,2021-03-18,2022-12-30,"ImmuneMed, Inc.",INDUSTRY
NCT00003491,Antineoplaston Therapy in Treating Patients With Stage IV Lung Cancer,Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Adenocarcinoma of the Lung,TERMINATED,Slow accrual,PHASE2,INTERVENTIONAL,17,Stage IV Lung Cancer,Antineoplaston therapy (Atengenal + Astugenal),DRUG,,1996-03-20,1998-07-31,Burzynski Research Institute,OTHER
NCT00024674,Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: Continuous Infusion for 10 Days,,WITHDRAWN,Support withdrawn - Study continued by NCI - see record NCT00006981,PHASE1,INTERVENTIONAL,0,Neoplasms,SS1(dsFv)-PE38,DRUG,,2001-02,,INSYS Therapeutics Inc,INDUSTRY
NCT01938274,Leisure Expectations About Physical Activity Study,Establishing Appropriate Activity Expectations After Total Joint Replacement,WITHDRAWN,Enrollment never started,NA,INTERVENTIONAL,0,"Hip Osteoarthritis, Knee Osteoarthritis",,OTHER,"Change in type, frequency, intensity, and duration of expected leisure activities from pre- to post-intervention.",2018-01-01,2019-07-22,West Virginia University,OTHER
NCT06473974,"Open-label, Single-arm, Proof of Concept Study in Subjects with Mild-to-moderate Facial Hyperpigmentation","An Open-label, Single Arm, Proof of Concept Study to Evaluate the Efficacy, Tolerability and Safety of Bright Aura Hyperpigmentation Treatment in Subjects with Mild-to-moderate Facial Hyperpigmentation",WITHDRAWN,"This study had been withdrawn by the sponsor as they are in process to approach FDA with rationale to get agency feedback and share written response on IRB query.

Thereafter, they may again approach with new application and FDA written response.",PHASE2,INTERVENTIONAL,0,Facial Hyperpigmentation,Test cosmetic product,DRUG,Overall hyperpigmentation score using modified Griffiths 10-point scale.,2025-01-01,2025-12-15,"Kayuraeffect, LLP",INDUSTRY
NCT04495374,Oral Pregabalin as Preemptive Analgesia in Abdominal Hysterectomy,Use of Oral Pregabalin as Preemptive Analgesia in Abdominal Hysterectomy: Evaluation of Postoperative Pain and Opioid Consumption,TERMINATED,Due to an atypical health scenario caused by the COVID-19 pandemic,PHASE4,INTERVENTIONAL,58,"Pain, Postoperative, Analgesia, Gabapentin Adverse Reaction, Opioid Abuse",Pregabalin 300mg,"DRUG, OTHER","Postoperative Pain in Rest Assessed 24 Hours After Abdominal Hysterectomy Surgery Using the Visual Analog Scale (VAS), Postoperative Pain Assessed 24 Hours After Abdominal Hysterectomy Surgery, Using the McGill Pain Questionnaire, Postoperative Pain in Active Movement Assessed 24 Hours After Abdominal Hysterectomy Surgery Using the Visual Analog Scale (VAS)",2019-09-02,2020-09-30,Universidade Federal de Alfenas,OTHER
NCT05362474,Targeting Leukotrienes in Kidney Disease,Targeting Leukotrienes in Kidney Disease: A Pilot Study,TERMINATED,Funding not available,PHASE3,INTERVENTIONAL,6,Diabetic Kidney Disease,Montelukast,DRUG,Change in Albuminuria at 3 Months,2022-07-01,2023-06-20,"University of Colorado, Denver",OTHER
NCT03955718,Developing and Testing Motherly App: a Smartphone Application to Promote Mothers' Mental Health,Developing and Testing Motherly: An Automated Gamified Smartphone Application to Promote Mothers' Mental Health,WITHDRAWN,The study stopped because of delays in the development of the smartphone app intervention,NA,INTERVENTIONAL,0,Maternal Depression,,"BEHAVIORAL, BEHAVIORAL",Maternal depression,2019-09-25,2020-06-01,University of Sao Paulo,OTHER
NCT06597656,A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Therapeutic Plasma Exchange (Plasmapheresis) in Participants With Duchenne Muscular Dystrophy (DMD) and Pre-existing Antibodies to AAVrh74,"An Open-Label, Systemic Gene Delivery Study to Evaluate the Safety, Tolerability and Expression of Delandistrogene Moxeparvovec Following Plasmapheresis in Subjects With Duchenne Muscular Dystrophy and Pre-existing Antibodies to AAVrh74",TERMINATED,Study is being terminated due to a business decision.,PHASE1,INTERVENTIONAL,3,Duchenne Muscular Dystrophy,,"GENETIC, PROCEDURE","Change From Baseline in Quantity of Delandistrogene Moxeparvovec Dystrophin Expression Adjusted by Muscle Content Biopsied Muscle as Measured by Western Blot, Change From Baseline in Quantity of Delandistrogene Moxeparvovec Dystrophin Expression in Biopsied Muscle as Measured by Immunofluorescence (IF) Fiber Intensity, Change From Baseline in Quantity of Delandistrogene Moxeparvovec Dystrophin Expression in Biopsied Muscle as Measured by IF Percent Dystrophin-positive Fibers (PDPF), Mean Concentration of Vector Genome Copies Using Polymerase Chain Reaction in Muscle Tissue Biopsy, After Delandistrogene Moxeparvovec Administration",2024-09-18,2025-08-05,"Sarepta Therapeutics, Inc.",INDUSTRY
NCT04697056,A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ANB019 in the Treatment of Subjects With Ichthyosis",TERMINATED,Administrative Reason,PHASE2,INTERVENTIONAL,5,Ichthyosis,"Imsidolimab, placebo","DRUG, BIOLOGICAL",Change From Baseline in Ichthyosis Area Severity Index (IASI) Total Score at Week 16,2021-01-25,2021-11-19,Vanda Pharmaceuticals,INDUSTRY
NCT02267551,Non-inferiority Study Comparing daVinci Skills Simulator to Mimic dV-Trainer for Preparing Residents to Perform Live Human Surgery,Non-inferiority Study Comparing daVinci Skills Simulator to Mimic dV-Trainer for Preparing Residents to Perform Live Human Surgery,TERMINATED,low enrollment,NA,INTERVENTIONAL,,Simulation for Preparation of Robotic Surgery,,"OTHER, OTHER",Operative Time,2014-04,2015-09,Atlantic Health System,OTHER
NCT01764451,Permeability MRI in Cerebral Cavernous Malformations Type 1 in New Mexico: Effects of Statins,Permeability MRI in Cerebral Cavernous Malformations Type 1 in New Mexico: Effects of Statins,TERMINATED,"Research was completed before January 18, 2017, \& does not meet the Applicable Clinical Trial requirement to register \& report results per the guidance provided in ""Clinical Trials Registration \& Results Information Submission"" dated 09/21/2016.",EARLY_PHASE1,INTERVENTIONAL,12,"Cavernous Angioma, Familial, Cerebral Cavernous Malformations, Cerebral Cavernous Hemangioma",Simvastatin,DRUG,Change in blood brain barrier permeability over three months for the treatment group compared to the control group.,2012-03,2016-01,University of New Mexico,OTHER
NCT01123031,Oral vs Intravenous and Proton Pump Inhibitor (PPI）for Peptic Ulcer Bleeding (PUB),Oral vs Intravenous Proton Pump Inhibitor（PPI） in Patients With Peptic Ulcer Bleeding After Successful Endoscopic Therapy- a Prospective Randomized Comparative Trial,WITHDRAWN,The study was terminated and the PI has left the institution.,PHASE4,INTERVENTIONAL,0,Upper Gastrointestinal Bleeding,"lansoprazole, esomeprazole","DRUG, DRUG",Re-bleeding within 14 days in Patients With Peptic Ulcer Bleeding After Successful Endoscopic Therapy,2010-04,2012-03,Changhua Christian Hospital,OTHER
NCT01532245,The Use of Constant-flow Technique for Determining the Lower Inflexion Point of Pressure-volume Curve and Intrinsic PEEP During One-lung Ventilation,,WITHDRAWN,No participants,NA,INTERVENTIONAL,0,"One Lung Ventillation (OLV), Two Lung Ventillation (TLV), Positive End Expiratory Pressure (PEEP), Zero End-expiratory Pressure (ZEEP)",,"OTHER, OTHER, OTHER","intrinsic positive end-expiratory pressure (PEEP) during ventillation, lower inflexion point (LIP) of P-V curve during one lung ventillation (OLV), net change of Lower Inflexion Point (LIP)- intrinsic positive end-expiratory pressure (PEEPi) ditstance with PEEP, net change of lower inflexion point (LIP)-PEEPi ditstance without PEEP",2011-12,2018-10-23,The Cleveland Clinic,OTHER
NCT04182945,Fever Algorithm Development of a Non-invasive Wearable Core Body Temperature Sensor System in Intensive Care Unit Patients,Fever Algorithm Development of a Non-invasive Wearable Core Body Temperature Sensor System in Intensive Care Unit Patients,TERMINATED,Not enough patients having fever symptoms,NA,INTERVENTIONAL,20,Fever,,OTHER,"Continuous and non-invasive skin temperature and heat flux, Continuous and invasive core body temperature",2019-12-11,2021-03-31,greenTEG AG,INDUSTRY
NCT05778877,"A Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SEL-302 in Pediatric Subjects With MMA","Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SEL-302 (MMA-101 Following Administration of SEL-110) in Pediatric Subjects With Mut Subtype Isolated Methylmalonic Acidemia (MMA)",WITHDRAWN,Decided by sponsor,"PHASE1, PHASE2",INTERVENTIONAL,0,Methylmalonic Acidemia (MMA),SEL-302,DRUG,"Safety and tolerability of SEL-302, PD Activity of SEL-302, PD Activity of SEL-302, Assess the change in Neutralizing antibody (Nab) titers for MMA-101 with treatment of SEL-110",2022-12-19,2029-08,"Selecta Biosciences, Inc.",INDUSTRY
NCT02920177,Platelet-rich Plasma Versus Corticosteroid Injection for the Treatment of Femoroacetabular Impingement,Platelet-rich Plasma Versus Corticosteroid Injection for the Treatment of Femoroacetabular Impingement,TERMINATED,low enrollment,PHASE4,INTERVENTIONAL,4,Femoroacetabular Impingement,"platelet-rich plasma injection, Kenalog 10 MG/ML Injectable Suspension","DRUG, DRUG",Change From Baseline in Pain Score on the Visual Analog Scale,2016-08-01,2018-08-10,University of Michigan,OTHER
NCT05910775,Role Of Non-Specific Effects in The Treatment of Depression With Esketamine,Role Of Non-Specific Effects in The Treatment of Depression With Esketamine,TERMINATED,"The study was suspended due to challenges in recruiting a sufficient number of participants within a reasonable timeframe. Despite our efforts, enrollment did not meet the required threshold to proceed as planned.",NA,INTERVENTIONAL,1,Depressive Episode,,BEHAVIORAL,Group Difference in Change in Question 6 Score on Treatment Credibility and Expectancy Scale (CEQ-6),2024-07-13,2024-12-31,Yale University,OTHER
NCT03265977,A Phase II Study of H56:IC31 in Healthy Adolescents,"A Randomized, Placebo Controlled, Double-Blind Phase II Study to Evaluate Safety, Immunogenicity, and Prevention of Infection With Mycobacterium Tuberculosis (Mtb) of H56:IC31 in Healthy Adolescents",WITHDRAWN,"Design, sponsorship changed prior to initiation. No study procedures done.",PHASE2,INTERVENTIONAL,0,Tuberculosis Infection,H56:IC31,"BIOLOGICAL, OTHER","Frequency and severity of adverse events, ESAT-6 free IGRA conversion from a negative to positive test at any time point after Day 84 and through end of follow-up for the primary endpoint.",2018-06,2021-06-30,Aeras,OTHER
NCT01177501,Trial of High Dose Topotecan With Carboplatin in Patients With Relapsed Ovarian Carcinoma,"Phase I Trial of High-dose Topotecan in Association With Carboplatin, With Peripheral Blood Stem Cell Support in Patients With First Relapsed Ovarian Carcinoma Without Platinum-treatment Since 6-12 Months",TERMINATED,choice of the principal investigator,PHASE1,INTERVENTIONAL,3,"Ovarian Cancer, Relapses",Topotecan,DRUG,Identification of the maximum tolerated dose (MTD) of topotecan at 6 weeks,2009-04,2012-03,Assistance Publique - Hôpitaux de Paris,OTHER
NCT00137501,Two Dose Regimens of Nifedipine for the Management of Preterm Labor,Study of Different Doses of Nifedipine to Treat Preterm Labor,TERMINATED,The trial was terminated because of difficulties in recruitement.,PHASE3,INTERVENTIONAL,102,"Labor, Premature",Nifedipine,DRUG,Uterine quiescence at 48 hours of initiation of tocolysis,2003-05,2009-06,American University of Beirut Medical Center,OTHER
NCT06012981,Psychological Treatment in Psychiatric Inpatient Care,Psychological Treatment in Psychiatric Inpatient Care,TERMINATED,Unforeseen difficulties in recruiting participants.,NA,INTERVENTIONAL,1,"Compulsory Psychiatric Care Act, Psychosis, Acceptance & Commitment Therapy, Psychiatric Hospitalization, Psychiatric Disorder",,BEHAVIORAL,"Change in Personal Questionnaire, Change in Bull's Eye Values Survey, Change in PHQ-9, Change in GAD-7, Change in Psy-flex",2023-09-01,2023-11-15,Uppsala University,OTHER
NCT04861181,"NIRAPK : Study of the Relationship(s) Between Clinical, Biological and Pharmacokinetic Metrics and Toxicities When Niraparib is Used as Maintenance Treatment for Ovarian Cancer Patients.","Study of the Relationship(s) Between Clinical, Biological and Pharmacokinetic Metrics and Toxicities When Niraparib is Used as Maintenance Treatment (300mg or 200 mg/Day) for Ovarian Cancer Patients.",TERMINATED,End of inclusion period.,PHASE4,INTERVENTIONAL,12,"Adult Patients With Platinum-sensitive, Relapsed, High Grade Serous Epithelial Ovarian Cancer","Pharmacokinetics, Dosage of Niraparib",BIOLOGICAL,"Identification of metrics (clinical, biological, pharmacokinetic) that are considered as toxicity induction causes (hematological toxicity or nephrotoxicity)",2021-05-05,2025-04-17,Hospices Civils de Lyon,OTHER
NCT04176419,Perioperative Analgesia on Postoperative Opioid Usage and Pain Control in H&N Cancer Surgery,Investigating the Effect of a Perioperative Analgesia Protocol on Postoperative Opioid Usage and Pain Control in Patients Undergoing Major Head and Neck Cancer Surgery Requiring Microvascular Free Flap Reconstruction,TERMINATED,Workforce shortage,PHASE3,INTERVENTIONAL,30,"Postoperative Pain Control, Opioid Consumption","Ketamine, Placebo Ketamine, Lidocaine, Placebo Lidocaine, Acetaminophen, Placebo Acetaminophen, Gabapentin, Placebo Gabapentin, Celecoxib, Placebo Celecoxib","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Total opioid consumption measured in daily morphine equivalent, Pain levels on Visual Analog Scale (VAS)",2020-01-17,2021-06-23,Case Comprehensive Cancer Center,OTHER
NCT01068119,Same-Day Discharge After Coronary Percutaneous Transluminal Coronary Angioplasty (PTCA),Feasibility and Safety of Same-Day Discharge of Troponin Negative Patients After Coronary PTCA Via the Transfemoral Approach,TERMINATED,Slow enrollment and high number of screen failures,PHASE4,INTERVENTIONAL,57,Acute Coronary Syndrome,,PROCEDURE,"Number of cardiac MACE, major cerebral events, and groin complications",2010-02,2012-03,Piedmont Healthcare,OTHER
NCT06148519,Comparing Preschool-Aged Refractive Measurements and Amblyopia Risks Using the 2WIN-S Portable Refractor with Vision Screening by Cycloplegic Refraction in Bangkok,Comparing Preschool-Aged Refractive Measurements and Amblyopia Risks Using the 2WIN-S Portable Refractor with Vision Screening by Cycloplegic Refraction in Bangkok,TERMINATED,"Because the research team plans to change the protocol, we do not plan to conduct cycloplegic refraction, which requires dilation. Instead, we will use only 2-WINS for eye and vision screening. Additionally, we will change the study site",NA,INTERVENTIONAL,250,2WIN-S Portable Refractor,,DIAGNOSTIC_TEST,Significant refractive errors defined by AAPOS,2023-08-23,2024-04-30,Department of Medical Services Ministry of Public Health of Thailand,OTHER_GOV
NCT03804619,Accelerated Intermittent Theta-Burst Stimulation for Opiate Use Disorder,Accelerated Intermittent Theta-Burst Stimulation for Opiate Use Disorder,WITHDRAWN,No participants enrolled. No longer continuing study.,NA,INTERVENTIONAL,0,"Opiate Dependence, Suicidal Ideation, Depression, Opioid Use, Opioid-Related Disorders, Opioid-use Disorder, Major Depressive Disorder",,DEVICE,Change in Beck Scale for Suicidal Ideation (SSI) score,2024-01-01,2024-07-11,Stanford University,OTHER
NCT01952730,Pilot Study of GVAX in Colorectal Cancer Cells,"A Pilot Safety Study of Vaccination With Autologous, Lethally Irradiated Colorectal Cancer Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Human Granulocyte-Macrophage Stimulating Factor",TERMINATED,Slow Accrual,PHASE1,INTERVENTIONAL,1,Colorectal Cancer,GVAX,BIOLOGICAL,Number of Patients Who Fail to Receive the First Six Scheduled Vaccinations Because of Toxicity,2013-11-08,2020-02,Massachusetts General Hospital,OTHER
NCT05191628,Amniotic Membrane Visio-AMTRIX in Recurrent Macular Hole,Amniotic Membrane Visio-AMTRIX in Recurrent Macular Hole,TERMINATED,Low accrual rate,PHASE2,INTERVENTIONAL,12,"Macular Holes, Retinal Detachment",Visio-AMTRIX,BIOLOGICAL,Closure of recurrent macular hole,2020-06-10,2022-10-10,TBF Genie Tissulaire,INDUSTRY
NCT05788328,A Drug-Drug Interaction Study to Estimate the Effect of PF-07081532 on the Pharmacokinetics of Dabigatran and Rosuvastatin in Overweight or Obese Adult Participants,"A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE STUDY TO ESTIMATE THE EFFECT OF PF-07081532 ADMINISTRATION ON THE SINGLE-DOSE PHARMACOKINETICS OF DABIGATRAN AND ROSUVASTATIN IN OVERWEIGHT OR OBESE ADULT PARTICIPANTS",TERMINATED,The decision to terminate clinical development of lotiglipron is based on pharmacokinetic data from Phase 1 drug-drug-interaction studies and laboratory measurements of elevated transaminases in these Phase 1 studies as well as a Phase 2 study.,PHASE1,INTERVENTIONAL,16,Healthy,"Dabigatran etexilate (DE), Rosuvastatin, PF-07081532","DRUG, DRUG, DRUG","Area Under the Concentration-Time Curve From Time Zero (0) Extrapolated to Infinity (AUCinf) of Total Dabigatran in Period 1, 4 and 7, Area Under the Concentration-Time Curve From Time 0 to the Last Measurable Concentration (AUClast) of Total Dabigatran in Period 1, 4 and 7, AUCinf of Rosuvastatin in Period 2, 5 and 8, AUClast of Rosuvastatin in Period 2, 5 and 8",2023-03-27,2023-09-11,Pfizer,INDUSTRY
NCT03120767,Wellness Initiative at New York University,Wellness Initiative at New York University,WITHDRAWN,Due to inability to enroll patients,NA,INTERVENTIONAL,0,Health Promotion,,"BEHAVIORAL, BEHAVIORAL",Perceived Stress Scale,2017-09-01,2019-04-30,NYU Langone Health,OTHER
NCT04454567,A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors,"A Phase 2a, Multi-Center, Single-Blind, Placebo-Controlled Study Evaluating Treatment Intensification With ABI-H0731 in Subjects With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors",TERMINATED,"Study stopped due to a change in the Sponsor's overall development strategy from treatment of chronic disease to finite, curative treatments, and is based partially on the advice and feedback from experts and regulators.",PHASE2,INTERVENTIONAL,2,Chronic Hepatitis B,"ABI-H0731, Placebo, NrtI","DRUG, DRUG, DRUG","Number of Participants With an Adverse Event, Number of Participants With Premature Discontinuation of Treatment, Number of Participants With a Laboratory Abnormality, Number of Participants With HBV DNA <Lower Limit of Quantification (LLOQ) at Week 48",2020-11-11,2021-04-08,Assembly Biosciences,INDUSTRY
NCT06041828,Regular Home-use Dual Light Photodynamic Therapy in the Prevention of Osteolysis After Dental Implant Surgery,Impact of Regular Home-use Dual Light Photodynamic Therapy in the Prevention of Osteolysis After Dental Implant Surgery,WITHDRAWN,The study has been temporarily halted due to time constraints at the study site.,NA,INTERVENTIONAL,0,"Osteolysis, Dental Implants",,"DEVICE, OTHER",Incidence of osteolysis around dental implants,2025-12,2025-12-31,Koite Health Oy,INDUSTRY
NCT01737892,Assessment and Evaluation of Pharmacokinetic Profile of E004 in Healthy Adults,"Assessment and Evaluation of Pharmacokinetic Profile of E004 in Healthy Adults (A Randomized, Evaluator-Blind, Single-Dose, Two Arm, Crossover, PK Study in Healthy Volunteers)",TERMINATED,unable to validate analytical method,"PHASE1, PHASE2",INTERVENTIONAL,21,Asthma,"Arm T Epinephrine Inhalation Aerosol HFA, 125 mcg, 1 inhalation, Arm C-Epinephrine Inhalation Aerosol CFC","DRUG, DRUG",Calculation and Comparison of relative Bioavailability of Epinephrine,2012-11,2012-11,"Amphastar Pharmaceuticals, Inc.",INDUSTRY
NCT00038792,Phase I/II Trial rHuKFG for the Treatment of Steroid Refractory Gastrointestinal Acute GVHD,A Phase I/II Trial of Recombinant Human Keratinocyte Growth Factor (rHuKFG) for the Treatment of Steroid Refractory Gastrointestinal Acute Graft-versus-host Disease (aGvHD),TERMINATED,Slow accrual.,"PHASE1, PHASE2",INTERVENTIONAL,7,Acute Graft Versus Host Disease,Recombinant Human Keratinocyte Growth Factor,DRUG,Number of Participants with resolution of diarrhea,2000-10,2003-01,M.D. Anderson Cancer Center,OTHER
NCT03997292,Intravenous Thrombolysis Registry for Acute Ischemic Stroke in China,Intravenous ThrombolysisRegistry for Acute Ischemic Stroke in China,WITHDRAWN,The study has been terminated due to key change of protocol,,OBSERVATIONAL,0,Ischemic Stroke,"Alteplase, Urokinase","DRUG, DRUG",mRS of 90 days after thrombolysis,2018-03-01,2020-09-01,General Hospital of Shenyang Military Region,OTHER
NCT00795236,Melatonin Studies of Totally Blind Children,Melatonin Studies in Young Blind Children and Adolescents,TERMINATED,Unique provision in the American Recovery and Reinvestment Act prevented approval of second year no-cost-extension in which completion of analyses were planned.,NA,INTERVENTIONAL,13,"Sleep Disorder, Blindness",Melatonin,DRUG,"To Test for a Proportional Gender Difference in Circadian Status (Free-running Versus Entrained) in Blind Children and in Adolescents, a Chi-square Test of Significance Will be Used for Each Age Group., To Test for a Proportional Difference in Circadian Status (Free-running Versus Entrained) Between Pre and Post- Pubertal Males in Blind Boys and Young Men, a Chi-square Test of Significance Will be Used for Each Age Group., To Determine the Efficacy of Melatonin Treatment in Entraining Blind Free-running Children and Young Adults, a Binomial Test Will be Used.",2009-11,2015-06,Oregon Health and Science University,OTHER
NCT04546711,Energy Expenditure and Quality of Life in Epilepsy,Effects of Ketogenic Diet on Epilepsy: Metabolism and Quality of Life,WITHDRAWN,decided not to process with study,,OBSERVATIONAL,0,Epilepsy,,OTHER,"Change in the Frequency of Seizures Assessed with Participant Seizure Frequency Report, Change in Severity of Seizures Assessed by Seizure Severity Questionnaire (SSQ), Change in the Quality of Life in Epilepsy (QOLIE-31-P) Score",2023-06,2025-08,"University of Wisconsin, Madison",OTHER
NCT04902911,Point of Care Evaluation of Novir 2019-nCoV Immunoglobulin G/ Immunoglobulin M (IgG/IgM) Antibody Test (Collodial Gold),Point of Care Evaluation of Novir 2019-nCoV Immunoglobulin G/ Immunoglobulin M (IgG/IgM) Antibody Test (Collodial Gold),TERMINATED,"Failed to meet FDA criteria on one target at FDA, CDC, and market is not looking for rapid antibody tests.",,OBSERVATIONAL,91,Covid19,,DEVICE,Novir 2019-nCoV IgG/IgM Antibody test,2021-04-13,2022-08-17,Medical College of Wisconsin,OTHER
NCT02010411,Alpha1 Antitrypsin Aerosol Therapy in Cystic Fibrosis,Effects of Prolastin Aerosol Therapy on Bacterial Density in the Airways of Patients With Cystic Fibrosis,TERMINATED,Technical problems with measure of CFU's. Outcomes published: PMID:16986483,PHASE2,INTERVENTIONAL,17,Cystic Fibrosis,Prolastin (drug),DRUG,"Bacterial density in sputum as determined by colony forming units at 2, 4 and 6 hours after Prolastin therapy.",2004-06,2005-10,Université de Sherbrooke,OTHER
NCT05245071,Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA,"Open-label, Phase 2 Study, Evaluating the Efficacy and Safety of Tusamitamab Ravtansine in Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA",TERMINATED,"Sponsor decision, the decision is not related to any safety concern.",PHASE2,INTERVENTIONAL,22,Non-squamous Non-small Cell Lung Cancer,Tusamitamab ravtansine,DRUG,Objective Response Rate (ORR),2022-06-01,2024-11-20,Sanofi,INDUSTRY
NCT02324205,Assessment of Diagnostic Accuracy and Performance of Digital Breast Tomosynthesis Compared to Mammography (ADAPT),Assessment of Diagnostic Accuracy and Performance of Digital Breast Tomosynthesis Compared to Mammography (ADAPT Trial) ADAPT-BX: Recruitment Plan for Initially Asymptomatic Women Referred for Breast Biopsy,TERMINATED,Sponsor met enroll. need for planned second study before meeting enroll. ceiling in protocol,NA,INTERVENTIONAL,196,"Breast Cancer, Tumors, Breast",,DEVICE,"Number of Participants With DBT, FFDM and Biopsy Specimens Collected.",2015-03,2017-08-29,GE Healthcare,INDUSTRY
NCT00200694,"Anti-Proteinuric Response to ACEI, ARB and Diuretics Combination.",,TERMINATED,difficulty in patients's inclusion,PHASE4,INTERVENTIONAL,18,Heavy Proteinuria,"ramipril 5 mg + valsartan 80 mg/day,, ramipril 10 mg + valsartan 160 mg/day,, ramipril 5 mg + valsartan 80 mg/day + increased dosage of furosémide.","DRUG, DRUG, DRUG",,2005-03,2007-03,Nantes University Hospital,OTHER
NCT01841931,Buprenorphine Treatment: A Safe Alternative for Opioid Dependent Pain Patients,Buprenorphine Tx:A Safe Alternative for Opioid Dependent Pain Patients,TERMINATED,Principal Investigator is no longer at this site,NA,INTERVENTIONAL,4,Opioid Use Disorder,Buprenorphine/Naloxone,DRUG,"Opiate Withdrawal, Pain Severity",2013-02,2013-08,Maimonides Medical Center,OTHER
NCT01071902,Safety and Efficacy of Moxidex Otic,Safety and Efficacy Evaluation of Topical Moxidex Otic Solution in the Treatment of Acute Otitis Media With Otorrhea in Tympanostomy Tubes,TERMINATED,Management decision,PHASE3,INTERVENTIONAL,400,Acute Otitis Media,"Moxidex otic solution, Moxifloxacin otic solution","DRUG, DRUG, OTHER, DEVICE",Clinical Cure at End of Treatment,2010-02,2011-10,Alcon Research,INDUSTRY
NCT03905902,"DCVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma","A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of DCVAC/OvCa Added to Standard of Care in Patients With Relapsed Platinum-sensitive Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma",WITHDRAWN,Company decision,PHASE3,INTERVENTIONAL,0,"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Carcinoma","DCVAC/OvCa, DCVAC/OvCa placebo","BIOLOGICAL, BIOLOGICAL",Overall Survival(OS),2021-08,2021-08-16,SOTIO a.s.,INDUSTRY
NCT01134445,An Electronic Data Capture Study to Assess the Long-term Performance of the DePuy PROXIMA™ Hip in Primary Total Hip Replacement,"Prospective, International Multi-centre, Uncontrolled, Post Marketing Surveillance Study to Monitor the Long-term Performance of the DePuy PROXIMA™ Hip in Subjects With Indications Suitable for a Primary Total Hip Arthroplasty",TERMINATED,Study terminated early for business reasons,PHASE4,INTERVENTIONAL,42,"Rheumatoid Arthritis, Osteoarthritis, Post-traumatic Arthritis, Avascular Necrosis, Traumatic Femoral Fractures, Congenital Hip Dysplasia",,DEVICE,Kaplan-Meier survivorship calculated at the five-year time-point,2010-02-01,2016-06-01,DePuy International,INDUSTRY
NCT03109795,Anxiety-mediated Impairments in Large Elastic Artery Function and the Autonomic Nervous System,Anxiety-mediated Impairments in Large Elastic Artery Function and the Autonomic Nervous System,TERMINATED,Funding ended,PHASE4,INTERVENTIONAL,35,"Anxiety, Hypertension","Clonidine Pill, Hydrochlorothiazide","DRUG, DRUG",Aortic Stiffness,2017-04-10,2023-06-30,University of Iowa,OTHER
NCT06590675,Development and Evaluation of a ChlorHexidine Gluconate bAthing pRotocol for Healthcare Settings in Low- and Middle-income Countries,Development and Evaluation of a ChlorHexidine Gluconate bAthing pRotocol for Healthcare Settings in Low- and Middle-income Countries,TERMINATED,Funding Withdrawn,NA,INTERVENTIONAL,19,Multidrug Resistant Bacterial Infection,Chlorhexidine Gluconate (CHG),DRUG,"Safety of locally prepared 1% and 2% chlorhexidine gluconate (CHG) cleansing: Skin integrity, Safety of locally prepared 1% and 2% CHG cleansing: Systemic responses",2025-02-19,2025-03-19,University of Pennsylvania,OTHER
NCT05678257,A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer,"A Randomised, Open-label, Phase II, Dose/Schedule Optimisation Study of NUC-3373/Leucovorin/Irinotecan Plus Bevacizumab (NUFIRI-bev) Versus 5-FU/Leucovorin/Irinotecan Plus Bevacizumab (FOLFIRI-bev) for the Treatment of Patients With Previously Treated Unresectable Metastatic Colorectal Cancer",TERMINATED,"A pre-planned initial analysis concluded that the study was unlikely to achieve its primary objective of demonstrating superior progression-free survival. Based on the Steering Committee's recommendation, the Sponsor has closed the study.",PHASE2,INTERVENTIONAL,180,"Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma, Colorectal Cancer Metastatic, Neoplasm, Colorectal","Fosifloxuridine Nafalbenamide, Leucovorin, Irinotecan, Bevacizumab, 5-FU","DRUG, DRUG, DRUG, BIOLOGICAL, DRUG",Median Progress-free Survival (PFS),2023-04-18,2024-08-29,NuCana plc,OTHER
NCT02469701,Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease,Nivolumab and Ablation For Patients With Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease: A Brown University Oncology Research Group Phase II Study,TERMINATED,Lack of accrual,PHASE2,INTERVENTIONAL,10,"Non-small Cell Lung Cancer, Lung Cancer, Metastatic Lung Cancer, NSCLC",nivolumab and ablation,DRUG,Response Rate of the Combination of Ablation and the PD-1 Inhibitor Nivolumab for Patients With Non-small Cell Lung Cancer (NSCLC) Who Have Progressed Following at Least 1 Prior Chemotherapy Regimen for Metastatic or Locally Advanced Disease.,2016-02,2018-03,howard safran,OTHER
NCT03891381,Electromyographic Monitoring and Postoperative Recovery,Electromyographic Monitoring and Postoperative Recovery,TERMINATED,PI left institution,NA,INTERVENTIONAL,130,Postoperative Residual Neuromuscular Blockade,,DEVICE,Incidence of postoperative residual neuromuscular blockade,2019-03-26,2020-10-20,Endeavor Health,OTHER
NCT03809481,"Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs Argatroban","Open-Label, Randomised, Active Controlled, Multi-Centre Ph 3 Study to Evaluate the Safety and Efficacy of Danaparoid vs Argatroban in Acute HIT",TERMINATED,Prolonged delay as a result of impact of Covid19 pandemic,PHASE3,INTERVENTIONAL,7,Heparin-induced Thrombocytopenia,"Danaparoid Sodium, Argatroban","DRUG, DRUG",Composite Efficacy Response,2019-05-16,2022-06-10,Aspen Global Incorporated,INDUSTRY
NCT04142619,Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01),"Phase I, Open-label Dose-escalation Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCARTCS1A (Allogenic Engineered T-cells Expressing Anti-CS1 Chimeric Antigen Receptor) Administered in Patients With Relapsed/Refractory Multiple Myeloma",TERMINATED,The trial was discontinued due to sponsor's decision and not a consequence of any safety concern.,PHASE1,INTERVENTIONAL,11,Relapsed/Refractory Multiple Myeloma,UCARTCS1A,BIOLOGICAL,Safety of UCARTCS1A,2019-11-21,2023-06-18,Cellectis S.A.,INDUSTRY
NCT02719730,Upgrade the Grains Study: Increasing Whole Grain Consumption in Low-income Children With Obesity,The Metabolic Impact of Concurrent Food Insecurity and Obesity,TERMINATED,Change in study design to be a pilot with no randomization to intervention/control,NA,INTERVENTIONAL,5,Obesity,,BEHAVIORAL,Change in whole grains consumption (ounce equivalents),2016-06-22,2016-08-02,UCSF Benioff Children's Hospital Oakland,OTHER
NCT02454530,Use of Biosimilar Nivestim® to Prevent Chemo-induced Neutropenia. Real Life Study,PROPHYLACTIC TREATMENT FOR CHEMO-INDUCED NEUTROPENIA. USE OF G-CSF BIOSIMILAR (NIVESTIM(REGISTERED)) ACCORDING TO THE CHEMOTHERAPY CONTEXT: ADJUVANT VERSUS METASTATIC.,TERMINATED,The study was stopped due to the judicial liquidation of the CRO in charge of this study.,,OBSERVATIONAL,1160,Chemotherapy-Induced Neutropenia,Nivestim®,BIOLOGICAL,Percentage of Participants by Level of Importance of Factors Determining the Use of Nivestim,2014-09,2017-01,Pfizer,INDUSTRY
NCT01014767,Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors,CPT-SIOP-2009: Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Patients With Choroid Plexus Tumors,TERMINATED,PI departure from coordinating institution,PHASE3,INTERVENTIONAL,27,"Brain Cancer, Choroid Plexus Tumors","Carboplatin, Cisplatin, Cyclophosphamide, Dactinomycin, Doxorubicin, Etoposide, Irinotecan, Leucovorin, Methotrexate, Temozolomide, Vincristine","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Time to Disease Progression, Toxicity During First 4 Months of Therapy",2009-11,2014-01,Tufts Medical Center,OTHER
NCT00556400,Treatment of Menorrhagia in Women With Thrombocytopenia Using Platelets or Platelets and Hormones,Treatment of Menorrhagia in Women With Thrombocytopenia: Comparison of Platelet Transfusion Alone to Platelet Transfusion With Continuous Oral Contraceptive Pills,TERMINATED,Early termination because of insufficient accrual.,"PHASE1, PHASE2",INTERVENTIONAL,1,"Aplastic Anemia, Menorrhagia, Amenorrhea","Lo-Ovral Oral Contraceptive Pills, Placebo - sugar pill","DRUG, DRUG",Stop Vaginal Bleeding or Spotting.,2007-11,2012-06,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),NIH
NCT01053507,Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction,Evaluation of the Efficacy of Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction,TERMINATED,Enrollment rate was slower than anticipated.,PHASE4,INTERVENTIONAL,23,Post-Traumatic Headache,"sumatriptan/naproxen sodium, Placebo","DRUG, DRUG","Headache Days, Change in Number of Associated Headache Symptoms",2010-05,2012-11,"Cady, Roger, M.D.",INDIV
NCT01906307,A Phase 1 Study of LJPC-501 in Patients With Hepatorenal Syndrome,A Phase 1 Study of LJPC-501 in Patients With Hepatorenal Syndrome,TERMINATED,Corporate decision,PHASE1,INTERVENTIONAL,6,Hepatorenal Syndrome Type I and Type II,LJPC-501,DRUG,Adverse events through 5 days of treatment,2014-03,2015-12,La Jolla Pharmaceutical Company,INDUSTRY
NCT04226807,Impact of Earlier Postpartum Contact on Postpartum Visit Compliance and Maternal Wellbeing,Re-imagining the Postpartum Process: The Impact of Earlier Postpartum Contact on Attendance at Postpartum Visits and Maternal Wellbeing,TERMINATED,"Low participation rate, study converted to a cohort study instead",NA,INTERVENTIONAL,52,Postpartum Care,,OTHER,Attendance at comprehensive postpartum care visit,2021-01-31,2022-01-31,Montefiore Medical Center,OTHER
NCT00436436,O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation Therapy,A Phase 2 Study of O-Benzylguanine (O-BG) and Temozolomide in Patients With Glioblastoma Progressing at Least 3 Months After Completion of Primary Treatment With Radiation Therapy and Temozolomide,TERMINATED,Study closed to accrual after the company chose to stop development of the drug.,PHASE2,INTERVENTIONAL,12,Brain and Central Nervous System Tumors,"O6-benzylguanine, temozolomide","DRUG, DRUG",Confirmed Best Objective Tumor Response Rate (Complete or Partial Response) in Patients With Methylguanine Methyltransferase (MGMT)-Positive Tumors as Assessed by Immunohistochemistry (IHC),2006-11-13,2010-04-14,National Cancer Institute (NCI),NIH
NCT04203511,INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301),"A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of INCMGA00012, an Anti-PD-1 Antibody, in Combination With Chemoradiation in Participants With Unresectable, Stage III Non-Small Cell Lung Cancer (POD1UM-301)",WITHDRAWN,Sponsor Strategic/Business Decision,PHASE3,INTERVENTIONAL,0,Non-small Cell Lung Cancer,"Retifanlimab, Placebo, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel, Etoposide","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, RADIATION",Progression-free survival (PFS),2020-07-31,2025-01-31,Incyte Corporation,INDUSTRY
NCT02375711,Immunosenescence and Hepatitis B Virus (HBV) Vaccine Efficacy in Chronic Renal Disease Patient,Evaluation of Immunosenescence as a Predictive Biomarker of HBV Vaccine Efficacy in Chronic Renal Disease Patient,TERMINATED,Problems in including patients in the study,NA,INTERVENTIONAL,20,Chronic Renal Disease,Blood sample,BIOLOGICAL,Cluster of Differentiation (CD) 8+ CD 57+ CD 28- / CD 8+ T lymphocytes Ratio in Peripheral Blood,2014-03,2017-09,Centre Hospitalier Universitaire de Besancon,OTHER
NCT05167422,Trusted Messenger Intervention,Preliminary Study of a Trusted Messenger Intervention to Promote Vaccine Uptake in Adult Inpatient Psychiatric Hospitals,TERMINATED,Inability to recruit,NA,INTERVENTIONAL,2,Vaccine Hesitancy,,BEHAVIORAL,Vaccine acceptance- This will be measured using the COVID Vaccine Hesitancy Questionnaire,2021-09-14,2023-07-14,Dartmouth-Hitchcock Medical Center,OTHER
NCT03140722,Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents,"Phase 2, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Treatment of Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents",TERMINATED,Revised study design.,PHASE2,INTERVENTIONAL,2,"Anemia, Dialysis-Dependent Chronic Kidney Disease","vadadustat, epoetin alfa","DRUG, DRUG",Change From Baseline in Hemoglobin (Hb) Over Time During the Treatment Period,2017-05-02,2018-03-21,Akebia Therapeutics,INDUSTRY
NCT02598622,A Pilot Study Investigating the Effects of Acetyl-L-Carnitine and Vincristine-Induced Neuropathy in Pediatric Patients With ALL,A Phase II Pilot Study Investigating the Effects of Acetyl-L-Carnitine and Vincristine-Induced Neuropathy in Pediatric Patients With ALL,TERMINATED,Drug availability,PHASE2,INTERVENTIONAL,8,Vincristine Induced Neuropathy,"Acetylcarnitine, Placebo","DRUG, DRUG",Grade of Neurotoxicity Will be Captured by an Adaptation of the Total Peripheral Neuropathy Score.,2009-09,2016-01,Indiana University,OTHER
NCT02440529,Surgeon-Patient Communication: A Randomized Controlled Trial Evaluating the Impact of an Orthopaedic Related Smoking Cessation Discussion After Fracture Surgery,,TERMINATED,Research staff decision,NA,INTERVENTIONAL,1,Orthopaedic Decision Making,,"BEHAVIORAL, BEHAVIORAL",Patient Comprehension,2016-01,2018-04,"University of Missouri, Kansas City",OTHER
NCT00682929,Cannabis for Spasticity in Multiple Sclerosis,Cannabis for Spasticity in Multiple Sclerosis: A Placebo-Controlled Study,TERMINATED,Unable to complete subject recruitment,"PHASE1, PHASE2",INTERVENTIONAL,41,Multiple Sclerosis,"Inhaled Cannabis, Oral THC, Oral Placebo, Inhaled placebo","DRUG, DRUG, DRUG, DRUG","Change From Week 0 to Week 3 in the Rate of Torque Increase, Flexion, Change From Week 0 to Week 3 in the Rate of Torque Increase, Extension, Change From Week 0 to Week 7 in the Rate of Torque Increase, Flexion, LIDO Machine Score - Rate of Torque Increase, Extension",2004-04-14,2011-08-17,"University of California, Davis",OTHER
NCT04613453,"Reducing Adolescent Suicide Risk: Safety, Efficacy, and Connectome Phenotypes of Intravenous Ketamine","Reducing Adolescent Suicide Risk: Safety, Efficacy, and Connectome Phenotypes of Intravenous Ketamine",TERMINATED,Terminated early due to concerns from the NIH DSMB regarding the rate of recruitment and the resulting inability to accomplish the initially approved study aims,PHASE2,INTERVENTIONAL,12,"Adolescent Suicide, Adolescent Depression","Ketamine Infusion, Midazolam Infusion","DRUG, DRUG",Columbia-Suicide Severity Rating Scale (C-SSRS),2022-01-21,2024-12-03,Yale University,OTHER
NCT03394937,Safety of Intranodal ECI-006 in Melanoma Patients,"Study to Assess the Safety and Tolerability of ECI-006 mRNA Immunotherapy by Intranodal Administration in Melanoma: (1) Following Surgical Resection, and (2) in Patients With Stable Disease After Standard of Care Immunotherapy Treatment",TERMINATED,Expiry of study medication,PHASE1,INTERVENTIONAL,21,Melanoma,ECI-006,BIOLOGICAL,"Incidence and severity of treatment-emergent adverse events (TEAEs), including the incidence of dose-limiting toxicities (DLTs), graded using the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.03",2017-06-27,2021-01-29,eTheRNA immunotherapies,INDUSTRY
NCT02058537,Bethanechol for Eosinophilic Esophagitis,Bethanechol for Treatment of Eosinophilic Esophagitis (EoE),TERMINATED,"Initial PI left, study not continued",PHASE2,INTERVENTIONAL,2,Eosinophilic Esophagitis (EoE),Bethanechol,DRUG,Change From Baseline High Resolution Esophageal Manometry With Impedance to Day 7,2014-02,2014-07,University of Iowa,OTHER
NCT05276895,Effect of Natural Senolytic Agents & NLRP3 Inhibitors on Osteoarthritis,"Evaluation of the Efficacy of Natural Senolytic Agents and NLRP3 Inhibitors in Treatment of Osteoarthritis: Randomized, Double Blinded ,Placebo Controlled Trial",SUSPENDED,unavailability of drugs,NA,INTERVENTIONAL,60,Osteoarthritis,,"DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, OTHER",Change from baseline in pain on the visual analogu scale at end of treatment,2022-07-01,2024-12-01,Assiut University,OTHER
NCT05729139,Cemiplimab/Peg-Interferon-α in Advanced CSCC,Cemiplimab/PEG-Interferon-α Combination for Advanced Cutaneous Squamous Cell Carcinoma (aCSCC),WITHDRAWN,PI is leaving institution prior to study opening for accrual.,PHASE1,INTERVENTIONAL,0,"Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma, Advanced Squamous Cell Carcinoma","Cemiplimab-Rwlc, PEG-IFN alfa-2a","DRUG, DRUG","Total Incidence of Dose Limiting Toxicities (DLTs), Adverse Events (AEs), and Serious Adverse Events (SAEs) Leading to Discontinuation or Death",2023-07,2028-07,Baptist Health South Florida,OTHER
NCT04162639,The Relationship Between Cadaveric Allograft Skin and HLA-Sensitivity in Burn Patients,The Relationship Between Cadaveric Allograft Skin and Human-leukocyte Antigens (HLA)-Sensitivity in Burn Patients,WITHDRAWN,PI is working on getting funding for the study and wishes to withdraw the study until that funding is secured.,PHASE4,INTERVENTIONAL,0,Burns,Skin allograft,BIOLOGICAL,"Change in participant's panel reactive antibody (PRA) score at 1 month, Change in participant's panel reactive antibody (PRA) score at 6 months, Change in participant's panel reactive antibody (PRA) score at 12 month",2021-02,2023-02,Virginia Commonwealth University,OTHER
NCT02637375,A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer,A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer,WITHDRAWN,Study never opened (terminated as study drug no longer available),NA,INTERVENTIONAL,0,Breast Cancer,"Ganetespib, Paclitaxel, Doxorubicin, Cyclophosphamide","DRUG, DRUG, DRUG, DRUG",Change in GR protein,2016-05,2018-12,University of Chicago,OTHER
NCT00999557,Bimatoprost Ophthalmic Solution in Increasing Eyebrow and Eyelash Growth in Patients Who Have Undergone Chemotherapy for Breast Cancer and in Healthy Participants,Efficacy of Topical Bimatoprost in Promoting Hair Growth in the Region of the Eyebrow and Eyelashes for Post-chemotherapy Patients Versus Normal Patients,WITHDRAWN,Study was never opened,NA,INTERVENTIONAL,0,"Alopecia, Breast Cancer","bimatoprost ophthalmic solution, placebo","DRUG, DRUG",Measuring regrowth of eyebrows and eyelashes by Bimatoprost Opthalmic solution,2016-01,,Jonsson Comprehensive Cancer Center,OTHER
NCT03517501,The Safety And Efficacy of ART-123 in Subjects With Sepsis and Coagulopathy,"Scarlet-2: A Randomized, Double-Blind,Placebo-Controlled, Phase 3 Study to Assess The Safety And Efficacy of ART-123 in Subjects With Sepsis and Coagulopathy",WITHDRAWN,Sponsor will amend study design by incorporating reconfirmation of coagulopathy following discussion with FDA regarding findings from SCARLET1 study.,PHASE3,INTERVENTIONAL,0,Sepsis and Coagulopathy,"ART-123, Placebo Comparator - Placebo","DRUG, DRUG",28 day,2019-07,2023-05,Asahi Kasei Pharma America Corporation,INDUSTRY
NCT02607501,"European eCLIPS™ Safety, Feasibility and Efficacy Study","A Multi-center Post Marketing Study Evaluating the Safety, Technical Feasibility, and Efficacy of the eCLIPs™ Family of Products for the Treatment of Bifurcation Intracranial Aneurysms.",TERMINATED,Insufficient accrual rate,NA,INTERVENTIONAL,20,"Saccular Aneurysm, Intracranial Aneurysm",,DEVICE,"Safety End Point: absence of a major territorial stroke or death (procedural)., Absence of a major territorial stroke or neurological death, Complete aneurysm occlusion (Raymond 1 ), Complete aneurysm occlusion (Raymond 1 )",2016-04-01,2021-09-30,Evasc Medical Systems Corp.,INDUSTRY
NCT00600301,Vitrectomy Without Internal Limiting Membrane Removal in the Treatment of Diffuse Diabetic Macular Edema: a Comparative Kenalog Vs Bevacizumab Intravitreal Injection Vs Control Study,,WITHDRAWN,undefined,PHASE3,INTERVENTIONAL,0,Diffuse Diabetic Macular Edema,Triamcinolone Acetonide and Bevacizumab,DRUG,,2008-01,2008-01,Asociación para Evitar la Ceguera en México,OTHER
NCT00894101,Positron Emission Tomography Imaging With [F-18] FLT Compared to [F-18] FDG in Cancer Patients for Treatment Evaluation,"A Phase II/III, Open Label, Non-Randomized, Multi-Center Study of Positron Emission Tomography Imaging With [F-18] FLT Compared to [F-18] FDG in Cancer Patients for Treatment Evaluation",WITHDRAWN,The main sponsor of this multi-center trial has submitted this protocol. A single participating site should not register this study.,"PHASE2, PHASE3",INTERVENTIONAL,0,Head and Neck Cancer,[F-18] FLT,DRUG,The basic safety data of [F-18] FLT tracer will be collected. The treatment response evaluated based on the [F-18] FLT results will be compared to the response evaluated based on the standard PET trace [F-18] FDG.,2009-05,2010-04,"University of California, Irvine",OTHER
NCT04722601,"A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma","A Multicenter, Single-Arm, Phase I/II Dose Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Minimally-Pretreated Follicular Lymphoma",TERMINATED,funding,"PHASE1, PHASE2",INTERVENTIONAL,2,Follicular Lymphoma,"Venetoclax, Obinutuzumab, CC-486","DRUG, DRUG, DRUG","Phase I Objective: Maximum Tolerated Dose of Venetoclax and CC-486 As Assessed by Rate of Reported Dose Limiting Toxicities (Side Effects) According to CTCAE Criteria Version 5, Phase I Objective: Number of Participants Who Discontinue Venetoclax, CC-486 and Obinutuzumab Regimen Due to Reported Side Effects as Assessed by CTCAE Criteria Version 5, Phase I Objective: Number of Participants Taking Venetoclax, CC-486 and Obinutuzumab Who Report Serious Side Effects As Assessed by CTCAE Version 5, 4. Phase II Objective: Number of Participants Who Do Not Show Signs of Cancer After Taking CC-486 and Obinutuzumab (Oral Therapies) As Assessed by PET/CT Whole Body Scan (Based on Lugano Criteria)",2021-09-01,2023-03-31,University of Chicago,OTHER
NCT00495365,A Dose Conversion Study of Epoetin Alfa in Subjects With the Anemia of Chronic Kidney Disease.,Evaluation of Dose Conversion From Variable Dosing Intervals of Darbepoetin Alfa to Variable Dosing Intervals of Epoetin Alfa in Patients With the Anemia of Chronic Kidney Disease,TERMINATED,This study was stopped due to slow enrollment,PHASE4,INTERVENTIONAL,8,"Anemia, Chronic Renal Insufficiency",Epoetin alfa,DRUG,The primary objective was to evaluate the proportion of subjects who maintained hemoglobin levels within 10% of entry levels and/or a range of 11-13 g/dL for the 24-week duration of the study.,2003-06,2003-09,"Ortho Biotech Products, L.P.",INDUSTRY
NCT00460967,"Safety and Effectiveness Investigation for Dry, Non-Exudative Age Related Macular Degeneration (AMD) Using Rheopheresis","Safety and Effectiveness, in a Multi-Center, Randomized, Sham Controlled Investigation for Dry, Non-Exudative Age Related Macular Degeneration (AMD)Using Rheopheresis",SUSPENDED,In light of the company's current financial position we have indefinately suspended the Rheo-AMD trial.,PHASE3,INTERVENTIONAL,325,Age-Related Maculopathy,,"DEVICE, DEVICE",BCVA (Best Corrected Visual Acuity),2007-01,2009-12,OccuLogix,INDUSTRY
NCT03445000,ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer,A Single Arm Phase II Trial Evaluating the Activity of Alectinib for the Treatment of Pretreated RET-rearranged Advanced NSCLC,TERMINATED,Low recruitment rate,PHASE2,INTERVENTIONAL,14,"Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Recurrent",Alectinib,DRUG,Best Overall Response (BOR),2018-11-06,2021-03-31,ETOP IBCSG Partners Foundation,NETWORK
NCT00809536,Investigation Of How PD 0332334 And Metformin Are Eliminated From The Body When They Are Administered At The Same Time,"A Phase 1, Open-Label, Randomized, Cross-Over Study To Estimate The Pharmacokinetics Of PD 0332334 And Metformin When Administered Concurrently In Healthy Subjects",TERMINATED,Please Detailed Description for termination reason.,PHASE1,INTERVENTIONAL,24,Generalized Anxiety Disorder,"Metformin, Metformin, PD 0332334, PD 0332334","DRUG, DRUG, DRUG, DRUG","Metformin and PD 0332334 area under the curve (AUC) from time 0 to infinity (AUCinf), Metformin and PD 0332334 AUC from 0 to last quantifiable concentration (AUClast), Metformin and PD 0332334 half-life (t1/2), Metformin and PD 0332334 maximum plasma concentration",2009-01,2009-02,Pfizer,INDUSTRY
NCT01303211,A Case-control Study of the Efficacy of a New Serogroup A Meningococcal Conjugate Vaccine (MenAfriVac) in Mali and Niger,A Case-control Study of the Efficacy of a New Serogroup A Meningococcal Conjugate Vaccine (MenAfriVac) in Mali and Niger,WITHDRAWN,No cases on NmA meningitis were recorded following vaccination with MenAfriVac,,OBSERVATIONAL,0,Meningococcal Disease,,,serogroup A meningococci disease,2012-02,2013-11,London School of Hygiene and Tropical Medicine,OTHER
NCT00928811,Study to Evaluate the Safety of Chronic Administration of Simulect to Subjects Receiving a First Kidney Transplant,One-year Exploratory Study to Evaluate the Safety of Partial Replacement of CNI With Chronic Administration of Simulect in de Novo Normal-risk Kidney Transplant Recipients Treated With MPA,TERMINATED,Investigator left University 04/2010,"PHASE2, PHASE3",INTERVENTIONAL,5,End Stage Renal Disease,"basiliximab, basiliximab","DRUG, DRUG","To evaluate the risk of sensitization against the chimeric antibody, Simulect.",2009-05,2010-04,Drexel University College of Medicine,OTHER
NCT03880071,DIalectical Behavior Therapy and Acceptance Commitment Therapy Short Program for BOrderLine persOnality Disorder,Efficacy of a Dialectical Behavior Therapy and Acceptance Commitment Therapy Short Program for Prevention of Suicidal Behavior in Patients With Borderline Personality Disorder,WITHDRAWN,Abandoned study,NA,INTERVENTIONAL,0,"Female, Borderline Personality Disorder",,"BEHAVIORAL, BEHAVIORAL",Number of proven suicide attempts using the Columbia-Suicide severity rating scale (C-SSRS) at 1 year follow-up,2019-11-30,2020-03-09,"University Hospital, Montpellier",OTHER
NCT00709007,"Directly Administered Antiretroviral Therapy (DAART) Among HIV-1infected Injecting Drug Users (IDUs) in Chennai, India","Evaluating the Role of Directly Administered Antiretroviral Therapy (DAART) in Conjunction With Opiate Substitution in Delivery of Highly Active Antiretroviral Therapy to HIV-1-infected Injecting Drug Users (IDUs) in Chennai, India",WITHDRAWN,No participants satisfied eligibility criteria and were enrolled into the study since July 2008.,"PHASE2, PHASE3",INTERVENTIONAL,0,"HIV Infections, Heroin Dependence",,"BEHAVIORAL, BEHAVIORAL",HIV RNA < 400 copies/ml,2008-07,2011-07,Johns Hopkins University,OTHER
NCT03449771,PrEP and Consumptions,Screening of Psychoactive Substances Use and Anxio-depressive Disorders in Consultation for HIV Pre-exposure Prophylaxis,TERMINATED,Inclusion of the last patient,NA,INTERVENTIONAL,237,"Psychoactive Substance Use, Mood Disorders",,OTHER,Estimate the acceptability and the impact on the management of a systematic identification of the use of psychoactive substances and / or anxio-depressive disorders by self-questionnaire in PrEP consultants,2018-01-03,2019-11-03,"University Hospital, Montpellier",OTHER
NCT05029934,Efficacy of EndoClot™ Spraying After Endoscopic Resection of Large Colorectal Polyps,Efficacy of EndoClot™ Spraying After Endoscopic Resection of Large Colorectal Polyps: A Randomized Trial.,TERMINATED,insufficient recruitment of study patients,NA,INTERVENTIONAL,96,"Wound Endoscopical, Colon, After Polyp Resection, Colon",,PROCEDURE,"delayed bleeding complication: hospitalization, delayed bleeding complication: transfusion, delayed bleeding complication: repeat endoscopy, delayed bleeding complication:",2021-08-18,2023-01-27,Universitätsklinikum Hamburg-Eppendorf,OTHER
NCT00390364,Everolimus in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Therapy,Phase II Study of Single Agent RAD001 in Patients With Colon Cancer and Activating Mutations in the PI3KCA Gene,TERMINATED,Withdrawn due to low accrual,PHASE2,INTERVENTIONAL,1,Colorectal Cancer,everolimus,"DRUG, PROCEDURE, PROCEDURE, PROCEDURE, PROCEDURE, PROCEDURE, PROCEDURE, PROCEDURE, PROCEDURE, PROCEDURE",Response Rate: The Total Number of Participants With Progression of Disease,2006-10,2007-10,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,OTHER
NCT02911909,Moderated Blood Flow Restriction After Anterior Cruciate Ligament Reconstruction,Moderated Blood Flow Restriction After Anterior Cruciate Ligament,TERMINATED,Recruitment was unsuccessful,NA,INTERVENTIONAL,7,Anterior Cruciate Ligament Tear,,"DEVICE, OTHER",Muscle Strength,2017-10-01,2019-10-21,University of Missouri-Columbia,OTHER
NCT02003794,Randomized Controlled Study of the Effectiveness of IV Fluid Infusion in Patients With Acute Ischemic Stroke (IVIS),Randomized Controlled Study of the Effectiveness of IV Fluid Infusion in Patients With Acute Ischemic Stroke (IVIS),TERMINATED,More progressive stroke in one arm,PHASE3,INTERVENTIONAL,120,Ischemic Stroke,0.9% NaCl solution,DRUG,NIHSS ≤ 4,2013-05,2015-01,Chulalongkorn University,OTHER
NCT02226094,Safety and Efficacy of Deep Wave Trabeculoplasty (DWT) in Primary Open Angle Glaucoma and Ocular Hypertension,"A Prospective, Randomized, Controlled Clinical Feasibility Investigation of the Safety and Efficacy of Deep Wave Trabeculoplasty (DWT) in Primary Open Angle Glaucoma (POAG) and Ocular Hypertension (OHT) Subjects",TERMINATED,Lack of funding,"PHASE1, PHASE2",INTERVENTIONAL,35,"Primary Open-angle Glaucoma (POAG), Ocular Hypertension (OHT)",,"DEVICE, DEVICE, DEVICE, DEVICE","Percent decrease in IOP and change in dependence on IOP-lowering medications from baseline, Intra-procedural and post-procedural adverse events",2013-11,2015-12,"OcuTherix, Inc.",INDUSTRY
NCT04287894,Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment,"A Phase Ib, Open-label, Single-center Study to Assess the Safety of Cancer-immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment of Locally Advanced NSCLC.",TERMINATED,Based on initially defined safety rules not continued with expansion phase of study (too much toxicity with neo-adjuvant immunotherapy),PHASE1,INTERVENTIONAL,18,Stage III NSCLC,"Durvalumab, Tremelimumab, Pemetrexed, Cisplatin","DRUG, DRUG, DRUG, DRUG, RADIATION, PROCEDURE",Safety of CIT-induction with Tremelimumab and Durvalumab prior to CRT in stage III NSCLC,2018-12-28,2024-11-04,The Netherlands Cancer Institute,OTHER
NCT00483951,Cardiovascular Disease Screening,Suburban/NHLBI Cardiovascular Disease Screening Protocol,TERMINATED,"Per IRB recommendation, a separate protocol will be prepared for retrospective data analysis. The current protocol does not have specific hypotheses.",,OBSERVATIONAL,1325,"Congenital Heart Disease, Atherosclerosis, Myocardial Ischemia, Myocardial Infarction, Acquired Heart Disease",,"DEVICE, DEVICE",Complete characterization of patients for screening purpose onto a research protocol.,2008-01-28,2020-11-03,"National Heart, Lung, and Blood Institute (NHLBI)",NIH
NCT04121351,Physiological Demands Related to Exercises in Singing for Lung Health,Physiological Demands Related to Exercises in Singing for Lung Health: A Pilot Study (PHRESH Study),TERMINATED,COVID-19 pandemic meant continuation of the study was unfeasible at this time.,,OBSERVATIONAL,8,Healthy,,OTHER,"Oxygen consumption in mL per kilogram per minute during different components of Singing for Lung Health(physical warm up, rhythm exercises, pitch exercises, vocal exercises, repertoire and relaxation)",2019-10-01,2021-04-23,Imperial College London,OTHER
NCT02680951,Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia,Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia: A Phase I Study (AflacLL1401),WITHDRAWN,Withdrawn due to lack of participants.,PHASE1,INTERVENTIONAL,0,Acute Myeloid Leukemia,"Dasatinib, Fludarabine, Cytarabine, Idarubicin, Intrathecal (IT) cytarabine","DRUG, DRUG, DRUG, DRUG, DRUG","Safety of Dasatinib assessed by the Number of Adverse Events, Number of Dose-Limiting Toxicities (DLT), Maximum Tolerated Dose (MTD)",2015-12,2017-12-15,Emory University,OTHER
NCT03936751,Obstructive Sleep Apnea Treatment on Cardiovascular Events in Patients With Acute Cardiogenic Pulmonary Edema: CPAP-CARE STUDY.,Impact of Obstructive Sleep Apnea Treatment on Cardiovascular Events in Patients With Acute Cardiogenic Pulmonary Edema: a Multicenter Randomized Controlled Study (CPAP-CARE STUDY).,TERMINATED,COVID-19 pandemic and philips cpap machine recall,PHASE4,INTERVENTIONAL,150,"Obstructive Sleep Apnea, Pulmonary Edema Cardiac Cause",,"DEVICE, DEVICE",Rate of ACPE recurrence,2019-04-01,2022-12-31,University of Sao Paulo,OTHER
NCT03904602,EdemaWear to Reduce Edema in Hospitalized Patients With CVI:,EdemaWear to Reduce Edema in Hospitalized Patients With Chronic Venous Insufficiency: A Pilot Study,TERMINATED,Patients experienced translocation of edema from lower extremities to trunk heightening concern about triggering congestive heart failure in frail elders.,NA,INTERVENTIONAL,3,Chronic Venous Insufficiency,,DEVICE,change in lower leg volume,2019-08-19,2019-09-15,Massachusetts General Hospital,OTHER
NCT05666453,A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj. in ABO-Incompatible Liver Transplantation,"A Multi-center, Prospective, Randomized, Controlled, Open-label, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of Intravenous Immunoglobulin to Prevent Biliary Complications After ABO Incompatible Adult to Adult Living Donor Liver Transplantation",TERMINATED,Change of Clincal Development Plan,PHASE2,INTERVENTIONAL,59,Liver Transplantation,LIV-GAMMA SN Inj.,"BIOLOGICAL, OTHER",Rate of biliary complications,2022-04-25,2024-07-01,"SK Plasma Co., Ltd.",INDUSTRY
NCT01548339,Laparoscopic Cholecystectomy for Acute Cholecystitis After 72 Hours of Symptoms,Laparoscopic Cholecystectomy for Acute Cholecystitis: is the Rule of 72 Hours Still Actual?,TERMINATED,Intermediary analysis showing increased morbidity in the delayed group,NA,INTERVENTIONAL,86,"Acute Cholecystitis, Cholecystectomy",,PROCEDURE,"Number of Participants With Adverse Event (""Global Morbidity"").",2009-02,2015-10,University of Lausanne Hospitals,OTHER
NCT00325572,Evaluation and Treatment of Copper/Zinc Imbalance in Children With Autism,Evaluation and Treatment of Copper/Zinc Imbalance in Children With Autism,TERMINATED,Lack of efficacy to proceed to Phase 2,PHASE1,INTERVENTIONAL,89,"Autism, Pervasive Developmental Disorder",oral zinc and vitamin C supplements,"DRUG, OTHER",Copper/Zinc Ratio of Children With Autism Compared to Typically Developing Children Phase 2: Change in Copper/Zinc Ratio With Supplementation of Zinc and Vitamin C,2006-11,2011-12,Milton S. Hershey Medical Center,OTHER
NCT05100901,Tolerance and Safety of an Oral Nutritional Supplement,Tolerance and Safety of an Oral Nutritional Supplement Containing Monoacylglycerol Oil (MAG Oil) as the Main Lipid Source in Healthy Adolescents and Adults,TERMINATED,Adolescent cohort will be conducted as separate trial,NA,INTERVENTIONAL,12,Healthy Volunteers,,DIETARY_SUPPLEMENT,Number of subjects who develop gastrointestinal intolerance leading to premature discontinuation,2021-09-24,2021-10-15,Société des Produits Nestlé (SPN),INDUSTRY
NCT00890630,Intracervical Catheters for Induction of Labour in Women With Prelabour Rupture of Membranes at Term,Intracervical Catheters for Induction of Labour in Women With Prelabour Rupture of Membranes at Term: A Pilot Study.,TERMINATED,Inadequate Patient Recruitment.,PHASE2,INTERVENTIONAL,5,"Fetal Membranes, Premature Rupture, Induced Labor",Oxytocin,"PROCEDURE, DRUG",Feasibility,2010-04,2011-07,McMaster University,OTHER
NCT02184130,Altered Vestibular Perception and Transcranial Magnetic Stimulation,Altered Vestibular Perception by Virtual Lesions of Cerebral and Cerebellar Structures Using Repetitive Transcranial Magnetic Stimulation - Implications for Human Vestibular Dysfunction,TERMINATED,"insufficient funds and participants, thus terminated",NA,INTERVENTIONAL,7,"Verticality Perception, Self-motion Perception",,OTHER,changes in verticality perception and self-motion perception after TMS (transcranial magnetic stimulation),2011-10,2017-09,University of Zurich,OTHER
NCT02696928,Methylene Blue Against Vivax Malaria in Ethiopia,Feasibility of Methylene Blue-based Combination Therapy in the Radical Treatment of Adult Patients With Plasmodium Vivax Malaria in Ethiopia: a Randomised Controlled Pilot Trial,WITHDRAWN,Lack of ethical approval in Ethiopia,PHASE2,INTERVENTIONAL,0,Vivax Malaria,"Artemeter-Lumefantrine and MB (combination therapy), Artemeter-Lumefantrine (combination therapy), Artemeter-Lumefantrine and Primaquine (combination therapy)","DRUG, DRUG, DRUG",Study feasibility,2016-04,2018-01,Heidelberg University,OTHER
NCT00882765,Genistein in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery,"A Pre-Surgical, Randomized Clinical Trial of Genistein in Resectable Pancreatic Adenocarcinoma",WITHDRAWN,Study has been closed due to no accrual.,PHASE2,INTERVENTIONAL,0,Pancreatic Cancer,,DIETARY_SUPPLEMENT,Changes in microvessel density of tumor specimen after 2 weeks of treatment with genistein,2009-05,,Jonsson Comprehensive Cancer Center,OTHER
NCT00233467,Characterization of the Use of Antipsychotics in Posttraumatic Stress Disorder During the Past Decade,Characterization of the Use of Antipsychotics in Posttraumatic Stress Disorder During the Past Decade,WITHDRAWN,Funding expired; no subjects enrolled as this was a retrospective chart review,,OBSERVATIONAL,0,"PTSD, Posttraumatic Stress Disorder",,,,2005-09-01,2005-09-30,Tuscaloosa Research & Education Advancement Corporation,OTHER
NCT00523367,"COPD Patients Diagnosed With GERD,COPD Exacerbations After Treatment With High Dose PPI",COPD Patients Diagnosed With Gastro Esophageal Reflux Disease Have Decreased Rates of COPD Exacerbations After Treatment With High Dose Proton Pump Inhibitor Therapy (Esomeprazole or Lansoprazole),TERMINATED,terminated due to enrollment,NA,INTERVENTIONAL,25,"Gastroesophageal Reflux, Chronic Obstructive Pulmonary Disease",,PROCEDURE,Number of Participants With Gastro Esophageal Reflux Disease One Year After Treatment.,2007-08,2010-10,University of Florida,OTHER
NCT00906100,Prevalence of Atrial Delay That Would Preclude Optimization of Atrioventricular (AV) Delay in Patients With Biventricular (BiV) Device,Prevalence of Prolonged Inter/Intra-Atrial Delay That Would Preclude Optimization of Atrioventricular (AV) Delay in Patients Undergoing Biventricular (BiV) Device Placement,WITHDRAWN,"Dr Obel is deceased and no other investigators on study to provide information. old record, IRB has no information; outside of retention period.",,OBSERVATIONAL,0,Heart Failure,,,to determine the proportion of patients who are undergoing Biventricular (BiV) Implantable Cardioverter Defibrillator (ICD) implantation in whom optimization of atrioventricular (AV) delay is not possible due to prolonged inter-atrial/intra-atrial delay.,2008-05,2010-05,University of Texas Southwestern Medical Center,OTHER
NCT03592407,Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal Cancer,A Phase 2 Trial of Neoadjuvant Pembrolizumab in Combination With Epacadostat (INCB024360) in Patients With Non-Metastatic Esophageal/Gastroesophageal Squamous Cell and Adenocarcinomas Treated With Neoadjuvant Chemoradiation: A Window-Of-Opportunity Study,WITHDRAWN,Safety concerns,PHASE2,INTERVENTIONAL,0,"Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","Epacadostat, Pembrolizumab","DRUG, OTHER, BIOLOGICAL, OTHER","Temporal anti-tumor immune response defined as tumor infiltrating cytotoxic T-cells, circulating T-cells, T regulatory cells (Tregs), and myeloid-derived suppressor cells (MDSCs) in tumor and blood samples, Incidence of adverse events per Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4.0",2018-07-01,2020-04,City of Hope Medical Center,OTHER
NCT00130507,Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab,"Randomized Trial to Assess the Benefit of Adding Trastuzumab to Capecitabine and Vinorelbine as Second Line for HER2positive Breast Cancer Patients With Locally Advanced or Metastatic Disease, Previously Treated With Trastuzumab and Taxanes",TERMINATED,A new alternative treatment caused the decrease in the rhythm of recruitment.,PHASE2,INTERVENTIONAL,14,Breast Cancer,"Vinorelbine, Capecitabine, Trastuzumab","DRUG, DRUG, DRUG",Clinical benefit rate,2005-11-04,2009-07-25,Spanish Breast Cancer Research Group,OTHER
NCT04726592,Efficacy of CLORazepate for the Treatment of MIGraine Attack in the Emergency Room,Randomized Double Blinded Monocentric Study Evaluating the Efficacy of CLORazepate for the Treatment of MIGraine Attack in the Emergency Room,TERMINATED,It has been determined that continuing with enrollments in this study is no longer justified due to the lack of significant impact on the expected outcomes.,PHASE3,INTERVENTIONAL,323,"Migraine, Migraine Without Aura, Migraine With Aura, Headache","Clorazepate Dipotassium, Placebo, Ketoprofen, Metoclopramide","DRUG, DRUG, DRUG, DRUG",Pain relief,2021-07-08,2024-04-10,Assistance Publique - Hôpitaux de Paris,OTHER
NCT06327711,Benefits of Nutritional Ingredients for Type 2 Diabetes,Proof of Concept Study: Long-term Benefits of a Blend of Nutritional Ingredients for Type 2 Diabetes,WITHDRAWN,Change in study scope,NA,INTERVENTIONAL,0,Diabetes type2,,"OTHER, OTHER","Matsuda Index, Fasted Glucose, Fasted Insulin",2024-09,2025-10,Abbott Nutrition,INDUSTRY
NCT00515086,Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM),A Phase II Trial of RAD001 in Patients With Recurrent Glioblastoma Multiforme,TERMINATED,Early termination due to slow enrollment and protocol-defined stopping rule.,PHASE2,INTERVENTIONAL,41,Glioblastoma Multiforme,Everolimus,"DRUG, PROCEDURE","Surgery Group: Percentage Change From the Baseline in S6 Kinase Levels, No Surgery Group: Best Overall Tumor Response",2007-08,2009-08,Novartis Pharmaceuticals,INDUSTRY
NCT00846573,Hyperpolarized Noble Gas MR Imaging for Pulmonary Disorders,Hyperpolarized Noble Gas MR Imaging for Pulmonary Disorders,TERMINATED,The study was halted prematurely as the PI was no longer an employee of UMass Medical School.,NA,INTERVENTIONAL,14,"COPD, Cystic Fibrosis, Asthma, Healthy",Hyperpolarized Helium-3,DRUG,Hyperpolarized Helium-3 MR Images,2008-11,2011-04,"University of Massachusetts, Worcester",OTHER
NCT04966169,Effectiveness of GentleWave on the Healing of Apical Periodontitis: A Prospective Cohort Study,Effectiveness of GentleWave on the Healing of Apical Periodontitis: A Prospective Cohort Study,TERMINATED,PI Departure from the University of Iowa,NA,INTERVENTIONAL,23,Apical Periodontitis,,DEVICE,"Change from baseline of Cone Beam Computed Tomography Periapical Index (CBCTPAI) across 1 year, Change from baseline of peripical index (PAI) across 1 year., Change from baseline of modified wound healing scale (Mod-CWHS) across 1 year, Change from baseline of pain severity in 0-10 pain severity scale across 1 year, Change from Day 2 of research subject's thoughts on treatment result across 1 year.",2021-08-27,2025-06-30,University of Iowa,OTHER
NCT03285269,Extension of the RUSH Protocol for Volume Responsiveness,Extension of the Rapid Ultrasound for Shock and Hypotension to Evaluate Volume Responsiveness,WITHDRAWN,Study was not initiated because it was not approved by KPSC IRB.,,OBSERVATIONAL,0,Shock,,"DIAGNOSTIC_TEST, DEVICE, PROCEDURE",Test Characteristics of the E-RUSH Protocol to Predict Fluid Responsiveness,2017-11,2018-11,Kaiser Permanente,OTHER
NCT00188669,The Use of Pentoxifylline and Vitamin E in the Treatment of Chronic Breast Pain,A Phase II Study of the Use of Pentoxifylline and a-Tocopherol in the Treatment of Chronic Breast Pain Associated With Breast Radiotherapy,TERMINATED,date: August 2006. No annual renewal,PHASE2,INTERVENTIONAL,48,Breast Neoplasms,"pentoxifylline, alpha-Tocopherol","DRUG, DRUG","To assess improvement in breast pain with use of the interventional agents., To assess improvement in patient function with the use of the interventional agents.",2002-07,,"University Health Network, Toronto",OTHER
NCT00512369,Effects of PA-1 Transcriptional Regulation on Monocyte Function,"Angiotensin, the Vascular Endothelium, and Fibrinolysis - The Effects of PAI-1 Transcriptional Regulation on Human Monocyte Function",TERMINATED,Investigator left institution,,OBSERVATIONAL,125,Atherosclerosis,,,,2006-03,2011-07,Vanderbilt University,OTHER
NCT05579769,Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.,A Phase II Pediatric Study of a Graft-VS.-Host Disease (GVHD) Prophylaxis Regimen With no Calcineurin Inhibitors After Day +60 Post First Allogeneic Hematopoietic Cell Transplant for Hematological Malignancies,TERMINATED,Principal Investigator left institution,PHASE2,INTERVENTIONAL,3,"Hematologic Malignancy, Myeloid Malignancy","Ruxolitinib, Mesna, Anti-thymocyte globulin (ATG), Cyclosporine, Cyclophosphamide, Fludarabine, Methotrexate, Bone marrow infusion, Busulfan, Thiotepa","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, RADIATION, DRUG, DRUG, DRUG",Proportion of saGVHD Using a ProphylaxisRegimen With no Calcineurin Inhibitors After Day 100 Post First Allogeneic HLA-Matched Sibling or Unrelated Donor HCT for Hematological Malignancies.,2023-03-14,2024-05-08,St. Jude Children's Research Hospital,OTHER
NCT00256841,Hypo-Hyperfractionated Chest Radiation for Non Small Cell Lung Cancer With Taxotere/Xeloda Combination Chemotherapy,"Dose Escalation of Xeloda or 5FU Continuous Infusion in Combination With Taxotere and Concurrent Once Weekly, Hypofractionated Chest Radiotherapy for Advanced Non Small Cell Lung Cancer: A Phase I/II Study",WITHDRAWN,Lack of funding,"PHASE1, PHASE2",INTERVENTIONAL,0,"Carcinoma, Non-Small-Cell Lung",Chemotherapy,"DRUG, PROCEDURE",Saftey,2005-09,2007-10,Clinical Oncology Research Associates,OTHER
NCT00211354,Treatment of Retinal Vein Occlusion (RVO) With Open-Label Anecortave Acetate (15mg.),,WITHDRAWN,No subjects enrolled,PHASE2,INTERVENTIONAL,0,Retinal Vein Occlusion,Anecortave Acetate,DRUG,to investigate the use of anecortave acetate for treatment of retinal vein occlusion,2002-03,2007-04,"Manhattan Eye, Ear & Throat Hospital",OTHER
NCT05050305,Marizomib Central Nervous System (CNS),"A Phase 2 Study With Safety Run-In of Marizomib, Pomalidomide, and Dexamethasone For Relapsed and Refractory Multiple Myeloma and CNS Myeloma",WITHDRAWN,Study support withdrawn,PHASE2,INTERVENTIONAL,0,"Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory","Marizomib, Pomalidomide, Dexamethasone","DRUG, DRUG, DRUG","Maximum Tolerated Dose (MTD) Safety Run-In, Dose Limiting Toxicity (DLT), The number and proportion of adverse events, graded as defined by CTCAE version 5.0., Overall response rate (ORR)",2024-03,2027-12,Dana-Farber Cancer Institute,OTHER
NCT05339594,REINVENT Registry (Registry of the Nerve Gap Repair From Integra),Post-Market Clinical Follow-up Registry of Patients Requiring Nerve Gap Repair From Integra,TERMINATED,"Slow Enrollment, Sponsor Decision",,OBSERVATIONAL,17,Peripheral Nerve Injuries,,"DEVICE, DEVICE",The primary clinical outcome measure is an evaluation of meaningful recovery as expressed by the Medical Research Council (MRC) scale as determined by the 2-point discrimination test (2PD).,2022-05-30,2024-06-03,Integra LifeSciences Corporation,INDUSTRY
NCT02173756,Evaluation of Oral Morphine Gel in Oral Mucositis Induced by Chemotherapy in Children and Young Adults,,TERMINATED,Numerous premature study discontinuations due to adverse events,PHASE3,INTERVENTIONAL,25,Cancer,"morphine gel, placebo gel","DRUG, DRUG",change in pain of mucositis before and after meal,2014-06,2017-09,"University Hospital, Strasbourg, France",OTHER
NCT03549351,Evaluation of Measurable Residual Disease in Patients With Acute Myeloid Leukemia as Surrogate Endpoint for Survival,Prospective Evaluation of Measurable Residual Disease in Intensively Treated Patients With Acute Myeloid Leukemia (AML) as Surrogate Endpoint for Survival,TERMINATED,Study turned out no longer feasible,,OBSERVATIONAL,51,"Leukemia, Myeloid, Acute",,OTHER,Correlation between Measurable Residual Disease (MRD) and Survival with respect to treatment effects,2019-06-01,2022-09-11,University Hospital Heidelberg,OTHER
NCT03823131,"Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat","The Trifecta Study: Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat",TERMINATED,Treatment Ineffective,PHASE2,INTERVENTIONAL,14,"Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Unresectable Head and Neck Squamous Cell Carcinoma","Epacadostat, Pembrolizumab, CORVax, Tavokinogene telseplasmid","DEVICE, DRUG, DRUG, BIOLOGICAL, DRUG",Best Overall Response Rate,2019-05-02,2022-07-31,"Chase Heaton, MD",OTHER
NCT00787137,Single Dose PG102 in Patients With Active Psoriatic Arthritis,"A Randomised, Double Blind, Placebo Controlled, Single Ascending Dose, Phase I Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PG102 (Anti-CD40 Monoclonal Antibody) In Patients With Active Psoriatic Arthritis",TERMINATED,poor recruitment,PHASE1,INTERVENTIONAL,17,"Arthritis, Psoriatic","PG102, Placebo comparator","DRUG, DRUG","The Number of Reported Adverse Events, The Percentage of Participants With Adverse Events, The Number of Episodes of Change in Vital Signs, The Number of Episodes of Change in Electrocardiogram, The Number of Episodes of Change From Screening in Laboratory Assessments",2008-12,2010-05,PanGenetics UK Limited,INDUSTRY
NCT03626545,Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy,"A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Canakinumab in Combination With Docetaxel Versus Placebo in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancer (NSCLC) Previously Treated With PD-(L)1 Inhibitors and Platinum-based Chemotherapy (CANOPY 2)",TERMINATED,The study was early terminated due to the lack of efficacy of study treatment observed in the analysis of the primary endpoint of the randomized part,PHASE3,INTERVENTIONAL,245,Non-Small-Cell Lung,"Canakinumab, Docetaxel","DRUG, DRUG, OTHER","Safety run-in Part: Percentage of Participants With Dose Limiting Toxicities (DLTs), Randomized Part: Overall Survival (OS)",2019-01-23,2021-12-20,Novartis Pharmaceuticals,INDUSTRY
NCT03609372,The STOP-HPV Trial 6: Single Arm Evaluation of the Maintenance of the STOP-HPV Bundle,Improving HPV Vaccination Delivery in Pediatric Primary Care: The STOP-HPV Trial 6. Single Arm Evaluation of the Maintenance of the STOP-HPV Bundle,WITHDRAWN,"With the pandemic, we needed to take a 15 month pause in between earlier RCTs. This RCT no longer made sense to conduct.",NA,INTERVENTIONAL,0,"Vaccination, Immunization",,BEHAVIORAL,"Change in the rate of missed vaccination opportunities among all clinicians, Change in the rate of missed vaccination opportunities among consenting clinicians",2018-08-07,2021-03,"University of California, Los Angeles",OTHER
NCT05581095,"Empowering Mindfulness, Body Respect, and Compassionate Eating Among Women Who Binge Eat During Pregnancy","EMBRACE MOMS 2 BE: A Pilot Feasibility, Acceptability, and Preliminary Efficacy Study of a Mindful Eating Self-Help Program for Women Who Binge Eat During Pregnancy",SUSPENDED,We have experienced difficulty with recruitment and will be altering the study's eligibility criteria.,NA,INTERVENTIONAL,50,"Pregnancy, Binge Eating",,"BEHAVIORAL, BEHAVIORAL","Enrollment, Attrition, Program Satisfaction, App Usability, Mindful Eating, Binge Eating, Intuitive Eating",2023-08,2024-09,"University of North Carolina, Charlotte",OTHER
NCT00186095,Mixed Chimeric Transplantation for Primary Amyloidosis,Mixed Chimeric Transplantation for Primary Amyloidosis,WITHDRAWN,"Closed, never started.",NA,INTERVENTIONAL,0,Amyloidosis,,PROCEDURE,Treatment of patients with nonmyeloablative allogeneic transplant for amyloidosis.,2000-12,2006-09,Stanford University,OTHER
NCT00343395,Rosiglitazone and Metformin: Outcomes Trial in Nondiabetic Patients With Stable Coronary Syndromes (Romance) Pilot Study,"A Single-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Combined Rosiglitazone/Metformin (Avandamet®) vs. Placebo on Serological Outcomes in Non-Diabetic Patients With Stable Coronary Syndromes",TERMINATED,FDA concerns regarding Avandamet,PHASE4,INTERVENTIONAL,200,Coronary Artery Disease,AVANDAMET,DRUG,"To demonstrate the effect (change from baseline) of each study intervention on hs-C-reactive protein., To demonstrate the safety of the interventions on clinical outcomes (death, MI, cardiovascular hospitalizations) and serious drug-related adverse events.",2006-06,2008-01,"Intermountain Health Care, Inc.",OTHER
NCT01551095,Self-Propelled Percutaneous Endoscopic GastroJejunostomy (PEG-J),Self-Propelled Percutaneous Endoscopic GastroJejunostomy (PEG-J): A Pilot Study,TERMINATED,Proof of principle was achieved after inclusion of 7 patients,PHASE2,INTERVENTIONAL,7,GERD,,DEVICE,Safety: Number of Participants With Adverse Events,2012-01,2012-05,Johns Hopkins University,OTHER
NCT04306939,Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study,Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study,SUSPENDED,Suspended for analysis and to consider further enrollment.,,OBSERVATIONAL,120000,"Chronic Pancreatitis, Inflammatory Bowel Diseases, Hepatitis, NASH - Nonalcoholic Steatohepatitis, Acute Pancreatitis, Rheumatoid Arthritis, Diabetes Mellitus, Dyslipidemias, Multiple Sclerosis, Irritable Bowel Syndrome, Chronic Pain, Chronic Disease, Chronic Kidney Diseases, Crohn Disease, Celiac Disease, Biliary Cirrhosis, Bile Acid Synthesis Defect, Gastritis, Cholecystitis, Cholelithiases, IPMN, Cyst Pancreas, Cystic Fibrosis, Pancreatic Exocrine Insufficiency, Diarrhea Chronic, Constipation - Functional, Constipation Chronic Idiopathic",,"OTHER, BEHAVIORAL, OTHER","Define the molecular disorders contributing to clinicopathological disease definitions for common complex disorders, Define risk factors for disease progression, severity, complications and poor quality of life., Common disease mechanisms and repurposing of medications.",2014-11-01,2026-12,University of Pittsburgh,OTHER
NCT05583539,Thromboelastography Guided Blood Product Transfusion for Upper Gastrointestinal Bleeding in Cirrhosis,A Pilot Study of Thromboelastography Guided Blood Product Transfusion for Patient With Cirrhosis and Upper Gastrointestinal Bleeding,WITHDRAWN,Never IRB approved,NA,INTERVENTIONAL,0,"Cirrhosis, Liver, Coagulopathy, GastroIntestinal Bleeding",,DIAGNOSTIC_TEST,Volume of fresh frozen plasma transfused,2025-01-16,2025-06-30,Vanderbilt University Medical Center,OTHER
NCT01653977,Impact of Early Goal-directed Fluid Therapy in Hypovolemic Patients Undergoing Emergency Surgery,"Impact of Early Goal-directed Fluid Therapy in Hypovolemic Patients Undergoing Emergency Surgery A Prospective, Randomised, Open Trial",TERMINATED,recrutment difficulties,NA,INTERVENTIONAL,20,"Hypovolemic Shock, Trauma, Emergency, Surgery",,"OTHER, OTHER",Delta lactate,2010-02,2014-12,"University Hospital, Geneva",OTHER
NCT04814875,A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy,"Phase 1b/2a Study Investigating ATX-101 in Combination With Platinum-based Chemotherapy in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancer",TERMINATED,"For technical reasons, it was decided by the sponsor to close the ongoing ovarian cancer study, AM ATX101-03, immediately.","PHASE1, PHASE2",INTERVENTIONAL,16,"Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, High Grade Serious or Endometrioid Carcinoma of the Ovary, Fallopian Tube, or Primary Peritoneal Cancer",ATX-101 + Carboplatin + Pegylated liposomal doxorubicin (ACD),DRUG,"Part 1: To determine the maximum tolerated dose (MTD) of ATX-101 in combination with carboplatin/pegylated liposomal doxorubicin. Measured by incidence of Dose Limiting Toxicity., Part 2: To assess the progression free survival (PFS) of ATX-101 in combination with carboplatin/pegylated liposomal doxorubicin. Measured by Tumor assessments.",2021-09-01,2023-11-30,THERAPIM PTY LTD,INDUSTRY
NCT00864175,Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast Cancer,"A Phase 1/2, Modified Dose Escalation, Open Label Trial to Determine the Therapeutic Effect and Safety of INCB007839 Combined With Trastuzumab in Patients With Previously Untreated HER2 Positive Metastatic Breast Cancer",TERMINATED,Incyte suspended development of the compound.,"PHASE1, PHASE2",INTERVENTIONAL,68,Breast Cancer,"INCB007839, INCB007839, INCB007839, INCB007839, trastuzumab, Docetaxel","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG",Overall response rate (complete + partial response) using RECIST (Response Evaluation Criteria in Solid Tumor) criteria,2007-07,2011-10,Incyte Corporation,INDUSTRY
NCT04707157,Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Diabetic Peripheral Neuropathic Pain,"Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Diabetic Peripheral Neuropathic Pain",TERMINATED,"The trial was slow to enroll, and the sponsor made a business decision to terminate the trial earlier than planned.",PHASE2,INTERVENTIONAL,68,Diabetic Peripheral Neuropathic Pain,"LY3556050, Placebo","DRUG, DRUG",Change From Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS),2021-05-06,2022-06-13,Eli Lilly and Company,INDUSTRY
NCT02306512,Mohs and Immunofluorescence for Malignant Melanoma In Situ,Mohs Micrographic Surgery for Primary Cutaneous Malignant Melanoma In Situ Using Immunofluorescence,WITHDRAWN,PI is leaving the University of Miami,NA,INTERVENTIONAL,0,"Lentigo Maligna, Melanoma In Situ",,"PROCEDURE, PROCEDURE, PROCEDURE, PROCEDURE",IF MART-1 versus Standard H&E and IHC MART-1,2015-06,2015-11,University of Miami,OTHER
NCT03222401,Trial to Assess the Efficacy of F598 in Preventing an Experimental Urethral Infection With N. Gonorrhoeae in Healthy Males,"IGHID 11705 A Randomized, Open-label, Controlled Clinical Trial to Assess the Efficacy of F598 in Preventing an Experimental Urethral Infection With Neisseria Gonorrhoeae in Healthy Male Subjects",TERMINATED,"Interim analysis suggested that the trial, as designed, was not adequately powered to detect a therapeutic effect.",PHASE2,INTERVENTIONAL,10,Neisseria Gonorrhoeae,"1 mg/kg single infusion of F598, 3 mg/kg single infusion of F598, 10 mg/kg single infusion of F598","DRUG, DRUG, DRUG",Assess the efficacy of F598 in preventing an experimental urethral infection with N. gonorrhoeae,2017-11-29,2018-03-02,"Alopexx Pharmaceuticals, LLC",INDUSTRY
NCT03429712,Patient- and Task-specific Radiation Dose Optimization for Pediatric Abdominopelvic CT Applications,Patient- and Task-specific Radiation Dose Optimization for Pediatric Abdominopelvic CT Applications,TERMINATED,Terminated due to slow enrollment.,NA,INTERVENTIONAL,19,Split Dose CT,,DEVICE,Image Noise,2018-09-15,2019-04-12,Duke University,OTHER
NCT01889212,Imaging With 11C-erlotinib PET/CT to Identify Responders to Erlotinib Treatment in NSCLC,Imaging With 11C-erlotinib PET/CT to Identify Responders to Erlotinib Treatment in NSCLC,TERMINATED,Due to technical problems,NA,INTERVENTIONAL,4,Lung Cancer,,OTHER,Accumulation of 11c-erlotinib in tumors before and after treatment with erlotinib,2013-04,2015-04,University of Aarhus,OTHER
NCT00366912,Unloading Respiratory Muscles During NIV: Comparison of a Spontaneous and Auto-adjusting Controlled Mode,,TERMINATED,No longer recruiting: participants are no longer being recruited or enrolled,NA,INTERVENTIONAL,10,Respiratory Failure,,DEVICE,"Work of breathing, pressure time product",2006-08,2007-04,Krankenhaus Kloster Grafschaft,OTHER
NCT02972281,Systematic Search for Primary Immunodeficiency in Adults With Infections,Systematic Search for Primary Immunodeficiency in Adults With Unexplained Recurrent and/or Severe Infections With Encapsulated Bacteria,TERMINATED,deficient inclusions,NA,INTERVENTIONAL,120,"Complement Deficiency, Antibody Deficiency, Chronic Sinus Infection, Meningitis, Bacterial, Pneumonia, Bacterial, Otitis Media, Streptococcal Infection, Neisseria Infections, Haemophilus Influenza, Pneumococcal Infections",Immunological diagnosis tests,BIOLOGICAL,Frequency of Primary immunodeficiencies (PIDs) in adult patients with recurrent and/or severe bacterial infection with encapsulated bacteria,2015-03,2020-03,"University Hospital, Lille",OTHER
NCT05389319,A Study to Assess the Safety and Immunogenicity of a COVID-19 Vaccine Booster in Healthy Adults,"A Phase Ia, Dose-finding Study to Assess the Safety and Immunogenicity of an Orf Virus-based COVID-19 Vaccine Booster (Prime-2-CoV_Beta) in Healthy Adults",SUSPENDED,The clinical trial was temporarily suspended to account for investigating IMP quality aspects.,PHASE1,INTERVENTIONAL,60,COVID-19,Prime-2-CoV_Beta,BIOLOGICAL,"Proportion of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) throughout the study, Proportion of participants with solicited local adverse events (first 7 days after Prime-2-CoV_Beta booster vaccination): pain at injection site, redness, induration, and swelling., Proportion of participants with solicited systemic adverse events (first 7 days after Prime-2-CoV_Beta booster vaccination): fever, fatigue, headache, chills, vomiting, nausea, diarrhea, new or worsened muscle pain, new or worsened joint pain., Proportion of participants with unsolicited treatment-emergent adverse events throughout the study",2022-06-24,2028-08-31,University Hospital Tuebingen,OTHER
NCT00558194,Addressing Emotional and Cognitive Factors in Behavioral Weight Loss Treatment (Part 2),Addressing Emotional and Cognitive Factors in Behavioral Weight Loss Treatment,WITHDRAWN,Lack of funds,NA,INTERVENTIONAL,0,"Overweight, Obesity",,"BEHAVIORAL, BEHAVIORAL",Weight Loss,2009-08,2011-01,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),NIH
NCT05224856,To Evaluate the Safety and Efficacy of Inhaled CT-P63 and CT-P66 Combination Therapy in Symptomatic Patients With COVID-19 Not Requiring Supplemental Oxygen,"A Phase 3, Randomized, Parallel-group, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Inhaled CT-P63 and CT-P66 Combination Therapy in Symptomatic Patients With Coronavirus Disease 2019 (COVID-19) Not Requiring Supplemental Oxygen",WITHDRAWN,The sponsor has decided to stop development of the inhaled CT-P63/66 combination therapy.,PHASE3,INTERVENTIONAL,0,COVID-19,CT-P63 and CT-P66 / Placebo,BIOLOGICAL,Time to clinical recovery,2022-04,2023-01,Celltrion,INDUSTRY
NCT00974922,Vitamin D Deficiency in Patients With Hypertension,"Vitamin D Deficiency, Renin Inhibitor Response, and Vitamin D Supplementation in Patients With Hypertension",TERMINATED,Administrative/Sponsor Business Decision - terminated - study was not completed,PHASE4,INTERVENTIONAL,40,"Vitamin D Deficiency, Hypertension",Aliskiren,"DRUG, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Change From Baseline in Ambulatory Diastolic Blood Pressure,2009-08,2011-12,UConn Health,OTHER
NCT04713202,Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl,Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl (NET-PACS Trial) Big Ten Cancer Research Consortium BTCRC-GI19-400,WITHDRAWN,Funder decision,PHASE2,INTERVENTIONAL,0,"Neuroendocrine Tumors, Carcinoid Syndrome, Diarrhea","Telotristat ethyl, Peptide Receptor Radionuclide Therapy","DRUG, DRUG, OTHER",FACT-QS global QoL Score,2021-03-03,2024-02,Chandrikha Chandrasekhara,OTHER
NCT00608751,A Feasibility Study of Adaptive Intensity-Modulated Radiation Therapy,A Feasibility Study of Adaptive Intensity-Modulated Radiation Therapy in the Definitive Treatment of Head-and-Neck Cancer,TERMINATED,Lack of accrual and software issues,EARLY_PHASE1,INTERVENTIONAL,5,Head and Neck Cancer,,RADIATION,Feasibility of adaptive radiation therapy in the definitive treatment (MLC-based IMRT or helical tomotherapy),2007-01,2008-01,Washington University School of Medicine,OTHER
NCT03010137,Incisional Negative Pressure Wound Therapy in High Risk Patients Undergoing Panniculectomy: A Prospective Randomized Controlled Trial,Incisional Negative Pressure Wound Therapy in High Risk Patients Undergoing Panniculectomy: A Prospective Randomized Controlled Trial,TERMINATED,Lack of staff resources to properly consent and enroll patients into the study.,NA,INTERVENTIONAL,30,"Complications Wounds, Negative Pressure Wound Therapy, Wound Healing Delayed, Incisional, Panniculectomy, Incisional Negative Pressure Wound Therapy, Incisional Vac, Wound Vac, Obese, Renal Failure, Kidney Transplant; Complications, Wound Healing Complication",,"PROCEDURE, PROCEDURE, DEVICE, DEVICE","Major Wound Healing Complications, Minor Wound Healing Complications",2015-12,2019-03-13,"University of California, Davis",OTHER
NCT04432337,Role of Type 2 Diabetes in Potentiating the Inflammatory Response Post Extracorporeal Circulation After Cardiac Surgery,"Role of Type 2 Diabetes in Potentiating the Inflammatory Response Post Extracorporeal Circulation, Mediated by the NLRP3 Inflammasome, in Patients After Cardiac Surgery",WITHDRAWN,Departure of the principal investigator,NA,INTERVENTIONAL,0,"Inflammatory Response, Extracorporeal Circulation; Complications, Cardiac Surgery, Type 2 Diabetes",,PROCEDURE,Variation in the plasma concentration of cytokines IL-1β and IL18,2021-01-01,2021-03-01,University Hospital Center of Martinique,OTHER
NCT01587495,Pharmacokinetics and Safety of Ertapenem in the Postpartum Period,Pharmacokinetics and Safety of Ertapenem in the Postpartum Period,TERMINATED,study terminated due to low subject accrual,PHASE1,INTERVENTIONAL,3,Endometritis,Ertapenem,DRUG,Measure fraction of total and unbound Ertapenem.,2012-03,2014-01,Daniel Benjamin,OTHER
NCT01331395,Effect of Traditional Chinese Medicine on In Vitro Fertilization (IVF) Success Rates,"A Randomized, Controlled Clinical Trial of the Effect of Traditional Chinese Medicine on IVF Success Rates",TERMINATED,Enrollment rate slower than anticipated.,NA,INTERVENTIONAL,8,"Primary Female Infertility, Secondary Female Infertility",,OTHER,"The proportion of subjects who receive an embryo transfer which results in a live birth., The proportion of subjects in the active treatment group experiencing no SAE's attributable to ACU.",2011-06,2013-06,Pacific Fertility Center,OTHER
NCT01917539,Efficacy of Pulsed Light Therapy for Meibomian Gland Dysfunction and Dry Eye Syndrome,Efficacy of Pulsed Light Therapy for Meibomian Gland Dysfunction and Dry Eye Syndrome,WITHDRAWN,Trouble enrolling patients,NA,INTERVENTIONAL,0,"Meibomian Gland Dysfunction, Dry Eye Syndrome",,"DEVICE, DEVICE",Anatomical improvement of the meibomian glands and their secretions.,2013-06,2015-05,University of Miami,OTHER
NCT02042157,Quality of Life in Adults Impaired Functioning - A Randomized Controlled Trial of Bidet vs Usual Toileting,Quality of Life in Adults Impaired Functioning - A Randomized Controlled Trial of Bidet vs Usual Toileting,TERMINATED,Equipment malfunction.,NA,INTERVENTIONAL,28,"Toileting in Adults With Impaired Functional Status, Caregiver Burden for Those Who Care for Adults With Impaired Functional Status, UTI in Adults With Impaired Functional Status",,"BEHAVIORAL, OTHER","Improved quality of life as measured QoL questionnaire, Caregiver burden for caregivers of adults with functional limitations as measured by a validated caregiver burden questionnaire.",2015-01-01,2016-12-31,Stanford University,OTHER
NCT01245101,Addition of Raltegravir to Established Antiretroviral Suppressive Therapy,"A Prospective, Open-Label, Double-Arm, Crossover, Single-Center Pilot Study to Evaluate the Addition of Raltegravir to Established Suppressive Antiretroviral Therapy While Monitoring Changes in Markers of Immune Activation Among HIV-1 Infected Individuals Without Adequate Immune Restoration",TERMINATED,Poor enrollment.,PHASE4,INTERVENTIONAL,15,HIV,"Raltegravir, Raltegravir","DRUG, DRUG",Episomal HIV cDNA Formation,2010-11,2013-05,University of Miami,OTHER
NCT03839901,Rehabilitation Programmes for Scapholunate Instability,"A Pilot Study to Investigate Two Different Physiotherapy Rehabilitation Programmes, to Treat the Conservatively Managed Scapholunate Instability.",TERMINATED,There were insufficient numbers recruited before the end of the student project,NA,INTERVENTIONAL,2,"Wrist Strain, Wrist Sprain, Scaphoid-Lunate Instability",,OTHER,Grip strength using E-link dynamometer,2017-08-01,2018-08-01,University of Bradford,OTHER
NCT03122301,Effects of Stellate Ganglion Block on Hot Flashes in Hispanic Women With Breast Cancer,Effects of Stellate Ganglion Block on Hot Flashes in Hispanic Women With Breast Cancer: A Pilot Randomized Sham-Controlled Trial,TERMINATED,Study stopped due to inadequate enrollment.,PHASE2,INTERVENTIONAL,2,"Hot Flashes, Hot Flushes, Vasomotor Symptoms","Stellate Ganglion Block injection with bupivicaine, Saline","DRUG, DRUG",2 Month Subject Reported Daily Hot Flashes (Mean),2017-06-01,2020-07-01,Northwestern University,OTHER
NCT04232501,"Radial, Sequential Compression Device Deep Venous Thrombosis Detection Study",Effect of Novel Sequential Compression Device on the Incidence of Deep Venous Thrombosis on Complex Surgical Spine Patients,WITHDRAWN,"Due to COVID-19, Radial slowed their operations. Hence the investigational device is not available.",NA,INTERVENTIONAL,0,Deep Venous Thrombosis,,DEVICE,Incidence of Deep Vein Thrombosis (DVT),2021-01-08,2021-01-08,Stanford University,OTHER
NCT03648619,"Automatized ""Semi-Whole-Body""-MRI Protocol for Cancer Staging","Evaluation of an Innovative Automatized ""Semi-Whole-Body""-MRI Protocol to Increase Patient Comfort and Cost-effectiveness of Oncologic Imaging",TERMINATED,Insufficient recruitment,NA,INTERVENTIONAL,10,Oncology,,DIAGNOSTIC_TEST,to compare lesion detectability between wb-MRI and the gold standard PET/CT,2017-09-01,2018-09-01,Kantonsspital Baden,OTHER
NCT00576992,Demographics and Findings of Upper Endoscopy Patients,"A Clinical Study of Demographics and Findings During Endoscopy in Patients With Abdominal Pain, Dyspepsia, GERD, and Associated Symptoms",TERMINATED,Recruitment not being met,,OBSERVATIONAL,1177,"Barrett Esophagus, Gastroesophageal Reflux",,,"Determine the prevalence of gastric and esophageal disease in patients presenting with the complaints of dyspepsia, GERD, or extraesophageal symptoms",2003-01,2017-05,Midwest Biomedical Research Foundation,OTHER
NCT00442507,Erlotinib and Avastin in Patients With Cancer of the Esophagus or Gastroesophageal Junction,A Phase II Trial of Erlotinib and Avastin in Previously Treated Patients With Cancer of the Esophagus or Gastroesophageal Junction,TERMINATED,Slow accrual,PHASE2,INTERVENTIONAL,6,"Esophageal Neoplasms, Esophageal Diseases","Erlotinib, Avastin","DRUG, DRUG",Time to Progression (TTP),2007-03,2009-01,Washington University School of Medicine,OTHER
NCT01527292,Phase II Trial of Stereotactic Radiation Therapy (SRT) Versus SRT Plus Vertebral Augmentation Procedure (VAP) for Vertebral Metastasis,Randomized Phase II Trial of Stereotactic Radiation Therapy (SRT) Versus SRT Plus Vertebral Augmentation Procedure (VAP) for Vertebral Metastasis,TERMINATED,Unable to enroll,NA,INTERVENTIONAL,3,Vertebral Metastasis,,"RADIATION, RADIATION",Numerical Rating Pain Scale (NRPS) Change in Patients,2012-02,2015-09-02,University of Louisville,OTHER
NCT02306811,Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839,A Long-Term Follow-up Study Assessing the Safety and Efficacy of Vatelizumab in Multiple Sclerosis (MS) Patients Who Completed Treatment in Study DRI13839,TERMINATED,Study discontinued based on planned interim analysis of the primary endpoint. Not linked to any safety concern.,PHASE2,INTERVENTIONAL,62,Relapsing-remitting Multiple Sclerosis,Vatelizumab,DRUG,Proportion of patients experiencing adverse events,2015-02,2016-07,"Genzyme, a Sanofi Company",INDUSTRY
NCT00435305,Steady State Serum and Epithelial Lining Fluid (ELF) Antibiotics Concentrations Under Continous Infusion,Antibiotic Concentrations in Serum and Epithelial Lining Fluid Under Continous Infusion,TERMINATED,"difficulties by enrolling patients fundings consumed, no staff could be recruited and payed to continue enrolling patients,",,OBSERVATIONAL,40,"Pneumonia, Bacteremia","Meropenem, Vancomycin, Linezolid, Piperacillin/Tazobactam, Cefepim, Ceftazidim","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG",,2006-11,2007-11,University Hospital Tuebingen,OTHER
NCT03184805,STOPping Versus Continuing Antiplatelet Therapy During Noncardiac Surgery and Procedures After Next Generation Drug-eluting Stent Implantation,Randomized Controlled Comparison: STOPping Versus Continuing Antiplatelet Therapy During Noncardiac Surgery and Procedures After Next Generation Drug-eluting Stent Implantation (STOP-ASP Trial),TERMINATED,Investigator judged that this study can not be maintained because participant registration rate is low.,NA,INTERVENTIONAL,140,Coronary Artery Disease,"Continuing aspirin, Stopping aspirin","DRUG, DRUG","A composite of cardiac death, nonfatal myocardial infarction (MI), cerebrovascular accident, definite or probable stent thrombosis, any revascularization and BARC(Bleeding Academic Research Consortium) ≥3 bleeding during index hospitalization for surgery or procedure",2017-06-23,2018-04-09,Yonsei University,OTHER
NCT02582294,Fabry's Disease and Pregnancy (PREFAB),"Description of Obstetrical Care, Mainly Anesthesic, in Patients With Fabry's Disease",TERMINATED,Difficulty in patient recruitment,,OBSERVATIONAL,12,"Fabry's Disease, Pregnancy",,OTHER,Proportion of Fabry's disease patients having had an epidural block in childbirth.,2015-10,2018-06-01,Groupe Hospitalier Diaconesses Croix Saint-Simon,OTHER
NCT06712966,EngageRx With Integrated Self-Measurement of Blood Pressure,EngageRx With Integrated Self-Measurement of Blood Pressure,WITHDRAWN,Study deemed not human subjects research and will proceed as quality improvement.,NA,INTERVENTIONAL,0,Hypertension,,OTHER,Net Promoter Score,2025-02-01,2025-08-01,"University of California, San Francisco",OTHER
NCT04478266,Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer,"A Randomized, Multicenter, Double-blind Phase 3 Study of Amcenestrant (SAR439859) Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+), HER2 (-) Breast Cancer Who Have Not Received Prior Systemic Anti-cancer Treatment for Advanced Disease",TERMINATED,The study was terminated based on the review by an independent data monitoring committee of the prespecified interim analysis of the Phase 3 AMEERA-5 efficacy data. No new safety signals were observed.,PHASE3,INTERVENTIONAL,1068,Breast Cancer,"Amcenestrant-matching placebo, SAR439859, Palbociclib, Letrozole, Goserelin, Letrozole-matching placebo","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG",Progression-free Survival (PFS),2020-10-14,2023-05-26,Sanofi,INDUSTRY
NCT06290622,"PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL","PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL Post Chimeric Antigen Receptor T-cEll Therapy fAilUre (PLATEAU Study)",WITHDRAWN,Investigator request to no longer pursue this study. Lack of support from drug company. This trial never opened. Withdrew IND.,PHASE1,INTERVENTIONAL,0,"Diffuse Large B Cell Lymphoma, Lymphoma, B-Cell, Lymphoma, Follicular","Retifanlimab, INCAGN02385, INCAGN02390",DRUG,Identify the optimal biological dose (OBD) for Retifanlimab in combination with INCAGN02385 and INCAGN02390 in relapsed/refractory DLBCL.,2024-08-30,2028-01-31,University of Alabama at Birmingham,OTHER
NCT04950751,Immunogenicity and Safety of Adjuvanted SCB-2020S Vaccines in Adults,"An Observer-blind, Randomized, Controlled, Phase 2 Study to Evaluate the Immunogenicity and Safety of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2020S) in Adults",WITHDRAWN,sponsor decided to withdrawn the study as development strategy has changed,PHASE2,INTERVENTIONAL,0,COVID-19,"candidate vaccine, SCB-2020S",BIOLOGICAL,"Geometric mean titer (GMT) of SARS-CoV-2 neutralising antibodies to B.1.351 variant, Proportion of subjects achieving seroconversion of SARS-CoV-2 neutralising antibodies to B.1.351 variant, Geometric mean fold rise (GMFR) of SARS-Cov-2 neutralising antibodies to B.1.351 variant",2021-08,2022-04,Clover Biopharmaceuticals AUS Pty,INDUSTRY
NCT03089502,Efficacy of Cardio-Oncology Rehabilitation Exercise for Women With Breast Cancer and Treatment Related Cardiotoxicity,A Randomized Control Trial of the Efficacy of a Cardio-Oncology Rehabilitation Exercise Program to Improve Cardiorespiratory Fitness in Women With Breast Cancer and Treatment Related Cardiotoxicity (CORE Study).,TERMINATED,Limited recruitment,NA,INTERVENTIONAL,2,"Breast Cancer, Left Ventricular Dysfunction, Heart Failure, Systolic",,OTHER,Cardiopulmonary Fitness,2018-04-01,2018-05-01,"University Health Network, Toronto",OTHER
NCT02460302,Vaginal Progesterone Versus Placebo for the Treatment of Vaginal Atrophy,Vaginal Progesterone Versus Placebo for the Treatment of Vaginal Atrophy - a Double Blind Randomized Control Trial,WITHDRAWN,Inadequate staffing and funds,PHASE2,INTERVENTIONAL,0,"Atrophic Vaginitis, Menopause, Vulvovaginal Atrophy","Vaginal progesterone, Placebo","DRUG, DRUG",Perceived Improvement in most bothersome vulvovaginal symptom,2016-12,,"Mount Sinai Hospital, Canada",OTHER
NCT01032837,A Study of Tamiflu (Oseltamivir) for Treatment of Influenza With a Focus on (H1N1) 2009 Flu Strain,"A Randomized, Multicenter Trial of Oseltamivir [Tamiflu] Doses of 75 mg for 5 or 10 Days Versus 150 mg for 5 or 10 Days to Evaluate the Effect on the Duration of Viral Shedding in Influenza Patients With Pandemic (H1N1) 2009",TERMINATED,Study closed prematurely due to the end of the influenza (H1N1) 2009 pandemic,PHASE4,INTERVENTIONAL,102,Influenza,"Oseltamivir, Oseltamivir, Placebo","DRUG, DRUG, DRUG",Time to Cessation of Viral Shedding,2009-11,2010-10,Hoffmann-La Roche,INDUSTRY
NCT02301845,Validation of Aspiration Markers,Validation of a Marker for Aspiration and Endotracheal Tube Cuff Leak.,WITHDRAWN,IRB disapproval,PHASE1,INTERVENTIONAL,0,"Pneumonia, Aspiration",Diatoms Shells,DRUG,Cuff leak and microaspiration,2016-02,2016-03,Massachusetts General Hospital,OTHER
NCT00956072,Imatinib Mesylate With or Without Surgery in Treating Patients With Metastatic Gastrointestinal Stromal Tumor That is Responding to Imatinib Mesylate,A Phase III Randomized Study Evaluating Surgery of Residual Disease in Patients With Metastatic Gastro-intestinal Stromal Tumor Responding to Imatinib Mesylate.,TERMINATED,low accrual,PHASE3,INTERVENTIONAL,12,Gastrointestinal Stromal Tumor,imatinib mesylate,"DRUG, PROCEDURE",Progression-free survival,2009-05,,European Organisation for Research and Treatment of Cancer - EORTC,NETWORK
NCT05026372,Two-Session Couples Class to Improve Relationship Health,Two-Session Couples Class to Improve Relationship Health,TERMINATED,"Participant drop out exceeded expectations (out of 63 couples randomized, 18 completed follow up). Study may be resumed with revised procedures for preventing drop out.",NA,INTERVENTIONAL,126,Stress,,"BEHAVIORAL, BEHAVIORAL, BEHAVIORAL","Perceived Stress Scale, Perceived Stress Scale",2019-05-29,2023-05-31,Sam Houston State University,OTHER
NCT00587795,Orthopedic Study of the Aircast StabilAir Wrist Fracture Brace,Orthopedic Study of the Aircast StabilAir Wrist Fracture Brace,TERMINATED,Inability to enroll subjects,NA,INTERVENTIONAL,1,Radius Fractures,,"DEVICE, OTHER",Change in Distal Radius Fracture at 8 Weeks,2006-04,2008-11,Mayo Clinic,OTHER
NCT02448095,Retrospective Evaluation of CML Patients in the National Compassionate Program,Ponatinib Survey: Retrospective Evaluation of CML Patients in the National Compassionate Program According to the 648/96 Decree,TERMINATED,lack of interest,,OBSERVATIONAL,38,"Chronic Myeloid Leukemia, Philadelphia Positive",Ponatinib,DRUG,Number of adverse events,2015-12-22,2018-07-17,Gruppo Italiano Malattie EMatologiche dell'Adulto,OTHER
NCT04262895,TTI-0102 for Veterans With TBI,"TTI-0102, a Cysteamine Precursor for Mild to Moderate TBI: Dosing and Feasibility Study",WITHDRAWN,Funding withdrawn due to delay in FDA IND submission,"PHASE1, PHASE2",INTERVENTIONAL,0,"Mild to Moderate TBI, Posttraumatic Stress Disorder","TTI-0102, Placebo","DRUG, DRUG",Objective cognition,2021-10-01,2021-10-15,VA Office of Research and Development,FED
NCT05442775,"A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)","A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)",TERMINATED,The DMC recommended the trial be discontinued due to futility following a planned second interim analysis of the parent trial (CY 5031).,PHASE3,INTERVENTIONAL,71,Amyotrophic Lateral Sclerosis,Reldesemtiv,DRUG,Long-term Safety and Tolerability,2022-08-04,2023-06-07,Cytokinetics,INDUSTRY
NCT00517075,Treatment of Negative Symptoms of Schizophrenia With Transcranial Magnetic Stimulation (TMS),Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Negative Symptoms and Social Dysfunction in Schizophrenia Patients,TERMINATED,Unable to adequately recruit subjects.,PHASE2,INTERVENTIONAL,14,"Schizophrenia, Schizoaffective Disorder",,"DEVICE, DEVICE, DEVICE, DEVICE",Clinical Improvement of Negative Symptoms (Positive and Negative Syndrome Scale [PANSS] Negative Symptoms Subscale) Relative to Pre-treatment Baseline.,2004-09,2011-06,New York State Psychiatric Institute,OTHER
NCT01811875,Post-Marketing Safety Study Following Long-Term Prophylactic OptivateTreatment in Subjects With Severe Haemophilia A,"Multicentre, Non-controlled, Prospective, Post-Marketing Safety Study Following Long-Term Prophylactic OptivateTreatment in Subjects With Severe Haemophilia A",TERMINATED,Study no longer required as Optivate German license expired in Sep-2017.,PHASE4,INTERVENTIONAL,7,Haemophilia A,Optivate 500IU,BIOLOGICAL,Number of Participants That Did Not Develop Inhibitors to FVIII (<0.6BU),2014-11-21,2017-08-31,Bio Products Laboratory,OTHER
NCT04825275,Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial,Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial,TERMINATED,The study was stopped due to slow accrual.,EARLY_PHASE1,INTERVENTIONAL,7,"Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme of Brain, Glioblastoma Multiforme, Adult",Posaconazole Pill,DRUG,Posaconazole Concentration in Cerebrospinal Fluid Using Microdialysis Catheters,2022-05-13,2024-11-06,Milton S. Hershey Medical Center,OTHER
NCT03159975,Safety and Immunogenicity Study of GX-70 in TB Patient,"A Open-label, Dose Escalation, Phase 1 Clinical Trial to Evaluate the Tolerability, Safety and Immunogenicity of GX-70, a DNA-based Therapeutic Vaccine, Administered Intramuscularly by Electroporation (EP) in Patients With Pulmonary Tuberculosis Who Have High Risk Factors for Relapse or Treatment Failure",WITHDRAWN,Unconfirmed research expenses,PHASE1,INTERVENTIONAL,0,"Pulmonary Tuberculoses, High Risk Factors for Relapse, Treatment Failure","GX-70 by electroporation, GX-70 by electroporation, GX-70 by electroporation","DRUG, DRUG, DRUG",MTD (Maximum Tolerant Dose),2018-03,2018-08,Yonsei University,OTHER
NCT02169375,Sensorimotor Based Brain Computer Interface,Effect of Normalizer Adaptation on Accuracy in a Sensorimotor Based Brain-Computer Interface,TERMINATED,Insufficient improvement in primary measures under either condition.,NA,INTERVENTIONAL,6,Healthy Volunteers,,OTHER,Accuracy of a mu rhythm BCI using adaptation versus no adaptation.,2010-11,2011-06,University of Michigan,OTHER
NCT04928781,Smoking Cessation Study,Smoking Cessation Intervention for Hospitalized Heart & Vascular Center (HVC) Patients at a Dartmouth-Hitchcock Medical Center Serving a Rural Population,WITHDRAWN,PI and funding source collectively decided to close study due to lack of smoking cessation counselor required for study,NA,INTERVENTIONAL,0,Smoking Cessation,,BEHAVIORAL,"Percentage of participants that self-report sustained smoking cessation, Percentage of participants that self-report sustained smoking cessation, Percentage of participants that self-report sustained smoking cessation",2022-06-28,2023-06-01,Dartmouth-Hitchcock Medical Center,OTHER
NCT06427512,Mechanisms Underlying Cardiovascular Consequences Associated With COVID-19 and Long COVID,Mechanisms Underlying Cardiovascular Consequences Associated With COVID-19 and Long COVID - Characterizing Long COVID Phenotypes Using Physiological and Molecular Studies,WITHDRAWN,Funding not available,,OBSERVATIONAL,0,COVID-19,,,Prevalence of Microvascular dysfunction,2022-03,2025-03,Columbia University,OTHER
NCT02172001,"A Randomized, Double-blind, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Against Placebo","A Phase III, Randomised, Double-blind, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Against Placebo in Subjects With Iron Deficiency Anaemia and Who Are Intol-erant or Unresponsive to Oral Iron Therapy",WITHDRAWN,Study design not adequate,PHASE3,INTERVENTIONAL,0,Iron Deficiency Anemia,"Iron isomaltoside 1000, Natrium Chloride 0,9%","DRUG, DRUG",Proportion of subjects with an Hb increase of ≥ 2 g/dL from baseline at any time from week 1 to week 5,,,Pharmacosmos A/S,INDUSTRY
NCT05796765,Phase 2B Micronized DHACM vs. Saline in the Treatment of Knee Osteoarthritis,"A Phase 2B, Prospective, Double-Blind, Randomized Controlled Trial of the Micronized DHACM Injectable Product Compared to Saline Placebo Injection for the Treatment of Osteoarthritis of the Knee",TERMINATED,Study discontinued early by Sponsor,PHASE2,INTERVENTIONAL,43,Knee Osteoarthritis,"Micronized DHACM 40 mg, Micronized DHACM 100 mg, Saline","BIOLOGICAL, BIOLOGICAL, DRUG","Change in WOMAC pain subscale score between baseline and Day 180, Change in WOMAC function subscale score between baseline and Day 180, Proportions of subjects who report treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)",2023-03-24,2023-12-15,"MiMedx Group, Inc.",INDUSTRY
NCT03792581,COntrolled MAp Trauma Brain Injury (COMAT Study),Individualizing Mean Arterial Pressure of Head Trauma Injury Patients Using an Novel Automated System for Vasopressor Administration : a Randomized Controlled Trial,WITHDRAWN,The sponsor was not the good one. We will redo the clincal trial gov to be concordant with the actual sponsor,NA,INTERVENTIONAL,0,Closed-Loop Communication,,DEVICE,MEAN ARTERIAL PRESSURE (MAP),2019-04-01,2019-12-30,Erasme University Hospital,OTHER
NCT05223881,Gastroparesis in Cystic Fibrosis,13^C-Spirulina Platensis Gastric Emptying Breath Test for Diagnosis of Gastroparesis in Patients With Cystic Fibrosis,WITHDRAWN,Study is not feasible at this time due to staffing limitations,NA,INTERVENTIONAL,0,Gastroparesis,,DEVICE,Rate of gastric emptying,2022-02-14,2023-03-30,University of Miami,OTHER
NCT00172367,Chemoprevention Trial for Uremia-Associated Urothelial Carcinoma,,WITHDRAWN,"This study was for National Science Council project. The study was not funded, so the study was withdrawn.",PHASE2,INTERVENTIONAL,80,"Carcinoma, Transitional Cell",Lycopene,DRUG,changes of intermediate biomarker status after lycopene supplementation,2006-01,,National Taiwan University Hospital,OTHER
NCT06429800,A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus,"A Phase 1 Study to Evaluate the Safety and Preliminary Efficacy of ATA3219, Allogeneic Anti-CD19 Chimeric Antigen Receptor T-cell (CAR T) Therapy, in Subjects With Systemic Lupus Erythematosus",WITHDRAWN,Financial,PHASE1,INTERVENTIONAL,0,"Lupus Nephritis, Systemic Lupus Erythematosus",ATA3219,DRUG,"Number of Participants With treatment-emergent adverse events, including adverse events of special interest, Number of Participants With Dose-limiting Toxicities, Maximum Tolerated dose, Recommended Phase 2 dose of ATA3219",2025-04-16,2025-04-16,Atara Biotherapeutics,INDUSTRY
NCT04517253,"A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGS","A Phase 2/3, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Baricitinib in Adult and Pediatric Japanese Patients With NNS/CANDLE, SAVI, and AGS",TERMINATED,The study was terminated due to efficacy/effectiveness reasons,"PHASE2, PHASE3",INTERVENTIONAL,10,"Nakajo-Nishimura Syndrome, Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature Syndrome, STING-Associated Vasculopathy With Onset in Infancy, Aicardi Goutieres Syndrome",Baricitinib,DRUG,"Change From Baseline in Mean Daily Diary Scores in Participants With CANDLE (Primary Treatment Period), Change From Baseline in Mean Daily Diary Scores in Participants With SAVI (Primary Treatment Period), Change From Baseline in Mean Daily Diary Scores in Participants With AGS (Primary Treatment Period)",2020-10-27,2024-11-28,Eli Lilly and Company,INDUSTRY
NCT02166775,Correlation Between Sagittal Balance of the Spine and Psychopathological Profile,,TERMINATED,Departure of psychologist in charge of questionnaires and scales administered to patients as part of the evaluation of primary endpoint,,OBSERVATIONAL,205,"Kyphosis in Depressed or Anxious Patients, Lordosis in Patients With Manic",,,sagittal balance of the spine : - kyphosis in depressed or anxious patients- lordosis in patients with manic,2014-01,2016-03,"University Hospital, Strasbourg, France",OTHER
NCT03409757,Velphoro and Impact on the Oral Cavity and Gut Microbiome,Velphoro and Impact on the Oral Cavity and Gut Microbiome,TERMINATED,Insufficient Patient Recruitment,,OBSERVATIONAL,22,Hyperphosphatemia,Velphoro,"DRUG, OTHER, OTHER, OTHER, OTHER",change in relative abundances of iron depending bacterial species within the microbiome from before Velphoro medication to afterwards,2018-02-28,2020-10-06,RWTH Aachen University,OTHER
NCT05737212,"Studying the Safety, Efficacy, and Pharmacokinetic Characteristics of BNCT in Patients With Recurrent High-grade Gliomas","A Multi-centered, Radiation Dose Escalation, Open, Exploratory, Phase 1/2a Clinical Trial on the Safety, Efficacy and Pharmacokinetic Characteristics of BNCT(Boron Neutron Capture Therapy) in Patients With Recurrent High-grade Gliomas",TERMINATED,"The Phase 1 clinical trial was completed, and the study was stopped to initiate a Phase 2 trial with a revised protocol.","PHASE1, PHASE2",INTERVENTIONAL,7,"Recurrent High-grade Glioma, Recurrent Glioblastoma, Recurrent Anaplastic Astrocytoma, Recurrent Anaplastic Oligodendroglioma",,"RADIATION, RADIATION, RADIATION","Phase I: To explore the adequate radiation dose level of BNCT based on confirmation of the maximum tolerated dose of BNCT, Phase IIa: Proportion of 6-month PFS evaluated by central imaging according to the modified RANO criteria",2022-12-05,2024-06-11,"Dawonmedax Co., Ltd.",INDUSTRY
NCT03498781,Good Intentions Study,The Impact of Multiple Behavior Change on the Effectiveness of Implementation Intentions to Promote Fitness Center Visitation,TERMINATED,Lack of interest in pool of potential participants,NA,INTERVENTIONAL,2,"Obesity, Overweight",,"OTHER, OTHER",Fitness center attendance,2018-04-25,2018-11-21,USDA Grand Forks Human Nutrition Research Center,FED
NCT02850419,Heat-Activated Target Therapy of Local-Regional Relapse in Breast Cancer Patients,Heat-Activated Target Therapy (Radiotherapy + Hyperthermia + Lyso-Thermosensitive Liposomal Doxorubicin) of Local-Regional Relapse in Breast Cancer Patients,WITHDRAWN,Administrative,PHASE2,INTERVENTIONAL,0,Breast Cancer,ThermoDox (Thermally Sensitive Liposomal Doxorubicin),"DRUG, RADIATION, DEVICE","Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, Loco-regional breast tumor control in patient who underwent ThermoDox + hyperthermia + radiotherapy as measured by target lesion clinical response rate combining RECIST criteria with digital photography to gauge response.",2017-03,2020-02,Imunon,INDUSTRY
NCT02050230,Hemodynamic Effects of Stored Blood Transfusion in Intensive Care Patients,Hemodynamic Effects of Stored Blood Transfusion in Intensive Care Patients,TERMINATED,Protracted recruitment of patients,PHASE4,INTERVENTIONAL,11,Pulmonary Hypertension,Blood transfusion,BIOLOGICAL,"Pulmonary arterial pressure, Pulmonary vascular resistance",2014-01,2016-06,Medical University of Vienna,OTHER
NCT03913130,Extension Study to Study PQ-110-001 (NCT03140969),"An Open-Label, Extension Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of QR-110 in Subjects With Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene",TERMINATED,Terminated \[Study prematurely terminated due to sponsor decision for reasons unrelated to safety\],"PHASE1, PHASE2",INTERVENTIONAL,9,"Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Vision Disorders, Sensation Disorders, Neurologic Manifestations, Eye Diseases, Eye Diseases, Hereditary, Eye Disorders Congenital, Retinal Disease",QR-110,DRUG,"Frequency of Ocular AEs, Frequency of Non-ocular AEs",2019-05-13,2022-10-03,Laboratoires Thea,INDUSTRY
NCT04307628,Response of Gut Microbiota and Cardiometabolic Biomarkers to Consumption of Walnuts,Response of Gut Microbiota and Cardiometabolic Biomarkers to Consumption of Walnuts,WITHDRAWN,Study logistics still being worked out. On hold for now.,NA,INTERVENTIONAL,0,"Healthy, Normal Weight, Overweight, Obese",,"OTHER, OTHER","Assessing the influence of walnuts on the fecal metagenome, Assessing the influence of walnuts on fecal secondary bile acids, Assessing the influence of walnuts on fecal short-chain fatty acids, Urolithins measured in plasma by UPLC/MS, Fecal calprotectin will be measured by ELISA",2022-06-01,2024-11-30,"University of California, Davis",OTHER
NCT00258765,Adjuvant Docetaxel-Zoledronic Acid in High-risk Early Prostate Cancer Following Prostatectomy.,"A Phase IIb Randomised Clinical Trial of the Tolerability, Safety and Efficacy of Adjuvant Docetaxel-Zoledronic Acid After Prostatectomy for High-risk Early Prostate Cancer (AD-ZAP).",TERMINATED,Poor recruitment \& not feasible to continue,PHASE2,INTERVENTIONAL,1,Prostate Cancer,"Zoledronic Acid, Docetaxel","DRUG, DRUG",safety and tolerabilty of adjuvant chemotherapy with docetaxel and Zometa,2006-05,,Novartis Pharmaceuticals,INDUSTRY
NCT00283400,Treatment of Subarachnoid Hemorrhage With Human Albumin,Treatment of Subarachnoid Hemorrhage With Human Albumin,TERMINATED,Study met safety endpoints,NA,INTERVENTIONAL,47,Subarachnoid Hemorrhage,25% human albumin,DRUG,Safety and Tolerability of the 25% Human Albumin Dosages and the Functional Outcome.,2006-01,2011-04,Baylor College of Medicine,OTHER
NCT03024944,TAU PET Imaging in Northern Manhattan Study of Metabolism and Mind,TAU PET Imaging in Northern Manhattan Study of Metabolism and Mind,WITHDRAWN,18F-THK5351 was reported non-specific binding of MAO receptors.,PHASE2,INTERVENTIONAL,0,"Diabetes Mellitus, Alzheimer Dementia",18F-THK-5351,DRUG,Amount of Tau Accumulation by Measuring Standardized Uptake Value Ratio (SUVR),2017-12,2020-01,Columbia University,OTHER
NCT02030444,Extensive Staging in Lung Cancer,Randomized Study Comparing Standard Staging of Lung Cancer With Extended Staging Including EBUS-TBNA and PET-MRI,TERMINATED,due to difficulties with recruiting,NA,INTERVENTIONAL,32,Lung Neoplasms,,PROCEDURE,Progression free survival,2014-08,2018-08,St. Olavs Hospital,OTHER
NCT04326764,Panobinostat Maintenance After HSCT fo High-risk AML and MDS,"A Randomized, Multicenter Phase III Study to Assess the Efficacy of Panobinostat Maintenance Therapy vs. Standard of Care Following Allogeneic Stem Cell Transplantation in Patients With High-risk AML or MDS (ETAL-4 / HOVON-145)",TERMINATED,Change of marketing authorisation holder,PHASE3,INTERVENTIONAL,52,"Acute Myeloid Leukaemia (AML), Myelodysplastic Syndromes (MDS)",Panobinostat,DRUG,Overall survival (OS),2018-07-24,2023-02-13,Goethe University,OTHER
NCT01091064,Impact Of A Health Care Protocol For Patients Suffering Symptoms Of Mild Acute Viral Bronchiolitis On Early Release In The Emergency Department,IMPACT OF A HEALTH CARE PROTOCOL FOR PATIENTS SUFFERING SYMPTOMS OF MILD ACUTE VIRAL BRONCHIOLITIS ON EARLY DISCHARGE IN THE EMERGENCY DEPARTMENT.,WITHDRAWN,The study was stopped because it was not approved for funding,PHASE2,INTERVENTIONAL,0,Bronchiolitis,,OTHER,emergency revisit rate,2011-10,2014-04,Laval University,OTHER
NCT00506064,Melatonin Postoperative Sleep Study in Breast Cancer Patients,Melatonin Postoperative Sleep Study in Breast Cancer Patients,TERMINATED,Terminated due to low accrual.,PHASE1,INTERVENTIONAL,4,Breast Cancer,"Melatonin, Placebo","DRUG, DRUG, BEHAVIORAL",Objective Sleep Response of Patients,2004-02,2008-09,M.D. Anderson Cancer Center,OTHER
NCT04829799,Effect of Intracameral Phenylephrine/Ketorolac on Intraoperative Pain,Effect of Intracameral Phenylephrine/Ketorolac on Intraoperative Pain,WITHDRAWN,"Per study team, the study will not proceed",PHASE4,INTERVENTIONAL,0,Pain Reduction,"1% preservative-free lidocaine, Phenylephrine 1.0%/ Ketorolac 0.3%","DRUG, DRUG",Visual analog scale to measure pain,2022-02,2023-08,University of Florida,OTHER
NCT00780832,Comparison of Caffeine Reduction and Anticholinergic Medications for Treatment of Overactive Bladder,Comparison of Caffeine Reduction and Anticholinergic Medications for Treatment of Overactive Bladder,TERMINATED,Insufficient elligible patients available in a reasonable time frame.,NA,INTERVENTIONAL,8,Overactive Bladder,Anticholinergic medication,"BEHAVIORAL, DRUG",Change in Bladder Function Questionnaire score,2008-05,2013-04,IWK Health Centre,OTHER
NCT04505098,A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults,A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults (MITIGATE),TERMINATED,The study was suspended by the IRB of record and subsequently terminated,PHASE4,INTERVENTIONAL,39600,"Covid19, Atherosclerosis, Cardiovascular Diseases, Upper Respiratory Tract Infections",Icosapent ethyl,DRUG,Rate of confirmed viral URIs,2020-08-07,2022-12-15,Kaiser Permanente,OTHER
NCT03821831,Treating Children With Obstructive Sleep Apnea After Surgery Failure,Residual Pediatric Obstructive Sleep Apnea: Closing the Treatment Gap,TERMINATED,COVID hindered enrollment,,OBSERVATIONAL,8,"Pediatric Obstructive Sleep Apnea, Pediatric Obesity",,"DEVICE, DEVICE","Measure of change in OSA severity, Change from baseline total score Pediatric Sleep Questionnaire (PSQ) at 12 months",2021-12-03,2023-05-08,University of Alberta,OTHER
NCT02573545,Evaluation of a Support Software in the Planning and Real-time Monitoring of the Insertion of Needles in Interventional Magnetic Resonance Imaging (MRI): Liver Biopsy Case,Evaluation of a Support Software in the Planning and Real-time Monitoring of the Insertion of Needles in Interventional Magnetic Resonance Imaging (MRI): Liver Biopsy Case,TERMINATED,Difficulty recruiting patients,NA,INTERVENTIONAL,148,Liver Biopsy,,"DEVICE, DEVICE",Total duration of the intervention (planning and implementation),2013-01,2017-10,"University Hospital, Strasbourg, France",OTHER
NCT00975039,Study Using WST11 in Patients With Non-Resectable or Inoperable Cholangiocarcinoma,Evaluation of the Safety and Efficacy of WST11-mediated Vascular Targeted Photodynamic Therapy in Non-resectable or Inoperable Cholangiocarcinoma,TERMINATED,Early end of enrolment with regards to difficulty met to enrol patients .,PHASE2,INTERVENTIONAL,8,Cholangiocarcinoma,WST11,DRUG,"Evaluation of the safety based on analysis of adverse events , clinical laboratory tests, electrocardiogram, physical examination, absence of local or general complications and phototoxicity of WST11 in inoperable or non resectable cholangiocarcinoma",2009-09,2012-09,Steba Biotech S.A.,OTHER
NCT04186039,"Functional Evaluation of the Fetal Lung by Functional Magnetic Resonance Imaging - Blood Oxygenation Level Dependent (MRI-BOLD), in Congenital Diaphragmatic and Parietal Malformations",Functional Magnetic Resonance Imaging - Blood Oxygenation Level Dependent (MRI-BOLD) of the Feta Lung in Congenital Diaphragmatic and Parietal Malformations,WITHDRAWN,Study manager's decision,NA,INTERVENTIONAL,0,"Congenital Diaphragmatic Hernia, Omphalocele, Gastroschisis",,DIAGNOSTIC_TEST,"Value of the Blood Oxygenation Level Dependent of the fetal lung, Postnatal respiratory evolution",2020-05,2022-05,Assistance Publique - Hôpitaux de Paris,OTHER
NCT02487277,"PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma",Perioperative Stromal Depletion Strategies in Pancreatic Ductal Adenocarcinoma,TERMINATED,Low accrual,PHASE2,INTERVENTIONAL,3,Adenocarcinoma,"PEGPH20, Gemcitabine, Nab-paclitaxel","DRUG, DRUG, DRUG","Incidence of Clinically Relevant Pancreatic Fistula, Rate of Pathologic Complete Response (pCR)",2015-07-14,2018-05-18,Andrew Ko,OTHER
NCT01391377,Effects of Niacin on Good Cholesterol in People With Peripheral Arterial Disease,The Effects of Chronic High-density Lipoprotein (HDL) Elevation With Extended Release Niacin on Peripheral Arterial Disease,TERMINATED,Tredaptive has been suspended worldwide,NA,INTERVENTIONAL,7,Peripheral Arterial Disease,"Niacin/Laropiprant combination, Sugar pill","DRUG, DRUG",Plaque composition,2011-07,2014-12,Bayside Health,OTHER_GOV
NCT00740181,"Decitabine, Cytarabine, GCSF for Refractory AML/MDS","A Phase II Study With Decitabine, Low Dose Cytarabine and G-CSF in High-risk Myelodysplastic Syndromes, Refractory Acute Myeloid Leukemia or Acute Myeloid Leukemia in Patients With Significant Co-morbidities.",TERMINATED,Lack of efficacy,PHASE2,INTERVENTIONAL,9,"Myelodysplasia, Leukemia",chemotherapy,DRUG,Response Rate,2008-08,2010-04,Brown University,OTHER
NCT01407081,SMARTease Trial: Evaluating Stroke Help Distance Interventions to Improve Cognitive Performance Post-Stroke,SMARTease Trial - Turning SMART Goals Into Smart Actions: Evaluating Stroke Help Distance Interventions to Improve Cognitive Performance Post-Stroke,TERMINATED,Poor recruitment,NA,INTERVENTIONAL,11,"Cognitive Impairment, Stroke",,BEHAVIORAL,Change in functioning on goal attainment scaling,2011-08,2012-04,Nova Scotia Health Authority,OTHER
NCT02734719,Increasing Bone Density by Application of Surface Electrical Stimulation,Increasing Bone Density by Application of Surface Electrical Stimulation,TERMINATED,Device is not available.,NA,INTERVENTIONAL,3,"Osteoporosis, Electrical Stimulation, Posture",,DEVICE,density of bone measured by central Dxa measurement,2021-10-01,2023-05-30,University of Belgrade,OTHER
NCT03893019,MB-CART20.1 Melanoma,Multicenter Phase I Trial of MB-CART20.1 for the Treatment of Patients With Metastatic Melanoma,TERMINATED,The risk-benefit assessment was not as expected.,EARLY_PHASE1,INTERVENTIONAL,9,Melanoma (Skin),MB-CART20.1,BIOLOGICAL,"Determination of MTD, Safety and Toxicity Assessment per Adverse Event reporting classified according to CTCAE V5.0",2019-03-08,2023-01-30,Miltenyi Biomedicine GmbH,INDUSTRY
NCT06424730,Team Based Equity Conscious Telemedicine Approach to Hypertension,Team Based Equity Conscious Telemedicine Approach to Improve Hypertension Among Black Patients,WITHDRAWN,closed because we were funded for another similar study,NA,INTERVENTIONAL,0,Hypertension,,"OTHER, BEHAVIORAL, BEHAVIORAL","Barriers / Facilitators for Recruitment, Feasibility of Telemedicine Approach - Proportion of Subjects",2024-09-20,2024-09-20,Wake Forest University Health Sciences,OTHER
NCT03984812,"Evaluation of the Safety, Tolerability and Pharmacokinetics (PK) of GSK3732394 First-Time-in-Human (FTIH) Study","A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK3732394 in Healthy Participants",TERMINATED,The study was terminated early (following completion of SAD Cohort 3; 80 mg) based on PK/PD modelling which demonstrated the medicine's intended target profile was not achievable.,PHASE1,INTERVENTIONAL,24,HIV Infections,"GSK3732394, Placebo","DRUG, DRUG","Part 1: Number of Participants With Non-serious Adverse Event (SAEs) and SAEs, Part 2: Number of Participants With Non-SAEs and SAEs, Part 1: Number of Participants With Clinical Chemistry Parameters by Maximum Grade Increase Post-Baseline, Part 2: Number of Participants With Clinical Chemistry Parameters by Maximum Grade Increase Post-Baseline, Part 1: Number of Participants With Hematology Parameters by Maximum Grade Increase Post-Baseline, Part 2: Number of Participants With Hematology Parameters by Maximum Grade Increase Post-Baseline, Part 1: Number of Participants With Urinalysis Parameters by Any Increase in Discrete or Character Values Post Baseline, Part 2: Number of Participants With Urinalysis Parameters by Any Increase in Discrete or Character Values Post Baseline, Part 1: Number of Participants With Worst Case Pulse Rate Post Baseline, Part 2: Number of Participants With Worst Case Pulse Rate Post Baseline, Part 1: Change From Baseline in Body Temperature, Part 2: Change From Baseline in Body Temperature, Part 1: Change From Baseline in Respiratory Rate, Part 2: Change From Baseline in Respiratory Rate, Part 1: Number of Participants With Worst Case Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Post Baseline, Part 2: Number of Participants With Worst Case SBP and DBP Post Baseline, Part 1: Number of Participants With Clinical Significant Abnormal Electrocardiogram (ECG) Findings, Part 2: Number of Participants With Clinical Significant Abnormal ECG Findings",2019-06-17,2020-03-23,ViiV Healthcare,INDUSTRY
NCT00562081,The Virtual Asthma Clinic,Evaluation of an Internet-based Approach to Long-term Treatment of Asthma.,TERMINATED,Poor recruitment.,PHASE4,INTERVENTIONAL,27,Asthma,,"BEHAVIORAL, BEHAVIORAL","Emergency department visits and unscheduled physician visits, Good asthma control days, Time to first severe exacerbation",2005-03,2007-06,University of Alberta,OTHER
NCT02890381,"Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants 6 to 24 Months of Age","Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID cp ΔM2-2, Lot RSV#009B, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age",TERMINATED,Interim data indicated this vaccine will not meet the protocol criteria for a good vaccine candidate.,PHASE1,INTERVENTIONAL,17,Respiratory Syncytial Virus Infections,"RSV LID cp ΔM2-2 Vaccine, Placebo","BIOLOGICAL, BIOLOGICAL","Number of Participants With Solicited Adverse Events (AEs) by Grade, Number of Participants With Unsolicited AEs by Grade, Number of Participants With Serious Adverse Events (SAEs), Number of Participants Infected With RSV Vaccine, Peak Titer of Vaccine Virus Shed, Duration of Virus Shedding in Nasal Washes, Number of Participants With a Greater Than or Equal to 4-fold Rise in Serum RSV-neutralizing Antibody Titer, Serum Antibody Responses to RSV F Glycoprotein as Assessed by Enzyme-linked Immunosorbent Assay (ELISA)",2016-10-05,2017-04-24,National Institute of Allergy and Infectious Diseases (NIAID),NIH
NCT04311281,FDDNP Protocol for Visualizing Brain Proteinopathies to Assist in the Diagnosis of Persons With Suspected CTE and AD,[F-18] FDDNP-PET Clinical Protocol for Visualizing Brain Proteinopathies to Assist in the Diagnosis of Persons With Suspected Chronic Traumatic Encephalopathy and Alzheimer's Disease,WITHDRAWN,Insufficient Funding,,OBSERVATIONAL,0,"Suspected Chronic Traumatic Encephalopathy (CTE) or Traumatic Encephalopathy Syndrome (TES), Suspected Alzheimer's Disease (AD)",[F-18]FDDNP-PET,BIOLOGICAL,Clinical Dementia Rating Sum of Box Scores (CDR-SB),2021-05,2021-05-03,"University of California, Los Angeles",OTHER
NCT03700892,In-vivo Effects of E-cigarette Aerosol on Innate Lung Host Defense,In-vivo Effects of E-cigarette Aerosol on Innate Lung Host Defense,TERMINATED,"Covid-19 has been shown to increase risk associated with vaping. To increase participant safety and use real world vaping habits, the investigators plan to continue studying vaping effects on the airways in an observational format.",NA,INTERVENTIONAL,19,"Smoking, Healthy",,"OTHER, OTHER",CA-induced Changes in Whole Lung MCC,2018-10-19,2020-03-03,"University of North Carolina, Chapel Hill",OTHER
NCT04363892,Combined Optical and Infrared Imaging for Early Prediction of Erythema During Breast and Chestwall Radiotherapy,A Prospective Cohort Clinical Trial to Assess the Skin Imaging Spectral and Morphological Changes During Breast Adjuvant Radiotherapy as an Early Predictor of Acute Skin Toxicities,TERMINATED,The PI resigned,NA,INTERVENTIONAL,7,Breast Cancer,,OTHER,"Establish the correlation between optical and IR skin imaging and skin toxicity, Establish the correlation between optical and IR skin imaging and skin toxicity, Establish the correlation between optical and IR skin imaging and skin toxicity, Establish the correlation between optical and IR skin imaging and skin toxicity, Establish the correlation between optical and IR skin imaging and skin toxicity",2020-07-01,2021-06-14,Nova Scotia Health Authority,OTHER
NCT00573092,Analyzing Gene Regions That May Interact With the Effectiveness of High Blood Pressure Drugs,Genome-Wide Case-Only Study of Antihypertensive Drug-Gene Interactions,WITHDRAWN,Withdrawn,,OBSERVATIONAL,0,"Myocardial Infarction, Cerebrovascular Accident, Death, Sudden, Cardiac",,,Genomic regions for each of the four major drug classes that influence drug and gene interaction,2007-09,2016-11,University of Washington,OTHER
NCT05497011,A Study to Evaluate the Safety and Efficacy of PiCSO in Anterior STEMI Patients,A Randomized Controlled Study to Evaluate the Safety and Efficacy of Pressure-controlled Intermittent Coronary Sinus Occlusion (PiCSO) in Anterior STEMI Patients With TIMI 0-2 at Presentation.,WITHDRAWN,Study terminated due to lack of financing,NA,INTERVENTIONAL,0,"STEMI - ST Elevation Myocardial Infarction, Anterior Wall Myocardial Infarction",,DEVICE,"12% performance goal rate of PiCSO device or PiCSO procedure related adverse events reported through 30 days, Difference in myocardial infarct size",2023-03-30,2028-06-30,Miracor Medical SA,INDUSTRY
NCT05414071,Clinical Investigation of NMS Assist,The Impact of a Digital Artificial Intelligence System on the Monitoring and Self-management of Non-motor Symptoms in People With Parkinson's,WITHDRAWN,The study sponsor has changed and is no longer the University of Plymouth. A new record is being created under the updated sponsor.,NA,INTERVENTIONAL,0,Parkinson,,DEVICE,Patient (and care partner) activation,2023-12-01,2025-03-01,University of Plymouth,OTHER
NCT03626844,Maternal Outcomes Following Manual Lysis of the Placenta.,Maternal Outcomes Following Manual Lysis of the Placenta After Fifteen Compared to Thirty Minutes. A Randomized Controlled Trial.,SUSPENDED,Insufficient resources.,NA,INTERVENTIONAL,100,Third Stage of Delivery,,"PROCEDURE, PROCEDURE",Hemoglobin Drop,2018-11-20,2020-09,"HaEmek Medical Center, Israel",OTHER
NCT04480164,Evaluation of the Safety and Efficacy of N-desmethylclobazam in Patients With Peripheral Neuropathic Pain,A Randomized Double-blind Ascending-dose Placebo-controlled Study of N-desmethylclobazam in Patients With Peripheral Neuropathic Pain,SUSPENDED,low recruitment rate and end of study finding,PHASE2,INTERVENTIONAL,76,Neuropathic Pain,NDMC,DRUG,Weekly Average of daily Pain intensity score (WAP),2020-06-24,2023-05-31,Besson Marie,OTHER
NCT02685202,Temporomandibular Disorder (TMD) Pain in Response to Jaw Advancement in People With TMD and Obstructive Sleep Apnea,The Course of Temporomandibular Pain in Response to Mandibular Advancement Therapy Among Adults With Temporomandibular Disorder and Obstructive Sleep Apnea,TERMINATED,Funding depleted,NA,INTERVENTIONAL,9,"Myalgia, Apnea, Obstructive Sleep",,DEVICE,Change in the Weekly Mean Pain Index Score,2016-03,2017-03,"University of North Carolina, Chapel Hill",OTHER
NCT04438902,Osimertinib Combined With Anlotinib in EGFR T790M Mutated NSCLC Patients With Progression on Osimertinib Treatment,"A Prospective, Multi-center, Interventional Study of Osimertinib Combined With Anlotinib in Acquired EGFR T790M Mutated NSCLC Patients With Gradual Progression on Osimertinib Treatment",TERMINATED,Many patients can't tolerate the combination treatment due to adverse events.,PHASE2,INTERVENTIONAL,3,Non Small Cell Lung Cancer,osimertinib mesylate tablets and anlotinib hydrochloride capsules,DRUG,progression-free survival (PFS),2020-12-12,2023-02-16,First Affiliated Hospital of Zhejiang University,OTHER
NCT05078437,Assessment of Medication Optimization in Rural Kentucky Appalachian Patients With Mild Cognitive Impairment or Dementia,Assessment of Medication Optimization in Rural Kentucky Appalachian Patients With Mild Cognitive Impairment or Dementia: The AMOR Kentucky Study,TERMINATED,Funding ended,NA,INTERVENTIONAL,16,"Dementia, Mild Cognitive Impairment",,BEHAVIORAL,"Mean Change From Baseline in the Medication Appropriateness Index, Participant Satisfaction, Connectivity Issues",2021-10-14,2023-05-14,Daniela Moga,OTHER
NCT03530345,Efficacy and Safety of Intravenous Neridronic Acid in CRPS,"Randomized, Double-blind, Placebo-controlled Trial Investigating the Efficacy and Safety of Intravenous Neridronic Acid in Subjects With Complex Regional Pain Syndrome (CRPS)",TERMINATED,Sponsor decision,PHASE3,INTERVENTIONAL,182,Complex Regional Pain Syndrome (CRPS),"Neridronic acid 100 mg, Placebo","DRUG, DRUG",Change From Baseline to Week 12 in the Average Pain Intensity Score (Weekly Average of Pain Values Recorded Daily in the Electronic Diary),2018-05-30,2019-07-31,Grünenthal GmbH,INDUSTRY
NCT02152072,Using Simulation-Based Training to Incorporate Lung Ultrasound Into Physical Examination,,WITHDRAWN,No Participant Enrolled,,OBSERVATIONAL,0,"Medical Students,Lung Ultrasound,Simulation Training",,OTHER,Assess the pre and post-performance of medical students in using lung ultrasound (LUS) for patients with shortness of breath.,2014-07,2014-09,Tulane University Health Sciences Center,OTHER
NCT00783575,Genetic Markers as Predictors of Phenotypes in Pediatric Onset Crohn's Disease,Genetic Markers as Predictors of Phenotypes in Pediatric Onset Crohn's Disease,WITHDRAWN,PI has left institution,,OBSERVATIONAL,0,"Crohn's Disease, Ulcerative Colitis, Inflammatory Bowel Disease",,,Genotype a cohort of IBD children for 4 NOD2/CARD15 mutations.,2002-10,2015-01,Medical College of Wisconsin,OTHER
NCT00742157,"Evaluate the Efficacy and Safety Growth Hormone, Glutamine and Diet in Patients With Short Bowel Syndrome (SBS)","An Open-label Evaluation of the Long-term Efficacy and Safety of a Standardized Regimen of Growth Hormone, Glutamine and a Modified Diet in the Treatment of Patients With Short Bowel Syndrome",TERMINATED,Lack of Enrollment,PHASE4,INTERVENTIONAL,5,Short Bowel Syndrome,Growth Hormone,DRUG,Documenting the Reduction of TPN Infusion/Week for Participants at 6 Months Compared to Baseline.,2003-09-01,2008-10-20,University of Nebraska,OTHER
NCT06949657,Occurrence and Influencing Factors of Cognitive Impairment in Elderly Patients With Schizophrenia and,Occurrence and Influencing Factors of Cognitive Impairment in Elderly Patients With Schizophrenia and the Application Effect of Acceptance and Commitment Therapy Nursing Model,TERMINATED,the sponsor has determined that access to the full dataset is no longer available,NA,INTERVENTIONAL,78,"Schizophrenia Disorders, Cognitive Impairment, Acceptance and Commitment Therapy",,"OTHER, OTHER",Change in Cognitive Function,2023-10-13,2024-09-19,"Third People's Hospital, Huzhou City, Zhejiang Province, China",OTHER
NCT02975557,Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD),"A Phase I/II Randomized, Placebo-Controlled, Double-Blind, Single-Center, Tolerability And Preliminary Efficacy Study Of Use of Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)",TERMINATED,Slow accrual of subjects. May take longer than expected to complete the trial.,"PHASE1, PHASE2",INTERVENTIONAL,15,"Dry Eye, Ocular Graft vs Host Disease, Meibomian Gland Dysfunction","Brimonidine 0.15%, Brimonidine 0.075%, Placebo","DRUG, DRUG, DRUG",Primary Tolerability End Point: The Test Substance Tolerance (Visual Analog Scale) at 12 Weeks.,2016-05,2017-04-13,"Sandeep Jain, MD",OTHER
NCT06782919,Trunk Control Training and Walking in Older Adults,Evaluating the Effect of Biofeedback-Based Training on Trunk Neuromuscular Control and Spinopelvic Motion and Loading During Gait in Older Adults With and Without Chronic Low Back Pain,WITHDRAWN,NIH Funding terminated,NA,INTERVENTIONAL,0,"Chronic Low Back Pain (CLBP), Aging",,OTHER,"Trunk neuromuscular control, Spinopelvic and lower limb motion, Spinopelvic forces",2025-05,2026-09,Beth Israel Deaconess Medical Center,OTHER
NCT03515330,A Pilot Study of mDOT for Immunosuppressant Adherence in Adult Liver Transplant Recipients,A Pilot Study of Mobile Directly Observed Therapy (mDOT) for Immunosuppressant Adherence in Adult Liver Transplant Recipients,WITHDRAWN,Merged IRB study created,NA,INTERVENTIONAL,0,"Medication Adherence, Liver Transplant",,OTHER,12-week immunosuppression medication adherence,2020-06-29,2020-11-12,Johns Hopkins University,OTHER
NCT05883228,Anesthesiologist Perspectives/Opinions/Ethics on Intraoperative/Intraprocedural Code Status and Intraoperative/Intraprocedural Code Status Management Plans,Anesthesiologist Perspectives/Opinions/Ethics on Intraoperative/Intraprocedural Code Status and Intraoperative/Intraprocedural Code Status Management Plans,WITHDRAWN,Pre-empted by another survey,,OBSERVATIONAL,0,"Physician's Role, Opinions",,,Aggregate Responses to Questions on Survey of ASA Members and Anesthesiologists,2023-09,2025-03,Joseph Hendrix,OTHER
NCT03571828,"Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma","A Phase 1, First-in-Human, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With Relapsed / Refractory Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma",TERMINATED,Amgen decided to discontinue study because of a business decision and not because of safety reasons,PHASE1,INTERVENTIONAL,10,"Diffuse Large B-cell Lymphoma(DLBCL), Mantle Cell Lymphoma (MCL), Follicular Lymphoma (FL)",AMG 562,DRUG,"Number of Participants Who Experienced a Dose Limiting Toxicity (DLT), Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)",2018-10-29,2022-01-12,Amgen,INDUSTRY
NCT00465907,"Study of Weekly Paclitaxel, Carboplatin and Irinotecan to Treat Lung Cancer","Phase II Study of Weekly Paclitaxel, Carboplatin and Irinotecan in Patients With Advanced Non-Small Cell Lung Cancer Nad Malignant Pleural Effusion",TERMINATED,Low accrual,PHASE2,INTERVENTIONAL,7,Lung Cancer,"Paclitaxel, Carboplatin and Irinotecan",DRUG,"To evaluate the efficacy and toxicity of the weekly combination chemotherapy of paclitaxel, carboplatin and irinotecan in Stage IIIB and IV NSCLC patients with malignant pleural effusion",2003-05,2014-02,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,OTHER
NCT01303107,Comparative Mixture of Non-racemic and Racemic Enantiomers of Bupivacaine in Cesarean,A Non-Inferiority Phase 3 Comparative Study Between a Heavy Levobupivacaine in 50% Enantiomeric Excess (Bupivacaine S75:R25) and Heavy Racemic Bupivacaine for Cesarean Operation,WITHDRAWN,The Sponsor has no interest in continuing the study.,PHASE3,INTERVENTIONAL,0,Cesarean Delivery,Bupivacaine,DRUG,latency of sensitive block at T6,,,Cristália Produtos Químicos Farmacêuticos Ltda.,INDUSTRY
NCT03709992,Trospium Chloride vs Tamsulosin in Treatment of Ureteral Stent Related Symptoms:,Trospium Chloride vs Tamsulosin in Treatment of Ureteral Stent Related Symptoms: A Randomized Controlled Trial,SUSPENDED,Because of COVID-19 Crisis,NA,INTERVENTIONAL,200,"Ureter Stone, Quality of Life, Ureter Obstruction","Trospium Chloride, Tamsulosin","DRUG, DRUG",Ureteral Stent Symptoms Questionnaire (USSQ) score,2020-12-18,2024-11-01,Mansoura University,OTHER
NCT01809171,Placebo-controlled Trial With Vitamin D to Prevent Worsening/Relieve Aromatase Inhibitor-induced Musculoskeletal Symptoms in Breast Cancer Patients,Placebo-controlled Trial With Vitamin D to Prevent Worsening/Relieve Aromatase Inhibitor-induced Musculoskeletal Symptoms in Breast Cancer Patients,TERMINATED,Inclusion problems,"PHASE2, PHASE3",INTERVENTIONAL,15,"Breast Cancer, Musculoskeletal Disease","Vitamin D3, Placebo","DRUG, DRUG",Change from baseline in musculoskeletal pain and 250HD levels,2013-10,2015-08,Universitaire Ziekenhuizen KU Leuven,OTHER
NCT01055028,Paclitaxel + Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma,Paclitaxel in Combination With Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma,TERMINATED,Poor accrual,PHASE2,INTERVENTIONAL,18,"Angiosarcomas, Soft Tissue Sarcoma","Bevacizumab, Paclitaxel","DRUG, DRUG",Progression-free Survival (PFS),2010-02,2016-06-24,Stanford University,OTHER
NCT01027234,This Study Will Assess the Safety and Tolerability of AZD8418 After Single Increasing Oral Doses,"A Phase I, Single-center, Randomized, Double-blind, Placebo-controlled Single-ascending Dose, First Time Into Man Study to Assess the Safety, Tolerability, and Pharmacokinetics (Part A) and an Open-label Assessment of the Effect of Food on the Pharmacokinetics (Part B) of Orally Administered AZD8418",TERMINATED,Pre-Clinical Safety Tox Findings,PHASE1,INTERVENTIONAL,40,Healthy,"AZD8418, Placebo","DRUG, DRUG",To assess the safety and tolerability of AZD8418 following the oral administration of single ascending doses and to estimate the maximum tolerated dose in healthy volunteers.,2009-11,2010-03,AstraZeneca,INDUSTRY
NCT02016534,Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors,"A Multicenter, Phase 2, Single Arm, Two Cohort Study Evaluating the Efficacy, Safety, and Pharmacokinetics of AMG337 in Subjects With MET Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma or Other MET Amplified Solid Tumors",TERMINATED,Amgen decision following interim review of efficacy and safety data from the AMG 337 program.,PHASE2,INTERVENTIONAL,60,Stomach Neoplasms,AMG 337,DRUG,Objective Response Rate (RECIST v1.1) in subjects with MET Amplified measurable G/GEJ/E adenocarcinoma (Cohort 1),2014-02,2016-10,Amgen,INDUSTRY
NCT01125501,Protandim and the Metabolic Syndrome,Protandim and the Metabolic Syndrome: A Preliminary Study to Define Protein Signatures That Change Along With Lowered Oxidative Stress Measured as F2 Isoprostanes or TBARS and Inflammation Measured as hsCRP,WITHDRAWN,funding not available,NA,INTERVENTIONAL,0,Metabolic Syndrome,,DIETARY_SUPPLEMENT,Measure Decrease in Oxidative Stress markers.,2010-04,2010-06,"SomaLogic, Inc.",INDUSTRY
NCT03370601,Evaluation of the Clinical and Immunological Impact of Two Therapeutic Strategies in Chronic Inflammatory Diseases,Evaluation of the Clinical and Immunological Impact of Two Therapeutic Strategies (Increasing the Infliximab Dose or Introduction of Immunosuppressive Therapy) in Patients Chronic Inflammatory Bowel Diseases in Loss of Response to Infliximab,TERMINATED,Not enough recruitment Lack of funding CR,NA,INTERVENTIONAL,9,Inflammatory Bowel Diseases,"Infliximab, Mercaptopurine, Azathioprine, Infliximab","DRUG, DRUG, DRUG, DRUG",Number of patients in Clinical remission,2017-01-03,2019-01,"University Hospital, Lille",OTHER
NCT04304365,Home Follow-up After Medication Abortion,Feasibility of Home Follow-up After Medication Abortion (MAB),WITHDRAWN,Unable to implement the study due to delays from COVID-19 policies which postponed the start.,NA,INTERVENTIONAL,0,"Medical; Abortion, Fetus",,"OTHER, OTHER, OTHER","Completed follow-up for the clinic group, Completed follow-up for the home group",2020-10,2021-05,Boston Medical Center,OTHER
NCT05005000,Autologous Intra-Articular Micro-Fragmented Adipose Transfer for the Treatment of Thumb Carpometacarpal Joint Arthritis,Autologous Intra-Articular Micro-Fragmented Adipose Transfer for the Treatment of Thumb Carpometacarpal Joint Arthritis,WITHDRAWN,Difficulties getting subjects recruited and enrolled.,PHASE2,INTERVENTIONAL,0,Arthritis,"Micro-Fragmented Adipose Tissue (MFAT), Triamcinolone Acetonide 10mg/mL","BIOLOGICAL, DRUG",Percent Change in Score on Pain Visual Analog Scale (VAS),2022-05-12,2023-05-25,NYU Langone Health,OTHER
NCT01785836,"An Extension Study to Assess the Safety, Tolerability, Efficacy, and Treatment Adherence of Dapsone in Acne Vulgaris",,WITHDRAWN,Study was never initiated due to company decision. No study subjects were ever enrolled or dosed.,PHASE1,INTERVENTIONAL,0,Acne Vulgaris,"Dapsone Formulation A, Dapsone Formulation B, Dapsone Formulation C, Dapsone 5% Gel","DRUG, DRUG, DRUG, DRUG",Change from Baseline in Inflammatory Lesion Count,2013-03,2013-10,Allergan,INDUSTRY
NCT03335436,Gabapentin in the Post-cesarean Pain Management of Buprenorphine Patient,"A Randomized, Double-blind, Placebo-controlled Trial of Gabapentin in the Post-cesarean Pain Management of Buprenorphine Patient",WITHDRAWN,Lack of enrollment,PHASE4,INTERVENTIONAL,0,"Cesarean Delivery, Pain Management","Gabapentin, Placebo","DRUG, DRUG","Total opioid use 24 hours after cesarean delivery, Total opioid use at time of hospital discharge after cesarean delivery",2018-04-01,2020-12,Vanderbilt University Medical Center,OTHER
NCT00612911,Cell Therapy in Dilated Cardiomyopathy: Observational Study,Cell Therapy in Dilated Cardiomyopathy: A Safety and Feasibility Study Using Autologous Bone Marrow Mononuclear Cells,TERMINATED,finish study as protocol,,OBSERVATIONAL,24,"Cardiomyopathy, Dilated",,OTHER,echocardiography,2005-02,2007-08,"Ministry of Health, Brazil",OTHER_GOV
NCT00990834,Muscle Characteristics Associated With Statin Therapy,Muscle Characteristics Associated With Statin Therapy,WITHDRAWN,Unable to recruit subjects.,NA,INTERVENTIONAL,0,"Hydroxymethylglutaryl-CoA Reductase Inhibitors, Myopathy",simvastatin,DRUG,"Atrogin-1 expression., Intramuscular Ras level.",2009-11,2011-06,Scripps Health,OTHER
NCT01981044,SERI® Surgical Scaffold Postmarket Study of Soft Tissue Support in Ventral Hernia Repair,A SERI® Surgical Scaffold Postmarket Study of Soft Tissue Support in Ventral Hernia Repair,TERMINATED,Difficulty accruing patients; business decision,NA,INTERVENTIONAL,1,Ventral Hernia Repair,,DEVICE,"Rate of Hernia Recurrence, Rate of Hernia Recurrence, Rate of Hernia Recurrence",2013-09-25,2016-02-24,"Sofregen Medical, Inc.",INDUSTRY
NCT00401921,A Study of the Effects of Minocycline on Cognitive Function After Carotid Endarterectomy,"A Randomized, Placebo-Controlled Study of the Effects of Minocycline on Cognitive Function After Carotid Endarterectomy",WITHDRAWN,PI moved to a new facility,PHASE2,INTERVENTIONAL,0,Carotid Stenosis,"Minocycline, Placebo oral capsule","DRUG, DRUG",Neuropsychological assessment,2006-10,2010-06,Brigham and Women's Hospital,OTHER
NCT03324516,The Effect of Temporal Muscle Suspension of Temporal Hollowing,The Effect of Temporal Muscle Suspension of Temporal Hollowing: A Prospective Randomized Clinical Trial,WITHDRAWN,"Due to limited support staff and time, study was unable to get started",NA,INTERVENTIONAL,0,Temporal Wasting,,"PROCEDURE, PROCEDURE",Percent change in temporal hallowing,2020-07-01,2021-01-01,Johns Hopkins University,OTHER
NCT03714906,Stellate Ganglion Block in Head and Neck Cancer Surgery,Utility of Pre-Operative Stellate Ganglion Blockade for Pain Control in Unilateral Head and Neck Cancer Surgery,TERMINATED,"Slow accrual, lack of benefit between intervention and control arms on interim analysis",NA,INTERVENTIONAL,22,"Head and Neck Cancer, Pain, Postoperative",,PROCEDURE,Brief Pain Inventory,2019-03-22,2022-09-15,Augusta University,OTHER
NCT01679106,The Effects of Continuous Transversus Abdominis Plane (TAP) Catheters on Postoperative Pain After Renal Transplantation,,TERMINATED,Study closed because of low enrolment,NA,INTERVENTIONAL,3,Pain,,"OTHER, OTHER","Effect of continuous TAP analgesia and pain scores, Effect of TAP analgesia and opioid requirements, Effect of continuous TAP analgesia on pain scores, effect of continuous TAP analgesia on pain scores, Effect of continuous TAP analgesia on pain scores, Effect of TAP analgesia on opioid requirements, Effect of TAP analgesia on opioid requirements, Effect of TAP analgesia on opioid requirements",2012-08,2014-05,The Cleveland Clinic,OTHER
NCT03760484,Fecal Microbiota Transplant (FMT) Plus Fidaxomicin for Severe or Fulminant Clostridium Difficile Infection,"Serial Fecal Microbiota Transplant (FMT) Plus Fidaxomicin in the Treatment of Severe or Fulminant Clostridium Difficile Infection, With Detailed Characterization in Microbiota, Metabolomics and Host Immune Response",TERMINATED,Difficulty enrolling participants/COVID pandemic/lack of continued in-kind support from product manufacturer.,PHASE2,INTERVENTIONAL,4,Clostridium Difficile,"Fidaxomicin 200 mg, fecal microbiota transplantation (FMT)","DRUG, BIOLOGICAL",C Difficile Infection (CDI) Resolution- Short Term (Two Weeks After Final Fecal Microbiota Transplant (FMT)),2019-01-21,2020-03-10,University of Alberta,OTHER
NCT04510584,Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer,Halting Early Advancement of Residual Disease by Treatment With Bevacizumab and Atezolizumab in Ovarian Cancer,WITHDRAWN,"19 patients screenfailed, stopping recruitment before first patient enrollment to analyze pilot results from screening samples.",PHASE2,INTERVENTIONAL,0,"Ovarian Endometrioid Tumor, Fallopian Tube Cancer, Primary Peritoneal Cancer, TP53 Mutation","Atezolizumab, Bevacizumab","DRUG, DRUG",Number of participants where increase in circulating deoxyribonucleic acid (ctDNA) level is related to progression,2021-07-16,2023-02-22,"University Health Network, Toronto",OTHER
NCT01888133,Adopting a Physically Active Lifestyle Through Organized Walk Events Among Joslin Clinic Patients,Adopting a Physically Active Lifestyle Through Organized Walk Events Among Joslin Clinic Patients,TERMINATED,Lack of funding,NA,INTERVENTIONAL,22,"Diabetes, Physical Activity",,"BEHAVIORAL, BEHAVIORAL",Change in steps/day,2013-04,2014-04,Joslin Diabetes Center,OTHER
NCT04167137,Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants,"A Phase 1, Open-label, Multicenter Study of SYNB1891 Administered by Intratumoral Injection to Patients With Advanced/Metastatic Solid Tumors and Lymphoma Alone and in Combination With Atezolizumab",TERMINATED,Business reasons,PHASE1,INTERVENTIONAL,32,"Metastatic Solid Neoplasm, Lymphoma","SYNB1891, Atezolizumab","DRUG, DRUG",Number of Participants With Dose-limiting Toxicity,2019-12-12,2021-12-09,Synlogic,INDUSTRY
NCT00182039,POISE Trial: Perioperative Ischemic Evaluation Study,Perioperative Ischemic Evaluation Study (POISE) Trial,TERMINATED,Please see detailed description for reason why study was terminated.,PHASE3,INTERVENTIONAL,8351,Cardiovascular Diseases,"Metoprolol controlled release (CR), Placebo","DRUG, DRUG","major cardiovascular events (defined as cardiovascular death, nonfatal myocardial infarction, or nonfatal cardiac arrest)",2002-10,2007-08,Hamilton Health Sciences Corporation,OTHER
NCT04079439,Physical Activity With Tailored E-health Support for Individuals With Intellectual Disability,Physical Activity With Tailored E-health Support for Individuals With Intellectual Disability (PA-IDe Study): a Randomised Controlled Trial,TERMINATED,"Because of COVID-19 the study was stopped. It has been changed to include a pilot trial, which has been conducted in 2021/2022 (trial registration: NCT04929106). The RCT will hopefully be conducted in the near future.",NA,INTERVENTIONAL,60,Intellectual Disability,,BEHAVIORAL,Steps per day,2020-01-01,2022-01-01,University Hospital of North Norway,OTHER
NCT00324077,Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase,A Phase I Dose Escalation Study of the Combination of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase,WITHDRAWN,Insufficient Enrollment,PHASE1,INTERVENTIONAL,0,"Myeloid Leukemia, Chronic, Chronic-Phase",Dasatinib in combination with imatinib,DRUG,To determine the maximum tolerated dose (MTD) and recommended dose of dasatinib when combined with imatinib in chronic phase CML patients.,2006-08,,Bristol-Myers Squibb,INDUSTRY
NCT04078477,Prevention of Pressure Ulcer by Lateral Tilt Bed in Neurocritical Care,Prevention of Pressure Ulcer by Lateral Tilt Bed in Neurocritical Care,TERMINATED,In accordance with the interim statistical analysis conducted after 250 patients.,NA,INTERVENTIONAL,300,Pressure Ulcer,,OTHER,Incidence of pressure ulcer,2020-01-08,2024-10-09,Regional Hospital Liberec,OTHER
NCT00878345,Dexmedetomidine Versus Pentobarbital for Pediatric Procedural Sedation,Dexmedetomidine Versus Pentobarbital Sedation Protocol for Non-painful Procedural Sedation in Pediatrics,WITHDRAWN,Study was never opened,NA,INTERVENTIONAL,0,Sedation,"dexmedetomidine sedation protocol, pentobarbital sedation protocol","DRUG, DRUG",failure of sedation,2009-11,2010-06,Washington University School of Medicine,OTHER
NCT01866345,"Randomized, Blinded, Controlled Clinical Trial of Surgically Facilitated Orthodontic Treatment","Randomized, Blinded, Controlled Clinical Trial of Surgically Facilitated Orthodontic Treatment in the Mandibular Anterior Region",WITHDRAWN,Cannot find subjects to particpate,NA,INTERVENTIONAL,0,Orthodontic Malocclusion,,"PROCEDURE, PROCEDURE",Rate of orthodontic tooth movement,2013-08,2014-02,University of Minnesota,OTHER
NCT04607772,Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL),"A Multicenter, Phase 1/2 Study of Selinexor in Combination With Backbone Treatments or Novel Therapies in Patients With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)",WITHDRAWN,Sponsor decision,"PHASE1, PHASE2",INTERVENTIONAL,0,Relapsed or Refractory Diffuse Large B-Cell Lymphoma,"Selinexor, Rituximab, Bendamustine, Polatuzumab Vedotin, Ibrutinib, Lenalidomide, Tafasitamab, Venetoclax, Gemcitabine, Oxaliplatin","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Phase 1: Maximum Tolerated Dose (MTD), Phase 1: Recommended Phase 2 Dose (RP2D), Phase 2: Overall Response Rate (ORR) per the Lugano Classification 2014",2020-11-18,2025-12,Karyopharm Therapeutics Inc,INDUSTRY
NCT05112575,Evaluation of Patient Stress Level Caused by Radiological Investigations in Early Postoperative Phase After Craniotomy,Evaluation of Patient Stress Level Caused by Radiological Investigations in Early Postoperative Phase After Craniotomy (IPAST-CRANIO): Protocol of a Swiss Prospective Cohort Study,TERMINATED,Failed resources.,,OBSERVATIONAL,152,"Postoperative Pain, Postoperative Nausea",,RADIATION,"The primary endpoint of the study is the difference in subjective distress after craniotomy, measured just before and after postoperative MRI or CT.",2020-09-20,2023-02-01,University of Zurich,OTHER
NCT03992157,Evaluation of Ambulatory ECG Telemetry for the Early Detection of Atrial Fibrillation During Hospital Assessment of Cerebral Infarction,Evaluation of Ambulatory ECG Telemetry for the Early Detection of Atrial Fibrillation During Hospital Assessment of Cerebral Infarction,TERMINATED,"Medical practices have evolved and are not conform with the study procedure. Actually, all patients receive an ambulatory ECG telemetry monitoring",NA,INTERVENTIONAL,8,Cerebral Infarction,,DEVICE,Diagnostic impact of outpatient ECG telemetry,2018-12-27,2019-07-03,Hopital Foch,OTHER
NCT02361957,The Effect of the Multispecies Probiotic Ecologic 825 Versus Placebo in Ulcerative Colitis Patients,The Effect of the Multispecies Probiotic Ecologic 825 Versus Placebo in Ulcerative Colitis Patients,SUSPENDED,We recruited 25 of the 40 participants from intended study population. Recruitment in new populations requires an METC amendment.,NA,INTERVENTIONAL,40,Ulcerative Colitis,,"DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Intestinal permeability measured by the Lactulose Mannitol test (L/M test),2014-11,2015-12,Wageningen University,OTHER
NCT00610701,Lateral Versus Anterior Spanning External Fixator for Tibial Plateau Fractures,Lateral Versus Anterior Spanning External Fixator for Tibial Plateau Fractures,TERMINATED,Extremely low enrollment and very little follow-up for meaningful data,NA,INTERVENTIONAL,35,"Fractures, Closed",,"DEVICE, DEVICE",Quadriceps Strength,2006-03,2014-02,University of Missouri-Columbia,OTHER
NCT00739128,Response to Hepatitis B Vaccine in Celiac Disease Patients,Intradermal Immunization Against Hepatitis B Virus in Celiac Disease- a Randomized Controlled Trial,TERMINATED,Believed that a better study was to compare the response to engerix B vs Sci-B-Vac vaccine in this patient group.,NA,INTERVENTIONAL,210,Celiac Disease,"hepatitis B vaccine (EngerixB), hepatitis B vaccine (EngerixB)","BIOLOGICAL, BIOLOGICAL",1. The primary endpoint of the study will be comparison of the geometric mean titers of anti-HBs between the intradermal and the intramuscular groups.,2009-02,2011-03,Shaare Zedek Medical Center,OTHER
NCT01551628,A Pilot Study of Recombinant Human Arginase 1 (rhArg1) in Patients With Relapsed or Refractory Leukemia or Lymphoma,A Pilot Study of the Safety and Preliminary Efficacy of Recombinant Human Arginase 1 (rhArg1) in Patients With Relapsed or Refractory Leukemia or Lymphoma,TERMINATED,slow patient recruitment,PHASE1,INTERVENTIONAL,1,"Leukemia, Lymphoma",Recombinant human arginase 1 Peg5000,DRUG,safety of PEG-BCT-100 in patients with relapsed or refractory leukemia or lymphoma receiving PEG-BCT-100,2012-04,2013-05,Bio-Cancer Treatment International Limited,INDUSTRY
NCT04596267,Pitolisant Effects on Alcohol Self-Administration in Heavy Drinkers,The Effects of the Histamine-3 Receptor Inverse Agonist Pitolisant on Alcohol Self-Administration in Heavy Drinkers,TERMINATED,Study funding was exhausted prior to reaching the recruitment goal due to pandemic related delays,PHASE1,INTERVENTIONAL,9,"Alcohol Use Disorder, Alcohol Drinking","Pitolisant, Placebo","DRUG, DRUG","Alcohol Consumption in Alcohol Self-Administration Trials, Alcohol Consumption (BAC): Observation Period, Minute 10, Alcohol Consumption (BAC): Observation Period, Minute 20, Alcohol Consumption (BAC): Observation Period, Minute 30, Alcohol Consumption (BAC): Observation Period, Minute 40, Alcohol Consumption (BAC): Self-administration Block 1, Minute 30, Alcohol Consumption (BAC): Self-administration Block 1, Minute 60, Alcohol Consumption (BAC): Self-administration Block 2, Minute 30, Alcohol Consumption (BAC): Self-administration Block 2, Minute 60",2021-09-13,2023-02-03,Boston Medical Center,OTHER
NCT02099500,Autologous Adipose-Derived Stromal Cell Delivered Via Intramuscular Injections for the Treatment of Critical Limb Ischemia,"An Open-label, Non-Randomized, Patient Funded, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Via Intramuscular Injections for the Treatment of Critical Limb Ischemia",WITHDRAWN,no participants enrolled,PHASE1,INTERVENTIONAL,0,Critical Limb Ischemia,,"PROCEDURE, OTHER","Improvement from baseline in perfusion as measured by ankle-brachial index and collateral artery number, Number of adverse events reported",2014-03,2017-06,Ageless Regenerative Institute,INDUSTRY
NCT03327636,A Trial Comparing USG-HIFU vs AS in Management of Low-risk PTMC,A Prospective Randomized Trial Comparing Ultrasound-guided High Intensity Focused Ultrasound (HIFU) Ablation With Active Surveillance (AS) in the Management of Low-risk Papillary Thyroid Microcarcinoma (PTMC),SUSPENDED,not start in coming years,NA,INTERVENTIONAL,103,Papillary Thyroid Microcarcinoma,,DEVICE,The proportion of tumors exhibiting disease progression,2022-10-01,2024-12-31,The University of Hong Kong,OTHER
NCT03908944,Postoperative Pain and Headache After Craniotomy,Postoperative Pain and Headache After Craniotomy,WITHDRAWN,PI- Dr. Jellish passed away. The study was terminated with the IRB,PHASE2,INTERVENTIONAL,0,Postoperative Pain,"Methadone, Standard of Care","DRUG, DRUG","Post craniotomy pain, Headache intensity",2019-01-02,2022-01-02,Steven Edelstein,OTHER
NCT01605344,Crossover Evaluation of Effect of Atorvastatin on PK of Irinotecan in CRC Patients Receiving FOLFIRI,"A Prospective, Randomized, Crossover Evaluation of the Effect of Atorvastatin on the Pharmacokinetics of Irinotecan in Colorectal Cancer Patients Receiving FOLFIRI",WITHDRAWN,Study was withdrawn due to lack of patient enrollment.,PHASE1,INTERVENTIONAL,0,Advanced Adenocarcinoma of the Colon or Rectum,"FOLFIRI., Atorvastatin","DRUG, DRUG",Area under the plasma concentration versus time curve (AUC) of irinotecan.,2012-04,2014-07,UNC Lineberger Comprehensive Cancer Center,OTHER
NCT03605134,The Impact of Routine Measurement of Cardiac Troponin (hsTnT) on Outcome in Elderly Patients Undergoing Major Surgery,The Impact of Routine Measurement of Cardiac Troponin (hsTnT) on Outcome in Elderly Patients Undergoing Major Surgery,TERMINATED,Not enough patient recruited,,OBSERVATIONAL,63,"Surgery--Complications, Mortality, Elderly",,"DIAGNOSTIC_TEST, DIAGNOSTIC_TEST",surgical mortality,2018-08-23,2019-08-07,Universitair Ziekenhuis Brussel,OTHER
NCT01010464,An Adhesion Reduction Plan in the Management of the Surgical Open Abdomen,"Effect of an Adhesion Reduction Plan on Enteric Adhesions, Obstruction, and Fistulae in the Management of the Surgical Open Abdomen: A Prospective, Randomized Clinical Trial in Trauma and Emergency General Surgery",WITHDRAWN,No participants enrolled,NA,INTERVENTIONAL,0,Open Abdomen,,PROCEDURE,Extent and severity of adhesions,2011-01,2012-08,"University of Maryland, Baltimore",OTHER
NCT03095664,Effect of a Lifestyle Intervention on Nutritional Status and Prognosis of Endometrial Cancer Survivors,Effect of a Lifestyle Intervention on Nutritional Status and Prognosis of Endometrial Cancer Survivors,SUSPENDED,"Study stopped due to COVID-19 pandemic, as conducting a behaviour-change programme in groups was not recommended to prevent the spread of the virus.",NA,INTERVENTIONAL,286,"Endometrium Cancer, Life Style, Obesity",,BEHAVIORAL,Overall survival,2016-11,2025-11,Brazilian National Cancer Institute,OTHER_GOV
NCT03768999,Comparison of Magnetic Resonance Coronary Angiography (MRCA) With Coronary Computed Tomography Angiography (CTA),Development of Magnetic Resonance Coronary Angiography (MRCA) Stenosis Assessment Quantification Method by Comparison With Coronary Computed Tomography Angiography (CTA),TERMINATED,Because of COVID 19 we experienced slow pace of recruitment.,,OBSERVATIONAL,16,Magnetic Resonance Angiography,,DIAGNOSTIC_TEST,The SI drop (%) threshold that corresponds to the significant stenosis in coronary CTA.,2019-09-03,2025-07-31,Johns Hopkins University,OTHER
NCT00519532,Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease,"A Multicenter, Multinational, Phase 3b, Open-label Extension Trial to Evaluate the Long-term Effect of the 24-hour Transdermal Delivery of Rotigotine on Motor Function, Sleep Quality, and Nocturnal and Non-motor Symptoms in Subjects With Idiopathic Parkinson's Disease",TERMINATED,Due to clinical trial supplies shortage,PHASE3,INTERVENTIONAL,84,Parkinson's Disease,Rotigotine,DRUG,"Change From Baseline in UPDRS III Score at Week 13 (End of Maintenance), Change From Baseline in Parkinson Disease Sleep Scale (PDSS) at Week 13 (End of Maintenance)",2007-07,2009-05,UCB Pharma,INDUSTRY
NCT04048863,"Effect of B. Braun Peripheral Advantage Program on Complications, Indwell Time and First Stick Success of PIVC Therapy","Assessment of the Effect of B. Braun Peripheral Advantage Program on Complications, Indwell Time and First Stick Success of PIVC Therapy",TERMINATED,This study was terminated due to recruitment futility resulting from the significant impact of the COVID-19 pandemic to our intended study population and facility personnel.,NA,INTERVENTIONAL,44,Complications Associated With Device,,"DEVICE, DEVICE",Complications Associated With PIVC Use,2020-01-24,2021-07-27,B. Braun Medical Inc.,INDUSTRY
NCT02193763,Bedside Ultrasound Assisted Pediatric Lumbar Puncture,Bedside Ultrasound Assisted Pediatric Lumbar Puncture--A Randomized Controlled Trial,WITHDRAWN,"PI has relocated to another institution, no other site PI to take over",NA,INTERVENTIONAL,0,Infant/ Neonate Lumbar Puncture,,PROCEDURE,"Traumatic lumbar puncture, Unsuccessful lumbar puncture",2009-08,2024-06,Wake Forest University Health Sciences,OTHER
NCT00165919,Immune Response to Hepatitis C Virus,Immunologic Determinants of Hepatitis C Virus Infection Resolution or Persistence,WITHDRAWN,Not a clinical trial; human specimens from treatment site for basic research.,,OBSERVATIONAL,0,"Hepatitis C, HIV Infections",,OTHER,This is NOT a clinical trial; thus no outcomes. Specimens from human subjects taken at clinical site and sent unidentified to laboratory for assays.,2005-09,2005-09,Emory University,OTHER
NCT02717728,Effectiveness of Fascia Iliaca Nerve Block for Post Hip Arthroscopy,"Effectiveness of Fascia Iliaca Nerve Block for Post Hip Arthroscopy Pain Management: A Randomized Double-blind, Placebo Controlled Study",WITHDRAWN,lack of funding,PHASE3,INTERVENTIONAL,0,"Hip Surgery Corrective, Anesthesia; Functional",,"PROCEDURE, PROCEDURE","The investigators will measure morphine consumption as the endpoint, to compare the efficacy of each group",2020-12,2021-12,Boston Children's Hospital,OTHER
NCT01076400,A Study of Adavosertib (MK-1775) in Combination With Topotecan/Cisplatin in Participants With Cervical Cancer (MK-1775-008),"A Two Part, Phase I-IIa Study Evaluating MK1775 in Combination With Topotecan/Cisplatin in Adult Patients With Cervical Cancer",TERMINATED,The sponsor permanently suspended new enrollment into the trial and discontinued the study; which was not related to any concerns over product safety.,"PHASE1, PHASE2",INTERVENTIONAL,7,Cervical Cancer,"adavosertib, Topotecan, Cisplatin, Placebo to adavosertib","DRUG, DRUG, DRUG, DRUG","Part 1: Percentage of Participants Whose Best Confirmed Response is Partial Response (PR) or Complete Response (CR), Part 1: Number of Participants With Dose Limiting Toxicities (DLTs), Part 2: Length of Time for Progression-free Survival (PFS)",2010-05-31,2011-06-13,Merck Sharp & Dohme LLC,INDUSTRY
NCT04781907,Patient Performed Tissue Expansion for Two-stage Alloplastic Breast Reconstruction,Patient Performed Tissue Expansion for Two-stage Alloplastic Breast Reconstruction,WITHDRAWN,Change in Research Priorities,NA,INTERVENTIONAL,0,"Tissue Expansion, Breast Reconstruction",,PROCEDURE,"Percent of Participants who had their breast tissue expanders successfully exchanged from expander to implant, Incidence of Adverse Events",2024-06,2025-06,"University of Wisconsin, Madison",OTHER
NCT04253236,To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA).,"A Phase 2, Multicenter, Non-Randomized, Open-Label Study of RVT-1401 for the Treatment of Patients With Warm Autoimmune Hemolytic Anemia",TERMINATED,Sponsor decision,PHASE2,INTERVENTIONAL,5,Warm Autoimmune Hemolytic Anemia,"RVT-1401 680 mg/weekly, RVT-1401 340 mg/weekly","DRUG, DRUG","Number of Responders at Week 13, Number of Participants With Any Treatment-emergent Adverse Event (TEAE), Serious AE (SAE), Treatment-related Adverse Event (AE), and Death",2020-08-11,2021-04-01,Immunovant Sciences GmbH,INDUSTRY
NCT00983736,Study to Evaluate Efficacy and Safety in Male Subjects With Premature Ejaculation,"A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Two Doses of Tramadol Hydrochloride Orally Disintegrating Tablets in Male Subjects With Premature Ejaculation",TERMINATED,This study was terminated because of recruitment difficulties.,PHASE3,INTERVENTIONAL,1050,Premature Ejaculation,"Tramadol Hydrochloride, Placebo","DRUG, DRUG",Increase in IELT (Intravaginal ejaculatory time),2009-10,2010-09,"Bausch Health Americas, Inc.",INDUSTRY
NCT04776044,Clinical Trial to Evaluate the Safety and Efficacy of ATR-002 in Adult Hospitalized Patients With COVID-19,"RESPIRE - A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Clinical Trial to Evaluate the Safety and Efficacy of ATR-002 in Adult Hospitalized Patients With COVID-19",TERMINATED,general circumstances around COVID-19 and current availability of hospitalized patients,PHASE2,INTERVENTIONAL,133,COVID-19,"ATR-002, Placebo","DRUG, DRUG",Clinical severity status on a 7-point ordinal scale,2021-04-12,2022-08-09,Atriva Therapeutics GmbH,INDUSTRY
NCT01009944,Genetic Mechanisms in Human Hypertension Renin-angiotensin-aldosterone System (RAAS) Inhibition Study,Genetic Mechanisms in Human Hypertension RAAS Inhibition Study,WITHDRAWN,Not funded.,NA,INTERVENTIONAL,0,Hypertension,"Lisinopril, Atenolol",DRUG,One type of blood pressure medication will better treat individuals with certain genetic backgrounds.,2007-01,2019-03-19,Brigham and Women's Hospital,OTHER
NCT01314664,A Prospective Registry to Assess the Effectiveness and Local Tolerability of Intravesical Valrubicin in Subjects With Non-muscle Invasive Bladder Cancer (NMIBC),A PROSPECTIVE REGISTRY TO ASSESS THE EFFECTIVENESS AND LOCAL TOLERABILITY OF INTRAVESICAL VALRUBICIN IN SUBJECTS WITH NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC),TERMINATED,"Business decision, not safety related",,OBSERVATIONAL,15,"Bladder Cancer, CIS",,,,2011-05,2012-01,Endo Pharmaceuticals,INDUSTRY
NCT05232864,"Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis","A Three-year, Open-label Extension Study of Subcutaneous Secukinumab to Evaluate the Long-term Efficacy, Safety and Tolerability in Patients With Active Lupus Nephritis",TERMINATED,Study terminated by sponsor based on a futility analysis of the core study CAIN457Q12301,PHASE3,INTERVENTIONAL,31,Lupus Nephritis,Secukinumab,DRUG,Percentage of Participants Achieving Complete Renal Response (CRR),2022-08-22,2023-08-23,Novartis Pharmaceuticals,INDUSTRY
NCT00243009,Fludarabine and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Metastatic Kidney Cancer That Cannot Be Removed By Surgery,Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Metastatic Renal Cell Carcinoma,TERMINATED,"Due to a lack of a referal base, study was terminated.",PHASE2,INTERVENTIONAL,1,Kidney Cancer,"cyclosporine, fludarabine phosphate, mycophenolate mofetil","DRUG, DRUG, DRUG, PROCEDURE, PROCEDURE, RADIATION",Response rate (complete and partial response) at 6 and 12 months after transplantation,2005-06,2006-04,OHSU Knight Cancer Institute,OTHER
NCT02091063,ACY-1215 for Relapsed/Refractory Lymphoid Malignancies,"A Study of the Selective HDAC6 Inhibitor, ACY-1215, for the Treatment of Patients With Relapsed or Refractory Lymphoid Malignancies",TERMINATED,Lack of funding,"PHASE1, PHASE2",INTERVENTIONAL,23,"Lymphoma, Lymphoid Malignancies",ACY-1215,DRUG,"Number of Patients Who Experience a Dose-limiting Toxicity (DLT), Objective Response Rate",2014-04-02,2019-05-05,Jennifer Amengual,OTHER
NCT03326687,Pairing Word Retrieval and Physical Endurance Tasks to Treat Anomia in People With Aphasia,Pairing Word Retrieval and Physical Endurance Tasks to Treat Anomia,WITHDRAWN,Insufficient personnel,NA,INTERVENTIONAL,0,Aphasia,,"BEHAVIORAL, BEHAVIORAL",Number of words named in a category,2018-05-01,2018-06-08,University of Nebraska Lincoln,OTHER
NCT04665921,A Study of SGN-STNV in Advanced Solid Tumors,A Phase 1 Study of SGN-STNV in Advanced Solid Tumors,TERMINATED,Study closed due to portfolio prioritization,PHASE1,INTERVENTIONAL,111,"Carcinoma, Non-Small Cell Lung, HER2 Negative Breast Neoplasms, Ovarian Neoplasms, Uterine Cervical Neoplasms, Endometrial Neoplasms, Esophageal Neoplasms, Gastroesophageal Junction Carcinoma, Stomach Neoplasms, Colorectal Neoplasms, Exocrine Pancreatic Adenocarcinoma, Appendiceal Adenocarcinoma, Pseudomyxoma Peritonei",SGN-STNV,DRUG,"Incidence of adverse events (AEs), Incidence of laboratory abnormalities, Incidence of dose limiting toxicities",2021-01-18,2024-03-01,Seagen Inc.,INDUSTRY
NCT04642014,Application of Convalescent Plasma in the Treatment of SARS CoV-2 Disease (COVID-19) With Evaluation of Therapy Effectiveness,"A Multi-centre, 18-months, Single-group Study of Application of Convalescent Plasma in the Treatment of SARS CoV-2 Disease (COVID-19) With Metabolomic and Laboratory Evaluation of Plasma Therapy Effectiveness",TERMINATED,The main reasons for the premature termination of the study are the inability to reliably assess the effectiveness of therapy due to the emergence of new variants of SARS-CoV-2 and reports of the lack of benefits of using plasma in previous studies.,NA,INTERVENTIONAL,396,COVID-19 Convalescent Plasma Treatment,COVID-19 convalescent plasma treatment,BIOLOGICAL,"Death, for any reason",2020-12-22,2022-01-04,Wroclaw Medical University,OTHER
NCT04182516,Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors,A Phase I Dose Escalation Study of NMS-03305293 in Adult Patients with Selected Advanced/Metastatic Solid Tumors,TERMINATED,The study closure is related to sponsor decision to shift towards the clinical development of NMS-03305293 in combination in a broader range of indication and not based on emerging safety or efficacy concerns.,PHASE1,INTERVENTIONAL,52,Advanced/Metastatic Solid Tumors,NMS-03305293,DRUG,Number of Participants with first-cycle dose limiting toxicity,2019-11-25,2024-05-16,Nerviano Medical Sciences,INDUSTRY
NCT05929716,"An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma","An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma",WITHDRAWN,Per Principal Investigator request,PHASE2,INTERVENTIONAL,0,"Large B-cell Lymphoma, B-cell Lymphoma","Magrolimab, Rituximab, CAR T leukapheresis, Radiation","DRUG, DRUG, DRUG, DRUG","Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0",2023-09-30,2028-03-01,M.D. Anderson Cancer Center,OTHER
NCT03535506,Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery,Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery,TERMINATED,lack of accrual,PHASE2,INTERVENTIONAL,17,DCIS,Palbociclib,DRUG,Feasibility: Recruitment Rates,2018-10-08,2023-12-06,Georgetown University,OTHER
NCT01632384,The Effects of Smoking Withdrawal On Resting State Functional Connectivity,The Effects of Smoking Withdrawal on Resting State Functional Connectivity,WITHDRAWN,study close-out,NA,INTERVENTIONAL,0,Smoking,,BEHAVIORAL,Blood-oxygen-level-dependent (BOLD) signal,2012-02,2012-09,Duke University,OTHER
NCT00357981,Continuous Use of the Contraceptive Patch and the Personal Economic Impact.,Patient Experiences Using Evra for Management of Menstrual Related Symptoms.,WITHDRAWN,Both sponsor and UCSF decided this study was not clinical relevant at this time,NA,INTERVENTIONAL,0,"Dysmenorrhea, Menstruation Disturbances, Menstruation Disorders","ORTHO EVRA, the contraceptive patch",DRUG,"Birth control satisfaction after four months of patch use, Health-related work productivity scales after four months of patch use",,,"University of California, San Francisco",OTHER
NCT00997581,Apremilast Therapy for Acute Gouty Arthritis,Apremilast Therapy for Acute Gouty Arthritis,WITHDRAWN,Colaborator withdrew support.,PHASE2,INTERVENTIONAL,0,Acute Gout,"apremilast, indomethacin SR","DRUG, DRUG","Subject-reported number of swollen joints, the number of tender joints, the number of warm joints, as well as self-report pain, global assessment, and functional status. Subject-reported time to resolution of symptoms will be measured.",2010-04,2010-12,Dartmouth-Hitchcock Medical Center,OTHER
NCT01885819,Autologous Adipose Tissue Stromal Vascular Fraction Cells for Rheumatoid Arthritis,Feasibility Study of Non-Expanded Autologous Adipose Tissue Derived Stromal Vascular Fraction Cells in Disease Modifying Anti-Rheumatic Drugs (DMARD) Resistant Rheumatoid Arthritis,WITHDRAWN,per sponsor decision,"PHASE1, PHASE2",INTERVENTIONAL,0,Rheumatoid Arthritis,Autologous stromal vascular fraction cells,BIOLOGICAL,Number of participants with adverse events,2013-06,2016-12,Translational Biosciences,INDUSTRY
NCT02470819,Genomic and Proteomic Profiling Targets Influenced Treatment in Metastatic Breast Cancer,A Two Arm Pilot Study Utilizing Molecular Profiling to Find Potential Targets and Influence Treatments for Patients With Metastatic Breast Cancer or Advanced Gynecological Malignancies,WITHDRAWN,Investigator elected to end the study,NA,INTERVENTIONAL,0,"Metastatic Breast Cancer, Breast Tumor, Advanced Gynecologic Cancer",,GENETIC,Progression-free survival,2014-03,2018-10-30,Avera McKennan Hospital & University Health Center,OTHER
NCT00226330,GALLEX 6: Study to Evaluate the Safety and Tolerability of Tesaglitazar in Patients With Type 2 Diabetes Mellitus,"A Double-Blind, Multi-Centre, Active-Controlled (15, 30, and 45 mg Pioglitazone) Long-Term Extension Study to Evaluate the Safety and Tolerability of Tesaglitazar (0.5 and 1 mg) in Patients With Type 2 Diabetes Mellitus (GALLEX 6)",TERMINATED,The development program has been terminated,PHASE3,INTERVENTIONAL,1100,"Diabetes Mellitus, Type 2","Tesaglitazar, Pioglitazone","DRUG, DRUG","Adverse events, Laboratory variables, Physical examination, Cardiac evaluation, Hypoglycemic events, Electrocardiogram, Vital signs (blood pressure and pulse), Body weight",2005-03,2006-12,AstraZeneca,INDUSTRY
NCT04218565,Golimumab for the Treatment of Refractory Behcet's Uveitis,Efficacy and Safety of Golimumab in the Treatment of Refractory Uveitis in Patients With Behcet's Disease,TERMINATED,only one patient enrolled,PHASE2,INTERVENTIONAL,1,"Behcet Syndrome, Uveitis",Golimumab (GOL),BIOLOGICAL,"Efficacy of Golimumab on BD Uveitis, Efficacy of Golimumab on BD Uveitis, Efficacy of Golimumab on BD Uveitis, Difference of recurrence rate before and after intervention",2020-02-15,2022-12-15,Wenjie Zheng,OTHER
NCT00921765,Reversal of Ketamine Pharmacodynamic Effects With Naloxone,Naloxone Block of Low-dose (Analgetic Dose) Ketamine,TERMINATED,Problems with patient recruitment,PHASE4,INTERVENTIONAL,3,Pain,"Saline, Saline + Ketamine, Naloxone + Placebo, Naloxone + Ketamine","DRUG, DRUG, DRUG, DRUG",Pain intensity (0-10 Numerical Rating Scale),2009-12,2017-12,Ullevaal University Hospital,OTHER
NCT02462200,Shave Margins in Breast Conservation Therapy,Shave Margins in Breast Conservation Therapy (SMART): A Randomized Controlled Trial,TERMINATED,Insufficient funding,PHASE2,INTERVENTIONAL,81,"Breast Cancer, Cancer of Breast, Cancer of the Breast",,"PROCEDURE, PROCEDURE, BEHAVIORAL, DEVICE, OTHER, DEVICE, PROCEDURE","Proportion of patients with positive margins on pathological specimen analysis, Patient perceptions of the surgery as measured by BREAST-Q questionnaire and novel 3-dimensional breast imaging, Compare intraoperative NIR fluorescence from goggle system with pathologic tissue exam results",2016-06-13,2019-11-27,Washington University School of Medicine,OTHER
NCT03890536,Intestinal Microbiome Composition in Infants With Biliary Atresia (BA),Intestinal Microbiome Composition in Infants With Biliary Atresia,WITHDRAWN,Study never began enrolling. Study team left institution.,,OBSERVATIONAL,0,"Biliary Atresia, Intrahepatic Cholestases, Normal Controls",,,Change in intestinal microbiome signature.,2023-12,2032-03,"Children's Hospital Medical Center, Cincinnati",OTHER
NCT01026844,Hydroxychloroquine With or Without Erlotinib in Advanced Non-small Cell Lung Cancer (NSCLC),A Phase I Study of Hydroxychloroquine With or Without Erlotinib in Advanced NSCLC,TERMINATED,slow enrollment,PHASE1,INTERVENTIONAL,27,Non-small Cell Lung Cancer,"erlotinib, hydroxychloroquine","DRUG, DRUG",Describe the Number and Type of Observed Dose Limiting Toxcities,2007-07,2012-11,Massachusetts General Hospital,OTHER
NCT00440544,A Phase I Trial of a LTK63 Adjuvated Tuberculosis Nasal Subunit Vaccine (Ag85B-ESAT6),A Phase I Trial of the Safety and Immunogenicity of an Adjuvated TB Subunit Vaccine (Ag85B-ESAT6 + LTK63) Administered at 0 and 2 Months,TERMINATED,Safety Issues,PHASE1,INTERVENTIONAL,9,Tuberculosis,"Ag85B-ESAT6 fusion protein H1, Ag85B-ESAT6 fusion protein H1, Ag85B-ESAT6 fusion protein H1, Ag85B-ESAT6 fusion protein H1, Ag85B-ESAT6 fusion protein H1, Ag85B-ESAT6 fusion protein H1","BIOLOGICAL, BIOLOGICAL, BIOLOGICAL, BIOLOGICAL, BIOLOGICAL, BIOLOGICAL","To evaluate the safety profile (medical examinations, adverse events and laboratory safety tests) of a nasal TB subunit vaccine with and without adjuvant given as two doses with 2 months interval.",2007-01,2008-02,"St George's, University of London",OTHER
NCT03336034,Assessment of Responsiveness to Treatment by Experience Sampling Method,Assessment of Responsiveness to Treatment of the Experience Sampling Method (ESM) in Irritable Bowel Syndrome (IBS) Using Linaclotide,TERMINATED,Slow inclusion rate.,,OBSERVATIONAL,16,Constipation-predominant Irritable Bowel Syndrome,,,"Mean abdominal pain scores as measured by the ESM tool., Maximum abdominal pain scores as measured by the ESM tool.",2018-01-01,2022-05-01,Maastricht University Medical Center,OTHER
NCT05980234,MDR - Longevity IT Oblique and Offset Liners,"PMCF Study to Provide Safety, Performance, and Clinical Benefits Data of the Longevity IT Oblique and Offset Liners in Primary and Revision Total Hip Arthroplasty - A Retrospective Enrollment/Prospective Follow-up Consecutive Series Study",TERMINATED,"Zimmer Biomet received the CE mark for the Continuum and Trilogy IT Acetabular System, which includes the Longevity IT Offset and Oblique Liners, in June 2024.",,OBSERVATIONAL,6,"Non-inflammatory Degenerative Joint Disease (NIDJD), Avascular Necrosis, Protrusio Acetabuli, Traumatic Arthritis, Slipped Capital Femoral Epiphyses, Fracture of the Pelvis, Diastrophic Variant, Osteoarthritis, Fused Hip",,"DEVICE, DEVICE",Incidence of treatment-emergent Adverse Events (safety),2023-08-30,2024-11-07,Zimmer Biomet,INDUSTRY
NCT04740034,A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma,"A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of AMG 340, a Bispecific Antibody Targeting PSMA in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma",TERMINATED,Sponsor strategic decision,PHASE1,INTERVENTIONAL,42,Metastatic Castration-resistant Prostate Cancer,AMG 340,DRUG,"Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs), Number of Participants Who Experienced Dose Limiting Toxicities (DLTs), Median Concentration of AMG 340",2021-04-29,2024-06-24,Amgen,INDUSTRY
NCT04383509,Electroconvulsive Treatment Followed by Cognitive Control Training,Cognitive Remediation Following Electroconvulsive Therapy in Patients With Treatment Resistant Depression: Randomized Controlled Trail of an Intervention for Relapse Prevention,TERMINATED,Difficult recruitment,NA,INTERVENTIONAL,21,"Depressive Episode, Electroconvulsive Therapy, Cognitive Remediation",,"BEHAVIORAL, BEHAVIORAL","Change in severity of depressive symptoms, clinician-rated (HAM-D), Change in severity of depressive symptoms, self-reported (BDI-II), Change in depressive symptoms and quality of life, self-reported (RDQ)",2020-05-10,2023-07-01,University Ghent,OTHER
NCT00751309,Lung Allograft Rejection Gene Expression Observational (LARGO) Study,Lung Allograft Rejection Gene Expression Observational (LARGO) Study,TERMINATED,Restructuring and refocus of company.,,OBSERVATIONAL,2044,"Graft Rejection, Lung Disease",,OTHER,"Rejection episodes of at least moderate histologic grade which resulted in treatment of the patient with additional corticosteroids, anti-T cell antibodies, or total lymphoid irradiation., Obliterative Bronchiolitis diagnosed pathologically by biopsy or by a progressive decline in pulmonary function tests consistent with a diagnosis of Bronchiolitis Obliterans Syndrome (BOS)., Allograft function as determined via pulmonary function tests., The absence of histologic rejection and normal or unchanged allograft function., Documented CMV infection by culture, histology, or PCR, and at least one clinical sign or symptom of infection., Infections other than CMV, e.g. bacterial, other viral, and fungal infections.",2004-04,2009-01,XDx,INDUSTRY
NCT03655899,Metabolomic Alterations in the Vascular Compartment in Patients With Sepsis,Metabolomic Alterations in the Vascular Compartment in Patients With Sepsis - an Observational Study,TERMINATED,Analysis of cell phenotypes was not possible,,OBSERVATIONAL,37,Endothelial Dysfunction,,,Shock induced endotheliopaty,2017-10-23,2019-03-12,Pär Johansson,OTHER
NCT00252499,Insulin Resistance in Non-alcoholic Fatty Liver Disease,Insulin Resistance in Non-alcoholic Fatty Liver Disease,TERMINATED,Protocol drug change required new clinicaltrails.gov entry,NA,INTERVENTIONAL,13,"Fatty Liver, Insulin Resistance","rosiglitazone, fenofibrate, placebo for rosiglitazone, placebo for fenofibrate","DRUG, DRUG, DRUG, DRUG",Liver/Spleen Ratio at 6 Months,2005-10,2010-08,US Department of Veterans Affairs,FED
NCT00086632,Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer Treatment,"An Open-Label, Phase II Study of Ovarex® MAb-B43.13 as an Adjuvant Treatment to Platinum-Based Front-Line Chemotherapy of Advanced Epithelial Carcinoma of Ovarian, Tubal, or Peritoneal Origin",TERMINATED,closed by sponser,PHASE2,INTERVENTIONAL,40,Ovarian Cancer,oregovomab,DRUG,,2004-07,2007-12,Unither Pharmaceuticals,INDUSTRY
NCT02754232,Telemedical Training for Chronically Ill COPD Patients: a Cross Sectoral Study,Telemedical Training in a Daily Perspective for Chronically Ill COPD Patients: a Cross Sectoral Study,WITHDRAWN,Due to resource problems in the clinic at University Hospital Odense,NA,INTERVENTIONAL,0,"Pulmonary Disease, Chronic Obstructive",,OTHER,The Stand up - sit down five times test (FTSST),2016-08,2016-08,Odense University Hospital,OTHER
NCT04471857,Hypnosis for Children Undergoing Anorectal Manometry,Using Medical Hypnotherapy in Children With Defecation Disorders,TERMINATED,Due to COVID-19 recruitement stopped since intended sample size was an estimation and not based on power calculation,NA,INTERVENTIONAL,34,Constipation,,BEHAVIORAL,The primary outcome of this study will be the assessment of distress as measured by the non-blinded observer.,2017-01-09,2020-03-04,Nationwide Children's Hospital,OTHER
NCT05748912,Lung Function Outcomes Following Removal of Airway Mucus Plugs in Patients With Asthma (FOCUS),Lung Function Outcomes Following Removal of Airway Mucus Plugs in Patients With Asthma,WITHDRAWN,No participants were enrolled in protocol A due to COVID-related restrictions and funding issues.,NA,INTERVENTIONAL,0,Asthma,,PROCEDURE,"Change in FEV1 (Forced Expiratory Volume in the 1st second of Forced Expiration), Incidence of Treatment-Emergent Adverse Events",2022-01-26,2025-03-25,"University of California, San Francisco",OTHER
NCT04941430,7T MRI Scan for the Early Detection of Melanoma Brain Metastases,Pilot Study of 7T MRI for Early Diagnosis of Melanoma Brain Metastases,TERMINATED,Insufficient Accrual,NA,INTERVENTIONAL,2,"Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8",,DIAGNOSTIC_TEST,"Presence or absence of brain metastases on 7 tesla (T) magnetic resonance imaging (MRI) as compared to the standard of care 3T MRI, Primary tumor size",2021-06-25,2025-01-10,University of Southern California,OTHER
NCT03858530,Ultrasound Elastography to Predict Development of SOS,Using Ultrasound Elastography to Predict Development of Sinusoidal Obstruction Syndrome,TERMINATED,Slow patient accrual and so Multicenter study was started that had similar aims.,NA,INTERVENTIONAL,21,"Bone Marrow Transplant Complications, Sinusoidal Obstruction Syndrome, Veno-occlusive Disease, Stem Cell Transplant Complications",,DIAGNOSTIC_TEST,Number of Days Between SWE Exams for VOD/SOS,2018-05-01,2024-01-16,Children's Mercy Hospital Kansas City,OTHER
NCT04966065,Evaluation of the Parietex TM Parastomal No Hole Mesh for Repair of Parastomal Hernias in End-colostomies,Evaluation of the Parietex TM Parastomal No Hole Mesh for Repair of Parastomal Hernias in End-colostomieswith a Laparoscopic Modified Sugarbaker Technique in a Prospective Multicenter International Observational Study,TERMINATED,too slow patiënts recruitment,,OBSERVATIONAL,10,Parastomal Hernia,,DEVICE,Evaluation of the QoL with the Stomy-QoL score assessment,2016-03-14,2018-12-31,"University Hospital, Ghent",OTHER
NCT01847300,cSBI-M for Young Military Personnel,Computerized Screening and Brief Intervention for Young Military Personnel,WITHDRAWN,not funded,NA,INTERVENTIONAL,0,"Alcohol Abuse, Tobacco Dependence, Substance Abuse",,BEHAVIORAL,alcohol use,2013-09,2017-02,Boston Children's Hospital,OTHER
NCT00247936,Combined Thoracoscopic and Laparoscopic Esophagectomy vs. Hand-assisted Transhiatal Esophagectomy: A Prospective Trial.,Combined Thoracoscopic and Laparoscopic Esophagectomy vs. Hand-assisted Transhiatal Esophagectomy: A Prospective Trial.,WITHDRAWN,"Prior to recruitment, study terminated lack of recruitment interest.",NA,INTERVENTIONAL,0,Adenocarcinoma,,PROCEDURE,short-term surgical outcome of minimally invasive esophagectomy vs. transhiatal esophagectomy,2004-05,2004-05,"University of California, Irvine",OTHER
NCT01067911,Optimizing Dietary Fatty Acids to Lower Metabolic Risk Factors Among Canadians,Optimizing Dietary Fatty Acids to Lower Metabolic Risk Factors Among Canadians,TERMINATED,"Not enough enrollment, study needs to be revised",NA,INTERVENTIONAL,12,Postprandial Lipaemia,,"DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Outcome Plasma triglyceride and fatty acids after eating an oil or fat,2009-07,2013-01,University of British Columbia,OTHER
NCT00973271,Diazoxide Choline Controlled-Release Tablet (DCCR) for Very High Triglycerides,"A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Study Assessing the Efficacy, Safety and Tolerability of Diazoxide Choline Controlled-Release Tablet (DCCR) in Subjects Without Diabetes Mellitus Having Very High Fasting Triglyceride Levels, With Double-Blind Active-Controlled Extension Assessing Safety and Tolerability",WITHDRAWN,Did not continue with development of DCCR in Very High Triglycerides,PHASE3,INTERVENTIONAL,0,Hypertriglyceridemia,"290 mg DCCR, 435 mg DCCR, 135 mg fenofibric acid, Placebo, atorvastatin","DRUG, DRUG, DRUG, DRUG, DRUG",The effect of DCCR on triglycerides in subjects without diabetes mellitus who have very high triglycerides over a period of 84 days,2011-03,2011-12,"Essentialis, Inc.",INDUSTRY
NCT02365909,Study Evaluating Sphenopalatine Ganglion Block (SPGB) for Treatment of Postdural Puncture Headache (PDPH),A Prospective Randomized Double-Blind Placebo Controlled Study Evaluating Sphenopalatine Ganglion Block (SPGB) for Treatment of Postdural Puncture Headache (PDPH),TERMINATED,Study stopped due to difficulty recruiting patients,EARLY_PHASE1,INTERVENTIONAL,6,Postdural Puncture Headache,"0.5% bupivacaine, normal saline","DRUG, DRUG",Headache verbal pain score,2015-06-29,2016-08-30,University of Arkansas,OTHER
NCT03257332,Determining Early Development of Faecal Incontinence and Anorectal Muscle Function After Surgery for Rectal Cancer.,The EDFI-Cohort: Determining Early Development of Faecal Incontinence and Anorectal Muscle Function After Curative Surgery for Rectal Cancer.,WITHDRAWN,Not possible to include participants,,OBSERVATIONAL,0,"Rectum Cancer, Quality of Life, Faecal Incontinence, Low Anterior Resection Syndrome",,PROCEDURE,Global health status/quality of life: EORTC QLQ-C30,2019-11-12,2022-12-31,Slagelse Hospital,OTHER
NCT03879798,DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer,"A Phase I/II Study of DS-3201b, an EZH1/2 Inhibitor, in Combination With Irinotecan in Patients With Recurrent Small Cell Lung Cancer",TERMINATED,Due to DLTs,"PHASE1, PHASE2",INTERVENTIONAL,22,Small Cell Lung Cancer,"DS-3201b, irinotecan","DRUG, DRUG","Maximum Tolerated Dose (MTD) (Phase l) of DS-3201/Valemetostat, Objective Response Rate (ORR) (Phase II)",2019-03-15,2023-05-02,Memorial Sloan Kettering Cancer Center,OTHER
NCT00467987,Effect of Androgel on Atherogenesis in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism,"Effect of Androgel on Atherogenesis, Inflammation, Cardiovascular Risk Factors And Adiposity in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism.: a Prospective, Randomized and Controlled-Study",TERMINATED,Company no longer making same drug doses.,NA,INTERVENTIONAL,47,Type 2 Diabetic Male With Hypogonadotrophic Hypogonadism,"androgel, placebo","DRUG, DRUG",Carotid Intima Media Thickness,2007-06-01,2018-10-11,University at Buffalo,OTHER
NCT03967587,Evaluation of Intravascular Monitoring of Partial PRessure of Oxygen for Neonatal intensiVE Care Patients,Evaluation of Intravascular Monitoring of Partial PRessure of Oxygen for Neonatal intensiVE Care Patients,TERMINATED,The clinical investigation IMPROVE has been closed after a decision by the Swedish Medical Products Agency that the trial must comply to the new European medical regulation MDR.,NA,INTERVENTIONAL,6,"Catheters, Oxygen Saturation, Newborn, Infant, Disease",,DEVICE,Measurement performance of an intravascular oxygen sensor in the Neosense system.,2020-11-19,2021-03-06,Neosense Technologies,INDUSTRY
NCT03706521,A Study Utilizing Imaging Techniques and Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis,"A Phase 2, 52 Week, Single Center, Open-Label Study Utilizing Imaging Techniques and Evaluating the Safety and Efficacy of SM04690 Injectable Suspension for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis",TERMINATED,The study was terminated early due to COVID-19-related issues.,PHASE2,INTERVENTIONAL,13,Knee Osteoarthritis,SM04690,DRUG,"Change from baseline in cartilage thickness in the target knee, Change from baseline in cartilage volume in the target knee, Change from baseline in cartilage quality in the target knee",2019-03-11,2020-12-21,"Biosplice Therapeutics, Inc.",INDUSTRY
NCT05650606,Inpatient Rehabilitation and Post-Discharge Outcomes With High Intensity Gait Training (HIGT) of Patients With Stroke,Inpatient Rehabilitation and Post-Discharge Outcomes of Patients With Stroke Participating in High Intensity Gait Training,TERMINATED,Poor enrollment,NA,INTERVENTIONAL,2,Cerebral Vascular Accident,,"OTHER, OTHER","10 Meter Walk Test at Self Selected Speed, 10 Meter Walk Test at Self Selected Speed, 10 Meter Walk Test at Self Selected Speed, 10 Meter Walk Test at Fast Speed, 10 Meter Walk Test at Fast Speed, 10 Meter Walk Test at Fast Speed, 6 Minute Walk Test, 6 Minute Walk Test, 6 Minute Walk Test, Stroke Impact Scale (SIS), Life Space Assessment (LSA), Cost of inpatient rehabilitation and post-discharge health care services",2023-03-18,2023-10-11,Sunnyview Rehabilitation Hospital,OTHER
NCT02336906,Urotherapy vs. Urotherapy With Constipation Treatment for Children With Lower Urinary Tract Dysfunction,"A Controlled Randomized, Physician Blinded Study to Assess Isolated Uro-therapy vs. Urotherapy With Constipation Treatment for Patients With Lower Urinary Tract Dysfunction (LUTD) Not Meeting ROME-III Constipation Criteria",WITHDRAWN,Changes in departmental staff have led to a cut in research alotments.,PHASE4,INTERVENTIONAL,0,Diurnal Enuresis,polyethylene glycol 3350,"DRUG, BEHAVIORAL, BEHAVIORAL",Complete (Vancouver score - ≤90% of screening value) or Partial (Vancouver score ≤ 50% screening value) response at the end of intervention.,2020-01,2020-12,Rabin Medical Center,OTHER
NCT01200004,"Study of Grifola Frondosa (Maitake), Azacitidine, and Lenalidomide","A Phase I Study of Epigenetic Immunomodulation Through the Use of Azacitidine, Lenalidomide, and Grifola Frondosa in Patients With Advanced Malignancy",TERMINATED,Slow Accrual.,PHASE1,INTERVENTIONAL,1,Advanced Cancers,"Azacitidine, Lenalidomide, Grifola Frondosa","DRUG, DRUG, DRUG",Maximum Tolerated Dose (MTD),2012-04,2013-07,M.D. Anderson Cancer Center,OTHER
NCT00949377,Can Methylnaltrexone Safely Treat Opioid Related Constipation in the Emergency Department?,Can Methylnaltrexone Safely Treat Opioid Related Constipation in the Emergency Department?,WITHDRAWN,Unable to recruit enough patients at a single center.,PHASE4,INTERVENTIONAL,0,Colonic Inertia,"Methylnaltrexone Bromide (MNTX), Placebo","DRUG, DRUG",Laxation,2009-09,2011-12,Beth Israel Medical Center,OTHER
NCT05063357,131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse Intrinsic Pontine Glioma,Safety of 131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse Intrinsic Pontine Glioma Previously Treated With External Beam Radiation Therapy,WITHDRAWN,Corporate business decision. Not due to safety or efficacy concerns.,PHASE1,INTERVENTIONAL,0,DIPG,131I-Omburtamab,"DRUG, DEVICE",Determining the safety of up to 36 participants with 131I-omburtamab administered directly into the tumor by CED in patients with DIPG assessed by CTCAE v.5.0,2022-03,2026-12,Y-mAbs Therapeutics,INDUSTRY
NCT03105401,Phenomenological and Psychopathological Factors Associated to Hallucinations in Parkinson's Disease,Phenomenological and Psychopathological Factors Associated to Hallucinations in Parkinson's Disease,TERMINATED,recruitment difficulties,,OBSERVATIONAL,32,Parkinson Disease,,OTHER,Hallucinations Prevalence,2017-05-15,2018-04-25,Hospices Civils de Lyon,OTHER
NCT03725267,Melatonin for Renal Protection in Patients Receiving Polymyxin B,Melatonin for Renal Protection in Patients Receiving Polymyxin B:a Randomized Clinical Trial,TERMINATED,"Due to COVID 19 pandemic social isolation measures, we had to stop recruting hospitalized patients.",PHASE2,INTERVENTIONAL,88,"Acute Kidney Injury, Melatonin, Polymyxin B Adverse Reaction","Melatonin Pill, Placebo oral capsule","DRUG, DRUG",Acute Kidney Injury according to RIFLE criteria,2018-10-01,2021-07-01,Hospital de Clinicas de Porto Alegre,OTHER
NCT05683600,Efficacy and Safety of COVID-19 Vaccine as Booster Vaccination in Adults 18 Years of Age or Older,"A Multicentre, Randomized, Double-blinded, Placebo-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 as Booster Vaccination in Adults 18 Years of Age or Older",TERMINATED,According to the development of the novel coronavirus epidemic situation and the company's R\&D decision,PHASE3,INTERVENTIONAL,3000,COVID-19,"Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001, Placebo","BIOLOGICAL, BIOLOGICAL",First occurrence of confirmed symptomatic COVID-19 incidence rate per person-years of follow-up,2022-12-29,2023-07-12,"Guangzhou Patronus Biotech Co., Ltd.",INDUSTRY
NCT03491007,Neurosteroids in PTSD - Biomarkers to Therapeutics,Neurosteroids in PTSD - Biomarkers to Therapeutics,TERMINATED,PI obtained outside employment that was not compatible with this award,PHASE2,INTERVENTIONAL,5,Posttraumatic Stress Disorder,DHEA,DRUG,Functional Connectivity Between Amygdala-hippocampus Assessed Using fMRI Based Shifted-attention Emotion Appraisal (SEAT) Paradigm.,2019-07-08,2020-11-16,VA Office of Research and Development,FED
NCT03146871,"Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent",A Pilot/Safety Study of sEphB4-HSA in Combination With a Hypomethylating Agent (HMA) for Patients With Relapsed or Refractory Myelodysplastic Syndrome (MDS) and AML Previously Treated With a Hypomethylating Agent,TERMINATED,Lack of funding,PHASE2,INTERVENTIONAL,7,"Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Recurrent Adult Acute Myeloid Leukemia","Azacitidine, Decitabine, Recombinant EphB4-HSA Fusion Protein","DRUG, DRUG, OTHER, OTHER, BIOLOGICAL","Incidence of adverse events graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v)4.0, Overall response defined as the occurrence of complete response, marrow complete response, partial response, or hematological improvement assessed by the IWG Working Group Criteria for MDS and AML, Time to death from any cause, Time to disease progression, Tolerability defined as the ability to complete two courses of treatment without the occurrence of dose limiting toxicity and the ability to begin course 3 within 4 weeks and graded according to the NCI CTCAE v4.0",2017-04-20,2019-03-27,University of Southern California,OTHER
NCT01678144,Study on Safety and Performance of Medtentia Mitral Valve Repair System in Surgical Repair of Mitral Regurgitation,Evaluation of the Safety and Performance of the Medtentia Mitral Valve Repair System When Used in Adults Undergoing Mitral Valve Repair Surgery,TERMINATED,Strategic decision by Sponsor,NA,INTERVENTIONAL,12,"Mitral Regurgitation, Mitral Insufficiency",,DEVICE,"Safety: All-cause Mortality Occurring in the Time From Surgery Through Hospital Discharge., Performance: Percentage of Participants With Improvement by at Least 2 Mitral Regurgitation Classes From Baseline (SC) to Three Months (V03) as Measured by Trans-thoracic Echocardiography (TTE).",2011-06-30,2016-04-22,Medtentia International Ltd Oy,INDUSTRY
NCT01956864,Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer,A Phase I Study of High-Dose Oral Vitamin D for the Prevention of Hepatocellular Carcinoma in Subjects With Cirrhosis,WITHDRAWN,PI transferred from Georgetown to Johns Hopkins University. No participants enrolled at either site. Funding lapsed.,PHASE1,INTERVENTIONAL,0,"Cirrhosis, Hepatocellular Carcinoma",Vitamin D,DRUG,Number of participants on high dose Vitamin D with adverse events,2013-09,2016-02-11,Johns Hopkins University,OTHER
NCT03907709,Effects of In-Home Addiction Treatment for First Responders,Effects of an In-Home Treatment Program for First Responders With Substance Use Disorder: A Retrospective Analysis,SUSPENDED,Resource allocation,,OBSERVATIONAL,15,Substance Use Disorders,,BEHAVIORAL,"Rate of Retention in Treatment, Brief Addiction Monitor questionnaire, Positive Outcomes Measures Survey",2019-04-08,2020-07-28,"In-Home Addiction Treatment Institute, Inc.",OTHER
NCT00907699,Laboratory Study Using Samples From Patients With Non-Small Cell Lung Cancer Treated on Clinical Trial CASE-2507,Study of Epithelial Growth Factor Receptor Mutations in Tumor Specimens and Blood Samples From Patients With Non-Small Cell Lung Cancer Enrolled on Clinical Trial CASE-2507,WITHDRAWN,Slow Accrual,,OBSERVATIONAL,0,Lung Cancer,,"GENETIC, GENETIC, GENETIC, GENETIC, GENETIC, GENETIC, GENETIC, OTHER","Predictive value of T790M mutation status of the second biopsy (before maintenance therapy on CASE-2507) on progression-free survival (PFS), Difference of PFS between those with and without T790M mutation, Difference of clinical response rate between T790M mutation statuses, Predictive value of mutation status on clinical response, Association between T790M mutation and baseline clinical-pathological factors and smoking status",2008-08,,Case Comprehensive Cancer Center,OTHER
NCT00209898,Hepatitis C Treatment of Inmates,"Hepatitis C Treatment of Inmates. A Randomized, Open-label Study Evaluating the Feasibility, Safety and Efficacy of Treatment With Peginterferon Alfa-2a in Combination With Ribavirin in Inmate Patients With Chronic Hepatitis C",TERMINATED,Low inclusion rate,PHASE4,INTERVENTIONAL,42,Chronic Hepatitis C,,PROCEDURE,"- adherence, - Sustained virologic response rates defined as percentage of patients with non-detectable HCV-RNA as measured by Roche AMPLICOR HCV Test, v2.0 (>50 IU/mL).",2003-08,2009-01,Haukeland University Hospital,OTHER
NCT00246298,A Study to Assess the Effectiveness of PROCRIT (Epoetin Alfa) Dosing Every 2 Weeks Versus Once a Week in Anemic HIV-infected Patients,"A Randomized, Open-Label Study Assessing the Efficacy of Initiating PROCRIT (Epoetin Alfa) Dosing at Q2W vs. PROCRIT Dosing at QW in Anemic HIV-infected Subjects",TERMINATED,OBI business decision not to complete any additional research in HIV.,PHASE2,INTERVENTIONAL,31,"Anemia, HIV",epoetin alfa,DRUG,Change in hemoglobin from baseline to the end of study at Week 12,2005-10,2006-09,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INDUSTRY
NCT01838863,Control of Major Bleeding After Trauma Study,"A Prospective, Randomized Comparison of Fresh Frozen Plasma Versus Standard Crystalloid Intravenous Fluid as Initial Resuscitation Fluid",TERMINATED,Futility,PHASE2,INTERVENTIONAL,144,"Trauma, Hemorrhagic Shock","Type AB plasma, Crystalloid fluid (standard of care for resuscitation)","BIOLOGICAL, DRUG",Number of Participants That Died Within 28 Days Post Injury,2014-04-07,2017-04-03,Denver Health and Hospital Authority,OTHER
NCT00701714,"Randomized, Controlled, Double-blind Multicenter Safety Study to Evaluate the Safety and Immunogenicity of Subcutaneous EPO HEXAL vs. ERYPO® in the Treatment of Anemia Associated With Chronic Renal Insufficiency in Predialysis Patients","Randomized, Controlled, Double-blind Multicenter Safety Study to Evaluate the Safety and Immunogenicity of Subcutaneous EPO HEXAL vs. ERYPO® in the Treatment of Anemia Associated With Chronic Renal Insufficiency in Predialysis Patients",TERMINATED,investigation of adverse events,PHASE3,INTERVENTIONAL,337,"Anemia, Chronic Renal Insufficiency","HX575 recombinant human erythropoietin alfa, ERYPO","DRUG, DRUG","Change in Hemoglobin Level, Weekly Epoetin Dose",2007-09,2010-01,Sandoz,INDUSTRY
NCT03515395,Entertainement and Training After a Hip Fracture,Acceptance and Frequency of Use of a Computer Game Based Exercise Training in Geriatric Patients After Hip Fracture Surgery,WITHDRAWN,"Low recruitement, no scientific staff",,OBSERVATIONAL,0,"Hip Fractures, Exercise, Aging",,BEHAVIORAL,Acceptance of technology,2018-08-15,2021-06-30,Geriatrische Klinik St. Gallen,OTHER
NCT02746939,Student Outcomes in Fitness and Nutrition ISEO,"Student Behavior Outcomes in Fitness and Nutrition Integrated Science Education Outreach (InSciEd Out, ISEO)",WITHDRAWN,Staffing change,NA,INTERVENTIONAL,0,Obesity,,BEHAVIORAL,Number of participants with completion of ISEO Fitness and Nutrition Curriculum,2016-03-29,2017-12-31,Mayo Clinic,OTHER
NCT05395039,Virtual Communication in the Hospital: Impact on Patients and Surrogates,Communication in the Hospital: Impact on Patients With Alzheimer's Disease and Other Causes of Cognitive Impairments and Their Surrogate Decision Makers,WITHDRAWN,"Recruitment effort yielded no enrollments, so this study was stopped. We are re-evaluating the study design.",NA,INTERVENTIONAL,0,"Communication, Anxiety, Depression, Distress, Emotional",,OTHER,"Measure change in ratings of communication quality among study participants using the FICS at baseline, 6-8 weeks after patient discharge, and 6 months after patient discharge",2026-03-31,2026-03-31,Indiana University,OTHER
NCT01005875,Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma,RAD 0901- Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma,TERMINATED,"Sponsor(Bayer)did not wish to continue with study due to slow accrual. Therefore, there is insufficient data and will not be any study results/outcomes.",NA,INTERVENTIONAL,5,"Hepatocellular Carcinoma, Liver Cancer",Sorafenib,"DRUG, RADIATION",Determine the Safety and Tolerability of Sequential SBRT and Sorafenib in Patients With Unresectable Hepatocellular Carcinoma,2009-11,2013-06,University of Alabama at Birmingham,OTHER
NCT04515472,Effect of Gender Affirming Hormone Therapy on Glucose Metabolism,Effect of Gender Affirming Hormone Therapy on Glucose Metabolism,TERMINATED,VA policy released 3/17/25 to phase out treatment for gender dysphoria,EARLY_PHASE1,INTERVENTIONAL,24,Transgender Persons,Botnia Clamp,"DRUG, OTHER","Effects of Chronic estrogen therapy on insulin secretion, Effects of Chronic estrogen therapy on insulin sensitivity, Effects of Chronic testosterone therapy on insulin secretion, Effects of Chronic testosterone therapy on insulin sensitivity",2020-06-17,2025-03-17,The University of Texas Health Science Center at San Antonio,OTHER
NCT02950181,Descriptive Analysis of Near Infrared Spectroscopy in Critically Ill and Injured Pediatric and Neonatal Patients,Descriptive Analysis of Near Infrared Spectroscopy in Critically Ill and Injured Pediatric and Neonatal Patients,TERMINATED,"Concerns over standard of care and recruiting process. Investigator left UAMS, therefore study halted immediately",NA,INTERVENTIONAL,299,"Stroke, Diabetic Ketoacidosis, Increased Intracranial Pressures, Altered Mental Status",,DEVICE,Observing Cerebral oximetry readings when patients present to the pediatric emergency department,2014-07-29,2019-01-01,Arkansas Children's Hospital Research Institute,OTHER
NCT00586365,Naproxen for the Prevention of HO After Complex Elbow Trauma,Effectiveness of Naproxen for the Prevention of Heterotopic Ossification After Complex Elbow Trauma: a Prospective Randomized Trial,WITHDRAWN,Too difficult to satisfy all the inclusion criteria.,PHASE4,INTERVENTIONAL,0,Heterotopic Ossification,Naproxen,DRUG,There is no difference in ulnohumeral flexion,2007-10,2010-10,Massachusetts General Hospital,OTHER
NCT02702700,Photo-induction as a Means to Improve Cisplatin Delivery to Pleural Malignancies,Photo-induction as a Means to Improve Cisplatin Delivery to Pleural Malignancies: a Clinical Phase I Trial,TERMINATED,Drug supply issue,PHASE1,INTERVENTIONAL,1,"Pleural Effusion, Malignant","Cisplatin, liposomal, Verteporfin","DRUG, DRUG, DEVICE","Safety of the treatment as assessed by 30-day postoperative mortality, Tolerability of the treatment as assessed by 30-day postoperative mortality, Feasibility, Acute respiratory failure rate, Dyspnea according to CTCAE v4.0, Chest pain rate according to CTCAE v4.0, Dyspnea according to Medical Research Council (MRC) chronic dyspnea scale (5-point)",2016-01,2018-08-28,Centre Hospitalier Universitaire Vaudois,OTHER
NCT00988507,Dose Ranging Study of Ferroquine With Artesunate in African Adults and Children With Uncomplicated Plasmodium Falciparum Malaria,"Parallel Group, Double-blind, Randomized Study Assessing the Efficacy, Safety and Pharmacokinetic Profiles of Ferroquine Associated With Artesunate and a Single-blind Dose Level of Ferroquine Alone in a 3-day Treatment of Uncomplicated Malaria Due to Plasmodium Falciparum in an Immune Symptomatic African Adult and Pediatric Population.",TERMINATED,Company decision to modify the ferroquine development strategy; discontinuation not due to safety or activity unexpected findings,PHASE2,INTERVENTIONAL,440,Plasmodium Falciparum Infection,"Ferroquine (SSR97193), Placebo, artesunate","DRUG, DRUG, DRUG",Recrudescent infections at D28 in the groups with ferroquine associated with artesunate. Recrudescence is defined as the recurrence of the same original strain of Plasmodium falciparum regardless of clinical symptoms,2009-10,2010-11,Sanofi,INDUSTRY
NCT05047536,KZR-261 in Subjects With Advanced Solid Malignancies,"A Phase 1 Study of KZR-261, a Small Molecule Sec61 Inhibitor, in Subjects With Advanced Solid Malignancies",TERMINATED,Sponsor decision.,PHASE1,INTERVENTIONAL,61,Advanced/Metastatic Solid Tumor,KZR-261,DRUG,"Number and Percentage of Participants Experiencing Adverse Events as Assessed by CTCAE v5.0 (Part 1 & 2), Number and Percentage of Participants Experiencing Dose-limiting Toxicities, Maximum Plasma Concentration of KZR-261 (Part 1), The Plasma Concentration Time Curve of KZR-261 (Part 1)",2021-09-30,2025-01-17,"Kezar Life Sciences, Inc.",INDUSTRY
NCT00547911,Augmenting Effects of L-DOPS With Carbidopa and Entacapone,L-Dihydroxyphenylserine (L-DOPS) for Norepinephrine Deficiency: Interactions With Carbidopa and Entacapone,TERMINATED,Study terminated due to contamination droxidopa,"PHASE1, PHASE2",INTERVENTIONAL,14,"Parkinson Disease, Multiple System Atrophy, Autonomic Nervous System Diseases","Droxidopa, Carbidopa, Entacapone","DRUG, DRUG, DRUG","Plasma LDOPS Concentrations After 400 mg of Droxidopa + 200 mg of Either Placebo, Carbidopa, or Entacapone, Plasma Norepinephrine Concentrations After 400 mg of Droxidopa + 200 mg of Either Placebo, Carbidopa, or Entacapone, Plasma DHMA Concentrations After 400 mg of Droxidopa + 200 mg of Either Placebo, Carbidopa, or Entacapone, Plasma DHPG Concentrations After 400 mg of Droxidopa + 200 mg of Either Placebo, Carbidopa, or Entacapone",2007-10,2013-04,National Institute of Neurological Disorders and Stroke (NINDS),NIH
NCT02483871,Dose Optimization of Rosuvastatin in Early Stage and Metastatic Estrogen Receptor Positive Breast Cancer Patients on Endocrine Therapy,,WITHDRAWN,Enrollment did not meet anticipated goals. Eligibility was a challenge.,PHASE1,INTERVENTIONAL,0,Breast Cancer,Rosuvastatin,DRUG,"Safety by adverse event, Maximum tolerated dose",2015-10,2017-05-10,Duke University,OTHER
NCT04920734,Description of Therapy Options and Successes in the Long-term Course of Delirium in the Recovery Room - CESARO II,Description of Therapy Options and Successes in the Long-term Course of Delirium in the Recovery Room - Multicenter Observational Study (CESARO-2),TERMINATED,Lack of equipment,,OBSERVATIONAL,5,Delirium,,,Morbidity,2021-10-01,2022-03-30,"Charite University, Berlin, Germany",OTHER
NCT00747032,To Demonstrate the Superior Efficacy of NYC 0462 Ointment Over That of the Placebo in the Treatment of Plaque Psoriasis,"Multi-Center, Double-Blind, Randomized, Vehicle-controlled, Parallel-Group Study Comparing NYC-0462 Ointment To a Vehicle Control",WITHDRAWN,Study withdrawn due to business decisions. No subjects were treated.,PHASE3,INTERVENTIONAL,0,Plaque Psoriasis,"NYC 0462 Ointment, Placebo","DRUG, DRUG",Reduction in plaque elevation score,2010-09,2011-04,Fougera Pharmaceuticals Inc.,INDUSTRY
NCT02767232,Pediatric High-Risk Deep Venous Thrombosis Lytic Outcomes Trial,Pediatric High-Risk Deep Venous Thrombosis Lytic Outcomes Trial,WITHDRAWN,Did not receive NIH Funding,PHASE3,INTERVENTIONAL,0,"Deep Vein Thrombosis, Post-Thrombotic Syndrome, Venous Thrombosis","Recombinant tissue plasminogen activator (rt-PA), Standard Anticoagulation Therapy","DRUG, DRUG",Development of Post-Thrombotic Syndrome (PTS),2018-07,2023-06,"University of Colorado, Denver",OTHER
NCT03706963,Remote Telemonitoring to Improve Prehabilitation and Surgical Outcomes of Patients Undergoing Elective Abdominal Surgery,Remote Telemonitoring to Improve Prehabilitation and Surgical Outcomes of Patients Undergoing Elective Abdominal Surgery,TERMINATED,Intervention is no longer being used,NA,INTERVENTIONAL,169,Abdominal Surgery,,OTHER,"Effectiveness of the study intervention during the preoperative period to increase patients compliance with prehabilitation goals as measured by average steps per day, Patient compliance of telemonitoring with activity trackers as measured by percentage of time the patient is wearing the device properly",2019-01-15,2022-07-10,Washington University School of Medicine,OTHER
NCT00512577,Transfusion Alternatives Pre-operatively in Sickle Cell Disease (TAPS),Transfusion Alternatives Pre-operatively in Sickle Cell Disease,TERMINATED,Study was terminated by Trial Steering Committee.,PHASE3,INTERVENTIONAL,70,Sickle Cell Disease,,OTHER,The frequency of all clinically significant complications in sickle Cell patients (Hb SS or SB0 thal) undergoing low or medium risk planned surgery.,2007-07,2011-03,NHS Blood and Transplant,OTHER_GOV
NCT01910675,PCC and Fibrinogen Compared With FFP in PPH,Use of Prothrombin Complex Concentrate and Fibrinogen Compared With Fresh Frozen Plasma (and Fibrinogen if Needed) in the Treatment of Postpartum Haemorrhage,WITHDRAWN,Impossible to get a written informed consent beforehand,PHASE4,INTERVENTIONAL,0,Postpartum Haemorrhage,"PCC, FFP","DRUG, DRUG",Blood loss,2013-07,2018-10,Helsinki University Central Hospital,OTHER
NCT03335501,Comparison of the Efficacy of Rapid-acting Aspart and Faster Acting Aspart Within the Context of Single-hormone Closed-loop Strategy at Regulating Postprandial Glucose Levels,"An Open-label, Double-blind, Randomized, Two-way, Cross-over Pilot Study to Provide Preliminary Evidence of the Efficacy of Rapid-acting Aspart Compared to Faster Acting Aspart Within the Context of Single-hormone Closed-loop Strategy at Regulating Postprandial Glucose Levels in Adults With Type 1 Diabetes",WITHDRAWN,The owner of the algorithm does not wish that this study be undertaken,PHASE2,INTERVENTIONAL,0,Type 1 Diabetes Mellitus,,"DEVICE, DEVICE, OTHER",Change in plasma glucose levels 1 hour after the meal,2018-04-01,2018-12-31,Institut de Recherches Cliniques de Montreal,OTHER
NCT00507312,Assessment of Myocardial Disease in Man Using Novel Non-invasive Diagnostic Tools,Assessment of Myocardial Disease in Man Using Novel Non-invasive Diagnostic Tools,TERMINATED,Suspended while we determine if usable data can be collected from this device.,PHASE1,INTERVENTIONAL,41,Cardiovascular Diseases,,"DEVICE, DEVICE","To validate the diagnostic ability of the two devices against echo and clinical data as the ""gold standard"".",2007-10,2010-12,Prof Henry Krum,OTHER
NCT01527019,Comparison in the Treatment of Acute Cystitis Using Cephalosporin and Norfloxacin (CECI),A Phase III Non-Inferiority Open-label Multicenter Randomized Clinical Trial to Compare CEPHALOSPORIN to NORFLOXACIN in the Treatment of Acute Cystitis,WITHDRAWN,the company suspended the persecution of this combination,PHASE3,INTERVENTIONAL,0,Cystitis,"Norfloxacin, Cephalosporins, Cephalosporins","DRUG, DRUG, DRUG",Bacteriological Eradication,2012-10,,Eurofarma Laboratorios S.A.,INDUSTRY
NCT04965467,Fabry Aim Children Early (ACE) Project,Fabry Aim Children Early (ACE) Project-Screening for Fabry Disease in a Pediatric Population at Risk,WITHDRAWN,Withdrawn due to financial reasons,,OBSERVATIONAL,0,Fabry Disease,,DIAGNOSTIC_TEST,The proportion of Fabry disease,2021-07-27,2022-02-28,Children's Hospital of Fudan University,OTHER
NCT05051800,Enhancing Coping and Communication in Children With Cancer and Their Parents,Enhancing Coping and Communication in Children With Cancer and Their Parents: A Novel Internet Intervention,TERMINATED,Recruitment of participants was interrupted by the COVID-19 pandemic and the funding for the study ended before the targeted enrollment could be completed.,NA,INTERVENTIONAL,100,Pediatric Cancer,,BEHAVIORAL,"Change in Total Behavior Problems on the Child Behavior Checklist from baseline to 6 months, Change in Total Behavior Problems on the Youth Self Report from baseline to 6 months",2019-02-01,2021-06-30,Vanderbilt University,OTHER
NCT00661336,A Phase I Trial of Normothermic Isolated Limb Infusion (ILI) With Melphalan Plus Buthionine Sulfoximine (BSO) in Patients With Locally Advanced Malignant Melanoma,"An Open-Label, Multicenter, Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability and Anti-tumor Activity of Systemic Buthionine Sulfoximine (BSO) in Combination With Normothermic Isolated Limb Infusion of Melphalan in Subjects With Locally Advanced In-Transit Malignant Melanoma",WITHDRAWN,The study was withdrawn due to lack of patients.,PHASE1,INTERVENTIONAL,0,Melanoma (Skin),"buthionine sulfoximine, melphalan","DRUG, DRUG, GENETIC, OTHER, OTHER, OTHER, PROCEDURE",Maximum tolerated dose of melphalan when administered as an isolated limb infusion in combination with a systemic infusion of buthionine sulfoximine (BSO),2008-04,,Duke University,OTHER
NCT03714711,Pain Profile and Pain Medication Use After THA and TKA,Patient Pain and Opioid Use Profile After Total Hip and Total Knee Arthroplasty,WITHDRAWN,PI decided to close due to current funding and future funding constraints on internal studies.,,OBSERVATIONAL,0,"Pain, Postoperative",,"PROCEDURE, PROCEDURE",Change in Patient Pain level,2025-08,2026-08,Duke University,OTHER
NCT03007771,Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia,A Feasibility Study of Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia in Human Subjects,WITHDRAWN,Decision was made to not go forward with the study,PHASE1,INTERVENTIONAL,0,"Healthy Participants, Pelvic Neoplasms, Soft-tissue Sarcoma, Bladder Cancer, Cervical Cancer, Rectal Cancer",,DEVICE,"Feasibility of the MR-HIFU device as measured by whether an area can be heated to the designated temperature and held at that temperature for an appropriate time frame, Feasibility of the MR-HIFU device as measured by whether an area can be heated while simultaneously maintaining patient comfort, Feasibility of the MR-HIFU device as measured by whether coupling can be maintained with the body area in the same position while having contact with the transducer for an appropriate time frame.",2017-09-30,2018-09-30,Washington University School of Medicine,OTHER
NCT02904434,Gastrointestinal Implications of Voriconazole Exposure,Gastrointestinal Implications of Voriconazole Exposure: Determining Age-dependent Differences in Intestinal Metabolism Affecting Oral Bioavailability of Voriconazole in Children,WITHDRAWN,IRB terminated the study,,OBSERVATIONAL,0,Infection,,OTHER,VoriconazoleArea Under the Curve (AUC),2016-09,2020-06,Children's Hospital of Philadelphia,OTHER
NCT01395264,Saccadometry in Primary Headache Syndromes,Saccadometry in Primary Headache Syndromes,TERMINATED,Lack of available clinical time to complete,,OBSERVATIONAL,42,"Migraine, Cluster Headache, Control, Menstrual Migraine",,,To see if Saccadometry results differ between controls and migraine subjects,2011-08,2017-10-27,Tim Young,OTHER
NCT01355809,Six-Minute Walk Test Comparing Helium/Oxygen to Nitrogen/Oxygen for COPD Rehabilitation,"Single Centre, Exploratory, Phase II, Cross-over, Randomised Trial, Evaluating the Effect of Spontaneously Breathing He/O2 65%/35% to Either Spontaneously Breathing N2/O2 65%35% or Non-Invasive Ventilated N2/O2 65%/35% on a 6 Minute Walk Test in Severe COPD Patients",TERMINATED,Due to low recruitment rate the sponsor decided to discontinue the study.,PHASE2,INTERVENTIONAL,3,"Pulmonary Disease, Chronic Obstructive","Inhalation gas, Inhalation Nitrogen/Oxygen, Inhalation Helium/Oxygen","DRUG, DRUG, DRUG",Distance walked,2009-12,2011-05,Air Liquide SA,INDUSTRY
NCT02937909,A Study to Evaluate the Benefits of Using a Range of Wound Care Products From a Single Manufacturer,"A Prospective Study With Historical Data Comparison to Evaluate the Benefits of Using a Range of Products From a Single Manufacturer for Training, Competencies in Wound Care and the Appropriate Use of Product",TERMINATED,Due to Inadequate patient recruitment,NA,INTERVENTIONAL,21,Wound - in Medical Care,,OTHER,Incidence of inappropriate use of dressings for the wound condition and patient lifestyle,2017-02-15,2017-12-06,BSN Medical Ltd. UK,INDUSTRY
NCT01051544,Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive,Randomised Study of First TIME Immunotolerance Induction in Patients With Severe Type A Haemophilia With Inhibitor at High Risk of Failure: Comparison of Induction of Immune Tolerance With FVIII Concentrates With or Without Von Willebrand Factor Acronym: RES.I.S.T.- Naive,WITHDRAWN,complete per PI,NA,INTERVENTIONAL,0,Severe Hemophilia A,"FVIII Concentrates, FVIII/VWF concentrates","DRUG, DRUG","Primary end point is the success in inducing immune tolerance, defined as: the abolition of the inhibitor to < 0.6 BU within 33 months of ITI with a factor VIII recovery ≥ 66% and half-life ≥ 6 hrs, and measured after a 72-hour washout period.",2009-09-25,2020-06-25,City of Hope Medical Center,OTHER
NCT05255263,Goal-directed Labor Epidural Analgesia Maintenance,"Programmed Intermittent Epidural Bolus vs. Continuous Epidural Infusion: a Multicenter, Pragmatic, Cluster-randomized Trial",WITHDRAWN,"Study is currently on hold, pending further evaluation and coordination.",NA,INTERVENTIONAL,0,Labor Onset and Length Abnormalities,,"OTHER, OTHER",Spontaneous Vaginal Delivery,2022-06-01,2022-06-01,"University of California, San Francisco",OTHER
NCT04257721,Predictive Score for Maxillary Osteonecrosis After Invasive Oral Surgery,Development of a Predictive Score for Maxillary Osteochimionecrosis After Invasive Oral Surgery in Patients Treated Whith Biphosphonates or Biotherapies: the PREV-ONM Study,TERMINATED,rate of inclusions too low,,OBSERVATIONAL,45,"Osteonecrosis Due to Drugs, Jaw",,,occurrence of osteonecrosis of the jaw,2019-10-10,2022-04-06,Centre Hospitalier Sud Francilien,OTHER
NCT01250457,Topical Timolol for the Treatment of Benign Vascular Periocular Lesions,Topical Timolol for the Treatment of Benign Vascular Periocular Lesions,WITHDRAWN,"Unknown, PI has left the institution. There was no enrollment.",PHASE4,INTERVENTIONAL,0,Benign Vascular Periocular Lesions,topical Timolol,DRUG,lesion resolution,2010-06,2012-07,Loyola University,OTHER
NCT03179501,"NP001, Alzheimer's Disease, and Blood Markers of Inflammation",Effect of Single Dose NP001 on Blood Markers of Inflammation in Individuals With Mild-to-Moderate Alzheimer's Disease,TERMINATED,Poor recruitment,PHASE1,INTERVENTIONAL,4,Alzheimer Disease,"NP001, Placebo","DRUG, DRUG",Inflammatory monocyte-associated biomarkers,2017-09-01,2018-07-31,Beau Nakamoto,OTHER
NCT01623219,Community-Based Telemedicine to Reduce Risk to Georgia Veterans With Post Traumatic Stress Disorder,Community-Based Telemedicine to Reduce Risk to Georgia Veterans With PTSD,WITHDRAWN,Unable to recruit,NA,INTERVENTIONAL,0,"Post Traumatic Stress Disorder, PTSD",,BEHAVIORAL,CAPS-Clinician Administered PTSD Scale,2012-03,,Emory University,OTHER
NCT03053765,Optimizing Fidelity of Interpersonal Psychotherapy,Optimizing Fidelity of Interpersonal Psychotherapy for Depression,TERMINATED,Conflict of Interest (COI) cannot be managed,NA,INTERVENTIONAL,115,Depression,,OTHER,expert evaluation of conduct of IPT using IPT Quality and Adherence Measure,2012-08-03,2020-01-31,University of Iowa,OTHER
NCT00651365,A Safety and Dose-finding Study of JNJ-38877605 in Patients With Advanced or Refractory Solid Tumors.,"A Phase I Study to Determine the Safety, Pharmacokinetics and Pharmacodynamics of the Selective Met Inhibitor JNJ-38877605 in Subjects With Advanced or Refractory Solid Tumors",TERMINATED,Early termination due to increase in serum creatinine levels and minimal PD activity.,PHASE1,INTERVENTIONAL,14,Neoplasms,JNJ-38877605,DRUG,"Determine the safety and tolerability of JNJ-38877605 by assessment of the adverse event profile (throughout the study), dose-limiting toxicity (Cycle 1), and the maximum tolerated dose.",2008-02,2010-12,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INDUSTRY
NCT04544800,Development of Upper Aerodigestive Tract Splint,Development of Upper Aerodigestive Tract Splint,TERMINATED,PI Relocation,NA,INTERVENTIONAL,7,Splints,,DEVICE,"Patient Splint Satisfaction Questionnaire, Physician Splint Satisfaction Questionnaire",2018-05-31,2023-05-31,"University Health Network, Toronto",OTHER
NCT04771000,A Study of Micro Dose Ambrisentan in Hospitalized Patients With Respiratory Insufficiency Due to COVID-19,"A Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Ambrisentan in Patients With Severe COVID-19",TERMINATED,Lack of recruitment,PHASE2,INTERVENTIONAL,88,"Covid19, Hypoxemia","Ambrisentan, Placebo","DRUG, DRUG",Proportion of subjects alive and not having developed respiratory failure from randomization to Day 14,2021-02-08,2023-02-27,Noorik Biopharmaceuticals AG,INDUSTRY
NCT06256900,Flow Controlled Ventilation in Robot-assisted Laparoscopic Surgery,"Flow Controlled Ventilation to Improve Postoperative Pulmonary Outcome After Robot-assisted Laparoscopic Surgery - a Prospective, Randomised, Single-blinded, Controlled and Single-centre Investigation",WITHDRAWN,The preparation and execution of this study were discontinued due to a range of practical constraints. Including logistical and operational challenges that would have compromised the study's feasibility and effective and questioning reliable results.,NA,INTERVENTIONAL,0,"Mechanical Ventilation Complication, Postoperative Pulmonary Atelectasis",,"OTHER, OTHER",Differences in the number of patients developing postoperative pulmonary complications,2024-10-29,2024-10-29,Cantonal Hospital of St. Gallen,OTHER
NCT02718092,"Comparing Fully Covered, Self Expanding Metal Stent (FCSEMS) and Plastic Stents for EUS- Guided Drainage of WON","Randomized Trial Comparing Fully Covered, Self Expanding Metal Stent (FCSEMS) and Plastic Stents for EUS- Guided Drainage of Walled -Off Necrosis (WON)",WITHDRAWN,Decided not to pursue study,NA,INTERVENTIONAL,0,Walled-off Necrosis,,"DEVICE, DEVICE","Short term efficacy as measured by interval decrease in size in WON (Walled Off Necrosis) collection to 10% of the pre-treatment volume as measured in centimeters^3., Short term efficacy as measured with improvement in symptoms using Visual Analog Scale (VAS), Short term efficacy as measured with improvement in symptoms using the SF-36 questionnaire scale, Long term efficacy as measured by interval decrease in size in WON collection to 10% of the pre-treatment volume as measured in centimeters^3., Long term efficacy as measured with improvement in symptoms using Visual Analog Scale (VAS), Long term efficacy as measured with improvement in symptoms using the SF-36 questionnaire scale",2016-02,2017-08-23,Indiana University,OTHER
NCT04602507,Ivermectin in Adults With Severe COVID-19.,Ivermectin in Adults With Severe COVID-19. Double-blind Randomized Clinical Trial,TERMINATED,Lack of severe COVID-19 cases in the place of study,PHASE2,INTERVENTIONAL,75,"Covid19, Severe Acute Respiratory Syndrome",Ivermectin,"DRUG, OTHER",Admission to the intensive care unit.,2020-12-10,2021-12-09,CES University,OTHER
NCT05431244,Pilot Study of Antiviral Treatment in Combination With Low-dose Gemcitabine in EBV-associated Gastric Cancer (EBVaGC),Pilot Study of Antiviral Treatment in Combination With Low-dose Gemcitabine in EBV-associated Gastric Cancer (EBVaGC),WITHDRAWN,Research withdrawal before patient registration due to difficulty in continuing research,NA,INTERVENTIONAL,0,Gastric Cancer,Antiviral treatment in combination with low-dose gemcitabine,DRUG,Objective Response Rate (ORR),2022-07-01,2024-07-01,Samsung Medical Center,OTHER
NCT04373044,"Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19",A Phase II Randomized Double-Blind Trial of Baricitinib or Placebo Combined With Antiviral Therapy in Patients With Moderate and Severe COVID-19,TERMINATED,The study was terminated after the release of results of ACTT-2 (NCT04401579).,PHASE2,INTERVENTIONAL,6,Symptomatic COVID-19 Infection Laboratory-Confirmed,"Baricitinib, Hydroxychloroquine, Placebo Administration","DRUG, DRUG, DRUG",Proportion of patients requiring invasive mechanical ventilation or dying,2020-05-01,2021-05-12,University of Southern California,OTHER
NCT03646344,Heme Arginate in Transplantation Study,Heme Arginate in Transplantation Study - a Multi-centre Blinded Parallel-group Randomised Trial of Heme Arginate Versus Placebo to Reduce Delayed Graft Function in Kidney Transplant Recipients,TERMINATED,COVID,PHASE3,INTERVENTIONAL,47,"Renal Transplant Rejection, Renal Transplant Failure","Heme Arginate 25 MG/ML, 0.9% Sodium-chloride","DRUG, DRUG",Delayed Graft Function,2019-03-12,2021-02-23,University of Edinburgh,OTHER
NCT05783492,INK Feasibility Study,Intranasal Ketamine for Procedural Sedation: a Feasibility Cohort Study,WITHDRAWN,Lack of availability of drug,PHASE3,INTERVENTIONAL,0,Procedural Sedation,Intranasal ketamine,DRUG,Adequacy of sedation,2024-01-01,2024-04-30,London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's,OTHER
NCT05045092,A Follow-up Study of Neonates Receiving Extracorporeal Life Support in China,A Follow-up Study of Neonates Receiving Extracorporeal Life Support in China,WITHDRAWN,lack of funding,,OBSERVATIONAL,0,"Extracorporeal Life Support, Neurodevelopment, Neonate, Mortality, Extracorporeal Membrane Oxygenation",,,Mortality or severe/moderate neurodevelopmental delay at two-year old,2024-01-01,2027-12-31,Children's Hospital of Fudan University,OTHER
NCT03613792,Remifentanil Plus Ketamine for Dynamic Flexible Bronchoscopy,Remifentanil Plus Ketamine Versus Midazolam Plus Fentanyl for Dynamic Flexible Bronchoscopy: Randomized Double-blind Clinical Trial,WITHDRAWN,Change in procedure means limited value for study question,PHASE4,INTERVENTIONAL,0,Bronchoscopy,"Remifentanil, Fentanyl, Midazolam, Ketamine","DRUG, DRUG, DRUG, DRUG",Patient Satisfaction with Sedation Instrument (PSSI),2023-09,2023-12,Beth Israel Deaconess Medical Center,OTHER
NCT04629534,Mothers' Own Milk Optimization for Preterm Infants Project (MoMO PIP) Pilot Study,"Mothers' Own Milk Optimization for Preterm Infants Project (MoMO PIP): Maternal Diet and Vitamin D Supplementation Effects on Preterm Infants, a Randomized Control Pilot Study.",TERMINATED,"low enrollment, lack of funding",PHASE4,INTERVENTIONAL,8,"Vitamin D Deficiency, Nutritional Deficiency","High dose Cholecalciferol, Cholecalciferol","DRUG, DRUG","Number of Infants With Sufficient 25(OH)D Stores at 3 Months, Number of Mothers With Sufficient 25(OH)D Stores at 3 Months, Number of Mothers With Elevated Calcium Concentrations at 1 Month, Number of Mothers With Elevated Calcium Concentrations at Month 2, Number of Mothers With Elevated Calcium Concentrations at Month 3, Number of Mothers With Elevated Urine Calcium Creatinine Ratio at Month 1, Number of Mothers With Elevated Urine Calcium Creatinine Ratio at Month 2, Number of Mothers With Elevated Urine Calcium Creatinine Ratio at Month 3, Number of Infants With Elevated Calcium Concentration at Month 1, Number of Infants With Elevated Calcium Concentration at Month 2, Number of Infants With Elevated Calcium Concentration at Month 3",2021-05-06,2022-04-01,Medical University of South Carolina,OTHER
NCT02602132,Clamping vs. Free Drainage Before the Removal of Short-term Indwelling Urethral Catheters in Internal Medicine Patients.,Clamping vs. Free Drainage Before the Removal of Short-term Indwelling Urethral Catheters in Internal Medicine Patients.,TERMINATED,Not enough participants. very slow and poor recruitment,NA,INTERVENTIONAL,17,Complication of Urinary Catheter,,PROCEDURE,Incidence of recatheterization,2016-03,2021-02-09,David Guadarrama-Ortega,OTHER
NCT00486798,FAST-A Study to Evaluate the Efficacy and Safety of Quetiapin IR in Patients With Acute Psychosis,,TERMINATED,study was not ethically acceptable to continue and therefore it was finally stopped,PHASE3,INTERVENTIONAL,,"Psychotic Disorders, Schizophrenia, Bipolar Disorder",Quetiapine,"DRUG, PROCEDURE, PROCEDURE, PROCEDURE, PROCEDURE",Assessment of Positive and Negative Syndrome Scale-Excitatory Subscale (PANSS-EC) at day 5 compared with baseline at day 1,2007-05,2007-08,AstraZeneca,INDUSTRY
NCT03865563,Selective Transvenous Chemoembolization of Primary Pancreatic Tumors,Selective Transvenous Chemoembolization of Primary Pancreatic Tumors,WITHDRAWN,We need to make significant adjustments to proposed drug and its delivery method,PHASE1,INTERVENTIONAL,0,Pancreatic Adenocarcinoma,Retrograde venous infusion of gemcitabine/lipiodol,DRUG,"Feasibility as determined by technical success of Pancreatic Retrograde Venous Infusion (PRVI) with gemcitabine and Lipiodol®, Safety as measured by number of participants with Grade 3, 4, and 5 toxicities",2019-07,2021-12,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,OTHER
NCT02428621,Early Treatment for Class II Division 1 Malocclusion With Twicare® and Herbst Removable Appliances,"Prospective Multicentric, Open-label, Randomized Study Assessing the Efficacy of the Removable and Adjustable Preformed Twicare® Appliance Versus Removable Herbst Appliance Treatment in Class II Malocclusion",TERMINATED,the study is discarded by the sponsor.,NA,INTERVENTIONAL,62,"Malocclusion, Angle Class II, Division 1",,"DEVICE, DEVICE",A point-nasion-B point (ANB) angle change,2015-07,2017-10,FCI System,INDUSTRY
NCT03319914,Observational Follow-up to ST-001 Calciphylaxis Pain Treatment With Intravenous Sodium Thiosulfate,Observational Follow-up to ST-001 Calciphylaxis Pain Treatment With Intravenous Sodium Thiosulfate,TERMINATED,Subjects did not receive Hope Pharmaceuticals' Sodium Thiosulfate Injection.,,OBSERVATIONAL,5,Calciphylaxis,,,"Observation of delayed adverse events, standard of care treatments for calciphylaxis following participation in ST-001",2017-10-20,2018-11-09,Hope Pharmaceuticals,INDUSTRY
NCT04184206,Effects of Attention Training Interventions on Depression,Effects of Attention Training Interventions on Depression,TERMINATED,"Moved institutions, study terminated",NA,INTERVENTIONAL,3,"Depression, Attention Training, Symptoms, Cognitive, Symptoms, Affective, Symptoms, Behavioral",,"BEHAVIORAL, BEHAVIORAL, BEHAVIORAL","changes in questionnaire measures including severity of depression (e.g., Beck Depression Inventory [BDI-II]: minimum/maximum values = 0/63, higher scores indicate worse outcome), changes in neural measures including ""functional connectivity"" functional magnetic resonance imaging (fMRI) collected during rest conditions, changes in behavioral task performance including related to affective (e.g., Probabilistic Reward Task [PRT]), changes in behavioral task performance including related to cognitive processing (e.g., Flanker Task).",2021-08-31,2022-04-30,Mclean Hospital,OTHER
NCT01475604,"Impact of Noninvasive Targeted Pulsed Electromagnetic Field (tPEMF) on Opioid Use, Pain, and Joint Function Following Total Knee Arthroplasty","Impact of Noninvasive Targeted Pulsed Electromagnetic Field (tPEMF) on Opioid Use, Pain, and Joint Function Following Total Knee Arthroplasty: A Double-Blind, Randomized, Sham-controlled Trial",TERMINATED,Sponsor decision,PHASE4,INTERVENTIONAL,23,"Osteoarthritis, Knee",,"DEVICE, DEVICE",The average daily morphine equivalent dose consumption at 2 weeks post-surgery.,2011-11,2012-07,"Amp Orthopedics, Inc.",INDUSTRY
NCT02192567,Open Label Study of DS-5573a,"Phase 1, Open Label Study to Assess the Safety and Pharmacokinetics of DS-5573a in Japanese Patients With Advanced Solid Malignant Tumors",TERMINATED,Business decision,PHASE1,INTERVENTIONAL,19,Advanced Solid Malignant Tumors,DS-5573a,DRUG,"Number of subjects experiencing dose limiting toxicities, Number of subjects experiencing adverse events, Pharmacokinetic profile of DS-5573a",2014-09,2017-01,"Daiichi Sankyo Co., Ltd.",INDUSTRY
NCT02794467,Placebo-controlled Proof of Concept Study of Epelsiban in Women With Adenomyosis,"A Phase II, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Proof of Concept Study With an Interim Futility Analysis of Epelsiban in Patients With Adenomyosis",WITHDRAWN,Study was prematurely discontinued due to GSK's change in prioritization for the portfolio and is not due to any safety concerns or regulatory interaction.,PHASE2,INTERVENTIONAL,0,Adenomyosis,"Epelsiban, Placebo","DRUG, DRUG","Mean percent change from baseline in monthly menstrual blood loss (MBL) to menstrual Cycle 3, Number of subjects with adverse events (AE)",2016-07,2016-10,GlaxoSmithKline,INDUSTRY
NCT06079736,A Study Of PGN-EDO51 In Participants With Duchenne Muscular Dystrophy Amenable To Exon 51-Skipping Treatment,"A Phase 2, Open-Label, Multiple Ascending Dose Study of PGN-EDO51 With a Long-Term Extension in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment (CONNECT1-EDO51)",TERMINATED,PGN-EDO51 development terminated by Sponsor,PHASE2,INTERVENTIONAL,7,Duchenne Muscular Dystrophy,PGN-EDO51,DRUG,"Adverse events and serious adverse events (safety and tolerability of PGN-EDO51 in MAD period), Adverse events and serious adverse events (long-term safety and tolerability of PGN-EDO51 in LTE period)",2024-01-03,2025-08-28,PepGen Inc,INDUSTRY
NCT00553709,Study of Nicotine for the Prevention of PONV,The Role of Transcutaneous Nicotine in the Prevention of Postoperative Nausea and Vomiting in Non-smokers,TERMINATED,Unexpected difficult recruitment. Study drug expired,PHASE2,INTERVENTIONAL,200,Postoperative Nausea and Vomiting,Nicotine,DRUG,Prevention of PONV,2007-10,2009-08,"University Hospital, Geneva",OTHER
NCT02835209,Positioning During SBT in NICU Infants,Effect of Position on the Spontaneous Breathing Trial,WITHDRAWN,Change in clinical practice that logistically prevented this study from being engaged.,,OBSERVATIONAL,0,"Respiratory Distress Syndrome, Newborn, Ventilator-associated Lung Injury",,OTHER,"Impact of infant positioning on spontaneous breathing test (SBT) pass rates, Impact of infant positioning on spontaneous breathing test (SBT) fail rates",2017-11,2018-09,Christiana Care Health Services,OTHER
NCT05082571,Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease,"A Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Once Daily Oral Vadadustat for the Treatment of Pediatric Subjects With Anemia of Chronic Kidney Disease After Conversion From an Erythropoiesis-stimulating Agent",WITHDRAWN,Sponsor decision,PHASE3,INTERVENTIONAL,0,Anemia of Chronic Kidney Disease,vadadustat,DRUG,Mean Change in Hemoglobin (Hb) Values Between Baseline and the Primary Evaluation Period (Average Hb From Weeks 21 to 28),2025-01,2026-10,Akebia Therapeutics,INDUSTRY
NCT00003471,Antineoplaston Therapy in Treating Patients With Low-Grade Astrocytoma,Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients With Low Grade Astrocytoma,TERMINATED,Slow accrual,PHASE2,INTERVENTIONAL,7,"Low-Grade Astrocytoma, Nos",Antineoplaston therapy (Atengenal + Astugenal),DRUG,Number of Participants With Objective Response,1996-03,2003-07,Burzynski Research Institute,OTHER
NCT04992598,Hypnosis to Reduce Pain and Drugs for Shoulder Dislocation Management,Hypnosis to Reduce Pain and Drugs for Shoulder Dislocation Management in the Emergency Department,WITHDRAWN,departure of the study coordinating investigator,NA,INTERVENTIONAL,0,Shoulder Dislocation,,"OTHER, PROCEDURE",Analgesic consumption,2024-06-01,2024-08-01,Centre Hospitalier Régional Metz-Thionville,OTHER
NCT01173263,Effect of Bispectral Index (BIS) Titrated Propofol Sedation on Lower Esophageal Sphincter Pressures and Esophageal Function in Intensive Care Patients,Effect of BIS Titrated Propofol Sedation on Lower Esophageal Sphincter Pressures and Esophageal Function in Intensive Care Patients,TERMINATED,recruitment difficulties,NA,INTERVENTIONAL,1,"Respiration, Artificial",,"OTHER, OTHER, OTHER",Deepening propofol sedation - as determined by BIS - lowers esophageal pressure in critical care patients.,2010-07,2011-03,The Cleveland Clinic,OTHER
NCT00521963,Intraarticular Injection of Infliximab,Interventional Study: Administration of Intraarticular Injection of Infliximab in Patients With Inflammatory Arthritis Who Failed Intraarticular Injection of Corticosteroids,WITHDRAWN,poor accrual,"PHASE2, PHASE3",INTERVENTIONAL,0,Arthritis,Intraarticular injection of infliximab,BIOLOGICAL,suppression of inflammation,2010-03,2011-03,"HaEmek Medical Center, Israel",OTHER
NCT04216563,ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor,Phase II Study of Dual Targeting of BCR-ABL1 by Adding the Allosteric Inhibitor ABL001 in Patients With Chronic Myeloid Leukemia (CML) and Minimal Residual Disease (MRD) While on Therapy With Tyrosine Kinase Inhibitors,TERMINATED,"75% \< Participants, Administrativley Complete",PHASE2,INTERVENTIONAL,7,"Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia",Asciminib,DRUG,Participants With a Molecular Response,2020-07-29,2025-03-17,M.D. Anderson Cancer Center,OTHER
NCT01517763,Comparison Study of the ICON™ Auto Series With and Without SensAwake™ and ThermoSmart™ and Conventional Continuous Positive Airway Pressure in Obstructive Sleep Apnea Patients,,TERMINATED,"The site closed down, therefore the study has been terminated.",NA,INTERVENTIONAL,32,"Sleep Apnea, Obstructive",,"DEVICE, DEVICE, DEVICE",Adherence With Treatment Per Night Averaged Over Total Time Period Measured Via Internal Software on the Device and Reported on Using InfoSmart™ Software.,2012-01,2014-09,Fisher and Paykel Healthcare,INDUSTRY
NCT02339987,Procure Tumor and Initiate Melanoma Tumor-Reactive Tumor Infiltration,Procure Tumor and Initiate Melanoma Tumor-Reactive Tumor Infiltration,TERMINATED,"original PI left institute, no plan to continue using samples",,OBSERVATIONAL,27,Melanoma,,,"Evaluate Feasibility of conducting TIL procurement in a single-site setting, Evaluate Safety of conducting TIL procurement in a single-site setting",2014-11,2018-06-04,Saint John's Cancer Institute,OTHER
NCT01876693,A Prospective Study of Prophylactic Gastrostomy in Head and Neck Cancer Patients Undergoing Chemoradiotherapy,A Prospective Study of Prophylactic Gastrostomy in Head and Neck Cancer Patients Undergoing Chemoradiotherapy in Medical Practice,TERMINATED,slow accrual in experiment arm,NA,INTERVENTIONAL,95,"Carcinoma, Squamous Cell of Head and Neck",,PROCEDURE,treatment interruption due to toxicity,2013-05,2015-06,Mahidol University,OTHER
NCT03338114,Study to Evaluate the Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Upper or Lower Extremity Muscles Most Affected in Subjects With ALS,An Open Label Study to Evaluate the Safety and Efficacy of FLX-787-ODT for Treatment of Fasciculations in the Tongue and Upper or Lower Extremity Muscles Most Affected in Subjects With Amyotrophic Lateral Sclerosis (ALS),WITHDRAWN,Sponsor Decision,"PHASE1, PHASE2",INTERVENTIONAL,0,"Amyotrophic Lateral Sclerosis, Fasciculation",FLX-787-ODT (orally disintigrating tablet),DRUG,"Change from Baseline of Diastolic Blood Pressure in mmHg, Change from Baseline of Systolic Blood Pressure in mmHg, Change from Baseline in Heart Rate in beats per minute, Change from Baseline in Respiration Rate in breaths per minute, Change from Baseline in Body Temperature in degrees Celsius or Fahrenheit, Change from Baseline of Oral Cavity Examination, Incidence of Treatment-Emergent Adverse Events",2017-11,2018-08,"Flex Pharma, Inc.",INDUSTRY
NCT02038816,Azacitidine Plus Deferasirox (ICL670) in Higher Risk Myelodysplastic Syndromes (MDS),A PHASE II STUDY OF Azacitidine Plus Deferasirox (ICL670) in Higher Risk Myelodysplastic Syndromes (MDS),TERMINATED,"accrual too slow, insufficient patients",PHASE2,INTERVENTIONAL,1,Myelodysplastic Syndromes,"Deferasirox + Azacitidine, Azacitidine","DRUG, DRUG",Difference in proportion of patients with hematologic improvement as defined by the IWG criteria30 with the addition of deferasirox to azacitidine compared with azacitidine alone in higher risk non-responding MDS patients after 6 cycles of azacitidine.,2014-03,2016-09-29,Sunnybrook Health Sciences Centre,OTHER
NCT02085616,Effectiveness of the Swedish National Tobacco Quitline,Smoking Cessation by Telephone. Effectiveness and Cost-effectiveness of Proactive and Reactive Services at the Swedish National Tobacco Quitline (SNTQ).,TERMINATED,"Interim analysis, revealed no additional effect of proactive over reactive service.",NA,INTERVENTIONAL,586,"Smoking Cessation, Tobacco Cessation",,"BEHAVIORAL, BEHAVIORAL",Point prevalence abstinence,2009-02,2011-10,Uppsala University,OTHER
NCT06371716,Ex-vivo Ultrasound Guided Radiofrequency Ablation on Pancreatic Solid Lesions,Application of a New System of Ultrasound (US) Guided - Radiofrequency Ablation (RFA) on Explanted Pancreas From Patients With Solid Pancreatic Masses: Study of Efficacy,TERMINATED,resectable pancreatic adenocarcinoma and neuroendocrine pancreatic neoplasms are difficult to be enrolled. Pancreatic resectable cancers are treated nowadays with chemotherapy and big neuroedocrine pancreatic lesions rare,NA,INTERVENTIONAL,45,"Pancreatic Cancer, Endoscopic Ultrasound, Radiofrequency Ablation",,"PROCEDURE, PROCEDURE, PROCEDURE",diameter (millimeters) of coagulative necrosis obtained by RadioFrequency Ablation,2019-09-12,2020-06-12,IRCCS San Raffaele,OTHER
NCT06119204,"SAFE-LCD Trial, for Insulin-treated Adults Living With Type 2 Diabetes",Trial to Determine Safety And Efficacy of a Digital Low-Calorie Diet Programme (SAFE-LCD) for Insulin-treated Adults Living With Type 2 Diabetes,TERMINATED,Slow recruitment,NA,INTERVENTIONAL,21,"Type 2 Diabetes Treated With Insulin, Diet Habit",,"OTHER, OTHER",Weight loss,2024-01-26,2024-09-09,Oviva UK Ltd,OTHER
NCT00716404,Post-Market Observational Study of Intra-Renal Drug Delivery,Post-Market Observational Study of Intra-Renal Drug Delivery,WITHDRAWN,FlowMedica was purchased by AngioDynamics. Study will be re-started by AngioDynamics.,,OBSERVATIONAL,1000,Targeted Renal Therapy,,DEVICE,,2008-04,,"FlowMedica, Inc.",INDUSTRY
NCT05052684,The Leaflex™ Brazilian Standalone Study,The Leaflex™ Brazilian Standalone Study,TERMINATED,Reprioritization of attention and resources by Sponsor,NA,INTERVENTIONAL,1,Aortic Valve Stenosis,,DEVICE,Change in aortic valve area,2022-10-03,2024-11-14,Pi-cardia,INDUSTRY
NCT01989052,Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma,A Phase 1/2 Unblinded Trial of Carboxyamidotriazole Orotate (CTO) Alone or in Combination With Lomustine for Bevacizumab-Naïve Adult Patients With Recurrent Malignant Glioma,TERMINATED,This study was terminated early due to funding issues prior to completion of phase I,PHASE1,INTERVENTIONAL,9,Malignant Glioma (WHO Grade III or IV),"CTO, Lomustine","DRUG, DRUG","Phase 1: Determine the maximum tolerated dose (MTD) of CTO when combined with lomustine, Phase 2: Percentage of subjects who remain alive and progression-free at 6 months",2014-05,2016-02,Annick Desjardins,OTHER
NCT05145452,N-3 Polyunsaturated Fatty Acids to Prevent and Treat Diabetic Neuropathy,N-3 Polyunsaturated Fatty Acids to Prevent and Treat Diabetic Neuropathy,SUSPENDED,delay due to COVID caused treatment product expiration,NA,INTERVENTIONAL,60,Diabetic Neuropathies,,DIETARY_SUPPLEMENT,"Sensorimotor function, Cardiovascular autonomic function, Muscle endurance",2021-01-14,2025-12-31,University of Missouri-Columbia,OTHER
NCT01111552,"Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)","A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder",TERMINATED,"The study was terminated early due to Sponsor decision, closure of this combination therapy program is unrelated to any safety issues, no signals of concern.",PHASE3,INTERVENTIONAL,237,Major Depressive Disorder (MDD),"Escitalopram, Aripiprazole, Placebo","DRUG, DRUG, DRUG",Phase C: Mean Change From End of Phase B (Week 8) in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score to End of Phase C (Week 14),2010-07-29,2011-09-27,"Otsuka Pharmaceutical Development & Commercialization, Inc.",INDUSTRY
NCT03165747,Effect of VSL#3 on Bone Mineral Density in Postmenopausal Women,"Effect of VSL#3 on Bone Mineral Density in Postmenopausal Women: a Pilot Randomized, Placebo-Controlled Trial",TERMINATED,Investigator terminated trial pursuant to research contract rights.,PHASE2,INTERVENTIONAL,35,Menopausal Osteoporosis,VSL#3,"DRUG, OTHER",Change in Bone Mineral Density (BMD) of the Lumbar Spine (L1-L4 Segment) as Measured by Dual Energy X-ray Absorptiometry (DEXA),2017-10-01,2019-03-23,Emory University,OTHER
NCT00171431,The Effect of Tegaserod on Patterns of Flow in the Small Bowel of Patients With Irritable Bowel Syndrome (IBS),The Effect of Tegaserod on Patterns of Flow in the Small Bowel of Patients With Irritable Bowel Syndrome (IBS),TERMINATED,This study was terminated early in May 2006 due to low patient enrollment,PHASE3,INTERVENTIONAL,20,"Constipation Predominant, Irritable Bowel Syndrome (IBS-C)",Tegaserod,DRUG,"To evaluate the effects of tegaserod on motility and small intestinal flow patterns after meal in female patients with IBS-C, by using Multiple Intraluminal Impedance",2004-11,2006-05,Novartis Pharmaceuticals,INDUSTRY
NCT00817531,Efficacy Study of Dasatinib in Locally Advanced Triple-Negative Breast Cancer Patients,"A Biologic Efficacy Study of Dasatinib, a Multi-Targeted Tyrosine Kinase, in Locally Advanced Triple-Negative Breast Cancer Patients Developing Effective Therapies for Er-Negative Breast Cancer Using Genomics and Proteomics: Project 3",TERMINATED,terminated due to futility after interim analysis,PHASE2,INTERVENTIONAL,22,Breast Cancer,Dasatinib,DRUG,Clinical Efficacy,2008-12,2011-02,Baylor Breast Care Center,OTHER
NCT03340402,Preoperative Accelerated Partial Breast Irradiation for Triple Negative Breast Cancer Using Proton Beam Scanning,Pilot Study of Preoperative Accelerated Partial Breast Irradiation for Triple Negative Breast Cancer Using Proton Beam Scanning,WITHDRAWN,Slow Accrual,NA,INTERVENTIONAL,0,Breast Cancer,,"RADIATION, DEVICE",Cumulative incidence of grade ≥ 3 acute dermatitis,2017-12-07,2019-10-23,Massachusetts General Hospital,OTHER
NCT00754637,Microplasty Tibial Tray Data Collection,Microplasty Tibial Tray Multi-Center Data Collection,WITHDRAWN,The study was withdrawn because it no longer fit the business need.,,OBSERVATIONAL,0,Joint Disease,,,Knee Society Score,2009-12,2023-06,Zimmer Biomet,INDUSTRY
NCT02472639,Impact of Ostom-i Alert Sensor on Quality of Life in Patients With Ileostomy,Impact of Ostom-i Alert Sensor on Quality of Life in Patients With Ileostomy,TERMINATED,Patient compliance issues,NA,INTERVENTIONAL,7,Ostomy,,"DEVICE, OTHER",Patient Quality of Life as Measured by the 20-item Stoma-QOL Questionnaire at 1 Month and 3 Month Follow-up After Using the Ostomi-I Alert Versus Standard Stoma Care Without the Ostom-i Alert.,2015-06-10,2016-05-26,Cedars-Sinai Medical Center,OTHER
NCT04770181,New Mothers Alpha-Stim,Effects of Cranial Electrotherapy Stimulation on Psychological Distress and Maternal Functioning in New Mothers During the Postpartum Period,WITHDRAWN,No participants were enrolled and will not be restarted.,NA,INTERVENTIONAL,0,"Anxiety, Depression, Insomnia, Sleep Quality",,"DEVICE, DEVICE",To measure the effect of CES on anxiety in new mothers during the postpartum period.,2024-11,2026-08,"Christina Murphey, RN, PhD",INDIV
NCT04311112,Safety and Efficacy of Zuretinol Acetate in Subjects With Inherited Retinal Disease,Safety and Efficacy of Zuretinol Acetate Oral Solution in Subjects With Inherited Retinal Disease Caused by Mutations in Retinal Pigment Epithelium Protein 65 or Lecithin:Retinol Acyltransferase,WITHDRAWN,The asset was transferred to another company,"PHASE2, PHASE3",INTERVENTIONAL,0,Retinal Disorder,"Placebos, ZA Low dose, ZA high dose","DRUG, DRUG, DRUG",Change in functional vision at Week 12 using a visual navigation course at different ambient illumination levels,2020-12,2023-09,Retinagenix Holdings,INDUSTRY
NCT00247130,Comparison of Intravenous Omeprazole to Ranitidine on Recurrent Bleeding After Endoscopic Treatment of Bleeding Ulcer,"A Prospective, Randomized Trial Comparing the Effect of Intravenous Omeprazole to That of Intravenous Ranitidine on the Maintenance of Hemostasis After Successful Endoscopic Treatment of Bleeding Peptic Ulcer",WITHDRAWN,Superiority of iv omeprazole to ranitidine has already been proven by others.,PHASE4,INTERVENTIONAL,0,Peptic Ulcers,"Omeprazole, Ranitidine","DRUG, DRUG",No evidence of hemorrhage or vessel exposure on a second endoscopy,2005-10,2007-07,Keio University,OTHER
NCT00563628,Changes in Macular Thickness After Patterns Scan Laser,Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Macular Edema Post Treatment.,TERMINATED,Undefined,PHASE4,INTERVENTIONAL,8,"Non Proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy",,DEVICE,Retinal thickness after treatment,2007-10,2008-02,Asociación para Evitar la Ceguera en México,OTHER
NCT02722928,Ventilation With High Oxygen Content and Postoperative Pneumocephalus,Impact of Intraoperative Ventilation With High Oxygen Content to Reduce the Incidence and Extent of Postoperative Pneumocephalus in Patients Undergoing Craniotomies,TERMINATED,Variability of the pneumocephalus volume mean was higher than initially assumed,NA,INTERVENTIONAL,100,Pneumocephalus,,OTHER,"Volume of Postoperative Pneumocephalus, Occurrence of Postoperative Pneumocephalus",2015-08,2018-12-26,Ohio State University,OTHER
NCT02597465,"A Randomized, Open-Label, Comparative, Parallel-Group, Multicenter Study of SPARC1507","A Randomized, Open-Label, Comparative, Parallel-Group, Multicenter Study of SPARC1507 in Subjects With Cancer",WITHDRAWN,Sponsor decided not to initiate the study for alternate commercial strategy,PHASE3,INTERVENTIONAL,0,Advanced Biliary Tract Cancer,"SPARC1507, Reference1507","DRUG, DRUG","Progression Free Survival (PFS) of subjects treated with SPARC1507 versus IC, per Response Evaluation Criteria in Solid Tumors version 1.1",2018-12-01,2019-12-01,Sun Pharma Advanced Research Company Limited,INDUSTRY
NCT05929300,A Yoga Program for Patients Undergoing Prostate Cancer Surgery,Developing and Pilot-testing a Yoga Program to Address Post-prostatectomy Side-effects Among Veterans With Prostate Cancer,WITHDRAWN,Lack of recruitment,NA,INTERVENTIONAL,0,"Prostate Cancer, Erectile Dysfunction, Urinary Incontinence",,"BEHAVIORAL, OTHER","Change in level of erectile dysfunction from baseline to 4-weeks of pre-habilitation yoga and to 8-weeks of rehabilitation yoga, Change in level of urinary incontinence from baseline to 4-weeks of pre-habilitation yoga and to 8-weeks of rehabilitation yoga",2023-10-18,2024-09-04,VA Office of Research and Development,FED
NCT05365100,A Study of BN102 in Patients With Previously Treated CLL/SLL and B-cell NHL,A Multicenter Phase 1/2 Clinical Study to Evaluate the Safety and Efficacy of BN102 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and B-cell Non-Hodgkin's Lymphoma (NHL),WITHDRAWN,Due to company decision,"PHASE1, PHASE2",INTERVENTIONAL,0,"CLL/SLL, NHL",BN102,DRUG,"Number of Participants with Adverse Events and Clinical Laboratory Abnormalities, To assess the preliminary anti-tumor activity of BN102 based on Overall response rate(ORR) assessed by the Investigator",2022-07,2024-07-30,BioNova Pharmaceuticals (Shanghai) LTD.,INDUSTRY
NCT02477800,221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease,"A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease",TERMINATED,Study was discontinued based on futility analysis done and not based on safety concerns. Follow-up visits and closing out study activities are completed,PHASE3,INTERVENTIONAL,1653,Alzheimer's Disease,"Aducanumab (BIIB037), Aducanumab (BIIB037), Placebo","DRUG, DRUG, DRUG",Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) Score at Week 78,2015-08-13,2019-08-08,Biogen,INDUSTRY
NCT03888807,Biofreeze® vs. a Placebo on Knee Osteoarthritis Walking Gait Characteristics and Pain,The Effect of Biofreeze® vs. a Placebo on Knee Osteoarthritis Walking Gait Characteristics and Pain,TERMINATED,Decided not go move forward with this population as recruitment was difficult,PHASE4,INTERVENTIONAL,6,Knee Osteoarthritis,"Biofreeze, Placebo","DRUG, DRUG","Change in Numeric Pain Rating Scale, Change in Knee Flexion, Change inHip Flexion, Change in Step Length",2018-03-01,2024-07-31,Sport and Spine Rehab Clinical Research Foundation,OTHER
NCT03509207,Vorinostat (SAHA) in Uterine Sarcoma,A Pilot Study of Peroral Vorinostat (SAHA) in Patients With Refractory Histone Deacetylase-positive Uterine Sarcoma,TERMINATED,"The early termination was NOT due to safety reasons, terminated because of the very slow recruitment and problematic access to the study medication in Europe",PHASE2,INTERVENTIONAL,3,"Leiomyosarcoma, Endometrial Stromal Tumors, Carcinosarcomas Uterine",Vorinostat Oral Capsule,DRUG,Progression-free Survival (PFS),2017-12-14,2019-02-04,Medical University of Graz,OTHER
NCT03523507,fMRI-neuronavigated rTMS Treatment for Symptoms of Depression Associated With Concussive TBI in the Military Population,"A Randomized, Sham-controlled, Double-blinded Study of Bilateral Prefrontal Individual Connectome-targeted Repetitive Transcranial Magnetic Stimulation to Treat the Symptoms of Depression Associated With Concussive Traumatic Brain Injury.",TERMINATED,Study terminated due to COVID-19 restrictions,NA,INTERVENTIONAL,10,"Traumatic Brain Injury, Concussion, Mild, Depressive Symptoms",,"DEVICE, DEVICE",Improvement in Depressive Symptoms,2019-07-01,2020-10-27,Henry M. Jackson Foundation for the Advancement of Military Medicine,OTHER
NCT04708236,A Study of ORTD-1 in Patients Hospitalized With COVID-19 Related Pneumonia,"A Blinded, Controlled, Escalating Dose Study of ORTD-1 for Treatment of Hospitalized Patients With SARS-CoV-2 (COVID-19) Related Pneumonia.",WITHDRAWN,recruitment,"PHASE1, PHASE2",INTERVENTIONAL,0,COVID-19,"ORTD-1 low dose, ORTD-1 mid dose, ORTD-1 high dose","DRUG, DRUG, DRUG, OTHER","Incidence of adverse events, Incidence of laboratory abnormalities, Incidence of anti-drug antibodies",2021-04,2021-07,"Oryn Therapeutics, LLC",INDUSTRY
NCT04935411,Russian Registry of Patients With nAMD,Russian Registry of Patients With Neovascular Age-Related Macular Degeneration (nAMD),TERMINATED,"Enough participants were included, which made it possible to answer the objectives of the study.",,OBSERVATIONAL,2665,Neovascular Age-Related Macular Degeneration,,OTHER,"Number of patients by gender, Age at the diagnosis, Percentage of patients with comorbidities and concomitant procedures and medications, Patients with unilateral or bilateral disease, Time from diagnosis to entry to the registry, Social Characteristics (Working and Disability status), Visual acuity, Presence of edema and/or neuroepithelium detachment and/or pigment epithelium detachment, Presence of macular atrophy, Central retinal thickness, Fluid type, Indication for intravitreal anti-VEGF therapy",2020-12-20,2022-12-05,Novartis Pharmaceuticals,INDUSTRY
NCT06488911,To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and Bezafibrate,"A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects With Primary Biliary Cholangitis",TERMINATED,Intercept made a business decision to terminate the study based on FDA's request for voluntary withdrawal of Ocaliva and the issuance of clinical hold on studies under US IND involving OCA.,PHASE3,INTERVENTIONAL,63,Primary Biliary Cholangitis,FDC tablet (OCA 5 mg + BZF 400 mg SR),DRUG,Number of participants reporting adverse events (AE) and serious adverse event (SAE),2024-07-01,2025-10-21,Intercept Pharmaceuticals,INDUSTRY
NCT02057211,Mesenchymal Stem Cells to Intervene in the Development of Type 1 Diabetes: a Blinded Randomized Study,Mesenchymal Stem Cells to Intervene in the Development of Type 1 Diabetes: a Blinded Randomized Study,TERMINATED,Changed regulations of culture procedure,PHASE2,INTERVENTIONAL,10,Type 1 Diabetes Mellitus,autologous mesenchymal stem cell transplantation,"BIOLOGICAL, PROCEDURE",∆-change of C-peptide Area Under the Curve (AUC) (0-120 min) for a mixed meal tolerance test at two year follow-up when compared to pre-treatment values at enrolment.,2014-04,2017-11,Uppsala University Hospital,OTHER
NCT04172844,"Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia","A Multisite Phase Ib Study of Pevonedistat, Azacitidine (or Decitabine), and Venetoclax (PAVE) for the Treatment of Patients With Acute Myelogenous Leukemia (AML)",TERMINATED,Takeda P3001 study didn't meet primary endpoint of improvement in event-free survival. There is no regulatory path forward for pevonedistat.,PHASE1,INTERVENTIONAL,16,Acute Myelogenous Leukemia,"Azacitidine, Venetoclax, Pevonedistat","DRUG, DRUG, DRUG","Recommended phase 2 dose of pevonedistat when co-administered with azacitidine and venetoclax in patients with AML., The toxicity profile of pevonedistat, azacitidine, and venetoclax combination therapy.",2020-01-13,2022-02-27,Medical College of Wisconsin,OTHER
NCT03771144,Anatomopathology of the Subscapularis and Infraspinatus Muscles in Children With Brachial Plexus Obstetric Paralysis,Anatomopathology of the Subscapularis and Infraspinatus Muscles in Children With Brachial Plexus Obstetric Paralysis,TERMINATED,Investigator's decision,NA,INTERVENTIONAL,7,Brachial Obstetrical Palsy,,PROCEDURE,quantity of fibrosis on tissue muscle,2019-06-11,2020-06-23,"University Hospital, Montpellier",OTHER
NCT06502444,Moving Forward Together 2.0: An Activity Intervention,Moving Forward Together 2.0: An Activity Intervention,WITHDRAWN,An insufficient number of prospective volunteers provided informed consent to provide a fair test of whether the intervention would be effective. More people were needed to make shared online feedback and support a useful component.,NA,INTERVENTIONAL,0,"Activity, Motor, Emotion Regulation",,BEHAVIORAL,"Global Physical Activity Questionnaire, Post-traumatic Stress Disorder Checklist-Civilian (PCL-C):, Positive and Negative Affect Schedule (PANAS), Emotion Regulation Questionnaire (ERQ), Program acceptability measure., Physical activity progress., Affect Grid (Russell et al., 1989).",2024-08-01,2024-11-20,Rosalind Franklin University of Medicine and Science,OTHER
NCT00356434,A Comparison of Sequential Compression Devices and Foot Pumps in the Obstetric Population,Study of Patient Compliance and Comfort Using Sequential Compression Devices and Foot Pumps for DVT Prevention,TERMINATED,PI assigned to a different hospital;difficulty recruiting patients,NA,INTERVENTIONAL,11,Thrombophilia,,"DEVICE, DEVICE","Comfort Level, Patient Compliance",2008-11,2009-12,Johns Hopkins University,OTHER
NCT01254734,Transoral Robotic Surgery in Treating Patients With Benign or Stage I-IV Head and Neck Cancer,Outcomes in Transoral Robotic Microsurgery for Head and Neck Tumors,TERMINATED,The study will be rewritten as a data registry study,NA,INTERVENTIONAL,7,"Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Stage I Adenoid Cystic Carcinoma of the Oral Cavity, Stage I Lymphoepithelioma of the Nasopharynx, Stage I Lymphoepithelioma of the Oropharynx, Stage I Mucoepidermoid Carcinoma of the Oral Cavity, Stage I Squamous Cell Carcinoma of the Hypopharynx, Stage I Squamous Cell Carcinoma of the Larynx, Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage I Squamous Cell Carcinoma of the Nasopharynx, Stage I Squamous Cell Carcinoma of the Oropharynx, Stage I Verrucous Carcinoma of the Larynx, Stage I Verrucous Carcinoma of the Oral Cavity, Stage II Adenoid Cystic Carcinoma of the Oral Cavity, Stage II Lymphoepithelioma of the Nasopharynx, Stage II Lymphoepithelioma of the Oropharynx, Stage II Mucoepidermoid Carcinoma of the Oral Cavity, Stage II Squamous Cell Carcinoma of the Hypopharynx, Stage II Squamous Cell Carcinoma of the Larynx, Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage II Squamous Cell Carcinoma of the Nasopharynx, Stage II Squamous Cell Carcinoma of the Oropharynx, Stage II Verrucous Carcinoma of the Larynx, Stage II Verrucous Carcinoma of the Oral Cavity, Stage III Adenoid Cystic Carcinoma of the Oral Cavity, Stage III Lymphoepithelioma of the Nasopharynx, Stage III Lymphoepithelioma of the Oropharynx, Stage III Mucoepidermoid Carcinoma of the Oral Cavity, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Verrucous Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Lymphoepithelioma of the Nasopharynx, Stage IV Lymphoepithelioma of the Oropharynx, Stage IV Mucoepidermoid Carcinoma of the Oral Cavity, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity",,"PROCEDURE, OTHER, PROCEDURE","Assessment of the feasibility of Transoral Robotic Surgery (TORS) in improving transoral accessibility within the upper aerodigestive tract in patients with benign or malignant head and neck tumors, Assessment of the total operative time to perform transoral surgery using TORS in patients with benign or malignant head and neck tumors, Assessment of blood loss during transoral surgery using TORS in patients with benign or malignant head and neck tumors, Assessment of hospitalization time of in patients with benign or malignant head and neck tumors undergoing transoral surgery using TORS, Assessment of the need to convert to an open procedure during transoral surgery using TORS in patients with benign or malignant head and neck tumors, Assessment of complications of transoral surgery using TORS in patients with benign or malignant head and neck tumors",2011-04,2014-11,City of Hope Medical Center,OTHER
NCT02661334,Measuring Uniformed Servicemembers' Fitness Scores on Creatine Loading and Exercise,Measuring Uniformed Servicemembers' Fitness Scores on Creatine Loading and Exercise (MUSSCLE),TERMINATED,Failure to recruit,NA,INTERVENTIONAL,6,Physical Fitness,,"DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT","Determine the effect of creatine supplementation on anaerobic performance in the PFT by measuring change in repetitions of push-ups and sit-ups., Determine the effect of creatine supplementation on aerobic performance in the PFT by measuring change in 1.5 mile run time., Determine the effect of creatine supplementation on body composition as it relates to the PFT by measuring change in abdominal circumference",2015-08-01,2018-02-13,David Grant U.S. Air Force Medical Center,FED
NCT00216164,Rituximab and Gemcitabine for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma,Phase II Study of Rituximab and Gemcitabine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Hoosier Oncology Group LYM03-64,TERMINATED,Study terminated due to lack of response at the first efficacy analysis,PHASE2,INTERVENTIONAL,8,"Lymphoma, B-Cell","Rituximab, Gemcitabine","DRUG, DRUG",· Evaluate response rates to the rituximab plus gemcitabine treatment combination in patients with relapsed or refractory DLBCL.,2005-04,2007-03,Hoosier Cancer Research Network,OTHER
NCT00848809,Pharmacokinetics of Vancomycin in the ICU in Renal Replacement Therapy,Pharmacokinetics of Vancomycin in Various Modalities of Renal Replacement Therapy in the Intensive Care Unit,WITHDRAWN,PI had difficult enrollment.,,OBSERVATIONAL,0,Acute Kidney Injury,,"PROCEDURE, PROCEDURE",To determine the effect of different types of renal replacement therapies on the elimination and volume of distribution of vancomycin.,2008-12,2009-04,Avera McKennan Hospital & University Health Center,OTHER
NCT02377609,To Validate an Analytical Method to Measure Concentration of Tacrolimus in Blood Taken From Finger Pricks,Cross-validation of the Finger Prick Dried Blood Spot Assay Method With the Established Whole Blood Method for Quantitative Determination of Tacrolimus Blood Concentrations in Transplant Patients,TERMINATED,DBS method not be validated against the standard of care venepuncture method due to quality of blood sample and variable tacrolimus extraction,,OBSERVATIONAL,108,"Validation, Dried Blood Spot, Transplant Patients",Tacrolimus,DRUG,"Cross-validate the dried blood spot (DBS) method by defining the relationship between tacrolimus concentrations determined via DBS method, with those determined using the established and validated whole blood method",2013-10,2014-09,Astellas Pharma Europe Ltd.,INDUSTRY
NCT04044209,"A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS","A Phase II of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS",WITHDRAWN,No patients were able to be screened nor enrolled.,PHASE2,INTERVENTIONAL,0,"Myelodysplastic Syndromes, Acute Myeloid Leukemia","AG-120, Nivolumab","DRUG, DRUG","Overall response rate, Change in duration of response",2020-02-12,2023-09,Yale University,OTHER
NCT03417999,Pharmacokinetic Study of Intranasal Dexmedetomidine in Pediatric Patients With Congenital Heart Disease,Dose Escalation Pharmacokinetic Study of Intranasal Atomized Dexmedetomidine in Pediatric Patients With Congenital Heart Disease,TERMINATED,"All subjects who were enrolled completed the study. However, the PI left the institution and the study was terminated before all cohorts were enrolled.",PHASE1,INTERVENTIONAL,28,"Dexmedetomidine, Congenital Heart Disease",Dexmedetomidine,DRUG,"Number of Samples Obtained Per Subject, Time of Peak Drug Concentration Level of Dexmedetomidine, Serum Drug Concentration Levels of Dexmedetomidine, Dose-limiting Toxicities (DLT) and/or Maximum Plasma Level > 1000 pg/mL",2018-06-14,2021-10-12,Children's Hospital of Philadelphia,OTHER
NCT03632109,Gent for Pharyngeal Gonorrhea (GC),Gentamicin for Pharyngeal Gonorrhea - A Demonstration Study,TERMINATED,Efficacy,"PHASE2, PHASE3",INTERVENTIONAL,13,Pharyngeal Gonococcal Infection,gentamicin 360mg IM,DRUG,Cure Rate Defined as the Percentage of Persons With Pharyngeal Gonorrhea Treated With Gentamicin 360mg IM Who Have a Negative Culture 4-7 Days Following Treatment,2018-09-17,2019-03-12,University of Washington,OTHER
NCT02737709,Paclitaxel Detection in NSCLC Treated With TC Regimen,"A Clinical Experience Trial to Detect the Plasma Paclitaxel Drug Concentration in Chinese Non -Small Cell Lung Cancer (NSCLC) Patients Treated With a Paclitaxel Plus Carboplatin (TC) Regimens, and Explore Individualized Treatment Using Pharmacokinetically-guided Dosing Strategy",TERMINATED,The study have difficulty in recruiting subjectes,PHASE2,INTERVENTIONAL,51,Non-small Cell Lung Cancer,Paclitaxel and Carboplatin regimen,DRUG,Change of tumor sizes from baseline,2016-03,2018-10-25,Sun Yat-sen University,OTHER
NCT05808309,Identification of Genomic Biomarkers for Rheumatoid Arthritis With Late Onset,Identification of Genomic Biomarkers for Rheumatoid Arthritis With Late Onset,WITHDRAWN,No funding,,OBSERVATIONAL,0,Rheumatoid Arthritis,,OTHER,"Genomic signature for late onset rheumatoid arthritis, Gene expression for late onset rheumatoid arthritis",2025-05-28,2028-01-01,Centre Hospitalier Sud Francilien,OTHER
NCT06577337,Single and Multiple Ascending Doses of M5542 Administered in Healthy Volunteers,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of Single and Multiple Ascending Doses of M5542 Administered Subcutaneously in Healthy Participants",SUSPENDED,Sponsor decision,PHASE1,INTERVENTIONAL,54,Healthy,"M5542, Placebo","BIOLOGICAL, BIOLOGICAL","Part A: Number of Participants with Treatment-Emergent Adverse Events (TEAEs), Part B: Number of Participants with Treatment-Emergent Adverse Events (TEAEs), Part A: Number of Participants with Abnormal Laboratory Assessments, 12-Lead Electrocardiogram (ECG), and Vital Signs, Part B: Number of Participants with Abnormal Laboratory Assessments, 12-Lead Electrocardiogram (ECG), and Vital Signs",2024-09-12,2028-03-31,"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany",INDUSTRY
NCT01278745,Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation,Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation (CTOT-11),TERMINATED,Due to inability to meet accrual goals within the funding period,PHASE2,INTERVENTIONAL,362,"Cardiac Allograft Vasculopathy, Heart Transplant Recipients","Rituximab induction/conventional immunosuppression (tacrolimus, MMF, and steroid taper), Rituximab placebo/conventional immunosuppression (tacrolimus, MMF, and steroid taper)","BIOLOGICAL, DRUG",Change in Percent Atheroma Volume (PAV),2011-09,2015-10,National Institute of Allergy and Infectious Diseases (NIAID),NIH
NCT05363839,"To Assess the Safety, Tolerability and Pharmacokinetics of ACH-000029 in Healthy Subjects","A Phase 1, Single-center, Placebo-controlled, Double-blind, Randomized Trial to Assess the Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of ACH-000029 in Healthy Subjects",TERMINATED,"Based on the unblinded clinical data, the trial was terminated.",PHASE1,INTERVENTIONAL,8,Healthy Volunteers,"ACH-000029, Placebo","DRUG, DRUG","Number (%) of subjects experiencing orthostatic hypotension at any timepoint, Maximum change in timepoint-matched systolic blood pressure and diastolic blood pressure., Maximum change in timepoint-matched resting heart rate., Assessment of abnormal clinical laboratory tests (Hemoglobin & mean corpuscular hemoglobin concentration), Assessment of abnormal clinical laboratory tests (Hematocrit), Assessment of abnormal clinical laboratory tests (Mean corpuscular volume), Assessment of abnormal clinical laboratory tests (RBC count), Assessment of abnormal clinical laboratory tests (WBC count (absolute and differential)), Assessment of abnormal clinical laboratory tests (Platelets), Assessment of abnormal clinical laboratory tests (Mean platelet volume), Assessment of abnormal clinical laboratory tests (Anion gap, bicarbonate, calcium, chloride, cholesterol, glucose, magnesium, potassium, sodium, creatinine, uric acid, triglycerides, urea), Assessment of abnormal clinical laboratory tests (Lactate Dehydrogenase (LDH), Alanine Transaminase (ALT), gamma-glutamyl transferase (GGT), Alkaline phosphatase (ALP) , aspartate aminotransferase (AST), phosphatase, creatinine phosphokinase), Assessment of abnormal clinical laboratory tests (Albumin), Assessment of abnormal clinical laboratory tests (Glomerular filtration rate), Assessment of abnormal clinical laboratory tests (Globulin), Assessment of abnormal clinical laboratory tests (Total bilirubin), Assessment of abnormal clinical laboratory tests (Total protein), Coagulation, Assessment of abnormal Urinalysis (Bilirubin, blood, glucose, ketones, nitrites, protein), Assessment of abnormal Urinalysis (Leukocyte esterase), Assessment of abnormal Urinalysis (Microscopic analysis), Assessment of abnormal Urinalysis (pH), Assessment of abnormal Urinalysis (Specific gravity), Assessment of abnormal Vital signs (temperature), Assessment of abnormal Vital signs (respiratory rate), Assessment of abnormal Vital signs (blood pressure), Assessment of abnormal Vital signs (heart rate), Assessment of Physical examinations (height), Assessment of Physical examinations (weight), Assessment of Physical examinations (BMI), Assessment of Physical examinations, Assessment of Neurological examinations, 12-lead ECG assessment of PR interval, 12-lead ECG assessment of QRS duration, 12-lead ECG assessment of QT interval, 12-lead ECG assessment of QTc, C-SSRS, Monitoring of adverse events, Pharmacokinetic assessment 1, Pharmacokinetic assessment 2, Pharmacokinetic assessment 3, Pharmacokinetic assessment 4, Pharmacokinetic assessment 5, Pharmacokinetic assessment 6, Pharmacokinetic assessment 7, Pharmacokinetic assessment 8, Pharmacokinetic assessment 9, Pharmacokinetic assessment 10, Pharmacokinetic assessment 11",2022-05-06,2022-11-02,Syneos Health,OTHER
NCT00667277,Phase II Study of Bevacizumab (Avastin®) in Myelofibrosis,Phase II Study of Bevacizumab (Avastin®) in Myelofibrosis,TERMINATED,lack of response activity in the setting of an unacceptable toxicity profile,PHASE2,INTERVENTIONAL,13,Myelofibrosis,bevacizumab (Avastin),DRUG,Reason for Therapy Discontinuation,2008-03,2010-03,Ronald Hoffman,OTHER
NCT01506401,The Oscillation for Acute Respiratory Distress Syndrome (ARDS) Treated Early (OSCILLATE) Trial,The Oscillation for ARDS Treated Early (OSCILLATE) Trial,TERMINATED,Enrolment halted by Steering Committee on advice from Data Monitoring Committee.,PHASE3,INTERVENTIONAL,548,Acute Respiratory Distress Syndrome (ARDS),,"DEVICE, PROCEDURE",All-cause hospital mortality,2009-06,2012-09,Canadian Critical Care Trials Group,OTHER
NCT03055481,A Trial of the Irradiance Level of Phototherapy for Neonatal Jaundice,A Prospective Multicenter Non-inferiority Randomized Controlled Trial of the Irradiance Level of Phototherapy for Neonatal Jaundice,TERMINATED,it was estimated that the recruitment of the planned number of patients could not be completed within further 5 years.,NA,INTERVENTIONAL,100,Neonatal Jaundice,,"OTHER, OTHER",Retreatment rate of neonatal jaundice,2017-07-01,2022-01-31,Nagoya University,OTHER
NCT02028312,"A Phase IV, Randomized, Parallel Group, Investigator-Masked Evaluation of the Effect of Loteprednol Etabonate Ophthalmic Gel 0.5% on the Initiation of Dry Eye Treatment With Restasis®",,WITHDRAWN,Per Sponsor,PHASE4,INTERVENTIONAL,0,Dry Eye Disease,"Loteprednol etabonate, Artificial Tears, Restasis","DRUG, DRUG, DRUG",Fluorescein corneal staining scores,2014-01,2016-06,"Edward Holland, MD",OTHER
NCT02995512,Mechanistic Effects of Colchicine in Patients With Myocardial Infarction,"Mechanistic Effects of Colchicine in Patients With Myocardial Infarction A Single Center Phase 4 Single Arm Open-label Study Evaluating the FDA-approved Drug, Colchicine, at the FDA-approved Gout Dose in Patients With Myocardial Infarction",WITHDRAWN,feasibility,PHASE4,INTERVENTIONAL,0,Myocardial Infarction,Colchicine 0.6 mg tablets,DRUG,Number of neutrophils adherent to TNFα-stimulated endothelial cells,2017-05-01,2018-09-12,NYU Langone Health,OTHER
NCT05779228,Visual Mode Switching in Color Perception,Visual Mode Switching in Color Perception,WITHDRAWN,Grant was not funded,NA,INTERVENTIONAL,0,"Perception of Things Changing Color, Adaptive Behavior",,BEHAVIORAL,"Change in unique yellow settings, Change in BOLD functional MRI activity, Change in EEG activity",2026-01-01,2032-02-04,University of Minnesota,OTHER
NCT04310865,Yinhu Qingwen Granula for the Treatment of Severe CoVID-19,"An Adaptive, Randomized, Double-blind, Parallel-controlled Clinical Trial of Yinhu Qingwen Granula for the Treatment of Severe CoVID-19",SUSPENDED,There were no eligible patients with CoVID-19 in the paticipated centers.,"PHASE2, PHASE3",INTERVENTIONAL,116,"COVID-19, Severe Pneumonia, Chinese Medicine","Yinhu Qingwen Granula, Yin Hu Qing Wen Granula(low does)","DRUG, DRUG, OTHER",changes in the ratio of PaO2 to FiO2 from baseline,2021-11,2023-04,Zhong Wang,OTHER
NCT05565092,"Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Study of ALXN1820 in Adult Participants With Sickle Cell Disease","A Phase 2a, Randomized, Open-Label Study to Evaluate Multiple Dosing Regimens of Subcutaneous ALXN1820 in Adult Participants With Sickle Cell Disease",TERMINATED,Sponsor decision to terminate program.,PHASE2,INTERVENTIONAL,2,Sickle Cell Disease (SCD),ALXN1820,DRUG,Number of Participants With Treatment-Emergent Adverse Events and Serious Adverse Events,2023-02-22,2024-01-09,"Alexion Pharmaceuticals, Inc.",INDUSTRY
NCT00652236,Cost of Long Term Disability in Patients With Chronic Non-Specific Low Back Pain,Cost of Long Term Disability in Patients With Chronic Non-Specific Low Back Pain. Three-Year Follow up of a Randomized Trial,TERMINATED,Study was terminated according the study protocol end of 2007,,OBSERVATIONAL,174,Low Back Pain,,OTHER,cost- effectiveness,2006-01,2008-02,Klinik Valens,OTHER
NCT02904265,Efficacy Study of Acetazolamide Versus Diazepam in Continuous Spike and Wave/Landau-Kleffner Syndrome,Non-inferiority Prospective Randomized Trial of Acetazolamide Versus Diazepam in Patients With Continuous Spike and Wave in Sleep (CSWS)/Landau Kleffner Syndrome (LKS),TERMINATED,Lack of enrollment,"PHASE2, PHASE3",INTERVENTIONAL,3,"Landau-Kleffner Syndrome, Status Epilepticus, Electrographic","Diazepam, Acetazolamide","DRUG, DRUG",Short-term Tolerability of Acetazolamide vs Diazepam,2016-09,2019-07-26,Mayo Clinic,OTHER
NCT00637364,High Intensity Focused Ultrasound Tumor Treatment for Pancreatic Cancer Pain,"An Open Label, Non-Randomized, Single-Center, Therapeutic Trial Examining the Feasibility, Safety, and Efficacy of FEP-BY02, a High Intensity Focused Ultrasound Tumor Treatment Device, in Patients With Pancreatic Cancer Pain",SUSPENDED,Sponsor is not proceeding with USA human trial at this time,"PHASE1, PHASE2",INTERVENTIONAL,5,"Pain, Pancreatic Adenocarcinoma, Ductal Adenocarcinoma",,PROCEDURE,"Safety of the FEP-BY02 HIFU system determined by the frequency and severity of adverse events (AEs) categorized and graded for severity according to the Common Terminology Criteria for Adverse Events, Version 3.0 (CTCAE)",2008-03,,CMED HIFU Development Corporation,INDUSTRY
NCT04771299,Assessing the Role of Cariprazine in Improving Cognition in Euthymic Bipolar Patients,"Efficacy of Cariprazine in Improving Cognitive Functioning in Euthymic Patients With Bipolar I Disorder: A Proof of Concept Randomized, Double Blind Placebo Controlled Trial",TERMINATED,Research support no longer available.,PHASE3,INTERVENTIONAL,1,"Bipolar I Disorder, Cognitive Impairment",Cariprazine,"DRUG, OTHER","Improvement in cognitive performance, Improvement in functioning",2021-07-07,2024-09-08,Lakshmi N Yatham,OTHER
NCT00113399,Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery,"A Phase III Trial for Locally Recurrent, Previously Irradiated Head and Neck Cancer: Concurrent Re-Irradiation and Chemotherapy Versus Chemotherapy Alone",TERMINATED,Terminated early due to low accrual.,PHASE3,INTERVENTIONAL,15,Head and Neck Cancer,"filgrastim, cisplatin, docetaxel, fluorouracil, paclitaxel","BIOLOGICAL, DRUG, DRUG, DRUG, DRUG, RADIATION",Overall Survival,2005-04,,Radiation Therapy Oncology Group,NETWORK
NCT03603587,Bioclinical Study of Scalp Photoaging of a Population Male Over 65 Years Old.,Bioclinical Study of Scalp Photoaging of a Population Male Over 65 Years Old. Mono-centric Prospective Study,TERMINATED,Organisation issues,NA,INTERVENTIONAL,1,"Skin Aging, Skin Cancer",,"PROCEDURE, DIAGNOSTIC_TEST, DIAGNOSTIC_TEST, DIAGNOSTIC_TEST, DIAGNOSTIC_TEST, DIAGNOSTIC_TEST, DIAGNOSTIC_TEST, DIAGNOSTIC_TEST",Scalp skin biomarkers,2019-02-14,2019-09-20,Centre Hospitalier Universitaire de Saint Etienne,OTHER
NCT02907619,An Open-label Extension Study To Evaluate Safety Of PF-06252616 In Boys With Duchenne Muscular Dystrophy,"A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY OF PF-06252616 IN BOYS WITH DUCHENNE MUSCULAR DYSTROPHY",TERMINATED,Termination Date: 30Aug2018; Reason for termination: Lack of Efficacy,PHASE2,INTERVENTIONAL,59,Duchenne Muscular Dystrophy,PF-06252616,BIOLOGICAL,"Number of Participants With Dose Reduced or Temporary Discontinuation Due to AEs, Number of Participants With Severe Treatment-Emergent Adverse Events (TEAEs), Number of Participants Who Discontinued From the Study Due to TEAEs, Number of Participants With Laboratory Test Abnormalities (Without Regard to B5161004 Baseline Abnormality) - Hematology, Number of Participants With Laboratory Test Abnormalities (Without Regard to B5161004 Baseline Abnormality) - Coagulation, Number of Participants With Laboratory Test Abnormalities (Without Regard to B5161004 Baseline Abnormality) - Liver Function, Number of Participants With Laboratory Test Abnormalities (Without Regard to B5161004 Baseline Abnormality) - Renal Function, Number of Participants With Laboratory Test Abnormalities (Without Regard to B5161004 Baseline Abnormality) - Electrolytes, Number of Participants With Laboratory Test Abnormalities (Without Regard to B5161004 Baseline Abnormality) - Hormones, Number of Participants With Laboratory Test Abnormalities (Without Regard to B5161004 Baseline Abnormality) - Clinical Chemistry, Number of Participants With Laboratory Test Abnormalities (Without Regard to B5161004 Baseline Abnormality) - Urinalysis, Number of Participants With Laboratory Test Abnormalities (Without Regard to B5161004 Baseline Abnormality) - Fecal Blood, Number of Participants With Data of Serum Ferritin, Serum Iron and % Transferrin Saturation Meeting Categorical Summarization Criteria - B5161004 Baseline, Number of Participants With Significant Results of Physical Examinations Including Nose and Throat Mucosal Examinations, Summary of Pubertal Development by Tanner Stage, Summary of Testicular Volume, Number of Participants With Post-Baseline Vital Signs Data Meeting Categorical Summarization Criteria - B5161004 Baseline, Number of Participants With Post-Baseline Vital Signs Data Meeting Categorical Summarization Criteria - Overall Baseline, Number of Participants With Post-Baseline ECG Data Meeting Categorical Summarization Criteria - B5161004 Baseline, Number of Participants With Post-Baseline ECG Data Meeting Categorical Summarization Criteria - Overall Baseline, Number of Participants With Iron Accumulation Data Meeting Categorical Summarization Criteria, Change From Baseline in Left Ventricular Ejection Fraction (LVEF) by Cardiac MRI - B5161004 Baseline, Change From Baseline in Left Ventricular Ejection Fraction (LVEF) by Cardiac MRI - Overall Baseline, Change From Baseline in Left Ventricular Ejection Fraction (LVEF) by Echocardiogram - B5161004 Baseline, Change From Baseline in Left Ventricular Ejection Fraction (LVEF) by Echocardiogram - Overall Baseline, Bone Age to Chronological Age Ratio, Whole Body and Spine DXA: Bone Mineral Density Z-Score, Height Adjusted Over Time, Number of Participants With Suicidal Ideation or Suicidal Behavior",2016-10-13,2018-11-22,Pfizer,INDUSTRY
NCT05664100,First in Human Safety Study of FX-345 in Adults With Sensorineural Hearing Loss,"A Phase 1b, Prospective, Randomized, Single-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety of FX-345 Administered as a Single Intratympanic Injection in Adults With Acquired Adult-Onset Sensorineural Hearing Loss",TERMINATED,Business reasons,PHASE1,INTERVENTIONAL,6,"Hearing Loss, Sensorineural","FX-345, Placebo","DRUG, DRUG","Number of Participants With Treatment-emergent Adverse Event(s) (TEAEs), Cmax, AUClast, CL/F, Vss, t1/2, Tmax, Elimination rate constant",2022-12-15,2023-04-12,Frequency Therapeutics,INDUSTRY
NCT01579136,Do Home Monitors Improve Blood Pressure Control?,,TERMINATED,Lack of subjects,NA,INTERVENTIONAL,26,"Hypertension, Diabetes Mellitus",,BEHAVIORAL,change in blood pressure over time,2011-12,2012-12,Exempla Saint Joseph Hospital,OTHER
NCT01798836,Oestradiol Pre-treatment in an Ultrashort Flare GnRH Agonist/GnRH Antagonist Protocol in Poor Responders Undergoing IVF,Oestradiol Pre-treatment in an Ultrashort Flare GnRH Agonist/GnRH Antagonist Protocol in Poor Responders Undergoing IVF,TERMINATED,Obtained results were not good. Protocol was proved ineffective.,"PHASE2, PHASE3",INTERVENTIONAL,17,Infertility,,"PROCEDURE, PROCEDURE","Live birth rate, Clinical pregnancy rate",2013-02,2015-02,National and Kapodistrian University of Athens,OTHER
NCT00578344,"Bone Marrow Transplantation, Hemoglobinopathies, SCALLOP","Allogeneic Bone Marrow Transplantation From HLA Identical Related Donors for Patients With Hemoglobinopathies: Hemoglobin SS, Hemoglobin SC, or Hemoglobin SB0/+ Thalassemia",TERMINATED,Terminated due to no new subject enrollment during the last 3 year period.,NA,INTERVENTIONAL,8,"Sickle Cell Disease, Hemoglobin SC","Busulfan, Campath 1H, Cyclophosphamide and MESNA","DRUG, BIOLOGICAL, DRUG","Number of Participants Evaluated for Evidence of Recovery of Organ Function Measured Via MRI or PET Scan., Number of Participants With Pre and Post Transplant PET Scan to Assess Organ Recovery Based on Rate of Acquisition., Number of Participants With Immune Response to Immunization After BMT in Participants With SCD, Hemoglobin SC, or Hemoglobin Sb0/+.",2005-07,2012-07,Tami D. John,OTHER
NCT03803111,Effects of Iron Therapy and Exercise Training in Patients With Heart Failure and Iron Deficiency,A Randomized Trial on Sequential Effects of Iron Therapy and Exercise Training in Patients With Heart Failure and Iron Deficiency,WITHDRAWN,Sponsoring and Screening of first patients was not sufficient,NA,INTERVENTIONAL,0,"Heart Failure With Reduced Ejection Fraction, Exercise Training, Ferric Carboxymaltose","Initial FCM, Subsequent FCM","BEHAVIORAL, DRUG, DRUG, BEHAVIORAL",Exercise capacity (Peak VO2),2021-01-01,2022-03-15,Herzzentrum Bremen,OTHER
NCT01812434,Phosphodiesterase-5 (PDE-5) Inhibition in Heart Transplant Recipients,Evaluation of Phosphodiesterase-5 Inhibition on Endothelial Function in Heart Transplant Recipients,WITHDRAWN,PI Left University,NA,INTERVENTIONAL,0,Cardiac Allograft Vasculopathy,"Sildenafil, Placebo","DRUG, DRUG",Mean change in SAE and in the number of endothelial progenitor cells after 4 weeks of treatment between placebo and sildenafil,2010-10,2015-03,University of Minnesota,OTHER
NCT03732534,Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome,Open-Label Rollover Study for Continuing NBI-98854 Administration for the Treatment of Pediatric Subjects With Tourette Syndrome,TERMINATED,Study stopped early due to investigational drug not meeting primary endpoint in the main study T-Force GOLD (NBI-98854-TS2003); no safety concerns identified.,PHASE2,INTERVENTIONAL,6,Tourette Syndrome,NBI-98854,DRUG,Number of Participants With Treatment-Emergent Adverse Events (TEAEs),2018-10-17,2019-02-18,Neurocrine Biosciences,INDUSTRY
NCT03484234,Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-VII: Sirolimus-eluting (Ultimaster) vs. Everolimus-Eluting Stents (Xience),"A Multi-center, Randomized, Study to Compare the Effectiveness of Sirolimus-eluting Stent (Ultimaster Stent) or Everolimus-eluting Stent (XIience Alpine Stent) for Long Coronary Lesions.",TERMINATED,At sponsor's discretion : The purpose of study is no longer maintained,NA,INTERVENTIONAL,36,"Coronary Artery Disease, Coronary Stenosis",,"DEVICE, DEVICE",In-segment late luminal loss,2018-07-27,2019-09-06,Seung-Jung Park,OTHER
NCT03311334,A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors,"A Phase 1b/2, Multicenter, Open-Label Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors Nivolumab or Pembrolizumab in Adult Patients With Advanced Solid Tumors",TERMINATED,Sponsor's decision to terminate development of the program.,"PHASE1, PHASE2",INTERVENTIONAL,47,"Renal Cell Carcinoma (RCC), Urothelial Carcinoma, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer (PROC), Serous Epithelial Ovarian Cancer, Fallopian Tube Cancer","DSP-7888 Dosing Emulsion, Nivolumab, Pembrolizumab","DRUG, DRUG, DRUG","Number of Patients With Adverse Events and Serious Adverse Events, Determination of the Recommended Phase 2 Dose (RP2D) by Assessing Dose-limiting Toxicities (DLTs)., Phase II: The Objective Response Rate (ORR) of DSP-7888 Dosing Emulsion Administered With Pembrolizumab in Patients With Platinum-resistant Ovarian Cancer (PROC).",2017-12-14,2022-11-29,"Sumitomo Pharma America, Inc.",INDUSTRY
NCT04300764,Gamification to Increase Mobility in the Hospital,Gamification to Increase Mobility in the Hospital,WITHDRAWN,Trial was never launched due to COVID19 pandemic,NA,INTERVENTIONAL,0,"Coronary Artery Disease, Coronary Heart Disease, Hypertension, Diabete Mellitus, Dyslipidemias, Obesity, Heart Failure",,BEHAVIORAL,Change in mean daily step count during hospitalization,2026-01-01,2026-12-31,University of Pennsylvania,OTHER
NCT04820621,Study of the Influence of Liver Function on Blood Concentrations of Runcaciguat in Participants With Different Degrees of Liver Impairment,"Investigation of the Pharmacokinetics, Safety and Tolerability of Runcaciguat in Participants With Hepatic Impairment (Classified as Child Pugh A or B) and in a Control Group of Age-, Weight-, and Gender-matched Participants Following a Single Oral 15 mg Modified Release (MR) Tablet Dose in a Non-randomized, Non-controlled, Non-blinded, Observational Study With Group Stratification",TERMINATED,This study is prematurely terminated due to changes in sponsor's overall development strategy. The decision of termination is not related to any safety concern of the compound.,PHASE1,INTERVENTIONAL,5,Chronic Kidney Disease,Runcaciguat (BAY1101042),DRUG,"Area under the concentration vs. time curve from zero to infinity after single (first) dose (AUC) of BAY1001042, Unbound AUC (AUCu) of BAY1001042, Maximum observed drug concentration in measured matrix after single dose administration (Cmax) of BAY1001042, Unbound Cmax (Cmax,u) of BAY1001042",2021-04-07,2021-07-01,Bayer,INDUSTRY
NCT04093414,Left Bundle Area Versus Selective His Bundle Pacing,"Left Bundle Area Versus Selective His Bundle Pacing (LEFTBASH): Single Center, Open Label, Randomized Pilot Study to Evaluate Capture Thresholds and Acute Echocardiographic Hemodynamic Characteristics",TERMINATED,slow enrollment,NA,INTERVENTIONAL,9,"Bradycardia, Sinus Node Dysfunction, Atrioventricular Block",,DEVICE,"Ventricular Capture Threshold, 3 Months Unipolar or Bipolar",2019-10-07,2022-02-22,"David Haines, MD",OTHER
NCT05214716,FilmArray Pneumonia Panel for Antimicrobial Treatment of HAP/VAP in Intensive Care Units,"Single Center, Randomized, Open Label, Prospective Clinical Trial of BioFire FilmArray Assay for Antimicrobial Treatment of Hospital-acquired or Ventilator-associated Pneumonia in Intensive Care Units",TERMINATED,"Even if the study period was extended, it was expected that the target subjects would not be able to be registered, so the study was terminated early.",NA,INTERVENTIONAL,41,"Pneumonia, Ventilator-Associated, Pneumonia, Hospital Acquired, Critically Ill",,DIAGNOSTIC_TEST,"The proportion of appropriate/optimal early antibiotic regimen, The time to the administration of appropriate antibiotics",2022-07-12,2024-03-21,Kyungmin Huh,OTHER
NCT04413487,Early Detection of Heart Problems in Cancer Patients Receiving Chemotherapy,Strain Echocardiogram in Early Detection of Left Ventricular Dysfunction in Cancer Patients Receiving Chemotherapy,WITHDRAWN,Study never started due to change in standard of care guideline,,OBSERVATIONAL,0,Heart Failure,,OTHER,Change in left ventricular ejection fraction (LVEF),2020-03,2020-05-28,The Guthrie Clinic,OTHER
NCT00923806,Gene Therapy Using Anti-CEA Cells to Treat Metastatic Cancer,Phase I/II Study of Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA) Using Lymphodepleting Conditioning Followed by Infusion of Anti-CEA TCR-Gene Engineered Lymphocytes,TERMINATED,Study was terminated due to poor accrual.,PHASE1,INTERVENTIONAL,3,Metastatic Cancer,"PG13-CEA_TCR (Anti-CEA TCR PBL), Aldesleukin","BIOLOGICAL, DRUG",clinical response of the administration of anti-CEA TCR engineered peripheral blood lymphocytes in patients receiving the non-myeloablative conditioning regimen and aldesleukin in patients with metastatic cancer.,2008-12,2011-11,National Cancer Institute (NCI),NIH
NCT04003233,Limited-efficacy Testing of Spring Distraction System (SDS) and Unilateral One-way Rod (MID-C) for Early Onset Scoliosis,Limited-efficacy Testing of Spring Distraction System (SDS) and Unilateral One-way Rod (MID-C) for Early Onset Scoliosis,WITHDRAWN,Due to the termination of the collaboration of ApiFix ltd. and the UMC Utrecht,NA,INTERVENTIONAL,0,"Early-Onset Scoliosis Deformity of Spine (Disorder), Idiopathic Scoliosis",,"DEVICE, DEVICE","Limited-efficacy of SDS and MID-C in terms of curve correction maintenance: changes in cobb angle, Incidence of Treatment-Emergent Serious Adverse Events of SDS and MID-C",2019-07-01,2022-12-01,UMC Utrecht,OTHER
NCT02581384,"Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors","Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors",TERMINATED,"The study closed primarily due to weak accrual, as well as study design limitations.","PHASE1, PHASE2",INTERVENTIONAL,5,"Ewing Sarcoma, Rhabdomyosarcoma, Wilms Tumor, Osteosarcoma, Non-Rhabdomyosarcoma Soft Tissue Sarcoma, Nos, Renal Tumor, Rhabdoid Tumor, Clear Cell Renal Cell Carcinoma, Sarcoma, Sarcoma, Ewing, Soft Tissue Sarcoma",,RADIATION,"Number of Participants With Dose Limiting Toxicity [Phase I], Overall Response Rate [Phase II]",2017-01,2020-08,Dana-Farber Cancer Institute,OTHER
NCT00520533,Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma,"A Pilot Study of the Safety, Efficacy, and Effects on Functional Imaging of the Combination of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma",TERMINATED,Closed prematurely due to toxicity,PHASE1,INTERVENTIONAL,8,Renal Cell Carcinoma (RCC),"Chimeric monoclonal antibody cG250, Sunitinib malate","BIOLOGICAL, DRUG","Number of Patients With Adverse Events (AEs), Serious Adverse Events (SAEs), Dose Limiting Toxicities (DLTs) or Adverse Events Leading to Discontinuation.",2008-02,2012-09,Ludwig Institute for Cancer Research,OTHER
NCT01280747,Examination of Pregabalin Access for Treatment of Indicated Pain Disorders: the ExPAND Study,Examination of Pregabalin Access for Treatment of Indicated Pain Disorders: the ExPAND Study,TERMINATED,See termination reason in detailed description.,,OBSERVATIONAL,42,"Fibromyalgia, Painful Diabetic Peripheral Neuropathy",,"OTHER, OTHER, OTHER, OTHER","Quantify the between-group difference (baseline to 6 mo.) in direct all-cause medical costs for patients with pDPN and FM in real-world treatment settings with a prior authorization (PA) versus no PA policy in place restricting access to, pregabalin, Evaluate the within-group differences (baseline to 6 mo.) in pain alleviation (using the 11 point numerical rating scale) in patients with pDPN and FM in real-world settings with a PA versus no PA policy in place restricting access to, pregabalin.",2011-01,2012-04,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,INDUSTRY
NCT02680847,Safety and Pharmacokinetic Study of ALO-02 in Children Ages 7-17 With Pain,An Open-label Study To Evaluate The Pharmacokinetics And Safety Of Alo-02 (Oxycodone Hydrochloride And Naltrexone Hydrochloride) Extended-release Capsules In Children And Adolescents 7-17 Years Of Age Who Require Opioid Analgesia,TERMINATED,The trial was terminated on 08FEB2018. Pfizer has decided to withdraw the New Drug Application and has notified FDA. There are no efficacy or safety concerns.,PHASE4,INTERVENTIONAL,32,Moderate-severe Pain,ALO-02,DRUG,"Average Steady-state Concentration (Css, av) of Oxycodone, Apparent Oral Clearance (CL/F) of Oxycodone, Number of Participants With All-causality and Treatment-related Adverse Events (AEs), Number of All-causality and Treatment-related AEs, by Intensity, Number of Participants With All-causality and Treatment-related Serious Adverse Events (SAEs), Number of Participants With Clinical Opiate Withdrawal Scale (COWS)",2016-01-21,2018-01-24,Pfizer,INDUSTRY
NCT03555149,A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC),"A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)",TERMINATED,The Sponsor made the decision to terminate the study due to start up and recruitment issues caused by limited resource availability at the treating centers.,"PHASE1, PHASE2",INTERVENTIONAL,96,Colorectal Cancer,"Regorafenib, Atezolizumab, Imprime PGG, Bevacizumab, Isatuximab, Selicrelumab, Idasanutlin, AB928","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, GENETIC",Best Confirmed Overall Response Rate (ORR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1,2018-09-27,2022-09-26,Hoffmann-La Roche,INDUSTRY
NCT05485038,General Anesthesia Versus Awake Surgery in Resection of Gliomas and Metastases of Motor Areas,"General Anesthesia Versus Awake Surgery in Resection of Gliomas and Metastases of Motor Areas: a Randomised, Controlled Trial",SUSPENDED,technical issues,NA,INTERVENTIONAL,72,"Gliomas Benign, Glioma, Malignant, Metastases to Brain",,"PROCEDURE, PROCEDURE","Composite event of deterioration of early motor function, severe disturbance of consciousness or death from any cause, Dynamics of early motor function (in grades), Dynamics of late motor function (in grades)",2022-09-01,2027-08-31,Sklifosovsky Institute of Emergency Care,OTHER_GOV
NCT02140138,An Open Label Randomised Trial of RNActive® Cancer Vaccine in High Risk and Intermediate Risk Patients With Prostate Cancer,An Open Label Randomised Phase II Trial of RNActive® Cancer Vaccine (CV9104) in High Risk and Intermediate Risk Patients With Prostate Cancer,TERMINATED,Recruitment was terminated after enrolment of 35 instead of 36 evaluable patients for administrative reasons.,PHASE2,INTERVENTIONAL,35,Prostate Carcinoma,CV9104,"BIOLOGICAL, DEVICE",Induction of antigen-specific cellular and humoral immune response to the vaccine antigens.,2014-06,2016-04,CureVac,INDUSTRY
NCT00526838,Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies,"A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL228 Administered Intravenously to Subjects With Advanced Malignancies",TERMINATED,Sponsor decision,PHASE1,INTERVENTIONAL,84,"Cancer, Lymphoma",XL228,DRUG,"To assess the safety and tolerability of XL228 administered as a once-weekly or twice-weekly 1-hour intravenous (IV) infusion in subjects with advanced malignancies., To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of XL228 administered as a once- or twice-weekly 1-hour IV infusion in subjects with advanced malignancies.",2007-09,2010-12,Exelixis,INDUSTRY
NCT01826838,"Study of Dasatinib, Androgen Deprivation Therapy and Radiation","A Phase I Study of Dasatinib, Androgen Deprivation Therapy and Radiation For Intermediate and High Risk Prostate Cancer",WITHDRAWN,Lack of patients,PHASE1,INTERVENTIONAL,0,Prostate Cancer,Dasatinib,DRUG,Maximum tolerated dose of dasatinib with concurrent standard radiation and hormone therapy,2013-01,2013-04,Brown University,OTHER
NCT06093958,Paradoxical Response to Chest Wall Loading in Mechanically Ventilated Patients,"Paradoxical Response to Chest Wall Loading in Mechanically Ventilated Patients: Incidence, Mechanism, and Novel Techniques for Detecting it at the Bedside",WITHDRAWN,Administratively closed by IRB after continuing review was never submitted and no patients enrolled.,NA,INTERVENTIONAL,0,"ARDS, COVID-19, Mechanical Ventilation Pressure High, Ventilator-Induced Lung Injury",,DIAGNOSTIC_TEST,Lung compliance (mL/mmHg),2021-12-01,2022-12-01,HealthPartners Institute,OTHER
NCT00897858,Studying Cerebrospinal Fluid Proteins and Angiogenesis Proteins in Young Patients With Newly Diagnosed Central Nervous System Tumors,Evaluation of Cerebral Spinal Fluid (CSF) Proteome and Angiogenesis Proteins in Children With Newly Diagnosed Central Nervous System Tumors,WITHDRAWN,"This non-therapeutic study was registered in error. The PRS team doesn't delete studies once registered, so they recommended changing the status to Withdrawn",,OBSERVATIONAL,0,Brain and Central Nervous System Tumors,,,"Number of IRB approvals of the study, Number of patients with proteomic data received at the Operations and Biostatistics Center, Number of differentially expressed biomarker proteins",2006-08,,Pediatric Brain Tumor Consortium,NETWORK
NCT00930748,Evaluation of MRI for Prostate Cancer,Evaluation of the Potential of Endorectal MRI for the Staging and Recurrence of Prostate Cancer,TERMINATED,The MRI company forbidded additional scans with endorectal colil in this machine,,OBSERVATIONAL,40,Prostatic Neoplasms,,"DEVICE, DEVICE",• MRI and pathology correlation,2008-11,2011-06,Sheba Medical Center,OTHER_GOV
NCT03045848,Biofreedom Prospective Multicenter Observational Registry,Prospective Multicenter Observational Study for Evaluating Efficacy and Safety of Biofreedom Stent in Patients With Coronary Artery Disease (Biofreedom Registry),TERMINATED,Impossible device delivery because of sponsor change,,OBSERVATIONAL,194,"Coronary Artery Disease Aggravated, Myocardial Ischemia, Myocardial Infarction",,DEVICE,Device-oriented composite end point (TLF),2018-07-05,2020-11-10,Wonju Severance Christian Hospital,OTHER
NCT00728507,Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis,"A Phase II Randomized, Open-label Trial of a Rifapentine Plus Moxifloxacin-Based Regimen for Intensive Phase Treatment of Smear-Positive Pulmonary Tuberculosis",TERMINATED,Funding withdrawn,PHASE2,INTERVENTIONAL,121,Tuberculosis,"Rifapentine, Moxifloxacin, Pyrazinamide, Isoniazid, Isoniazid, Rifampin, Pyrazinamide, Ethambutol","DRUG, DRUG","To Compare, by Treatment Group, the Percentage of Patients With a Negative Sputum Culture at the End of Intensive Phase Therapy., To Compare the Safety and Tolerability of the 2 Intensive Phase Regimens.",2009-11,2013-04,Johns Hopkins University,OTHER
NCT03568292,Virtual Reality in Reducing Pain and Anxiety in Cancer Participants Undergoing Painful Procedures,Effects of Virtual Reality on Pain and Anxiety in Cancer Patients Undergoing Painful Procedures,SUSPENDED,Awaiting new cohort to open,NA,INTERVENTIONAL,60,Malignant Neoplasm,,"OTHER, OTHER, DEVICE, OTHER","Pain as assessed according to a visual analog scale (VAS), Anxiety",2022-03-01,2027-03-01,University of Southern California,OTHER
NCT01283971,A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor,"A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor",TERMINATED,The study was closed due to the slow enrollment rate.,PHASE4,INTERVENTIONAL,96,Rheumatoid Arthritis,"tocilizumab [RoActemra/Actemra], adalimumab, placebo to tocilizumab, placebo to adalimumab, methotrexate, folate","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG",Percentage of Participants With Disease Activity Score 28 Joints (DAS28) Remission at Week 24,2011-05,2012-08,Hoffmann-La Roche,INDUSTRY
NCT03312244,Pyridostigmine as Immunomodulator in People Living With HIV,Study of the Role of Peripheral Acetylcholinesterase Inhibitor Pyridostigmine as Immunomodulators in a Population of Patients Living With Human Immunodeficiency Virus Infection.,SUSPENDED,"Due to COVID-19, effective 3/19/2020 recruitment is halted until further notice",PHASE2,INTERVENTIONAL,60,"HIV-1-infection, CD4+ T Lymphocytopenia, Immune Deficiency, Immuno-senescence","Pyridostigmine Bromide, Placebo","DRUG, DRUG",CD4+ T cell count,2019-07-01,2022-06-30,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,OTHER
NCT02676544,Prostate Embolization for Massive Benign Prostatic Hypertrophy (BPH),Prostate Embolization for Massive Benign Prostatic Hypertrophy (BPH),TERMINATED,Device approved for this use,"PHASE1, PHASE2",INTERVENTIONAL,9,"Benign Prostatic Hypertrophy, Lower Urinary Tract Symptoms",,DEVICE,Clinical Improvement in Lower Urinary Tract Symptoms (LUTS),2015-12,2021-06-30,Rhode Island Hospital,OTHER
NCT04885634,Semaglutide for the Reduction of Arrhythmia Burden in Overweight AF Patients,Semaglutide for the Reduction of Arrhythmia Burden in Overweight and Obese Patients With Atrial Fibrillation (Pilot Study),WITHDRAWN,Not received funding.,PHASE3,INTERVENTIONAL,0,"Atrial Fibrillation, Overweight and Obesity","Semaglutide Injectable Product, Placebo","DRUG, DRUG","Number of Participants to Complete Recruitment, Number of Participants to Complete Follow-up, Total Resource Requirement",2022-10,2024-11,Axel Brandes,OTHER
NCT02604199,"A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection","A Multicenter, Randomized, Double-blind, Placebo-controlled, Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination With Entecavir or Tenofovir in Patients With HBeAg Negative, Chronic Hepatitis B Virus (HBV) Infection",TERMINATED,Company decision to discontinue trial,PHASE2,INTERVENTIONAL,58,Hepatitis B,"ARC-520 Injection, entecavir, tenofovir, antihistamine","DRUG, OTHER, DRUG, DRUG, DRUG",Change From Baseline in Quantitative Hepatitis B Surface Antigen (Log qHBsAg) at Day 113,2015-09,2017-01,Arrowhead Pharmaceuticals,INDUSTRY
NCT01829009,Resistance Exercise Effect on Physical Performance and Functional Status in Sarcopenic Older Women,Resistance Exercise Effect on Physical Performance and Functional Status in Sarcopenic Older Women,WITHDRAWN,Financial issues,NA,INTERVENTIONAL,0,Sarcopenia,,OTHER,Improvement in gait speed and functional status in sarcopenic older women,,,"National Institute of Medical Sciences and Nutrition, Salvador Zubiran",OTHER
NCT01062698,Trial and Cost Effectiveness Evaluation of Intra-arterial Thrombectomy in Acute Ischemic Stroke,The Contribution of Intra-arterial Thrombectomy in Acute Ischemic Stroke in Patients Treated With Intravenous Thrombolysis,TERMINATED,Efficacy,NA,INTERVENTIONAL,412,"Cerebral Stroke, Cerebrovascular Accident",Alteplase (rt-PA)/Actilyse,"DRUG, PROCEDURE",Modified Rankin Score (mRs ),2010-06,2016-03,"Central Hospital, Nancy, France",OTHER
NCT01108263,Use of INTEGRA™ Flowable Wound Matrix to Manage Diabetic Foot Ulcers,"The Use of INTEGRA™ Flowable Wound Matrix to Manage Diabetic Foot Ulcers in High Risk Populations: A Prospective, Randomized, Controlled Trial",TERMINATED,Sponsor Terminated,PHASE4,INTERVENTIONAL,5,"Diabetes, Foot Ulcer",INTEGRA™ Flowable Matrix (Collagen),DRUG,Overall Decrease in Wound Size,2010-06,2011-08,Georgetown University,OTHER
NCT00006121,Oxaliplatin in Treating Women With Advanced or Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy,Phase II Study of Oxaliplatin Single Agent in Patients With Metastatic Breast Cancer After Failure of Anthracycline/Taxane Based Chemotherapy,TERMINATED,low accrual,PHASE2,INTERVENTIONAL,18,Breast Cancer,oxaliplatin,DRUG,,2000-05,,European Organisation for Research and Treatment of Cancer - EORTC,NETWORK
NCT02796521,Evaluation of Effectiveness of Nutritional Practical Counseling for Elderly Patients at Risk of Malnutrition on Nutritional Status at Home,Evaluation of the Effectiveness of Nutritional Practical Counseling for Elderly Patients at Risk of Malnutrition (and Their Caregivers) on Nutritional Status at Home,TERMINATED,no more budget for personal to enrol participants,NA,INTERVENTIONAL,12,Malnutrition,,"OTHER, OTHER",Improvement of nutritional status,2015-03,2017-02,"University Hospital, Grenoble",OTHER
NCT00597116,An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma,"A Randomized Phase II Trial To Evaluate The Efficacy And Safety Of Vandetanib (ZD6474, ZACTIMA ™) Versus Vinorelbine In Patients With Inoperable Or Relapsed Malignant Mesothelioma.",TERMINATED,Recruitment stopped according to early stopping rule (by protocol),PHASE2,INTERVENTIONAL,25,Mesothelioma,"Vinorelbine, Vandetanib","DRUG, DRUG",Number of Participants With Disease Control.,2007-12,2010-01,"Genzyme, a Sanofi Company",INDUSTRY
NCT05453916,Comparing the Efficacy of Nitazoxanide Versus Rifaximin in Adult Patients With Irritable Bowel Syndrome Without Constipation,A Randomized Single-Blind Controlled Trial Comparing the Efficacy of Nitazoxanide Versus Rifaximin in Adult Patients With Irritable Bowel Syndrome Without Constipation,WITHDRAWN,Institutional and funding constrains,"PHASE1, PHASE2",INTERVENTIONAL,0,Irritable Bowel Syndrome With Diarrhea,"Nitazoxanide 500Mg Oral Tablet, Rifaximin 550Mg Tab","DRUG, DRUG",Proportion of Subjects Who Had Adequate Relief of Global IBS Symptoms for at Least 2 of the 4 Weeks During the Primary Evaluation Period,2022-07-01,2024-12-31,Sadat City University,OTHER
NCT04481516,Yoga in NHS Health Care Workers With COVID-19 Related Stress,Effect of Breathing-based Meditation (Sudarshan Kriya Yoga) in NHS Health Care Workers With Possible COVID-19 Related Stress and Anxiety Disorder,WITHDRAWN,Put on hold due to COVID and then withdrawn.,,OBSERVATIONAL,0,Stress,,OTHER,"Alleviated stress 1 - short term, Alleviated stress 2 - short term, Alleviated stress 3 - short term",2020-07-01,2021-12-28,Doncaster And Bassetlaw Hospitals NHS Foundation Trust,OTHER
NCT04187404,"A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma","A Phase 1/2 Trial of a Novel Therapeutic Vaccine (EO2401) in Combination With Immune Check Point Blockade, for Treatment of Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma",TERMINATED,Strategic decision,"PHASE1, PHASE2",INTERVENTIONAL,70,"Adrenocortical Carcinoma, Pheochromocytoma, Paraganglioma","EO2401, Nivolumab","BIOLOGICAL, BIOLOGICAL",Adverse events assessment,2020-07-23,2024-10-02,Enterome,INDUSTRY
NCT03150004,Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients with Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS),A Phase II Study of the Efficacy and Pharmacogenomics of Cladribine-based Salvage Chemotherapy in Patients with Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS),TERMINATED,No longer have funding support to complete the pharmacogenetics component.,PHASE2,INTERVENTIONAL,53,"Acute Myeloid Leukemia, Myelodysplastic Syndrome","Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen, Cladribine and Cytarabine (CLLDAC) Regimen","DRUG, DRUG","CLAG-M Arm: Minimal residual disease (MRD) complete remission (CR), CLLDAC Arm: Minimal residual disease (MRD) complete remission (CR), CLLDAC Arm: Subjects receiving a second cycle., Overall survival, Progression-free survival",2017-06-14,2025-03-14,Medical College of Wisconsin,OTHER
NCT00255684,"Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer",Non-Myeloablative Conditioning and Unrelated Umbilical Cord Blood Transplantation for Children and Adults With Serious Oncohematologic Diseases,TERMINATED,low accrual,NA,INTERVENTIONAL,16,"Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms","graft-versus-tumor induction therapy, cyclophosphamide, cyclosporine, fludarabine phosphate, mycophenolate mofetil","BIOLOGICAL, DRUG, DRUG, DRUG, DRUG, PROCEDURE, RADIATION",Number of Participants Who Survived 100 Days or Longer,2003-12,2016-06,University of Rochester,OTHER
NCT02409433,Comparative Trial of IV Lacosamide Versus Phenytoin for Seizure Management,"Prospective, Randomized, Single-blinded Comparative Trial of IV Lacosamide Versus Phenytoin for Seizure Management",TERMINATED,due to slow recruitment and budgetary restraints study was prematurely terminated,PHASE4,INTERVENTIONAL,3,Seizures,"lacosamide, Phenytoin","DRUG, DRUG",Incidence of Clinical Adverse Events,2014-08,2015-11,London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's,OTHER
NCT02750033,Intraoperative Margin Assessment During Mohs Surgery,Intraoperative Margin Assessment During Mohs Surgery,WITHDRAWN,Protocol changed to meet IRB requirements for patient safety,,OBSERVATIONAL,0,"Squamous Cell Carcinoma (SCC), Basal Cell Carcinoma (BCC)",,DEVICE,Sensitivity and specificity of MMS compared to histopathology during Mohs surgery,2016-10,2017-03,Seton Healthcare Family,OTHER
NCT03931252,Thermic Effect of Feeding in Cystic Fibrosis,Thermic Effect of Feeding in Cystic Fibrosis,WITHDRAWN,Unable to recruit participants,NA,INTERVENTIONAL,0,Cystic Fibrosis,,"DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Energy Expenditure,2022-01,2022-12,Virginia Commonwealth University,OTHER
NCT05065047,Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma,Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma,TERMINATED,\<75% participation,PHASE1,INTERVENTIONAL,6,Multiple Myeloma,Belantamab mafodotin,DRUG,"Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0, Change From Baseline in Pain Scores on the Visual Analog Scale at 6 Weeks",2023-01-05,2025-11-06,M.D. Anderson Cancer Center,OTHER
NCT00652249,Diagnosing Malfunctioning Hydrocephalic Shunt Valves With a Flow Sensor,A Flow Monitor for Pediatric Hydrocephalic Shunts - Study of Flow Sensor With the Shunt Valve,WITHDRAWN,Due to lack of enrollment.,,OBSERVATIONAL,0,Hydrocephalus,,,Volumetric flow of patient cerebrospinal fluid through an Extra-Ventricular Drainage System as a function of the shunt valve pressure release setting and drainage bag position.,2009-03,2010-12,Transonic Systems Inc.,INDUSTRY
NCT02665338,TMS-fMRI for Neural Pathway in Smokers,Repetitive TMS Modulates Dorsal Lateral Prefrontal-Ventral Medial Prefrontal Pathway to Decrease Craving in Smokers,TERMINATED,"We planned to enroll more participants but we could not recruit more participants. In addition, the covid-19 pandemic made the recruitment worse than the previous years.",NA,INTERVENTIONAL,11,Nicotine Dependence,,DEVICE,Changes in fMRI Neural Activation Patterns,2014-04-28,2015-06-16,Xingbao Li,OTHER
NCT01833338,Non-invasive and Invasive Plaque Characterisation,Coronary Artery Plaque Characterisation With Non-invasive Multi-Slice Computed Tomography and Invasive Intravascular Ultrasound and Optical Coherence Tomography in Patients With Acute Coronary Syndromes Without ST-segment Elevation,TERMINATED,The study was terminated based on an included stopping rule in the study protocol,NA,INTERVENTIONAL,30,Non ST Elevation Myocardial Infarction,,DEVICE,Accuracy of detection of thrombus with MSCT as compared to IVUS and OCT will be investigated.,2011-06,2013-05,University Medical Center Groningen,OTHER
NCT02886858,tDCS in the Prevention of Relapse After Electroconvulsive Therapy,tDCS as Continuation Treatment to Sustain Remission After Electroconvulsive Therapy in Depression,TERMINATED,investigator and sponsor decided by mutual agreement to stop study prematurely,NA,INTERVENTIONAL,1,Depression,,"DEVICE, DEVICE","Relapse rate 6 months after remission, defined as the reappearance of a depressive syndrome, measured by a scoring MADRS >15.",2017-02-13,2019-04-19,Hôpital le Vinatier,OTHER
NCT02795338,Multi-modality Localization of Eloquent Brain Function,Multi-modality Localization of Eloquent Brain Function-A Comparison of Technologies for Improved Applicability,WITHDRAWN,Project did not receive funding and was never started,,OBSERVATIONAL,0,Brain Neoplasms,,PROCEDURE,"Location in the brain of the fMRI activations relative to intra-operative brain mapping, Location in the brain of the MEG activations relative to intra-operative brain mapping, Accuracy of fMRI and MEG in pre-operative brain mapping",2018-02-27,2018-02-27,University of Nebraska,OTHER
NCT02928458,Clinical and Financial Impact of an Evidenced-Based Adhesive Small Bowel Obstruction Management Protocol,Clinical and Financial Impact of an Evidenced-Based Adhesive Small Bowel Obstruction Management Protocol,WITHDRAWN,Inadequate enrollment,NA,INTERVENTIONAL,0,Intestinal Obstruction,"Omnipaque, MD-Gastroview","DRUG, DRUG",Compare average length of stay for patients admitted with ASBO prior to and after implementation of this protocol.,2015-09-01,2017-09-13,The Guthrie Clinic,OTHER
NCT04046848,Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia A,Phase 1/2 Study to Assess the Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Previously Treated Adult Patients With Severe Hemophilia A,TERMINATED,Study was terminated due to SADRs,"PHASE1, PHASE2",INTERVENTIONAL,36,Severe Hemophilia A,OCTA101,DRUG,"Patients Experiencing Adverse Events, Participants Experiencing Dose-limiting Toxicities (DLTs), Patients Experiencing Thromboembolic Events, Patients Experiencing Local Injection Site Reactions of Any Grade, Inhibitor Formation to FVIII",2019-07-03,2022-02-18,Octapharma,INDUSTRY
NCT04962048,The Influence of Pulse-synchronized Negative Pressure on the Dermal Microcirculation,The Influence of Pulse-synchronized Negative Pressure on the Dermal Microcirculation,TERMINATED,"Results not goal-oriented, premature termination.",NA,INTERVENTIONAL,4,"Microcirculation, Diabetes",,"DEVICE, OTHER",Change of toleration / wellbeeing due to intervention of PSNP with Numeric Rating Scale,2021-05-28,2022-05-17,Orputec,OTHER
NCT00628355,Lidocaine Injection and Ischemic Compression on Chronic Pelvic Pain Treatment,Local Injection of Lidocaine Versus Ischemic Compression in Treatment of Woman With Chronic Pelvic Pain Caused by Abdominal Myofascial Pain Syndrome: Randomized Clinical Trial.,TERMINATED,Lidocaine injection group showed significant improvement in pain,PHASE4,INTERVENTIONAL,30,Pelvic Pain,lidocaine,"DRUG, PROCEDURE","Intensity of Pain, Clinical Response Rate",2008-02,2010-03,University of Sao Paulo,OTHER
NCT03620500,Balance in Children With Cochlear Implants,Balance and Vestibular Impairments in Children With Cochlear Implantation,WITHDRAWN,No participants enrolled,,OBSERVATIONAL,0,"Cochlear Implants, Sensory-Neural Hearing Loss, Balance Disorder",,BEHAVIORAL,Change in the Peabody Developmental Motor Scales,2018-08-03,2023-08-03,Vanderbilt University Medical Center,OTHER
NCT00250692,A Study to Test the Pain-relieving Effect of Laughing Gas in Infants,Analgesic Effect of Nitrous Oxide in Neonates Undergoing Heel Stick,WITHDRAWN,unknown - no record of study conduct in departmental archive,PHASE3,INTERVENTIONAL,0,Analgesic Affect,Nitrous Oxide,DRUG,"NIPS scale, salivary cortisol level",,,"University of California, Los Angeles",OTHER
NCT02062892,Differentiating Everolimus Versus Sirolimus in Combination With Calcineurin Inhibitors in Kidney Transplant Patients,Differentiating Sirolimus and Everolimus in Combination With Calcineurin Inhibitors in Long-term Maintenance of Kidney Transplant Patients - The Effects on Vascular Endothelial and Kidney Function. The DESIRE Study.,WITHDRAWN,Patients meeting the inclusion/ exclusion criteria did not agree to participate. It became obvious that recruitment goals could not be met.,PHASE4,INTERVENTIONAL,0,Kidney Transplantation,"Everolimus, Sirolimus","DRUG, DRUG","Creatinine Outcome Measure (1), Calculated Glomerular Filtration Rate (1), Calculated Glomerular Filtration Rate (2), Kidney Injury Molecule-1 (1), Kidney Injury Molecule-1 (2), S-Adenosylhomocysteine Hydrolase (1), S-Adenosylhomocysteine Hydrolase (2), S-Adenosylmethionine (1), S-Adenosylmethionine (2), Creatinine Outcome Measure (2)",2013-12,2014-06,"University of Colorado, Denver",OTHER
NCT04025892,Pregnancy Tracking Pilot,A Pilot and Feasibility Study of Daily Weight Tracking to Manage Gestational Weight Gain During Pregnancy,WITHDRAWN,Inadequate resources to support study start-up,NA,INTERVENTIONAL,0,Gestational Weight Gain,,BEHAVIORAL,Frequency of scale use,2020-03,2020-05,Duke University,OTHER
NCT04614636,FT538 in Subjects With Advanced Hematologic Malignancies,"A Phase I, Open-Label, Multicenter Study of FT538 as Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination With Monoclonal Antibodies in Relapsed/Refractory Multiple Myeloma",TERMINATED,This study was terminated by the Sponsor.,PHASE1,INTERVENTIONAL,42,"Acute Myeloid Leukemia, AML, Adult, Multiple Myeloma, Myeloma","FT538, Cyclophosphamide, Fludarabine, Daratumumab, Elotuzumab","DRUG, DRUG, DRUG, DRUG, DRUG","Incidence of dose-limiting toxicities (DLTs) within each dose level cohort, Nature of dose-limiting toxicities within each dose level cohort",2020-10-17,2023-08-08,Fate Therapeutics,INDUSTRY
NCT00702611,Efficacy Study of Granulocytapheresis Plus Steroids vs Steroids Alone in Active Steroid Dependant Ulcerative Colitis,An Open Randomized Multicenter Clinical Investigation to Compare the Efficacy and Safety of Prednisone Plus Adacolumn® GMA Apheresis vs Prednisone Alone in the Treatment of Patients With Mild or Moderately Active Steroid Dependent Ulcerative Colitis,TERMINATED,Lack of enrollment,PHASE4,INTERVENTIONAL,133,Ulcerative Colitis,,DEVICE,Proportion of patients in steroid free clinical remission defined by Mayo Score less or equal to 2 with no individual subscore >1 at week 24,2008-06,2013-07,Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa,OTHER
NCT02441309,A Eurosarc Study of Mifamurtide in Advanced Osteosarcoma (MEMOS),A Mechanistic Study Of Mifamurtide (MTP-PE) In Patients With Metastatic And/Or Recurrent Osteosarcoma,TERMINATED,Failed to recruit sufficient numbers of patients in the funded period,PHASE2,INTERVENTIONAL,8,Osteosarcoma,"Mifamurtide, Ifosfamide","DRUG, DRUG","Biological Response Data Based on Pharmacodynamic Endpoints on Tumour Biopsy Material, Radiological Response Defined as Complete or Partial Response and Assessed Using RECIST Criteria",2014-10,2016-11-04,University of Oxford,OTHER
NCT05999799,A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis,"A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Dose Finding Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GSK1070806 SC Injection in Adult Participants With Moderate to Severe Atopic Dermatitis",TERMINATED,Sponsor decision to early terminate the study based on the pre-defined futility criterion for efficacy. No safety concerns were identified.,PHASE2,INTERVENTIONAL,161,"Dermatitis, Atopic","GSK1070806, Placebo","DRUG, DRUG",Percent Change from Baseline (PCFB) in the Eczema Area and Severity Index (EASI) at Week 16,2023-11-16,2025-07-23,GlaxoSmithKline,INDUSTRY
NCT02619487,The Impact of Mobile Technology on Clinical Outcomes in Children and Adolescents With Type 1 Diabetes,The Impact of Mobile Technology on Clinical Outcomes in Children and Adolescents With Type 1 Diabetes,WITHDRAWN,"Due to limited staff resources, we were unable to start enrolling participants.",NA,INTERVENTIONAL,0,"Diabetes Mellitus, Type 1",,"OTHER, OTHER",glycemic control assessed by HbA1C level.,2019-03,2019-12-13,University of Louisville,OTHER
NCT03020121,Validation of BD Onclarity™ HPV Assay With PreservCyt® -ASCUS Samples,Validation of BD Onclarity™ HPV Assay With PreservCyt® -ASCUS Samples,TERMINATED,Lower than anticipated rate of subject enrollment,NA,INTERVENTIONAL,28,Uterine Cervical Neoplasm,,PROCEDURE,"Sensitivity, Specificity, PositivePredictive Value, Negative Predictive Value, Likelyhood ratio, Absolute Risk, Relative Risk, Positive Percent Agreement, Negative PercentAgreement, Non reportable rate",2016-11,2017-05,"Becton, Dickinson and Company",INDUSTRY
NCT04423614,Preoperative Inspiratory Muscle Training,Telehealth-Delivered Preoperative Inspiratory Muscle Training: An Innovative Solution to Conserve Scarce ICU Resources,WITHDRAWN,Study staff were busy with other projects and unable to devote time to this study,NA,INTERVENTIONAL,0,Mechanical Ventilation Complication,,"OTHER, OTHER","Maximal inspiratory pressure, Muscle fiber cross-sectional area and fiber type proportion.",2021-12,2022-01-05,University of Florida,OTHER
NCT02853084,HL2351 CAPS Phase II Study,"An Open Label, Single Arm Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of HL2351 in Patients With Cryopyrin Associated Periodic Syndromes",TERMINATED,difficult of recruiting,PHASE2,INTERVENTIONAL,8,Cryopyrin-Associated Periodic Syndromes (CAPS),HL2351,DRUG,"Change in Diary Symptom Sum Score (DSSS), Change in SAA, CRP, ESR levels, Change in physician's global assessment of autoinflammatory using 100mm VAS score disease, Change in patient's(parents or legal guardians) global assessment of autoinflammatory using 100mm VAS score disease, Pharmacokinetic profile(Cmax), Pharmacokinetic profile(AUClast), Pharmacokinetic profile(AUCinf), Pharmacokinetic profile(Tmax), Pharmacokinetic profile(t1/2)",2015-10,2019-01,Handok Inc.,INDUSTRY
NCT03472833,High-dose Vitamin D3 in Pancreas Cancer,"Influence of High Dose Vitamin D3 Intake on Outcome in Pancreatic Cancer Surgery: Prospective, Randomized, Open, Controlled Pilot Study",TERMINATED,"slow recruitment, patients lost to follow-up due to Covid-19 pandemic.",PHASE3,INTERVENTIONAL,25,"Pancreas Cancer, Vitamin D Deficiency, Quality of Life","High-dose, Standard dose","DRUG, DRUG",25(OH) vitamin D,2018-04-01,2021-04-20,Medical University of Graz,OTHER
NCT03359733,A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor,"An Open-Label, Phase 1, Two-Way, Crossover Study of the Effect of Food on the Pharmacokinetics of TAK-659 in Patients With Advanced Solid Tumor and/or Lymphoma Malignancies",WITHDRAWN,Business decision: no safety or efficacy concerns,PHASE1,INTERVENTIONAL,0,"Lymphoma, Malignant, Advanced Solid Neoplasms",TAK-659,DRUG,"Cmax: Maximum Observed Plasma Concentration for TAK-659, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-659, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-659, Cmax: Maximum Observed Plasma Concentration for TAK-659, AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-659, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-659",2018-02-28,2019-08-20,"Calithera Biosciences, Inc",INDUSTRY
NCT03220438,TMS Enhancement of Visual Plasticity in Schizophrenia,Testing TMS Enhancement of Visual Plasticity in Schizophrenia,TERMINATED,Principal Investigator took another position elsewhere,NA,INTERVENTIONAL,17,Schizophrenia,,DEVICE,fMRI Blood Oxygenation Level Dependent (BOLD) Response of Visual Plasticity,2017-09-27,2019-07-16,"University of Maryland, Baltimore",OTHER
NCT00246558,"Tight Achilles Tendon, Hyperpronation and Anterior Knee Pains","Is There a Connection Between a Tight Achilles Tendon, Hyperpronation of the Foot and Pain in the Anterior Part of the Knee",WITHDRAWN,The study stopped due to unforeseen circumstances.,,OBSERVATIONAL,0,Anterior Knee Pain Syndrome,,,,2005-11,2005-11,"Northern Orthopaedic Division, Denmark",OTHER
NCT01818219,Effects of Abnormal Respiratory Mechanics and Assisted Mechanical Ventilation on Neuro-regulation of Respiration,Effects of Abnormal Respiratory Mechanics and Assisted Mechanical Ventilation on Neuro Regulation of Respiration,TERMINATED,Only half recruitment : restrictive respiratory mechanics group not achievable for technical problems,NA,INTERVENTIONAL,15,Neuroregulation of Breathing,,PROCEDURE,Eadi-time curve,2013-02,2013-09,"University Hospital, Angers",OTHER_GOV
NCT05087628,PRV-3279-2a Trial in Systemic Lupus,"Phase 2a, Randomized, Double-blind, Placebo-controlled Trial of PRV-3279 EVAluation In Lupus",TERMINATED,termination for strategy reasons,PHASE2,INTERVENTIONAL,28,Systemic Lupus Erythematosus,PRV-3279,"BIOLOGICAL, OTHER","To evaluate the ability of PRV-3279 to prevent flare, defined by LFA international consensus definition of flare, worsening on CGIC, and increase in hSLEDAI/BILAG scores",2022-01-24,2024-06-24,"Provention Bio, a Sanofi Company",INDUSTRY
NCT05571865,Diabetic Cardiomyopathy and Heart Failure,Preventing Diabetic Cardiomyopathy and Heart Failure by Ketone Bodies,WITHDRAWN,Did not receive funding as anticipated.,NA,INTERVENTIONAL,0,"Diabetic Cardiomyopathies, Heart Failure",,DIETARY_SUPPLEMENT,"Primary Outcome Measure-I, Primary Outcome Measure-II",2025-07,2026-06,University of Louisville,OTHER
NCT05950971,Rhythm Control Versus Rate Control for New Onset Atrial Fibrillation,Rhythm Control Versus Rate Control for New Onset Atrial Fibrillation After Non-cardiac Non-thoracic Surgery,TERMINATED,"Study enrollment too slow, 1 over 6 months",NA,INTERVENTIONAL,1,"Atrial Fibrillation New Onset, Atrial Fibrillation Paroxysmal","Amiodarone, diltiazem or esmolol",DRUG,Rate of sinus conversion,2021-07-01,2022-01-21,Seoul National University Hospital,OTHER
NCT05307471,Physiopathologic Study of Induced by Thoracotomy / Thoracoscopy Neuropathy Mechanism,"Physiopathologic Study of Induced by Thoracotomy / Thoracoscopy Neuropathy Mechanism Clinical, Psychophysical, Electrophysiological Approach, and in Response to Therapy",TERMINATED,No neuropathic pain in recruited subjects,,OBSERVATIONAL,34,"Thoracotomy, Thoracoscopy",,OTHER,"Presence of spontaneous pain on the operated hemithorax, Presence of spontaneous pain on the operated hemithorax, Presence of spontaneous pain on the unoperated hemithorax, Presence of spontaneous pain on the unoperated hemithorax, Intensity of spontaneous pain on the operated hemithorax, Intensity of spontaneous pain on the operated hemithorax, Intensity of spontaneous pain on the unoperated hemithorax, Intensity of spontaneous pain on the unoperated hemithorax, Characteristics of spontaneous pain on the operated hemithorax, Characteristics of spontaneous pain on the operated hemithorax, Characteristics of spontaneous pain on the unoperated hemithorax, Characteristics of spontaneous pain on the unoperated hemithorax, Measurement of threshold sensitivity to cold on the operated hemithorax, Measurement of threshold sensitivity to cold on the operated hemithorax, Measurement of threshold sensitivity to cold on the unoperated hemithorax, Measurement of threshold sensitivity to hot on the operated hemithorax, Measurement of threshold sensitivity to hot on the operated hemithorax, Measurement of threshold sensitivity to hot on the unoperated hemithorax, Measurement of nociceptive threshold sensitivity to cold on the operated hemithorax, Measurement of nociceptive threshold sensitivity to cold on the operated hemithorax, Measurement of nociceptive threshold sensitivity to cold on the unoperated hemithorax, Measurement of nociceptive threshold sensitivity to hot on the operated hemithorax, Measurement of nociceptive threshold sensitivity to hot on the operated hemithorax, Measurement of nociceptive threshold sensitivity to hot on the unoperated hemithorax, Measurement of threshold tactile sensitivity on the operated hemithorax, Measurement of threshold tactile sensitivity on the operated hemithorax, Measurement of threshold tactile sensitivity on the unoperated hemithorax, Measurement of pressure pain threshold on the operated hemithorax, Measurement of pressure pain threshold on the operated hemithorax, Measurement of pressure pain threshold on the unoperated hemithorax, Measurement of the vibration sensitivity threshold on the operated hemithorax, Measurement of the vibration sensitivity threshold on the operated hemithorax, Measurement of the vibration sensitivity threshold on the unoperated hemithorax, Thermographic photo of the operated hemithorax, Thermographic photo of the operated hemithorax, Thermographic photo of the unoperated hemithorax, Measurement of the conduction velocity in the operated hemithorax, Measurement of the conduction velocity in the unoperated hemithorax",2013-10-28,2021-11-15,"University Hospital, Clermont-Ferrand",OTHER
NCT01025271,Cerebrospinal Fluid Pharmacokinetics of Daptomycin,Cerebrospinal Fluid Pharmacokinetics of Daptomycin,TERMINATED,unable to enroll subjects study stopped due to lack of enrollment,NA,INTERVENTIONAL,2,Meningitis,Daptomycin,DRUG,Characterize the CSF and Plasma Concentration-time Profile of Daptomycin in Patients With External Ventricular Drain (EVD) Related Meningitis,2010-05,2011-05,University of Pittsburgh,OTHER
NCT05177471,Efficacy and Safety of JAK Inhibitors in Systemic Sclerosis-associated Interstitial Lung Disease,Efficacy and Safety of JAK Inhibitors in Patients With Systemic Sclerosis and Interstitial Lung Disease,WITHDRAWN,no eligible patients,,OBSERVATIONAL,0,"Systemic Sclerosis, Interstitial Lung Disease",,,relative change in FVC after 12 months of JAK inhibitor,2022-01-19,2024-08-26,"Central Hospital, Nancy, France",OTHER
NCT02630134,"Device for Monitoring Pain During Intraoperative, Pre/Post Surgical Periods: Comparison With Standard of Care Monitoring","MyHealthTrendsTM Device for Pain for Monitoring Pain During the Intraoperative, Pre and Post Surgical Periods: Comparison With Standard of Care Pain Monitoring.",TERMINATED,"Study stopped, recruitment difficult, subject compliance very difficult.",NA,INTERVENTIONAL,6,"Pain Measurement, Assessment, Pain",,OTHER,Pain score,2011-03,2012-10,NYU Langone Health,OTHER
NCT00487799,A Study of Ularitide in the Treatment of Subjects With Acute Decompensated Heart Failure,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Ularitide in the Treatment of Subjects With Acute Decompensated Heart Failure",WITHDRAWN,Facet no longer has ownership of ularitide.,PHASE1,INTERVENTIONAL,32,"Heart Failure, Congestive",Ularitide,DRUG,The MTD of ularitide infused over 48 hours.,,,Facet Biotech,INDUSTRY
NCT01117571,Multi-Center Study to Evaluate the ConforMIS iUni Knee Implant,"A Prospective, Multi-Center Study to Evaluate the ConforMIS iUni® G2 Unicompartmental Knee Resurfacing Device",TERMINATED,Decision of investigational team,,OBSERVATIONAL,120,Osteoarthritis,,DEVICE,"Knee Society Score, WOMAC Osteoarthritis Index",2010-04,2023-01-10,Restor3D,INDUSTRY
NCT02431663,Ketamine in Refractory Convulsive Status Epilepticus,"Efficacy of Ketamine in Refractory Convulsive Status Epilepticus in Children: a Multicenter, Randomized, Controlled, Open-label, No-profit, With Sequential Design Study.",TERMINATED,Futility,PHASE3,INTERVENTIONAL,57,Status Epilepticus,Ketamine,DRUG,Number of participants with resolution of refractory convulsive status epilepticus,2015-04,2020-03-31,Meyer Children's Hospital IRCCS,OTHER
NCT05090787,Clinical Investigation of the TECNIS 1-Piece Intraocular Lens,Clinical Investigation of the TECNIS 1-Piece Intraocular Lens,WITHDRAWN,Business Decision,NA,INTERVENTIONAL,0,Cataract,,"DEVICE, DEVICE","mean monocular, photopic BCDVA",2025-01-01,2025-07-01,"Johnson & Johnson Surgical Vision, Inc.",INDUSTRY
NCT05370521,A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens,"A Randomized, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of Tildacerfont in Adult Subjects With Polycystic Ovary Syndrome (PCOS) and Elevated Adrenal Androgens",TERMINATED,The study was discontinued early by the sponsor,PHASE2,INTERVENTIONAL,27,Polycystic Ovary Syndrome,"Tildacerfont, Placebo","DRUG, DRUG",Change in DHEAS,2022-05-15,2023-08-31,Spruce Biosciences,INDUSTRY
NCT04353921,PSIL201 Long-term Follow-up Study: Psilocybin or Niacin / Major Depressive Disorder,"A Two-Year Observational Follow-up Study of Subjects With Major Depressive Disorder Following a Randomized, Double-Blind Single-Dose of Psilocybin or Niacin-Control",TERMINATED,Low enrollment and inability to achieve statistical significance,,OBSERVATIONAL,24,Major Depressive Disorder,,OTHER,Montgomery-Asberg Depression Rating Scale,2020-06-30,2022-10-18,Usona Institute,OTHER
NCT00642421,Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients,"Safety and Biological Activity of a New Prolonged Release Formulation of Octreotide Acetate, C2l-OCT-01 PR, Administered Intra Muscularly Every 4, 5 or 6 Weeks in Acromegalic Patients",TERMINATED,Commercial reasons,PHASE3,INTERVENTIONAL,40,Acromegaly,"C2L-OCT-01 PR, 10 or 20 mg, C2L-OCT-01 PR, 20 mg","DRUG, DRUG","To assess the safety profile of a new prolonged release formulation of octreotide acetate, C2L-OCT-01 PR, administered intra muscularly every 4, 5 or 6 weeks in acromegalic patients.",2008-02,2009-08,"Ambrilia Biopharma, Inc.",INDUSTRY
NCT00206414,"Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer","Arimidex/Faslodex/Iressa Study: A Phase II Trial of Primary Systemic Therapy Using a Combination of Arimidex, Faslodex and Iressa (Gefitinib) in Postmenopausal Women With Hormone Receptor Positive Breast Cancer",TERMINATED,Difficulty accruing subjects the study accrual was closed,PHASE2,INTERVENTIONAL,15,BREAST CANCER,"Iressa Day 1 given with Arimidex and Faslodex, Iressa Day 21 given with Arimidex and Faslodex","DRUG, DRUG","Primary study objective - To determine the clinical response rate of primary breast cancer to the combination of Arimidex, Faslodex, and Iressa",2003-01,2006-09,Baylor Breast Care Center,OTHER
NCT04576806,Physiological Effects of 38°C vs. 22°C Fluid Therapy in Critically Ill Patients,Physiological Effects of 38°C vs. 22°C Fluid Therapy in Critically Ill Patients: A Randomized Controlled ICU Study,WITHDRAWN,Other research priorities during Covid-19 pandemic.,NA,INTERVENTIONAL,0,"Critical Illness, Sepsis, Fluid Overload, Hemodynamic Instability",Fluid bolus,"OTHER, DRUG, OTHER",MAP,2021-04-30,2021-10-30,Karolinska Institutet,OTHER
NCT01535404,Right Versus Left Apical Transvenous Pacing for Patients With Preserved Left Ventricular Systolic Function Study,Right Versus Left Apical Transvenous Pacing for Patients With Preserved Left Ventricular Systolic Function (RIVELA) Study,TERMINATED,Slow enrollment,NA,INTERVENTIONAL,36,Bradyarrhythmia,,"DEVICE, DEVICE",Reduction in LVEF,2012-01,2016-05,"Haran Burri, MD",OTHER
NCT00089804,Study of LJP 394 in Lupus Patients With History of Renal Disease,"A Randomized, Double-Blind, Placebo-Controlled, Three-Arm, Parallel-Group, Multicenter, Multinational Safety and Efficacy Trial of 300 mg and 900 mg of Abetimus Sodium in Systemic Lupus Erythematosus (SLE) Patients With a History of Renal Disease",TERMINATED,Interim efficacy analysis indicated it would be futile to continue study.,PHASE3,INTERVENTIONAL,943,"Lupus Erythematosus, Systemic, Lupus Nephritis","abetimus sodium (LJP 394) and/or placebo solution, abetimus sodium (LJP 394), Phosphate-buffered saline","DRUG, DRUG, DRUG",To determine whether abetimus sodium is more effective than placebo in delaying the time to renal flare in SLE patients with a history of SLE renal disease. Weekly administration with a 52-week treatment duration.,2004-10,2009-02,La Jolla Pharmaceutical Company,INDUSTRY
NCT00469404,Single Dose Trial Comparing the Plasma Levels of Two Different Analgesic Transdermal Patch Formulations (Protocol ID 297307),Single Dose Bioequivalence Trial Comparing a Down-Scaled New Analgesic Transdermal Patch Formulation to an Analgesic Reference Patch.,TERMINATED,The trial end was achieved according to the definition in the trial protocol,PHASE1,INTERVENTIONAL,24,Healthy,Buprenorphine,DRUG,,2007-05,2007-11,Grünenthal GmbH,INDUSTRY
NCT06160804,Evaluating Femoral Traction,Evaluating Skeletal Traction for Patients With Femoral Shaft Fractures Treated With Intramedullary Nailing Within 24 Hours of Presentation,TERMINATED,Enrolling subjects intro the trial was difficult. It would not have been possible to complete the study within a reasonable timeline based on the current enrollment.,NA,INTERVENTIONAL,18,Femoral Shaft Fracture,,"PROCEDURE, PROCEDURE",Time to reduce a femoral shaft fracture,2024-03-19,2025-09-23,University of Chicago,OTHER
NCT03905616,HIERARCHY OF VISION,Hierarchical Processing of Visual Movement,WITHDRAWN,abandonment,NA,INTERVENTIONAL,0,Neurologic Signs,,DEVICE,Non-invasive Blood oxygenation level dependent (BOLD) fMRI activity,2019-07-22,2021-02-17,Hospices Civils de Lyon,OTHER
NCT00767884,Effect of Panretinal Photocoagulation on Optic Nerve Head Topography,Effect of Panretinal Photocoagulation on Optic Nerve Head Topography and Nerve Fiber Layer Parameters,TERMINATED,Low subject recruitment,,OBSERVATIONAL,13,Diabetic Retinopathy,,,Changes in optic nerve head topography before and after panretinal photocoagulation,2008-10-29,2013-10-17,University of Nebraska,OTHER
NCT04064684,Inhaled Steroids for the Treatment of Early Pediatric Acute Respiratory Distress Syndrome,"Inhaled Steroids for the Treatment of Early Pediatric Acute Respiratory Distress Syndrome (PARDS), a Randomized Pilot Trial",TERMINATED,Enrollment difficulties after the start of the COVID-19 pandemic.,PHASE2,INTERVENTIONAL,2,Acute Respiratory Distress Syndrome,"Budesonide, Placebo","DRUG, DRUG, DEVICE",Number of Ventilator-free Days (VFD),2020-02-04,2020-03-30,"The University of Texas Health Science Center, Houston",OTHER
NCT05228249,Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma,"Loncastuximab Tesirine in Combination With BEAM (Carmustine, Etoposide, Ara-C, Melphalan) Conditioning Regimen Prior to Autologous Stem Cell Transplant (ASCT) and for Maintenance Therapy in Diffuse Large B-Cell Lymphoma (DLBCL)",WITHDRAWN,"PI left institution and funding sponsor closed study. Study did not open to accrual, and no participants were enrolled.",PHASE1,INTERVENTIONAL,0,"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma","Carmustine, Cytarabine, Etoposide, Loncastuximab Tesirine, Melphalan","PROCEDURE, DRUG, DRUG, DRUG, BIOLOGICAL, DRUG","Incidence of dose-limiting toxicity (Part 1), Incidence of toxicity requiring dose delay or modification (Part 2)",2023-04,2027-10-01,Fred Hutchinson Cancer Center,OTHER
NCT03790449,Evaluation of a Mobile Preconception Lifestyle Programme in Couples Undergoing In Vitro Fertilisation,Evaluation of a Mobile Preconception Lifestyle Programme in Couples Undergoing in Vitro Fertilisation: a Multicentre Randomized Controlled Trial (PreLiFe-RCT),TERMINATED,"Due to the worldwide Covid-19 pandemic, all Belgian fertility clinics stopped offering IVF as of March 13th 2020. We had to stop recruitment and follow-up of study subjects. We therefore adjusted our primary outcome to time to ongoing pregnancy.",NA,INTERVENTIONAL,211,Infertility,,"BEHAVIORAL, BEHAVIORAL",Cumulative ongoing pregnancy rate (COPR) within 12 months after randomisation,2019-01-02,2021-03-13,Universitaire Ziekenhuizen KU Leuven,OTHER
NCT01302938,Web-based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Subjects With Overactive Bladder,"Exploratory, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single Center, Web-Based Phase IV Pilot Methodology Trial To Evaluate The Efficacy And Safety Of Tolterodine ER In Subjects With Overactive Bladder",TERMINATED,Stop date for randomization: 31/5/2012. Recruitment terminated due to lack of recruitment. No new safety issues were identified.,PHASE4,INTERVENTIONAL,18,Overactive Bladder,"Tolterodine ER, Placebo","DRUG, DRUG",Change From Baseline in Mean Number of Micturitions Per 24 Hours at Week 12,2011-03,2012-08,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,INDUSTRY
NCT04078438,Neurofeedback In Treatment Resistant Depression,Neurofeedback Treatment on Depressive Symptoms and Functional Recovery in Treatment-resistant Patients With Major Depressive Disorder: an Open-label Pilot Study,TERMINATED,Because of researcher foreign training,NA,INTERVENTIONAL,70,"Depression, Neurofeedback",treatment as usual,"DEVICE, DRUG, OTHER","Changes in Hamilton Rating Scale for Depression [HAM-D] score at baselline and the 1-, 4-, and 12-week time points",2014-06-27,2020-02-08,Yeungnam University Hospital,OTHER
NCT01403428,Non Invasive Positive Pressure Ventilation in Status Asthmaticus,"Effect Of Early Initiation Of Noninvasive Positive Pressure Ventilation On ICU Length Of Stay In Children With Status Asthmaticus, A Prospective Randomized Trial",WITHDRAWN,"In a pilot of early noninvasive positive pressure ventilation, the children did so well that early NPPV is now used in all children who meet criteria.",PHASE2,INTERVENTIONAL,0,Status Asthmaticus,,OTHER,length of stay,2011-06,2014-03,Southern Illinois University,OTHER
NCT00549328,Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer,"A Phase II, Non-randomized, Multi-center Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer",TERMINATED,Study enrolment was delayed in starting and too slow to support further development in this setting,PHASE2,INTERVENTIONAL,14,"Lung Cancer, Non-Small Cell",Pazopanib (GW786034),DRUG,Percentage of Participants Who Achieved Either a Confirmed Complete Response or Partial Response Per RECIST Criteria,2008-02,2009-04,GlaxoSmithKline,INDUSTRY
NCT02382965,Ultrasound in Deep Brain Stimulation,Transcranial Focused Ultrasound for Deep Brain Stimulation in Humans,TERMINATED,PI left University no data available,,OBSERVATIONAL,40,Sub-cortical Stimulation,,DEVICE,Somatosensory evoked potential amplitude,2015-05-01,2017-04-01,University of Minnesota,OTHER
NCT00879528,Consolidation PET-based and Donor-based After Salvage Therapy in Patients With HL in Relapse or Refractory,Consolidation PET-based and Donor-based After Salvage Therapy in Patients With Hodgkin Lymphoma in Relapse or Refractory,TERMINATED,Failure of accrual achievement,,OBSERVATIONAL,264,Hodgkin's Lymphoma,,"OTHER, OTHER","Patients with negative PET after salvage therapy. To assess prospectively the overall survival and progression-free, Patients with positive PET after salvage therapy. Evaluate the role of allogeneic transplantation in these patients after salvage chemotherapy and compare the results with those obtained by 2 cycles of high dose chemotherapy with stem cell",2009-05,2015-09,Fondazione Italiana Linfomi - ETS,OTHER
NCT04641000,The Alberta BLOOM Long Term Follow Up Study,The Alberta BLOOM Long Term Follow Up Study: The Microbiome of Preterm Children in Immune Development,TERMINATED,The BLOOM-LTFU study has evolved into the ongoing BLOOM-PCS Study (REB20-1442).,,OBSERVATIONAL,15,"Infant, Premature, Diseases, Infant, Asthma, Asthma in Children, Allergies, Infant, Extremely Premature",,,"Microbiome Establishment and Assembly, Metabolome, Asthma Risk, Allergies",2020-11-20,2022-03-26,University of Calgary,OTHER
NCT01374100,Effect of Qigong Therapy in Patients With Advanced Lung and Gastrointestinal Cancer Undergoing Chemotherapy,Effect of Qigong Therapy in Patients With Advanced NSCLC and GI Cancer Undergoing Chemotherapy,TERMINATED,"Slow accrual, and revised power calculation for primary end-points",NA,INTERVENTIONAL,52,"Carcinoma, Non-Small-Cell Lung, Cancer of the Gastrointestinal Tract",,"BEHAVIORAL, BEHAVIORAL","Change in Depression and Anxiety, Change in Quality of Life (QoL)",2009-02,2011-05,McGill University,OTHER
NCT05780736,A Study to Evaluate Nivolumab in the Treatment of Early Stage Esophageal or Gastroesophageal Cancer,Prospective Evaluation of Nivolumab in Adjuvant Esophageal Carcinoma/Gastroesophageal Junction Carcinoma: A Non-interventional Study,TERMINATED,"A decision was made to terminate the study due to expected timelines associated with start-up, participant enrollment, ethics committee approval and data availability from the study.",,OBSERVATIONAL,33,"Esophageal Carcinoma, Gastroesophageal Junction Carcinoma",,,Disease-free Survival (DFS),2023-08-04,2024-08-23,Bristol-Myers Squibb,INDUSTRY
NCT04284371,The Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) Pediatric Patients,"The Prevalence of Liver Steatosis, Steatohepatitis, Fibrosis, and Hemosiderosis in Overweight and Obese US Military Dependent Pediatric Patients Using MR Elastography and Quantitative MRI",TERMINATED,lack of funding - no results to report,,OBSERVATIONAL,150,"Steatohepatitis, Nonalcoholic, Hemosiderosis, Overweight Adolescents, Obesity, Childhood, Liver Steatosis",,,"LiverMultiScan (LMS), MRE",2016-02-10,2021-01-26,The Geneva Foundation,OTHER
NCT04316611,Potassium Chloride in Out-of-hospital Cardiac Arrest Due to Refractory Ventricular Fibrillation,Evaluation of the Effectiveness of Potassium Chloride in the Management of Out-of-hospital Cardiac Arrest by Refractory Ventricular Fibrillation,WITHDRAWN,"As the inclusion period in the study has ended and regulatory authorizations have expired on 26/12/2023, with no inclusions conducted.",PHASE2,INTERVENTIONAL,0,Out-of-hospital Cardiac Arrest (OHCA),Potassium chloride,DRUG,Survival at hospital admission,2023-12,2024-12,Assistance Publique - Hôpitaux de Paris,OTHER
NCT02855034,Evaluation of Discriminating Power of Two Biomarkers in the Evaluation of Cerebral Lesions Due to Head Injuries in Infants and Children,Evaluation of Discriminating Power of Two Biomarkers (Protein S100B/Copeptin) in the Evaluation of Cerebral Lesions Due to Head Injuries in Infants and Children,TERMINATED,Difficulties in recruiting control patients to the emergency department,NA,INTERVENTIONAL,167,Traumatic Brain Injury,,OTHER,Copeptin dosage,2016-05-27,2023-10-10,"University Hospital, Montpellier",OTHER
NCT03303664,Inpatient Multimodal Path to RecOVEry,Inpatient Multimodal Path to RecOVEry,WITHDRAWN,System-wide implementation of intervention prevented randomized trial design,NA,INTERVENTIONAL,0,"Pain, Opioid Use",,OTHER,Use of Opioid Overdose Reversal Treatment,2017-07-11,2018-02-26,Wake Forest University Health Sciences,OTHER
NCT01575899,Efficacy of Seven-day Combined Rabeprazole Plus Levofloxacin Plus Augmentin for Eradication of Helicobacter Pylori,Efficacy of Seven-day Combined Rabeprazole Plus Levofloxacin Plus Augmentin for Eradication of Helicobacter Pylori.,TERMINATED,Early termination due to efficacy,PHASE4,INTERVENTIONAL,208,Helicobacter Pylori Infection,"Levofloxacin-Amox/clav., Clarithromycin-Amoxicillin","DRUG, DRUG",Eradication Rate (Participants Naive to Anti-H. Pylori Treatment),2007-12,2009-12,Buddhist Tzu Chi General Hospital,OTHER
NCT03212963,Evaluation of Adrenal Suppression Potential and Pharmacokinetics of Halobetasol Lotion 0.05%,"An Open Label Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of Twice Daily Halobetasol Propionate Lotion, 0.05% in Subjects 12 to 16 Years 11 Months of Age With Plaque Psoriasis Receiving Two Weeks of Treatment",TERMINATED,Sponsor's Decision,PHASE4,INTERVENTIONAL,16,Plaque Psoriasis,Halobetasol Topical Lotion,DRUG,"Investigator's Global Assessment, Percent BSA Affected With Disease, Percent Body Surface Area Treated With Test Article, Number of Subjects With Abnormal Hypothalamus-Pituitary-Adrenal Axis Response",2017-03-21,2019-08-12,Sun Pharmaceutical Industries Limited,INDUSTRY
NCT03857893,New Non-Hormonal Treatment by Radiofrequency for Vulvo-Vaginal Atrophy,Thermal Treatment of Vulvo-vaginal Atrophy (VVA) Using Novel Low-energy Dynamic Quadripolar Radio-Frequency (DQRF),TERMINATED,The study was delayed due to the Covid 19 pandemic. The study was stopped prematurely due to a lack of efficiency (reported by the patients),NA,INTERVENTIONAL,53,"Vulvo-vaginal Atrophy, Genitourinary Syndrome of Menopause",pH-Cream,"DEVICE, DRUG","Change from baseline to week 12 (+4 weeks) of self-assessment of the most bothersome symptom dyspareunia, evaluated by a questionnaire, Change from baseline to week 12 (+4 weeks) of vaginal cell maturation (Maturation Index)., Change from baseline to week 12 (+4 weeks) of vaginal pH",2019-03-01,2021-12-08,Serge Rozenberg,OTHER
NCT02515916,Fertility Preservation- Oncology Treatment Effects and Psychological Impact,Fertility Preservation- Oncology Treatment Effects and Psychological Impact,TERMINATED,Not enough subjects,,OBSERVATIONAL,2,Cancer,,OTHER,"AMH (anti-mullerian hormone) blood levels, Quality of life on the Dyadic Adjustment Scale",2017-05-30,2021-03-12,Weill Medical College of Cornell University,OTHER
NCT00710216,Comparison of Telbivudine Versus Lamivudine on the Early Dynamics and Kinetics of Viral Suppression in Chronic Hepatitis B,"Randomized, Open-Label, Phase IV Trial in Nucleus(t)id-Naive Patients With Chronic Hepatitis B to Examine the Effect of Telbivudine Compared to Lamivudine on the Early Dynamics and Kinetics of Viral Suppression (Early-Viral-Dynamics Study)",WITHDRAWN,Sponsor withdraw,PHASE4,INTERVENTIONAL,40,"Hepatitis B, Chronic","Lamivudine, Telbivudine","DRUG, DRUG",Decrease in viral load after 2 weeks of therapy measured in serum HBV-DNA concentration (Copies/ml or IU/ml).,,,University of Ulm,OTHER
NCT00903006,"Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer","A Phase I-II, Randomization, Open-Label Clinical Trial of Fulvestrant Versus the Combination of Fulvestrant, MK-0646, and Dasatinib as First-Line Therapy for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer",TERMINATED,Low Accrual,"PHASE1, PHASE2",INTERVENTIONAL,11,Breast Cancer,"Fulvestrant, MK-0646, Dasatinib","DRUG, DRUG, DRUG","Phase I Maximum Tolerated Dose (MTD) for Dose Level 1, Patient Response (+ Time to Disease Progression)",2009-11,2013-05,M.D. Anderson Cancer Center,OTHER
NCT00750906,"ECT/Succinylcholine: Biochemical, Serum and Cardiovascular Changes","The Muscle Biochemical, Serum Potassium and Cardiovascular Changes After Succinylcholine in Patients Undergoing Electroconvulsive Therapy.",TERMINATED,Study on hold since 2009. Awaiting FDA approval of Sugammdex to complete second arm of study.,,OBSERVATIONAL,13,Depression,,,,2008-10,2015-04-30,"University of California, San Francisco",OTHER
NCT00347906,Photodynamic Therapy (PDT) Versus Transpupillary Thermotherapy (TTT) in Occult Choroidal Neovascularization (CNV) in Age-related Macular Degeneration (AMD),Photodynamic Therapy Versus Transpupillary Thermotherapy in Occult CNV in Age-related Macular Degeneration,TERMINATED,Difficulties in recruiting patients,NA,INTERVENTIONAL,,Age-Related Macular Degeneration,,PROCEDURE,,2003-11,2005-09,"University Hospital, Linkoeping",OTHER
NCT00793104,Evaluation of the CR Plug (Allograft) for the Treatment of a Cartilage Injury in the Knee.,Evaluation of the Composite of Cancellous and Demineralized Bone Plug (CR-Plug) for Repair of Focal Cartilage Lesions in the Femoral Condyle,TERMINATED,Slow enrolment \& potential regulatory changes for allograft in cartilage repair,PHASE3,INTERVENTIONAL,10,Knee Injury,,PROCEDURE,The Knee Injury and Osteoarthritis Outcome Score (KOOS) at 24 Months,2008-11,2012-03,RTI Surgical,INDUSTRY
NCT06646133,Machine Learning and 3D Image-Based Modeling for Real-Time Body Weight and Body Composition Estimation During Emergency Medical Care: Study 2,Machine Learning and 3D Image-Based Modeling for Real-Time Body Weight and Body Composition Estimation During Emergency Medical Care: Study 2 - Measure the Accuracy and Speed of Weight Estimations Using a 3D Camera System During Simulated Medical Emergencies,WITHDRAWN,No funding received.,,OBSERVATIONAL,0,"Body Weights and Measures, Body Weight in the Overweight and Obese Class - I Population, Weight Estimation, Emergency Drug Dosing",,"DIAGNOSTIC_TEST, DIAGNOSTIC_TEST","Weight estimation accuracy, Weight estimation time, Drug dose accuracy",2027-07-01,2028-02-28,Florida Atlantic University,OTHER
NCT04428333,Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma,"A Randomized, Double-Blind, Adaptive, Phase II/III Study of GSK3359609 in Combination With Pembrolizumab and 5FU-Platinum Chemotherapy Versus Placebo in Combination With Pembrolizumab Plus 5FU-Platinum Chemotherapy for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma",TERMINATED,The trial was stopped by the sponsor based on assessment of the clinical data,PHASE3,INTERVENTIONAL,117,"Neoplasms, Head and Neck","Feladilimab, Pembrolizumab, Placebo, Platinum based chemotherapy, Fluorouracil (5FU)","DRUG, DRUG, DRUG, DRUG, DRUG","Overall Survival (OS) in mITT Population, OS in Programmed Death Receptor-ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1 Population, Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 in mITT Population",2020-08-12,2023-09-19,GlaxoSmithKline,INDUSTRY
NCT00042952,"Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer","A Phase II Study Of Imatinib Mesylate (Gleevec, Formerly Known As STI571; IND 61,135, NSC #716051) In Patients With Refractory Seminoma",TERMINATED,Administratively complete.,PHASE2,INTERVENTIONAL,32,"Ovarian Dysgerminoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Ovarian Germ Cell Tumor, Stage II Malignant Testicular Germ Cell Tumor, Stage II Ovarian Germ Cell Tumor, Stage III Malignant Testicular Germ Cell Tumor, Stage III Ovarian Germ Cell Tumor, Testicular Seminoma",imatinib mesylate,"DRUG, PROCEDURE, OTHER",Response rate defined as either a complete or partial response using RECIST criteria,2002-06,,National Cancer Institute (NCI),NIH
NCT00122980,Stroke With Transfusions Changing to Hydroxyurea,Stroke With Transfusions Changing to Hydroxyurea,TERMINATED,The study has been stopped due to safety and futility concerns.,PHASE3,INTERVENTIONAL,134,"Hemochromatosis, Cerebrovascular Accident, Anemia, Sickle Cell, Hematologic Diseases",Hydroxyurea,"PROCEDURE, PROCEDURE, DRUG, PROCEDURE","Occurrence of an Adjudicated Secondary Stroke During the 30-month Treatment Period, Liver Iron Content (LIC) Change-from-baseline",2006-10,2010-12,St. Jude Children's Research Hospital,OTHER
NCT00280579,Cyanide Poisoning in Fire Victims,,WITHDRAWN,Not sufficient time to conduct the study,,OBSERVATIONAL,0,Carbon Monoxide Poisoning,,,Cyanide concentration,2006-01,2007-01,"Rigshospitalet, Denmark",OTHER
NCT03334162,Playful Sensorimotor Training in Pediatric Brain Tumor Patients,Playful Sensorimotor Training to Reduce the Symptoms of Chemotherapy-induced Peripheral Neuropathy in Pediatric Brain Tumor Patients- a Randomized Controlled Trial,SUSPENDED,study temporarily paused due to an Amendment request,NA,INTERVENTIONAL,20,"Pediatric Cancer, Pediatric Brain Tumor, Chemotherapy-induced Peripheral Neuropathy, Sensorimotor Polyneuropathy",,BEHAVIORAL,Ped-mTNS score (assesses the change in the severity of CIPN symptoms),2019-05,2020-11,University of Basel,OTHER
NCT02606786,Effectiveness of Lumbopelvic Stabilization Exercises for Pregnancy-related Low Back Pain,Effectiveness of Lumbopelvic Stabilization Exercises for Pregnancy-related Low Back Pain,WITHDRAWN,Difficulty with participant recruitment and retainment,NA,INTERVENTIONAL,0,Pregnancy-related Low Back Pain,,OTHER,Change in Modified Oswestry Low Back Pain Questionnaire,2015-03,2016-12,Texas Woman's University,OTHER
NCT00073970,Celecoxib in Treating Patients With Relapsed Prostate Cancer Following Radiation Therapy or Radical Prostatectomy,A Trial Of COX-2 Inhibitors In PSA Recurrence After Definitive Radiation Or Radical Prostatectomy For Prostate Cancer,TERMINATED,Study stopped due to increased cardiovascular risks associated with Celebrex,PHASE2,INTERVENTIONAL,37,Prostate Cancer,celecoxib,DRUG,Effect of COX-2 inhibitors on PSA level,2003-04,2006-01,UNC Lineberger Comprehensive Cancer Center,OTHER
NCT01369641,The Effect of Sodium Thiosulfate Eardrops on Hearing Loss in Patients Who Receive Cisplatin Therapy,"A Pilot, Randomized, Self-controlled Study of the Effects of Intratympanic Sodium Thiosulfate on the Degree of Hearing Loss in Patients Receiving Cisplatin Therapy",TERMINATED,Poor accrual,NA,INTERVENTIONAL,1,Cancer,"Sodium Thiosulfate (STS), Cisplatin","PROCEDURE, DRUG, OTHER, DRUG",Efficacy of Intratympanic Sodium Thiosulfate (STS),2011-08-24,2013-05-02,Sidney Kimmel Cancer Center at Thomas Jefferson University,OTHER
NCT00930241,Twice Daily Versus Once Daily Administration of the Tacrolimus in Lung Transplantation,Prospective Randomized Trial to Compare a Twice Daily to a Once Daily Administration of the Tacrolimus in Lung Transplanted Patients,TERMINATED,"logistic reasons (insufficient funding, technical problems with MEMS)",PHASE3,INTERVENTIONAL,25,Lung Transplantation,"Advagraf®, Prograf®","DRUG, DRUG",Improvement of adherence as measured by Tacrolimus trough level below the target level and dispensing of less than 50% of the prescribed doses in the last three days measured electronically before this subtherapeutic drug monitoring,2009-07,2012-07,Hannover Medical School,OTHER
NCT02876094,Effect of Low-Dose Celecoxib on SMN2 in Patients With Spinal Muscular Atrophy,"A Pilot, Open-Label, Dose Response Study Investigating the Effect of Low-Dose Celecoxib on SMN2 in Patients With Spinal Muscular Atrophy (SMA)",TERMINATED,Terminated: Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention,PHASE2,INTERVENTIONAL,1,Spinal Muscular Atrophy (SMA),celecoxib,DRUG,low-dose oral celecoxib administered to patients with SMA type II and III is associated with an increase in the levels of peripheral leukocyte SMN protein compared to baseline,2019-01-29,2020-08-06,Hugh McMillan,OTHER
NCT04007822,Pain Navigator Tool for Self-management in Back Pain: PATiENCe Trial,Evaluation of the 'Pain Navigator Tool' During Physiotherapy Consultations in Patients With Chronic Low-back Pain: a Service Evaluation Trial.,WITHDRAWN,Unable to collect data due to COVID19,,OBSERVATIONAL,0,"Chronic Low-back Pain, Self Efficacy, Therapeutic Alliance, Communication",,BEHAVIORAL,"Semi-Structured Interview, Change in the Health Care Providers Pain and Impairment Relationship Scale, The Pain Self-Efficacy Questionnaire",2019-07-01,2020-03-01,Glasgow Caledonian University,OTHER
NCT03421756,Stem Cell Transplant in Patients With Severe Sickle Cell Disease,A Pilot Study Evaluating the Efficacy of Non-Myeloablative Matched Related Donor Peripheral Blood Stem Cell Transplant in Patients With Severe Sickle Cell Disease,TERMINATED,Trial terminated due to low rate of enrollment,EARLY_PHASE1,INTERVENTIONAL,1,Sickle Cell Disease,"Alemtuzumab, Sirolimus","DRUG, RADIATION, DRUG",Treatment Success,2018-03-29,2022-05-15,Kathleen Dorritie,OTHER
NCT01986751,Effectiveness of Perineural Clonidine as an Adjuvant With Ropivacaine for Popliteal Nerve Block in Patients Undergoing Foot and Ankle Surgery,Effectiveness of Perineural Clonidine as an Adjuvant With Ropivacaine for Popliteal Nerve Block in Patients Undergoing Foot and Ankle Surgery,TERMINATED,failure to enroll,"PHASE1, PHASE2",INTERVENTIONAL,14,Pain,"Clonidine, ropivacaine","DRUG, DRUG","Mean Time to Onset of Sensory and Motor Block Between the Study Group and the Control Group, Compare the Mean Duration of Sensory and/or Motor Block Between the Study Group and the Control Group",2014-01,2015-12,University of Alabama at Birmingham,OTHER
NCT05827302,Integrating ePReBMs From Phoenix in Respiratory Diseases,Integrating Electronic Patient Reported Biometric Measures (ePReBMs) From the Health Gauge Phoenix Smart Watch in Respiratory Diseases,TERMINATED,Resource Issues,NA,INTERVENTIONAL,7,"Pulmonary Hypertension, COPD, Interstitial Lung Disease, Healthy Volunteers",,DEVICE,Length of time wearing device,2023-10-11,2024-05-06,University of Alberta,OTHER
NCT01125072,Use of Echocardiography in the Evaluation of Chest Pain in the Emergency Department,Use of Echocardiography in the Evaluation of Chest Pain in the Emergency Department,WITHDRAWN,PI no longer with institution,,OBSERVATIONAL,0,Chest Pain,,OTHER,,2005-06,2017-11,NYU Langone Health,OTHER
NCT04619095,Reducing Pain and Anxiety Through Dietary Fiber Supplementation in Children With Abdominal Pain,"Randomised, Blinded, Parallel, Placebo-controlled Study to Evaluate Whether Supplementation of the Dietary Fiber Psyllium Can Reduce Abdominal Pain and Improve Quality of Life and Anxiety in Children With Abdominal Pain.",WITHDRAWN,We were unable to recruit any participants,NA,INTERVENTIONAL,0,Functional Abdominal Pain Syndrome,,"DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Change in abdominal pain scores as measured by an abdominal pain diary,2022-06-01,2023-11-01,University of Calgary,OTHER
NCT06375772,A Controlled Human Rhinovirus Infection Study of 2-Deoxy-D-Glucose in Healthy Adults,"A Randomized, Double-blind, Placebo-controlled Phase 2 Study Using the Rhinovirus Challenge Model to Investigate the Efficacy and Safety of 2-Deoxy-D-Glucose as Pre-exposure Prophylaxis",TERMINATED,Re-calculated sample size,PHASE2,INTERVENTIONAL,64,Acute Nasopharyngitis,2-Deoxy-D-glucose,"DRUG, OTHER",The difference in the rate of rhinovirus-associated illness between 2-DG and placebo,2024-04-02,2024-08-13,G.ST Antivirals GmbH,INDUSTRY
NCT03758495,Rescuing the Ruminating Brain: Identifying Biomarkers of Rumination and Mindfulness Through Concurrent EEG and Functional Magnetic Resonance Imaging (fMRI) Studies of Schizophrenia and Depression,Rescuing the Ruminating Brain: Identifying Biomarkers of Rumination and Mindfulness Through Concurrent EEG and fMRI Studies of Schizophrenia and Depression,WITHDRAWN,This study was not intended to be published as a trial.,,OBSERVATIONAL,0,"Schizophrenia, Depressive Disorder, Major",,OTHER,"Electroencephalography (EEG), Magnetic Resonance Imaging (MRI), Memory and Attention task",2018-11-01,2018-11-02,VA Office of Research and Development,FED
NCT03575195,Microbiota Intervention to Change the Response of Parkinson's Disease,Microbiota Intervention to Change the Response of Parkinson's Disease,SUSPENDED,Conducting an interim analysis,"PHASE1, PHASE2",INTERVENTIONAL,86,Parkinson Disease,Rifaximin,"DRUG, OTHER","MDS-UPDRS Part III, Percent of OFF time according to home motor diaries",2019-07-15,2026-08,"University of California, San Francisco",OTHER
NCT01040039,Pilot Study to Assess Gut Mucosal B Cells in Individuals With HCV and HIV,Pilot Study to Assess Gut Mucosal B Cells in Individuals Co-Infected With HCV and HIV,TERMINATED,Investigator left Rockefeller University,,OBSERVATIONAL,20,"HIV Infections, Hepatitis C Virus",,,"Numbers of HCV-specific gut mucosal B cells in HCV+HIV+, compared to HCV+HIV- subjects",2009-11,2011-09,Rockefeller University,OTHER
NCT01798277,Trial Comparing Ablation With Medical Therapy in Patients With Ventricular Tachycardia,Ablation Versus Medical Therapy in Patients With Coronary Artery Disease and Sustained Ventricular Tachycardia Randomized Trial (VeTAMed),WITHDRAWN,Low Enrolment,PHASE3,INTERVENTIONAL,0,"Ventricular Tachycardia, Coronary Artery Disease",Medical therapy (sotalol or amiodarone),"PROCEDURE, DRUG",Recurrence of Ventricular Tachycardia,2013-04,2015-12,Newmarket Electrophysiology Research Group Inc,OTHER
NCT02042677,Assessment of a Skin Barrier,User Assessment of a One-Piece Skin Barrier,TERMINATED,Slow recruitment of participants,,OBSERVATIONAL,18,Ileostomy,,,"barrier adhesion, barrier tack, comfort, leakage, ease of barrier removal",2014-01,2014-09,Hollister Incorporated,INDUSTRY
NCT01615536,The Role of Canine Fossa Trephination in the Severely Diseased Maxillary Sinus,The Role of Canine Fossa Trephination in the Severely Diseased Maxillary Sinus,WITHDRAWN,Inability to recruit subjects,NA,INTERVENTIONAL,0,"Disorder of Maxillary Sinus, Aspirin-sensitive Asthma With Nasal Polyps, Rhinosinusitis",,"PROCEDURE, PROCEDURE",Standard validated symptom scores,2010-12,2014-01,IWitterick,OTHER
NCT02053311,Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents,Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) Previously Treated With Novel Hormonal Agents and Non-progressive Disease After Treatment With a Taxane: A Multicentre Randomized Double-blind Placebo-controlled Phase III Trial,WITHDRAWN,"Due to former trials, drug has not demonstrated a clinical profile sufficient to move forward in mCRPC",PHASE3,INTERVENTIONAL,0,Prostate Cancer,"Orteronel, Placebo","DRUG, DRUG",Event-free survival,2014-08-19,2034-08-19,Swiss Cancer Institute,OTHER
NCT04805671,Evaluation of ADG20 for the Treatment of Mild or Moderate COVID-19,"A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ADG20 in the Treatment of Ambulatory Participants With Mild or Moderate COVID-19 (STAMP)",TERMINATED,"All primary efficacy data has been collected and analyzed. Based on the safety data gathered to date, it has been determined that continued participation by study subjects would not yield any additional beneficial safety information.","PHASE2, PHASE3",INTERVENTIONAL,399,COVID-19,"ADG20, Normal saline","DRUG, DRUG","Incidence of COVID-19 Related Hospitalizations or All-cause Death, Incidence of Treatment-emergent Adverse Events, Incidence of Solicited Injection Site Reactions, Changes From Baseline in Clinical Laboratory Tests (ie, CBC With Differential, Serum Chemistry, Coagulation), Changes From Baseline in Vital Signs (Body Temperature, Heart Rate, Respiration Rate, and Systolic and Diastolic Blood Pressure)",2021-07-26,2022-11-03,"Invivyd, Inc.",INDUSTRY
NCT03937271,Objective Measurement Methods for Autoimmune Disease and Dry Eye Syndrome,"Using the Objective Measurement Methods and TCM Questionnaire to Explore the Association Among TCM Pattern, TCM Tongue Diagnosis and TCM Pulse Diagnosis for Autoimmune Disease and Dry Eye Syndrome",WITHDRAWN,Leak of research funding,,OBSERVATIONAL,0,"Sjögren's Syndrome, Systemic Lupus Erythematosus, Rheumatoid Arthritis, Systemic Sclerosis, Ankylosing Spondylitis, Dry Eye Syndrome",,"DIAGNOSTIC_TEST, DIAGNOSTIC_TEST, DIAGNOSTIC_TEST, DIAGNOSTIC_TEST, DIAGNOSTIC_TEST","TCM pattern, TCM tongue diagnosis, TCM pulse diagnosis, Heart rate variability (HRV)",2019-04-01,2020-12-31,"Taipei Veterans General Hospital, Taiwan",OTHER_GOV
NCT04265534,"KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC","A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)",TERMINATED,Lack of Clinical Benefit,PHASE2,INTERVENTIONAL,40,"Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung, KEAP1 Gene Mutation, NRF2 Gene Mutation, NFE2L2 Gene Mutation","Telaglenastat, Carboplatin Chemotherapy, Pemetrexed Chemotherapy, Pembrolizumab Immunotherapy, Placebo, Dexamethasone 4 mg","DRUG, DRUG, DRUG, BIOLOGICAL, DRUG, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DRUG","Progression-Free Survival (PFS), Assessed by Investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, Safety and Tolerability of Telaglenastat Plus Standard-of-Care Pembrolizumab and Chemotherapy Assessed by Type, Incidence, Severity, Seriousness, and Study Drug Relatedness of Adverse Events per CTCAE v5.0, Recommended Phase 2 Dose of Telaglenastat in Combination with Standard-of-Care Pembrolizumab and Chemotherapy Assessed by Incidence and Nature of Protocol Defined Dose-Limiting Toxicities (DLTs) During the Safety Run-in Period",2020-07-24,2022-02-09,"Calithera Biosciences, Inc",INDUSTRY
NCT00686699,Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Participants With Schizophrenia (Study P04628),"A Phase 2a, Multiple Dose, Placebo Controlled, Randomized, Two Way Crossover Study to Assess the Efficacy of SCH 420814 in Reducing Anti Psychotic-Induced Extra Pyramidal Symptoms Among Subjects With Schizophrenia and Schizoaffective Disorders",TERMINATED,The study was terminated after 9 participants completed due to lack of enrollment for 6 months.,PHASE2,INTERVENTIONAL,11,"Akathisia, Drug-Induced, Dyskinesia, Drug-Induced, Parkinsonian Disorders","Preladenant, Placebo","DRUG, DRUG",Lowest Extrapyramidal Symptom Rating Score (ESRS) Total Score Within the 6-hour Evaluation on Day 14 of Each Treatment Period,2006-07-10,2008-03-06,Merck Sharp & Dohme LLC,INDUSTRY
NCT01747499,Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation,Phase I/II Trial of Intravenous Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation,TERMINATED,Enrolling 8 more patients would be statistically unlikely that the primary endpoint would be reached (reduce day 180 grade II-IV GVHD rates to 20% or less),"PHASE1, PHASE2",INTERVENTIONAL,54,"Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Precursor Cell Lymphoblastic Leukemia-Lymphoma",Azacitidine,DRUG,"Phase I: to Determine the Maximum Tolerated Dose (MTD) of Azacitidine in Patients Undergoing Matched (8 Out of 8) Unrelated Donor Transplant for Any Hematological Malignancy in Remission or With Stable Disease., Phase II: Number of Participants With Grades II-IV Acute GvHD",2013-04-15,2018-12-24,Washington University School of Medicine,OTHER
NCT02556463,A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors,"A Phase I, First-Time-in-Human Study of MEDI9197, a TLR 7/8 Agonist, Administered Intratumorally as a Single Agent in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors",TERMINATED,Company strategy,PHASE1,INTERVENTIONAL,53,"Solid Tumors, CTCL, Cancer","MEDI9197, durvalumab","DRUG, BIOLOGICAL","Safety and tolerability as determined by assessment of dose limiting toxicities and the maximum tolerated dose or maximal assessed dose per protocol of MEDI9197 when administered by intratumoral injection to subjects with solid tumor cancers, Safety and tolerability as determined by assessment of dose limiting toxicities and the maximum tolerated dose or maximal assessed dose per protocol of MEDI9197 when administered by intratumoral injection to subjects with CTCL, Safety & tolerability as determined by dose limiting toxicities and maximum tolerated or assessed dose of MEDI9197 administered by IT injection in combo with durvalumab and durvalumab plus palliative radiation to subjects with solid tumor cancers.",2015-11-04,2018-10-26,MedImmune LLC,INDUSTRY
NCT00386321,"Yt90 Zevalin and Combination Chemotherapy (Z-CHOP)in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-cell Lymphoma","Yt90Zevalin Plus CHOP, Z-CHOP",TERMINATED,Participants are no longer being examined or treated.,PHASE2,INTERVENTIONAL,10,Diffuse Large B-cell Lymphoma,Yttrium 90 -labeled ibritumomab tiuxetan (Zevalin),DRUG,2-year progression-free survival and overall survival of patients,2006-04,2010-01,Chulalongkorn University,OTHER
NCT01555021,Pharmacogenomics for Antidepressant Guidance and Education,Pharmacogenomics for Antidepressant Guidance and Education,TERMINATED,"The study was an inpatient, but PI left inpatient at MGH on July 1, 2012",,OBSERVATIONAL,4,Treatment Resistant Depression,,GENETIC,Change in Quick Inventory of Depressive Symptoms-Self Rating (SR) 16 Item,2011-12,2012-07,Massachusetts General Hospital,OTHER
NCT03698916,Delivra-Celecoxib 8% Cream and Osteoarthritis,A Multicenter Observational Study on the Use of Delivra-Celecoxib 8% Cream on Pain Experienced by Patients With Osteoarthritis of the Knees.,TERMINATED,Unable to recruit,,OBSERVATIONAL,6,"Osteoarthritis, Knee",Celecoxib cream 8%,DRUG,"Can study personnel enrol at least 70% of all eligible patients., Can study personnel collect 100% of the data scheduled to be collected from at least 70% of the enrolled subjects., Calculate the Sample standard deviation of Western Ontario and McMaster University (WOMAC) Osteoarthritis index scores from this population., Calculate Sample standard deviations of Patient Global Assessment (PGA) scores from this population., Calculate Sample standard deviations of Numeric Rating Score (NRS) Pain Index from this population.",2018-07-23,2019-05-02,Credit Valley Rheumatology,OTHER
NCT02204904,Observational Study to Evaluate Allogeneic HSCT Outcomes for Cerebral Adrenoleukodystrophy (CALD),A Prospective and Retrospective Data Collection Study to Evaluate Outcomes in Males ≤17 Years of Age Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Cerebral Adrenoleukodystrophy,TERMINATED,Sufficient enrollment for Month 24 safety and efficacy endpoints,,OBSERVATIONAL,59,"X-Linked Adrenoleukodystrophy (X-ALD), Cerebral Adrenoleukodystrophy (CALD), Adrenoleukodystrophy (ALD)",,GENETIC,"Incidence of transplant-related mortality (TRM)., Incidence and timing of neutrophil engraftment., Incidence and timing of platelet engraftment, Incidence of engraftment failure or allograft rejection., Incidence of primary donor-derived chimerism of ≥50%., Frequency and severity of Criteria for Adverse Events (CTCAE) ≥Grade 3 AEs, CTCAE ≥Grade 3 infections, and all SAEs., Proportion of subjects who experience either ≥Grade II acute (Graft versus Host Disease) GVHD or chronic GVHD., Incidence of ≥Grade II acute GVHD., Incidence of chronic GVHD., Number of emergency room visits., Number and duration of intensive care unit stay., Number and duration of in-patient hospitalization.",2015-04,2019-12-06,Genetix Biotherapeutics Inc.,INDUSTRY
NCT03026647,Suture Material for Closure of Hysterotomy,Evaluation of Suture Material for Closure of Hysterotomy,WITHDRAWN,Not moving forward staff shortage,,OBSERVATIONAL,0,"Cesarean Section; Complications, Wound, Hematoma",,PROCEDURE,Preferred suture,2017-01-31,2018-05,St. Louis University,OTHER
NCT01040338,Effects of Nicotine on Brain Opioid Receptors,Functional Characterization of OPRM1 A118G in Nicotine Dependence: IV Nicotine Study,TERMINATED,Issues \& unreliability with \[11C\]Carfentanil production,,OBSERVATIONAL,15,Nicotine Dependence,Nicotine,DRUG,MOR binding potential,2010-02,2011-03,University of Pennsylvania,OTHER
NCT02179138,Paper Applicator Acceptability Study,"EVALUATION OF A USER-FILLED, PAPER APPLICATOR FOR DELIVERY OF TENOFOVIR 1% GEL AMONG WOMEN IN RURAL KWAZULU-NATAL, SOUTH AFRICA",WITHDRAWN,Study no longer relevant based on change in regulatory pathway for TFV 1% gel,"PHASE1, PHASE2",INTERVENTIONAL,0,HIV Prevention,TFV 1% gel,DRUG,"Overall acceptability, context of use, challenges encountered, Applicator Preference",,,CONRAD,OTHER
NCT00035958,Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis,Toward Improved Understanding of Pathogenesis and Treatment of Childhood Onset Dermatomyositis,TERMINATED,Incorporating the recommendations of the NIH-formed DSMB in the study procedures would make the project budget over the limit for this funding mechanism.,"PHASE2, PHASE3",INTERVENTIONAL,75,Dermatomyositis,"Prednisone, Methotrexate, Etanercept","DRUG, DRUG, DRUG",,2002-08,2002-08,"Children's Hospital Medical Center, Cincinnati",OTHER
NCT00489658,"Eflornithine + Nifurtimox Late-Stage Human African Trypanosomiasis (HAT)in West Nile, Uganda","Efficacy and Safety of an Eflornithine + Nifurtimox Combination for Treatment of Late-Stage Human African Trypanosomiasis (HAT) in West Nile, Uganda",TERMINATED,"Because of unexpectedly reduced disease prevalence in the study area, a pragmatic decision was taken to terminate recruitment in March 2003.","PHASE2, PHASE3",INTERVENTIONAL,31,"Trypanosomiasis, African",Eflornithine plus Nifurtimox combination therapy,DRUG,"Treatment failure (death within 30 days of inclusion, or later if judged as related to Human African trypanosomiasis; termination of treatment due to adverse events; evidence of infection relapse at or after discharge, up to 24 months post discharge)",2002-10,,Epicentre,OTHER
NCT00886548,Echocardiographic Examination Performed by Nurses in Cardiac Intensive Care Unit,Echocardiographic Examination Performed by Nurses in Cardiac Intensive Care Unit. Is it Clinical Useful?,WITHDRAWN,Delayed inclusion,,OBSERVATIONAL,0,"Heart Failure, Myocardial Infarction, Pleural Effusion",,PROCEDURE,Change of diagnosis,2009-04,2010-05,Helse Nord-Trøndelag HF,OTHER
NCT05729048,Starling/CRRT Observational Study,Starling Continuous Renal Replacement Therapy (CRRT) Observational Study,WITHDRAWN,Study Sponsor decided not to move forward with this project.,,OBSERVATIONAL,0,Hemodynamic Monitoring,,DEVICE,"Change in stroke volume (SV) after CRRT initiation, Change in cardiac output (CO) after fluid removal, Change in cardiac index (CI) after fluid removal, Change in stroke volume (SV) after fluid removal, Change in stroke volume index (SVI) after fluid removal, Change in Thoracic Fluid Content (TFC) after fluid removal, Change in heart rate (HR) after fluid removal, Change in systolic blood pressure (SBP) after fluid removal, Change in diastolic blood pressure (DBP) after fluid removal, Change in central venous pressure (CVP) after fluid removal, Change in mixed venous oxygen saturation (SVO2) after fluid removal, Change in lactate after fluid removal, Changes in systolic blood pressure (SBP) from beginning to end of CRRT, Changes in diastolic blood pressure (DBP) from beginning to end of CRRT, Changes in mean arterial pressure (MAP) from beginning to end of CRRT",2023-07-15,2025-03-14,Baxter Healthcare Corporation,INDUSTRY
NCT00552578,Buprenorphine as a Treatment in Opiate Dependent Pain Patients,A Randomized Controlled Trial Testing Buprenorphine as a Treatment in Opiate Dependent Pain Patients,TERMINATED,"""Tapering doses"" protocol arm was not effective for treatment retention outcome.",PHASE4,INTERVENTIONAL,12,"Opiate Addiction, Refractory Pain","buprenorphine/naloxone, buprenorphine/naloxone","DRUG, DRUG",Relapse to Substance Abuse,2007-10,2008-10,State University of New York at Buffalo,OTHER
NCT04132778,Digital Prevention of Asthma,A Novel Digital Self-management System Targeting Automated Prevention of Asthma,TERMINATED,The recruitment stopped due insufficient funding.,NA,INTERVENTIONAL,331,"Asthma, Care Management, Patient",,DEVICE,Symptom control,2019-10-14,2024-12-01,Karolinska Institutet,OTHER
NCT06145880,ADOPT: Improving Diagnosis of Pulmonary Hypertension With AI and Echo,Artificial Intelligence: Improving Early Detection of Pulmonary Hypertension by Transthoracic Echocardiography: ADOPT,WITHDRAWN,The Commercial Funder withdrew the funding,,OBSERVATIONAL,0,Pulmonary Hypertension,,DIAGNOSTIC_TEST,"Detect patients with pulmonary hypertension (PH) with the novel artificial intelligence tool (AIT), Detect patients without pulmonary hypertension (PH) with the novel artificial intelligence tool (AIT), Detect patients with pre-capillary pulmonary hypertension (PH) with the novel artificial intelligence tool (AIT), Detect patients with post-capillary pulmonary hypertension (PH) with the novel artificial intelligence tool (AIT), Compare the artificial intelligence tool (AIT) performance for detecting pulmonary hypertension (PH) with the current probability criteria, Evaluate early detection capabilities of the artificial intelligence tool (AIT) compared to standard of care clinical diagnosis",2023-12-01,2025-12-01,Royal United Hospitals Bath NHS Foundation Trust,OTHER
NCT00569062,A Study of GW856553X For the Treatment of Depression,"A Randomized, Double Blind, Placebo Controlled Study to Explore the Antidepressant Properties of P38a Kinase Inhibitor GW856553X 15mg Compared to PBO in Subjects With Major Depressive Disorder Exhibiting Symptoms of Loss of Energy and Interest and Psychomotor Retardation, for a Six Week Treatment Period",TERMINATED,Negative data from a GSK PoC study in RA combined with evidence of greater sensitivity of toll-like receptor pathways to p38 inhibition.,PHASE2,INTERVENTIONAL,30,"Depressive Disorder, Major",GW856553X,"DRUG, OTHER","Change from Randomization at Week 6 in Bech subscale (6-item of 17-item Hamilton depression rating [HAMD-17] scale) score, Change from Randomization (Week 0) at Week 6 in Inventory for Depressive Symptomatology-Clinician rated (IDS-C) scale total score, Change from randomization (Week 0) at Week 6 in Quick Inventory of Depressive symptomatology 16 item self report (QIDS-SR16) scale total score, Change from Randomization (Week 0) at Week 6 in the morning serum levels of the pro-inflammatory biomarkers",2007-09-12,2008-06-25,GlaxoSmithKline,INDUSTRY
NCT03144661,An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies,"A Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies",TERMINATED,Strategic Business Decision,PHASE1,INTERVENTIONAL,25,"Hepatocellular Carcinoma (HCC), Cholangiocarcinoma, Esophageal Cancer, Nasopharyngeal Cancer, Ovarian Cancer, Solid Tumors",INCB062079,DRUG,Safety and tolerability of INCB062079 as measured by assessment of adverse events (AEs),2017-05-25,2020-06-10,Incyte Corporation,INDUSTRY
NCT00903461,Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma,Safety and Efficacy Evaluation of Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma,TERMINATED,drug supply issues,PHASE1,INTERVENTIONAL,7,"Carcinoma, Squamous Cell of Head and Neck, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma, Head And Neck",EGFR Antisense DNA,BIOLOGICAL,Disease progression,2012-04,2016-08,University of Pittsburgh,OTHER
NCT02055170,Neoadjuvant Finasteride for Patients With Non-small Cell Lung Cancer,Neoadjuvant Finasteride for Patients With Non-small Cell Lung Cancer,TERMINATED,Unable to improve on poor accrual to study.,PHASE2,INTERVENTIONAL,4,Non-small Cell Lung Cancer,finasteride 5mg oral daily,DRUG,Change in proliferation,2014-06,2018-03-27,CancerCare Manitoba,OTHER
NCT03341273,Placebo-Controlled Trial of Antibiotic Therapy in Adults With Suspect Lower Respiratory Tract Infection (LRTI) and a Procalcitonin Level,"Targeted Reduction of Antibiotics Using Procalcitonin in a Multi-center, Randomized, Double-Blinded, Placebo-Controlled Non-Inferiority Study of Azithromycin Treatment in Outpatient Adults With Suspect Lower Respiratory Tract Infection (LRTI) and a Procalcitonin (PCT) Level of < / = 0.25 ng/mL (TRAP-LRTI)",TERMINATED,Due to covid,NA,INTERVENTIONAL,514,Lower Respiratory Tract Infection,Azithromycin,"DRUG, OTHER, DEVICE",Clinical Improvement at Day 5 Visit (D5V),2017-12-08,2020-08-15,National Institute of Allergy and Infectious Diseases (NIAID),NIH
NCT00446173,Autologous Stem Cell Transplants for Chronic Myelogenous Leukemia,Autologous Purged Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia (CML),WITHDRAWN,Terminated due to low accrual.,PHASE2,INTERVENTIONAL,0,Leukemia,"Busulfan, Cyclophosphamide, G-CSF, GM-CSF","DRUG, DRUG, DRUG, DRUG","Time to absolute neutrophil count (ANC) recovery to 500, Survival Time",2007-03,2009-01,M.D. Anderson Cancer Center,OTHER
NCT04298983,Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced Prostate Cancer,Phase II Clinical Trial of Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced Prostate Cancer,TERMINATED,Abemaciclib efficacy,PHASE2,INTERVENTIONAL,9,Prostate Cancer,"Abemaciclib 150 MG by mouth twice daily, Androgen deprivation therapy (ADT)","DRUG, DRUG, RADIATION",Clinical Response Rates,2021-02-25,2024-09-04,University of Alabama at Birmingham,OTHER
NCT05385341,Rehabilitation Exercise with MObile Technology and Education After Acute Coronary Syndrome,Is Tele-rehabilitation an Efficacious Alternative to Traditional Center Based Cardiac Rehabilitation After Acute Coronary Syndrome?,WITHDRAWN,The start of the study took too long and there are already many publications on the subject,NA,INTERVENTIONAL,0,Acute Coronary Syndrome,,"OTHER, OTHER",Effect analysis 2 month after inclusion,2024-12,2025-12-31,"University Hospital, Toulouse",OTHER
NCT01680354,Surgical Correction of Astigmatism,Comparative Study of Surgical Laser Correction of Astigmatism,WITHDRAWN,Institution changed surgical method to small incision lenticule extraction. Study never started.,NA,INTERVENTIONAL,0,Astigmatism,,"PROCEDURE, PROCEDURE",Visual acuity,2012-09,,Aarhus University Hospital,OTHER
NCT00038766,CNI-1493 for Treatment of Moderate to Severe Crohn's Disease,"A Randomized, Double-Blind, Placebo-controlled Study of CNI-1493 for Treatment of Moderate to Severe Crohn's Disease",TERMINATED,Unable to enroll into study.,PHASE2,INTERVENTIONAL,33,Crohn Disease,"semapimod, semapimod, placebo","DRUG, DRUG, DRUG",Change in CDAI,2002-06,2003-06,Ferring Pharmaceuticals,INDUSTRY
NCT06226766,JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors,"Phase I/II Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors",TERMINATED,the decision is based on a strategic realignment of our clinical trial priorities to optimize the overall development pathway for JSKN033,"PHASE1, PHASE2",INTERVENTIONAL,11,Advanced Solid Tumor,JSKN033 Injection,DRUG,"Incidence and severity of treatment-emergent adverse events (TEAEs), treatment-related adverse events (TRAEs), serious adverse events (SAEs), assessed by CTCAE V5.0, RP2D( recommend Phase II dose), DLTs （Dose-limiting toxicities）, Objective Response Rate (ORR) Following Treatment With JSKN033 in Participants With Advanced Solid Malignant Tumors",2024-01-18,2025-07-31,"Jiangsu Alphamab Biopharmaceuticals Co., Ltd",INDUSTRY
NCT02906722,Nebulized and Intravenous Colistin in Ventilator Associated-pneumonia,"Efficacy of Nebulized Versus Intravenous Colimycin for Treating Ventilator-associated Pneumonia Caused by Gram-negative Multidrug-resistant Bacteria: a Prospective, Multicenter, Randomized and Double-blind Study",TERMINATED,Lack of inclusion,PHASE3,INTERVENTIONAL,7,Ventilator-associated Pneumonia,"Intravenous colimycin, Intravenous placebo, Nebulized colimycin, Nebulized placebo","DRUG, DRUG, DRUG, DRUG",Clinical cure of VAP caused by Gram-negative multidrug resistant bacteria,2017-07-31,2018-06-19,Assistance Publique - Hôpitaux de Paris,OTHER
NCT01156051,Effect of Guanfacine Extended-Release on Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia,Effect of Guanfacine Extended-Release on Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia,TERMINATED,extended beyond completion date; chose to close out rather than renew IRB review,PHASE4,INTERVENTIONAL,29,"Attention-Deficit/Hyperactivity Disorder, Attention Deficit Disorder, Insomnia, Sleep Disorders","Guanfacine extended-release tablets, Placebo comparator","DRUG, DRUG",Change in Polysomnographic Total Sleep Time (TST),2010-06,2012-02,Children's Specialized Hospital,OTHER
NCT02088151,Selective Retinal Pigment Epithelium Laser Therapy for Macular Disease of the Retina,Selective Retinal Pigment Epithelium Laser Therapy (SRT) for Macular Disease of the Retina,TERMINATED,Suitable device for laser no longer available,NA,INTERVENTIONAL,18,"Macular Edema, Central Serous Chorioretinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration, Retinal Neovascularization",,DEVICE,Visual Acuity according to ETDRS protocol,2010-06,2022-02-01,"Insel Gruppe AG, University Hospital Bern",OTHER
NCT03672851,Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Leukemia,Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Leukemia,TERMINATED,adverse effect,PHASE1,INTERVENTIONAL,2,"Acute Leukemia, Acute Leukemia in Relapse, Acute Myeloid Leukemia, Relapsed or Refractory Acute Leukemia",anti-CD123 CAR-T treatment,DRUG,"Dose-limiting toxicity (DLT), Incidence of adverse events, Disease response (CR or CRi)",2019-04-17,2019-07-31,Second Affiliated Hospital of Xi'an Jiaotong University,OTHER
NCT02037529,Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer,A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer,SUSPENDED,Total enrollment number is being lowered,PHASE3,INTERVENTIONAL,201,"Breast Adenocarcinoma, HER2/Neu Negative, Invasive Breast Carcinoma, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7","Eribulin Mesylate, Paclitaxel","DRUG, OTHER, DRUG, OTHER","Cumulative Dose Level Triggering a Grade 2 or Higher Neuropathy Event., Mean Change in Patient Reported PRO-CTCAE",2014-01-17,2024-10-31,Academic and Community Cancer Research United,OTHER
NCT00216437,Dose Escalation Study Combining Oral Capecitabine (Xeloda) and Radiotherapy for Patients With Unresectable Liver or Cholangiocarcinoma,"A Phase I Dose Escalation Study to Assess the Maximum Tolerated Dose and Feasibility of Combining Oral Capecitabine (Xeloda) and Conformal Radiotherapy (CRT) for Patients With Unresectable Hepatocellular Carcinoma, Multiple Hepatic Metastases or Cholangiocarcinoma",TERMINATED,lack of accrual,PHASE1,INTERVENTIONAL,30,Cancer of Liver,Capecitabine (Xeloda),DRUG,Dose-limiting toxicity.,2004-12,2007-03,James A. Haley Veterans Administration Hospital,FED
NCT04823845,Plantar Wart Treatment Using Adapalene Gel,Plantar Wart Treatment Using Adapalene Gel,WITHDRAWN,Study never received IRB approval.,EARLY_PHASE1,INTERVENTIONAL,0,Plantar Wart,Topical Adapalene Gel 0.1%,DRUG,Time Until Plantar Wart Resolution,2022-05-01,2023-02-10,University of Louisville,OTHER
NCT05029154,Exercise Preconditioning in Ovarian Cancer,Effect of Exercise Preconditioning in Ovarian Cancer on Treatment-Related Cardiotoxicity,TERMINATED,Accrual not meeting pre-specified numbers.,NA,INTERVENTIONAL,8,Ovarian Cancer,,"BEHAVIORAL, BEHAVIORAL",VO2 Peak,2021-10-21,2025-06-04,University of Virginia,OTHER
NCT05645822,Screen and Treat Implementation for HAT Control,Screen and Treat Implementation in Insecure Areas With Limited Capacities for HAT Control,WITHDRAWN,"There is a problem with the provision of the treatment, we are unable to provide sufficient number of treatments for the study participants",,OBSERVATIONAL,0,"Sleeping Sickness, Trypanosomiasis, African",,OTHER,Assess the feasibility of an alternative operational approach for the diagnosis and treatment of gHAT patients in areas with limited access and diagnostic capacities.,2024-01-01,2024-01-30,"Institute of Tropical Medicine, Belgium",OTHER
NCT01400451,Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF),A Phase I Trial of Vemurafenib and Ipilimumab in Subjects With V600 BRAF Mutation-positive Metastatic Melanoma,TERMINATED,More than 2 of 6 patients treated experienced dose limiting toxicities.,PHASE1,INTERVENTIONAL,18,Melanoma,"Ipilimumab (BMS-734016), Vemurafenib","DRUG, DRUG","During the Lead In Period: Number of Participants With Adverse Events (AEs), AEs Leading to Drug Discontinuation, Serious Adverse Events (SAEs), and Deaths in Participants Treated With Vemurafenib Alone, During the Combination Treatment Period: Number of Participants With Adverse Events (AEs), AEs Leading to Drug Discontinuation, Serious Adverse Events (SAEs), and Deaths in Participants Treated With Concurrent Ipilimumab and Vemurafenib, Number of Participants With Hepatic Dose Limiting Toxicities (DLT) in Participants Treated With Concurrent Ipilimumab and Vemurafenib",2011-11,2013-12,Bristol-Myers Squibb,INDUSTRY
NCT00620945,Use of Phenoxybenzamine [PBZ] IV to Assist High Flow Low Pressure Perfusion [HFLPP] on Cardio-pulmonary Bypass,Use of Phenoxybenzamine [PBZ] IV to Assist High Flow Low Pressure Perfusion [HFLPP] on Cardio-pulmonary Bypass in Infants and Children With Congenital Heart Disease and to Assist Steady State Alfa-blockade in the Intensive Care Phase,TERMINATED,New protocol now being used for cardiopulmonary bypass,NA,INTERVENTIONAL,87,"Congenital Heart Surgery, Cardiopulmonary Bypass",Phenoxybenzamine,DRUG,Number of Participants Achieving High Flow Low Pressure on Cardiopulmonary Bypass,2006-06,2009-02,The Cleveland Clinic,OTHER
NCT01377545,Continuous Infraclavicular Nerve Blocks: Needle Versus Catheter Local Anesthetic Bolus,Continuous Infraclavicular Nerve Blocks: Needle Versus Catheter Local Anesthetic Bolus,WITHDRAWN,lack of funding,PHASE4,INTERVENTIONAL,0,Nerve Block,,"PROCEDURE, PROCEDURE",Sensory Level,2013-01,2013-01,"University of California, San Diego",OTHER
NCT02035345,Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment,Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment,TERMINATED,Extended Carboplatin Infusion did not Reduce Frequency of Hypersensitivity Reactions,PHASE4,INTERVENTIONAL,15,"Recurrent Ovarian Cancer, Platinum Sensitive Ovarian Cancer",Carboplatin,DRUG,"Number of Participants With Carboplatin Infusion Hypersensitivity Reactions Using a Slowed Carboplatin Infusion Program, Number of Patients With Carboplatin Reactions of Different Severity",2014-01,2016-06,Massachusetts General Hospital,OTHER
NCT04329572,Efficacy and Safety of Hydroxychloroquine and Azithromycin for Patients With Moderate to Severe COVID-19,"Open, Multicentric, Non Randomized, Exploratory Clinical Trial to Assess the Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Acute Respiratory Syndrome (COVID-19) Caused by SARS-CoV-2 Virus",SUSPENDED,"Azidus, the CRO hired for this study by Prevent Senior has lost the interest to conduct this study.",EARLY_PHASE1,INTERVENTIONAL,400,COVID-19,"Hydroxychloroquine Sulfate, Azithromycin Tablets","DRUG, DRUG","Evolution of acute respiratory syndrome, oxygen saturation hemodynamic stability",2020-04-23,2023-06-30,Azidus Brasil,INDUSTRY
NCT03601572,Hypnoanalgesia in Surgical and Endovenous Treatment of Varicosis,Hypnoanalgesia in Surgical and Endovenous Treatment of Varicosis,WITHDRAWN,Abandoned research,,OBSERVATIONAL,0,Varicose Veins,,OTHER,"Evaluate the effects of hypnosis, Evaluate the effects of hypnosis",2018-09-02,2018-10-01,"University Hospital, Montpellier",OTHER
NCT04254172,A Low Interventional Study to Monitor Activity Using Wearable Sensors in Duchenne Muscular Dystrophy,"A SINGLE-SITE, PROSPECTIVE, NATURAL HISTORY LOW INTERVENTIONAL STUDY TO ESTABLISH NORMATIVE DATA OF REAL-WORLD ACTIVITY MEASURES USING WEARABLE SENSORS IN AMBULATORY BOYS WITH DUCHENNE MUSCULAR DYSTROPHY (DMD)",TERMINATED,"This low-interventional study (involving no study drug) has been terminated early due to the COVID-19 pandemic, and not for any safety or efficacy reasons.",,OBSERVATIONAL,2,Duchenne Muscular Dystrophy (DMD),,DEVICE,Mean change from baseline and variability of activity measures,2020-02-19,2020-08-19,Pfizer,INDUSTRY
NCT04460495,Quantifying Oxygen Utilization of Tumors Using Oxygen-Enhanced Molecular MRI,Quantifying Tumor Respiration Using Oxygen-Enhanced Molecular MRI,TERMINATED,insufficient accrual,NA,INTERVENTIONAL,8,Malignant Brain Neoplasm,,"PROCEDURE, PROCEDURE, PROCEDURE","Change in pH-weighted amine CEST MRI to measure tumor acidity (MTRasym at 3ppm) before/after oxygen enrichment, Change in oxygen-weighted SAGE-EPI to measure oxygen extraction (R2') before and after oxygen enrichment, Tumor blood flow as measured by cerebral blood flow (CBF) from arterial spin labeling (ASL).",2020-07-07,2021-09-16,Jonsson Comprehensive Cancer Center,OTHER
NCT01600677,Determining the Impact of a Medication Delivery Unit on Medication Adherence of Adults With Common Cardiac Conditions,Determining the Impact of a Medication Delivery Unit on Medication Adherence Immediately Following Hospitalization of Adults With Common Cardiac Conditions,TERMINATED,"Terminated on 2/28/13, low enrollment; last participant med visit 5/13/13.",NA,INTERVENTIONAL,11,"Medication Adherence, Medication Nonadherence, Adverse Reaction to Drug",,"DEVICE, OTHER",Medication Adherence,2012-05,2013-05,University of Pittsburgh,OTHER
NCT05189977,A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline,"A Phase 1, Open-label, Fixed-sequence, Cross-over Trial to Assess the Effects of a Single Dose of Prazosin or Propranolol in the Presence of Brexpiprazole/Sertraline at Steady-state on Blood Pressure",TERMINATED,"The decision to terminate the trial early was not based on safety concerns. The trial was terminated early due to some implausible blood pressure values being captured, which was the primary endpoint of the study.",PHASE1,INTERVENTIONAL,34,Post-traumatic Stress Disorder (PTSD),"Propranolol, Prazosin","DRUG, DRUG","Changes between the control and treatment periods on Day 19 vs. Day 1, Day 20 vs. Day 2, and Day 21 vs. Day 3, with prazosin or propanolol in the presence of brexpiprazole + sertraline or sertraline alone at steady state, Maximum change in SBP, measured in mmHg, from supine to standing position in the presence of brexpiprazole + sertraline or sertraline alone at steady state will be assessed., Maximum change in diastolic blood pressure (DBP), measured in mmHg, from supine to standing position in the presence of brexpiprazole + sertraline or sertraline alone at steady state will be assessed., Maximum change in resting heart rate (HR), measured in beats per minute (bpm), from supine to standing position will be assessed in the presence of brexpiprazole + sertraline or sertraline alone at steady state will be assessed.",2022-09-07,2023-08-03,"Otsuka Pharmaceutical Development & Commercialization, Inc.",INDUSTRY
NCT05862675,The Role and Mechanism of Immune Regulation in Acute Lung Injury in Children,The Role and Mechanism of Immune Regulation in Acute Lung Injury in Children,WITHDRAWN,"Due to a time conflict in the research, the project research has been temporarily suspended.",,OBSERVATIONAL,0,Acute Lung Injury,,DIAGNOSTIC_TEST,Degree of inflammation in acute lung injury through measure physiological parameter,2023-05-02,2026-05-30,Children's Hospital of Chongqing Medical University,OTHER
NCT05999357,JDQ443 for KRAS G12C NSCLC Brain Metastases,A Phase II Study evaluaTing intRacranial effIcacy of JDQ443 in patiEnts With KRAS G12C+ NSCLC and bRain Metastases,WITHDRAWN,Novartis discontinued develpment of JDQ443,PHASE2,INTERVENTIONAL,0,"Non Small Cell Lung Cancer Metastatic, Brain Metastases, Adult, KRAS G12C",JDQ443,DRUG,brain metastases overall response rate (ORR),2024-04-15,2028-08,Maastricht University Medical Center,OTHER
NCT00480857,Salvage Radiation Therapy and Taxotere for PSA Failure After Radical Prostatectomy,Salvage Radiation Therapy and Docetaxel (Taxotere) for Biochemical Failure After Radical Prostatectomy,TERMINATED,Lack of funding.,PHASE2,INTERVENTIONAL,19,Prostate Cancer,Docetaxel (Taxotere),DRUG,Percentage of Patients Alive Without Progression at 4 Years,2007-03,2014-07,University of Michigan Rogel Cancer Center,OTHER
NCT01009957,Everolimus on CKD Progression in ADPKD Patients,Everolimus on CKD (Chronic Kidney Disease) Progression in ADPKD Patients,TERMINATED,"After primary completition date, experimental drug was no longer available","PHASE2, PHASE3",INTERVENTIONAL,71,Polycystic Kidney Diseases,Everolimus,DRUG,Reduction of GFR (according to MDRD formula) during a two-year follow up,2008-06,2015-06,A. Manzoni Hospital,OTHER
NCT01776957,Post Abortion IUD & Recurrent Abortion 2005-2006,Preventing Repeat Abortion: Is the Immediate Insertion of Intrauterine Devices Post-abortion a Cost-effective Option Associated With Fewer Repeat Abortions? Findings From 2005-2006 Data,TERMINATED,"This study is a retrospective chart review study, not a clinical trial.",,OBSERVATIONAL,1308,Induced Abortion,,DEVICE,The proportion of repeat abortions at five years from the index abortions,2012-07,2012-12,University of British Columbia,OTHER
NCT02576457,"Safety, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Severe Sepsis","A Phase 1b/2a, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Subjects With Severe Sepsis",TERMINATED,Business Objectives Have Changed,PHASE1,INTERVENTIONAL,35,"Severe Sepsis, Septic Shock",BMS-936559,"BIOLOGICAL, OTHER","Part 1: Safety of BMS-936559 in subjects with severe sepsis - measured by the incidence rates of death, AEs, SAEs, AEs leading to discontinuation, AEs of special interest and laboratory abnormalities, Part 1: Tolerability of BMS-936559 in subjects with severe sepsis, Part 2: All-cause mortality within 90 days of study drug administration",2015-12-02,2017-03-15,Bristol-Myers Squibb,INDUSTRY
NCT05505201,Effectiveness of Transcranial Magnetic Stimulation in Subacute Stroke Patients With Severe Upper Limb Paresis,Effectiveness of Add-on Inhibitory Repetitive Transcranial Magnetic Stimulation Over the Contralesional Primary Motor Cortex in Subacute Stroke Patients With Severe Upper Limb Motor Impairment,TERMINATED,It seems almost impossible to reach the specified sample size.,NA,INTERVENTIONAL,6,Stroke Rehabilitation,,"DEVICE, DEVICE",Change from baseline in the Fugl-Meyer Assessment for Upper Extremity,2022-11-11,2025-05-28,Izmir Katip Celebi University,OTHER
NCT01856881,Multiple Ascending Dose Study in Subjects With Type 2 Diabetes,"A Randomized, Double-blind, Placebo-controlled, Ascending Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 876 in Subjects With Type 2 Diabetes",TERMINATED,"This study was terminated on August 29th, 2014 due to a business decision by the Sponsor. The study was not terminated due to a safety reason.",PHASE1,INTERVENTIONAL,86,Diabetes Mellitus,AMG 876,DRUG,"Subject incidence of treatment-emergent adverse events, Subject incidence of anti-AMG 876 antibodies",2013-03,2015-03,Amgen,INDUSTRY
NCT06378528,Ketamine-assisted Psychotherapy for Adolescent PTSD (KAP),A Preliminary Trial of Safety and Feasibility of Ketamine-assisted Psychotherapy in Adolescents With Posttraumatic Stress-disorder,SUSPENDED,Budgeting/funding,EARLY_PHASE1,INTERVENTIONAL,5,Posttraumatic Stress Disorder,Ketamine,"DRUG, DEVICE",Summary of Adverse Events Attributable to Ketamine Administration,2026-03,2027-03,"University of Wisconsin, Madison",OTHER
NCT05123586,A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Two-Arm, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of LY3361237 as a Treatment for Adults With At Least Moderately Active Systemic Lupus Erythematosus",TERMINATED,Study terminated due to lack of efficacy,PHASE2,INTERVENTIONAL,85,Systemic Lupus Erythematosus,"LY3361237, Placebo","DRUG, DRUG",Percentage of Participants With Arthritis and/or Rash at Baseline Who Achieve Remission of Arthritis and/or Rash,2022-03-07,2023-12-29,Eli Lilly and Company,INDUSTRY
NCT03994783,Transplant Antibody-Mediated Rejection: Guiding Effective Treatments,A Multicentre Randomised Controlled Trial to Assess the Efficacy of Adding Rituximab to Standard of Care in Treating Acute Antibody-mediated Rejection in Kidney Transplantation,TERMINATED,Stopped at start of COVID-19 pandemic - non-feasible,PHASE3,INTERVENTIONAL,3,"Kidney Transplant Rejection, Antibody-mediated Rejection","Rituximab, Methylprednisolone, Intravenous Immunoglobulin","DRUG, DRUG, DRUG, PROCEDURE",Allograft Survival as assessed by statistical model,2019-07-17,2023-01-09,Imperial College London,OTHER
NCT00532883,Hydroxyurea and Magnesium Pidolate to Treat People With Hemoglobin Sickle Cell Disease,Effectiveness of Hydroxyurea and Magnesium Pidolate Alone and in Combination in Hemoglobin SC Disease: A Phase II Trial,TERMINATED,Enrollment has been terminated due to a slow rate of enrollment.,PHASE2,INTERVENTIONAL,44,Hemoglobin SC Disease,"Hydroxyurea, Magnesium Pidolate","DRUG, DRUG, OTHER",Distribution of the Density of Hemoglobin SC Red Cells,2007-01,2009-08,St. Jude Children's Research Hospital,OTHER
NCT03359941,Acupuncture Treatment for Vertebral Compression Fracture,Acupuncture Treatment for Pain Relief and Functional Recovery in Patients With Vertebral Compression Fracture,TERMINATED,Low recruit rate,NA,INTERVENTIONAL,7,"Spinal Fracture, Compression Fracture, Fractures, Bone",,PROCEDURE,Pain intensity on the Visual Analog Scale (VAS),2016-02-01,2016-12-19,Korean Medicine Hospital of Pusan National University,OTHER
NCT01929954,Safety Study of Gintuit™ in Subjects Requiring Socket Grafting,"Phase 1/2, Randomized, Controlled Assessment of the Safety Of Gintuit™ Versus Bio-Gide® in Subjects Requiring Socket Grafting",TERMINATED,Changes in corporate business environment,"PHASE1, PHASE2",INTERVENTIONAL,5,Edentulous Alveolar Ridge,Gintuit,"BIOLOGICAL, DEVICE",Number of participants with adverse events,2013-07,2015-03,Organogenesis,INDUSTRY
NCT02129205,A Dose Escalation Study of PF-06650808 in Patients With Advanced Solid Tumors,A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF-06650808 IN PATIENTS WITH ADVANCED SOLID TUMORS,TERMINATED,The study was terminated due to a change in sponsor prioritization.,PHASE1,INTERVENTIONAL,40,"Neoplasms, Breast Cancer","PF-06650808, PF-06650808","DRUG, DRUG","Number of Participants With Dose-limiting Toxicities (DLT) (Part 1), Percentage of Participants With Objective Response (Part 1 and Part 2)",2014-06,2017-07,Pfizer,INDUSTRY
NCT03984305,Utilization of Target Ranges to Treat Parkinson's Disease With the PKG,Utilization of Target Ranges to Treat Patients With Parkinson's Disease by Objective Measurement Using the Personal KinetiGraph® (PKG®) Compared to Standard of Care Assessment (TARGET-PD)- A Randomized Controlled Trial,TERMINATED,Terminated due to significant protocol updates that resulted in initiating a new study,NA,INTERVENTIONAL,41,Parkinson Disease,,"DEVICE, DEVICE",Change in Patient Outcomes Using Movement Disorder Specialist - Unified Parkinson's Disease Rating Scale (MDS-UPDRS),2019-10-15,2020-10-16,Global Kinetics Corporation,INDUSTRY
NCT06215794,Effect of Glossopharyngeal Nerve Block on Pharyngeal Dysphagia Induced by Gastroesophageal Reflux Disease,A Randomized Controlled Study to Explore the Effect of Glossopharyngeal Nerve Block on Pharyngeal Dysphagia Induced by Gastroesophageal Reflux Disease,WITHDRAWN,ethical issues,NA,INTERVENTIONAL,0,Dysphagia,,"BEHAVIORAL, PROCEDURE",Rosenbek penetration-aspiration scale,2024-01-30,2024-05-15,Zeng Changhao,OTHER
NCT05227456,Failed Endometrial Ablation Treatment With Implantable Progesterone (FEAT) Study,Failed Endometrial Ablation Treatment With Implantable Progesterone (FEAT) Study,WITHDRAWN,Difficulty in Recruitment,PHASE2,INTERVENTIONAL,0,"Abnormal Uterine Bleeding, Dysmenorrhea",Etonogestrel 68mg implant,"DRUG, DEVICE",Hysterectomy,2022-07-01,2024-04-30,Saskatchewan Health Authority - Regina Area,OTHER
NCT03174522,The Efficacy and Safety of REX-001 to Treat Ischemic Ulcers in Subjects With CLI Rutherford Category 5 and DM,"The Efficacy and Safety of Intra-arterial Administration of REX-001 to Treat Ischemic Ulcers in Subjects With Critical Limb Ischemia (CLI) Rutherford Category 5 and Diabetes Mellitus: A Pivotal, Placebo-controlled, Double-blind, Parallel-group, Adaptive Trial",TERMINATED,Independent Data Monitoring Committee recommendation to stop due to futility,PHASE3,INTERVENTIONAL,49,"Peripheral Arterial Disease (PAD), Diabetes Mellitus (DM), Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Cardiovascular Disease, Critical Limb Ischemia (CLI)","REX-001, Placebo","DRUG, DRUG",Complete healing of all ischemic ulcers on the index leg.,2017-04-25,2023-02-13,Ixaka Ltd,INDUSTRY
NCT03893331,AcQMap® Global Registry of Procedural and Long-term Clinical Outcomes (AcQMap Registry),AcQMap® Global Registry of Procedural and Long-term Clinical Outcomes (AcQMap Registry),TERMINATED,Sponsor no longer performing clinical studies. Will be only a manufacturing facility,,OBSERVATIONAL,479,Ablation of Arrhythmia's,,DEVICE,Procedural Ablation Outcomes,2019-06-13,2023-11-08,Acutus Medical,INDUSTRY
NCT01474031,Prospective Study Deltamotion - DAA THA Study,Prospective Study Deltamotion - DAA THA Study,TERMINATED,Main investigator has left the department and therefore the study had ended,,OBSERVATIONAL,29,Arthrosis,,OTHER,biomechanics,2011-10,2013-07,Universitaire Ziekenhuizen KU Leuven,OTHER
NCT00990522,Study of the Efficacy of Sharp Debridement for the Management of Chronic Wounds,"A Prospective, Randomized, Controlled Study of the Efficacy of Sharp Debridement for the Management of Chronic Wounds",WITHDRAWN,"No participants enrolled, per PI discretion",NA,INTERVENTIONAL,0,Wounds,,PROCEDURE,The primary objective of this study is to evaluate subjects enrolled and randomized to the weekly sharp debridement group.,2009-05,2011-02,Southwest Regional Wound Care Center,OTHER
NCT00635531,A Study to Evaluate the Use of Extended Release Alprazolam in the Treatment of Adolescents With Panic Disorder,"A Randomized, Double-blind, Placebo-controlled Study of Xanax XR in the Treatment of Adolescents With a Primary Diagnosis of Panic Disorder",TERMINATED,Please see Detailed Description for termination reason.,PHASE4,INTERVENTIONAL,16,Panic Disorder,alprazolam XR,"OTHER, DRUG","Endpoint change from baseline in the Panic Disorder Severity Scale for Adolescents (PDSS-A) total score, Endpoint change from baseline in the weekly frequency of 4-symptom panic attacks",2004-04,2004-09,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,INDUSTRY
NCT05450445,myHealthHub for Older Adult Inpatients,"myHealthHub for Older Adult Inpatients to Lower Loneliness and Improve Patient Engagement, Quality of Life and Mental Health",WITHDRAWN,"In the post-COVID environment, we had great difficulty convincing a hospital to join us and collaborate with us, so the study was dropped. We did not formally start the study or recruit any participants.",NA,INTERVENTIONAL,0,"Patient Engagement, Stress, Loneliness, Quality of Life",,"DEVICE, DEVICE",Changes in Loneliness,2022-09-01,2023-09-01,Lady Davis Institute,OTHER
NCT00415272,Pulmonary Rehabilitation in Patients With Fibrotic Interstitial Lung Disease,,TERMINATED,Inadequate enrollment.,NA,INTERVENTIONAL,,Fibrotic Interstitial Lung Disease,,BEHAVIORAL,,,2007-07,"University of California, San Francisco",OTHER
NCT03119077,"Single Ascending Dose, First-in-Human Study on Safety, Tolerability and Pharmacokinetics of BAY1161116","Randomized, Double-blind, Placebo-controlled, Escalating Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of Orally Administered BAY1161116 in Healthy Postmenopausal Women Including Food-effect and Drug-drug-interaction With Itraconazole",TERMINATED,Study early terminated due to lower drug exposure,PHASE1,INTERVENTIONAL,32,Polycystic Ovary Syndrome,"BAY1161116, Placebo, Itraconazole","DRUG, DRUG, DRUG","Incidence of TEAEs, Severity of TEAEs, AUC of BAY1161116, Cmax of BAY1161116",2017-04-27,2018-01-31,Bayer,INDUSTRY
NCT00470639,Transcranial Magnetic Stimulation for Bipolar Depression,A Comparison of Left vs. Right Prefrontal Cortex Transcranial Magnetic Stimulation as a Treatment for Bipolar Depression,WITHDRAWN,Poor recruitment,"PHASE1, PHASE2",INTERVENTIONAL,0,Bipolar Depression,,DEVICE,"All measures at baseline and at the end of each week of treatment in the blind phase and after every 2 weeks of treatment in the open phase., Montgomery-Asberg Depression Rating Scale (MADRS), Clinical Global Impressions Scale (CGI)",2007-04,2008-12,The University of New South Wales,OTHER
NCT02714439,Low-Cost Imaging for Cervical Cancer Prevention in the Texas Lower Rio Grande Valley,Low-Cost Imaging for Cervical Cancer Prevention in the Texas Lower Rio Grande Valley,TERMINATED,PI has left the institution,EARLY_PHASE1,INTERVENTIONAL,157,Malignant Neoplasms of Female Genital Organs,Proflavine,"DRUG, PROCEDURE",Diagnostic Accuracy of the High-Resolution Microendoscopy (HRME),2016-10-25,2024-02-09,"The University of Texas Medical Branch, Galveston",OTHER
NCT04160039,Early Cycle Ergometry for Critically-Ill Liver Failure Patients in a Transplant Intensive Care Unit,Early Cycle Ergometry for Critically-Ill Liver Failure Patients in a Transplant Intensive Care Unit,TERMINATED,Principal Investigator left institution,NA,INTERVENTIONAL,97,"Liver Cirrhoses, Liver Failure, ICU Acquired Weakness",,DEVICE,Functional Status Score for the Intensive Care Unit (FSS-ICU),2019-11-10,2022-09-01,Medical College of Wisconsin,OTHER
NCT03130439,"Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer","A Phase 2 Study of Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer",TERMINATED,Slow accrual,PHASE2,INTERVENTIONAL,27,Breast Cancer,Abemaciclib,DRUG,Objective Response Rate,2017-05-26,2022-01-30,Dana-Farber Cancer Institute,OTHER
NCT01948219,ENTegral Artificial Larynx Clinical Trial,An Evaluation of the ENTegral Artificial Larynx (AL) in Patients Indicated for Total Laryngectomy,TERMINATED,Lack of recruitment,NA,INTERVENTIONAL,2,Total Laryngectomy,,DEVICE,Feasibility of device implant procedure,2014-10,2016-06-30,ProTiP Medical,INDUSTRY
NCT01351519,A Study of Aminolevulinic Acid Used to Enhance Visualization and Surgical Removal of Brain Tumors,A Phase 2 Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain,TERMINATED,Limited staff available for enrollment and limited availability of drug,PHASE2,INTERVENTIONAL,16,"Malignant Glioma, Glioma, Glioblastoma, Glioblastoma Multiforme, Astrocytoma",Aminolevulinic Acid,DRUG,"Time to disease progression after initial surgery., Complete Resection",2011-05,2015-01,MultiCare Health System Research Institute,OTHER
NCT02923830,Maintaining Patency in BioFlo Implanted Port Catheters With Saline Only Flushes,Maintaining Patency in BioFlo Implanted Port Catheters With Saline Only Flushes,TERMINATED,"We stopped inserting BioFlo ports, no more patients to recruit",PHASE4,INTERVENTIONAL,28,"Obstruction; Catheter, Infusion Catheter (Vascular), Catheter; Complications (Indwelling Catheter)",Saline-only catheter flush,"OTHER, DRUG","Number of Participants With Occurrence of First Complete Occlusion (Blockage), Number of Participants With Occurrence of First Partial Occlusion (Blockage), Number of Participants Who Required CathFlo (Alteplase) to Resolve an Occlusion",2016-04,2019-03-26,TriHealth Inc.,OTHER
NCT02885142,Early Rectal Cancer: Endoscopic Submucosal Dissection or Transanal Endoscopic Microsurgery?,,TERMINATED,difficulties to recruit all the patients,NA,INTERVENTIONAL,368,Anal Cancer,,PROCEDURE,Number of complete excision for TEM compare to number of complete excision for ESD in rectal carcinomas staged usT1N0 and rectal adenomas.,2016-11,2022-08-24,Assistance Publique Hopitaux De Marseille,OTHER
NCT00641342,Prevention of Parastomal Hernia by Primary Mesh Insertion,Prevention of Parastomal Hernia by Primary Mesh Insertion: a Randomized Double-blinded Controlled Multi-centre Study.,TERMINATED,Lack of recruitment from different study sites and due to structural changes in the included centers,"PHASE2, PHASE3",INTERVENTIONAL,198,Parastomal Hernia,,DEVICE,Parastomal hernia verified by CT-scan,2007-03,2015-02,"University Hospital, Gentofte, Copenhagen",OTHER
NCT04529070,Nightmare Rescripting and Rehearsal,Nightmare Rescripting and Rehearsal: Testing a 10-Minute Intervention to Treat Recurring Distressing Dreams in Primary Care.,TERMINATED,Lack of Funding and PI separated from the Air Force,NA,INTERVENTIONAL,68,"Nightmare, Sleep",,"BEHAVIORAL, BEHAVIORAL","Nightmare distress Questionnaire (change from nightmare distress baseline from screening at each 4 visits), Nightmare Frequency in the past week (change from nightmare frequency screening baseline at each 4 visits)",2021-01-21,2025-12-09,David Moss,FED
NCT06377241,ScentAware and OCT in MCI vs HC,A Proof-of-concept Pilot Study to Determine the Efficacy of SensifyAware and Retinal Imaging in Differentiating Mild Cognitive Impairment (MCI) From Cognitively Unimpaired Controls (HC),TERMINATED,slow enrollment,,OBSERVATIONAL,20,"Alzheimer Disease, Early Onset",,"DEVICE, DEVICE","Compare test scores of ScentAware olfactory test to the scores of the University of Pennsylvania Smell Identification Test (UPSIT) olfactory test in a clinical setting, Compare ScentAware test results conducted with support from clinical staff to the test results when ScentAware test was self-administered independently, Compare UPSIT test results conducted with support from clinical staff to the test results when ScentAware test was self-administered independently",2024-04-15,2024-06-05,"University of Wisconsin, Madison",OTHER
NCT01659554,"A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian, Primary Peritoneal & Fallopian Tube Cancers","A Phase II Combined Modality Protocol of Debulking Surgery With Heated Intraoperative Chemotherapy (HIPEC) Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancers",TERMINATED,Principal Investigator left institution,PHASE2,INTERVENTIONAL,4,"Recurrent Ovarian Cancer, Fallopian Tube Cancer","Cisplatin, Doxorubicin","DRUG, DRUG","Adverse Event Rate and/or Laboratory Changes, Toxicity Rating Based on NCI Common Toxicity Criteria",2012-03,2014-04,Columbia University,OTHER
NCT06099041,ND-YAG Laser Iris Depigmentation for Cosmoses,ND-YAG Laser Iris Depigmentation for Cosmoses,WITHDRAWN,"We found complications, intra ocular pressure elevation and iridocyclitis endangered the patients vision",NA,INTERVENTIONAL,0,Iris Depigmentation,,DEVICE,"Monitoring intra-ocular pressure (IOP) by the standard Goldman applanation tonometer before and after ND-YAG Laser for iris depigmentation, Safety of ND-YAG Laser, by visual acuity assessment in log-mar subjectively by using Snellen chart before and after ND-YAG Laser",2023-10-01,2024-10,Sohag University,OTHER
NCT02254954,"Clinical Study on Macitentan, RT and TMZ Concurrent Therapy Followed by Maintenance Macitentan and TMZ in Newly Diagnosed Glioblastoma","A Single-center, Open-label, Phase 1 Study of Macitentan, Radiotherapy and Temozolomide Concurrent Therapy Followed by Maintenance Therapy With Macitentan and Temozolomide in Subjects With Newly Diagnosed Glioblastoma",TERMINATED,Sponsor decision due to low recruitment,PHASE1,INTERVENTIONAL,30,Glioblastoma,Macitentan in combination with RT and TMZ,DRUG,"Number of subjects with dose-limiting toxicities observed during the first 10 weeks of study treatment (i.e., 6 weeks of concurrent therapy with macitentan, RT and TMZ and 4 weeks of monotherapy with macitentan).",2015-01-08,2016-09-29,Actelion,INDUSTRY
NCT04049266,"A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.","A Phase 2b/3, Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center Study to Investigate the Efficacy and Safety of Repeated Intravitreal Administration of KSI-301 in Subjects With Neovascular (Wet) Age-related Macular Degeneration.",TERMINATED,Primary Endpoint Not Met,"PHASE2, PHASE3",INTERVENTIONAL,559,Wet Macular Degeneration,"KSI-301, Aflibercept","DRUG, DRUG, OTHER","Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 48 and 52, Full Analysis Set Year 1",2019-10-08,2022-04-26,Kodiak Sciences Inc,INDUSTRY
NCT03159429,Nasal Ventilation Versus Voluntary Hypoventilation in the Rehabilitation of Hyperventilation Syndrome,"Nasal Ventilation Versus Voluntary Hypoventilation in the Rehabilitation of Hyperventilation Syndrome: a Randomized, Controlled Trial",TERMINATED,Staff no longer available.,NA,INTERVENTIONAL,19,Hyperventilation Syndrome,,"BEHAVIORAL, BEHAVIORAL",Change in Dyspnea at VO2max,2017-10-05,2020-01-15,"University Hospital, Montpellier",OTHER
NCT01082653,Safety/Efficacy Study for the Treatment of Amyotrophic Lateral Sclerosis,"Phase I, Single Center, Prospective, Non-randomized, Open Label, Safety/Efficacy Study of the Infusion of Autologous Bone Marrow-derived Stem Cells, in Patients With Amyotrophic Lateral Sclerosis",SUSPENDED,Suspended due to lack of funding.,PHASE1,INTERVENTIONAL,6,Amyotrophic Lateral Sclerosis,autologous bone marrow-derived stem cells,BIOLOGICAL,Safety,2010-03,2014-05,TCA Cellular Therapy,INDUSTRY
NCT03367637,A Novel mHealth Approach to Assess and Manage Palliative Care Needs for Cancer Patients in Kigali,A Novel mHealth Approach to Assess and Manage Palliative Care Needs for Cancer Patients in Kigali,WITHDRAWN,funding,NA,INTERVENTIONAL,0,Cancer Pain,,"OTHER, OTHER",Difference in pain score as measured by the expanded African Palliative Care Outcomes Scale (APCA POS),2018-01-01,2023-06,Massachusetts General Hospital,OTHER
NCT01060345,A Pilot Study of Chemo-prevention of Green Tea in Women With Ductal Carcinoma in Situ,A Pilot Study of Chemo-prevention of Green Tea in Women With Ductal Carcinoma in Situ (DCIS),TERMINATED,Drug no longer available,PHASE2,INTERVENTIONAL,20,Ductal Carcinoma in Situ,Polyphenon E,DRUG,Percent Change in K167 Staining,2010-05,2015-09,University of Chicago,OTHER
NCT05186077,Brain Circuitry Analysis in Bipolar Disorder,Brain Circuitry Analysis in Bipolar Disorder,TERMINATED,The original funding for this study ended and we were not able to secure new funding to continue,,OBSERVATIONAL,26,Bipolar Disorder,,"OTHER, OTHER, OTHER, OTHER",Characterize white matter (WM) connectivity with DWT to identify an anatomical substrate for BD that has future potential as a therapeutic target,2020-10-15,2025-07-31,Jennifer Sweet,OTHER
NCT03099057,Study of Prognostic Factors in Interventional Rhythmology,Study of Prognostic Factors in Interventional Rhythmology,TERMINATED,Lake of personnel,,OBSERVATIONAL,2805,Cardiac Surgery,,OTHER,The occurrence of adverse clinical events,2017-03-07,2020-03-13,"University Hospital, Brest",OTHER
NCT04926181,Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer,A Phase 2 Study of Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer,TERMINATED,Funding,PHASE2,INTERVENTIONAL,2,"Small Cell Neuroendocrine Carcinoma, Prostate Cancer, Small Cell Carcinoma","Apalutamide, Cetrelimab","DRUG, BIOLOGICAL",Composite Response Rate,2022-03-16,2024-03-31,Rahul Aggarwal,OTHER
NCT05536401,P200TE Agreement and Precision Study,P200TE Agreement and Precision Study,TERMINATED,Due to software changes,NA,INTERVENTIONAL,15,"Retina Disease, Glaucoma, Normal",,"DEVICE, DEVICE","Limit of Agreement (LOA) between the P200TE and predicate device measurements of full retinal thickness., Limit of Agreement (LOA) between the P200TE and predicate device measurements of retinal nerve fiber layer thickness (μm)., Limit of Agreement (LOA) between the P200TE and predicate device measurements of ganglion cell complex thickness (μm)., Limit of Agreement (LOA) between the P200TE and predicate device measurements of optic disc (disc area, rim area, cup-to-disc area, cup-to-disc vertical, cup-to-disc horizontal), Precision between the P200TE and predicate device measurements of full retinal thickness., Precision between the P200TE and predicate device measurements of retinal nerve fiber layer thickness., Precision between the P200TE and predicate device measurements of ganglion cell complex thickness, Precision between the P200TE and predicate device measurements of optic disc (disc area, rim area, cup-to-disc area, cup-to-disc vertical, cup-to-disc horizontal)",2022-09-02,2022-09-20,"Optos, PLC",INDUSTRY
NCT01608919,Predictive Value of Whole Blood Coagulation Parameters for Post-discharge Venous Thromboembolism After Cancer Resection,Predictive Value of Whole Blood Coagulation Parameters for Post-discharge Venous Thromboembolism After Cancer Resection.,TERMINATED,"Sara Cheng, MD has left the University of Colorado and we have closed this study.",NA,INTERVENTIONAL,4,Venous Thromboembolism,,OTHER,Venous thromboembolism free survival after surgery for gastrointestinal or urologic cancer,2012-11,2014-01,"University of Colorado, Denver",OTHER
NCT03958630,PET Imaging of Neuroinflammation in Neurodegenerative Diseases Via a Novel Translocator Protein (TSPO) Radioligand,PET Imaging of Neuroinflammation in Neurodegenerative Diseases Via a Novel TSPO Radioligand,TERMINATED,PI closed the protocol due to low recruitment,PHASE1,INTERVENTIONAL,13,Dementia,"11C-ER176, 11C-PIB","DRUG, DRUG, DIAGNOSTIC_TEST",Standard Uptake Value Ratio Compared to the Cerebellum (SUVR) Area Under the Curve (AUC) (60-90min),2019-07-03,2023-12-04,National Institute of Mental Health (NIMH),NIH
NCT02704130,TAE and MWA Combination Therapy in Early-stage Hepatocellular Carcinoma,Transarterial Embolization and Microwave Ablation Combination Therapy in Early-stage Hepatocellular Carcinoma: A Randomized Trial,TERMINATED,Lack of funding,NA,INTERVENTIONAL,8,"Hepatocellular Carcinoma, Hepatoma, Liver Cancer, Adult, Liver Cell Carcinoma, Liver Cell Carcinoma, Adult",,"DEVICE, PROCEDURE",Intrahepatic Disease-free Survival,2016-03,2018-01,Wake Forest University Health Sciences,OTHER
NCT02761928,"Investigation of Hypermobility, Biomarkers, and Pain Generators in Chronic Pain Patients","Investigation of Hypermobility, Biomarkers, and Pain Generators in Chronic Pain Patients",TERMINATED,"Insufficient enrollment, lack of funding to continue",,OBSERVATIONAL,31,"Low Back Pain, Mechanical, Spinal Stenosis, Nerve Root Disorder, Radiculopathy, Cervical, Benign Hypermobility Syndrome",,OTHER,Beighton hypermobility score,2016-01,2017-08-01,"The University of Texas Health Science Center, Houston",OTHER
NCT03182465,Predictive Value of ProCalcitonin for the Detection of Bacteraemia in Patients Presenting to the Emergency Department for Low Risk Chemo-induced Febrile Neutropenia,"Predictive Value of ProCalcitonin for the Detection of Bacteraemia in Patients Presenting to the Emergency Department for Low Risk Chemo-induced Febrile Neutropenia According to the MASCC Score: a Prospective, Monocentric Observational Study (CALIF)",TERMINATED,poor recruitment,NA,INTERVENTIONAL,54,"Febrile Neutropenia, Drug-Induced",,DIAGNOSTIC_TEST,Minimum level of ProCalcitonin,2017-10-04,2022-12-25,Cliniques universitaires Saint-Luc- Université Catholique de Louvain,OTHER
NCT07150767,"A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast Cancer","A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast Cancer",WITHDRAWN,The applicant voluntarily withdrew the case,PHASE1,INTERVENTIONAL,0,Locally Advanced Breast Cancer (LABC),BioTTT001 injection,BIOLOGICAL,Incidence of adverse events,2025-03-26,2027-03-26,"Beijing Bio-Targeting Therapeutics Technology Co., Ltd",INDUSTRY
NCT00696007,Neoadjuvant Chemotherapy Plus Nephroureterectomy for Locally Advanced Upper Tract Transitional Cell Cancer,Neoadjuvant Chemotherapy Plus Nephroureterectomy for Locally Advanced Upper Tract Transitional Cell Cancer,WITHDRAWN,Study was unable to recruit subjects meeting the study requirements.,PHASE2,INTERVENTIONAL,0,Transitional Cell Carcinoma,Gemcitabine and cisplatin,"DRUG, OTHER",Neoadjuvant chemotherapy (Gemcitabine and Cisplatin) Regime (3 cycles) before Nephroureterectomy,2008-04,2010-04,Lahey Clinic,OTHER
NCT04065165,Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome,Randomized Phase III Clinical Trial of Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome,WITHDRAWN,Company decision,PHASE3,INTERVENTIONAL,0,"Small Intestinal NET, Carcinoid Heart Disease","Telotristat Ethyl, Lanreotide","DRUG, DRUG",Number of bowel movements (BMs),2020-04,2027-10,European Organisation for Research and Treatment of Cancer - EORTC,NETWORK
NCT01713803,Evaluation of BEMA® Buprenorphine NX for Buprenorphine Induction of Opioid Dependent Subjects,Evaluation of BEMA® Buprenorphine NX for Buprenorphine Induction of Opioid Dependent Subjects,WITHDRAWN,FDA did not require a clinical trial for indication.,PHASE3,INTERVENTIONAL,0,Opioid Dependence,Buprenorphine and naloxone,DRUG,The mean change in clinical opioid withdrawal scale (COWS) total score from Baseline to 6 hours following the initial dose,,2017-05-01,BioDelivery Sciences International,INDUSTRY
NCT04376827,A Study of Guselkumab in Participants With Active Lupus Nephritis,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Guselkumab in Subjects With Active Lupus Nephritis",TERMINATED,"Due to enrollment challenges, J\&J Innovative Medicine decided to stop screening and terminate the study early. This decision was not based on a safety concern.",PHASE2,INTERVENTIONAL,33,Lupus Nephritis,"Guselkumab Dose 1, Placebo, Guselkumab Dose 2, Standard-of-care treatment","DRUG, DRUG, DRUG, DRUG",Percentage of Participants Achieving at Least 50 Percent (%) Decrease From Baseline in Proteinuria at Week 24,2020-09-15,2023-02-01,"Janssen Research & Development, LLC",INDUSTRY
NCT00957242,AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis,AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis (ACE-IPF),TERMINATED,Excess of mortality in the treatment group created safety concerns.,PHASE3,INTERVENTIONAL,145,Idiopathic Pulmonary Fibrosis,"warfarin, placebo","DRUG, DRUG","Death, Non-bleeding/Non-elective Hospitalization, or >10% Drop in Forced Vital Capacity",2009-10,2011-07,Duke University,OTHER
NCT03394573,Comparison of VA Guided Versus OCT Guided TER Using Aflibercept for Diabetic Macular Edema (AVOCT Study),"A Randomized, Study Investigating the Efficacy of Visual Acuity-based Versus Optical Coherence Tomography (OCT) -Based Treat and Extend Regimen Using Aflibercept in Patients With Diabetic Macular Edema",TERMINATED,insufficient recuritment due to covid,,OBSERVATIONAL,110,Diabetic Macular Edema,,"OTHER, OTHER",Functional outcomes,2017-09-16,2021-02-01,"Insel Gruppe AG, University Hospital Bern",OTHER
NCT01590394,Patency of a Prototype Large Plastic Biliary Stent in the Palliation of Malignant Distal Biliary Strictures.,Prospective Evaluation of Luminal Patency of a Prototype Large Plastic Biliary Stent in the Palliation of Malignant Distal Biliary Strictures.,TERMINATED,Difficulty in enrolling subjects and transporting scope for sterilization,NA,INTERVENTIONAL,3,"Stricture, Obstruction, Cancer",,DEVICE,Large Plastic Biliary Stents Will Have a Longer Patency Time Than Conventionally Used 10 Fr Stents in Subjects as Compared to Well-known Published Historical Control Data.,2012-09,2016-04,Mayo Clinic,OTHER
NCT04211922,Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib,"A Phase II, Multicenter, Single-arm Study to Evaluate Safety and Efficacy of Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib",TERMINATED,Sponsor R\&D Strategy Adjustment,PHASE2,INTERVENTIONAL,4,ALK-positive Non-small Cell Lung Cancer,Alkotinib Capsules,DRUG,Objective response rate (ORR) based on independent radiology review,2020-01-21,2022-10-11,"Suzhou Zelgen Biopharmaceuticals Co.,Ltd",INDUSTRY
NCT03501966,Surgical Idiopathic Intracranial Hypertension Treatment Trial,Randomized Trial of Medical Therapy (MT) vs. MT Plus Optic Nerve Sheath Fenestration vs. MT Plus Ventriculoperitoneal Cerebrospinal Fluid Shunting in Subjects With Idiopathic Intracranial Hypertension and Moderate to Severe Visual Loss,TERMINATED,Low enrollment,PHASE3,INTERVENTIONAL,7,Idiopathic Intracranial Hypertension,Acetazolamide,"DRUG, PROCEDURE, PROCEDURE",Perimetric Mean Deviation (PMD),2019-02-06,2019-08-28,Jaeb Center for Health Research,OTHER
NCT02488122,Effect of the High Impact Exercise on Bone Density in Prepuberal Girls,Effect of the High Impact Exercise on Bone Density in Prepuberal Girls in 12 Private Schools in Bogota - Colombia During 2016 - 2017. Open Label Randomized Controlled Trial,SUSPENDED,Because the study has not yet sponsorship.,NA,INTERVENTIONAL,276,"Bone Loss, Age-Related,",,"OTHER, OTHER",bone mineral density (BMD) are presented for the total Body total bone mineral density,2016-02,2017-05,Fundación Santa Fe de Bogota,OTHER
NCT00925522,Therapy Cool Path Ablate VT,Clinical Evaluation of Therapy Cool Path Duo Cardiac Ablation System for the Treatment of Ischemic Ventricular Tachycardia (VT),TERMINATED,Study data no longer needed,NA,INTERVENTIONAL,20,Ischemic Ventricular Tachycardia,,DEVICE,"Primary Safety is Defined as the Incidence of Intra-procedural, Acute or Sub-chronic, Serious Cardiac Adverse Events, up to 7 Days Post-procedure.",2009-06,2011-07,Abbott Medical Devices,INDUSTRY
NCT02900222,Study of Choroid Plexus Cauterization in Patients With Hydrocephalus,Study of Endoscopic Choroid Plexus Cauterization for Adult Patients With Hydrocephalus and Risk Factors for Perioperative Complications Following Shunt Surgery.,TERMINATED,Resources no longer available,NA,INTERVENTIONAL,1,Hydrocephalus,,PROCEDURE,Occurrence of post-operative complications,2016-09-01,2018-05-16,Ronald Benveniste,OTHER
NCT04361851,Study of Dara-Pembro for Multiple Myeloma Patients,LCI-HEM-DRMM-DPEM-001: Phase II Study of Daratumumab-Pembrolizumab for Multiple Myeloma Patients With ≥ Three Prior Lines of Therapy,WITHDRAWN,Low enrollment due to competing studies,PHASE2,INTERVENTIONAL,0,Multiple Myeloma,Pembrolizumab,DRUG,8-Month Progression-Free Survival (PFS8),2021-06-09,2027-05,Wake Forest University Health Sciences,OTHER
NCT02316951,Monitoring Postoperative Pain and Recovery Following Orthopedic Surgery,Monitoring Postoperative Pain and Recovery Following Orthopedic Surgery,TERMINATED,Logistical and enrollment issues,,OBSERVATIONAL,6,"Pain, Postoperative",,DEVICE,pain assessment (Correlate pain scores with motion measurements obtained through measurement of movement activity and video.),2015-07-09,2022-08-07,University of Florida,OTHER
NCT05273151,A Study With Intranasal Kinetic Oscillation Stimulation (KOS) in the Prevention of Chronic Migraine,An Open Pilot Study to Evaluate the Efficacy of Intranasal Kinetic Oscillation Stimulation in the Preventive Treatment of Chronic Migraine on Patients Not Responding to a Preventive Treatment Targeting the CGRP Pathway,TERMINATED,Slow inclusion due to new treatment (Gepants),NA,INTERVENTIONAL,13,Chronic Migraine,,DEVICE,Mean change in headache days,2023-12-04,2025-06-30,Chordate Medical,INDUSTRY
NCT01026051,"Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma","A Phase 2, Open Label, Non-Randomized Study to Evaluate the Safety, Tolerability, Immune Response and Clinical Response of Multiple Doses of MKC1106-MT in Subjects With Advanced Melanoma",TERMINATED,Financial/Business Reasons,PHASE2,INTERVENTIONAL,5,"Stage III Melanoma, Stage IV Melanoma",MKC1106-MT,BIOLOGICAL,"To evaluate the objective response, where response is defined as either complete response (CR), partial response (PR), or stable disease (SD) for 12 weeks or longer (CR, PR, and SD are defined according to RECIST 1.1 criteria)",2010-10,2012-07,Mannkind Corporation,INDUSTRY
NCT03520153,Characterization of Diabetes Mellitus in Fibrous Dysplasia/McCune-Albright Syndrome,Characterization of Diabetes Mellitus in Fibrous Dysplasia/McCune-Albright Syndrome,WITHDRAWN,The principal investigator is leaving Yale University and will not be continuing the work at her new institution.,,OBSERVATIONAL,0,"McCune-Albright Syndrome, Fibrous Dysplasia, Intraductal Papillary Mucinous Neoplasm, Diabetes Mellitus",,"PROCEDURE, PROCEDURE, DIAGNOSTIC_TEST","Glucose tolerance status, Insulin sensitivity, Insulin secretion, Beta cell capacity, Hepatic glucose fluxes (gluconeogenesis and glycogenolysis)",2018-08-07,2021-08,Yale University,OTHER
NCT00314353,Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon,Randomized Phase II Clinical Trial of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Line Treatment for Metastatic Colorectal Cancer,TERMINATED,The study was closed early due to low enrollment and new information regarding the benefit of the study regimen.,PHASE2,INTERVENTIONAL,7,Colorectal Neoplasms,"Bevacizumab, Oxaliplatin, Capecitabine, Irinotecan","DRUG, DRUG, DRUG, DRUG",One-year Progression-free Survival (PFS),2006-03,2010-06,NSABP Foundation Inc,NETWORK
NCT04355039,INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma,A Phase I Study of INCB053914 (Pan-PIM Kinase Inhibitor) and Pomalidomide With Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma,WITHDRAWN,Terminated for lack of funding.,PHASE1,INTERVENTIONAL,0,"Refractory Multiple Myeloma, Relapse Multiple Myeloma","Pomalidomide, Dexamethasone, INCB053914 50 mg bis in die (BID), INCB053914 65 mg BID, INCB053914 80 mg BID","DRUG, DRUG, DRUG, DRUG, DRUG",The number of subjects with dose-limiting toxicities.,2021-07-01,2024-07-01,Medical College of Wisconsin,OTHER
NCT02294357,Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib,A Phase 2 Study of Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib,TERMINATED,Early termination due to the difficulties to enroll subjects.,PHASE2,INTERVENTIONAL,45,Multiple Myeloma,"Carfilzomib, Dexamethasone, Prednisone, Methylprednisolone, Lenalidomide, Pomalidomide","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Overall response rate (ORR), Clinical Benefit Rate (CBR), Number of patients undergoing adverse events",2014-12,2020-09-22,Oncotherapeutics,INDUSTRY
NCT03608501,"A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation","An Open-Label, Single-Arm Phase II Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-Naive Multiple Myeloma Patients Non-Eligible for Autologous Stem-Cell Transplantation",WITHDRAWN,Business decision (no safety or efficacy concerns),PHASE2,INTERVENTIONAL,0,Multiple Myeloma,"Ixazomib, Thalidomide, Dexamethasone","DRUG, DRUG, DRUG",ORR During Induction,2019-09-30,2023-05-31,Takeda,INDUSTRY
NCT04424901,Trial of Open Label Dipyridamole- In Hospitalized Patients With COVID-19,"A Randomized, Open-label Study of the Vascular and Microbiologic Efficacy of Dipyridamole Plus Standard Care vs. Standard Care in Hospitalized COVID19 Patients",TERMINATED,reduction of Hospitalized COVID patients at UConnHealth,PHASE2,INTERVENTIONAL,41,"COVID-19 Pneumonia, Vascular Complications","Placebo, Dipyridamole Tablets","DRUG, DRUG","D-dimer, Platelet Count",2020-05-03,2022-04-24,UConn Health,OTHER
NCT04705701,Comparing Post Cardiac Surgery Outcomes in ESRD Patient's With Early Dialysis Versus Standard Care,Randomized Controlled Trial of Post Cardiac Surgery Outcomes in End Stage Renal Disease Patients Comparing Early Dialysis on the Day of Surgery Versus Standard Care,WITHDRAWN,Trial was withdrawn due to Covid-19 pandemic,NA,INTERVENTIONAL,0,"Respiratory Failure, Shock, Coagulopathy",,PROCEDURE,"length of mechanical ventilation, intensive care unit (ICU) stay",2021-09-01,2021-09-02,Northwell Health,OTHER
NCT03250312,The Effects of OMT on the Expression Patterns of Immune Cell Biomarkers,The Effects of Osteopathic Manipulations on the Expression Patterns of Immune Cell Biomarkers,TERMINATED,Study Partner Left. Samples degraded before analysis.,NA,INTERVENTIONAL,40,"Osteopathic Manipulation, Low Back Pain, Biomarkers",,OTHER,The effects of OMT on the amounts of immune cell biomarkers,2017-09-13,2019-08-31,A.T. Still University of Health Sciences,OTHER
NCT02497612,"To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose Regimen of Ferroquine and Artefenomel in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria","A Randomized, Double-blind, Phase IIb Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose Regimen of Ferroquine (FQ) With Artefenomel (OZ439) in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria",TERMINATED,"All treatment arms met the futility criteria for efficacy during the pre-planned interim analysis, therefore the study was stopped.",PHASE2,INTERVENTIONAL,377,Plasmodium Falciparum Infection,"Ferroquine SSR97193, Artefenomel","DRUG, DRUG, OTHER",Percentage of Participants With Polymerase Chain Reaction (PCR)-Adjusted Adequate Clinical and Parasitological Response (ACPR) at Day 28: African <=5 Years Per Protocol Population at Day 28 (PP28),2015-07-25,2019-09-23,Sanofi,INDUSTRY
NCT02047019,Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination in Subjects With Essential Hypertension Inadequately Controlled on Candesartan Cilexetil,"A Multicenter, Randomized, Double-Blind, Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination Taken Orally for 8 Weeks in Adult Subjects With Essential Hypertension Who Are Inadequately Controlled on 16 mg Candesartan Cilexetil Monotherapy",WITHDRAWN,GPDC decided to terminate the study,PHASE3,INTERVENTIONAL,0,Hypertension,"Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), Candesartan Cilexetil, Candesartan matching placebo, Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106) 30/16mg matching placebo, Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG",Change in mean seated systolic blood pressure (MSSBP).,2017-12-01,2019-12-08,Bayer,INDUSTRY
NCT05413941,Internet-based Cognitive Behavioral Therapy in Inflammatory Bowel Disease,Internet-based Cognitive Behavioral Therapy for Black and Latino Patients With Inflammatory Bowel Disease,WITHDRAWN,No participants were enrolled into this study. Study Start Date previously entered was for Aim 1 of the protocol and unrelated to this registration (see 'Detailed Description'). Primary Completion and Study Completion Dates reflect IRB closeout date.,NA,INTERVENTIONAL,0,"Inflammatory Bowel Diseases, Psychological Distress",,BEHAVIORAL,"Recruitment Rate, Adherence Rate",2022-09-26,2025-06-30,Montefiore Medical Center,OTHER
NCT01212094,Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe),Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe),TERMINATED,The efficacy on CSF biomarkers failed to reach criteria for continuation of the trial,"PHASE1, PHASE2",INTERVENTIONAL,44,Multiple Sclerosis,Rituximab,"DRUG, OTHER","Analysis of Changes in CSF CXCL13 Induced by Active Treatment (Rituximab) Measured 3 Months After 1st Drug Administration, Analysis of Changes in CSF BAFF Induced by Active Treatment (Rituximab) Measured 3 Months After 1st Drug Administration",2010-09,2015-12,National Institute of Neurological Disorders and Stroke (NINDS),NIH
NCT00767494,Travoprost/Brinzolamide Fixed Combination Versus Travatan and Versus AZOPT,,TERMINATED,Project Cancelled,PHASE3,INTERVENTIONAL,17,"Glaucoma, Ocular Hypertension","Travoprost/Brinzolamide fixed combination, Azopt, Travatan","DRUG, DRUG, DRUG",Mean IOP,2008-10,2009-02,Alcon Research,INDUSTRY
NCT02499666,Change in Exercise Capacity as Measured by Peak Oxygen Uptake After CTO PCI,"Evaluation of Exercise Capacity as Measured by Peak Oxygen Uptake, Before and After Percutaneous Revascularization of Chronic Total Occlusion",TERMINATED,difficulty recruiting patients,,OBSERVATIONAL,15,"Coronary Artery Disease, Angina Pectoris",Clopidogrel,"PROCEDURE, DEVICE, DRUG",Change in Exercise Capacity,2015-06-29,2017-10-30,Henry Ford Health System,OTHER
NCT00753766,Multifactorial Pre-operative Intervention in Diabetes Mellitus,Multifactorial Pre-Operative Intervention in Diabetes Mellitus,TERMINATED,Inadequate participant recruitment,NA,INTERVENTIONAL,1,"Diabetes Mellitus, Surgical Procedure, Unspecified",,OTHER,Percent of Screened Participants That Are Eligible and Choose Participation,2005-10,2008-09,VA Office of Research and Development,FED
NCT02788656,Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan),PARENT Trial Pilot Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan),TERMINATED,Inadequate Recruitment,PHASE4,INTERVENTIONAL,4,Congestive Heart Failure,"Angiotensin-Converting Enzyme Inhibitor, Angiotensin II Type 1 Receptor Blocker, sacubitril/valsartan","DEVICE, DRUG, DRUG, DRUG","Difference Between Mean Change in Mean Pulmonary Artery Pressure (PAPm) With Sacubitril/Valsartan Compared to the Mean Change in PAPm With Continued ACEi/ARB, The Acute Change in PAPm After the First Administration of Sacubitril/Valsartan",2016-09,2018-11-09,Brigham and Women's Hospital,OTHER
NCT02176551,Study Comparing Product 0405 to a Vehicle Control in the Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Subjects,"A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Product 0405 To A Vehicle Control In The Treatment Of Mild To Moderate Atopic Dermatitis In Pediatric Subjects",WITHDRAWN,Business Reasons,PHASE3,INTERVENTIONAL,0,Atopic Dermatitis,"Product 0405, Placebo for Product 0405","DRUG, DRUG",Statistically significant superiority of the test Product 0405 to the vehicle,2012-06,2013-05,Fougera Pharmaceuticals Inc.,INDUSTRY
NCT00891631,Primary Care iSBIRT to Reduce Serious Teen Health Risks,"Primary Care Internet/Intranet-based Screening, Brief Intervention, and Referral to Treatment (iSBIRT) System to Reduce Serious Teen Health Risks",WITHDRAWN,Grant application was not funded,"PHASE1, PHASE2",INTERVENTIONAL,0,"Substance-related Disorders, Depression, High-risk Sex",,"BEHAVIORAL, BEHAVIORAL",frequency of substance use and other risk behaviors,2009-09,2011-09,Boston Children's Hospital,OTHER
NCT00878202,Therapeutic Education by Telemedicine in Chronic Heart Failure,Impact of Clinical Follow-up and Therapeutic Education by Telemedicine in Chronic Heart Failure: a Randomized Multicenter Study.,TERMINATED,Insufficient recruitment,PHASE4,INTERVENTIONAL,100,Heart Failure,,DEVICE,Number of hospitalization days for heart failure,2009-03,2012-06,"University Hospital, Caen",OTHER
NCT02659202,Spinal Stimulation During Exercise in Heart Failure,Spinal Cord Stimulation to Inhibit Afferent Feedback During Exercise in Heart Failure,TERMINATED,Lack of funding to continue the study,NA,INTERVENTIONAL,7,Heart Failure,,DEVICE,Mean Arterial Pressure,2016-06,2018-03-23,Mayo Clinic,OTHER
NCT04273737,Amantadine in Treating Cognitive & Motor Impairments in Adolescents and Adults With Cerebral Palsy,Use of Amantadine in Treating Cognitive and Motor Impairments in Adolescents and Adults With Cerebral Palsy,TERMINATED,PI left institution.,PHASE4,INTERVENTIONAL,11,Cerebral Palsy,Amantadine Hydrochloride,DRUG,"Mean Brief-A Score, Mean Brief-A Score, Mean Brief-A Score",2020-02-28,2022-02-22,Columbia University,OTHER
NCT03594045,Efficacy and Safety of Apixaban in the Treatment of Heparin Induced Thrombocytopenia (HIT),A Phase II Study to Evaluate the Efficacy and Safety of Apixaban in the Treatment of Heparin Induced Thrombocytopenia (HIT),TERMINATED,Withdrawal of funding by sponsor,PHASE2,INTERVENTIONAL,5,"Heparin-induced Thrombocytopenia, Heparin-induced Thrombocytopenia and Thrombosis",Apixaban,DRUG,Cumulative Incidence of New Symptomatic Thromboembolic Complications (TEC) Within 30 Days of the Initiation of Apixaban,2018-12-18,2019-10-30,Massachusetts General Hospital,OTHER
NCT00871845,Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients,Effects of Dietary and Behavioral Intervention and Orlistat for Management of Obesity and Metabolic Syndrome on Response to Hepatitis C Therapy,TERMINATED,Protocol expired and not renewed,NA,INTERVENTIONAL,36,"Obesity, Insulin Resistance, Metabolic Syndrome, Hepatitis C",,BEHAVIORAL,"Percentage of Participants With HCV RNA (Early Virological Response), Body Weight Loss, Percentage of Participants With Early Virological Response (EVR) and Significant Weight Loss",2008-09,2011-08,Hossam Kandil,OTHER
NCT01143272,Probiotic Saccharomyces Boulardii for the Prevention of Antibiotic-associated Diarrhoea,"Saccharomyces Boulardii for the Prevention of Antibiotic-associated Diarrhoea - Randomised, Double-blind, Placebo-controlled Trial",TERMINATED,Masked independent interim analysis: completion of the trial was unlikely.,PHASE3,INTERVENTIONAL,477,"Antibiotic-associated Diarrhea, Clostridium Difficile, Diarrhea","Saccharomyces boulardii, Placebo","DRUG, DRUG",Total Number of Antibiotic-associated Diarrhea Episodes,2010-06,2012-10,Bernhard Nocht Institute for Tropical Medicine,OTHER_GOV
NCT00795639,Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS),"A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Safety And Efficacy Study Of Sitaxsentan Sodium In Subjects With Pulmonary Arterial Hypertension",TERMINATED,"Safety Issue: The trial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury.",PHASE3,INTERVENTIONAL,183,"Pulmonary Arterial Hypertension, Pulmonary Hypertension","Sitaxsentan, Placebo","DRUG, DRUG",Change From Baseline in Total Distance Walked During 6 Minute Walk Distance (6MWD) at Week 12,2008-12,2011-03,Pfizer,INDUSTRY
NCT01614977,Comparison of Antibiotic Therapy Alone or Combined With Corticosteroids for the Treatment of Nontuberculous Mycobacterial Cervicofacial Lymphadenitis in Children: A Randomized Double-Blind Placebo-Controlled Study,Comparison of Antibiotic Therapy Alone or Combined With Corticosteroids for the Treatment of Nontuberculous Mycobacterial Cervicofacial Lymphadenitis in Children: A Randomized Double-Blind Placebo-Controlled Study,WITHDRAWN,Technical problems.,PHASE3,INTERVENTIONAL,0,Nontuberculous Mycobacterial Lymphadenitis.,Methylprednisoline,DRUG,Resolution process of the involved lymph nodes,2011-10,2014-05,Rabin Medical Center,OTHER
NCT01438177,Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma,"A Phase II, Trial of Chloroquine in Combination With VELCADE and Cyclophosphamide in Patients With Relapsed and Refractory Myeloma",TERMINATED,PI left institution.,PHASE2,INTERVENTIONAL,11,Multiple Myeloma,"Velcade, Cyclophosphamide, Chloroquine","DRUG, DRUG, DRUG",Response Rate (CR + PR After 2 Cycles),2011-10,2014-02,NYU Langone Health,OTHER
NCT01584375,The Risk of Intraventricular Hemorrhage With Flat Midline Versus Right-Tilted Flat Lateral Head Positions,The Risk of Intraventricular Hemorrhage With Flat Midline Versus Right-Tilted Flat Lateral Head Positions in Preterm Infant Less Than 30 Weeks of Gestation: a Multicenter Randomized Control Trial,TERMINATED,Due to low patient recruitment,NA,INTERVENTIONAL,71,Intraventricular Hemorrhage,,"OTHER, OTHER",All grade IVH incidence,2012-04,2015-04,King Abdul Aziz General Hospital,OTHER_GOV
NCT03262701,Adjunctive Hydrogen Peroxide for Periodontal Therapy,Custom Tray Application of Peroxide Gel as an Adjunct to Scaling and Root Planing in the Treatment of Periodontitis: A 6-Month Randomized Trial,TERMINATED,COVID,PHASE4,INTERVENTIONAL,42,"Periodontitis, Chronic","Hydrogen Peroxide Gel, 13 weeks, Hydrogen Peroxide Gel, 26 weeks","DRUG, DRUG, OTHER","Periodontal Pocket Depth Reduction, Periodontal Pocket Depth Reduction, Periodontal Pocket Depth Reduction",2018-04-02,2021-02-08,Loma Linda University,OTHER
NCT04332081,Hyperbaric Oxygen for COVID-19 Patients,Open Label Single-Center Study of Emergency Hyperbaric Oxygen for Respiratory Distress in Patients With COVID-19,TERMINATED,The IRB has determined that the design of this trial should be changed to a randomized controlled trial. A new record will be created for the redesigned study.,NA,INTERVENTIONAL,80,COVID-19,,DEVICE,Mortality,2020-04-06,2020-05-29,NYU Langone Health,OTHER
NCT03900481,"Use of an Endoluminal-suturing Device for Endoscopic Gastric Reduction as an Aid for Class I Obesity, or Class II Obesity Without Comorbidity","Use of an Endoluminal-suturing Device for Endoscopic Gastric Reduction as an Aid for Class I Obesity, or Class II Obesity Without Comorbidity",TERMINATED,Premature end of inclusion,NA,INTERVENTIONAL,29,"Bariatric Surgery, Morbid Obesity",,PROCEDURE,Assessment of the excess weight loss,2019-09-17,2024-05-16,Assistance Publique Hopitaux De Marseille,OTHER
NCT00884819,Effects of Fenofibrate on Metabolic and Reproductive Parameters in Polycystic Ovary Syndrome,"Effects of Fenofibrate on Metabolic and Reproductive Parameters in Polycystic Ovary Syndrome. A Randomized, Double-Blind, Placebo-Controlled Trial",TERMINATED,Poor recruitment,NA,INTERVENTIONAL,4,Polycystic Ovary Syndrome,Fenofibrate,"DRUG, OTHER",Hepatic adiposity as assessed using MRI,2008-12,2015-02,London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's,OTHER
NCT01580319,Primary Prevention of Cardiovascular Diseases in Childhood and Adolescence: the Role of Physical Activity,Outpatient Strategy of Primary Prevention of Cardiovascular Diseases in Childhood and Adolescence: the Role of Physical Activity,TERMINATED,Difficulty in selecting the sample and follow-up lost.,NA,INTERVENTIONAL,27,"Obesity, Hypercholesterolemia, High Blood Pressure, Sedentary Lifestyle",,OTHER,"Reduction on risk factors for a cardiovascular diseases (reduction on BMI, cholesterol, LDL, glucose, high-sensitivity C-reactive protein, blood pressure and/or increase on HDL)",2009-04,2011-12,Instituto de Cardiologia do Rio Grande do Sul,OTHER
NCT03748719,Single Arm Trial of Preoperative Stereotactic Body Radiation Therapy (SBRT) for T3a or Gleason Grade Group 4 Prostate Cancer,A Single Arm Phase II Trial of Preoperative Stereotactic Body Radiation Therapy (SBRT) for T3a or Gleason Grade Group 4 Prostate Cancer,WITHDRAWN,No accrual interest,NA,INTERVENTIONAL,0,Prostate Cancer,,DEVICE,"Measure of PSA (Prostate Specific Antigen), Number of symptomatic adverse anastomotic events",2018-11-19,2019-12-04,H. Lee Moffitt Cancer Center and Research Institute,OTHER
NCT01317030,Tear Evaluation Between Habitual Contact Lens Wearers and Non Contact Lens Wearers,Tear Evaluation Between Habitual Contact Lens Wearers and Non Contact Lens Wearers Using a Schirmer Strip for Tear Collection,TERMINATED,Study was terminated due to a business decision to cancel the entire project.,,OBSERVATIONAL,25,Dry Eye,,"DEVICE, DEVICE, OTHER",Hyaluronan Levels,2011-02,2011-04,Bausch & Lomb Incorporated,INDUSTRY
NCT01570530,Atorvastatin Using as a Possible Prophylaxis of Postoperative Atrial Fibrillation After Cardiac Surgery,Atorvastatin Using as a Possible Prophylaxis of Postoperative Atrial Fibrillation After Cardiac Surgery,TERMINATED,End of finantial support,PHASE3,INTERVENTIONAL,90,Atrial Fibrillation,,"PROCEDURE, PROCEDURE",Number of patients with postoperative atrial fibrillation(atorvastatin and control groups),2011-01,2014-09,Fundación General Universidad de Valladolid,OTHER
NCT05027867,KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer,"An Open-Label, Multicenter, Phase 2 Study of the Safety and Efficacy of KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer (SCLC)",TERMINATED,Unanticipated and extremely high screen failure rate. There was no evidence of safety concerns in the study.,PHASE2,INTERVENTIONAL,3,"Small-cell Lung Cancer, Small Cell Lung Carcinoma, Small Cell Lung Cancer Extensive Stage, Small Cell Lung Cancer Recurrent",KRT-232,DRUG,Objective response rate (ORR) of each arm,2021-12-06,2022-08-26,"Kartos Therapeutics, Inc.",INDUSTRY
NCT01629667,"A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis","A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis",TERMINATED,Early termination of the study due to lack of efficacy.,PHASE2,INTERVENTIONAL,409,Idiopathic Pulmonary Fibrosis,"Tralokinumab, Tralokinumab","BIOLOGICAL, BIOLOGICAL, OTHER",Change From Baseline in Percent-predicted Forced Vital Capacity (FVC) at Week 52,2012-10,2016-01,MedImmune LLC,INDUSTRY
NCT03082300,A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations,"A Phase 1, Randomized, 2-period Crossover Study to Assess Bioequivalence of a Tablet Formulation Versus a Capsule Formulation of ASP8273 in Subjects With Non-small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations",TERMINATED,"Following recommendation by SOLAR Study IDMC, Astellas closed enrollment in ASP8273 studies.",PHASE1,INTERVENTIONAL,3,"Non-small Cell Lung Cancer (NSCLC), Epidermal Growth Factor Receptor (EGFR) Mutations",naquotinib,DRUG,"Pharmacokinetics of ASP8273 in plasma: Cmax, Pharmacokinetics of ASP8273 in plasma: AUCinf, Pharmacokinetics of ASP8273 in plasma: AUClast, Pharmacokinetics of ASP8273 in plasma: AUC72",2017-03-24,2017-06-19,"Astellas Pharma Global Development, Inc.",INDUSTRY
NCT05157724,Observational Study to Compare Two Prostate Laser Enucleation Techniques in Terms of Urinary Incontinence,Observational Study to Compare Two Prostate Laser Enucleation Techniques (Photo-vaporization of the Prostate (PLASMA) Versus HoLEP) in Terms of Overall Post-operative Urinary Incontinence,WITHDRAWN,organizational problems,,OBSERVATIONAL,0,"Prostatic Hyperplasia, Benign, Prostatic Adenoma",,PROCEDURE,Overall urinary incontinence (including stress urinary incontinence and urgency) between the two prostate enucleation procedures PLASMA and HOLEP at 3-month visit,2021-11,2026-11,Elsan,OTHER
NCT00006123,Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer,Autotransplantation and Her 2 Neu Antibody Immunotherapy in Advanced Breast Cancer,WITHDRAWN,Never started,"PHASE1, PHASE2",INTERVENTIONAL,0,Breast Cancer,"trastuzumab, carboplatin, carmustine, cisplatin, cyclophosphamide, thiotepa","BIOLOGICAL, DRUG, DRUG, DRUG, DRUG, DRUG, PROCEDURE",,2000-07,2000-07,Beth Israel Deaconess Medical Center,OTHER
NCT01686880,Y90 Radioembolization Prior to Surgical Resection or Radiofrequency for Hepatocellular Carcinoma in Cirrhotic Liver,Treatment With Yttrium90 Radioembolization Prior to Surgical Resection or Radiofrequency for Hepatocellular Carcinoma in Cirrhotic Liver,TERMINATED,poor recruitment and an unexpected low treatment rate,PHASE2,INTERVENTIONAL,10,"Hepatocellular Carcinoma, Liver Cirrhosis",,DEVICE,Peri-operative morbidity,2012-09,2015-01,Jules Bordet Institute,OTHER
NCT01166880,A Pilot Study Using Laser Speckle Imaging of Neonate Cerebral Vasculature,Imaging of Neonate Cerebral Vasculature,WITHDRAWN,Unable to find grant fundingsupport to continue builds the study device.,,OBSERVATIONAL,0,Newborn Distress,,DEVICE,Neonate Cerebral Blood Flow,2009-08,2010-09,"University of California, Irvine",OTHER
NCT03060980,"Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin","A Phase 3b, Randomized, Active Comparator, Open-label, Multicenter Study to Compare the Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and to Glimepiride as Add-on Therapy to Metformin in Patients With Type 2 Diabetes",TERMINATED,Decision by Sponsor,PHASE3,INTERVENTIONAL,245,"Diabetes Mellitus, Type 2","ITCA 650 20/60 mcg/day, Empagliflozin (oral), Glimepiride (oral)","DRUG, DRUG, DRUG","Reduction in glycosylated hemoglobin A1c, Reduction in weight",2017-03-03,2018-01-26,Intarcia Therapeutics,INDUSTRY
NCT03440879,Androgen Deprivation Therapy Muscle Protein Metabolism and Blood Glucose,The Effect of Androgen Deprivation Therapy on Regulation of Muscle Protein Metabolism and Blood Glucose,TERMINATED,Low recruitment rate,NA,INTERVENTIONAL,23,"Prostate Cancer, Resistance Exercise, Androgen Deprivation Therapy",Zoladex,DRUG,Muscle protein synthesis rate,2018-09-21,2023-03-02,Norwegian School of Sport Sciences,OTHER
NCT01282879,Evaluation of Antifungal Prophylaxis on Graft-versus-host Disease (GVHD) Patients,Evaluation of Antifungal Prophylaxis Against Invasive Fungal Infections During Corticosteroid Containing Therapy for Graft-versus-host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation,TERMINATED,"In interim analysis, this study met the primary hypothesis.",PHASE4,INTERVENTIONAL,36,Graft vs Host Disease,Itraconazole,DRUG,incidence of proven or probable invasive fungal infections,2009-12,2010-12,Samsung Medical Center,OTHER
NCT05296642,Exercise Induced Hypoalgesia Diabetes,Exploring the Use of Blood Flow Restriction in Addition to Aerobic Exercise as a Modality to Produce Exercise Induced Hypoalgesia in Participants With Painful Diabetic Peripheral Neuropathy.,WITHDRAWN,Principal investigator decision,NA,INTERVENTIONAL,0,"Diabetic Peripheral Neuropathy, Diabetic Peripheral Neuropathic Pain",,"OTHER, OTHER",Change in Pain Pressure Threshold (PPT),2022-08-01,2023-08-31,University of Miami,OTHER
NCT01093170,A Phase I Open Label Dose Escalation Trial of RNA-144101 in the Treatment of Geographic Atrophy,A Phase I Open Label Dose Escalation Trial of RNA-144101 in the Treatment of Geographic Atrophy,WITHDRAWN,"Study was not conducted, no subjects recruited.",PHASE1,INTERVENTIONAL,0,Geographic Atrophy,RNA-144101,DRUG,"Safety and tolerability of RNA-144101 as measured by vision testing, ophthalmic and physical exams, vital signs, clinical laboratory testing and AEs.",2011-03,2012-09,Mark Kleinman,OTHER
NCT02939469,Skin Sympathetic Nerve Activity and Cardiac Arrhythmias,STTR Phase II : Skin Sympathetic Nerve Activity and Cardiac Arrhythmias,WITHDRAWN,The PI passed away.,PHASE2,INTERVENTIONAL,0,Sympathetic Nerve Activity,,OTHER,Chane in Sympathetic nerve activity,2016-11-01,2018-11-01,Cedars-Sinai Medical Center,OTHER
NCT03112642,"Nerve Stimulator for Patients With Upper Extremity Disease, Vascular or Orthopedic Surgery",Does the Use of a Nerve Stimulator Improve the Outcome of Ultrasound-Guided Supraclavicular Block (Anesthesia) for Upper Extremity Surgery?,TERMINATED,covid pandemic limited participation,NA,INTERVENTIONAL,8,Other Biomechanical Lesions of Upper Extremity,,"PROCEDURE, DEVICE",Dermatomes With Complete Motor Block of the Upper Extremities at 30 Minutes,2013-11,2021-03-09,"Rutgers, The State University of New Jersey",OTHER
NCT04777786,Early Rehabilitation for Breast Cancer - A Randomized Control Trial,Implementation of a Prospective Surveillance Rehabilitation Model for Women With Breast Cancer - A Randomized Controlled Trial,TERMINATED,Lack of enrolled participants,NA,INTERVENTIONAL,3,"Neoplasms, Breast",,OTHER,Change in Active range of motion,2021-04-01,2023-03-31,University of South Carolina,OTHER
NCT03693183,Efficacy Study of Ketorolac and HPMC to Treat Dry Eye,"A Double-Masked, Randomized, Single-Center Study Evaluating the Effect of 0.30% Ketorolac/0.80% HPMC, 0.80% HPMC and Vehicle on Symptoms of Dry Eye After Exposure to the Controlled Adverse Environment (CAE)",WITHDRAWN,Study terminated by Sponsor,PHASE2,INTERVENTIONAL,0,Dry Eye,"Ketorolac/HPMC, HPMC, Vehicle","DRUG, DRUG, DRUG",Efficacy of Ketorolac and HPMC on ocular discomfort using the Ora Calibra® Ocular Discomfort scale.,2009-03,2009-06-15,"ORA, Inc.",INDUSTRY
NCT03792841,"Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC","A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Prostate Specific Membrane Antigen Half-life Extended Bispecific T-cell Engager Acapatamab in Subjects With Metastatic Castration-resistant Prostate Cancer",TERMINATED,Sponsor Decision,PHASE1,INTERVENTIONAL,212,"Metastatic Castration-resistant Prostate Cancer, Prostate Cancer","acapatamab, Pembrolizumab, Etanercept, Cytochrome P450 (CYP) Cocktail","DRUG, DRUG, DRUG, DRUG","Number of participants with dose-limiting toxicity, Number of participants with treatment-emergent adverse events, Number of participants with treatment-related adverse events, Number of participants with clinically significant changes in vital signs, Number of participants with clinically significant changes in electrocardiogram (ECG), Number of participants with clinically significant changes in clinical laboratory tests",2019-02-05,2023-06-29,Amgen,INDUSTRY
NCT03005054,StrataGraft® Skin Tissue as an Alternative to Autografting Full-thickness Complex Skin Defects,"Open-label, Controlled, Randomized, Multicenter, Dose Escalation Study Evaluating the Safety, Tolerability, and Efficacy of Single or Multiple Applications of StrataGraft® Skin Tissue as an Alternative to Autografting Full-thickness Complex Skin Defects",TERMINATED,Protracted enrollment and limited wound closure in the first three subjects,PHASE2,INTERVENTIONAL,3,"Trauma-related Wound, Burns, Skin Wound",StrataGraft Skin Tissue,"BIOLOGICAL, PROCEDURE","Percent Area of the StrataGraft Treatment Site Requiring Autografting by Three Months, Percentage of Participants With Complete Wound Closure of the Treatment Sites at Three Months",2017-04-24,2019-03-26,"Stratatech, a Mallinckrodt Company",INDUSTRY
NCT03204994,Fluorescence Targeted Pelvic Lymph Node Mapping,Investigating the Feasibility of Fluorescence Targeted Pelvic Lymph Node Mapping During Rectal Cancer Surgery,TERMINATED,Not able to recruit,"PHASE1, PHASE2",INTERVENTIONAL,1,"Cancer of Rectum, Lymph Node Disease",Indocyanine Green,DRUG,Number & location of lymph nodes identified with and without fluorescent probe during rectal cancer surgery,2017-08-01,2018-08-01,Oxford University Hospitals NHS Trust,OTHER
NCT00528294,Phase I Trial From GRID 18F-FDG-PET Biological Imaging-guided Intensitymodulated Radiotherapy (BG-IMRT) With Patients With Recurrent or New Head or Neck Tumor in Previously Radiated Area,Phase I Trial From GRID 18F-FDG-PET Biological Imaging-guided Intensitymodulated Radiotherapy (BG-IMRT) With Patients With Recurrent or New Head or Neck Tumor in Previously Radiated Area,TERMINATED,Study status unknown Investigator retired and no longer working in the institution.,PHASE1,INTERVENTIONAL,12,Head and Neck Tumors,,RADIATION,"Maximum tolerated dose., Superior local control with Grid 18F-FDG-PET BG-IMRT using previously obtained maximum tolerated dose.",2007-02,2015-09,"University Hospital, Ghent",OTHER
NCT02606266,Evaluation of the Benefit of Antiviral Treatment With Valganciclovir on Congenital CMV Infection-related Deafness on Hearing and Balance,Evaluation of the Benefit of Antiviral Treatment With Valganciclovir on Congenital CMV Infection-related Deafness on Hearing and Balance,TERMINATED,No eligibles patients,"PHASE2, PHASE3",INTERVENTIONAL,1,Congenital Cytomegalovirus (CMV),Valganciclovir,DRUG,Auditory threshold in db,2017-07-11,2018-12-11,Assistance Publique - Hôpitaux de Paris,OTHER
NCT05817266,Role of FCI in the Detection of Proctosigmoiditis Caused by IBD,Role of Field-Cycling Imaging in the Detection of Proctosigmoiditis Caused by Inflammatory Bowel Disease,WITHDRAWN,Funding period ended,NA,INTERVENTIONAL,0,"Inflammatory Bowel Diseases, Proctosigmoiditis",,DEVICE,Detection of proctosigmoiditis assessed by field-cycling imaging (FCI) scan,2024-03,2024-03-31,NHS Grampian,OTHER_GOV
NCT01044966,A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma,"Phase I/II Intraventricular DepoCyt (OD # 06-2348) in Glioblastoma (76,730, 11/06)",TERMINATED,The study was terminated due to lack of adequate patient enrollment into trial.,"PHASE1, PHASE2",INTERVENTIONAL,12,"Glioblastoma Multiforme, Glioma, Astrocytoma, Brain Tumor",ITV DepoCyt + Temozolomide,DRUG,Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0,2009-09,2014-09,Medical University of South Carolina,OTHER
NCT02540629,Implementation of Gold Standard EMS CPR Programs for 2% Improvement in Survival Rates of Out-of-Hospital Cardiac Arrest in a Metropolitan City,,TERMINATED,Human resource change in Research investigators and Seoul Fire Department,NA,INTERVENTIONAL,12670,Out-of-Hospital Cardiac Arrest,,PROCEDURE,Number of Participants With Survival to Hospital Discharge,2016-01-01,2018-12-31,Seoul National University Hospital,OTHER
NCT01667029,Study of Sulfasalazine in Treating Painful Neuropathy,"A Single-center, Randomized, Double-blind Clinical Study to Evaluate the Effect of Sulfasalazine on Painful Neuropathy",TERMINATED,poor enrollment,PHASE2,INTERVENTIONAL,8,Painful Neuropathy,"Sulfasalazine, placebo","DRUG, DRUG",Pain Score (First Treatment Period),2013-05,2017-08-10,Massachusetts General Hospital,OTHER
NCT04940429,Eye Movement Testing in Patients With Obesity and the Impact of Weight Loss Surgery,Oculometric Assessment of Dynamic Visual Processing in Patients With Obesity and the Impact of Bariatric Surgery,TERMINATED,"collaboration with research partner stopped, Covid",,OBSERVATIONAL,19,"Bariatric Surgery Candidate, Obesity, Morbid",,"DEVICE, DIAGNOSTIC_TEST",Change in Nfit score,2018-11-27,2021-06-17,Stanford University,OTHER
NCT02136342,Phase 1 Trial of Chlorogenic Acid in Patients With Advanced Cancer,Phase 1 Trial Evaluating Tolerability and Pharmacokinetics of Chlorogenic Acid for Injection in Patients With Advanced Cancer,TERMINATED,Study site change,PHASE1,INTERVENTIONAL,,Advanced Cancer,chlorogenic acid,DRUG,Number of adverse events,2014-05,,Chinese Academy of Medical Sciences,OTHER
NCT01692470,A Study on the Safety and Effectiveness of Rilpivirine Hydrochloride (Edurant) Among Adult Filipino Patients With Human Immunodeficiency Virus Type-I Infection,A Post-Marketing Surveillance Study on the Safety and Effectiveness of Rilpivirine Hydrochloride Among Adult Filipino Patients With Human Immunodeficiency Virus Type-I Infection,WITHDRAWN,The company decided to cancel this study in conformity with Philippines FDA Circular 2013-004,,OBSERVATIONAL,0,Human Immunodeficiency Virus Type 1 (HIV-1) Infection,No intervention,DRUG,"Number of patients with incidence of adverse events, Number of patients with incidence of discontinuation of study medication due to adverse events",2013-06,2015-12,Janssen Pharmaceutica,INDUSTRY
NCT02090283,Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis Bullosa,"An Open Label Extension, Multi-Center, Study to Evaluate the Safety of SD-101 Cream in Subjects With Epidermolysis Bullosa",TERMINATED,The Sponsor voluntarily recalled SD-101 and terminated the study due to GMP deficiencies identified during an FDA inspection at the site of the manufacturer.,PHASE2,INTERVENTIONAL,42,Epidermolysis Bullosa,SD-101 dermal cream (6%),DRUG,Number Of Participants With Treatment-Emergent Adverse Events (TEAEs),2014-03-26,2018-09-14,"Scioderm, Inc.",INDUSTRY
NCT04627441,Transcutaneous and Epidural Stimulation in SCI,A Pilot Study of the Characterization of Transcutaneous and Epidural Spinal Stimulation for Enabling Motor Function in Humans With Motor Complete Paraplegia,WITHDRAWN,COVID-related delays and insufficient funding.,NA,INTERVENTIONAL,0,"Paraplegia, Spinal, Paraplegia, Complete, Paraplegia; Traumatic",,"DEVICE, DEVICE","Kinematics, Electromyography, Foot pressure, Overground ambulation [as appropriate to the subject] (1), Overground ambulation [as appropriate to the subject] (2), Somatosensory evoked potentials, Transcranial magnetic stimulation motor evoked potentials, Monosynaptic spinal reflex testing, Trunk stability, Injury severity: American Spinal Injury Association (ASIA) Impairment Scale",2022-12-16,2025-12-16,"Kristin Zhao, PhD",OTHER
NCT00870441,Study Comparing the Safety of ASP2151 to Valacyclovir and Placebo in Healthy Volunteers,"A Phase 1, Randomized, Double-Blind, Multiple Dose, Multi-Center Study to Compare the Safety of ASP2151 to Valacylcovir and Placebo in Healthy Male and Female Subjects",TERMINATED,Study terminated due to treatment-emergent serious adverse events,PHASE1,INTERVENTIONAL,442,Safety of ASP2151,"ASP2151, Valacyclovir, Placebo","DRUG, DRUG, DRUG",Assessment of clinical laboratory evaluations and adverse events,2009-03,2010-04,Astellas Pharma Inc,INDUSTRY
NCT00761254,Domperidone for Relief of Gastrointestinal Disorders,Oral Domperidone for Relief of Gastrointestinal Disorders in Patients Who Failed Standard Therapy,TERMINATED,PI withdrew due to increased responsibilities in clinical department.,NA,INTERVENTIONAL,42,"Gastroparesis, GERD, Esophagitis, Dyspepsia, Chronic Idiopathic Constipation, Nausea, Vomiting",Domperidone,DRUG,Relief for patients with gastrointestinal disorders who have failed standard therapy,2008-08,2012-09,Carle Physician Group,INDIV
NCT01630694,Three-dimensional Craniofacial Phenotyping of Patients With Difficult Airway,Three -Dimensional (3-D) Craniofacial Phenotyping of Patients With Difficult Airway,TERMINATED,study stopped due to not meeting enrollment goal.,NA,INTERVENTIONAL,28,Failed or Difficult Intubation,,"PROCEDURE, PROCEDURE, PROCEDURE, PROCEDURE, PROCEDURE, PROCEDURE",Mean Hyomental Distance Ratio,2010-07,2012-10,University of Rochester,OTHER
NCT04809766,Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma,Phase I Study of Autologous Transgenic T-Cells Expressing High Affinity Mesothelin-Specific T-Cell Receptor (TCR) (FH-TCR Tᴍsʟɴ) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma,TERMINATED,Study terminated due to end of funding.,PHASE1,INTERVENTIONAL,9,"Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8","Autologous Mesothelin-specific TCR-T Cells, Cyclophosphamide, Fludarabine, Bendamustine","BIOLOGICAL, DRUG, DRUG, DRUG","Incidence of adverse events, Dose limiting toxicities",2021-12-14,2025-01-15,Fred Hutchinson Cancer Center,OTHER
NCT03821766,Haemodynamic Abnormalities Recorded With Cardiac Catheterization Along With Body's Surface Micro-accelerometers (KT-KCG),Do Abnormal Hemodynamic Features Generate Relevant Reactions and Vibrations at the Skin Level When Recorded by Micro Accelerometers,WITHDRAWN,Technical failure,,OBSERVATIONAL,0,"Heart Failure, Pulmonary Hypertension",,DEVICE,Micro-accelerations recorded at the body's surface,2020-02-01,2020-12-30,Erasme University Hospital,OTHER
NCT01154751,Data Registry Following Patients Using Supera Stent in the Femoral Arteries,Supera Treatment Registry Observing Neointimal Growth,TERMINATED,"Slow enrollment,increased loss to follow-ups and general lack of interest.",NA,INTERVENTIONAL,200,"Peripheral Artery Disease, Femoropopliteal Artery Stenosis, Peripheral Vascular Disease",,DEVICE,"Six-minute Walking Distance, Six-minute Walking Distance, Six-minute Walking Distance, Six-minute Walking Distance",2008-11,2015-08,Abbott Medical Devices,INDUSTRY
NCT02132429,"Phase I, Double-Blind,Placebo, MAD Study to Evaluate the Safety, Tolerability, PK, and PD of AMG 333 in Healthy Subjects and Migraine Subjects","Phase I, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 333 in Healthy Subjects and Migraine Subjects",TERMINATED,The study was stopped due to an administrative decision not safety.,PHASE1,INTERVENTIONAL,16,Migraine,"AMG 333, Placebo","DRUG, DRUG",Treatment-emergent AEs,2014-05,2014-12,Amgen,INDUSTRY
NCT01682031,Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy,"Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II Trial of Selenomethionine as a Modulator of Efficacy and Toxicity of Chemoradiation in Locally-Advanced Squamous Cell Carcinoma of the Head and Neck",TERMINATED,Due to a lack of funding,PHASE2,INTERVENTIONAL,18,"Chemotherapeutic Agent Toxicity, Mucositis, Radiation Toxicity, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Xerostomia",cisplatin,"DIETARY_SUPPLEMENT, OTHER, DRUG, RADIATION, PROCEDURE",Incidence of >= Grade 3 Mucositis,2009-06,2012-06,Roswell Park Cancer Institute,OTHER
NCT06183502,"HIV/STD Risk and PrEP Implementation Messaging Among Gay, Bisexual, and Other Men Who Have Sex With Men","Understanding HIV/STD Risk and Enhancing PrEP Implementation Messaging in a Diverse Community-Based Sample of Gay, Bisexual, and Other Men Who Have Sex With Men in a Transformational Era (MIC-DROP)",SUSPENDED,Temporarily paused due to funding,,OBSERVATIONAL,1275,"Sexually Transmitted Infections, Gay, Pre Exposure Prophylaxis",,"BEHAVIORAL, PROCEDURE, BEHAVIORAL","Monitoring Measure: Survey reports, Change in condom and PrEP use and adherence based on messages for current PrEP users, Change in condom and PrEP use and adherence based on messages for current non adherent PrEP users, Change in condom and PrEP use and adherence based on messages for people who never used PrEP",2024-06-29,2026-08,Emory University,OTHER
NCT03352453,A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive Disorder,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy and Safety Study of Rapastinel for Rapid Treatment of Symptoms of Depression and Suicidality in Adult Patients With Major Depressive Disorder",TERMINATED,Study stopped due to business reasons.,PHASE2,INTERVENTIONAL,138,"Depressive Disorder, Major","Rapastinel, Placebo","DRUG, DRUG","Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score, Change From Baseline in Sheehan - Suicidality Tracking Scale (S-STS) Total Score",2017-12-15,2019-06-21,"Naurex, Inc, an affiliate of Allergan plc",INDUSTRY
NCT01975272,The Use of Iron Therapy for Patients With Anemia After Caesarean Section,The Value of Iron Treatment for Postoperative Obstetric Patients With Anemia: a Randomized Double Blind Controlled Trial,TERMINATED,Disapointing randomization rate,PHASE4,INTERVENTIONAL,27,Postoperative Anaemia,"Ferinject, Ferrous fumarate, Placebo for ferrous fumarate, Placebo for ferinject","DRUG, DRUG, DRUG, DRUG",Hemoglobin,2015-03-02,2018-06-21,Maastricht University Medical Center,OTHER
NCT01305395,Strategies To Prevent Cardiac Allograft Vasculopathy Related Events in Heart Transplant Recipients,Early Vs Late Sirolimus-Initiation Strategies To Prevent Cardiac Allograft Vasculopathy Related Events in Heart Transplant Recipients,WITHDRAWN,"Due in part, to reduced transplant volume and enrollment has been difficult.",NA,INTERVENTIONAL,0,Cardiac Allograft Vasculopathy,"Sirolimus, Sirolimus, Sirolimus, Sirolimus, Sirolimus","DRUG, DRUG, DRUG, DRUG, DRUG",1. Change in maximal intimal thickness,2010-11,2015-01,University of Minnesota,OTHER
NCT01872377,Dose Escalation Study of CyberKnife® SBRT Boost for Patients With Unresectable Locally Advanced Pancreatic Cancer,Phase I Time-to-Event Continual Reassessment (TITE-CRM) Dose Escalation Trial of CyberKnife® Stereotactic Body Radiotherapy (SBRT) Boost With Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Pancreatic Cancer,TERMINATED,No longer recruiting patients to this study,NA,INTERVENTIONAL,7,Pancreatic Carcinoma Non-resectable,,RADIATION,Toxicity defined as grade 3 or 4 gastro-intestinal or other non-haematological toxicity,2013-07,2018-05-16,Ottawa Hospital Research Institute,OTHER
NCT00556075,Safety and Efficacy Study to Evaluate Proellex in the Treatment of Premenopausal Women With Symptomatic Endometriosis,"A Phase II, Three-Arm, Parallel Design, Dose-Ranging Placebo-Controlled, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Proellex in the Treatment of Premenopausal Women With Symptomatic Endometriosis",TERMINATED,Clinical hold for safety,PHASE2,INTERVENTIONAL,67,Endometriosis,"Proellex 25 mg, Placebo, Proellex 50 mg","DRUG, DRUG, DRUG","Difference Between the 50 mg Proellex Group and Placebo Group in the Month 4 Subject Diary Composite Pain Score, Difference Between the 25 mg and 50 mg Proellex Groups and Placebo Group in the Month 4 Subject Diary Composite Pain Score",2007-11,2009-07,Repros Therapeutics Inc.,INDUSTRY
NCT05709275,Hypoplastic Left Heart Syndrome: Subendocardial Viability After Norwood Palliation,Hypoplastic Left Heart Syndrome: Subendocardial Viability After Norwood Palliation,TERMINATED,early suspension of the study,,OBSERVATIONAL,6,Hypoplastic Left Heart Syndrome,,,Mortality during the hospital stay and after the discharge,2022-07-28,2024-09-30,IRCCS Policlinico S. Donato,OTHER
NCT03385057,Postoperative Ibuprofen Use and Risk of Bleeding in Pediatric Tonsillectomy,Postoperative Ibuprofen Use and Risk of Bleeding in Pediatric Tonsillectomy,WITHDRAWN,Study design flaws; research design needed to be reconfigured,PHASE1,INTERVENTIONAL,0,Tonsillectomy With or Without Adenoidectomy,"Ibuprofen, Acetaminophen","DRUG, DRUG",Post-tonsillectomy bleeding within 14 days of surgery.,2018-09,2023-01-01,Massachusetts Eye and Ear Infirmary,OTHER
NCT00871312,Evaluation of Topical Wound Oxygen (two2) Therapy,"A Randomized, Double-blinded, Parallel Group, Placebo-Controlled, Multi-Center Trial of Topical Wound Oxygen Therapy in the Treatment of Diabetic Lower Extremity Ulcers",TERMINATED,Low recruitment rate meaning unable to complete the study in a timely manner,NA,INTERVENTIONAL,21,Diabetic Ulcer,,"DEVICE, DEVICE",Wound closure,2007-05,2009-12,AOTI Ltd.,INDUSTRY
NCT06614842,Common Factors Group Psychotherapy for General Mental Health Concerns,Common Factors Group Psychotherapy for General Mental Health Concerns,WITHDRAWN,Inability for consistent recruitment.,NA,INTERVENTIONAL,0,"Major Depression, Generalized Anxiety, Stress Disorder, Post Traumatic, Stress, Mental Disorders",,BEHAVIORAL,"Generalized Anxiety Disorder-7 Screener, Patient Health Questionnaire-9 Screener, Patient Checklist-5, Yale-Brown Obsessive Compulsive Scale, Alcohol Use Disorders Identification Test, National Institute of Drug Abuse Modified Alcohol, Smoking, and Substance Involvement Screening Test",2025-01-17,2025-12-30,University of Alabama at Birmingham,OTHER
NCT00875342,Imaginal Exposure & D-Cycloserine (DCS) for Posttraumatic Stress Disorder (PTSD),D-cycloserine Enhanced Imaginal ExposureTherapy for Posttraumatic Stress Disorder (PTSD),TERMINATED,Trial is no longer enrolling due to priority of other non-pharmacologic PTSD trials.,NA,INTERVENTIONAL,41,Posttraumatic Stress Disorder,DCS,"DRUG, OTHER",Symptoms of Posttraumatic Stress Disorder-Clinician Administered PTSD Scale (CAPS),2008-05,2018-02-28,Weill Medical College of Cornell University,OTHER
NCT06952686,A Study of SRP-9005 in Limb Girdle Muscular Dystrophy Type 2C/R5 Pediatric and Adult Participants,"A Seamless Phase 1/3, Multicenter, Single Dose Systemic Gene Transfer Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9005 in Limb Girdle Muscular Dystrophy Type 2C/R5 Subjects (COMPASS)",WITHDRAWN,Study was Withdrawn per Sponsor decision.,PHASE3,INTERVENTIONAL,0,"Muscular Dystrophies, Limb-Girdle","SRP-9005, Corticosteroid","BIOLOGICAL, DRUG","Part A : Number of Participants with Treatment-emergent Adverse Events (TEAEs), Part A and B: Change from Baseline in gamma-Sarcoglycan (SG) Expression at Day 60 Post-dose in Ambulatory Participants as Measured by Immunofluorescence (IF) Percent Positive Fibers (PPF)",2025-06-30,2032-03-30,"Sarepta Therapeutics, Inc.",INDUSTRY
NCT05848583,Nutritional Tolerance and Safety of a Tube Feeding Formula,"A Single-Center, Open-Label Study on the Nutritional Adequacy, Tolerability, and Safety of a Standard Tube Feeding Formula in Adult Participants",TERMINATED,Recruitment,NA,INTERVENTIONAL,3,Enteral Feeding,,OTHER,Nutritional adequacy (caloric goals),2023-03-01,2023-11-15,Société des Produits Nestlé (SPN),INDUSTRY
NCT00044083,Clinical Trial of Tolcapone for Cognition in Schizophrenia,"Randomized, Double-Blinded, Placebo Controlled Study of the Effects of Tolcapone and Entacapone on Cognitive Function in Patients With Schizophrenia and Normal Controls Based on COMT Genotype",TERMINATED,Scientific Director request to use resources for other studies,PHASE2,INTERVENTIONAL,210,Schizophrenia,Tolcapone,"OTHER, DRUG","N-Back Task Performance, N-Back Task Activation Diagnosis Effect, N-Back Task Activation Drug Effect, N-Back Task Activation in DLPFC in Patients With Schizophrenia, N-Back Task Activation in Healthy Volunteers, N-Back Task Activation Genotype Effect in Healthy Volunteers, N-Back Task Activation by Genotype in Patients With Schizophrenia",2002-08,2015-12,National Institute of Mental Health (NIMH),NIH
NCT02122341,Clinical Evaluation of BackStop in Patients Undergoing Ureteroscopic Lithotripsy,"Post FDA-Approval Clinical Evaluation of BackStopTM in Patients Undergoing Ureteroscopic Lithotripsy: A Prospective, Randomized Clinical Trial",TERMINATED,Study has halted prematurely as we were not able to meet our target accrual.,NA,INTERVENTIONAL,35,Kidney Stones,,DEVICE,Rate of Prevention of Retrograde Stone or Stone Fragment Migration,2014-04,2016-07,University of Southern California,OTHER
NCT02999854,Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer,"A Phase III, Multicenter, Randomized Controlled Study to Compare Safety and Efficacy of a Haploidentical HSCT and Adjunctive Treatment With ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted ex Vivo of Host Alloreactive T-cells, Versus a Haploidentical HSCT With Post-transplant Cyclophosphamide in Patients With a Hematologic Malignancy",TERMINATED,"Insufficient efficacy, terminated by Sponsor",PHASE3,INTERVENTIONAL,63,"Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome","ATIR101, Cyclophosphamide","BIOLOGICAL, DRUG, PROCEDURE, PROCEDURE","Graft-versus-host Disease-free, Relapse-free Survival (GRFS)",2017-11-29,2021-12-17,Kiadis Pharma,INDUSTRY
NCT05523154,"""Answers in Hours"" A Randomized Controlled Trial Using Microbiome Metagenomics for Bile Duct Cultures",Nanopore Sequencing for Detecting Bacteria in Bile and Preventing Surgical Site Infections in Patients Undergoing Surgery for Benign or Malignant Pancreatic Tumors,TERMINATED,lack of funding,NA,INTERVENTIONAL,8,"Benign Pancreatic Neoplasm, Malignant Pancreatic Neoplasm",,"PROCEDURE, OTHER, DEVICE","Number of Participants With Surgical Site Infections, Improved Antibiotic Stewardship - Number of Antibiotics, Improved Antibiotic Stewardship - Duration",2023-01-19,2023-11-27,Mayo Clinic,OTHER
NCT03040505,Future Mental Projections in Schizophrenia,Future Mental Projections in Schizophrenia,TERMINATED,The number of subjects needed was overestimated (from assumptions made in the litterature).,,OBSERVATIONAL,56,Schizophrenia,,OTHER,Number of time location strategies,2017-04-05,2019-10-20,"University Hospital, Strasbourg, France",OTHER
NCT04131556,A Study Comparing the Pharmacokinetics and Palatability of Two Candidate Pediatric Powder-for-Oral-Suspension Formulations of Maribavir to the Current Maribavir Tablet Formulation Administered in Healthy Adult Participants,"A Phase 1, Open-label, Randomized, Crossover, Bioavailability, Dose Proportionality, and Food Effect Study Comparing the Pharmacokinetics and Palatability of Two Candidate Pediatric Powder-for-Oral-Suspension Formulations of Maribavir to the Current Maribavir Tablet Formulation Administered in Healthy Adult Subjects",TERMINATED,"The study was stopped because based on the planned interim analysis of the data of Part 1, palatability of both pediatric formulations was not acceptable.",PHASE1,INTERVENTIONAL,20,Healthy Volunteers,Maribavir,DRUG,"Part 1: Maximum Concentration (Cmax) Occurred at Time of Maximum Observed Concentration Sampled During a Dosing Interval (Tmax) of Maribavir in Plasma, Part 1: Time of Maximum Observed Concentration Sampled During a Dosing Interval (Tmax) of Maribavir in Plasma, Part 1: Area Under the Curve From the Time of Dosing to the Last Measurable Concentration (AUC0-last) of Maribavir in Plasma, Area Under the Curve Extrapolated to Infinity, Calculated Using the Observed Value of the Last Non-Zero Concentration (AUC0-Inf) of Maribavir in Plasma, Part 1: Terminal Half-Life (t1/2) of Maribavir in Plasma, Part 1: Apparent Total Body Clearance Following Extravascular Administration (CL/F) of Maribavir in Plasma, Part 1: Delay Between the Time of Dosing and Time of Appearance of Plasma Concentration (Tlag) of Maribavir in Plasma, Part 1: Number of Participants With Responses to Palatability Assessment up to Day 7",2019-10-25,2020-01-06,Shire,INDUSTRY
NCT02236702,Kappa Opioid Receptor Imaging in Depression (KOR Depression),Kappa Opioid Receptor Imaging in Depression (KOR Depression),TERMINATED,"The original PI, Alexander Neumeister, left NYULMC. No data was analyzed.",,OBSERVATIONAL,15,"Major Depressive Disorder, Anhedonia",,OTHER,[11C]LY2795050 volume of distribution (VT) values in specific brain regions of asymptomatic vs mildly symptomatic vs moderately symptomatic vs severely symptomatic individuals,2014-08,2016-02,NYU Langone Health,OTHER
NCT03648502,Validation of Cognitive Screenings for the Hearing Impaired,"Validation of ""Montreal Cognitive Assessment (MoCA) and Addenbrooke's Cognitive Examination III (ACE-III) ""as a Cognitive Screening Tools for the Hearing Impaired",TERMINATED,The corona virus pandemic\_UK national lockdown,NA,INTERVENTIONAL,78,"Dementia, Hearing Loss, Auditory Processing Disorder",,DIAGNOSTIC_TEST,"The adapted version Montreal Cognitive Assessment (MoCA) questionnaire total score among dementia/mild cognitive impairment/normal cognition group of hearing impaired older adult., The adapted version Addenbrooke's Cognitive Examination III (ACE-III) questionnaire total score among dementia/mild cognitive impairment/normal cognition group of hearing impaired older adult.",2018-11-09,2020-03-13,"University College, London",OTHER
NCT02487953,Electronic Nicotine Delivery Systems as a Smoking Cessation Treatment,Electronic Nicotine Delivery Systems (ENDS) as a Smoking Cessation Treatment,WITHDRAWN,Study design changed significantly; was submitted as a different protocol.,PHASE2,INTERVENTIONAL,0,Nicotine Dependence,Nicotine patch,"DRUG, OTHER, OTHER, OTHER",Continuous four-week abstinence from smoking during treatment,2018-07,2022-01,Duke University,OTHER
NCT05714553,NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours,"A Phase Ib/II Open Label, Multi-arm, Parallel Cohort Dose Finding and Expansion Study to Assess the Safety, Pharmacokinetics and Efficacy of NUC-3373, a Nucleotide Analogue, Given in Combination With Standard Approved Agents in Patients With Advanced Solid Tumours",TERMINATED,The NuTide:303 study was terminated at NuCana's discretion due to refinement of the pipeline strategy. The overall risk benefit assessment of NUC-3373 remains positive and future NUC-3373 studies are under consideration.,"PHASE1, PHASE2",INTERVENTIONAL,19,"Advanced Cancer, Advanced Solid Tumor, Neoplasm Malignant, Metastatic Cancer, Melanoma, Classical Hodgkin Lymphoma, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma, Subungual Squamous Cell Carcinoma, Oesophageal Carcinoma, MSI-H Colorectal Cancer, Gastric Cancer, Triple Negative Breast Cancer, Endometrial Carcinoma, Pleural Mesothelioma","Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab, Docetaxel","DRUG, DRUG, DRUG, DRUG","Number of patients tolerating dose levels (maximum tolerated dose; MTD) in each of the combinations, Number of patients reporting treatment-emergent adverse events (TEAEs) in each of the combinations, Number of patients achieving a reduction in tumour volume (Objective response rate; ORR)",2023-03-08,2025-05-30,NuCana plc,OTHER
NCT02747537,Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan,Phase 2 Clinical Trial Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With the Genomically-Targeted Agent Sorafenib in Combination With Irinotecan,WITHDRAWN,Could not recruit participants for the study,PHASE2,INTERVENTIONAL,0,Pediatric Solid Tumors,"Sorafenib, Irinotecan","DRUG, DRUG",Overall response rate,2016-06-24,2020-02-29,Washington University School of Medicine,OTHER
NCT00755937,Remicade® Crohn's Disease Registry Across Canada (Study P02793),Remicade® Treatment Registry Across Canada in Crohn's Disease,TERMINATED,Satisfied a post-marketing commitment to Canadian Health Authorities.,,OBSERVATIONAL,556,Crohn's Disease,,OTHER,"Clinical Response at 12 Months (Decrease in Crohn's Disease Activity Index [CDAI]>= 70 Points AND >= 25% From Baseline)., Clinical Response at 24 Months (Decrease in CDAI >= 70 Points AND >= 25% From Baseline)., Clinical Response at 36 Months (Decrease in CDAI >= 70 Points AND >= 25% From Baseline)., Clinical Remission at 12 Months (CDAI <= 150 Points)., Clinical Remission at 24 Months (CDAI <= 150 Points)., Clinical Remission at 36 Months (CDAI <= 150 Points).",2002-02,2007-09,Merck Sharp & Dohme LLC,INDUSTRY
NCT02708472,Safety and Efficacy of Synchronized Transcranial Magnetic Stimulation for the Treatment of Generalized Anxiety Disorder,Safety and Efficacy of Synchronized Transcranial Magnetic Stimulation (sTMS) for the Treatment of Generalized Anxiety Disorder (GAD) -An Open Label Investigator Initiated Trial,WITHDRAWN,This study never moved forward due to funding constraints.,NA,INTERVENTIONAL,0,Generalized Anxiety Disorder (GAD),,DEVICE,Mean change in score on the Hamilton Anxiety Rating Scale (HAM-A),2016-04-01,2018-01-22,University of Texas Southwestern Medical Center,OTHER
NCT01384695,A Feasibility Study of Confocal Microendoscopy in the Evaluation of Gastrointestinal Neoplasia -Project 1,A Feasibility Study of Confocal Microendoscopy in the Evaluation of Gastrointestinal Neoplasia - Project 1,TERMINATED,Low/no enrollment. No subjects were enrolled over the past year.,EARLY_PHASE1,INTERVENTIONAL,67,"GERD, Barrett's Esophagus","Fluorescein, Proflavine hemisulfate","DRUG, DRUG",to determine whether tissue is neoplastic or non-neoplastic,2009-06,2014-02,"Anandasabapathy, Sharmila, M.D.",INDIV
NCT00707239,Study Evaluating Safety and Efficacy of Tigecycline Versus Imipenem/Cilastatin Subjects With Hospital-Acquired Pneumonia,"A Phase 2, Multicenter, Randomized, Double-Blind, Comparative Study Of The Safety And Efficacy of 2 Doses Of Tigecycline Versus Imipenem/Cilastatin For The Treatment Of Subjects With Hospital-Acquired Pneumonia",TERMINATED,See termination reason in detailed description.,PHASE2,INTERVENTIONAL,108,"Pneumonia, Bacterial","tigecycline, tigecycline, imipenem/cilastatin","DRUG, DRUG, DRUG",Percentage of Participants With Clinical Response in Clinically Evaluable (CE) Population at Test-of-Cure (TOC) Visit,2008-12,2011-06,Pfizer,INDUSTRY
NCT00422877,"Taxoprexin® Treatment for Advanced Primary Cancers of the Liver, Gallbladder or Biliary Tract","Phase II Open-Label Study of Weekly Taxoprexin® (DHA-paclitaxel) Injection as Second Line Therapy for Patients With Advanced Primary Cancers of the Liver, Including Hepatocellular Carcinoma and Carcinoma of the Gallbladder or Biliary Tract",TERMINATED,"Sponsor suspended development of the drug on September 3, 2008.",PHASE2,INTERVENTIONAL,13,Cancer of the Liver,Taxoprexin,DRUG,Percentage of Participants Who Achieved an Objective Complete Response (CR) or Partial Response (PR),2007-01,2008-03,"American Regent, Inc.",INDUSTRY
NCT04598477,A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus),"An Open-Label, Multicenter, Follow-up Trial of ARGX-113-1904 to Evaluate the Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Pemphigus",TERMINATED,"Based on the lack of observed efficacy in the primary study ARGX-113-1904, the sponsor decided to discontinue the open-label extension study.",PHASE3,INTERVENTIONAL,183,"Pemphigus Vulgaris, Pemphigus Foliaceus","efgartigimod PH20 SC, prednisone","BIOLOGICAL, DRUG","Incidence of Treatment-Emergent Adverse Events (TEAE), Adverse Events of Special Interest (AESI), and Serious Adverse Events (SAE)",2021-07-15,2024-03-25,argenx,INDUSTRY
NCT02500901,Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC),Combined Targeting of the Androgen Receptor in Metastatic Castrate-Resistant Prostate Cancer With Enzalutamide and the Poly (ADP- Ribose) Polymerase (PARP) Inhibitor Niraparib: Hoosier Cancer Research Network GU14-202,TERMINATED,Suspended by funder,PHASE1,INTERVENTIONAL,2,Metastatic Prostate Cancer,"Enzalutamide, Niraparib","DRUG, DRUG",Maximum Tolerated Dose (MTD) for Subjects Receiving Enzalutamide With Niraparib Without Experiencing Dose-limiting Toxicity(s) (DLT),2016-03,2016-05-10,"Paul Mathew, MD",OTHER
NCT00427401,A Study To Evaluate PF-00915275 In Subjects With Type 2 Diabetes Mellitus For 4-Weeks,"A Double Blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF-00915275 After Oral Administration To Subjects With Type 2 Diabetes Mellitus For 4-Weeks",TERMINATED,"This study was terminated May 7, 2007. The study stopped due to tablet formulation issues. No safety issues were involved in the termination decision.",PHASE2,INTERVENTIONAL,40,"Diabetes Mellitus, Type 2",PF-00915275,DRUG,The primary end point is glucose lowering (24 hour mean glucose concentration).,2007-02,2007-06,Pfizer,INDUSTRY
NCT00234481,Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia,"A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL844 Administered Orally to Subjects With Chronic Lymphocytic Leukemia",TERMINATED,Study closed due to slow enrollment,PHASE1,INTERVENTIONAL,,"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma",XL844,DRUG,,,,Exelixis,INDUSTRY
NCT00378781,Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection,"Prospective, Randomized Trial Comparing Heparin and Minocycline-EDTA Flush for the Prevention of Catheter-Related Infections and Occlusions",WITHDRAWN,Study withdrawn.,NA,INTERVENTIONAL,0,Cancer,"Heparin, Minocycline-EDTA","DRUG, DRUG",Incidence of catheter-related infections during the study period (3 months),,,M.D. Anderson Cancer Center,OTHER
NCT00820703,The ASCEND Study: A Study to Investigate the Safety and Clinical Effect of Nexagon to Treat Slow Healing Diabetic Foot Ulcers,"A Randomized, Prospective, Double-blind, Vehicle-controlled, Dose-escalation, Single-center Study of the Safety and Clinical Effect of Nexagon® in the Treatment of Participants With Diabetic Foot Ulcers",TERMINATED,For business reasons,"PHASE1, PHASE2",INTERVENTIONAL,24,Diabetic Foot Ulcer,"Nexagon®, Nexagon® vehicle","DRUG, DRUG",To evaluate the safety and clinical effect of Nexagon® administered topically to diabetic foot ulcers.,2009-04,2009-12,"OcuNexus Therapeutics, Inc.",INDUSTRY
NCT04941703,"""CHANGE COVID-19 Severity""",Investigation of Choice Alteration of the Gut Metagenome on COVID-19 Severity,TERMINATED,Recruitment issues after COVID-19 abated; not enough hypoxic patients to meet criteria.,"PHASE1, PHASE2",INTERVENTIONAL,23,COVID-19 Infection,Magnesium Citrate plus probiotic,DRUG,COVID Ordinal Outcome Scale,2021-11-04,2022-06-25,Vanderbilt University Medical Center,OTHER
NCT04489927,Validation of the Measurement Accuracy of the Tcore Thermometer,Validierung Der Messgenauigkeit Des Tcore Thermometers in Der Anwendung Nicht-invasiver Temperaturmessung gegenüber herkömmlicher Invasiver Messung Auf Der Intensivstation Bei Wachen Patienten,TERMINATED,Patients couldn't be recruited (no patients with fewer available),,OBSERVATIONAL,75,"Temperature Change, Body",,DEVICE,Temperature,2021-10-01,2023-04-17,Drägerwerk AG & Co. KGaA,INDUSTRY
NCT03327727,VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults,"A Phase 2 Study of VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis in Adults With Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, or Allogeneic Hematopoietic Cell Transplant Recipients",TERMINATED,Business decision,PHASE2,INTERVENTIONAL,4,"Invasive Aspergillosis, Invasive Pulmonary Aspergillosis","Investigational Agent: VL-2397, Standard treatment: Voriconazole, Isavuconazole, or Liposomal amphotericin B","DRUG, DRUG",All-cause mortality (ACM),2018-02-20,2019-01-14,Vical,INDUSTRY
NCT00002961,Chemotherapy With or Without Total-Body Irradiation Prior to Bone Marrow Transplantation in Treating Children With Acute Lymphoblastic Leukemia,Randomized Trial of Busulfan or Total Body Irradiation Conditioning Regimens for Children With Acute Lymphoblastic Leukemia,TERMINATED,poor accrual,PHASE3,INTERVENTIONAL,43,Leukemia,"cyclophosphamide, cyclosporine, etoposide, methotrexate, Busulfan, Mesna","DRUG, DRUG, DRUG, DRUG, PROCEDURE, RADIATION, DRUG, DRUG, RADIATION",,1995-10,2001-02,Children's Hospital of Philadelphia,OTHER
NCT05656170,Stellate Ganglion to Prevent Atrial Fibrillation,Pre-Operative Stellate Ganglion to Prevent Post-Operative Atrial Fibrillation,WITHDRAWN,Unable to begin study,NA,INTERVENTIONAL,0,Atrial Fibrillation New Onset,"Bupivacain, Saline","PROCEDURE, DRUG, DRUG",Incidence of new onset atrial fibrillation after CABG surgery,2023-10-01,2024-04,Rush University Medical Center,OTHER
NCT03547869,Transcranial Direct Current Stimulation for Pain Treatment in Gulf War Illness.,Investigating Pain in Gulf War Illness With Transcranial Direct Current Stimulation.,TERMINATED,Funding finished,NA,INTERVENTIONAL,9,Gulf War Syndrome,,"DEVICE, DEVICE",Pain Symptom Changes Will be Measured by a Visual Analogue Scale for Pain .,2018-03-12,2023-01-25,The University of Texas at Dallas,OTHER
NCT07191054,LifeFlow Sepsis Study,Prospective Trial Of Patient Outcomes and PALS Sepsis Guideline Adherence In Patients Fluid Resuscitated With The LifeFlow® Rapid Infuser Compared To Traditional Methods,WITHDRAWN,"Study never started, no enrollments.",NA,INTERVENTIONAL,0,Sepsis,,"DEVICE, DEVICE","Time To first bolus completion, Time to third bolus completion, Time to hospital admission, Nursing satisfaction",2019-05-01,2020-03-30,Phoenix Children's Hospital,OTHER
NCT04254705,Organoid Study R334W,Response to CFTR-modulators in Intestinal Organoids of Patients With CF Having at Least One R334W Mutation,WITHDRAWN,Changes in modulator landscape,NA,INTERVENTIONAL,0,Cystic Fibrosis,,PROCEDURE,Response to CFTR-modulator in Intestinal Organoids: Increase in Forskolin induced swelling by addition of tezacaftor+ivacaftor after stimulation with Forskolin (0.8 µmol/L),2020-03-01,2021-03-01,Universitaire Ziekenhuizen KU Leuven,OTHER
NCT03922594,Surveillance of Zika-related Microcephaly in Sub-Saharan Africa and Asia,Surveillance of Zika-related Microcephaly in Sub-Saharan Africa and Asia,TERMINATED,"The disruptions due to the impact of the ongoing COVID-19 pandemic to the implementation of the study in each of the study sites, as well as to the coordination of the study at Institut Pasteur, prevented the completion of the study",,OBSERVATIONAL,150,"Microcephaly, Congenital Infection",,DIAGNOSTIC_TEST,"Incidence of microcephaly (per 10,000 live births), Proportion of microcephaly attributable to ZIKV, Proportion of microcephaly linked to other infectious etiologies",2019-05-20,2021-08-31,Institut Pasteur,INDUSTRY
NCT02443194,"The Effect of Duloxetine on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients","The Effect of Duloxetine on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients",TERMINATED,principle investigator decision due to many adverse events in patients,PHASE3,INTERVENTIONAL,50,Depression,"duloxetine, PLACEBO","DRUG, DRUG",changes in patients mood and cognitive function according to the neuropsychological assessment,2015-05,2015-11,michal roll,OTHER_GOV
NCT01485094,A Study to Assess the Safety and Efficacy of 7 Days Treatment With a Novel Analgesic in Subjects With Peripheral Neuropathic Pain,"Evaluation of the Efficacy, Tolerability, and Safety of 7 Days of Treatment With GRT6010 or Pregabalin in Comparison to Placebo in Subjects With Peripheral Neuropathic Pain.",TERMINATED,The trial was early terminated after it was concluded that there was no added benefit from exposing further participants after an unblinded interim analysis.,PHASE2,INTERVENTIONAL,114,Neuralgia,"GRT6010, Pregabalin, Matching Placebo","DRUG, DRUG, DRUG","Difference Between Baseline and End-of-double-blind Treatment Ongoing Pain Intensity Scores, The Difference Between Baseline and End-of-double-blind Treatment Brush-evoked Pain Intensity Scores",2012-02,2013-01,Grünenthal GmbH,INDUSTRY
NCT01322256,PET/CT Scanning for the Follow-up of Antibiotic Treatment of Infectious Osteoarthritis in the Diabetic Foot,Positron Emission Tomography - Computed Tomography (PET/CT) Scanning for the Follow-up of Antibiotic Treatment of Infectious Osteoarthritis in the Diabetic Foot,TERMINATED,The study has proven to be infeasible.,NA,INTERVENTIONAL,12,"Diabetic Foot, Osteoarthritis",Bloodwork,"PROCEDURE, PROCEDURE, PROCEDURE, PROCEDURE, BIOLOGICAL",The difference between AUCs for PET/CT scan and scintigraphy,2012-10,2014-10,Centre Hospitalier Universitaire de Nīmes,OTHER
NCT01242956,Video-based Training for Rehabilitation of Upper Limb Functions After Stroke,Video-based Training for Rehabilitation of Upper Limb Functions After Stroke: a New Treatment Exploiting the Mirror Neuron System,TERMINATED,Problem to recruit sufficient patient number,PHASE2,INTERVENTIONAL,100,"Stroke, Upper Limb Paresis",,"BEHAVIORAL, BEHAVIORAL",Wolf Motor Function Test,2011-09,2015-09,RWTH Aachen University,OTHER
NCT02586831,Diabetes Islet Preservation Immune Treatment,"A Pilot, Safety and Feasibility Trial of Anti-Thymocyte Globulin (ATG), Low Dose Interleukin-2 (IL-2), Adalimumab and Exenatide in the Treatment of New-Onset Type 1 Diabetes",WITHDRAWN,Study withdrawn prior to enrollment due to funding issues,"PHASE1, PHASE2",INTERVENTIONAL,0,"Diabetes Mellitus, Type 1, Hypoglycemia, Autoimmune Diseases, Diabetes Mellitus","Anti-Thymocyte Globulin (ATG), Interleukin 2, Exenatide, Adalimumab","DRUG, DRUG, DRUG, DRUG, OTHER, OTHER, OTHER, OTHER","Simulated C-peptide AUC, Proportion of regulatory T cells",2024-06-01,2024-06-01,Camillo Ricordi and Jay Skyler,OTHER
NCT00206453,Extension Neoadjuvant Taxotere: Study of the Effects of Taxotere in Patients With Breast Cancer,An Extension Phase II Study of the Clinical and Biologic Effects of Docetaxel (Taxotere) in Patients With Locally Advanced Breast Cancer,TERMINATED,accrual too difficult to meet,PHASE2,INTERVENTIONAL,25,Breast Cancer,Taxotere,DRUG,"biologic effects of Taxotere, to identify gene expression profiles predictive of response and to further describe the efficacy of Taxotere in women with locally advanced breast cancer",2002-01,2005-01,Baylor Breast Care Center,OTHER
NCT02853253,Rate of Bronchopulmonary Dysplasia in Preterms Neonates: a Trial Comparing SMOFlipid and Medialipide,Rate of Bronchopulmonary Dysplasia in Preterms Neonates Less Than 29 Weeks' Gestational Age and / or With Birth Weight Less Than 1000 g: a Double Blind Randomized Controlled Multicenter Trial Comparing SMOFlipid and Medialipide,WITHDRAWN,scientific question reconsidered,PHASE4,INTERVENTIONAL,0,Preterm Neonates,,"DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Rate of other free radical diseases,2017-01,2019-05,Hospices Civils de Lyon,OTHER
NCT03228953,Pharmacogenomic Testing in Major Depressive Disorder,Impact of Comprehensive Pharmacogenomic Testing on the Treatment of Major Depressive Disorder,TERMINATED,Investigator retired.,NA,INTERVENTIONAL,38,Major Depressive Disorder,,OTHER,Score on the Hamilton Rating Scale for Depression (HAMD-17),2017-08-01,2019-07-17,Columbia University,OTHER
NCT00414037,How do Sleeping Pills Affect Pain in the Brain?,Subchronic Effects of Eszopiclone (Lunesta) on Pain Behavior and Circuitry in Primary Insomnia,TERMINATED,"Funding terminated by sponsor, insufficient data collection",PHASE4,INTERVENTIONAL,40,Primary Insomnia,"Eszopiclone, Placebo","DRUG, DRUG",Sleep and pain ratings following 1 week of treatment as compared to baseline,2006-12,2008-12,"University of California, San Diego",OTHER
NCT03907072,Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy,"A Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of WVE-210201 With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy (DYSTANCE 51)",TERMINATED,Lack of efficacy,"PHASE2, PHASE3",INTERVENTIONAL,6,Duchenne Muscular Dystrophy,"WVE-210201 (suvodirsen), Placebo","DRUG, DRUG","Change From Baseline in Dystrophin Level (% Normal Dystrophin), Change From Baseline in North Star Ambulatory Assessment (NSAA)",2019-09-04,2020-01-09,Wave Life Sciences Ltd.,INDUSTRY
NCT02499172,Follow-up of Pregnant Women After a Mass Vaccination of Oral Cholera Vaccine (ShancholTM) in Nsanje Malawi,Follow-up of Pregnant Women After a Mass Vaccination of Oral Cholera Vaccine,TERMINATED,Financial reason,NA,INTERVENTIONAL,2758,"Miscarriage, Stillbirth, Cholera",Shanchol,BIOLOGICAL,Adverse Pregnancy Outcome,2015-06,2016-10-30,Johns Hopkins Bloomberg School of Public Health,OTHER
NCT05288595,TCR Alpha/Beta and CD19-deplete Haplo-HSCT,TCR Alpha/Beta and CD19-depleted Allogeneic Hematopoietic Cell Transplant for Malignant and Non-Malignant Disease,WITHDRAWN,Cancelled by Sponsor,PHASE2,INTERVENTIONAL,0,"Pediatric Patients, Hematologic Malignancy, Other Hematologic Condition",,DEVICE,"Incidence of severe (grade III-IV) acute graft-versus-host disease (GVHD) at day 100 after infusion of a TCRαβ+/CD19+ negative, peripheral blood stem cell (PBSC) product without additional GVHD prophylaxis.",2024-12,2028-04,"University of Colorado, Denver",OTHER
NCT03683095,Efficacy of Lymphovenous Bypass in the Treatment of Extremity Lymphedema,Efficacy of Lymphovenous Bypass in the Treatment of Extremity Lymphedema,WITHDRAWN,Insufficient resources,,OBSERVATIONAL,0,Lymph Leakage,,PROCEDURE,Extremity volume (v),2023-04-01,2024-10-01,Ottawa Hospital Research Institute,OTHER
NCT00826839,Oral Microdose Lupron Versus Luteal Estradiol Trial in Poor Responder In Vitro Fertilization (IVF) Patients,A Randomized Controlled Trial of Treatment Protocols to Optimize Outcomes in Poor Responder In Vitro Fertilization (IVF) Patients: E2 Patch/Antagonist Protocol Versus OCP/Microdose Lupron Protocol,WITHDRAWN,poor enrollment,PHASE4,INTERVENTIONAL,0,Infertility,"Oral contraceptive pill and microdose lupron, E2 patch/antagonist","DRUG, DRUG",Pregnancy rate,2009-01,2012-01,Weill Medical College of Cornell University,OTHER
NCT01288495,Randomized Control Trial of L-Alanine and Placebo in Fructose Intolerance,"Investigation of Supplemental L-alanine in the Management of Dietary Fructose Intolerance: a Double-blind, Randomized Crossover Study",TERMINATED,PI moved institutions and changed study protocol,NA,INTERVENTIONAL,15,Dietary Fructose Intolerance,,"DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",GI symptom score,2009-02,2011-12,Augusta University,OTHER
NCT03353727,Orthoptic Rehabilitation for Low Vision People With Innovative Mechanisms (Eye Tracker and Tactile Device),Orthoptic Rehabilitation for Low Vision People With Innovative Mechanisms (Eye Tracker and Tactile Device),TERMINATED,lack of Financial support,NA,INTERVENTIONAL,12,Low Vision,,OTHER,score assessing the feasibility of the rehabilitation,2017-06-20,2018-12-20,Fondation Ophtalmologique Adolphe de Rothschild,NETWORK
NCT04812327,Capturing Infectious COVID-19 Asymptomatic Cases in Singapore,Capturing Infectious COVID-19 Asymptomatic Cases in Singapore,WITHDRAWN,Study was cancelled prior enrollment due to business decision.,,OBSERVATIONAL,0,"Covid19, SARS CoV-2",,"DIAGNOSTIC_TEST, DIAGNOSTIC_TEST, DIAGNOSTIC_TEST","Assess the performance of the BD Veritor System for Rapid Detection of SARS-CoV-2 compared viral culture, over multiple collection time points",2021-06,2021-11,"Becton, Dickinson and Company",INDUSTRY
NCT04678986,ER2 and Deep Learning for Prediction of Adverse Health Outcomes,Emergency Room Evaluation for Older Users of Emergency Departments: Predicting Adverse Health Outcomes With Deep Learning Algorithms,WITHDRAWN,Study not begun in time and has been withdrawn because of feasibility,,OBSERVATIONAL,0,Emergencies,,OTHER,ED length of stay,2023-02-24,2023-02-24,Jewish General Hospital,OTHER
NCT01148186,An Intervention Study to Reduce the Use and Impact of Potentially Inappropriate Medications Among Older Adults,The Patient as a Driver of Change: an Intervention Study to Reduce the Use and Impact of Potentially Inappropriate Medications Among Older Adults,TERMINATED,Study funding period reached conclusion. Sample size sufficient to complete the analysis on benzodiazepines.,PHASE4,INTERVENTIONAL,300,"Polypharmacy, Incontinence, Insomnia, Anxiety",,BEHAVIORAL,"Complete discontinuation of the targeted potentially inappropriate medication (e.g. benzodiazepines, oxybutynin)",2010-06,2013-05,Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal,OTHER
NCT01199783,Application of Daptomycin in MRSA Infected Diabetic Foot in Comparison to Vancomycin Treatment,Application of Daptomycin in MRSA Infected Diabetic Foot in Comparison to Vancomycin Treatment,TERMINATED,"Patient number to be enrolled not reachable in prospected time frame, decision to stop the study prematurely was made.",PHASE3,INTERVENTIONAL,1,Diabetic Foot,"Daptomycin, Vancomycin","DRUG, DRUG",Clinical Response of the Infection at Test-of-cure (TOC) at Day 14 Post Therapy,2011-07,2013-12,Ruhr University of Bochum,OTHER
NCT06522854,Oral Sildenafil Citrate to Improve Maternal and Neonatal Outcomes in Low-resource Settings,Oral Sildenafil Citrate to Improve Maternal and Neonatal Outcomes in Low-resource Settings: A Randomized Pilot Feasibility Trial,WITHDRAWN,Funding not obtained,PHASE3,INTERVENTIONAL,0,"Intrapartum Fetal Distress, Neonatal Asphyxia, Intrapartum Asphyxia, Instrumental Delivery; Affecting Fetus","Sildenafil 50 mg Oral Tablet, Placebo Oral Tablet","DRUG, DRUG","Percentage of perinatal mortality, Percentage of use of bag and mask in neonates after delivery, Percentage of operative delivery, Indication for operative delivery",2025-05-01,2026-11-30,University of Alabama at Birmingham,OTHER
NCT01538966,Acromegaly Combination Treatment Study,"Comparison of Combination Low-Dose SRL + Daily Pegvisomant Therapy, Low-Dose SRL + Weekly Pegvisomant Therapy, and High-Dose SRL + Weekly Pegvisomant Therapy",TERMINATED,Review of the 12-month data showed patients who deviated from protocol with full IRB monitoring and reporting could not be optimally analyzed. Reopening the study for new enrollment is not feasible and the study was terminated with IRB approval.,NA,INTERVENTIONAL,76,Acromegaly,"Pegvisomant, Octreotide LAR, Lanreotide","DRUG, DRUG, DRUG",Cost Effectiveness,2012-03-29,2022-05-20,Cedars-Sinai Medical Center,OTHER
NCT01984866,CPR Prediction After Neoadjuvant Using Excisional Biopsy By Radiofrequency In Breast Cancer From II-III UICC Stages.,Complete Pathological Response Prediction After Neoadjuvant Treatment Using Excisional Biopsy By Radiofrequency In Breast Cancer From II-III UICC Stages.,TERMINATED,Recruitment was very low.,,OBSERVATIONAL,13,"Triple Negative, HER2+, Luminal B Breast Tumors (Stages II-III)in Female Patients",,,determination of the negative predictive value (NPV) of the excisional biopsy technique,2013-07,2018-08,Hospital General Universitario Gregorio Marañon,OTHER
NCT06062056,Motivational Interviewing for Vaccine Uptake in Latinx Adults,Leveraging Community-based Behavioral Health to Increase Vaccine Uptake in Latinx Adults With Mental Illness,TERMINATED,It's focus on vaccine hesitancy did not align with the administration's philosophy,NA,INTERVENTIONAL,3698,Vaccine Hesitancy,,"OTHER, BEHAVIORAL, BEHAVIORAL","Received COVID-19 vaccine/booster following an eligible behavioral health visit, Received influenza vaccine following an eligible behavioral health visit",2023-10-02,2025-04-30,Boston College,OTHER
NCT01201629,"Transcranial Direct Current Stimulation, Improve Functional Motor Recovery, Affected Arm",Does Transcranial Direct Current Stimulation Improve Functional Motor Recovery in the Affected Arm-Hand in Patients After an Acute Ischemic Stroke: A Randomized Control Trial,TERMINATED,Slow accrual over 6 year period,NA,INTERVENTIONAL,16,"Brain Infarction, Brain Ischemia",,"DEVICE, DEVICE",Total Functional Independence Measure (TFIM) Change Scores,2010-09-16,2015-12,University of Oklahoma,OTHER
NCT05469802,A Study of Purified Inactivated Zika Virus Vaccine (PIZV) in Healthy Adults,"A Randomized, Observer-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Immunogenicity of the Purified Inactivated Zika Virus Vaccine (PIZV) Administered on Days 1 and 29 in Healthy Participants Aged 18 to 49 Years in the US",WITHDRAWN,"Business reason, change in Zika virus epidemiology",PHASE2,INTERVENTIONAL,0,Healthy Volunteers,Purified Inactivated Zika Virus Vaccine (PIZV),"BIOLOGICAL, OTHER","Percentage of Participants With Seropositivity for Neutralizing Antibodies Against Zika Virus at 28 Days Post Dose 2, Percentage of Participants With Seroconversion for Neutralizing Antibodies Against Zika Virus at 28 Days Post Dose 2, Geometric Mean Titers (GMTs) for Neutralizing Antibodies Against Zika Virus at 28 Days Post Dose 2, Percentage of Participants With Solicited Local Injection Site Reactions for 7 Days After First Dose of Vaccination, Percentage of Participants With Solicited Local Injection Site Reactions for 7 Days After Second Dose of Vaccination, Percentage of Participants With Solicited Systemic Adverse Events (AEs) for 7 Days After First Dose of Vaccination, Percentage of Participants With Solicited Systemic AEs for 7 Days After Second Dose of Vaccination, Percentage of Participants With at Least One Unsolicited AE for 28 Days After First Dose of Vaccination, Percentage of Participants With at Least One Unsolicited AE for 28 Days After Second Dose of Vaccination, Percentage of Participants With at Least One Serious Adverse Event (SAE) Throughout the Entire Study Period, Percentage of Participants With at Least One Adverse Events of Special Interest (AESI) Throughout the Entire Study Period, Percentage of Participants With at Least One Medically-Attended Adverse Event (MAAE) Throughout the Entire Study Period",2024-01-02,2024-07-05,Takeda,INDUSTRY
NCT02664753,L-carnitine as an Adjunct Treatment for Septic Shock Patients With Acute Kidney Injury,"L-carnitine as an Adjunct Treatment for Septic Shock Patients With Acute Kidney Injury: a Multicentre, Randomized, 2-parallel Group, Superiority Trial",TERMINATED,"Exposure to serious adverse events related to the research (i.e., death), the mnts = 54% versus 58 deaths out of 121 patients = 48%).onitoring committee unanimously recommended discontinuation of the trial.",PHASE3,INTERVENTIONAL,254,"Severe Sepsis, Shock, Septic, Acute Kidney Injury","56 days of weight-adjusted L-Carnitine treatment, 10 days of intravenous placebo (isotonic saline)","DRUG, DRUG",Mortality,2018-03-05,2024-12-04,Centre Hospitalier Universitaire de Nīmes,OTHER
NCT04772053,Molecular Disease Characterization Initiative (MDCI),"A Global, Molecular Disease Characterization Initiative (MDCI) in Oncology Clinical Trials",TERMINATED,The study was terminated for reasons pertaining to feasibility,PHASE2,INTERVENTIONAL,6,"Lung Cancer, Non-Small Cell, Neoplasms",,PROCEDURE,"Number of Participants With Positive Inducible T-cell Co-Stimulator (ICOS) Status, Number of Participants With Positive New York Esophageal Squamous Cell Carcinoma 1 (NY-ESO-1)/Cancer Testis Antigen 2 (LAGE-1a) Status, Number of Participants With Positive Programmed Death Protein 1 Ligand (PD-L1) Status",2021-05-25,2022-11-15,GlaxoSmithKline,INDUSTRY
NCT00229853,Thoracoscopic Vascular Rings Chart Review,Thoracoscopic Vascular Rings Chart Review,TERMINATED,sufficient data gathered to support hypothesis,,OBSERVATIONAL,47,Cardiovascular Abnormalities,,,,2004-08,2007-07,Children's Healthcare of Atlanta,OTHER
NCT04811937,Development of a Computer-aided Polypectomy Decision Support,Development of a Computer-aided Polypectomy Decision Support,WITHDRAWN,The study was abandoned due to the Covid pandemic which prevented recruitment.,NA,INTERVENTIONAL,0,Adenomatous Polyps,,DIAGNOSTIC_TEST,"Accuracy of the CADp system, Completeness of polypectomy, Training CADp, Validity of the choice of primary outcome",2021-12,2023-04,Centre hospitalier de l'Université de Montréal (CHUM),OTHER
NCT00962572,The Effects of Aggressive Patient Management on Cancer Therapy Management,The Effects of Aggressive Patient Management on Cancer Therapy Management,WITHDRAWN,Investigator decided not to pursue,,OBSERVATIONAL,0,Cancer,,BEHAVIORAL,To test effects of intensive patient management on patient's compliance with referral and subsequent treatment protocol.,2009-01,2010-12,University of Mississippi Medical Center,OTHER
NCT04884295,"Dose-Finding, Safety, and Efficacy Study of XVR011 Added to Standard of Care in Patients Hospitalised for COVID-19","A 2-part Clinical Study Including a First in Human, Open Label, Single Ascending Dose Part (Phase 1) Followed by a Randomised, Double Blind, Placebo-controlled Part (Phase 2) to Evaluate the Efficacy and Safety of XVR011 in Patients Hospitalised for Mild to Moderate Coronavirus Disease 2019 (COVID-19)",TERMINATED,The sponsor does not intend to start Part 2 (Phase 2) due to change in company strategy for phase 2 design. This early end of trial is not due to reasons of safety or lack of efficacy. Part 1 (Phase 1) is completed as per protocol.,"PHASE1, PHASE2",INTERVENTIONAL,27,Covid19,XVR011,DRUG,Proportion of subjects with Adverse Events (all and serious),2021-08-26,2022-03-18,ExeVir Bio BV,INDUSTRY
NCT03281239,Study of the Impact of Welding Fumes on the Arterial System : RISCAS Study,Study of the Impact of Welding Fumes on the Arterial System : RISCAS Study,TERMINATED,"Due to the difficulties of inclusion, it was decided not to extend this period",NA,INTERVENTIONAL,51,Effects of Welding Fumes Components,,DIAGNOSTIC_TEST,Vascular reactivity,2017-11-28,2019-06-24,"University Hospital, Brest",OTHER
NCT00415077,"A Comparison of Photorefractive Keratectomy (PRK), PRK With Mitomycin-C and Laser Subepithelial Keratomileusis (LASEK) in the Treatment of Moderate and High Myopia","A Prospective Comparison of Photorefractive Keratectomy (PRK), PRK With Mitomycin-C and Laser Subepithelial Keratomileusis (LASEK) in the Treatment of Moderate and High Myopia",TERMINATED,Change in excimer laser systems prior to completion of study,NA,INTERVENTIONAL,960,MODERATE AND HIGH MYOPIA,,"PROCEDURE, PROCEDURE, PROCEDURE",Efficacy in terms of uncorrected visual acuity and post operative refraction. Safety in terms of maintenance of best spectacle corrected acuity within 2 lines of preoperative levels.,2004-06,,Walter Reed Army Medical Center,FED
NCT00363675,Evaluation of Hand Assessments in Children With Severe Hand Burns,Evaluation of Hand Assessments in Children With Severe Hand Burns,TERMINATED,"This was a pilot study, but the larger study was not funded.",NA,INTERVENTIONAL,3,Burns,,BEHAVIORAL,"Blocks & Box (Standardized Test)., Range of Motion, Total Active Motion (TAM), Grip Strength, Moberg Pickup Test",2006-08,2011-08,Massachusetts General Hospital,OTHER
NCT02456675,INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma,"A Phase 2, Open-Label Study of the Safety and Efficacy of INCB40093 and INCB40093 Combined With Itacitinib (INCB039110) in Subjects With Relapsed or Refractory Hodgkin Lymphoma",TERMINATED,A decision was made to terminate the study due to the changing treatment landscape for the development of new agents in combination in Hodgkin lymphoma.,PHASE2,INTERVENTIONAL,8,"Refractory Hodgkin Lymphoma, Recurrent Adult Hodgkin's Lymphoma","INCB040093 Monotherapy, INCB040093, itacitinib","DRUG, DRUG, DRUG",Objective Response Rate (ORR) as determined by the percentage of subjects achieving a partial response (PR) or complete response (CR),2015-06,2016-12-16,Incyte Corporation,INDUSTRY
NCT00358657,"Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders","HLA-Haploidentical Related Marrow Grafts for the Treatment of Primary Immunodeficiencies and Other Nonmalignant Disorders Using Conditioning With Low-Dose Cyclophosphamide, TBI and Fludarabine and Postgrafting Cyclophosphamide",TERMINATED,Low accrual,PHASE2,INTERVENTIONAL,14,"Immunodeficiency Syndrome, Severe Aplastic Anemia, Genetic Disorder","Cyclophosphamide, Fludarabine Phosphate, Mycophenolate Mofetil, Sirolimus, Tacrolimus","PROCEDURE, DRUG, DRUG, OTHER, DRUG, PROCEDURE, DRUG, DRUG, RADIATION","Graft Rejection, Graft Failure",2006-05-24,2019-05-25,Fred Hutchinson Cancer Center,OTHER
NCT06312657,Behavioral Effects of Drugs Inpatient 44 Neurobehavioral Mechanisms of Opioid Choice,Behavioral Effects of Drugs Inpatient 44: Neurobehavioral Mechanisms of Opioid Choice,TERMINATED,Funding ended,EARLY_PHASE1,INTERVENTIONAL,2,Opioid Use Disorder,Withdrawal,"BEHAVIORAL, BEHAVIORAL, DRUG",Task choices,2023-03-01,2025-03-28,"Joshua A. Lile, Ph.D.",OTHER
NCT03771001,5Minutes4Myself: A Wellness Program for Caregivers,5Minutes4Myself: A Wellness Program for Caregivers,TERMINATED,lack of funding to rebuild the app,NA,INTERVENTIONAL,25,"Autism, Stress, Autism Spectrum Disorder",,OTHER,"SF-36 Questionnaire, Perceived Stress Scale, Ryff's Psychological Well-Being Scale, Center for Epidemiological Depression Scale-Revised, Five facets of Mindfulness Questionnaire, Modified System Usability Scale, Participant Feedback",2015-11,2025-05-30,"University of Wisconsin, Madison",OTHER
NCT03325296,Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata.,Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata.,TERMINATED,Futility,PHASE2,INTERVENTIONAL,13,Alopecia Areata,LEO 124249,"DRUG, OTHER",Change from baseline to week 12 of investigator evaluated overall area score (ASoverall L+R) of eyebrow hair growth.,2017-10-30,2018-05-16,LEO Pharma,INDUSTRY
NCT02569827,Celgosivir or Modipafant as Treatment for Adult Participants With Uncomplicated Dengue Fever in Singapore,"A Phase Ib/IIa Single Centre, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Dose Ranging Trial in Adult Participants With Uncomplicated Dengue Fever in Singapore",WITHDRAWN,The investigational drug celgosivir will not be developed due to lack of VC funding.,"PHASE1, PHASE2",INTERVENTIONAL,0,Dengue Fever,"Celgosivir, Modipafant 50mg, Placebo, Modipafant 100mg","DRUG, DRUG, DRUG, DRUG","Viral load AUC for viremia, Platelet nadir",2018-12,2019-08-08,Singapore General Hospital,OTHER
NCT01315886,Conversion From Fast Acting Oral Opioids to Abstral®,Conversion From Fast Acting Oral Opioids to Abstral® (SL Fentanyl) in Opioid Tolerant Cancer Patients With Breakthrough Pain,TERMINATED,Recruitment difficulties,PHASE4,INTERVENTIONAL,8,Pain,SL fentanyl,DRUG,Response rate in patients converted to SL fentanyl.,2011-02-21,2011-12-07,Orexo AB,INDUSTRY
NCT06466486,An Exploratory Study to Investigate the Effect of FE 999302 When Given Together With Follitropin Delta During Controlled Ovarian Stimulation,"A Randomised, Partially Double-blind, Placebo-controlled, Parallel-group Exploratory Trial to Investigate the Effect of FE999302 in Women Undergoing Controlled Ovarian Stimulation With a Fixed Dose of Follitropin Delta in a Gonadotropin-releasing Hormone Antagonist Protocol",TERMINATED,"This is a company decision made not related to safety concerns. Rather, it reflects a broader portfolio assessment and the desire to focus on programs that can bring timely and meaningful benefit to patients.",PHASE1,INTERVENTIONAL,310,Fertility,"Follitropin delta, FE999302, FE999302 Placebo","DRUG, DRUG, DRUG",Number of good-quality blastocysts,2024-06-14,2025-09-05,Ferring Pharmaceuticals,INDUSTRY
NCT02687386,A Study of Intravenous EEDVsMit in Children With Recurrent / Refractory Solid or CNS Tumours Expressing EGFR,A Phase 1 Study of Intravenous EGFR-ErbituxEDVsMIT (EEDVsMit) in Children With Recurrent / Refractory Solid or CNS Tumours Expressing Epidermal Growth Factor Receptor (EGFR) (ECREST Study),TERMINATED,Study medication no longer in production,PHASE1,INTERVENTIONAL,9,"Solid Tumours, CNS Tumours",Mitoxantrone packaged EDV (EnGeneIC Delivery Vehicle),DRUG,"MTD at which fewer than one third of patients experience dose limiting toxicity as assessed by CTCAE v4.0, Incidence of treatment-related adverse events as assessed by CTCAE v4.0, Incidence of all adverse events as assessed by CTCAE v4.0, clinically significant changes in vital signs, ECGs and clinical laboratory tests",2016-02-08,2021-12-29,Dr David Ziegler,OTHER
NCT01097941,Effect of Age and Prior Immunity on Response to H1N1 Vaccines in Children,Evaluation of the Effect of Age and Prior Immunity on the Response to Live or Inactivated A/California/07/09 H1N1 Influenza Vaccines in Children,WITHDRAWN,Live H1N1 vaccine expired and unable to get new supply,PHASE4,INTERVENTIONAL,0,2009 H1N1 Influenza,"Live Attenuated H1N1 Influenza Vaccine, Influenza A (H1N1) 2009 Monovalent Vaccine, Influenza A (H1N1) 2009 Monovalent Vaccine/ Influenza A (H1N1) Monovalent Vaccine Live","BIOLOGICAL, BIOLOGICAL, BIOLOGICAL","The primary endpoint for assessment of the live attenuated vaccine take will be the AUC of the live vaccine virus shedding determined by 50% tissue culture infectious dose (TCID ) on MDCK cells at 33 degrees C, The primary endpoint for assessment of the live attenuated vaccine take will be the AUC of the live vaccine virus shedding determined by 50% tissue culture infectious dose (TCID ) on MDCK cells at 33 degrees C, The primary endpoint for assessment of the live attenuated vaccine take will be the AUC of the live vaccine virus shedding determined by 50% tissue culture infectious dose (TCID ) on MDCK cells at 33 degrees C",2010-03,2010-09,University of Rochester,OTHER
NCT04540354,Personalised Risk scOre For Implantation of Defibrillators in Patients With Reduced LVEF≤35% and a Low Risk for Sudden Cardiac Death,Personalised Risk scOre For Implantation of Defibrillators in Patients With Reduced LVEF≤35% and a Low Risk for Sudden Cardiac Death (PROFID-Reduced),WITHDRAWN,Study design needs to be updated considering the lack of a risk predictor with acceptable predictive performance for the discrimination between high- and low-risk patients and the overall low sudden cardiac death risk as found in the data analysis,NA,INTERVENTIONAL,0,"Myocardial Infarction, Heart Failure, Sudden Cardiac Death",Optimal Medical Therapy (OMT),"DRUG, DEVICE",Time from randomisation to the occurrence of all-cause death,2021-02-01,2023-01-31,Helios Health Institute GmbH,OTHER
NCT00566241,IGF-1 Therapy in Patients With Cystic Fibrosis,An Investigation Into the Use of IGF-1 Therapy in Patients With Cystic Fibrosis,TERMINATED,Insufficient recruitment,PHASE1,INTERVENTIONAL,15,Cystic Fibrosis,"recombinant human IGF-1, Placebo","DRUG, DRUG",Body weight and body composition,2008-06,2012-06,Stony Brook University,OTHER
NCT05048654,A Novel Ovarian Reserve Monitoring Algorithm for Patients at Risk of Ovarian Injury From Gonadotoxic Therapy,A Novel Ovarian Reserve Monitoring Algorithm for Patients at Risk of Ovarian Injury From Gonadotoxic Therapy,WITHDRAWN,Cancelled by PI,,OBSERVATIONAL,0,"Ovarian Diseases, Fertility Issues, Gonadal Disorders",,,Does the novel monitoring algorithm (intervention group) detect early Ovarian disfunction,2025-12-15,2029-06-30,"University of Colorado, Denver",OTHER
NCT02501005,Preventive aBlation of vEntricular tachycaRdia in Patients With myocardiaL INfarction,Preventive aBlation of vEntricular tachycaRdia in Patients With myocardiaL INfarction,TERMINATED,The study was stopped due to futility,NA,INTERVENTIONAL,163,Ventricular Tachycardia,,PROCEDURE,"Time to first event comprising all-cause mortality, unplanned hospital admission for congestive heart failure and unplanned hospital admission for symptomatic ventricular tachycardia (VT)/ ventricular fibrillation (VF)",2015-07-20,2018-07-20,Biotronik SE & Co. KG,INDUSTRY
NCT04981405,Real-world Evidence of COVID-19 Vaccines Effectiveness,"Real-world Evidence of COVID-19 Vaccine Effectiveness Against COVID-19 Hospitalization: the Case-control Study in St. Petersburg, Russia",TERMINATED,"low recruitment, end of COVID-19 pandemic",,OBSERVATIONAL,182,COVID-19 Pneumonia,COVID-19 Vaccines,BIOLOGICAL,Effectiveness of full vaccination against hospitalization with COVID-19 pneumonia,2021-07-16,2022-07-19,Ivan S Moiseev,OTHER
NCT03330405,Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors,A PHASE 1B/2 STUDY TO EVALUATE SAFETY AND ANTI TUMOR ACTIVITY OF AVELUMAB IN COMBINATION WITH THE POLY(ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) INHIBITOR TALAZOPARIB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS,TERMINATED,The study was terminated since there was no need for further safety or efficacy data to be collected. The participants having benefit from the investigational treatments have been moved to a continuation study (NCT05059522).,"PHASE1, PHASE2",INTERVENTIONAL,223,Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors,"Avelumab Phase 1b, Talazoparib Phase 1b, Avelumab Phase 2, Talazoparib Phase 2","DRUG, DRUG, DRUG, DRUG","Phase 1b: Number of Participants With Dose Limiting Toxicities (DLTs), Phase 2: Percentage of Participants With Confirmed Objective Response (OR) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 by Investigator Assessment, Phase 2: Percentage of Participants With Confirmed Objective Response (OR) as Per RECIST v1.1 and Prostate Cancer Working Group 3 (PCWG3) by Investigator Assessment",2017-10-19,2023-01-04,Pfizer,INDUSTRY
NCT01902966,Feasibility - Beta Adrenergic Blockade (BB) in Cervical Cancer (CX),"Effect of a Beta Adrenergic Blockade Combined With Relaxation/Guided Imagery Audio Intervention on Symptom Distress in Women With Advanced, Recurrent Incurable Cervical Cancer - Feasibility Study",TERMINATED,low accrual and lack of funding,NA,INTERVENTIONAL,6,Cervical Cancer,Propranolol,"DRUG, BEHAVIORAL, BEHAVIORAL, BEHAVIORAL",Proportion of Patients Completing Symptom Inventories,2013-09-11,2020-08-14,M.D. Anderson Cancer Center,OTHER
NCT01796522,Utility of Tocolytic Therapy for Maintenance Tocolysis in the Management of Threatened Preterm Delivery,Utility of Tocolytic Therapy for Maintenance Tocolysis in the Management of Threatened Preterm Delivery,WITHDRAWN,have been published new studies that it showed the ineffectiveness of the treatments proposed in this study.,PHASE3,INTERVENTIONAL,0,Preterm Delivery.,"progesterone 200 mg / day vaginally, nifedipine (60 mg / day orally)","DRUG, DRUG",The present study aims to evaluate the efficacy of these tocolytic drugs for maintenance tocolysis in the management of threatened preterm delivery.,2013-03,2013-05,Instituto de Investigacion Sanitaria La Fe,OTHER
NCT00262951,Chemoradiation in Locally Advanced Pancreatic Cancer,A Phase II Pilot Study of Multi-Agent Neo-Adjuvant Chemoradiation in Patients With Locally Advanced Pancreatic Adenocarcinoma,TERMINATED,Closed at a planned interim analysis by meeting a predefined toxicity endpoint,PHASE2,INTERVENTIONAL,23,Pancreatic Cancer,"recombinant interferon alfa, cisplatin, fluorouracil","BIOLOGICAL, DRUG, DRUG, RADIATION, PROCEDURE",Number of Patients in Whom Tumor Was Resectable,2005-01,2011-08,"Masonic Cancer Center, University of Minnesota",OTHER
NCT03665129,IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors,"A Phase I Study of the Anti-C5aR, IPH5401, in Combination With the Anti-PD-L1, Durvalumab, in Patients With Selected Advanced Solid Tumors",TERMINATED,early termination,PHASE1,INTERVENTIONAL,73,Advanced Solid Tumors,IPH5401 and Durvalumab,BIOLOGICAL,"Occurrence of Drug Limited Toxicities (DLTs), Adverse events (AEs)",2018-09-07,2021-02-24,Innate Pharma,INDUSTRY
NCT02030431,Dynaloc for Treatment of Femoral Neck Fractures,Dynaloc vs. Multiple Cancellous Screws for Treatment of Femoral Neck Fractures,TERMINATED,overweight of hard-ware removals in the Dynaloc group,NA,INTERVENTIONAL,150,Femoral Neck Fracture,,"DEVICE, DEVICE",Shortening of the femoral neck,2014-03,2015-10,Aarhus University Hospital,OTHER
NCT02931253,Metformin as an Upstream Therapy in Atrial Fibrillation,Metformin as an Upstream Therapy in Atrial Fibrillation,TERMINATED,Recruitment issue: Enrollment expectation not met,PHASE2,INTERVENTIONAL,6,Atrial Fibrillation,Metformin,DRUG,Number of Participants Who Maintain Sinus Rhythm,2017-04-11,2018-07-10,The Guthrie Clinic,OTHER
NCT01100437,Safety Study to Assess Opiate Withdrawal Signs and Symptoms in Opioid Dependent Patients,"A Single-Center, Randomized, Double-Blind, Two-Way Crossover Study to Evaluate Whether a Single-Dose Administration of Crushed and Whole EMBEDA Induces Clinical Opiate Withdrawal Signs and Symptoms in Opioid-Dependent Patients With Chronic, Non-Cancer Pain Who Are Stabilized on EMBEDA¿",TERMINATED,See termination reason in detailed description.,PHASE4,INTERVENTIONAL,14,Chronic Pain,"EMBEDA™ (morphine sulfate/naltrexone hydrochloride) crush, EMBEDA™ (morphine sulfate/naltrexone hydrochloride) whole","DRUG, DRUG",Number of Participants With Clinical Opiate Withdrawal Scale (COWS) Score Greater Than or Equal to (≥) 13 in the Treatment Phase,2010-04,2011-03,Pfizer,INDUSTRY
NCT06009653,Effects of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity,Effect of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity,WITHDRAWN,The study was discontinued prematurely for administrative reasons,PHASE4,INTERVENTIONAL,0,"Obesity, Metabolic Disease","Placebo, Tirzepatide","BEHAVIORAL, BEHAVIORAL, DRUG, DRUG","Change in body weight, Change in body weight",2023-09-13,2024-05-29,Washington University School of Medicine,OTHER
NCT04566445,HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005,"HORIZON: A Phase II, Open-label, Outcomes-assessor Masked, Multicentre, Randomised, Controlled Study to Evaluate the Safety and Efficacy of Two Doses of GT005 Administered as a Single Subretinal Injection in Subjects With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration",TERMINATED,Terminated for interim analysis demonstrating futility (trial highly unlikely to meet efficacy outcome). The trial is not ending early because of medical problems or concerns.,PHASE2,INTERVENTIONAL,255,Dry Age-related Macular Degeneration,GT005,DRUG,The Change From Baseline to Week 72 in Geographic Atrophy (GA),2020-09-28,2024-06-10,Gyroscope Therapeutics Limited,INDUSTRY
NCT04975945,Assessing Parenteral Antibiotics Versus Single-time Intra-operative Intra-dermal Antibiotic Administration for Prevention of SSI,A Randomized Controlled Study Assessing Prolonged Parenteral Antibiotics Versus Single-time Intra-operative Intra-dermal Antibiotic Administration in Elective Clean and Clean-contaminated Surgeries for Prevention of Surgical Site Infections,WITHDRAWN,"Technical and organisational issues at the center, leading to inability to enrol study participants",PHASE4,INTERVENTIONAL,0,"Surgical Wound Infection, Surgical Site Infection",Ceftriaxone Sodium,DRUG,"Incidence of Surgical site infection, Organism isolated from wound",2021-08,2022-01,The Grant Medical College & Sir J.J. Group of Hospitals,OTHER_GOV
NCT04742972,Prostate PMSABR Study,PSMA-PET Guided Stereotactic Ablative Body Radiotherapy for Oligometastasis in Metastatic Castration-resistant Prostate Cancer (mCRPC) With Progression on Enzalutamide (PMSABR Study),WITHDRAWN,"The lack of well-defined oligometastasis, high disease burden in mCRPC and high sensitivity of PSMA-PET scan, PMSABR study was made with high ambition and the assumption on recruitment was found to be invalid.",NA,INTERVENTIONAL,0,Prostate Cancer,,"RADIATION, OTHER",The 6-month progression-Free Survival rate,2021-02-25,2022-09-16,Darren Poon,OTHER
NCT04746495,Effect of Eplerenone on Novel Biomarkers of Mineralocorticoid Receptor Activation (ENOVA),Effect of Eplerenone on Novel Biomarkers of Mineralocorticoid Receptor Activation (ENOVA),WITHDRAWN,"Issues relate to COVID-19 and staffing challenges, as well as very tight finances.",PHASE4,INTERVENTIONAL,0,Hypertension,"Placebo, Eplerenone 50mg","DRUG, DRUG","Reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) Cycle threshold (Ct) value of mineralocorticoid receptor-regulated gene messenger ribonucleic acid (mRNA), RT-qPCR Ct value of mineralocorticoid receptor-regulated gene mRNA",2023-02,2023-12-01,University of Michigan,OTHER
NCT05054595,Audio-Recorded vs. Nurse-Led Brief Mindfulness-Based Intervention,Comparing the Effects of an Audio-Recorded Brief Mindfulness-Based Intervention With a Nurse-Led Brief Mindfulness-Based Intervention for Preoperative Knee and Hip Replacement Patients,WITHDRAWN,Lack of provider bandwidth,NA,INTERVENTIONAL,0,"Pain, Osteoarthritis, Knee, Osteoarthritis, Hip",,"BEHAVIORAL, BEHAVIORAL, BEHAVIORAL",Change in Pain Intensity Numeric Rating Scale,2021-09-20,2022-09-20,University of Utah,OTHER
NCT02684539,Autonomous Syncope Onset Prediction and Prevention,"Autonomous Syncope Onset Prediction and Prevention An Open-label, One-centre Pilot Study on Healthy Subjects With the Erigo Tilt Table",WITHDRAWN,project weill not be realized for organisational reasons,NA,INTERVENTIONAL,0,Syncope,,DEVICE,clinical sign of syncope,2014-04,2014-12,Swiss Federal Institute of Technology,OTHER
NCT04268888,Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC,A Two-arm Multi-stage (TAMS) Seamless Phase II/III Randomised Trial of Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC,SUSPENDED,Analysis meant the study should close to recruitment,"PHASE2, PHASE3",INTERVENTIONAL,522,Hepatocellular Carcinoma,Nivolumab and TACE/TAE,"DRUG, PROCEDURE","Overall Survival - phase III primary outcome, Time to TACE Progression (TTTP) - phase II primary outcome",2019-05-08,2026-06-30,The Clatterbridge Cancer Centre NHS Foundation Trust,OTHER
NCT01779427,Attention Intervention Management,Rehabilitation Research and Training Center for Traumatic Brain Injury Interventions--Attention Intervention Management,WITHDRAWN,"Based on data from pilot study, the PI and program officer have determined that this study was not feasible.",NA,INTERVENTIONAL,0,"Traumatic Brain Injury (TBI), Attention Deficit Hyperactivity Disorder (ADHD), Head Injury, Brain Concussion, Head Injuries, Closed",,BEHAVIORAL,Parent Report Measures,2013-01,2014-01,"Children's Hospital Medical Center, Cincinnati",OTHER
NCT02016573,Renal Denervation for Uncontrolled Hypertension,Renal Denervation for Uncontrolled Hypertension,WITHDRAWN,No participants enrolled into study and protocol has been superseded,NA,INTERVENTIONAL,0,Hypertension,,DEVICE,blood pressure control,2013-12,2015-04,Baker Heart and Diabetes Institute,OTHER
NCT02591173,Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure,Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure,TERMINATED,Difficulty recruiting,EARLY_PHASE1,INTERVENTIONAL,7,"Autonomic Nervous System Disorders, Pure Autonomic Failure, Shy-Drager Syndrome, Orthostatic Hypotension, Dysautonomic","Angiotensin-(1-7), Saline","DRUG, DRUG",Blood Pressure,2016-02,2020-07,Vanderbilt University Medical Center,OTHER
NCT06795373,Ritlecitinib (PF-06651600) in Participants With Chronic Spontaneous Urticaria,"A Single-center, Single-arm, Open-label Phase IIA Clinical Trial to Investigate Efficacy and Safety of Ritlecitinib (PF-06651600) in Participants With Chronic Spontaneous Urticaria",WITHDRAWN,Sponsor terminated study,PHASE2,INTERVENTIONAL,0,"Chronic Spontaneous Urticaria, CSU",Ritlecitinib,DRUG,Change in Urticaria Activity Score (UAS7),2025-12-31,2026-03-31,Ahuva D Cices,OTHER
NCT02197286,Targeted Vitamin D Treatment of Schizophrenia-Associated Hyperprolinemia,Vitamin-D Treatment Targeted to Hyperprolinemia-Associated Schizophrenia.,WITHDRAWN,Personnel changes at study site.,PHASE2,INTERVENTIONAL,0,"Schizophrenia, Schizoaffective Disorder","Cholecalciferol, Placebo","DRUG, DRUG",Clinical response to supplementation with vitamin D.,2015-02,,NYU Langone Health,OTHER
NCT02974686,Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation,Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation,TERMINATED,low recruitment,PHASE4,INTERVENTIONAL,1,"Kidney Transplant Rejection, Gastrointestinal Disorder, Functional","Everolimus, Mycophenolic Acid","DRUG, DRUG",Gastrointestinal Symptom Rating Scale,2016-11,2019-09,Washington University School of Medicine,OTHER
NCT04218786,Effect of Colchicine in Patients With Myocardial Infarction,Outcomes of Low-dose Colchicine in Patients With Myocardial Infarction: A Randomized Controlled Trial,WITHDRAWN,"Due to the pandemic, there were logistical issues in continuing the study.",PHASE2,INTERVENTIONAL,0,"Myocardium; Injury, Myocardial Infarction, Myocardial Ischemia","Colchicine, Placebo oral tablet","DRUG, DRUG",Major cardiovascular adverse events (number of events),2025-12,2026-06,Shifa Tameer-e-Millat University,OTHER
NCT00349986,LANTUSTITR: Insulin Glargine in Type 2 Diabetes Mellitus,The Determination of the First Dose and the Optimal Time of Administration of Insulin Glargine Combined With Oral Antidiabetic Drug in Poorly Controlled Type II Diabetic Patients,TERMINATED,prematurely terminated due to loss of interest,PHASE4,INTERVENTIONAL,4,"Diabetes Mellitus, Type 2",Insuline glargine,DRUG,HgbA1c measurement,2006-09,,Sanofi,INDUSTRY
NCT05264454,Effect of High-Flow Nasal Cannula on IVC Measurements Using Point of Care Ultrasound,Effect of High-Flow Nasal Cannula on IVC Measurements Using Point of Care Ultrasound,WITHDRAWN,due to Covid-19 the project will not be moving forward,NA,INTERVENTIONAL,0,Fluid Overload,,DEVICE,Inferior vena cava maximal diameter in millimeter,2022-07-01,2023-06-30,Nova Scotia Health Authority,OTHER
NCT04340154,Study of Sequential CAR-T Cell Treating Leukemia Children,Phase II Study of Sequential Chimeric Antigen Receptor T Cell Targeting at Different B-cell Antigens Treating Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Children,TERMINATED,ethic commitee decision,PHASE2,INTERVENTIONAL,81,"Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoid Leukemia",chimeric antigen receptor T cell,BIOLOGICAL,Objective response rate (ORR),2020-05-01,2024-11-30,Beijing Boren Hospital,OTHER
NCT05000294,Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types,Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types,SUSPENDED,interim analysis,"PHASE1, PHASE2",INTERVENTIONAL,29,"Bile Duct Cancer, Gall Bladder Cancer, Breast Cancer, Neuroendocrine Tumors, Ovarian Cancer, Pancreatic Adenocarcinoma, Soft Tissue Sarcoma, Vulvar Cancer, Prostate Cancer","Atezolizumab, Tivozanib","DRUG, DRUG",Objective response rate (ORR),2021-12-07,2027-06,University of Florida,OTHER
NCT01098331,Implant Radiation Therapy or Surgery in Treating Patients With Prostate Cancer,Surgery and Brachytherapy: A Randomized Evaluation. Randomized Controlled Trial of Brachytherapy Versus Radical Prostatectomy in Good Risk Prostate Cancer: A Feasibility Study,TERMINATED,Closed early due to poor recruitment,NA,INTERVENTIONAL,30,Prostate Cancer,,"PROCEDURE, PROCEDURE","Proportion of patients consenting to the treatment randomization, Feasibility of randomization in terms of average accrual rate per center during the last 6 months of recruitment",2008-06-01,2013-06-01,University of Southampton,OTHER
NCT00895531,Combination of Peripheral Nerve Block and DepoDur in Total Knee Joint Replacement,"Comparison of Peripheral Nerve Blocks vs. Combination of Peripheral Nerve Block and DepoDur in Total Knee Joint Replacement: A Prospective, Randomized Study",TERMINATED,Investigator left institution,PHASE4,INTERVENTIONAL,75,"Arthroplasty, Replacement, Knee",Depodur,"DRUG, PROCEDURE",Postoperative Pain,2009-12,2012-12,University of Louisville,OTHER
NCT04326231,Cognoa Autism Spectrum Disorder (ASD) Digital Therapeutic Engagement and Usability Study,Cognoa ASD Digital Therapeutic Engagement and Usability Study,TERMINATED,COVID and the Study was withdrawn (limited recruitment within study timeline),NA,INTERVENTIONAL,10,Autism Spectrum Disorder,,DEVICE,"Vineland Adaptive Behavior Scales, Third Edition",2020-03-17,2020-07-31,"Cognoa, Inc.",INDUSTRY
NCT03560102,Efficacy of Magnetic Resonance-guided High Intensity Focused Ultrasound for the Ablation of Breast Cancer,"Efficacy of Magnetic Resonance-guided High Intensity Focused Ultrasound for the Ablation of Breast Cancer: Correlation Between MRI and Histology. Single-Center, Single-Arm, Non-Randomized Trial",TERMINATED,recruitment difficulties,NA,INTERVENTIONAL,1,"Breast Cancer, Invasive Ductal",,DEVICE,Accuracy of MRI as Method for Assessment of Quantitative Treatment Success (Correlation With Results of the Histopathological Analysis Performed as Reference Method),2020-01-13,2020-02-05,Kantonsspital Winterthur KSW,OTHER
NCT04938102,Role of EndoFLIP in the Diagnostic Paradigm of Esophagogastric Junction Outflow Obstruction,Role of EndoFLIP in the Diagnostic Paradigm of Esophagogastric Junction Outflow Obstruction,WITHDRAWN,Administrative-not IRB approved,NA,INTERVENTIONAL,0,Esophagogastric Junction Disorder,Botulinum Toxin Type A Injection [Botox],DRUG,Symptom Resolution,2022-07,2024-10-11,University of Kansas Medical Center,OTHER
NCT02580045,Pharmacokinetics of Systemic Anti-Cancer Therapies in the Cerebrospinal Fluid (CSF) of Patients With Advanced Cancer,CSF Pharmacokinetics of Systemic Anti-Cancer Therapies in Patients With Advanced Cancer,TERMINATED,Inadequate Accrual,,OBSERVATIONAL,3,"Metastatic Cancer Patients on an Anti-cancer Therapy, Advanced Cancer, Brain Metastasis",,,"The concentration of drug metabolites of systemic anti-cancer therapies in the cerebrospinal fluid, Ratio of serum to CSF concentration of systemic anti-cancer therapies as measured by concentration of drug metabolites in serum and in CSF",2016-04-01,2018-02-22,Duke University,OTHER
NCT05609045,"A Phase 1, Randomised, Double-blinded, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of RH109 as Booster","A Phase 1, Randomised, Double-blinded, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of RH109 as Booster for Healthy Adults Who Have Received Homologous or Heterologous Vaccination With 3 Doses of COVID-19 Inactivated and/or mRNA Vaccine(s)",WITHDRAWN,business strategy adjustment,PHASE1,INTERVENTIONAL,0,COVID-19 Pandemic,"Lyophilized COVID-19 mRNA Vaccine, Sodium chloride","BIOLOGICAL, DRUG","Reactogenicity, Unsolicited Treatment Emergent Adverse Events (TEAEs):, Adverse Events of Special Interest (AESIs) and Serious Adverse Events (SAEs):",2023-06,2023-12,"Wuhan Rhegen Biotechnology Co., Ltd.",INDUSTRY
NCT04187872,LITT and Pembrolizumab in Recurrent Brain Metastasis,Recurrent Brain Metastasis Immune Effects and RespOnse to Laser Interstitial ThermotHerapy (LITT) and Pembrolizumab in Combination (TORCH),TERMINATED,Sponsor terminated,PHASE1,INTERVENTIONAL,10,"Melanoma, Non-small Cell Lung Carcinoma (NSCLC), Renal Cell Carcinoma (RCC), Small-cell Lung Cancer, Head and Neck Squamous Cell Cancer, Classical Hodgkin Lymphoma, Primary Mediastinal Large B-Cell Lymphoma, Urothelial Carcinoma, Microsatellite Instability-High Cancer, Gastric Cancer, Esophageal Cancer, Cervical Cancer, Hepatocellular Carcinoma, Merkel Cell Carcinoma, Brain Metastases, Adult",,COMBINATION_PRODUCT,Immune Effect of LITT plus pembrolizumab,2020-01-10,2023-12-01,University of Florida,OTHER
NCT04052672,Diet and Exercise Frailty Intervention in Cardiac Device Patients,Diet and Exercise Frailty Intervention in Cardiac Device Patients Trial Pilot,WITHDRAWN,Due to COVID-19 Pandemic Recruitment was not started,NA,INTERVENTIONAL,0,"Frailty, Cardiovascular Diseases",,OTHER,"Rate of identification of eligible patients, The proportion of eligible patients consenting to participate and randomized, The change in the rate of adherence to the trial interventions from baseline to 12 months, Barriers and facilitators of adherence to the intervention",2019-11-01,2020-12-30,Population Health Research Institute,OTHER
NCT05123508,Treatment of Breast Lift/Reduction Scars,Treatment of Surgical Scars Following Breast Lifts/Reductions,WITHDRAWN,No subjects enrolled,NA,INTERVENTIONAL,0,Scars,,"DEVICE, OTHER",Improvement in surgical scars,2021-06-30,2021-10-21,Sciton,INDUSTRY
NCT00969917,Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma,"A Phase 2, Open-Label Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma",WITHDRAWN,Company decision not to start the study,PHASE2,INTERVENTIONAL,0,Dedifferentiated Liposarcoma,IPI-504,DRUG,To determine the safety profile and overall response rate (ORR) of IPI 504 in patients with advanced dedifferentiated liposarcoma.,2010-01,2010-12,"Infinity Pharmaceuticals, Inc.",INDUSTRY
NCT03998189,Metabolic and Microbial Profiling of Lung Cancer,Pilot Study: Metabolic and Microbial Profiling of Lung Cancer,TERMINATED,Study deemed no longer feasible,NA,INTERVENTIONAL,1,"Nonsmall Cell Lung Cancer, Nonsmall Cell Lung Cancer Stage",,"OTHER, OTHER, OTHER, OTHER, OTHER, OTHER","Number of Participants Needed for Feasibility, Pre-Surgery and Post-Surgery Metabolic Signatures, Pre-Surgery and Post-Surgery Microbial Signatures",2019-10-11,2021-06-21,Wake Forest University Health Sciences,OTHER
NCT03641768,Risk Prediction for Alzheimer Dementia With Brain Imaging and Genetics,Risk Prediction for Alzheimer Dementia With Brain Imaging and Genetics,WITHDRAWN,Funding not received,NA,INTERVENTIONAL,0,"Alzheimer Dementia, Posttraumatic Stress Disorder, Traumatic Brain Injury",,"DEVICE, DEVICE, DEVICE, DEVICE","Cortical thickness as measured by MRI scans, Beta amyloid plaques as measured by PET scans, Tau proteins as measured by PET scans",2019-01-01,2021-01-01,Duke University,OTHER
NCT04104789,Kovanaze Vs. Articaine in Achieving Pulpal Anesthesia of Maxillary Teeth - General,Kovanaze Vs. Articaine in Achieving Pulpal Anesthesia of Maxillary Teeth: A Randomized Clinical Trial,WITHDRAWN,Manufacture of drug discontinued before any participants could be enrolled.,PHASE2,INTERVENTIONAL,0,"Caries,Dental, Apical Periodontitis","Kovanaze Nasal Spray, Articaine Injection","DRUG, DRUG",Success rate of pupal anesthesia,2020-09,2021-10,Virginia Commonwealth University,OTHER
NCT02863991,Oral ONC201 in Relapsed/Refractory Multiple Myeloma,Oral ONC201 in Relapsed/Refractory Multiple Myeloma,TERMINATED,This study was terminated due to a change in corporate priorities. The decision to terminate the study was not based on any safety concerns.,"PHASE1, PHASE2",INTERVENTIONAL,17,Multiple Myeloma,"ONC201, Dexamethasone","DRUG, DRUG",Response of Participants at Last On-study Visit (End of Treatment/Follow-up),2017-04-19,2019-12-16,Jazz Pharmaceuticals,INDUSTRY
NCT01578291,Parent Education and Medical Play: A Comparison of Psychological Preparation Strategies for Voiding Cystourethrogram,Parent Education and Medical Play: A Comparison of Psychological Preparation Strategies for Voiding Cystourethrogram,TERMINATED,"Recruitment was not on target, evised AAP guidelines may have contributed to the decrease in the number of potential participants",NA,INTERVENTIONAL,21,Vesicoureteral Reflux,,"BEHAVIORAL, BEHAVIORAL",Does Parent Education and Medical play reduce anxiety and discomfort associated with Voiding Cystourethrogam,2011-12,2013-01,Johns Hopkins University,OTHER
NCT01375374,Hormonal and Lipid Levels in Male Subjects After a Switch From Carbamazepine to Lacosamide,"Multicenter, Open-label, Single-arm Study to Evaluate Hormone and Lipid Levels in Male Subjects With Partial-onset Seizures After a Switch of Treatment From Carbamazepine as Adjunctive Treatment to Levetiracetam to Lacosamide as Adjunctive Treatment to Levetiracetam",TERMINATED,"Slow progress despite recruitment boosting efforts e.g., expert advice obtained from leading study center Investigators; decision thus made to terminate.",PHASE3,INTERVENTIONAL,11,"Epilepsy, Partial","Lacosamide, Levetiracetam","DRUG, DRUG",Change in Serum Sex Hormone Binding Globulin (SHBG) From Baseline to Treatment Period End (Comprised of a 4-week Titration Period and an 8-week Maintenance Period),2011-07,2013-03,UCB Pharma,INDUSTRY
NCT03929497,Flexible-dose Long-term Extension Study of Lu AF11167 in Patients With Schizophrenia With Prominent Negative Symptoms,"Interventional, Open-label, Flexible-dose, Long-term Safety Extension Study of Lu AF11167 in Patients With Schizophrenia",TERMINATED,Lack of efficacy based on the interim analysis in the 17972A study,PHASE2,INTERVENTIONAL,96,Schizophrenia,Lu AF11167,DRUG,Number of participants with Treatment-Emergent Adverse Events,2019-04-22,2020-09-14,H. Lundbeck A/S,INDUSTRY
NCT04124510,Efficacy and Safety of Flutiform K-haler in Patients With Uncontrolled Asthma Following Mid-dose ICS/LABA DPI Therapy,"An 12-week, Prospective, Interventional, Single-arm, Multi-centre, Phase III Study to Examine the Efficacy and Safety of Flutiform K-haler in Asthma Patients Who Are Not Adequately Controlled by Mid-doseICS/LABA DPI Treatment",TERMINATED,"The Contract of K-haler products had been terminated between Mundipharma and provider. Therefore, this clinical trial was terminated early.",PHASE3,INTERVENTIONAL,20,Asthma,Brand Name: Flutiform K-haler,DRUG,The primary endpoint of the study is the change in Asthma control test from baseline to Week 12 on treatment,2019-11-26,2020-09-14,Mundipharma Korea Ltd,INDUSTRY
NCT00843310,"Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma","Phase II Study of Revlimid (Lenalidomide), Melphalan, and Dexamethasone (ReMeDex) for Newly Diagnosed Multiple Myeloma Patients Not Undergoing Autologous Transplantation",TERMINATED,Due to slow accrual,PHASE2,INTERVENTIONAL,8,Multiple Myeloma,"Lenalidomide (Revlimid), Melphalan, Dexamethasone","DRUG, DRUG, DRUG","Toxicity, Time to Progression & Progression Free Survival",2008-11,2011-10,NYU Langone Health,OTHER
NCT00003513,"Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Neuroblastoma",Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Neuroblastoma,TERMINATED,slow accrual,PHASE2,INTERVENTIONAL,3,Neuroblastoma,Antineoplaston therapy (Atengenal + Astugenal),DRUG,,1996-12-16,1999-03-29,Burzynski Research Institute,OTHER
NCT02024620,Mobile Apps for the Treatment of Depression,Evaluation of Mood Coach in the Treatment of Major Depressive Disorder,WITHDRAWN,The mobile phone app upon which the study was based was not available.,NA,INTERVENTIONAL,0,Major Depressive Disorder,,"BEHAVIORAL, BEHAVIORAL",Change in Behavioral Activation for Depression Scale-Short Form,2014-03,2014-10,Central Arkansas Veterans Healthcare System,FED
NCT01620320,Stress Echocardiography Versus Coronary Angiography for Left Main Stenosis Detection,Évaluation de l'Echographie de Stress Par Comparaison à la Coronarographie Comme Outil Non Invasif de détection de la resténose Intra endoprothèse du Tronc Commun,WITHDRAWN,No Funding,,OBSERVATIONAL,0,"Left Main Coronary Artery Disease, Stenosis",,OTHER,Correlation between stress echocardiography results for the detection of left main prosthesis stenosis with coronary angiogram results.,2010-07,2013-07,Université de Sherbrooke,OTHER
NCT03012282,CT Perfusion Images in Assessing Treatment Response in Patients With Pancreatic Cancer,Evaluation of CT Perfusion Parameters as a Potential Biomarker for Treatment Response in Pancreatic Cancer,TERMINATED,Termination due to slow accrual,NA,INTERVENTIONAL,70,Pancreatic Ductal Adenocarcinoma,,DIAGNOSTIC_TEST,"Correlation between pre-treatment computed tomography (CT) tumor perfusion parameters and percentage of patients who achieve curative (R0) surgical resection after neoadjuvant chemotherapy, Correlation between pre-treatment CT tumor perfusion parameters and tumor response after treatment, Correlation of pre-treatment CT tumor perfusion parameters with overall survival, Correlation of pre-treatment CT tumor perfusion parameters with overall survival, Correlation of pre-treatment CT tumor perfusion parameters with progression free survival, Correlation of pre-treatment CT tumor perfusion parameters with progression free survival, Change in computed tomography (CT) tumor perfusion parameters (time to peak concentration), Change in CT tumor perfusion parameter (blood flow), Change in CT tumor perfusion parameter (blood volume), Change in CT tumor perfusion parameter (Ktrans)",2017-06-22,2022-06-01,University of Washington,OTHER
NCT04788459,"Safety and Immunogenicity of COVID-eVax, a Candidate Plasmid DNA Vaccine for COVID-19, in Healthy Adult Volunteers","A Phase I/II Study to Assess the Safety and Immunogenicity of COVID-eVax, a Candidate Plasmid DNA Vaccine for COVID-19, in Healthy Adult Volunteers",TERMINATED,The good progress of the Italian national vaccination campaign against COVID-19 made impossible to complete the study as planned.,"PHASE1, PHASE2",INTERVENTIONAL,68,"COVID-19, Protection Against COVID-19 and Infections With SARS-CoV- 2, COVID-19 Immunisation",COVID-eVax,"BIOLOGICAL, DEVICE","Incidence of solicited local Adverse events (AEs) at the injection site (for Phase 1), Incidence of solicited systemic AEs (for Phase 1), Incidence of unsolicited AEs (for Phase 1), White Blood Cell (WBC) levels (for Phase 1), Red Blood Cell (RBC) levels (for Phase 1), Platelets levels (for Phase 1), Alanine Transaminase (ALT) levels (for Phase 1), Aspartate Transaminase (AST) levels (for Phase 1), Creatine Phosphokinase (CPK) levels (for Phase 1), Quantitative antibody titers, binding to the specific SARS-CoV-2 antigen (for Phase 2), SARS-CoV-2 neutralizing antibody titer (for Phase 2), Change from baseline in antigen-specific cellular immune responses to SARS-CoV-2 (for Phase 2), Percentage of subjects who seroconverted (for Phase 2)",2021-02-25,2021-12-07,Takis,INDUSTRY
NCT02898259,"Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma","A Phase IB/II Trial of Lenalidomide (Revlimid®), Ixazomib and Rituximab (RIXAR) as Front-line Therapy for High Risk Indolent B Cell Lymphoma",TERMINATED,Funding was eliminated.,"PHASE1, PHASE2",INTERVENTIONAL,19,"B Cell Lymphoma, Lymphoma","Ixazomib, Lenalidomide, Rituximab","DRUG, DRUG, DRUG",Maximum Tolerated Dose (MTD) of Oral Ixazomib,2017-02-20,2022-06-06,Brian Hill,OTHER
NCT03335059,"Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors.","A Multicenter, Single-Arm Study Evaluating the Efficacy of Synergo® Radiofrequency-Induced Thermochemotherapy Effect (RITE) With Mitomycin C (Synergo® RITE + MMC) in CIS Non-Muscle Invasive Bladder Cancer (NMIBC) Bacillus Calmette-Guérin (BCG)-Unresponsive Patients With or Without Papillary NMIBC",TERMINATED,poor enrollment,PHASE3,INTERVENTIONAL,5,"Bladder Cancer, Bladder Neoplasm, Bladder Tumors, Cancer of Bladder, Cancer of the Bladder, Malignant Tumor of Urinary Bladder, Neoplasms, Bladder, Urinary Bladder Cancer, Carcinoma in Situ of Bladder, Papillary Carcinoma of Bladder (Diagnosis), BCG-Unresponsive Bladder Cancer",,COMBINATION_PRODUCT,complete response rate (CRR),2019-04-04,2020-02-26,Medical Enterprises Ltd.,INDUSTRY
NCT04290988,Circuitry Assessment and Reinforcement Training Effects on Recovery,Circuitry Assessment and Reinforcement Training Effects on Recovery (CARTER),TERMINATED,Lack of funding,NA,INTERVENTIONAL,7,"Aphasia, Primary Progressive Aphasia, Stroke",,"DEVICE, DEVICE",Change in Number of content units expressed in the Picture Description Test,2020-09-23,2025-09-01,Johns Hopkins University,OTHER
NCT01244503,Prediction of Severity of Liver Disease by a 13C Octanoate Breath Test (OBT),Prediction of Severity of Liver Disease in Patients With Suspected Nonalcoholic Fatty Liver Disease (NAFLD) by 13C Octanoate Breath Test (OBT),TERMINATED,Budgetary Issues,PHASE2,INTERVENTIONAL,61,"Metabolic Syndrome, Nonalcoholic Fatty Liver Disease",Sodium Octanoate Breath Test,DRUG,The Peak Value of the PDR (Percentage Dose Recovery of 13C) of OBT (Octanoate Breath Test),2011-02,2012-06,Virginia Commonwealth University,OTHER
NCT03043703,AirSense 10 AHI Validation Study,Accuracy of Detection and Reporting of Sleep-disordered Breathing Metrics Determined by the ResMed AirSense 10 in AirView,WITHDRAWN,Study has no principal investigator at the moment.,NA,INTERVENTIONAL,0,Sleep Apnea,,DEVICE,To evaluate the diagnostic accuracy of the AirSense 10 Apnea-Hypopnea-Index (AHI) algorithm compared to polysomnography (PSG) scored AHI.,2019-04,2020-06,ResMed,INDUSTRY
NCT04363203,VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL),VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL),SUSPENDED,concerns related to study drug,PHASE3,INTERVENTIONAL,300,"SARS-CoV-2, COVID-19","Hydroxychloroquine, Azithromycin, Placebo oral tablet","DRUG, DRUG, DRUG","Days to resolution of cough, fever and shortness of breath",2020-04-30,2021-08,Salomeh Keyhani MD,FED
NCT05567003,Percutaneous Endoluminal Benign Biliary Laser,Percutaneous Endoscopic Laser Incision for Benign Biliary Strictures: Prospective Evaluation of Safety and Efficacy,TERMINATED,Study did not meet enrollment targets.,PHASE4,INTERVENTIONAL,5,Benign Biliary Strictures With Current or Prior Biliary Obstruction,,PROCEDURE,"Incidence of Post Procedure Adverse Events, Feasibility of Procedure",2022-11-01,2024-02-05,"University of California, Los Angeles",OTHER
NCT04893642,Swedish Rectal Prolapse Trial,To Resect or Not Resect - The Randomized Swedish Rectal Prolapse Trial,TERMINATED,The study had planned to recruit 220 but was termianted in advance when 134 patients were randomized. This was done due to slow recruitment.,NA,INTERVENTIONAL,134,Rectal Prolapse,,"PROCEDURE, PROCEDURE, PROCEDURE, PROCEDURE","Bowel function, Bowel function, Bowel function, Quality of Life, Quality of Life, Quality of Life",2000-03-23,2018-06-01,Danderyd Hospital,OTHER
NCT03135470,Pain Medication After Ambulatory Surgery,"Adequacy and Adverse Effects of Pain Medication After Ambulatory Surgery, Observational Study",TERMINATED,"Phase II recruitment unsuccesful, phase III lacking personnel resources",,OBSERVATIONAL,146,"Pain, Postoperative, Medication Adherence, Adverse Drug Event",,,"Medication, Pain, Adverse effects, Sufficiency of pain medication",2017-04-03,2020-02-11,Helsinki University Central Hospital,OTHER
NCT03832673,Pembrolizumab-Epacadostat Combination to Treat Muscle-invasive Bladder UrotheLIAl canceR: PECULIAR Study,"PECULIAR: An Open Label, Monocenter, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab and Epacadostat, Preceding Radical Cystectomy, for Patients With Muscle-invasive Bladder Cancer.",WITHDRAWN,Regolatory National Agency (AIFA) not approved,PHASE2,INTERVENTIONAL,0,Muscle-invasive Bladder Cancer,"Pembrolizumab, Epacadostat","DRUG, DRUG",Pathologic complete response (pCR),2019-05-22,2019-05-22,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",OTHER
NCT01279369,The Use of Fetal Fibronectin to Predict Delivery Due to Abruptio Placenta,The Use of Fetal Fibronectin (fFN) in Predicting Preterm Delivery Due to Abruptio Placenta in Patients With Minor Maternal Trauma.,TERMINATED,Quantitative assessment of fFN only able to be performed at one laboratory.,,OBSERVATIONAL,3,"Pregnancy Related, Trauma, Abruptio Placentae",,,Delivery within 2 weeks of the trauma event,2009-10,2012-10,Winthrop University Hospital,OTHER
NCT01395394,"Phenylketonuria, Oxidative Stress, and BH4",The Ability of Kuvan® (Sapropterin Dihydrochloride) to Prevent Meal-induced Lipid Peroxidation and Endothelial Dysfunction in Patients With Phenylketonuria: a Pilot Study,TERMINATED,Difficulty with recruitment and agreed with Sponsor to report completed data as case reports,PHASE2,INTERVENTIONAL,12,Phenylketonuria,Kuvan,"DRUG, OTHER","Lipid Peroxidation, C-Reactive Protein (CRP)",2011-06,2013-06,Emory University,OTHER
NCT05526066,Study for Adolescents and Adults With Ornithine Transcarbamylase Deficiency to Evaluate Safety and Tolerability of ARCT-810,"Phase 2, Randomized, Double-Blind, Placebo-Controlled, Nested Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ARCT-810 in Adolescent and Adult Participants With Ornithine Transcarbamylase Deficiency",TERMINATED,The study was terminated after the completion of Cohort 1 (0.3 mg/kg) due to slow enrollment in this placebo-controlled study.,PHASE2,INTERVENTIONAL,8,"Ornithine Transcarbamylase Deficiency, OTC Deficiency, OTCD",ARCT-810,"BIOLOGICAL, OTHER","Incidence, severity and dose-relationship of adverse events (AEs)",2022-10-17,2024-10-31,"Arcturus Therapeutics, Inc.",INDUSTRY
NCT03849456,Safety and Tolerability of Cannabidivarin (CBDV) in Children and Young Adults With Autism Spectrum Disorder,Safety and Tolerability of GWP42006 in Children and Young Adults With Autism Spectrum Disorder,TERMINATED,Study terminated due to enrollment challenges during COVID-19 pandemic.,PHASE2,INTERVENTIONAL,1,Autism Spectrum Disorder,GWP42006,DRUG,Number of Participants Who Experienced Severe Treatment-Emergent Adverse Events (TEAEs),2020-01-07,2020-05-26,Jazz Pharmaceuticals,INDUSTRY
NCT05379322,The Use of Synovial Biopsies in Predicting Response to Biologic Therapy in Rheumatoid Arthritis Patients,The Use of Synovial Biopsies in Predicting Response to Biologic Therapy in Rheumatoid Arthritis Patients,WITHDRAWN,Decision of the local healthcare authority,PHASE3,INTERVENTIONAL,0,Rheumatoid Arthritis,"Anti-TNF, JAK inhibitor","DRUG, DRUG",Change in DAS28 score,2023-03-01,2023-03-01,Abu Dhabi Stem Cells Center,OTHER_GOV
NCT05977322,A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors.,"A Phase I, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry and Preliminary Activity of [177Lu]Lu-FF58 in Patients With Selected Advanced Solid Tumors.",TERMINATED,The decision was not based on any safety concerns,PHASE1,INTERVENTIONAL,24,"Pancreatic Ductal Adenocarcinoma, Gastroesophageal Adenocarcinoma, Glioblastoma Multiforme","68Ga-FF58, 177Lu-FF58","DRUG, DRUG","Incidence and severity of dose limiting toxicities of 177Lu-FF58, Incidence and severity of adverse events and serious adverse events of 177Lu-FF58, Dose modifications for 177Lu-FF58, Dose intensity for 177Lu-FF58",2023-10-06,2024-12-13,Novartis Pharmaceuticals,INDUSTRY
NCT04037631,Compare Visual Outcomes Using a New Diagnostic Device,Prospective Clinical Study to Compare Visual Performance Obtained With a New Diagnostic Device,TERMINATED,recruitment,,OBSERVATIONAL,24,Presbyopia,,DIAGNOSTIC_TEST,Corrected distance visual acuity (CDVA),2017-07-20,2020-05-01,Carl Zeiss Meditec AG,INDUSTRY
NCT06250153,TAU vs m-SBIRT in Primary Care,"In-Person Versus Text/Telephone Screening, Brief Intervention and Referral to Treatment in Primary Care",WITHDRAWN,funding,NA,INTERVENTIONAL,0,Substance Use Disorders,,BEHAVIORAL,"Positive screens for substance use, Change in treatment attendance",2024-01-01,2024-10-30,Medical University of South Carolina,OTHER
NCT04097353,Improving Health Behaviors for Pediatric Cancer Survivors,Harvesting Hope for Kids: Improving Diet and Physical Activity in Childhood Cancer Survivors,TERMINATED,Study recruitment of new participants was suspended during 2020 due to the Covid-19 pandemic.,NA,INTERVENTIONAL,31,Cancer,,"BEHAVIORAL, BEHAVIORAL","Change in Fruit and Vegetable Intake, Change in Physical Activity",2017-05-01,2019-12-31,Cynthia Gerhardt,OTHER
NCT01221753,Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study,"A Phase II Study of Docetaxel/Cisplatin/5-Fluorouracil (TPF) Induction Chemotherapy Followed by Concurrent Chemoradiotherapy Using a Modified Radiation Dose in Patients With Newly Diagnosed HPV Positive, Locally Advanced Squamous Cell Carcinoma of the Oropharynx",TERMINATED,Due to slow accrual,PHASE2,INTERVENTIONAL,7,"Squamous Cell Carcinoma of the Head and Neck, Human Papilloma Virus","docetaxel, cisplatin, 5-FU, cetuximab, carboplatin","DRUG, DRUG, DRUG, RADIATION, DRUG, DRUG",2-Year Local-Regional Control Rate,2011-07,2017-07,Dana-Farber Cancer Institute,OTHER
NCT01756053,Effects of ABT-089 on Smoking Abstinence Symptoms and Reward,A Pilot Feasibility Study of the Effects of ABT-089 on Smoking Abstinence Symptoms and Reward,TERMINATED,Trial discontinued based on the results of an interim futility analysis.,PHASE2,INTERVENTIONAL,17,Nicotine Addiction,"ABT-089, Placebo","DRUG, DRUG","Change in Abstinence-induced Cognitive Deficits (N-Back Accuracy), Change in Abstinence-induced Cognitive Deficits (N-Back Correct Response Time)",2013-03,2014-01,University of Pennsylvania,OTHER
NCT03827239,Investigation of the Effects of Sedentary Behaviour and Moderate Exercise on Glucose Tolerance and Insulin Sensitivity,Investigation of the Effects of Sedentary Behaviour and Moderate Exercise on Glucose Tolerance and Insulin Sensitivity,TERMINATED,Lack of funding caused us to cancel the study.,NA,INTERVENTIONAL,6,"Sedentary Lifestyle, Insulin Sensitivity, Glucose Metabolism",,OTHER,"Change in Insulin levels, Change in concentration of C-peptide, Changes in blood glucose levels, Change in metabolomic response to a test meal",2019-01-17,2019-12-31,University of Prince Edward Island,OTHER
NCT05787496,"A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms","A Phase 1, Open-Label, Safety, Tolerability, And Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms",TERMINATED,"As a result of program reprioritization and due to the limited clinical activity observed in the Phase 1 trial, the study has been discontinued.",PHASE1,INTERVENTIONAL,28,"Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia, Relapsed or Refractory Myelodysplastic Syndrome",NC525,DRUG,"To evaluate the frequency, duration, and severity of treatment-emergent adverse events [Safety and Tolerability]., To evaluate dose-limiting toxicities (DLTs) of NC525., Define a recommended Phase 2 dose (RP2D) of NC525, Define a minimally active dose (MAD) of NC525, Define a pharmacologically active dose (PAD) of NC525, Define a maximum tolerated dose (MTD) of NC525",2023-02-28,2025-01-31,"NextCure, Inc.",INDUSTRY
NCT02964988,uPAR PET/CT in Radium-223-dichloride Treatment of Patients With Metastatic Castration-resistant Prostate Cancer,uPAR PET/CT in Radium-223-dichloride Treatment of Patients With Metastatic Castration-resistant Prostate Cancer,TERMINATED,Recruitment issues and interim results,PHASE2,INTERVENTIONAL,17,"Prostate Cancer Metastatic, Bone Metastases",Injection of PET tracer 68Ga-NOTA-AE105,"DRUG, DEVICE","uPAR PET/CT imaging, Change in uPAR PET/CT after two cycles of Radium-223",2017-01,2019-10-11,"Rigshospitalet, Denmark",OTHER
NCT04064827,"A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)","A Phase 3, Prospective, Open-Label, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Paricalcitol Oral Solution for the Treatment of Secondary Hyperparathyroidism in Pediatric Subjects Ages 0 to 9 Years With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis",TERMINATED,Company Decision,PHASE3,INTERVENTIONAL,2,"Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT)",Paricalcitol,DRUG,"Percentage of Participants Who Achieve Positive Response During Dosing Period 1, Incidence of Hypercalcemia During Dosing Period 1",2020-09-16,2025-06-09,AbbVie,INDUSTRY
NCT00856661,Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4),"A Randomised, Double-Blind, Parallel-Group Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Desmoteplase in Subjects With Acute Ischemic Stroke",TERMINATED,The recruitment into DIAS4 has been stopped as the result of DIAS 3 indicates that the study is unlikely to reach its primary endpoint with the current protocol,PHASE3,INTERVENTIONAL,270,Stroke,"Desmoteplase, Placebo","DRUG, DRUG",Modified Rankin Scale Score (mRS) (Percentage of Participants With mRS Scores 0-2),2009-04,,H. Lundbeck A/S,INDUSTRY
NCT01128673,MRI Thermal Imaging of Infants Undergoing Cooling for Hypoxic Ischemic Encephalopathy(HIE),MRI Thermal Imaging of Infants Undergoing Cooling for HIE,WITHDRAWN,No funding,,OBSERVATIONAL,0,Hypoxic Ischemic Encephalopathy,,DEVICE,Brain temperature,2010-05,2018-06,Vanderbilt University,OTHER
NCT04963673,Evaluation of Interaction Between Immunosuppressive Drugs and Protein-bound Uremic Toxins in Renal Transplant Patients,Evaluation of Interaction Between Immunosuppressive Drugs and Protein-bound Uremic Toxins in Renal Transplant Patients,WITHDRAWN,no participants enrolled,,OBSERVATIONAL,0,"Kidney Transplant, Immunosuppression, Uremic; Toxemia",,OTHER,"plasma tacrolimus concentration without plasma uremic toxin adjustment, plasma tacrolimus concentration with plasma uremic toxin adjustment",2021-07-06,2023-09-12,"Centre Hospitalier Universitaire, Amiens",OTHER
NCT00256269,Oxaliplatin and Irinotecan in Recurrent or Metastatic Esophageal and Gastroesophageal (GE) Junction Carcinoma,A Phase II Study of Weekly Oxaliplatin and Irinotecan in the Treatment of Recurrent or Metastatic Esophageal Carcinoma and Carcinoma of the Gastroesophageal (GE) Junction,TERMINATED,Study was terminated by funding entity,PHASE2,INTERVENTIONAL,4,"Esophageal Cancer, Gastroesophageal Cancer","Oxaliplatin, Irinotecan","DRUG, DRUG",To assess the overall response rate,2005-06,2007-02-07,"University of California, Irvine",OTHER
NCT06749769,Simulation-Based Learning Experience in Strengthening Stoma Care Education,Investigation of the Effectiveness of Simulation-Based Learning Experience in Strengthening Stoma Care Education on Patients With Stoma,SUSPENDED,Due to changes in the clinical research team. The surgeon responsible for performing the study-related procedures has left the study hospital. The research team is currently seeking an appropriately qualified investigator to resume the study.,NA,INTERVENTIONAL,70,Stoma,,BEHAVIORAL,"Stoma Care Skills Rubric, Generalized Perceived Self-Efficacy Scale",2026-04,2026-12,Nuran Ayşen Pamir Aksoy,OTHER
NCT01432054,Human Tissue Repository for Wound Care,Human Tissue Repository for Wound Care,WITHDRAWN,business decision,,OBSERVATIONAL,0,Human Tissue Repository,,,"The study design is a collection of human biological specimens in Subjects with various wound classifications and types for the purpose of a Human Tissue Repository to be used as a resource for future tissue repair research at KCI USA, Inc",,,3M,INDUSTRY
NCT02763254,Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas,A Phase 2 Open Label Study to Investigate the Safety and Clinical Activity of Autologous EBV-specific T Cells (CMD-003) for the Treatment of Patients With EBV Positive Lymphomas,TERMINATED,Insufficient recruitment rate,PHASE2,INTERVENTIONAL,1,"Hodgkin Lymphoma, Lymphoma, Large B-Cell, Diffuse, Post-transplant Lymphoproliferative Disorder",baltaleucel-T,BIOLOGICAL,Best Overall Response,2016-11,2018-02-17,Cell Medica Ltd,INDUSTRY
NCT06884254,Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared With EU-sourced Perjeta® (Pertuzumab) in Patients With HER2-positive Hormone Receptor Negative Early Breast Cancer.,"A Phase 3, Randomized, Multicenter, Parallel-arm, Double-blind Study to Compare Efficacy and Safety of EG1206A (EirGenix' Pertuzumab) and Perjeta® (Pertuzumab) Sourced From EU as Neoadjuvant Treatment in Combination With Trastuzumab and Chemotherapy in Patients With HER2-positive Hormone Receptor-negative Early Breast Cancer",WITHDRAWN,"Following SA from both the US FDA and the EMA, EirGenix, Inc. has decided to streamline the clinical-development program for EG1206A (biosimilar to Perjeta). EirGenix has concluded that the continuation of the study in no longer necessary.",PHASE3,INTERVENTIONAL,0,Early Breast Cancer,"EG1206A, Perjeta","DRUG, DRUG",Determination of pathologic complete response (pCR) at time of surgery,2025-05,2027-12,"EirGenix, Inc.",INDUSTRY
NCT04625205,A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Advanced Melanoma,"An Open-label, Phase I Study of NEO-PTC-01 in Patients With Advanced or Metastatic Melanoma",TERMINATED,Sponsor decision,PHASE1,INTERVENTIONAL,22,"Unresectable Melanoma, Metastatic Melanoma","NEO-PTC-01, IL-2, PD-1 Inhibitors","BIOLOGICAL, DRUG, DRUG","Rate of adverse events (AEs), including serious adverse events (SAEs) and AEs leading to treatment discontinuation",2020-12-01,2025-03-26,BioNTech US Inc.,INDUSTRY
NCT05410366,"Safe Harbors in Emergency Medicine, Specific Aim 3",Safely Improving Emergency Diagnostic Testing Through Clinical Safe Harbors,WITHDRAWN,Pursuing an alternative clinical trial,,OBSERVATIONAL,0,"Low Back Pain, Headache, Head Injury, Minor",,OTHER,Radiation exposure,2022-09-30,2024-03-31,Vanderbilt University Medical Center,OTHER
NCT01030666,Effect of Postsurgical Systemic Doxycycline After Regenerative Periodontal Therapy,Effect of Postsurgical Systemic Doxycycline After Regenerative Periodontal Therapy. A Randomized Placebo-controlled Clinical Trial,TERMINATED,shelf life of investigational drug ran out before 90 patients could be included,PHASE4,INTERVENTIONAL,61,Periodontitis,"Doxycycline, Placebo, Prefgel/Emdogain, 0.12% chlorhexidine gluconate solution, Ibuprofen 400 mg (if necessary), 1% chlorhexidine gluconate gel (if necessary)","DRUG, DRUG, PROCEDURE, BIOLOGICAL, DRUG, DRUG, DRUG",Vertical Clinical Attachment (PAL-V) Gain 6 Months After Surgery,2007-04,2011-02,Peter Eickholz,OTHER
NCT03410056,Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid Arthritis,A Phase 1b/2a Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid Arthritis With Inadequate Response to Standard of Care Therapy,TERMINATED,Amgen made a business decision not to proceed with Phase 2.,"PHASE1, PHASE2",INTERVENTIONAL,36,Rheumatoid Arthritis RA,"Efavaleukin alfa, Placebo","DRUG, DRUG","Phase 1b: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE), Phase 1b: Number of Participants Who Experienced a Clinically Significant Change in Vital Signs, Phase 1b: Number of Participants Who Experienced a Clinically Significant Change in Laboratory Safety Tests, Phase 1b: Number of Participants Who Experienced a Clinically Significant Change in Electrocardiograms (ECGs), Phase 2a: Number of Participants Who Achieved an American College of Rheumatology 20 Percent Improvement Criteria (ACR 20) at Week 12",2018-05-22,2020-05-13,Amgen,INDUSTRY
NCT02532153,The Impact of Ketamine on the Reward Circuitry of Suicidal Patients,The Impact of Ketamine on the Reward Circuitry of Suicidal Patients: An MRI Study,WITHDRAWN,No funding.,PHASE3,INTERVENTIONAL,0,"Suicidal Ideation, Suicide",Ketamine Hydrochloride,DRUG,Columbia Suicide Severity Rating Scale (C-SSRS),2017-02,2017-02-28,Massachusetts General Hospital,OTHER
NCT01017237,Dexmedetomidine Sedation With Third Molar Surgery,Comparison of the Effectiveness of Sedation With i.v. Dexmedetomidine in Combination With Midazolam Alone or Midazolam and Low Dose Ketamine for Extraction of Third Molars.,TERMINATED,Protocol proved to be ineffective for adequate sedation for third molar surgery.,PHASE4,INTERVENTIONAL,18,Anesthesia,"Dexmedetomidine, Midazolam, Ketamine","DRUG, DRUG, DRUG","Amnesia: Lack of Picture Recall Shown Prior to Sedation., Amnesia: Lack of Recall One Day After Surgery of The Picture That Was Shown Prior to Sedation., Amnesia: Lack of Picture Recall Following Dexmedetomidine Infusion Plus Midazolam., Amnesia: Lack of Recall One Day After Surgery of The Picture That Was Shown Following Dexmedetomidine Infusion Plus Midazolam., Amnesia: Lack of Picture Recall Shown 15 Minutes Into Surgery, Amnesia: Lack of Recall One Day After Surgery of The Picture That Was Shown 15 Minutes Into Surgery., Amnesia: Lack of Picture Recall Shown 30 Minutes Into Surgery, Primary Title: Amnesia: Lack of Recall One Day After Surgery of The Picture That Was Shown 30 Minutes Into Surgery., Amnesia: Lack of Picture Recall at Surgery End Time., Amnesia: Lack of Recall One Day After Surgery of The Picture That Was Shown at Surgery End Time.",2009-07,2011-12,"University of North Carolina, Chapel Hill",OTHER
NCT04882072,A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK),"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Participants With Takayasu Arteritis",TERMINATED,Due to difficulties in enrollment and ongoing feasibility issues,PHASE3,INTERVENTIONAL,14,Takayasu Arteritis,"Ustekinumab, Glucorticoid Taper Regimen","DRUG, OTHER, DRUG",Time to Relapse (ToR) of Takayasu Arteritis (TAK) According to Protocol-defined Criteria Through the End of Double-blind Period,2021-09-15,2023-05-25,Janssen Pharmaceutical K.K.,INDUSTRY
NCT06560346,Understanding the Natural History Early in the Course or Presentation of Friedreich Ataxia,Understanding the Natural History Early in the Course or Presentation of Friedreich Ataxia (EARLY-FA); Evaluating New Clinical Outcome Assessments in Children With Friedreich Ataxia to Facilitate Clinical Trial Design.,WITHDRAWN,Lack of Funding,,OBSERVATIONAL,0,"Friedreich Ataxia, Rare Diseases",,"OTHER, OTHER",Correlation between growth (height in z-score) and disease severity in FRDA (mFARS score),2025-05-01,2028-12-01,Friedreich's Ataxia Research Alliance,OTHER
NCT02616146,Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring and Levonorgestrel-Ethinyl Estradiol Combined Oral Contraceptive in Adult Women at Risk for Pregnancy (MK-8342B-062),"A Phase 3, Randomized, Active-Comparator Controlled Clinical Trial to Study the Contraceptive Efficacy and Safety of the MK-8342B (Etonogestrel + 17β-Estradiol) Vaginal Ring and the Levonorgestrel-Ethinyl Estradiol (LNG-EE) 150/30 μg Combined Oral Contraceptive (COC) in Healthy Women 18 Years of Age and Older, at Risk for Pregnancy.",TERMINATED,Study terminated by Sponsor as a result of a business decision to discontinue the development program for MK-8342B for reasons unrelated to safety or efficacy.,PHASE3,INTERVENTIONAL,2016,Contraception,"ENG-E2 125 μg/300 μg vaginal ring, LNG-EE 150 μg/30 μg COC","DRUG, DRUG","Number of In-Treatment Pregnancies Per 100 Woman-Years of Exposure in Participants 18-35 Years of Age (Pearl Index), Number of Participants Who Experienced an Adverse Event (AE), Number of Participants Who Discontinued Treatment Due to an AE",2015-12-01,2016-10-06,Organon and Co,INDUSTRY
NCT01109888,Administration of Increased Dose of GnRH Antagonist for Coasting for Decreasing the Risk for Ovarian Hyperstimulation Syndrome( OHSS),Administration of Increased Dose of GnRH Antagonist for Coasting for Decreasing the Risk for Ovarian During Controlled Ovarian Stimulation(COH) for In Vitro Fertilisation(IVF),WITHDRAWN,there was no percipitant enrolled,"PHASE1, PHASE2",INTERVENTIONAL,0,Administration of Increased Dose of GnRH Antagonist for Coasting for Decreasing the Risk for Ovarian Hyperstimulation Syndrome( OHSS),Cetrotide,DRUG,,,,Wolfson Medical Center,OTHER_GOV
NCT01377961,Effect of Lycopene and Isoflavones on Glucose Metabolism,Effect of Lycopene and Isoflavones on Glucose Metabolism,WITHDRAWN,FDA needs more information from the manufacturing company of the supplements.,NA,INTERVENTIONAL,0,"Metabolic Syndrome, Diabetes Mellitus, Non-Insulin-Dependent",Randomized pills either containing combination of lycopene and isoflavones (dietary supplements) or Placebo to be taken for 12 weeks,"DRUG, OTHER, OTHER, OTHER, OTHER, OTHER","Insulin Resistance, A1C",2010-09,2015-08,"The University of Texas Medical Branch, Galveston",OTHER
NCT02915042,Dexmedetomidine vs Placebo for Pediatric Cleft Palate Repair,"A Randomized, Double-Blinded, Placebo Controlled Trial Using Single Dose Dexmedetomidine In The Treatment Of Pain In Patients Undergoing Cleft Palate Repair",WITHDRAWN,Recruitment concerns,PHASE4,INTERVENTIONAL,0,Cleft Palate,"Dexmedetomidine, Placebo","DRUG, DRUG","Postoperative pain control, Opioid consumption",2017-12-31,2019-12,Baylor College of Medicine,OTHER
NCT04251442,TKR With and Without the Use of Intra-operative Sensing,Randomized Controlled Trial of Patients Undergoing a Total Knee Arthroplasty With and Without the Use of Intraoperative Sensing Technology,WITHDRAWN,Per funding institution,NA,INTERVENTIONAL,0,Osteoarthritis,,DEVICE,Knee Society Score,2019-10-31,2020-10-30,"Hospital for Special Surgery, New York",OTHER
NCT02813369,Naloxegol Health Outcome Post Authorisation Safety Study,An Observational Post-Authorisation Safety Study (PASS) of MOVENTIG® (Naloxegol) Among Patients Aged 18 Years and Older Treated With Opioids Chronically,TERMINATED,Not feasible to reach the required number of patient cases by the defined end of data collection milestone (Q4 2022) knowing that the study completion was planned by the end of 2023,,OBSERVATIONAL,10000,Opioid Induced Constipation,"naloxegol, non-PAMORA laxative","DRUG, DRUG","Presence (yes/no) of bowel perforation, Presence (yes/no) of acute MI, Presence (yes/no) of stroke, Presence (yes/no) of all-cause mortality, Presence (yes/no) of hypertension",2016-09,2021-11,Kyowa Kirin Pharmaceutical Development Ltd,INDUSTRY
NCT06202066,Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas,A Phase II Study of Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) in Patients With Progressing Metastatic Neuroendocrine Carcinomas (NECs),SUSPENDED,pending protocol changes,PHASE2,INTERVENTIONAL,60,"Digestive System Neuroendocrine Neoplasm, Lung Neuroendocrine Neoplasm, Malignant Solid Neoplasm, Pancreatic Neuroendocrine Neoplasm","Incomplete Freund''s Adjuvant, Sargramostim, SVN53-67/M57-KLH Peptide Vaccine, Temozolomide","PROCEDURE, PROCEDURE, BIOLOGICAL, PROCEDURE, BIOLOGICAL, BIOLOGICAL, DRUG","Progression free survival (PFS), Incidence of adverse events",2026-02-15,2028-10-15,Roswell Park Cancer Institute,OTHER
NCT02653222,Chemical Renal Ethanol Sympatholysis Under CT Guidance Use for the Control of Therapy-Resistant Hypertension,Feasibility Study of Perivascular Computer Tomography-guided Ethanol Sympatholysis for the Treatment of Therapy-resistant Arterial Hypertension,TERMINATED,patient recruitment is difficult,PHASE2,INTERVENTIONAL,2,"Hypertension Resistant to Conventional Therapy, Kidney Failure, Chronic",Blood test,"PROCEDURE, PROCEDURE, RADIATION, BIOLOGICAL",Success or failure of the peri-arterial technique injection of ethanol under CT guidance.,2016-02,2018-02,"University Hospital, Grenoble",OTHER
NCT02673229,Comparison of Collagenase With Antibiotic Ointment of Minor Partial Thickness Burns,Comparison of Collagenase Santyl Ointment With Antibiotic Ointment in the Outpatient Care of Minor Partial Thickness Burns,TERMINATED,slow enrollment due to cost of medication and conflict of interest enrolling uninsured patients,PHASE4,INTERVENTIONAL,20,"Burn, Partial Thickness","Collagenase Santyl, Bacitracin","DRUG, DRUG","Number of Subjects With at Least 95% Wound Healing, Number of Subjects With at Least 95% Wound Healing",2013-09-30,2020-03-30,University of Kansas Medical Center,OTHER
NCT00596453,Impact of Antibiotic Treatment on Prostate-Specific Antigen (PSA) Variability,Impact of Antibiotic Treatment on PSA Variability,TERMINATED,Unable to recruit enough patients,PHASE4,INTERVENTIONAL,31,Prostate Infections,"Ciprofloxacin hydrochloride, Placebo","DRUG, DRUG",PSA Levels (Change in PSA Levels With and Without Antibiotics Therapy),2008-01,2011-06,Johns Hopkins University,OTHER
NCT03053453,Evaluation of Patient Reported Outcomes (PRO) After Total Knee Arthroplasty (TKA) Under Spinal Anesthesia,Evaluation of the Patient Reported Outcomes After Sensor-guided Total Knee Arthroplasty Under Spinal Anesthesia With Limited Motor-block.,TERMINATED,Departure of study surgeon investigator.,NA,INTERVENTIONAL,52,Knee Injuries,,"PROCEDURE, DEVICE","Knee Society Score (KSS), Knee Injury and Osteoarthritis Outcome Score (KOOS)",2016-12-06,2022-07-13,NYU Langone Health,OTHER
NCT00312637,Using Magnetic Resonance Spectroscopy With MRI to Non-invasively Determine Breast Cancer Extent of Disease,High-Resolution Axillary MRI With Magnetic Resonance Spectroscopy as a Non-Invasive Test for Determining Pathologic Lymph Node Status in Patients With Invasive Breast Cancer,WITHDRAWN,Lack of funding.,NA,INTERVENTIONAL,0,Breast Cancer,,PROCEDURE,,2005-03,2008-03,UNC Lineberger Comprehensive Cancer Center,OTHER
NCT04650945,"In-hospital Diabetes Management With Flash Glucose Monitoring (isCGM) - the INDIGO Study, Part A","In-hospital Diabetes Management With Flash Glucose Monitoring (isCGM) - the INDIGO Study, Part A",TERMINATED,Staff shortage,NA,INTERVENTIONAL,13,"Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Diabetes Mellitus",,OTHER,"Glucose time in range (3,9-10 mmol/l) (% pr day)",2021-01-04,2022-11-16,University of Aarhus,OTHER
NCT03008772,REWARDS- In-stent Restenosis,REWARDS-In-stent Restenosis,WITHDRAWN,Not funded,,OBSERVATIONAL,0,In-Stent Coronary Artery Restenosis,,,Rate of Instent Restenosis,2018-02,2024-01,Medstar Health Research Institute,OTHER
NCT00837382,Imagery Rescripting for Posttraumatic Nightmares in Rural Operation Enduring Freedom (OEF)/Operation Iraqi Freedom (OIF) Veterans With Posttraumatic Stress Disorder (PTSD),Imagery Rescripting for Posttraumatic Nightmares in Rural Operation Enduring Freedom (OEF)/Operation Iraqi Freedom (OIF) Veterans With Posttraumatic Stress Disorder (PTSD),TERMINATED,Primary investigator is no longer a part of the VA.,NA,INTERVENTIONAL,7,"Stress Disorders, Post-Traumatic, Sleep Disorders",,"BEHAVIORAL, BEHAVIORAL","Clinician Administered PTSD Scale (CAPS), Posttraumatic Stress Symptom Scale-Self-Report (PSS-SR) & Beck Depression Inventory-II (BDI-II)",2010-01,2010-08,US Department of Veterans Affairs,FED
NCT00596024,Lutein and Alzheimer's Disease Study,Lutein and Oxidative Stress in Alzheimer's Disease - A Pilot Study,TERMINATED,Lack of enrollment,PHASE2,INTERVENTIONAL,3,Alzheimer's Disease,,"DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",oxidative damage markers,2007-12,2009-07,Oregon Health and Science University,OTHER
NCT02799823,Transfemoral Replacement of Aortic Valve With HLT MeriDIAN Valve Early Feasibility Trial,Transfemoral Replacement of Aortic Valve With HLT MeriDIAN Valve Early Feasibility Trial,TERMINATED,HLT Business Decision,NA,INTERVENTIONAL,11,Aortic Valve Stenosis,,DEVICE,Primary Endpoint: Mortality at 30 days,2017-04-27,2023-01-20,HLT Inc.,INDUSTRY
NCT05963880,Concordance Between Central Blood PRessure dEvices In Nephrology Patients,Concordance Between Central Blood PRessure dEvices In Nephrology Patients (CBP-REIN),TERMINATED,lack of funding to enroll all planned participants,NA,INTERVENTIONAL,119,"Hypertension, Chronic Kidney Disease, Blood Pressure",,DEVICE,Central SBP difference,2021-04-26,2024-11-12,Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal,OTHER
NCT04165642,Single-Laser PVI: Single-encirclement Laserballoon Ablation for Pulmonary Veins Isolation,Single-Laser PVI: Single-encirclement Laserballoon Ablation for Pulmonary Veins Isolation,TERMINATED,due to unattainability of the expected sampling unit.,,OBSERVATIONAL,82,"Assessment of Safety of Laser Balloon Ablation, Assessment of Procedural Times of Laser Ballon Ablation",,OTHER,Success rate at 1 year,2019-10-01,2023-07-05,IRCCS Policlinico S. Donato,OTHER
NCT00469586,Efficacy and Safety of Inhaled Insulin Compared to Metformin and Glimepiride in Type 2 Diabetes,Efficacy and Safety of Inhaled Prandial Insulin Compared to Metformin Plus Glimepiride in Type 2 Diabetes,TERMINATED,See termination reason in detailed description,PHASE3,INTERVENTIONAL,174,"Diabetes, Diabetes Mellitus, Type 2","inhaled human insulin, metformin, glimepiride, inhaled human insulin","DRUG, DRUG, DRUG, DRUG",HbA1c change from baseline,2007-04-26,2008-04-24,Novo Nordisk A/S,INDUSTRY
NCT05288283,Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures,"A Randomized, Double-blind, Placebo-controlled, Multisite, Phase 3 Study to Investigate the Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P) in Children and Adolescents With Epilepsy With Myoclonic-Atonic Seizures",TERMINATED,The study was terminated due to a business decision.,PHASE3,INTERVENTIONAL,3,Seizures Associated With EMAS,"GWP42003-P, Placebo","DRUG, DRUG","Part A: Percent Change From Baseline in Epilepsy With Myoclonic-atonic Seizures (EMAS) Associated Seizure Frequency (Myoclonic-atonic, Atonic, Tonic, Clonic, or Tonic-clonic) Over the 14-week Treatment Period, Part B: Number of Participants With Treatment-emergent Adverse Events, Part B: Number of Participants With Clinically Significant Vital Sign Values, Part B: Number of Participants With Clinically Significant Physical Examination Values, Part B: Number of Participants With Clinically Significant 12-lead Electrocardiogram (ECG) Values, Part B: Number of Participants With Clinically Significant Laboratory Test Values, Part B: Number of Participants With Changes in Tanner Staging, Part B: Number of Participants With a Change in Columbia-Suicide Severity Rating Scale (C-SSRS) Ideation Scores, Part B: Number of Participants With a Change in the Number of Suicide Attempts Per C-SSRS Scores",2022-10-31,2023-09-28,Jazz Pharmaceuticals,INDUSTRY
NCT02992054,An Innovative Occupational Program Using New Technologies (KODRO) Life of Nursing,Randomized Controlled Trial for Assessing the Effects Resulting From an Innovative Occupational Program Using New Technologies (KODRO) on Nursing Home Residents' Quality of Life (Pilot Study),TERMINATED,The number of patients were enough for statistic treatment,,OBSERVATIONAL,239,Home Residents,,OTHER,Quality of life: QOL-AD score: questionnaire,2010-12,2014-06,"University Hospital, Montpellier",OTHER
NCT02087241,Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer,A Phase II Study of AZD1775 Plus Pemetrexed and Carboplatin Followed by a Randomised Comparison of Pemetrexed and Carboplatin With or Without AZD1775 in Patients With Previously Untreated Stage IV Non-Squamous Non-Small-Cell Lung Cancer,TERMINATED,The sponsor decided to terminate the study.,PHASE2,INTERVENTIONAL,22,Previously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer,"AZD1775, AZD1775 Matching Placebo, pemetrexed, carboplatin","DRUG, DRUG, DRUG, DRUG",Progression Free Survival,2014-03,2015-06,AstraZeneca,INDUSTRY
NCT01604941,Pharmacokinetics of SSP-004184 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy,"A Phase 2, 24 Week, Open Label, Multi-Center Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SSP-004184 (SPD602) in the Treatment of Chronic Iron Overload Requiring Chelation Therapy",TERMINATED,This study was terminated due to treatment stop resulting in an inability to draw conclusions from the data. Evaluation of nonclinical rat findings is ongoing.,PHASE2,INTERVENTIONAL,32,Iron Overload Due to Repeated Red Blood Cell Transfusions,SPD602,DRUG,"Change From Baseline in Liver Iron Concentration (LIC) as Assessed by FerriScan R2 Magnetic Resonance Imaging (MRI), Change From Baseline in LIC Adjusted by Transfusional Iron Intake And Assessed by FerriScan R2 MRI",2012-09-14,2014-04-18,Shire,INDUSTRY
NCT00926354,Application of AS101 for the Treatment of Thrombocytopenia in Solid Tumor Patients,Phase II Open Study to Evaluate Safety and Efficacy of AS101 for the Treatment of Thrombocytopenia in Solid Tumor,TERMINATED,Sponsor's considerations,PHASE2,INTERVENTIONAL,40,Chemotherapy Induced Thrombocytopenia,AS101,DRUG,"Incidence of thrombocytopenia events (platelets <70,000) over the study period of the study groups",2009-08,2010-08,BioMAS Ltd,INDUSTRY
NCT04764656,Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for nAMD in Portugal,Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for Neovascular Age-related Macular Degeneration (nAMD) in Portugal,TERMINATED,"The study was terminated earlier since the obtained sample was not representative of the Portuguese population, and pointed to the high fragility in evaluating the data, making it difficult to carry out a statistical study and draw valid conclusions.",,OBSERVATIONAL,81,Neovascular Age-related Macular Degeneration (nAMD),Brolucizumab,DRUG,Percentage of patients that are absent of subretinal fluid (SRF) and intra-retinal fluid (IRF) in the study eye,2021-05-10,2024-02-16,Novartis Pharmaceuticals,INDUSTRY
NCT03186729,Study of Antithrombotic Treatment After IntraCerebral Haemorrhage,Study of Antithrombotic Treatment After IntraCerebral Haemorrhage,TERMINATED,Lack of resources,PHASE4,INTERVENTIONAL,134,"Cerebral Hemorrhage, Intracranial Hemorrhages, Atrial Fibrillation, Anticoagulant-Induced Bleeding, Secondary Prevention",Antithrombotic Agent,DRUG,Fatal or non-fatal symptomatic ICH.,2018-07-01,2024-08-31,Oslo University Hospital,OTHER
NCT02652702,Study Comparing Circular Stapler-assisted Colostomy vs Hand-stitching Colostomy of Colorectal Cancer Patients,Randomized Clinical Trial Comparing the Safety and Efficiency of Circular Stapler-assisted Colostomy With Hand-stitching Colostomy for Colorectal Cancer Patients,TERMINATED,Not enough patients recruited,PHASE2,INTERVENTIONAL,60,Colorectal Carcinoma,,"PROCEDURE, PROCEDURE",colostomy associated complications,2016-12,2020-01,Zhejiang University,OTHER
NCT00237653,MICI-CMV:Valganciclovir in Recurrent Bouts of Cryptogenic Inflammatory Bowel Diseases With an Infection by Cytomegalovirus,Relevance of Valganciclovir in Recurrent Bouts of Cryptogenic Inflammatory Bowel Diseases With an Infection by Cytomegalovirus,TERMINATED,difficulty to include patients,PHASE3,INTERVENTIONAL,40,"Cytomegalovirus Infections, Inflammatory Bowel Diseases",Valganciclovir,DRUG,"Improvement of Crohns disease activity index score, Diminution or disappearance of gravity criteria, Endoscopy: improvement in appearance of lesions, or healing, Anatomopathology: improvement of histological criteria, or total regression, Anatomopathology: disappearance of viral infection criteria, Virology: reversal of CMV IgG serology and PCR results",2004-02,2007-12,"University Hospital, Grenoble",OTHER
NCT04401553,Prophylactic Antibiotics for Surgical Site Infections and Beta-Lactam Allergy,"First Tier Versus Second Tier Antibiotics for Surgical Site Infections Following Hysterectomy In the Patients With a Beta-Lactam Allergy: A Prospective, Randomized, Single-Blinded Clinical Trial",WITHDRAWN,The study never initiated.,PHASE4,INTERVENTIONAL,0,"Surgical Site Infection, Beta-lactam Allergy","cephalosporin, Second tier antibiotic (Vancomycin)","DRUG, DRUG",Surgical site infections during early postoperative period,2024-08-16,2026-08,University of Texas Southwestern Medical Center,OTHER
NCT02937402,Bronchoscopy With Bronchoalveolar Lavage in Identifying Biomarkers of Response to Immune Checkpoint Inhibitors in Patients With Non-small Cell or Small Cell Lung Cancer,Predictors of Response to Immune Checkpoint Inhibitors in Non-small Cell and Small Cell Lung Cancer,TERMINATED,Slow accrual,NA,INTERVENTIONAL,9,"Non-Small Cell Lung Carcinoma, Small Cell Lung Carcinoma",,"PROCEDURE, OTHER",Biomarker response to immune checkpoint inhibitor therapy as measured by Response Evaluation Criteria in Solid Tumors version 1.1 criteria,2018-04-05,2019-08-20,Vanderbilt-Ingram Cancer Center,OTHER
NCT01582282,Study of Metamucil on Blood Glucose and HbA1c in Type II NIDDM Subjects,A Clinical Study to Determine the Ability of Metamucil to Reduce Fasting Blood Glucose and HbA1c Levels in Type II NIDDM,TERMINATED,due to slow enrollment,PHASE4,INTERVENTIONAL,37,Non-Insulin-dependent Diabetes Mellitus,,"DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT","Change From Baseline in Fasting Glucose, Change From Baseline in Fasting HbA1c, Change From Baseline in Fasting HDL Cholesterol, Change From Baseline in Fasting LDL Cholesterol, Total Cholesterol Change From Baseline, Triglyceride Change From Baseline",1988-05,1990-01,Procter and Gamble,INDUSTRY
NCT02206724,Prospective Evaluation of Stereotactic Body Radiotherapy for Metastatic Prostate Cancer,PROSPECTIVE EVALUATION OF STEREOTACTIC BODY RADIOTHERAPY FOR METASTATIC PROSTATE CANCER,WITHDRAWN,Unable to enroll patients,NA,INTERVENTIONAL,0,Metastatic Prostate Cancer,,RADIATION,Radiation related toxicity,2014-07-16,2018-04-17,Sharp HealthCare,OTHER
NCT01259024,The LC Bead Trial; Transarterial Chemoembolization of Hepatocellular Carcinoma (HCC)With a Drug-eluting Bead,Hepatic Arterial Embolization of Hepatocellular Carcinoma With a Doxorubicin Eluting Bead,TERMINATED,inability to obtain CMS approval,NA,INTERVENTIONAL,1,Hepatocellular Carcinoma,,DEVICE,"To Collect Data on Patients With Hepatocellular Carcinoma (HCC) Being Treated With Chemoembolization With Doxorubicin Eluting Beads (DEB)., Determine Efficacy (Based on Whether the Study is Positive or Negative) of the Embolization With the LC Bead in Treatment of HCC With Imaging Outcomes Using Modified RECIST and EASL Criteria., Monitor Safety After Treatment of DEB by Measuring Liver Function Tests and Assessing Performance Status.",2011-12,2012-04,Washington University School of Medicine,OTHER
NCT03387059,Clinical Performance and Safety Investigation of ENDOmetrial Washing MEdical DEvice Forielle,"A Multicentre, Prospective Randomised Controlled, Interventional Clinical Investigation to Assess the Clinical Safety and Performance of Forielle, a Medical Device for Endometrial Washing in Restoring Favorable Endometrial Condition to Implantation After COS During Assisted Reproductive Practice (ENDOMEDE)",TERMINATED,"The study was terminated early, due to the poor feasibility and sustainability, leading to slow recruitment rate.",PHASE4,INTERVENTIONAL,9,Infertility,,DEVICE,Implantation Rate,2018-01-12,2018-06-12,"Merck KGaA, Darmstadt, Germany",INDUSTRY
NCT04349462,Post Critical Illness Dysphagia in the Intensive Care Unit,Post Critical Illness Dysphagia in the Intensive Care Unit (Dysphagia-ICU): a Single Centre Prospective Cohort Study,SUSPENDED,Recruitment has been suspended during COVID19 Pandemic,NA,INTERVENTIONAL,300,Dysphagia,,"DIAGNOSTIC_TEST, DIAGNOSTIC_TEST",Dysphagia,2019-09-04,2022-12,St. Joseph's Healthcare Hamilton,OTHER
NCT01033227,Safety and Efficacy of Sodium Nitrite in Sickle Cell Disease,A Safety and Efficacy Evaluation of Sodium Nitrite Injection for the Treatment of Vaso-Occlusive Crisis Associated With Sickle Cell Disease,TERMINATED,Low enrollment,"PHASE1, PHASE2",INTERVENTIONAL,5,Sickle Cell Disease,"sodium nitrite injection, usp",DRUG,48 Hour Sodium Nitrite Infusion Safety as Determined by Number of Participants With No Adverse Events,2009-12,2012-06,Children's Hospital Los Angeles,OTHER
NCT04699461,Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma,A Phase 2 Randomized Study of Loncastuximab Tesirine Versus Idelalisib in Patients With Relapsed or Refractory Follicular Lymphoma (LOTIS-6),TERMINATED,Administrative decision (not due to safety reason),PHASE2,INTERVENTIONAL,6,"Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma","Loncastuximab Tesirine, Idelalisib","DRUG, DRUG",Complete Response Rate (CRR),2021-11-04,2022-11-25,ADC Therapeutics S.A.,INDUSTRY
NCT02338570,Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE),Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of a First-line Treatment With VEGF Inhibitor,TERMINATED,"Stopped on November 16th 2016, because of recruitment failure.",PHASE4,INTERVENTIONAL,31,Renal Cell Carcinoma,Everolimus,DRUG,predictive factors identification,2015-07,2018-02,Mario Negri Institute for Pharmacological Research,OTHER
NCT02649270,"Tolerability, Safety and Pharmacokinetic Study of Humanized Anti-CD6 Monoclonal Antibody Injection in Chinese Psoriasis","Single and Multiple Dose -Based Tolerability, Safety and Pharmacokinetic Phase 1 Study of Humanized Anti-CD6 Monoclonal Antibody Injection in Chinese Patients With Psoriasis",TERMINATED,company strategy,PHASE1,INTERVENTIONAL,11,Psoriasis,T1h,BIOLOGICAL,Adverse events,2014-10,2017-10,"Biotech Pharmaceutical Co., Ltd.",OTHER
NCT04912570,Thrombus Aspiration in Heavy Thrombus Burden Acute ST-elevation Myocardial Infarction,Thrombus Aspiration in Heavy Thrombus Burden Acute ST-elevation Myocardial Infarction: TSUNAMI Trial,SUSPENDED,No catheters,NA,INTERVENTIONAL,124,"Coronary Artery Disease, Percutaneous Coronary Intervention, ST Elevation Myocardial Infarction",,"PROCEDURE, PROCEDURE","Angiographic results, Angiographic results, Angiographic results, In-hospital Major adverse cerebrovascular and cardiovascular events (MACCE), Short term Major adverse cerebrovascular and cardiovascular events (MACCE)",2022-07-01,2024-12-01,The Young Investigator Group of Cardiovascular Research,NETWORK
NCT00733369,A Study to Compare the Press Fit Condylar (P.F.C.) Sigma Rotating-platform High-flexion (RP-F) Versus the Press Fit Condylar (P.F.C.) Sigma Rotating-platform (RP) Knee Implants,"A Prospective, Single Blinded, Multi-centre Randomised Controlled Trial Comparing the Post Operative Range of Motion of the P.F.C. Sigma RP-F Knee With the P.F.C. Sigma RP Knee in Primary Total Knee Arthroplasty.",TERMINATED,This study was closed for the reason of slow recruitment with only 16% of the target subjects recruited over a 29 month period.,PHASE4,INTERVENTIONAL,106,Knee Osteoarthritis,,"DEVICE, DEVICE",Change From Pre-op to 1 Year Range of Motion.,2007-11,2014-08,DePuy International,INDUSTRY
NCT03244683,A Study of the Efficacy of ONS to Reduce Postoperative Complications Associated With Pancreatic Surgery,A Study of the Efficacy of Oral Nutritional Supplementation to Reduce Postoperative Complications Associated With Pancreatic Surgery,TERMINATED,Closed due to low enrollment,NA,INTERVENTIONAL,8,"Pancreatic Cancer, Chronic Pancreatitis",,"DIETARY_SUPPLEMENT, OTHER, OTHER",Postoperative complications,2017-08-28,2018-08-01,Ohio State University,OTHER
NCT05592483,"An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer","A Multi-center, Multi-country Prospective Observational Study of Patients Initiating T-DXd in the First or Second Treatment Line for HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer",TERMINATED,"The DESTINY-Breast RESPOND study was terminated early due to start-up delays and slow enrolment, despite extensive mitigation. Operational challenges alone prevent study continuation and were not related to any product or patient safety concerns.",,OBSERVATIONAL,78,Breast Cancer,,OTHER,"Real-World Time to Next Treatment (rwTTNT), T-Dxd treatment patterns for HER2+ cohort",2023-07-07,2024-05-29,AstraZeneca,INDUSTRY
NCT04532554,Growth Hormone in Obese Cases With Covid-19,The Impact of Growth Hormone in Obese Cases With Covid-19,WITHDRAWN,No participants enrolled,PHASE4,INTERVENTIONAL,0,Covid19,"Growth Hormone, Placebo","DRUG, DRUG",Need for hospitalization,2020-10-26,2020-12-20,ClinAmygate,OTHER
NCT01953354,Trichuris Suis Ova Treatment in Left-sided Ulcerative Colitis,"A Prospective, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study of Trichuris Suis Ova Treatment in Left-sided Ulcerative Colitis and Its Effects on Mucosal Immune State and Microbiota",TERMINATED,MFR's business decision to d/c TSO production -unrelated to any safety concern.,PHASE2,INTERVENTIONAL,16,"Colitis, Ulcerative","Trichuris suis ova (TSO), Placebo","BIOLOGICAL, BIOLOGICAL",Percentage of Participants Who Achieved a Clinical Response at Week 12,2013-11,2015-11,National Institute of Allergy and Infectious Diseases (NIAID),NIH
NCT01330654,Heart Rate Variability (HRV) to Evaluate Surgical Risk on Patients on Beta Blockers,Using Heart Rate Variability to Analyze the Effect of Beta Blockers on Intermediate Risk Patients Undergoing Laparoscopic Surgical Procedures,WITHDRAWN,no patients were enrolled. Study was closed prior to study start.,NA,INTERVENTIONAL,0,Cardiac Event Risk,metoprolol,DRUG,Heart Rate Variability,2011-03,2012-03,"University of California, San Francisco",OTHER
NCT07126405,Provider RCT PROMOTE,Provider Randomized Trial of the PROvider ReMote ObsTetric-Related Employment Education (PROMOTE),WITHDRAWN,Study has been combined with the patient portion of this study under Pro00116081,NA,INTERVENTIONAL,0,"Maternal Health, Pregnancy, Employment",,OTHER,"Frequency of EHR (electronic health record) documented work-related counseling, Number of participants who adhere to employer documentation recommendations, Number of participants with undesired wage or advancement reduction, Number of participants with accommodation requests granted, Number of participants with improved maternal-infant health in pregnancy",2025-08,2027-08,Duke University,OTHER
NCT01207154,Feasibility of Using Depth-of-sedation Measuring Equipment (BIS) to Guide Awake Fibreoptic Intubation,BIS-guided Conscious Sedation for Awake Intubation,WITHDRAWN,Difficulty in Recruitment due to lack of investigators and suitable patients,,OBSERVATIONAL,0,Known Difficult Intubation,,,To determine if bispectral index (BIS) can be used to guide conscious sedation for awake fibreoptic intubation,2010-12,2012-10-31,Oxford University Hospitals NHS Trust,OTHER
NCT00811122,"Biodistribution of 11C-PIB PET in Alzheimer's Disease, Frontotemporal Dementia, and Cognitively Normal Elderly","Biodistribution of 11C-PIB PET in Alzheimer's Disease, Frontotemporal Dementia, and Cognitively Normal Elderly",TERMINATED,A Fluorine-18 labeled version of the radiopharmaceutical (Flutemetamol) became available. This version is far superior to the Carbon-11 PiB. There is no need to make this compound available any longer.,EARLY_PHASE1,INTERVENTIONAL,2,Alzheimer's Disease,,"RADIATION, RADIATION","The agent 11C-PIB has similar biodistribution outside the brain in AD, FTD, and cognitively normal elderly individuals.",2009-11,2021-12,University of Utah,OTHER
NCT03425422,ANTHEM-HFrEF Pivotal Study,Autonomic Regulation Therapy to Enhance Myocardial Function and Reduce Progression of Heart Failure With Reduced Ejection Fraction,TERMINATED,Company decision to stop enrolling not associated with any safety concerns.,NA,INTERVENTIONAL,533,"Heart Failure, Heart Failure, Congestive, Heart Failure, Systolic",,DEVICE,"Event-free rate, Cardiovascular mortality and HF hospitalization",2018-05-01,2023-05-31,LivaNova,INDUSTRY
NCT03910322,The Effect of a Probiotic Strain on Aspirin-induced GI Damage,"The Effect of Daily Intake of Two Different Doses of Bif195 on Small-intestinal Damage Induced by Acetylsalicylic Acid- a Randomized, Double-blind, Placebo-controlled, Three-armed, Parallel Group Trial in Healthy Volunteers.",TERMINATED,Decision made by Sponsor,NA,INTERVENTIONAL,30,Reduction of Small Intestinal Ulceration Risk,,"DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",primary endpoint - Lewis score high dose Bif195 vs Placebo,2019-08-19,2019-12-01,Chr Hansen,INDUSTRY
NCT05959629,"Erbium, Chromium: Yttrium, Scandium, Gallium, Garnet (Er,Cr:YSGG) Laser in Root Canal Disinfection","A Clinical Use of Er,Cr:YSGG Laser: an Anti-biofilm Treatment",TERMINATED,Unable to follow up participants due to geographic location and other reasons.,NA,INTERVENTIONAL,56,"Endodontic Disease, Root Canal Infection",,"DEVICE, OTHER","The Change in Bacterial Count Between the Experimental Group (Laser) and the Standard of Care (NaOCl) Group (Routinely Used Irrigation Protocol)., The Change in Bacterial Count Between the Experimental Group (Laser) and the Standard of Care (NaOCl) Group (Routinely Used Irrigation Protocol)., The Change in Bacterial Count Between the Experimental Group (Laser) and the Standard of Care (NaOCl) Group (Routinely Used Irrigation Protocol).",2023-10-11,2024-05-02,University of Pennsylvania,OTHER
NCT02423902,A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer,"A Single-arm, Open-label Study of Ad-RTS-hIL-12 + Veledimex Following First-, Second-, or Third-Line Standard Treatment in Subjects With Locally Advanced or Metastatic Breast Cancer",TERMINATED,"The study was terminated after 9 subjects had enrolled under Protocol Amend 1 because of slower than expected accrual. Protocol Amendment 2 (16 May 2016) was submitted to the FDA and, based on the decision of the PI, was not submitted to the IRB.","PHASE1, PHASE2",INTERVENTIONAL,9,Metastatic Breast Cancer,"Ad-RTS-hIL-12, Veledimex","BIOLOGICAL, DRUG","Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Adverse Events Leading to Study Discontinuation",2015-07-18,2016-07-19,Alaunos Therapeutics,INDUSTRY
NCT02096588,Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin,Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin,TERMINATED,The Principal Investigator left Johns Hopkins,PHASE2,INTERVENTIONAL,34,"Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer","Simvastatin, Doxorubicin/cyclophosphamide","DRUG, DRUG",Change in Echocardiographic Global Longitudinal Strain (GLS),2014-05-20,2023-07-26,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,OTHER
NCT04681027,"Safety, Tolerability, Effectiveness, and Pharmacokinetic Data in Opioid-experienced Children","A Multicenter Study of the Safety, Tolerability, Effectiveness, and Pharmacokinetics of Oxymorphone HCL Extended-Release Tablets in Pediatric Subjects Requiring an Around-The-Clock Opioid for an Extended Period of Time",SUSPENDED,Study Suspended 06Feb2020 per FDA Request,PHASE3,INTERVENTIONAL,15,"Chronic Pain, Postsurgical Pain",Oxymorphone hydrochloride (HCl),DRUG,"Pain Intensity Score using FPS-R, Pain Intensity Score using NRS-11",2013-03-11,2021-01,Endo Pharmaceuticals,INDUSTRY
NCT00490061,Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy,A Multi-Institutional Phase II Study of Radiation and GW572016 (Lapatinib) for Patients With Stage III-IV Head and Neck Cancer Who Cannot Tolerate Concurrent Chemoradiotherapy.,TERMINATED,Poor accrual.,PHASE2,INTERVENTIONAL,17,"Head and Neck Cancer, Carcinoma, Squamous Cell, Head and Neck Cancers",Lapatinib,"DRUG, PROCEDURE, DEVICE, DEVICE",Progression Free Survival,2007-07,2016-06,Quynh-Thu Le,OTHER
NCT03271970,The Anatomic Determinants of Perforation Induced Hearing Loss,The Anatomic Determinants of Perforation Induced Hearing Loss,WITHDRAWN,PI no longer wishes to conduct the study. No participants were enrolled.,,OBSERVATIONAL,0,"Conductive Hearing Loss, Perforated Tympanic Membrane",,,"presence of perforation, absence of perforation, change in audiometric measurements",2017-04,2018-01-03,Duke University,OTHER
NCT05808673,Study of CMAB807X Pre- and Post-change in Manufacturing Site and Xgeva® in Healthy Volunteers,"A Randomized, Double-blind, Parallel Controlled, Phase I Three-arm Study, Comparing the PK, PD, Safety, and Immunogenicity of Pre- and Post-change CMAB807X, Post-change CMAB807X and Xgeva® in Healthy Chinese Male Subjects",WITHDRAWN,Changes in the company's production plan,PHASE1,INTERVENTIONAL,0,Healthy Volunteers,"Post-change CMAB807X, Pre-change CMAB807X, Xgeva®","BIOLOGICAL, BIOLOGICAL, BIOLOGICAL","Area Under the Plasma Concentration-time Curve From Zero (0) Hours Extrapolated to infinite time, Maximum Concentration of Denosumab",2023-02,2024-07,"Taizhou Mabtech Pharmaceutical Co.,Ltd",INDUSTRY
NCT05595941,Tele-yoga in the Rehabilitation of Patients With Chronic Post-stroke Sequelae,Effectiveness of Tele-yoga in the Rehabilitation of Patients With Chronic Post-stroke Sequelae : a Pilot Randomized Controlled Trial,TERMINATED,The planned recruitment and treatment period was limited by the financial resources allocated to the study.,NA,INTERVENTIONAL,11,Stroke Sequelae,,OTHER,"Berg balance scale, Berg balance scale",2022-10-01,2023-09-01,Hopital La Musse,OTHER
NCT02550054,Erythropoietin in Premature Infants to Prevent Encephalopathy,Erythropoietin in Premature Infants to Prevent Encephalopathy: A Multi-Centre Randomized Blinded Controlled Study of the Efficacy of Erythropoietin in China,TERMINATED,"The study was concluded as planned upon reaching its predetermined endpoint, which included the completion of data collection and achievement of the necessary sample size for statistical significance.",PHASE2,INTERVENTIONAL,58,Premature Infant,"Epo, Normal saline","DRUG, DRUG","Neurodevelopment(Bayley Scores), Neurological Evaluation(GMFM-88 Scores)",2015-09-08,2016-12-30,Children's Hospital of Fudan University,OTHER
NCT03467854,PK of Piperacillin/Tazobactam in Adults Undergoing ECMO,Pharmacokinetics (PK) of Piperacillin/Tazobactam in Adults Undergoing Extracorporeal Membrane Oxygenation (ECMO),TERMINATED,Lack or eligible patients.,,OBSERVATIONAL,2,Acute Respiratory Failure With Hypoxia,,,"Change in clearance rate, Change in volume of distribution",2019-01-01,2024-09-24,Columbia University,OTHER
NCT01886105,Combination of External Beam Radiotherapy With 153Sm-EDTMP to Treat High Risk Osteosarcoma,Combination of External Beam Radiotherapy With 153Sm-EDTMP to Treat High Risk Osteosarcoma,TERMINATED,Low accrual and loss of funding,PHASE2,INTERVENTIONAL,4,Metastatic Osteosarcoma,Sm-EDTMP,"DRUG, OTHER, RADIATION",Percentage of Treated Participants With 6-month Progression Free Survival,2013-08-19,2017-06-11,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,OTHER
NCT04560166,Naxitamab and GM-CSF in Combination With IT in Patients With High-Risk Neuroblastoma,"Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor in Combination With Irinotecan and Temozolomide in Patients With High-Risk Neuroblastoma With Primary Refractory Disease or in First Relapse. An International, Single-Arm, Multicenter Phase 2 Trial.",TERMINATED,Due to business priorities,PHASE2,INTERVENTIONAL,2,Neuroblastoma Recurrent,Naxitamab and GM-CSF in combination with irinotecan and temozolomide,DRUG,Overall Response Rate (ORR),2021-11-08,2022-09-21,Y-mAbs Therapeutics,INDUSTRY
NCT04345666,Can Testosterone Accelerate Injury Recovery After Arthroscopic Rotator Cuff Repair,"A Randomized, Blinded Controlled Trial to Determine if Testosterone Can Accelerate Injury Recovery After Arthroscopic Rotator Cuff Repair",WITHDRAWN,Unable to obtain funding to complete the study,"PHASE2, PHASE3",INTERVENTIONAL,0,Rotator Cuff Tears,"Testosterone cypionate, Placebos","DRUG, DRUG","American Shoulder and Elbow Score, American Shoulder and Elbow Score, American Shoulder and Elbow Score, Simple Shoulder Test, Simple Shoulder Test, Simple Shoulder Test, Single Alpha-Numeric Assessment Evaluation, Single Alpha-Numeric Assessment Evaluation, Single Alpha-Numeric Assessment Evaluation, Shoulder Activity Level, Shoulder Activity Level, Shoulder Activity Level, Shoulder Range of Motion, Shoulder Range of Motion, Shoulder Range of Motion, Shoulder strength, Shoulder strength, Shoulder strength",2021-08,2023-01,"Orthopedic Institute, Sioux Falls, SD",OTHER
NCT01010256,The Expression of PTEN Protein and mRNA in Malignant Cells of Chronic Myelomonocytic Leukemia,The Expression of PTEN Protein and mRNA in Malignant Cells of Chronic Myelomonocytic Leukemia,TERMINATED,PI moved institutions,,OBSERVATIONAL,4,Chronic Myelomonocytic Leukemia,,,,2009-11-01,2019-10-03,University of Arkansas,OTHER
NCT03923322,Botanical Tincture for Symptoms of Irritable Bowel Syndrome,Randomized Pilot Trial of Botanical Tincture for Symptoms of Irritable Bowel Syndrome Constipation Predominant (IBS-C) Diagnosed on ROME IV Criteria,WITHDRAWN,Budget limitations,PHASE2,INTERVENTIONAL,0,Irritable Bowel Syndrome Characterized by Constipation,Botanical Tincture,"DRUG, OTHER","Number of subjects recruited, Proportion of subjects who complete the study, Proportion of dosages of drug/placebo that are taken by participants",2025-01,2025-01,Stamford Hospital,OTHER
NCT03338751,Determine the Effect on Cognitive Impairment Measures by Providing Hearing-Assistance to Skilled Nursing Facility Residents,Determine the Effect on Cognitive Impairment Measures by Providing Hearing-Assistance to Skilled Nursing Facility Residents,WITHDRAWN,Unfunded Pilot Study,NA,INTERVENTIONAL,0,Hearing Impairment,,"DIAGNOSTIC_TEST, DIAGNOSTIC_TEST","Measure of Cognitive function using Mini-Cog, Perceived Hearing measured by Hearing Handicap Inventory for the Elderly-Screening Version (HHIE)",2018-01,2019-01,NYU Langone Health,OTHER
NCT05823922,Mobile Cognitive Behavioral Therapy for Medical and Graduate Students,Feasibility and Efficacy of Mobile Cognitive Behavioral Therapy for Medical and Graduate Students,TERMINATED,Low accrual,NA,INTERVENTIONAL,4,"Anxiety Disorders, Depression",,"BEHAVIORAL, BEHAVIORAL","Change in anxiety symptoms from baseline to end of treatment as measured by the GAD-7., Change in depressive symptoms from baseline to end of treatment as measured by the PHQ-9",2023-11-17,2024-11-30,Weill Medical College of Cornell University,OTHER
NCT06207422,The Effects of a Moderate Intensity Training Program Versus a High Intensity Training Program on Central Pain Processing,The Effects of a Moderate Intensity Training Program Versus a High Intensity Training Program on Central Pain Processing,TERMINATED,The study was terminated prematurely due to difficulties in participant recruitment. We reframed the project as a pilot feasibility study to better assess recruitment processes and inform the design of a future full-scale trial.,NA,INTERVENTIONAL,30,Healthy,,"OTHER, OTHER","Pressure pain threshold, Conditioned pain modulation, Exercise-induced hypoalgesia, Nociceptive flexion reflex - threshold, Nociceptive flexion reflex - temporal summation",2023-11-27,2024-08-23,University Ghent,OTHER
NCT01353482,"A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma","A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma",WITHDRAWN,UCL CTC were informed by Merck Sharp \& Dohme on 22.08.11 that support for the trial had been withdrawn in light of results from another trial with trial drug.,"PHASE1, PHASE2",INTERVENTIONAL,0,Malignant Pleural Mesothelioma,"Cisplatin, Pemetrexed, Vorinostat, Placebo","DRUG, DRUG, DRUG, DRUG","Phase I only - Dose-limiting toxicities, Phase I only - Number of cycles of pemetrexed-cisplatin given, Phase II only - Progression free survival",,,"University College, London",OTHER
NCT06022224,A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL,"A Phase 2/3, Placebo-Controlled, Randomized, Observer-Blind Study To Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of a 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL",TERMINATED,There were no participants enrolled into Phase 3 portion of the study because the study was prematurely terminated.,"PHASE2, PHASE3",INTERVENTIONAL,35,COVID-19,"hAd5-S-Fusion+N-ETSD, Placebo (0.9% (w/v) saline)","BIOLOGICAL, BIOLOGICAL",Number of Participants With Adverse Events,2020-12-09,2023-07-19,"ImmunityBio, Inc.",INDUSTRY
NCT04978324,Scaling and Root Planning With Localized Delivery of Autogenous Growth Factors- Platelet Rich Fibrin (PRF),Scaling and Root Planning With Localized Delivery of Autogenous Growth Factors- Platelet Rich Fibrin (PRF): A Randomized Split-mouth Clinical Trial,WITHDRAWN,Fellow graduated before successfully enrolling any participants,PHASE3,INTERVENTIONAL,0,"Periodontitis Chronic Generalized Severe, Periodontitis Chronic Generalized Moderate",leukocyte platelet rich fibrin (L-PRF),"BIOLOGICAL, PROCEDURE","Change in probing depths (PD), Change in clinical attachment level (CAL), Bleeding on probing (BOP), Plaque index (PI), Gingival index",2022-05,2022-12,Virginia Commonwealth University,OTHER
NCT01879280,Effect of Craniotomy on Temporalis Function,,WITHDRAWN,low enrollment,NA,INTERVENTIONAL,0,Pterional Craniotomy,,"PROCEDURE, PROCEDURE",Post-operative mobility of the jaw (e.g. lateral excursion and protrusion),2010-05,2012-05,Vanderbilt University,OTHER
NCT05437679,Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System,ANG-015 / MLU-3 (CHARTER Study): Characterization of Circulating Tumor Cells Isolated Using the Parsortix® System in High Risk and Early Metastatic Prostate Cancer Patients,TERMINATED,Futility (slow enrollment),,OBSERVATIONAL,9,"High Risk Prostate Carcinoma, Biochemically Recurrent Prostate Carcinoma, Castration-resistant Prostate Cancer, Prostate Cancer",,OTHER,"CTC number and phenotype, CTC genotype",2022-07-05,2023-08-22,Angle plc,INDUSTRY
NCT01757496,Cough Assist in Bronchiolitis,Cough Assist in RSV-bronchiolitis,TERMINATED,Difficulties with patient inclusion,NA,INTERVENTIONAL,1,"Bronchiolitis, Respiratory Syncytial Virus",,DEVICE,Oxygen requirement,2012-09,2018-10-10,"University Hospital, Antwerp",OTHER
NCT03716362,Neonatal Hearing Screening at Neonatal Intensive Care Unit,Neonatal Hearing Screening at Neonatal Intensive Care Unit of Assiut University Hospital,WITHDRAWN,no participant,,OBSERVATIONAL,0,Hearing Loss,,DEVICE,Prevalence of hearing loss in all neonates in Neonatal Intensive Care Unit,2018-11-01,2019-11,Assiut University,OTHER
NCT02038803,Efficacy of TOBI Podhaler vs. Tobramycin Inhalation Solution,Patient Preferences and Efficacy of TOBI Podhaler vs. Tobramycin Inhalation Solution (PETIS),TERMINATED,"The project was a student driven study. The student graduated prior to the subjects completing all research related activities. As a result, the study was closed prematurely.",,OBSERVATIONAL,5,Cystic Fibrosis,TOBIpodhaler,DRUG,Increased Adherence to the Medical Therapeutic Regimen,2013-10-10,2014-05-07,Rush University Medical Center,OTHER
NCT02461186,Arterolane-PQP Versus DHA-PQP in Uncomplicated Falciparum Malaria in Eastern Myanmar,"An Open-label Randomized Trial to Assess the Therapeutic Efficacy of Arterolane-piperaquine Versus Dihydroartemisinin-piperaquine for the Treatment of Uncomplicated Falciparum Malaria in Eastern Myanmar, an Area of Emerging Artemisinin-resistant Falciparum Malaria",WITHDRAWN,Change of the study site due to the current political climate in Myanmar.,"PHASE2, PHASE3",INTERVENTIONAL,0,"Uncomplicated Falciparum Malaria, Artemisinin-resistant","Arterolane maleate-piperaquine phosphate (Synriam), Dihydroartemisinin-piperaquine phosphate (Duocotexin)","DRUG, DRUG",Peripheral blood parasite half-life,2015-06,2017-06,University of Oxford,OTHER
NCT00706186,Safety and Feasibility of Sodium Oxybate in Mild Alzheimer's Disease Patients,Phase IV Study Safety & Feasibility of Sodium Oxybate in Mild Alzheimer's Disease Patients.,TERMINATED,"Withdrawn by Investigator, protocol in revision",PHASE4,INTERVENTIONAL,4,Mild Alzheimer's Disease,Sodium Oxybate,DRUG,To evaluate and monitor the safety and tolerability of 6 to 9 g/day sodium oxybate in patients with mild Alzheimer's disease (AD) between the ages of 50 and 65 years.,,,Clayton Sleep Insititute,INDUSTRY
NCT02694770,"A Study Evaluating the Efficacy and Safety of Neihulizumab vs ""Conventional Treatment"" to Treat Sr-aGvHD","A Phase II Study of Neihulizumab vs ""Conventional Treatment"" to Treat Steroid-refractory Acute Graft-vs-host Disease (Sr-aGvHD) in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation",WITHDRAWN,corporate decision,PHASE2,INTERVENTIONAL,0,Steroid-refractory aGvHD Subsequent to Allogeneic Hematopoietic Cell Transplantation,"Neihulizumab Treatment, Conventional Treatment","BIOLOGICAL, BIOLOGICAL",Overall response rate (Complete Response+Partial Response),2016-07,2018-02,AbGenomics B.V Taiwan Branch,INDUSTRY
NCT03395873,"Avelumab With Decitabine as First Line for AML Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy","A Phase I Study of Avelumab in Combination With Decitabine as First Line Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy",TERMINATED,Recent FDA approval of a new drug for the same patient population,PHASE1,INTERVENTIONAL,7,Acute Myeloid Leukemia,Avelumab,DRUG,Safety of Avelumab in combination with decitabine in AML.,2018-01-29,2019-05-15,Milton S. Hershey Medical Center,OTHER
NCT02557854,HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Solid Tumors,,WITHDRAWN,Lack of enrollment,PHASE1,INTERVENTIONAL,0,"Rhabdomyosarcoma, Neuroblastoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Desmoid",Doxorubicin HCl liposomal injection,"DRUG, DEVICE",Rate of dose limiting toxicities (DLTs) during cycle 1 of therapy with MR-HIFU hyperthermia directed liposomal doxorubicin,2016-12,2019-03-16,Theodore Laetsch,OTHER
NCT01450241,Short-term Antibiotic Treatment for Unexplained Fever in Solid Cancer Patients With Febrile Neutropenia,Short-term Antibiotic Treatment for Unexplained Fever in Solid Cancer Patients With Febrile Neutropenia: Randomized-controlled Trial,WITHDRAWN,"slow recruitment, no funding",NA,INTERVENTIONAL,0,Febrile Neutropenia,,"OTHER, OTHER","Composite outcome of all-cause mortality, severe infection, severe diarrhea or fever, Total febrile or antibiotic days",2012-01,2015-01,Rabin Medical Center,OTHER
NCT00960154,PEAK PlasmaBlade™ 4.0 Versus Traditional Electrosurgery in Lumpectomy,"A Prospective, Randomized, Controlled Study to Evaluate Use of the PEAK PlasmaBladeTM 4.0 in Breast Lumpectomy",TERMINATED,Termination due to acquisition of PEAK Surgical by Medtronic,NA,INTERVENTIONAL,50,Breast Cancer,,"DEVICE, PROCEDURE",Histological Metrics: Amount of Overlying Adherent Char on Slide; Damage to Tumor Epithelium; Effect of Electrosurgical Damage on Diagnostic Quality of Lumpectomy Specimen,2009-07,2012-02,Medtronic Surgical Technologies,INDUSTRY
NCT02461654,EuroPainClinics® Study III (Prospective Observational Study),EuroPainClinics® Study III (Prospective Observational Study),TERMINATED,The clinical trial was suspended for the reason that preliminary results in 20 patients didn't show a significant curative effect of observed treatment.,,OBSERVATIONAL,150,Disc Herniations,,OTHER,Pain as assessed by the Visual analogue scale,2018-12-31,2021-12-31,Europainclinics z.ú.,OTHER
NCT05895656,Exploration of Knee Injuries Using 3 Tesla and 7 Tesla Magnetic Resonance Imaging at the University Hospital of Poitiers,Exploration of Knee Injuries Using 3 Tesla and 7 Tesla Magnetic Resonance Imaging at the University Hospital of Poitiers.,WITHDRAWN,Recruitment issues,NA,INTERVENTIONAL,0,"Traumatic Knee Injury, Knee",,OTHER,"Describe and quantify post-traumatic injuries of the ligaments (Anterior Cruciate Ligament, Posterior Cruciate Ligament, Lateral Collateral Ligament, Medial Collateral Ligament) using 7T MRI compared to 3T MRI in cases of post-traumatic knee pain.",2023-06-15,2025-12-15,Poitiers University Hospital,OTHER
NCT04486222,Accelerated Bilateral rTMS on Geriatric Depression,"Therapeutic Effect of Accelerated Bilateral Repeated Transcranial Magnetic Stimulation on Geriatric Depression: a Prospective Double-blind, Randomized Controlled Trial",TERMINATED,difficulty in recruiting suitable candidate,NA,INTERVENTIONAL,2,"Transcranial Magnetic Stimulation, Depressive Disorder, Major",,DEVICE,Degree of Change in 17-item Hamilton Depression Rating Scale (HAM-D 17),2020-11-23,2022-12-21,National Taiwan University Hospital,OTHER
NCT03365531,RCT of Caloric Restriction vs. Alternate-Day Fasting in Non-Alcoholic Fatty Liver Disease,A Randomized Controlled Trial of Caloric Restriction vs. Alternate-Day Fasting in Patients With Non-Alcoholic Fatty Liver Disease,TERMINATED,Inadequate enrollment.,NA,INTERVENTIONAL,7,"NAFLD, Obesity, Diabetes Mellitus, Type 2",,"OTHER, OTHER",Hepatic Triglyceride by MRS,2018-03-01,2019-07-01,University of Florida,OTHER
NCT03362502,A Study to Evaluate the Safety and Tolerability of PF-06939926 Gene Therapy in Duchenne Muscular Dystrophy,"A PHASE 1B MULTICENTER, OPEN-LABEL, SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PF-06939926 IN AMBULATORY AND NON-AMBULATORY SUBJECTS WITH DUCHENNE MUSCULAR DYSTROPHY",TERMINATED,All participants who have received fordadistrogene movaparvovec in any Pfizer study will now be assessed for long-term safety in 1 combined study: C3391003,PHASE1,INTERVENTIONAL,23,Duchenne Muscular Dystrophy,,GENETIC,"Number of Participants With All-Causality Treatment-Emergent Adverse Events (TEAEs) for 1-Year Follow-Up, Number of Participants With All-Causality TEAEs by System Organ Class (SOC) and Preferred Term (PT) for 1-Year Follow-Up, Number of Participants With Treatment-Related TEAEs for 1-Year Follow-Up, Number of Participants With Treatment-Related TEAEs by SOC and PT for 1-Year Follow-Up, Number of Participants With All-Causality SAEs by SOC and PT for 1-Year Follow-Up, Number of Participants With Treatment-Related SAEs by SOC and PT for 1-Year Follow-Up, Number of Participants With Laboratory Test Abnormalities Without Regard to Baseline Abnormality for 1-Year Follow-Up - Hematology, Number of Participants With Laboratory Test Abnormalities Without Regard to Baseline Abnormality for 1-Year Follow-Up - Clinical Chemistry, Number of Participants With Laboratory Test Abnormalities Without Regard to Baseline Abnormality for 1-Year Follow-Up - Urinalysis, Change From Baseline on Left Ventricular Ejection Fraction as Measured by Cardiac Magnetic Resonance Imaging (MRI) for 1-Year Follow-Up, Number of Participants With Electrocardiograms (ECGs) Meeting the Pre-Defined Categorical Criteria for 1-Year Follow-Up, Number of Participants With Positive Responses on Columbia-Suicide Severity Rating Scale (C-SSRS) According to the Columbia Classification Algorithm of Suicide Assessment (C-CASA) Categories, Number of Participants With Vital Signs Meeting the Pre-Defined Categorical Criteria for 1-Year Follow-Up",2018-01-23,2025-07-28,Pfizer,INDUSTRY
NCT03368417,WIreless Monitoring and Financial Incentives for Uncontrolled HYpertension (WIFHY) Study,A Randomised Controlled Trial to Improve Hypertension Outcomes Using Wireless Home Blood Pressure Monitoring With Automatic Outcome-based Feedback and Financial Incentives,TERMINATED,Due to unforeseen delays and funding issues,NA,INTERVENTIONAL,42,Hypertension,,"OTHER, OTHER, BEHAVIORAL",Change in Systolic Blood Pressure (SBP),2017-12-20,2019-01-27,Duke-NUS Graduate Medical School,OTHER
NCT01685840,Guiding Evidence Based Therapy Using Biomarker Intensified Treatment,Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.,TERMINATED,Project was stopped due to futility,NA,INTERVENTIONAL,894,Heart Failure,,"OTHER, DEVICE",CV Death or Heart Failure Hospitalization,2012-12,2016-09-20,Duke University,OTHER
NCT00625040,Incretin Physiology and Beta-cell Function Before and After Weight-loss,Incretin Physiology and Beta-cell Function Before and After Weight-loss - Effects of Long-term Weight Loss Following Laparoscopic Adjustable Gastric Banding,TERMINATED,Not enough patients in the follow-up period,,OBSERVATIONAL,10,Obesity,,OTHER,Incretin effect before and one year after gastric banding in obese patients without diabetes,2008-01,2011-01,"Glostrup University Hospital, Copenhagen",OTHER
NCT04204668,Surgical Treatments for Neuroma Pain in Amputees,A Randomized Trial Comparing Surgical Treatments for Neuroma Pain in Amputees,WITHDRAWN,No participants enrolled,NA,INTERVENTIONAL,0,"Pain, Neuropathic, Amputation Neuroma, Phantom Limb Pain",,"PROCEDURE, PROCEDURE, PROCEDURE","Worst reported residual limb pain score on a numerical scale, Worst reported phantom limb pain score on a numerical scale",2021-04-01,2025-02-12,Johns Hopkins University,OTHER
NCT02432989,Establishing Early Exercise Interventions in Concussion Recovery,Rest vs. Early Return to Exercise Following Concussion (H15-00307),SUSPENDED,Not able to get enough participants,NA,INTERVENTIONAL,20,Brain Concussion,,BEHAVIORAL,Change in EEG Functional Connectivity Using Graph Theoretical Modeling,2015-04,2018-12,University of British Columbia,OTHER
NCT02014168,Safety and Immunogenicity of Co-administration of Candidate Influenza Vaccine MVA-NP+M1 and Viroflu® Seasonal Influenza Vaccine,A Phase I Study to Determine the Safety and Immunogenicity of Co-administration of the Candidate Influenza Vaccine MVA-NP+M1 and the Viroflu® Seasonal Influenza Vaccine,TERMINATED,Futility,PHASE1,INTERVENTIONAL,3,Influenza,"Viroflu® and MVA-NP+M1, Viroflu® and saline placebo","BIOLOGICAL, BIOLOGICAL","Cellular immune response generated by co-administration of MVA-NP+M1 and the Viroflu® seasonal influenza vaccine, Humoral immune response generated by co-administration of MVA-NP+M1 and the Viroflu® seasonal influenza vaccine",2014-01,2014-04,University of Oxford,OTHER
NCT06201091,The Effect of Swallowing Training for Elderly People in the Community,The Effect of Swallowing Training for Elderly People in the Community: A Preliminary Self-control Study,WITHDRAWN,ethical issues,NA,INTERVENTIONAL,0,Dysphagia,,BEHAVIORAL,Eating Assessment Tool-10,2024-01-10,2024-02-20,Zeng Changhao,OTHER
NCT02788318,Serotoninergic Pathways in Sudden and Unexpted Death in Epilepsy (SUDEP),Serotoninergic Pathways in Sudden and Unexpted Death in Epilepsy (SUDEP),TERMINATED,difficulty recruiting patients,,OBSERVATIONAL,2,Sudden Unexpected Death in Epilepsy (SUDEP),,"OTHER, OTHER",Density of Medullary 5-HT Neurons,2014-01,2019-01,Hospices Civils de Lyon,OTHER
NCT02067390,Urinary KIM-1 After Vancomycin or Linezolid Administration,Novel Urinary Biomarkers in the Detection of Vancomycin Associated Renal Injury,TERMINATED,Slow enrollment,,OBSERVATIONAL,5,Acute Kidney Injury,,,Urinary KIM-1 concentrations,2013-09,2019-05,Midwestern University,OTHER
NCT00451490,The Effect of Agomelatine or Fluoxentine on Heart Rate Variability in Patients With Major Depressive Disorder,The Effect of Agomelatine or Fluoxentine on Heart Rate Variability in Patients With Major Depressive Disorder,WITHDRAWN,This study not get the approval by the drug company,NA,INTERVENTIONAL,24,"Depressive Disorder, Major","Agomelatine, Fluoxentine","DRUG, DRUG","the Pittsburgh Sleep Quality Index, the Leeds Sleep Evaluation Questionnaire",2006-10,2007-12,National Taiwan University Hospital,OTHER
NCT00323310,Safety and Efficacy of MultiHance in Pediatric Patients,A Phase III Multi-Center Open Label Study to Evaluate Safety and Efficacy of MultiHance at the Dose of 0.10 mmol/kg in Magnetic Resonance Imaging of the Central Nervous System in Pediatric Patients,TERMINATED,Adequate statistical power at 92 dosed pts to meet study objectives.,PHASE3,INTERVENTIONAL,92,Central Nervous System Diseases,gadobenate dimeglumine,DRUG,"Delineation of Lesion Border (Change From Pre to Pre+Postdose) for Reader 1, Delineation of Lesion Border (Change From Pre to Pre+Postdose) for Reader 2, Delineation of Lesion Border (Change From Pre to Pre+Postdose) for Reader 3, Visualization of Lesion Internal Morphology (Change From Pre to Pre+Postdose) for Reader 1, Visualization of Lesion Internal Morphology (Change From Pre to Pre+Postdose) for Reader 2, Visualization of Lesion Internal Morphology (Change From Pre to Pre+Postdose) for Reader 3, Lesion Contrast Enhancement (CE) (Change From Pre to Pre+Postdose) for Reader 1, Lesion Contrast Enhancement (CE) (Change From Pre to Pre+Postdose) for Reader 2, Lesion Contrast Enhancement (CE) (Change From Pre to Pre+Postdose) for Reader 3, The Number of Patients Administered MultiHance (Gadobenate Dimeglumine) Reporting Adverse Events",2006-04,2008-09,"Bracco Diagnostics, Inc",INDUSTRY
NCT04274413,CFTR Related Pancreatitis Study,Assessing CFTR Function in Patients With CFTR Related Pancreatitis Using a Novel Sweat Test,WITHDRAWN,Due to funding and Covid-19 pandemic,NA,INTERVENTIONAL,0,"Cystic Fibrosis, CFTR Gene Dysfunction",,COMBINATION_PRODUCT,Assessment of CFTR function using the Beta Adrenergic Sweat Secretion Test,2021-02-01,2021-02-01,The Hospital for Sick Children,OTHER
NCT00804882,Hispanics With Metabolic Syndrome and Non-ischemic Heart Failure,Correlation in Hispanics of Accelerated Metabolic Risk Profile and Non-ischemic Heart Failure (CHAMP-HF),WITHDRAWN,Principal investigator is leaving the institution to obtain further training.,,OBSERVATIONAL,0,"Metabolic Syndrome, Heart Failure",,,"Evaluate ethnicity-specific differences in the association between increasing number of metabolic risk factors and increasingly compromised LV structure and function among Mexican Americans, in comparison to non-Hispanic whites.",2008-10,2009-05,Texas Tech University Health Sciences Center,OTHER
NCT02400424,Study of the Efficacy of SBRT on Unresectable Peripheral Primary Tumor,Multicenter Prospective Study of the Efficacy of Stereotactic Lung Radiation Therapy After Concomitant Radio-chemotherapy for Unresectable Stage III Non-small Cell Lung Carcinoma (NSCLC) With Peripheral Primary Tumor.,TERMINATED,Approval of adjuvant durvalumab after RT-CT (not anticipated in the study design) and small number of stage III NSLCL patients with peripheral tumor accessible to SBRT,NA,INTERVENTIONAL,25,Non-small-cell Lung Carcinoma,,RADIATION,Local control rate,2015-02,2020-06-25,Centre Leon Berard,OTHER
NCT01262859,Pilot Study for Locally Advanced Head and Neck Cancer,"Pilot Study of Induction Docetaxel, Cisplatin, Cetuximab and Bevacizumab (TPE-A) Followed by Concurrent Radiation, Cisplatin, Cetuximab and Bevacizumab (XPE-A) in Patients With Locally Advanced Head and Neck Cancer",WITHDRAWN,PI relocated to another institution. No subjects went on treatment.,PHASE2,INTERVENTIONAL,0,Head and Neck Neoplasms,bevacizumab,DRUG,Response rate,2010-12,2011-07,University of Pittsburgh,OTHER
NCT00702923,"CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer","Phase I Dose Escalation Trial of CP-675,206 (Tremelimumab, Anti-CTLA-4 Monoclonal Antibody) in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer",TERMINATED,Enrollment was halted prematurely due to slow accrual.,PHASE1,INTERVENTIONAL,12,Prostate Cancer,"Bicalutamide and CP-675,206 (Tremelimumab), Bicalutamide, CP-675,206 (tremelimumab), Bicalutamide, CP-675,206 (Tremelimumab), Bicalutamide, CP-675,206 (Tremelimumab), Bicalutamide, CP-675,206","DRUG, DRUG, DRUG, DRUG, DRUG",The Number of Participants Who Developed Cancer Antigen-specific Immune Responses,2008-07,2013-03,"University of Wisconsin, Madison",OTHER
NCT04909723,"Safety, Tolerability, and Pharmacodynamics of NOV-001 in Adult Subjects","Phase 1-2a Safety, Tolerability, and Pharmacodynamics Controlled Study of NOV-001 in Healthy Volunteers and Patients With Enteric Hyperoxaluria",TERMINATED,Sponsor decision to discontinue study.,"PHASE1, PHASE2",INTERVENTIONAL,153,"Healthy Volunteers, Enteric Hyperoxaluria","NB1000S, NB2000P, Placebo","COMBINATION_PRODUCT, BIOLOGICAL, DRUG, DRUG",Number of participants with treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0,2021-06-02,2023-04-06,Novome Biotechnologies Inc,INDUSTRY
NCT04628780,Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors,"A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTI-TUMOR ACTIVITY OF PF-07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS",TERMINATED,Pfizer has made an internal business decision to not continue further development of PF-07209960. This decision was not based on safety or regulatory considerations,PHASE1,INTERVENTIONAL,37,"Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Urothelial Carcinoma, Colorectal Carcinoma, Ovarian Carcinoma",PF-07209960,BIOLOGICAL,"Number of Participants With Dose Limiting Toxicities (DLTs), Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Number of Participants With Maximum Grade 3 or 4 TEAEs, Number of Participants With TEAEs Leading to Death, Number of Participants With Serious TEAEs, Number of Participants Discontinued From Study Due to TEAEs, Number of Participants With New or Worsening Hematology Laboratory Test Results to Grade >=1 During the On-Treatment Period, Number of Participants With New or Worsening Hematology Laboratory Test Results to Grade >=3 During the On-Treatment Period, Number of Participants With New or Worsening Chemistry Laboratory Test Results to Grade >=1 During the On-Treatment Period, Number of Participants With New or Worsening Chemistry Laboratory Test Results to Grade >=3 During the On-Treatment Period",2020-12-16,2023-05-26,Pfizer,INDUSTRY
NCT02461680,Treatment for Partial Lesions of the Fingers Flexor Tendons : Tangential Resection or Direct Suture,"Management Of The Partial Lesions Of The Fingers Flexor Tendons, Prospective Randomized Trial Of 2 Surgical Procedures: Tangential Resection Versus Direct Suture",TERMINATED,recruitment difficulty,NA,INTERVENTIONAL,3,"Flexor Tendon Injury, Lesions Of The Fingers Flexor Tendons",,"PROCEDURE, PROCEDURE",Total active motion Grasp,2016-02,2019-02,"University Hospital, Strasbourg, France",OTHER
NCT00574080,UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide,UARK 2006-15: A Phase III Randomized Study of Tandem Transplants With or Without Bortezomib (Velcade) and Thalidomide (Thalomid) to Evaluate Its Effect on Response Rate and Durability of Response in Multiple Myeloma Patients,TERMINATED,low accrual,PHASE3,INTERVENTIONAL,20,Multiple Myeloma,"Interim/Maintenance Dexamethasone, Induction/Consolidation Dexamethasone, Induction/Consolidation Cisplatin, Induction/Consolidation Adriamycin, InductionConsolidation Cyclophosphamide, Induction/Consolidation Etoposide, Induction Pegfilgrastim, Transplant 1 Dexamethasone, Transplant 1 Cisplatin, Transplant 1 Adriamycin, Transplant 1 Cyclophosphamide, Transplant 1 Etoposide, Transplant 1 Melphalan, Transplant 1 and 2 Pegfilgrastim, Transplant 2 Carmustine, Transplant 2 Etoposide, Transplant 2 Cytarabine, Transplant 2 Melphalan, Transplant 2 Dexamethasone, Transplant 1 and 2 Bortezomib, Transplant 1 and 2 Thalidomide","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, PROCEDURE, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG",Event Free Survival,2006-07,2011-03,University of Arkansas,OTHER
NCT01821196,Density of Neurons in the Stomach and Prognosis of Gastric Adenocarcinoma,Density of Neurons in the Stomach and Prognosis of Gastric Adenocarcinoma,WITHDRAWN,due to insufficient quality of biopsy samples,NA,INTERVENTIONAL,0,Stomach Neoplasms,,PROCEDURE,Density of PGP9.5 in gastric adenocarcinoma related to TNM stage and survival of stomach cancer,2012-12,2018-02,St. Olavs Hospital,OTHER
NCT02768662,A 6-Month Extension Study of OTO-104 in Meniere's Disease,"A 6-Month, Multicenter, Phase 3, Open-Label Extension Safety Study of OTO-104 Given At 3-Month Intervals by Intratympanic Injection in Subjects With Unilateral Meniere's Disease",TERMINATED,Negative Efficacy Results from the recently completed Phase 3 study 104-201506,PHASE3,INTERVENTIONAL,142,Meniere's Disease,OTO-104,DRUG,Otoscopic Examination - Tympanic Membrane Perforation at Week 24 (Month 6),2016-08,2017-09,"Otonomy, Inc.",INDUSTRY
NCT03441503,Child HCAHPS: Automated Day of Discharge Survey,Child HCAHPS: Day of Discharge Survey on an Electronic Interactive Patient Care System,TERMINATED,We were not able to enroll partner hospitals.,NA,INTERVENTIONAL,23578,"Inpatient Experience Survey Administration, Inpatient Experience Survey Response",,OTHER,Child HCAHPS Response Rate,2018-04-10,2022-04-10,Boston Children's Hospital,OTHER
NCT06232603,Medication Adherence Intervention in Chronic Recurrent Multifocal Osteomyelitis (CRMO),Assessing Medication Adherence in Patients With Chronic Recurrent Multifocal Osteomyelitis,TERMINATED,lack of staffing and funding support,NA,INTERVENTIONAL,9,Chronic Recurrent Multifocal Osteomyelitis,,OTHER,Medication possession ratio (MPR),2024-02-20,2024-06-18,Seattle Children's Hospital,OTHER
NCT00810576,Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma,A Phase II Study To Determine The Safety and Efficacy Of The Combination of Vorinostat and Bortezomib In Patients With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma,TERMINATED,Terminated due to slow accrual.,PHASE2,INTERVENTIONAL,1,Lymphoma,"Vorinostat, Bortezomib","DRUG, DRUG",Number of Patients With Response,2009-01,2010-04,M.D. Anderson Cancer Center,OTHER
NCT04288076,The Brain and Lung Interaction (BALI) Study,The Effect of Positive End Expiratory Pressure on Intracranial Pressure: The Brain and Lung Interaction (BALI) Study,WITHDRAWN,Low eligibility rate,NA,INTERVENTIONAL,0,"Intracranial Pressure, Mechanical Ventilation, Brain Injuries",,OTHER,Change in intracranial pressure,2020-09,2020-10-15,Beth Israel Deaconess Medical Center,OTHER
NCT00693017,Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures Associated With Idiopathic Generalised Epilepsy,"A Double-blind, Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures Associated With Idiopathic Generalised Epilepsy",TERMINATED,Sponsor's decision,PHASE3,INTERVENTIONAL,10,Epilepsy,"Zonisamide, Placebo","DRUG, DRUG",Number of Participants Considered Responders as Assessed During the Maintenance Period,2008-06,,Eisai Limited,INDUSTRY
NCT02916550,Breathing Intervention for Cardiac Anxiety,Anatomical and Psychophysiological Substrates of Interoception,TERMINATED,"Recruitment rate was lower than anticipated, preventing the study from achieving target sample size.",NA,INTERVENTIONAL,12,"Atrial Fibrillation, Implantable Cardioverter Defibrillator",,BEHAVIORAL,Cardiac anxiety,2016-09,2023-05,"Laureate Institute for Brain Research, Inc.",OTHER
NCT05622591,ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML,Dose Escalation Study to Evaluate the Safety and Tolerability of ELU001 in Pediatric Patients Who Have Relapsed and/or Refractory CBFA2T3::GLIS2 Positive Acute Myeloid Leukemia,WITHDRAWN,Lack of Funding - no safety issue with Drug; Company Permanently Closed,PHASE1,INTERVENTIONAL,0,"Acute Myeloid Leukemia, AML, Childhood, Relapsed Pediatric AML, Refractory Pediatric AML",ELU001,DRUG,Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of ELU001,2024-06-07,2024-06-07,Elucida Oncology,INDUSTRY
NCT00787618,Evaluate PK and Safety of Proellex® in Females With Various Stages of Impaired Renal Function and Healthy Females,"A Single-Dose, Open-Label, Parallel Group Study To Evaluate The Pharmacokinetics And Safety Profile Of PROELLEX® (CDB-4124) In Female Subjects With Various Stages Of Impaired Renal Function And In Healthy Female Volunteers",TERMINATED,Increased LFTs,"PHASE1, PHASE2",INTERVENTIONAL,6,Renal Impairment,50 mg Proellex,DRUG,Cmax of Proellex,2008-10,2009-07,Repros Therapeutics Inc.,INDUSTRY
NCT00557518,Study of Alagebrium in Patients With Insulin-Dependent Type 1 Diabetes and Microalbuminuria,"A Randomized, Placebo-Controlled Trial of Alagebrium in Patients With Insulin-Dependent Type 1 Diabetes and Microalbuminuria",TERMINATED,Study has been terminated early due to financial constraints.,PHASE2,INTERVENTIONAL,80,"Diabetes Mellitus, Type 1, Diabetic Nephropathy","Alagebrium, Placebo","DRUG, DRUG",Change from baseline in albumin excretion rate (µg/min),2007-11,2009-11,"Synvista Therapeutics, Inc",INDUSTRY
NCT03024060,Phase 3 Study of Levulan With New Blue Light for AK on the Face or Scalp,"A RANDOMIZED, VEHICLE-CONTROLLED PHASE 3 STUDY TO PROVE THE SAFETY AND EFFICACY OF LEVULAN KERASTICK (AMINOLEVULINIC ACID HCl) FOR TOPICAL SOLUTION, 20% AND 10 J/CM2 OF BLUE LIGHT DELIVERED AT 10 MW/CM2 OR 20 MW/CM2 BY A NEW LIGHT SOURCE FOR THE TREATMENT OF ACTINIC KERATOSES ON THE FACE OR SCALP",WITHDRAWN,Study withdrawn due to corporate business decision,PHASE3,INTERVENTIONAL,0,Actinic Keratosis,"ALA, Vehicle","DRUG, DRUG, DEVICE, DEVICE",Complete Clearance Rate,2017-03,2018-01,"DUSA Pharmaceuticals, Inc.",INDUSTRY
NCT01607359,Dabigatran Versus Warfarin Anticoagulation Before and After Catheter Ablation for the Treatment of Atrial Fibrillation,Dabigatran Versus Warfarin Anticoagulation Before and After Catheter Ablation for the Treatment of Atrial Fibrillation,WITHDRAWN,Withdrawn: It was decided not to proceed with the study at this time.,,OBSERVATIONAL,0,Atrial Fibrillation,,,"Clinical stroke, TIA or systemic embolic complication, Bleeding complication",2012-05,2017-04-20,Corewell Health East,OTHER
NCT03376659,Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma,"A Phase I/II Trial of the PD-L1 Inhibitor, Durvalumab Plus CV301 in Combination With Maintenance Chemotherapy for Patients With Metastatic Colorectal or Pancreatic Adenocarcinoma",TERMINATED,Study closed due to lack of enrollment.,"PHASE1, PHASE2",INTERVENTIONAL,8,"Metastatic Colorectal Cancer, Colorectal Adenocarcinoma, Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer","Durvalumab, CV301, Capecitabine, Bevacizumab","DRUG, BIOLOGICAL, DRUG, DRUG","Recommended Phase II Dose of Durvalumab, Progression Free Survival (PFS) Colorectal Cancer, Progression Free Survival (PFS) Pancreatic Cancer",2018-08-08,2023-08-01,Georgetown University,OTHER
NCT02828059,Continuous Wound Infiltration for Diminution of Post-surgery Pain After Caesarean Section,Continuous Wound Infiltration for Diminution of Post-surgery Pain After Caesarean Section (Dip-Caesar),WITHDRAWN,changed drug approval,,OBSERVATIONAL,0,Pain,Ropivacaine,DRUG,Maximal perceived pain intensity 24 h after surgery,2016-08,2016-08,Jena University Hospital,OTHER
NCT00953459,Sunitinib Malate in Treating Patients With Small Cell Lung Cancer,"Phase II Study of Sunitinib (SU011248) in Patients With Small Cell Lung Cancer Who Are Either Chemo-naïve (Extensive Disease) or Have a ""Sensitive"" Relapse",TERMINATED,poorly recruiting,PHASE2,INTERVENTIONAL,9,Lung Cancer,sunitinib malate,"DRUG, OTHER, RADIATION","Disease control rate (percentage of patients with complete response, partial response, or stable disease) 8 weeks after beginning treatment according to RECIST criteria",2009-02,2012-09,European Organisation for Research and Treatment of Cancer - EORTC,NETWORK
NCT00335959,"S0425 Oxaliplatin, Capecitabine, and RT in Treating Patients W/Stomach Cancer That Can Be Removed By Surgery",Neoadjuvant Chemoradiation Therapy With Oxaliplatin and Capecitabine for Patients With Surgically Resectable Gastric Cancer: A Pilot Phase II Trial With Molecular Correlates,TERMINATED,Closed due to slow accrual,PHASE2,INTERVENTIONAL,7,Gastric Cancer,"capecitabine, oxaliplatin","DRUG, DRUG, PROCEDURE, RADIATION",Pathologic Complete Response,2006-05,,SWOG Cancer Research Network,NETWORK
NCT01679080,The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta,The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta,TERMINATED,Eli Lilly has withdrawn support to the study of teriparatide and placebo pens. The study was not able to continue as a randomized study without the supply of placebo pens.,PHASE2,INTERVENTIONAL,9,Osteogenesis Imperfecta,"Zoledronic acid, Teriparatide","DRUG, DRUG, OTHER",Bone Mineral Density (BMD),2012-11,2021-06-01,University of Aarhus,OTHER
NCT01868880,Effect of Ivabradine and Beta-blockers Combination Versus Beta-blockers Up-titration on Right Ventricular Pacing,Effect of Heart Rate Control Using Ivabradine and Beta-blockers Combination Versus Beta-blockers Up-titration on Ventricular Pacing in Heart Failure Patients With an Implanted Cardioverter Defibrillator.,WITHDRAWN,difficulties in recruiting patients,PHASE4,INTERVENTIONAL,0,Heart Rate Control in ICD Patients With Heart Failure,"Ivabradine plus beta-blocker (bisoprolol), betablocker titration","DRUG, DRUG",Right ventricular pacing percentage increase > 50% or cardiovascular death or Heart failure decompensation or Crossover due to worsening heart failure.,2016-02,2023-12,Policlinico Casilino ASL RMB,OTHER
NCT05558280,Qarziba for Patients in Relapsed/Refractory High-grade Osteosarcoma,Maintenance Therapy With Qarziba for Patients in Relapsed/Refractory High-grade Osteosarcoma After Induction Multimodal Therapy - a Phase II Multi-center Study,SUSPENDED,study not started,PHASE2,INTERVENTIONAL,22,Osteosarcoma in Children,Dinutuximab beta,DRUG,Efficacy of Dinutuximab Beta as maintenance therapy in patients with OS relapsed/refractory that have achieved Complete Response (CR) or Partial Response (PR),2023-11-30,2026-12-15,Prof. Franca Fagioli,OTHER
NCT02538146,Effect of Acetyl-L-carnitine on Chronic Pancreatitis,Acetyl-L-carnitine as Pain Therapy in Chronic Pancreatitis,TERMINATED,Older participants could not tolerate the acidity of the product and withdrew.,EARLY_PHASE1,INTERVENTIONAL,3,Chronic Pancreatitis,,DIETARY_SUPPLEMENT,Pain score,2015-08,2016-10,Karin High,OTHER
NCT00720096,Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan,A Pilot Prospective Trial Of Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan In Recurrent Or Persistent Ovarian Cancer Within 12 Months Of Platinum-Based Chemotherapy,TERMINATED,"Funds for this project have been spent, and it is thereby terminated.",NA,INTERVENTIONAL,4,Ovarian Cancer,"Liposomal Doxorubicin, Topotecan","DRUG, DRUG","Assess Feasibility, Interpret Genomic Array",2008-07,2009-10,H. Lee Moffitt Cancer Center and Research Institute,OTHER
NCT00444262,Stroke Volume Optimisation in Patients With Hip Fracture,"Study Multicentric, Randomised, in Duplicate Blind Person of the Impact of a Per Operatory Strategy of Optimization of the Cardiac Output on the Forecast of the Old Subjects Operated for Fracture of the Upper End of the Femur "" FRACTALE """,TERMINATED,termination of the study due to difficulties to include patients,PHASE3,INTERVENTIONAL,215,Hip Fractures,VOLUVEN and others solute,"PROCEDURE, DRUG","We expect a 30% reduction in the number of per- and post-operative complications observed during hospitalisation in acute care beds in the ""optimised"" subgroup with respect to ""conventional"" subgroup. Complications include: death, per-operative",2007-04,2011-03,Assistance Publique - Hôpitaux de Paris,OTHER
NCT04605588,A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19,"A Triple Combination Antiviral Coronavirus Therapy (TriACT) RCT Comparing Nitazoxanide, Ribavirin and Hydroxychloroquine vs. Placebo",TERMINATED,Lack of participants willing to enroll,PHASE2,INTERVENTIONAL,7,"SARS-CoV Infection, Covid19","Nitazoxanide, Placebo Nitazoxanide, Ribavirin, Placebo Ribavirin, Hydroxychloroquine, Placebo Hydroxychloroquine","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG",Rate of Decline in Viral Load Over the 10 Days After Randomization,2020-12-02,2021-02-04,"Rutgers, The State University of New Jersey",OTHER
NCT03390088,Heart Failure Management in Azerbaijan,The Clinical Profiles and Treatment Management of Chronic Heart Failure in Azerbaijan,WITHDRAWN,The estimated number of patients could not be recorded in this study,,OBSERVATIONAL,0,Heart Failure,,,Heart failure related hospitalization,2018-01-28,2020-01-14,Prof. Dr. Mehdi Zoghi,OTHER
NCT04761835,STEP-IT-UP - Peanut Allergy Study for Infants,Subthreshold Peanut in Infants - Understanding Plasticity,WITHDRAWN,Withdrawn in IRB,PHASE2,INTERVENTIONAL,0,"Peanut Allergy, Food Allergy",Peanut powder or peanut butter,BIOLOGICAL,Oral food challenge threshold to peanut at week 52,2021-11-01,2028-11-01,Johns Hopkins University,OTHER
NCT04041908,Use of a Medical Food in Adults Undergoing Surgery,Observation of the Use of a Medical Food in Older Adults Undergoing Surgery,TERMINATED,Low enrollment,NA,INTERVENTIONAL,1,"Compliance, Patient",,OTHER,Product Compliance,2020-03-13,2020-04-10,Abbott Nutrition,INDUSTRY
NCT02644525,Efficacy and Microfilaricidal Kinetics of Imatinib for the Treatment of Loa Loa,"A Double-blinded, Randomized, Placebo-Controlled Dose Escalation Study to Examine the Efficacy and Microfilaricidal Kinetics and Safety of Imatinib for the Treatment of Loa Loa (A Pilot Study)",TERMINATED,Planned interim analysis demonstrated futility of intervention,PHASE2,INTERVENTIONAL,20,Loiasis,"Imatinib Mesylate, Imatinib Mesylate, Imatinib Mesylate, Placebo","DRUG, DRUG, DRUG, DRUG",Percent of Baseline Loa Loa Microfilariae,2019-09-16,2021-03-19,National Institute of Allergy and Infectious Diseases (NIAID),NIH
NCT00111917,Beryllium Infliximab Study: Clinical Interventional Trial,"Clinical Efficacy of Remicade in Chronic Beryllium Disease: A Randomized, Double-Blind, Placebo-Controlled, Investigator Initiated Trial",TERMINATED,Not enough patients meeting criteria to enroll in the time period,"PHASE1, PHASE2",INTERVENTIONAL,13,"Berylliosis, Beryllium Disease",Infliximab,"DRUG, OTHER",A-a Gradient at End Exercise,2005-02,2009-01,"Maier, Lisa, M.D.",INDIV
NCT02387840,Feasibility and Clinically Application of Magnetic Resonance Fingerprinting,Feasibility and Clinically Application of Magnetic Resonance Fingerprinting,TERMINATED,technician left institution,NA,INTERVENTIONAL,35,"Neurofibromatosis Type 1, Brain Tumor, Glioma",,"DEVICE, DEVICE",Average Duration of MRF Sequence - Feasibility,2015-03,2019-07-31,Case Comprehensive Cancer Center,OTHER
NCT06030050,Animal Assisted Intervention for Hemodialysis Outpatients,Animal Assisted Intervention for Hemodialysis Outpatients: A Mixed-method Randomized Controlled Trial for Treatment Adherence and Psychosocial Well-being,WITHDRAWN,The study was not feasible to conduct.,NA,INTERVENTIONAL,0,"End-Stage Kidney Disease, Chronic Kidney Failure, Chronic Pain",,BEHAVIORAL,Treatment adherence,2023-11-01,2024-02,The University of Texas Health Science Center at San Antonio,OTHER
NCT03520790,Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer,Vitamin D Receptor Agonist Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Patients With Metastatic Pancreatic Cancer,TERMINATED,Phase II was not pursued due to futility based on the results of the NAPOLI-3 therapeutic clinical trial.,PHASE1,INTERVENTIONAL,36,Pancreatic Cancer,"Gemcitabine, Nab-paclitaxel, Paricalcitol","DRUG, DRUG, DRUG, OTHER","Assess adverse events (per CTCAE v4.0 criteria), Overall survival",2018-12-05,2024-07-01,Dana-Farber Cancer Institute,OTHER
NCT03179059,Resolution of Uncertainty Through Testing,Resolution of Uncertainty Through Testing: The Impact of Pregnancy Tests on Reproductive and Maternal Health Beliefs and Behaviors in Uganda,TERMINATED,Difficulties in field coordination,NA,INTERVENTIONAL,600,Pregnancy Tests,,"DIAGNOSTIC_TEST, DIAGNOSTIC_TEST",Binary measures for the family planning take up,2017-09-28,2017-12-02,University of Illinois at Urbana-Champaign,OTHER
NCT04833959,Pilot Study of 89-Zr Panitumumab in Pancreas Cancer,Pilot Study of 89Zr Panitumumab in Pancreas Cancer,WITHDRAWN,Business Decision,PHASE1,INTERVENTIONAL,0,Pancreas Cancer,89Zr-panitumumab,DRUG,Incidence of treatment emergent adverse events assessed by CTCAE v5,2021-03-26,2024-03,Stanford University,OTHER
NCT02956980,Impact of Gender and Pubertal Status on Human Plasmacytoid Dendritic Cells. PLASMACYTOKID,Impact of Gender and Pubertal Status on Human Plasmacytoid Dendritic Cells - PLASMACYTOKID Study,TERMINATED,recruitment target not obtained,NA,INTERVENTIONAL,78,Innate Immune Responses,Blood Plasmacytoid dendritic cells (pDCs) absolute number,BIOLOGICAL,percentage of IFN1 producing pDCs,2017-06-21,2018-12-31,"University Hospital, Toulouse",OTHER
NCT03269396,Laryngeal Allograft Transplantation,A Prospective Nonrandomized Study of Laryngeal Allograft Transplantation Clinical Investigation,SUSPENDED,Protocol revision,NA,INTERVENTIONAL,10,"Larynx Stenosis, Larynx Disease, Laryngectomy, Larynx, Larynx Fracture",,PROCEDURE,Survival of the allograft at the one-year visit.,2023-05-19,2033-05,Mayo Clinic,OTHER
NCT01432496,Peritoneal Nebulization of Ropivacaine for Pain Control After Laparoscopic Colectomy,"A Multicentric, Randomized, Controlled, Double Blinded, Phase III Clinical Trial; Comparing Peritoneal Nebulization of Ropivacaine 150 mg With Peritoneal Nebulization of Saline",TERMINATED,There was insuficient recruitment in two centers,PHASE3,INTERVENTIONAL,130,Postoperative Pain,"Ropivacaine 150 mg, saline 15 ml","DRUG, DRUG",Postoperative pain,2011-09,2012-12,San Gerardo Hospital,OTHER
NCT04106362,"Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma",Randomized Phase II Trial of Radiotherapy With Concurrent Cisplatin +/- Concurrent Cetuximab for HPV-Positive Oropharyngeal Squamous Cell Carcinoma (OPSCC) in KRAS-Variant Patients,TERMINATED,low enrollment,PHASE2,INTERVENTIONAL,1,"Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, KRAS Protein Variant, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Cetuximab, Cisplatin","BIOLOGICAL, DRUG, OTHER, OTHER, RADIATION",Overall survival (OS),2020-01-14,2023-05-23,Jonsson Comprehensive Cancer Center,OTHER
NCT03059888,Trial of Orencia in Patients With Myasthenia Gravis,Pilot Trial of Orencia in Myasthenia Gravis Patients Inadequately Responsive to Conventional Immunotherapy,TERMINATED,Mutual decision of sponsor and investigator due to logistical challenges,EARLY_PHASE1,INTERVENTIONAL,6,Myasthenia Gravis,Abatacept Injection,DRUG,"Subjective Composite Score of Myasthenia Gravis (MG) Severity, Objective Composite Score of Myasthenia Gravis (MG) Severity, Muscle Strength (Dynamometry)",2017-04-12,2019-07-15,Johns Hopkins University,OTHER
NCT04157335,Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID),"A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Benralizumab in Patients With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)",TERMINATED,The study has a double-blind period and an open-label period. The study did not meet its primary endpoints after the primary LSLV and the decision was taken to terminate the study early.,PHASE3,INTERVENTIONAL,293,"Nasal Polyposis, Eosinophilic Chronic Rhinosinusitis","Benralizumab 30 mg, Matched placebo","BIOLOGICAL, BIOLOGICAL","Nasal Polyp Burden, Patient-reported Nasal Blockage (NB)",2019-11-25,2025-04-07,AstraZeneca,INDUSTRY
NCT05908617,Impact of Video Discharge Instructions on Heart Failure Patient's Knowledge,Heart Failure Patient Education Using Video and Paper Discharge Instructions,WITHDRAWN,Per PI this QI/QA resident project was not initiated. Record should be deleted.,NA,INTERVENTIONAL,0,Heart Failure,,OTHER,Change in Heart Failure Knowledge Score,2018-05-01,2018-08-07,Yasmeen Golzar,OTHER_GOV
NCT06073340,The Longitudinal Study of Stimulant Use Disorder,Observational Longitudinal Study of Individuals With Stimulant Use Disorder: Research and Development of a Biosignature,TERMINATED,Funding,,OBSERVATIONAL,72,"Stimulant Use, Stimulant-Related Disorder, Healthy",,,Stimulant Use,2023-11-16,2025-03-31,University of Texas Southwestern Medical Center,OTHER
NCT04511650,Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019,"Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Escalation and Proof-of-Concept Study to Evaluate the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019",TERMINATED,"After completion of Step 1 Part 1, the Sponsor discontinued the study based on challenges associated with recruiting and monitoring patients in the current pandemic environment.",PHASE2,INTERVENTIONAL,31,"COVID-19, Acute Respiratory Distress Syndrome (ARDS)","Razuprotafib Subcutaneous Solution, Placebo Subcutaneous Solution","DRUG, DRUG",Number and Percent of Subjects Who Were Alive and Free of Respiratory Failure Prior to Day 7 and Day 28,2020-10-21,2021-02-26,"EyePoint Pharmaceuticals, Inc.",INDUSTRY
NCT01620268,"An Open-Label, Study to Treat Patients With Renal Allograft and Polyoma BK Viruria","An Open-Label, Phase 2 Study to Treat Patients With Renal Allograft and Polyoma BK Viruria to Prevent Polyoma BK Viremia, Polyoma BK Nephropathy and Renal Allograft Rejection",TERMINATED,Lack of recruitment,PHASE2,INTERVENTIONAL,24,"Viruria, Viremia",Leflunomide and orotic acid,DRUG,Clearance of viruria,2012-07,2018-06,Changzheng-Cinkate,INDUSTRY
NCT04989218,Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma (ICC),An Open-label Window of Opportunity Trial to Evaluate the Activity of Durvalumab (MEDI4736) and Tremelimumab With Platinum-based Chemotherapy (Gemcitabine and Cisplatin) in Intrahepatic Cholangiocarcinoma (ICC),TERMINATED,Slow accrual and study sponsor decision.,"PHASE1, PHASE2",INTERVENTIONAL,1,Cholangiocarcinoma,Novel combination of chemotherapy and immunotherapy,DRUG,Objective Response Rate,2023-01-30,2024-05-01,University of Alabama at Birmingham,OTHER
NCT00427297,"Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya","Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya (6-12 Month RCT)",TERMINATED,There is no longer equipoise. DSMB recommended termination.,PHASE3,INTERVENTIONAL,34,HIV Infections,"AZT/3TC/NVP (zidovudine/lamivudine/nevirapine), d4T/3TC/NVP (stavudine/lamivudine/nevirapine), AZT/3TC/ABC (zidovudine/lamivudine/abacavir), d4T/3TC/ABC (stavudine/lamivudine/abacavir), ddI/ABC/LPV/r (didanosine/abacavir/lopinavir-ritonavir), ABC/ ddI or TDF / NVP or EFV (abacavir / didanosine or tenofovir / nevirapine or efavirenz), ABC/3TC/NVP (abacavir/lamivudine/nevirapine)","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG","Incidence of Mortality, Immunologic Failure, Viral Failure",2007-09,2009-12,University of Washington,OTHER
NCT03110510,FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study,SAMSUNG MEDICAL CENTER,WITHDRAWN,institution problem,PHASE2,INTERVENTIONAL,0,Biliary Tract Cancer,"Fluorouracil, Irinotecan Hydrochloride, leucovorin calcium","DRUG, DRUG, DRUG",Overall Overall Response Rate,2019-09-06,2019-09-06,Samsung Medical Center,OTHER
NCT01222013,Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+),Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+),SUSPENDED,"Study was suspended before recruitment, due to logistic issues.",PHASE2,INTERVENTIONAL,20,Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+),Imatinib Mesylate,DRUG,"Evaluate the efficacy, through molecular response and event-free survival, about the use of Imatinib in conjunction with chemotherapy after BFM ""like"" Induction in children with ALL Ph+.",,,Renato Melaragno,OTHER
NCT03960060,A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors,"Evaluation of CAR (Chimeric Antigen Receptor) Modified Autologous T Cell CCT301-59 in Patients With Recurrent or Refractory Solid Tumors on the Basis of Safety, Tolerability and Anti-tumor Activity Study.",TERMINATED,Adjustment of study strategy,PHASE1,INTERVENTIONAL,9,"Solid Tumor, Soft Tissue Sarcoma, Gastric Cancer, Pancreatic Cancer, Bladder Cancer",CCT301-59,BIOLOGICAL,"Safety of CCT301-59 CAR T cell therapy, Efficacy of CCT301-59 CAR T cell therapy, Kinetics of CAR T cells",2019-05-16,2023-06-30,"Shanghai PerHum Therapeutics Co., Ltd.",INDUSTRY
NCT00241462,Faslodex Observations During Regular Use by Advanced Mammacarcinoma Patients,Faslodex Observations During Regular Use by Advanced Mammacarcinoma Patients,TERMINATED,Due to poor patient enrollment,,OBSERVATIONAL,150,Breast Cancer,,,,2005-06,2009-12,AstraZeneca,INDUSTRY
NCT00827762,Behavioral Effects of Kuvan in Children With Mild Phenylketonuria,Behavioral Effects of Kuvan in Children With Mild Phenylketonuria,TERMINATED,Too few participants recruited within timeframe,,OBSERVATIONAL,2,Phenylketonuria,Kuvan,DRUG,Behavior Rating Inventory of Executive Function (BRIEF),2009-01,2010-01,Washington University School of Medicine,OTHER
NCT05161468,"Platelet-rich Plasma, Corticosteroid, or Lidocaine for Acromioclavicular Joint Pain",Bayesian Non-inferiority Trial of Injection Therapies for Acromioclavicular Joint Pain: a Randomized Clinical Trial,TERMINATED,Funding limitation did not allow the trial to run to completion,PHASE4,INTERVENTIONAL,34,Acromioclavicular Sprain,"Lidocaine injection, Corticosteroid Injection, Protein Rich Plasma(PRP) Injection","DRUG, DRUG, DRUG",Patient Reported Outcomes Measurement Information Systems (PROMIS) - Physical Function Scale Computer Adapted Test (PF-CAT),2021-08-12,2025-05-12,Brooke Army Medical Center,FED
NCT01161368,A Study Evaluating the Efficacy and Safety of Lapatinib + Vinorelbine in ErbB2 Positive Metastatic Breast Cancer Patients,A Phase II Study Evaluating the Efficacy and Safety of Lapatinib + Vinorelbine in ErbB2 Positive Metastatic Breast Cancer Patients Pretreated With Chemotherapy or Hormonal Treatment in Combination With Lapatinib for Metastatic Disease,TERMINATED,poor recruitment,PHASE2,INTERVENTIONAL,9,Metastatic Breast Cancer,"Lapatinib, Vinorelbine",DRUG,Progressive Free Survival,2010-09,2014-05,Central European Cooperative Oncology Group,OTHER
NCT00655668,A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma,"A Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid®) in Subjects With Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma",TERMINATED,Decision not to pursue as single agent in the study population.,PHASE2,INTERVENTIONAL,54,T-cell Non-Hodgkin's Lymphoma,Lenalidomide,DRUG,Participants Categorized by Best Response as Determined by Investigator,2008-03-01,2010-04-01,Celgene,INDUSTRY
NCT05539950,Cardiopulmonary Rehabilitation in Post-acute COVID-19 Syndrome,Cardiopulmonary Rehabilitation in Post-acute COVID-19 Syndrome,WITHDRAWN,Unable to get funds,NA,INTERVENTIONAL,0,Post Acute COVID-19 Syndrome,,"OTHER, OTHER",Changes in Cardiopulmonary exercise testing (CPET),2022-10-01,2024-12-31,Taipei Medical University Shuang Ho Hospital,OTHER
NCT03081897,Regional Anaesthesia and Substance P in Head and Neck Cancer,Influence of Regional Anaesthesia on the Expression of Substance P During Unilateral Neck Dissection Due to Head and Neck Cancer,SUSPENDED,for organizational reasons,NA,INTERVENTIONAL,40,Head and Neck Cancer,"SPRANC Block group, SPRANC Control group","DRUG, DRUG",Expression of Substance P,2016-07,2023-07-01,"Charite University, Berlin, Germany",OTHER
NCT00952510,Maastricht Neck Study: Cervical Range of Motion in Whiplash Patients,MaNeS (Maastricht Neck Study): Development of Chronic Disability in Neck Pain Patients After a Motor Vehicle Accident,TERMINATED,Respond was to low.,,OBSERVATIONAL,100,Whiplash Injuries,,,Active- and passive cervical range of motion measured with the 3Space InsideTrak HP system.,2009-09,2010-12,Maastricht University Medical Center,OTHER
NCT02781220,Implications for Management of PET Amyloid Classification Technology in the Imaging Dementia(IDEAS) Trial,Implications for Management of PET Amyloid Classification Technology in the Imaging Dementia(IDEAS) Trial,TERMINATED,IRB Study Closure - No HRPP Progress Update,,OBSERVATIONAL,69,"Mild Cognitive Impairment, Dementia, Alzheimer's Disease",,,Percentage of change in care practices after amyloid PET scan,2016-07,2023-06-10,University of Utah,OTHER
NCT00590720,A Phase 2A Study to Evaluate the Safety and Effect on Exercise Challenge Testing of MEDI-528 in Adults With Asthma,"A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Effect on Exercise Challenge Testing of Multiple Fixed Subcutaneous Doses of MEDI-528, A Humanized Anti-Interleukin-9 Monoclonal Antibody, in Adults With Stable Asthma and Exercise-Induced Bronchoconstriction",TERMINATED,Study is replaced by MI-CP198 per CPM.,PHASE2,INTERVENTIONAL,11,Asthma,MEDI528 50 mg,"BIOLOGICAL, OTHER","Incidence of Adverse Events, Incidence of Serious Adverse Events",2008-03,2009-10,MedImmune LLC,INDUSTRY
NCT02649920,Comparing the Efficiency of Cervical Ripening BALLoon (Cook) to the DINOprostone (Propess) for the Cervical Maturation in Case of Unfavorable Cervix (Bishop <6) in the Population of Obese Pregnant Women (BMI >= 30 kg/m²),"Pilot, Comparative, Not Randomized, Two Centers Study Comparing the Efficiency of Cervical Ripening BALLoon (Cook) to the DINOprostone (Propess) for the Cervical Maturation in Case of Unfavorable Cervix (Bishop <6) in the Population of Obese Pregnant Women (BMI >= 30 kg/m²)",TERMINATED,Delayed inclusion,NA,INTERVENTIONAL,2,Delivery,Dinoprostone,"DEVICE, DRUG",Bishop Score After 24 Hours of Maturation,2016-06,2016-11,Centre Hospitalier Departemental Vendee,OTHER
NCT04545320,Effectiveness of High-intensity Interval Training (HIIT) Versus Moderate-intensity Continuous Training (MICT) in Reducing Visceral Fat in Adults With Central Obesity,"Effectiveness of Once-a-week High-intensity Interval Training (HIIT) Versus Moderate-intensity Continuous Training (MICT) in Reducing Visceral Fat in Adults With Central Obesity, a Pilot Randomized Controlled Trial.",WITHDRAWN,No participants were enrolled in this study due to the COVID-19 pandemic.,NA,INTERVENTIONAL,0,Central Obesity,,"BEHAVIORAL, BEHAVIORAL, BEHAVIORAL",Visceral fat,2020-09-01,2022-10-31,The University of Hong Kong,OTHER
NCT00469820,"Vaccine Therapy With or Without Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Multiple Myeloma Undergoing Donor Stem Cell Transplant",Posttransplant Immunotherapy With Donor Lymphocyte Infusions and Autologous Tumor Vaccines After HLA-Matched Transplant,TERMINATED,low accrual,PHASE1,INTERVENTIONAL,1,"Leukemia, Multiple Myeloma and Plasma Cell Neoplasm","autologous tumor cell vaccine, peripheral blood lymphocyte therapy","BIOLOGICAL, BIOLOGICAL","Time to relapse, Overall survival, Safety and tolerability, in terms of incidence of graft-versus-host disease and local/systemic toxicities, Maximum tolerated dose of donor lymphocytes",2007-04,2010-03,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,OTHER
NCT04803123,Window Trial to Evaluate Molecular Response to PI3K Inhibition With Copanlisib in r/r Adult B-cell ALL,Window Trial to Evaluate Molecular Response to PI3K Inhibition With Copanlisib in Relapsed or Refractory Adult B-cell Acute Lymphoblastic Leukemia,TERMINATED,Sponsor halted clinical development of study drug,EARLY_PHASE1,INTERVENTIONAL,3,"Leukemia, Acute Lymphocytic",Copanlisib,DRUG,Evaluate the effect of copanlisib exposure on alpha-6 integrin expression levels in leukemic blasts using flow cytometry.,2021-06-21,2023-04-26,"Dorothy Sipkins, MD, PhD",OTHER
NCT04050579,OPIE in the Thin Interventricular Septum,A Single Center Trial of On-pump Intracardiac Echocardiography (OPIE) in the Thin Interventricular Septum,WITHDRAWN,"Study was determined to be focused on Quality Assurance (QA) and Quality Improvement (QI), rather than research, based on its primary purpose and activities. Study was closed prior to enrollment.",NA,INTERVENTIONAL,0,Hypertrophic Cardiomyopathy,,DEVICE,correlations,2020-09-15,2025-05-30,NYU Langone Health,OTHER
NCT03821896,Piloting Conversation Cards for Adolescents,"Feasibility, User Experiences, and Preliminary Effectiveness of Conversation Cards for Adolescents, a Patient-centered Communication and Behavior Change Tool: a Pragmatic, Pilot Randomized Controlled Trial",TERMINATED,Ongoing COVID-19 restrictions and very low (in-person) clinical activity prevented participant recruitment.,NA,INTERVENTIONAL,31,"Adolescent Obesity, Life Style, Health Behavior, Health Communication, Primary Health Care",,"BEHAVIORAL, BEHAVIORAL","Feasibility outcomes for resource, management, and scientific assessments per open-ended questions outlined by Tickle-Degnen's (2013)",2019-03-15,2022-07-07,University of Alberta,OTHER
NCT02465762,UltraShape Device Using the U-Sculpt/VDF Transducer for Flanks Fat,Clinical Study to Evaluate the Safety and Efficacy of the UltraShape Device Using the U-Sculpt/VDF Transducer for Flanks Fat and Circumference Reduction,SUSPENDED,Study design was amended to include a control - reregistered as NCT02465775,NA,INTERVENTIONAL,60,Unwanted Flanks Fat,,DEVICE,Efficacy flanks fat reduction,2015-08,2017-07,Syneron Medical,INDUSTRY
NCT00187746,Effect of Age on the Renal Clearance of Adefovir,Effect of Age on the Renal Clearance of Adefovir,WITHDRAWN,Budget exceeded for project.,PHASE4,INTERVENTIONAL,0,Other Conditions That May Be A Focus of Clinical Attention,Adefovir dipivoxil,DRUG,Renal Clearance of adefovir,2005-08,2008-04,"University of California, San Francisco",OTHER
NCT03012646,Safety and Tolerability of Inhaled Treprostinil in Adult PH Due to COPD,"A Prospective, Multicenter, Single-arm Study to Evaluate the Safety and Tolerability of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease",WITHDRAWN,Business decision,PHASE2,INTERVENTIONAL,0,"Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease",Inhaled Treprostinil,DRUG,Incidence of Adverse Events Among Participants through 48 Weeks,2017-04,2019-04,United Therapeutics,INDUSTRY
NCT03259308,Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis,"A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302)",TERMINATED,Sponsor decision to discontinue the SHP647 (ontamalimab) clinical trial development program for inflammatory bowel diseases (IBD) early.,PHASE3,INTERVENTIONAL,279,Ulcerative Colitis,"Ontamalimab, Placebo","DRUG, DRUG",Number of Participants With Remission Based on Composite Score at Week 12,2017-12-05,2020-10-06,Shire,INDUSTRY
NCT06301308,A Novel Application of 2% Lidocaine Injection for Male Rigid cycstoscopy-a Patient-blinded Randomised Trial,A Novel Application of 2% Lidocaine Injection for Male Rigid cycstoscopy-a Patient-blinded Randomised Trial,WITHDRAWN,"The standard measures of anaesthesia in cystoscopy are not uniform internationally, and given this, we were unable to recruit the first participant in the study.",PHASE3,INTERVENTIONAL,0,Bladder Cancer,"Intraurethral lidocaine gel alone, Intraurethral lidocaine gel + lidocaine 2% injection, intraurethral lidocaine gel + liquid paraffinl","DRUG, DRUG, DRUG",Access the pain score using the Visual Analogue Scale (VAS),2023-10-01,2024-02-29,Second Xiangya Hospital of Central South University,OTHER
NCT06134817,Geniculate Artery Embolization for Treatment of Persistent Knee Pain Post Total Knee Arthroplasty,Prospective Pilot Study on Geniculate Artery Embolization for Treatment of Persistent Knee Pain Post Total Knee Arthroplasty,TERMINATED,Departure of PI.,NA,INTERVENTIONAL,2,Knee Pain,,DEVICE,Change in Knee Injury and Osteoarthritis Outcome Score (KOOS) Pain Score From Baseline to Month 6,2024-05-24,2025-02-12,NYU Langone Health,OTHER
NCT03766750,Efficacy and Safety of Lima Association in the Control of Type II Diabetes Mellitus.,"Randomized, Double-blind, Multicenter, National, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Lima Association in the Control of Type II Diabetes Mellitus",WITHDRAWN,Sponsor decision,PHASE3,INTERVENTIONAL,0,Type2 Diabetes Mellitus,"LIMA association, Tradjenta, Forxiga","DRUG, DRUG, DRUG",Reduction of glycated hemoglobin levels measured between the first visit and the last visit.,2021-12,2023-11,EMS,INDUSTRY
NCT04692389,Jalosome® Soothing Gel Efficacy Grade 2 or 3 Radiodermatitis.,"The Efficacy of the Medical Device Jalosome® Soothing Gel in the Healing of Grade of 2 or 3 Radiodermatitis, Pain Intensity Reduction, as Well as Improvement of QoL in Oncology Patients: a Pilot Study.",WITHDRAWN,difficulties in patients recruitment,NA,INTERVENTIONAL,0,"Radiodermatitis, Oncology, Quality of Life, Pain",,DEVICE,Grade 2 or 3 radiodermatitis healing,2021-02-01,2023-03-31,Welcare Industries SpA,INDUSTRY
NCT01643291,Ultrasound Use for Difficult Lumbar Punctures in Pediatric Oncology Patients,Ultrasound Imaging Facilitates Lumbar Punctures in Pediatric Oncology Patients With Difficult Surface Landmarks and/or a History of Difficult Lumbar Puncture,TERMINATED,We were unable to recruit subjects for this study.,NA,INTERVENTIONAL,3,Leukemia,,PROCEDURE,Number of punctures,2012-07,2014-05,Nationwide Children's Hospital,OTHER
NCT03303313,"A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome","A Phase 2, Open Label, Multicenter Study of ALN-CC5 Administered Subcutaneously in Adult Patients With Atypical Hemolytic Uremic Syndrome",WITHDRAWN,Study terminated early due to lack of enrollment.,PHASE2,INTERVENTIONAL,0,Atypical Hemolytic Uremic Syndrome,Cemdisiran,DRUG,The effect of Cemdisiran on platelet count,2017-09-19,2018-09-12,Alnylam Pharmaceuticals,INDUSTRY
NCT04586920,A Study of LY3509754 in Healthy Non-Japanese and Japanese Participants,"A Phase 1, Randomized, Participant-and Investigator-Blind, Placebo-Controlled, Single-and Multiple-Ascending Dose, Drug-Drug Interaction and Food Effect Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3509754 in Healthy Non-Japanese and Japanese Participants",TERMINATED,Terminated due to safety findings,PHASE1,INTERVENTIONAL,104,Healthy,"LY3509754, Placebo, Itraconazole, Midazolam","DRUG, DRUG, DRUG, DRUG",Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration,2020-10-20,2022-10-14,Eli Lilly and Company,INDUSTRY
NCT05242510,Evaluation of Exotropia After Patching the Eye or After Prism Adaptation,Divergence Excess/Simulated Divergence Excess Exotropia (DESDEE),TERMINATED,lack of ability to enroll from other sites,NA,INTERVENTIONAL,1,Exotropia,,"PROCEDURE, PROCEDURE","Percent of participants reclassified as divergence excess exotropia, Percent of participants reclassified as simulated divergence excess exotropia",2024-08-27,2024-09-18,University of Rochester,OTHER
NCT00014313,Chemotherapy in Treating Patients With Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor,A Phase II Study to Evaluate the Role of Weekly Cisplatin With Oral Etoposide in Ewing's Sarcoma and Primitive Neuroectodermal Tumor (PNET) With Bone and/or Bone Marrow Metatstatic Disease,TERMINATED,low accrual,PHASE2,INTERVENTIONAL,3,Sarcoma,"cisplatin, etoposide","DRUG, DRUG",,2001-01,,European Organisation for Research and Treatment of Cancer - EORTC,NETWORK
NCT03777982,Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT,A Randomized Phase III Study - Conventional Androgen Deprivation Therapy With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and Androgen Deprivation Therapy,TERMINATED,PI is terminating the study due to slow/low accrual,PHASE3,INTERVENTIONAL,12,Prostate Cancer,"Prednisone, Apalutamide, Abiraterone Acetate, LHRH Agonist or Antagonist","DRUG, DRUG, DRUG, DRUG",Metastasis Free Survival,2020-04-20,2024-02-13,Dana-Farber Cancer Institute,OTHER
NCT03657082,Effects of PEP on IC During IT in Patients With COPD,Effects of Positive Expiratory Pressure on Inspiratory Capacity and Dyspnea in Patients With COPD During Exercise,TERMINATED,No financial support found,NA,INTERVENTIONAL,1,Chronic Obstructive Pulmonary Disease,,"DEVICE, DEVICE",Change in inspiratory capacity,2018-09-15,2021-12-30,Cliniques universitaires Saint-Luc- Université Catholique de Louvain,OTHER
NCT04435782,A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance Imaging,"A Prospective, Multicenter, Single-Arm, Open-Label, Phase 4 Study of the Effects of Selexipag on Right Ventricular Remodeling in Pulmonary Arterial Hypertension Assessed by Cardiac Magnetic Resonance Imaging",TERMINATED,The Sponsor decided to prematurely terminate the study due to the lower-than-expected recruitment rate.,PHASE4,INTERVENTIONAL,9,Pulmonary Arterial Hypertension,JNJ-67896049,DRUG,Change From Baseline to Week 26 in Right Ventricular Stroke Volume (RVSV) Assessed by Pulmonary Artery Flow Magnetic Resonance Imaging (MRI),2021-07-07,2023-07-28,Actelion,INDUSTRY
NCT02243124,A Study of Aezea® (Cenersen) in Transfusion Dependent Anemia Associated With Myelodysplastic Syndrome (MDS),A Study of Aezea® (Cenersen) in Transfusion Dependent Anemia Associated With Myelodysplastic Syndrome,TERMINATED,Company went out of business,PHASE1,INTERVENTIONAL,9,Myelodysplastic Syndromes,"cenersen, Dexamethasone","DRUG, DRUG",1) Interventional Drug Safety: dose limiting toxicities (DLT) of cenersen for each of three increasing dose levels as stipulated by the protocol in patients with lower risk MDS defined as low or intermediate-1 risk by IPSS.,2014-09,2015-12-31,"Eleos, Inc.",INDUSTRY
NCT04041024,Decision-making and Risk-taking in Bulimia,"Identification of Decision Making Processes in Food, Risky and Steal Situations in Bulimia Nervosa",TERMINATED,The PI has left the hospital and no one is replacing him,NA,INTERVENTIONAL,59,Bulimia Nervosa,,"OTHER, OTHER",oxygen variation in the brain,2020-10-28,2021-06-15,Hôpital le Vinatier,OTHER
NCT00677924,Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal Cancer,"A Dose-Escalation, Randomized Phase I/II Trial of Zalutumumab - a Human Monoclonal Anti-EGF Receptor Antibody - With or Without Irinotecan Chemotherapy in Cetuximab Refractory Colorectal Cancer Patients Who Have Failed Standard Chemotherapy and Progressed During or Within 3 Months of Stopping Cetuximab-Based Therapy",TERMINATED,Due to changes in portfolio review,"PHASE1, PHASE2",INTERVENTIONAL,9,Colorectal Cancer,Zalutumumab,DRUG,Number of Participants With Adverse Events (AEs),2008-04,2009-04,Genmab,INDUSTRY
NCT03054623,Hemodynamic Assessment of Distal Revascularization Interval Ligation,Prospective Hemodynamic Assessment of Distal Revascularization Interval Ligation,TERMINATED,PI Left Institution,,OBSERVATIONAL,4,"Steal Syndrome, Chronic Kidney Diseases, Arterio-Venous Fistula",,PROCEDURE,Difference in forearm pressures,2016-09-20,2018-08-11,University of South Florida,OTHER
NCT04389359,PROphylaxis for paTiEnts at Risk of COVID-19 infecTion,PROphylaxis for paTiEnts at Risk of COVID-19 infecTion (PROTECT): a Basket Trial of Prophylactic Interventions Amongst At-risk Patients,WITHDRAWN,Regulatory approvals not received,"PHASE2, PHASE3",INTERVENTIONAL,0,COVID-19,Hydroxychloroquine Sulfate 200 MG,DRUG,Time to confirmed diagnosis of COVID-19,2020-09,2025-08,Cambridge University Hospitals NHS Foundation Trust,OTHER
NCT00859859,Vagus Nerve Stimulation in Rheumatoid Arthritis,Vagus Nerve Stimulation in Rheumatoid Arthritis,TERMINATED,The protocol was terminated early (prior to complete enrollment) after interim analysis proved data to be statistically insignificant,PHASE1,INTERVENTIONAL,23,Rheumatoid Arthritis,,DEVICE,"Assessment of short-term and medium-term effects of vagus nerve intervention with endpoints such as autonomic function, cytokine synthesis, inflammatory markers as well as disease activity score and global health measurement in subjects",2006-10,2009-02,Northwell Health,OTHER
NCT02462759,A Study to Assess the Safety and Tolerability of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA).,"A Phase 2, Randomized, Double-blind, Sham-procedure Controlled Study to Assess the Safety and Tolerability and Explore the Efficacy of ISIS 396443 (BIIB058) Administered Intrathecally in Subjects With Spinal Muscular Atrophy Who Are Not Eligible to Participate in the Clinical Studies ISIS 396443-CS3B or ISIS 396443-CS4",TERMINATED,The study was terminated early to roll over participants to open label extension study NCT02594124.,PHASE2,INTERVENTIONAL,21,Spinal Muscular Atrophy,Nusinersen,"DRUG, PROCEDURE","Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs), Number of Participants With Change From Baseline in Clinical Laboratory Parameters, Number of Participants With Change From Baseline in Electrocardiograms (ECGs), Number of Participants With Change From Baseline in Vital Signs, Change From Baseline in Head Circumference, Change From Baseline in Chest Circumference, Change From Baseline in Arm Circumference, Change From Baseline in Weight for Age, Change From Baseline in Weight, Change From Baseline in Head to Chest Circumference (HCC) Ratio, Change From Baseline in Body Length, Number of Participants With Change From Baseline in Neurological Examination Outcomes, Number of Participants With Change From Baseline in Activated Partial Thromboplastin Time [aPTT], Number of Participants With Change From Baseline in Partial Thromboplastin Time [PTT], Number of Participants With Change From Baseline in International Normalized Ratio [INR]), Number of Participants With Presence of Urine Total Protein Post-baseline",2015-08-19,2018-09-24,Biogen,INDUSTRY
NCT02501759,Transrectal MRI-Guided Biopsy in Identifying Cancer in Patients With Suspected Prostate Cancer,Pilot Study of Transrectal Multiparametric MRI-Guided Biopsy: Role in Prostate Cancer Evaluation,TERMINATED,Low enrollment and funding loss.,NA,INTERVENTIONAL,2,"Health Status Unknown, Prostate Carcinoma",,"PROCEDURE, RADIATION, PROCEDURE, PROCEDURE, PROCEDURE","Proportion of MRI-guided Biopsies That Demonstrate a Higher Gleason Score Than Contemporaneous TRUS Guided Biopsy, Sensitivity of MRI-guided Biopsy, Sensitivity of TRUS-guided Biopsy",2015-05,2017-02-10,OHSU Knight Cancer Institute,OTHER
NCT06374680,C3 Laminectomy With Cervical Laminoplasty,Randomized Controlled Trial: Comparison of Radiological and Axial Pain Outcome Between C3-6 Laminoplasty and C3 Laminectomy With Cervical Laminoplasty,WITHDRAWN,This is because the same research has already been done.,,OBSERVATIONAL,0,Neck Pain,,PROCEDURE,neck pain,2017-03-20,2021-12-31,Seoul National University Hospital,OTHER
NCT00229879,Rare Tumor Case Review,Rare Tumor Case Review,TERMINATED,sufficient data gathered to support conclusion,,OBSERVATIONAL,,"Intrapericardial Teratoma Tumor, Tumors",,,,2004-12,2006-09,Children's Healthcare of Atlanta,OTHER
NCT02946996,Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients Receiving Androgen Deprivation Therapy,Randomized Phase II Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients Receiving Androgen Deprivation Therapy,TERMINATED,Investigator retired from clinical practice prior to enrollment goal being met.,PHASE2,INTERVENTIONAL,41,Prostate Cancer,Metformin,"DRUG, OTHER",AGE Level Reduction,2016-12-28,2024-08-19,Medical University of South Carolina,OTHER
NCT05573035,A Study to Investigate LYL845 in Adults With Solid Tumors,A Phase 1 Study to Assess the Safety and Efficacy of LYL845 in Adults With Relapsed and/or Refractory Metastatic or Locally Advanced Melanoma and Selected Solid Tumor Malignancies,TERMINATED,Pipeline Reprioritization,PHASE1,INTERVENTIONAL,39,"Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer",LYL845,BIOLOGICAL,"Incidence of dose-limiting toxicities (DLTs), Incidence of treatment-emergent adverse events (TEAEs), Severity of treatment-emergent adverse events (TEAEs), Determine recommended Phase 2 Dose Range (RP2DR)",2022-12-19,2025-01-09,"Lyell Immunopharma, Inc.",INDUSTRY
NCT02381925,Multicenter Registry Comparing Preoperative Imaging for Primary Hyperparathyroidism,Multicenter Registry Comparing Preoperative Imaging for Primary Hyperparathyroidism,WITHDRAWN,The study never opened due to funding issues,,OBSERVATIONAL,0,Parathyroid Adenoma,,,diagnostic performance of imaging,,2016-12,Duke University,OTHER
NCT03976076,A Study of Orally Administered JBPOS0101 in Refractory Infantile Spasms Patients,"A Phase 2 Study to Assess the Safety, Tolerability, Exploratory Efficacy, and Pharmacokinetics of Orally Administered JBPOS0101 for Refractory Infantile Spasms Patients",TERMINATED,Difficulty with patient recruitment due to COVID-19,PHASE2,INTERVENTIONAL,16,Refractory Infantile Spasms,JBPOS0101,DRUG,Number of Participants With Treatment Emergent Adverse Events (TEAEs),2020-04-15,2021-12-10,"Bio-Pharm Solutions Co., Ltd.",INDUSTRY
NCT02527876,"Exercise, Activity and Smoking in Young Adults",Exercise to Promote Quit Attempts in Young Adults,WITHDRAWN,Researcher left University,NA,INTERVENTIONAL,0,"Exercise, Delayed Control",,"BEHAVIORAL, BEHAVIORAL, BEHAVIORAL, DEVICE",Number of Participants With Increase in Physical Activity as assessed by FitBit,2015-08,2016-10,University of Minnesota,OTHER
NCT01326676,Polypill Effects on Sub Clinical Atherosclerosis (PESCA) Trial,PESCA - A Randomised Controlled Trial of a Cardiovascular Polypill Treatment Strategy Compared With Usual Care on Carotid Intima-media Thickness in Individuals at High Risk of Cardiovascular Disease,WITHDRAWN,Funding never attained,PHASE3,INTERVENTIONAL,0,Cardiovascular Disease,"Polypill: Red Heart Pill, Usual medication","DRUG, DRUG","change in intima-media (artery wall) thickness in the common carotid artery, change in intima-media (artery wall) thickness and extent of atherosclerotic plaques in the carotid artery bifurcation, change in central aortic blood pressure",2011-02,2012-09,Imperial College London,OTHER
NCT04139668,Vivitrol Treatment for Cannabis Use Disorder,Vivitrol Associated With Behavioural-Relapse Prevention Strategy as Treatment for Cannabis Use Disorder,TERMINATED,Funder contract terminated,PHASE2,INTERVENTIONAL,1,Cannabis Use Disorder,Naltrexone 380 MG [Vivitrol],"DRUG, BEHAVIORAL","Dropouts Due to Serious Adverse Events, Dropouts Due to Serious Adverse Events, Cannabis Abstinence, Cannabis Abstinence",2021-06-09,2022-06-13,Centre for Addiction and Mental Health,OTHER
NCT04258150,"Ipilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic Cancer","TRIPPLE-R: Phase 2 Study in Pretreated Patients With Advanced Pancreatic Cancer to Assess Efficacy of Ipilimumab, Nivolumab and Tocilizumab in Combination With Radiation",TERMINATED,primary endpoint was not met,PHASE2,INTERVENTIONAL,26,Pancreatic Cancer,"Nivolumab, Ipilimumab, Tocilizumab","DRUG, DRUG, DRUG, RADIATION",Objective response rate (ORR),2020-04-16,2021-11-23,Herlev Hospital,OTHER
NCT01758991,Improving SWAllowing After Stroke With Transcranial Direct Current Stimulation,Therapeutic Impact of tDCS on Dysphagia in the Acute Phase of Stroke / Impact thérapeutique de la tDCS Sur la Dysphagie en Phase Aigue de l'Accident Vasculaire cérébral,TERMINATED,lack of recruitment,NA,INTERVENTIONAL,100,"Acute Stroke, Dysphagia",,DEVICE,"VideoFluoroscopy (VFSS), Fiberoptic Endoscopic Evaluation of Swallowing (FEES)",2013-01,2023-05-08,University Hospital of Mont-Godinne,OTHER
NCT02557191,"Biomarkers, Neurodevelopment and Preterm Infants",Biomarkers to Predict Neurodevelopmental Outcomes in Very Preterm Infants,TERMINATED,Difficulty recruiting patients,,OBSERVATIONAL,4,"Preterm, Neurodevelopmental Disorder, Epigenetic Changes",,OTHER,Brain white matter development,2015-04,2018-12,Montefiore Medical Center,OTHER
NCT05942690,Osteopathic Intervention in Professional Handball Players,Ultrasound Evaluation of Diaphragmatic Contractility After Manual Osteopathic Intervention in Professional Handball Players: a Pilot Study,TERMINATED,no more possibly to include subjects (subject unavailability),NA,INTERVENTIONAL,20,Osteopathia,,PROCEDURE,Variation in the fraction of diaphragm thickening (right and left) measured on ultrasound before and after the procedure,2023-07-30,2023-07-31,"University Hospital, Toulouse",OTHER
NCT00805597,Clinical Trial of Postmastectomy Radiotherapy in Breast Cancer With One to Three Positive Nodes,A Phase Ⅲ Randomized Clinical Trial of Postmastectomy Radiotherapy in Breast Cancer With One to Three Positive Nodes,TERMINATED,The recuiting was to slow to complete the study,PHASE3,INTERVENTIONAL,40,Breast Cancer,,"RADIATION, RADIATION",overall survival,2008-06,2012-02,Chinese Academy of Medical Sciences,OTHER
NCT04268160,GPx Activity in Subjects With Aortic Stenosis Undergoing TAVR,Glutathione Peroxidase Activity in Subjects With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement.,WITHDRAWN,Funding issues and closed with the IRB,,OBSERVATIONAL,0,"Glutathione Peroxidase Activity, Aortic Stenosis, Transcatheter Aortic Valve Replacement",,"DIAGNOSTIC_TEST, DIAGNOSTIC_TEST, DIAGNOSTIC_TEST",Level of GPx in blood samples,2020-11,2021-06-15,University of Florida,OTHER
NCT04900324,Intramuscular Injections of Botulinum Toxin in Lateral Pterygoid Muscle in the Treatment of Temporomandibular Dysfunctions: Studying the Interest of MRI Guidance and Ultrasound Guidance,Intramuscular Injections of Botulinum Toxin in Lateral Pterygoid Muscle in the Treatment of Temporomandibular Dysfunctions: Studying the Interest of MRI Guidance and Ultrasound Guidance,TERMINATED,recruitment difficulties,NA,INTERVENTIONAL,4,Mandibular Dysfunction,,"DEVICE, DEVICE",Pain improvement,2021-09-13,2024-02-16,Centre Hospitalier Universitaire de Besancon,OTHER
NCT05599724,PMA-FERTITHEQUE Biocollection,Medical Assistance for Procreation Patient Library Targeting Patients With Idiopathic Infertility or Low Ovarian Reserve Before the Age of 35,TERMINATED,"The study was stopped due to organizational challenges affecting participant enrollment, follow-up, and the handling and routing of study samples.",,OBSERVATIONAL,250,"Infertility, Infertility Unexplained",,OTHER,clinical-biological markers,2022-11-11,2023-04-24,"University Hospital, Brest",OTHER
NCT05695976,GRETeL: Tumor Response to Standard Radiotherapy and TMZ Patients With GBM,A Study for Patients Newly Diagnosed With Glioblastoma Being Treated With Standard Radiotherapy and Temozolomide (TMZ) to Evaluate Tumor Response Via Liquid Biopsies (GRETeL),SUSPENDED,The study is suspended while preplanned interim analysis is being completed.,,OBSERVATIONAL,100,"Glioblastoma, Glioma, Malignant",,,"Median cf/ctDNA concentration at pre- and post-radiation, as well as median change in ct/ctDNA concentration, Median levels of cfDNA collected longitudinally after completion of radiation",2023-04-18,2029-01,Duke University,OTHER
NCT01040208,12 Week Safety Trial of Flibanserin in Depressed Women Taking an SSRI or SNRI With Decreased Sexual Desire and Distress,Safety of Flibanserin Versus Placebo in Women Taking a Selective Serotonin Reuptake Inhibitor or Norepinephrine Serotonin Reuptake Inhibitor With Decreased Sexual Desire,TERMINATED,Study terminated by Sponsor for administrative reasons prior to completion,PHASE3,INTERVENTIONAL,111,"Sexual Dysfunctions, Psychological, Depression","flibanserin 50 mg to 100 mg qhs, flibanserin 100 mg qhs, placebo 2 tablets qhs","DRUG, DRUG, DRUG",The Primary Safety Endpoint is the Occurrence of Adverse Events During the Treatment and Post Treatment Period.,2010-01,2011-01,"Sprout Pharmaceuticals, Inc",INDUSTRY
NCT03540225,Vaginal Progesterone for the Prevention of Preterm Birth in Twins,"Vaginal Progesterone for the Prevention of Preterm Birth in Twins: A Pilot Randomised, Factorial Designed Trial (POPPET)",WITHDRAWN,Fail to sort out the logistics of study drugs due to funding problems,PHASE3,INTERVENTIONAL,0,"Premature Birth, Twin Pregnancy",Progesterone,DRUG,The median gestational age (in days) at delivery,2020-04,2022-12,Chiu Yee Liona Poon,OTHER
NCT02732925,To Compare Conservative Management Vs. Balloon Kyphoplasty in the Treatment of VCFs in Patients With Multiple Myeloma,"Multiple Myeloma Spinal Disease Study; A Multi-centre, Prospective, Single Blinded, Randomized, Controlled Study to Compare Conservative Management Alone Vs. Balloon Kyphoplasty With the Treatment of VCFs in Patients With Multiple Myeloma",TERMINATED,Difficulties with recruitment due to change in referral rates.,NA,INTERVENTIONAL,2,Multiple Myeloma,,"DEVICE, PROCEDURE",the effect of sham procedure & conservative management alone (arm 1) versus balloon kyphoplasty (arm 2) on patient reported pain scores as assessed by VAS (at week 4),2017-06-09,2018-03-28,Royal National Orthopaedic Hospital NHS Trust,OTHER
NCT03563040,Study of Photopheresis in the Treatment of Erythrodermic MF and SS,"A Prospective, Multicenter, Single-Arm Cohort Study of Photopheresis in the Treatment of Erythrodermic MF and SS",WITHDRAWN,Lack of feasibility,PHASE2,INTERVENTIONAL,0,"Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome",Methoxsalen,"DRUG, DEVICE",Success rate of treatment (photopheresis),2020-12-01,2026-06-01,European Organisation for Research and Treatment of Cancer - EORTC,NETWORK
NCT01758289,Post Marketing Observational Study on Paricalcitol IV Administered to Venezuelan Patients,"A Prospective, Multicenter, Six-Month Study on the Effectiveness, Safety and Impact on Health Related Quality of Life (HRQoL) and Depression Symptoms of Paricalcitol Administered to Venezuelan Patients With Chronic Kidney Disease (Stage V) Who Are on Hemodialysis",TERMINATED,Changes in country regulation,,OBSERVATIONAL,105,"Chronic Kidney Disease Stage V, Hemodialysis",,,Percentage of Participants Achieving at Least a 30% Reduction From Baseline in the Levels of Parathyroid Hormone (PTH) at the Final Study Visit,2013-01,2013-11,"AbbVie (prior sponsor, Abbott)",INDUSTRY
NCT05591274,Virtual Reality Technology for Vasectomy Pain Modulation,Modulating Intraoperative Vasectomy Pain Using the SmileyScope Virtual Reality Interface,TERMINATED,Funding,NA,INTERVENTIONAL,120,"Vasectomy, Pain, Postoperative, Anxiety Postoperative",,DEVICE,"Pre-operative Anxiety, Post-operative Anxiety, Subjective Pre-operative Pain, Subjective Post-operative Pain, Post-procedure Satisfaction",2022-11-17,2024-03-28,University of Miami,OTHER
NCT06090318,Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss,A Phase 1b/2Study of Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss (MANTRA-4),WITHDRAWN,Sponsor Decision,"PHASE1, PHASE2",INTERVENTIONAL,0,"Advanced Solid Tumor, CDKN2A, NSCLC, Urothelial Carcinoma Bladder, Melanoma, Pancreas Adenocarcinoma, HNSCC, Renal Cell Carcinoma, Mesothelioma, Gastric Cancer","Milademetan, Atezolizumab","DRUG, DRUG","The number of participants with treatment related AEs meeting DLT-defined criteria assessed by CTCAE v5.0 when receiving milademetan in combination with atezolizumab in patients with advanced solid tumors with HZ CDKN2A loss and WT TP53, The appropriate dose of milademetan in combination with atezolizumab based on the number of participants with DLT-defined adverse events assessed by CTCAE v5.0 criteria, Treatment emergent AE of the identified RP2D of milademetan in combination with atezolizumab in patients with advanced solid tumors with HZ CDKN2A loss and WT TP53",2023-05-19,2023-05-30,Rain Oncology Inc,INDUSTRY
NCT00513318,Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients Wtih Advanced Hematopoietic Malignancies,Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients Wtih Advanced Hematopoietic Malignancies,TERMINATED,Insufficient enrollment to justify keeping open.,,OBSERVATIONAL,15,"Acute Myeloid Leukemia, Myelodysplasia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Multiple Myeloma, Lymphomas, Low-grade NHL and Chronic Lymphocytic Leukemia",,,,2004-08,2009-06,"University of California, San Francisco",OTHER
NCT01902810,Protective Effects of Propranolol in Adults,Protective Effects of Propranolol in Adults Following Major Burn Injury: A Safety and Efficacy Trial,TERMINATED,"At the request of the study site, this study has been closed and access to study-related data is unavailable. We are unable to submit the results-data.","PHASE2, PHASE3",INTERVENTIONAL,47,Burn,"Propranolol, Placebo","DRUG, DRUG",Cardiac rate pressure product,2013-07,2019-07-12,"The University of Texas Medical Branch, Galveston",OTHER
NCT05129423,A Study of MTPS9579A in Participants With Refractory Chronic Spontaneous Urticaria,"A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Pilot and Dose-Ranging Study of MTPS9579A in Participants With Refractory Chronic Spontaneous Urticaria",WITHDRAWN,Development of MTPS9579A was terminated for strategic/business reasons.,PHASE2,INTERVENTIONAL,0,Chronic Spontaneous Urticaria,"MTPS9579A, Placebo","DRUG, DRUG",Change From Baseline in the UAS7,2022-07-31,2024-08-31,"Genentech, Inc.",INDUSTRY
NCT00480623,A Phase I Trial of Satraplatin Plus Radiation Therapy for Prostate Cancer Patients With Biochemical Recurrence,A Phase I Trial of Satraplatin Plus Radiation Therapy for Prostate Cancer Patients With Biochemical Recurrence Following Radical Prostatectomy,TERMINATED,Sponsor decided to discontinue study drug development,PHASE1,INTERVENTIONAL,,Prostate Cancer,Satraplatin plus radiation therapy,DRUG,Determine maximum tolerated dose and dose limiting toxicity for the combination of Satraplatin and radiation therapy.,2007-05,2008-04,Agennix,INDUSTRY
NCT04685759,Exercise Regimens and Neoadjuvant Chemotherapy,Assessing the Non-inferiority of Virtual vs. In-person Concurrent Exercise Regimens in Patients Receiving Neoadjuvant Therapy Prior to Surgical Resection of a Primary GI Tumor,WITHDRAWN,Limited candidate pool,NA,INTERVENTIONAL,0,Cancer of Gastrointestinal Tract,,"OTHER, OTHER",Proportion of patients with a primary GI tumor who complete neoadjuvant treatment and are cleared for surgical resection,2022-04,2023-01,University of Texas Southwestern Medical Center,OTHER
NCT02153424,Early Post-marketing Study of Eliquis (Apixaban),Early Post-marketing Study of Eliquis (Apixaban),WITHDRAWN,Business objectives have changed.,,OBSERVATIONAL,0,Non-valvular Atrial Fibrillation (NVAF),Apixaban,DRUG,"Determine the reporting rate of on-treatment adverse events (AEs) by the treating physicians, Identify, describe, and report any suspected AEs that occur while on treatment with Apixaban or preventing stroke and systemic embolism in patients with NVAF",2014-04,2015-11,Bristol-Myers Squibb,INDUSTRY
NCT06594523,A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis,"A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Denifanstat in Patients With Noncirrhotic Metabolic Dysfunction-associated Steatohepatitis (MASH) and F2/F3 Fibrosis (FASCINATE-3)",WITHDRAWN,Business decision,PHASE3,INTERVENTIONAL,0,"MASH, NASH, Metabolic Dysfunction-associated Steatohepatitis, Noncirrhotic Metabolic Dysfunction-associated Steatohepatitis, Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver","Denifanstat, Placebo","DRUG, DRUG","Dual Primary Efficacy Endpoint 1: Interim Analysis: MASH Resolution (denifanstat 50 mg compared to placebo), Dual Primary Efficacy Endpoint 2: Interim Analysis: Improvement in Fibrosis (denifanstat 50 mg compared to placebo), Primary Endpoint: End of Study Analysis: Liver-related Composite Clinical Outcome (denifanstat 50 mg compared to placebo)",2025-03,2030-12,Sagimet Biosciences Inc.,INDUSTRY
NCT03301480,Contraceptive/HIV Affecting Risk in Adolescents,Contraceptive/HIV Affecting Risk in Adolescents,TERMINATED,An interim review of the data revealed that there was broad inter-participant variability.The study was stopped due to futility.,,OBSERVATIONAL,120,"Contraception, Hiv",,,"HIV replication in cervical tissue as measured by levels of HIV p24/viral transcripts, number of immune cells in cervical tissue, including CD45, CD3, CD4, and CD8 and their expression of CCR5, CCR6 and CD69, and CD11c+ DCs and CD14+ macrophages",2017-07-31,2018-09-17,University of Pittsburgh,OTHER
NCT02042235,Very Preterm Children With Language Delay and Parent Intervention,Parent-implemented Intervention for Very Preterm Children With Language Delay,TERMINATED,difficulted recruiting,NA,INTERVENTIONAL,67,"Preterm Birth, Language Development, Speech Therapy",,BEHAVIORAL,language score of the Developmental Neuropsychological assessment (NEPSY),2014-01,2018-01-31,Lille Catholic University,OTHER
NCT03645408,"The Effects of Exenatide, a GLP-1 Agonist, on Alcohol Self-Administration in Heavy Drinkers","The Effects of Exenatide, a GLP-1 Agonist, on Alcohol Self-Administration in Heavy Drinkers",TERMINATED,Due to COVID-19 hospital-wide policies halting recruitment,PHASE1,INTERVENTIONAL,8,Alcohol Use Disorder,Exenatide,"DRUG, OTHER",Alcohol Consumption,2019-05-02,2021-07-01,Boston Medical Center,OTHER
NCT05432908,Effect of Orofacial Myofunctional Therapy on Mouth Air Leak in Patients With Sleep Apnea Treated With CPAP,Effect of Orofacial Myofunctional Therapy on Unintentional Air Leak From the Oral Cavity in Patients With Obstructive Sleep Apnea Treated With Continuous Positive Upper Airway Pressure (CPAP),TERMINATED,Difficulties to recruit due to COVID pandemic,NA,INTERVENTIONAL,20,"OSA, Apnea+Hypopnea",,BEHAVIORAL,Effect of Orofacial Myofunctional Therapy on mouth air leak,2017-07-28,2021-07-01,University of Sao Paulo General Hospital,OTHER
NCT05344625,Ketamine-Assisted PsychoTherapy ViAbility in Treating Cancer-related Emotional Distress,Ketamine-Assisted Psychotherapy Viability in Treating Cancer-Related Emotional Distress,WITHDRAWN,Study team is not moving forward with protocol,EARLY_PHASE1,INTERVENTIONAL,0,"Cancer-related Problem/Condition, Depressive Symptoms, Anxiety Disorders",Ketamine 100 MG/ML,DRUG,Percentage of population completing at least one KAP session.,2023-10-31,2024-03-15,Northwell Health,OTHER
NCT02530125,Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission,Phase II Study of Pidilizumab (MDV9300) in Patients With Diffuse Large B-Cell Lymphoma Following First Remission,TERMINATED,sponsor decided to discontinue development of the study drug.,PHASE2,INTERVENTIONAL,4,"Stage III Diffuse Large B-Cell Lymphoma, Stage IV Diffuse Large B-Cell Lymphoma",Pidilizumab,"OTHER, BIOLOGICAL",Response to Pidilizumab,2015-09,2017-01,Northwestern University,OTHER
NCT01845025,Study of Safety of Foradil in Patients With Persistent Asthma,"A 26 Week, Randomized, Active-controlled Safety Study of Double-blind Formoterol Fumarate in Free Combination With an Inhaled Corticosteroid Versus an Inhaled Corticosteroid in Adolescent and Adult Patients With Persistent Asthma.",TERMINATED,Due to the action to withdraw the Foradil Aerolizer NDA in US; study was discontinued. This was a commercial reason and not due to any change in benefit-risk.,PHASE4,INTERVENTIONAL,827,Persistent Asthma,"Formoterol 12 mcg, Fluticasone propionate 100 mcg, Fluticasone propionate 250 mcg, Fluticasone propionate 500 mcg, Placebo","DRUG, DRUG, DRUG, DRUG, DRUG","Number of First Occurrence(s) of Any Composite Endpoint Including Asthma-related Hospitalizations, Intubations and Deaths During the Study at 26 Weeks",2013-05,2016-05,Novartis Pharmaceuticals,INDUSTRY
NCT04034225,Addition of SNS-301 to Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHN,"An Open-Label, Multi-Center Trial of SNS-301 Added to Pembrolizumab in Patients With Locally Advanced Unresectable or Metastatic/Recurrent Squamous Cell Carcinoma of the Head and Neck",TERMINATED,Terminated by the sponsor,"PHASE1, PHASE2",INTERVENTIONAL,25,Squamous Cell Carcinoma of the Head and Neck,"SNS-301, Pembrolizumab","DRUG, DRUG","Number of Participants With Adverse Events of SNS-301 in Addition to Pembrolizumab, Objective Response Rate by RECIST and iRECIST, Duration of Response by RECIST 1.1 and iRECIST, Disease Control Rate by RECIST 1.1 and iRECIST, Progression Free Survival by RECIST 1.1 and iRECIST, Overall Survival",2019-11-11,2021-06-28,"Sensei Biotherapeutics, Inc.",INDUSTRY
NCT03964025,Clinical Investigation to Determine the Accuracy and Benefit of Cardioskin™ in Patients With Known Atrial Fibrillation,Clinical Investigation to Determine the Accuracy and Benefit of Cardioskin™ in Patients With Known Atrial Fibrillation,WITHDRAWN,project stopped by the sponsor,NA,INTERVENTIONAL,0,Atrial Fibrillation,,DEVICE,"Sensitivity, specificity, positive and negative likelihood ratio, positive and negative predicted value of recording ""definite"" AF episodes (≥30 seconds) with the Cardioskin™ versus 3-lead Holter recorder after a 24 hour recording period[performance]., The incidence of device related (serious) adverse events [safety].",2021-07-01,2022-01-01,Institut de Recherches Internationales Servier,OTHER
NCT00316017,Hypertonic Resuscitation Following Traumatic Injury,Phase 3 Study of Hypertonic Resuscitation Following Traumatic Injury With Hypovolemic Shock,TERMINATED,"Futility \& potential safety concern (increased early mortality in the HS/HSD arms for those with no PRBC in 1st 24 hr, post-randomization subgp)",PHASE3,INTERVENTIONAL,895,"Shock, Traumatic","7.5% hypertonic saline/6% Dextran-70 (HSD), 7.5% hypertonic saline (HS), 0.9% normal saline","DRUG, DRUG, DRUG",28 Day Survival,2006-05,2009-08,University of Washington,OTHER
NCT03745040,Liposomal Bupivacaine in One-level Instrumented Posterior Spinal Fusion,Does Liposomal Bupivacaine Improve Postoperative Pain Control After One Level Posterior Spinal Fusion With Instrumentation,SUSPENDED,Lack of enrollment,PHASE4,INTERVENTIONAL,60,"Lumbar Spinal Stenosis, Lumbar Disc Herniation, Lumbar Disc Disease, Lumbar Spondylolisthesis",Liposomal bupivacaine,DRUG,Change in Visual Analog Pain Scores,2019-01-26,2028-08,Allina Health System,OTHER
NCT01301040,Early Cardiac Toxicity of Adjuvant CT in Elderly BC.,Early Detection of Chemotherapy Induced Cardiac Damage in Elderly Patients With Early Breast Cancer: a Randomized Phase II Trial Comparing (Neo) Adjuvant Epirubicin-cyclophosphamide (EC) Versus Docetaxel (Taxotere)-Cyclophosphamide (TC.),TERMINATED,Slow recruitment,PHASE2,INTERVENTIONAL,2,Breast Cancer,"epirubicin, cyclophosphamide, docetaxel",DRUG,The difference between cardiac strain rates measured at baseline and after 4 cycles of chemotherapy.,2011-03,2016-03,Jules Bordet Institute,OTHER
NCT02573740,"Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment","A Study to Evaluate the Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of Multiple Doses of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment Due to Alzheimer's Disease",TERMINATED,Insufficient target engagement of ABT-957 (preclinical data),PHASE1,INTERVENTIONAL,8,"Alzheimer's Disease, Mild Cognitive Impairment",ABT-957,"DRUG, OTHER","Percentage of participants reporting treatment-emergent adverse events, Level of spectrin breakdown product-145 (SBDP-145)",2015-12,2016-06,AbbVie,INDUSTRY
NCT01208740,Metformin in Patients With PCOS and Predictors of Poor Ovarian Response Ongoing In-vitro Fertilization,Effects of Metformin on the Ovarian Response to Gonadotropins for in Vitro Fertilization Treatment in Patients With Polycystic Ovary Syndrome and Predictors of Poor Ovarian Response,TERMINATED,Concerns about safety at the first interim analysis,PHASE4,INTERVENTIONAL,88,"Infertility, PCOS, Prognosis for Poor Response","Metformin, Placebo","DRUG, DRUG",Rate of cancellation due to low ovarian response,2009-01,2011-03,University Magna Graecia,OTHER
NCT03570489,Randomized Controlled Trial on Cardiovascular Exercise in Uncontrolled Epilepsy:,"Randomized Controlled Study of the Effect of Cardiovascular Exercise in Uncontrolled Epilepsy: Efficacy, Side Effects and Quality of Life",TERMINATED,Could not recruit patients because of Covid 19 restrictions and because of lack of efficacy for primary endpoint,NA,INTERVENTIONAL,28,Refractory Epilepsy,,"BEHAVIORAL, BEHAVIORAL",Proportion of patients with at least 50% seizure reduction,2018-11-30,2021-10-06,Vastra Gotaland Region,OTHER_GOV
NCT02855268,Study of Lademirsen (SAR339375) in Patients With Alport Syndrome,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of Lademirsen (SAR339375) for Subcutaneous Injection Administered Every Week in Patients With Alport Syndrome",TERMINATED,The results of the futility analysis led to the study termination. No unexpected safety findings were identified.,PHASE2,INTERVENTIONAL,43,Alport Syndrome,"lademirsen (SAR339375), Placebo","DRUG, DRUG","Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs), DB Period: Annualized Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 48",2019-11-02,2022-09-22,"Genzyme, a Sanofi Company",INDUSTRY
NCT01181791,Effects of Lactobacillus Reuteri in Premature Infants,Pilot Study to Evaluate the Effects of Lactobacillus Reuteri in Preterm Newborns,TERMINATED,Poor recruitment,NA,INTERVENTIONAL,65,Premature Infant Disease,,"DIETARY_SUPPLEMENT, OTHER",Time to reach full feeds,2010-07,2017-07,University of Miami,OTHER
NCT05359874,Improvement of the Operative Outcome in Patients With Primary VEGF + Unifocal Breast Cancer or DCIS Through the Intraoperative Visualization of the Tumor Using Molecular Imaging and Bevacizumab-IRDye-800CW,Improvement of the Operative Outcome in Patients With Primary VEGF Positive Unifocal Breast Cancer or Ductal Carcinoma in Situ (DCIS) Through the Intraoperative Visualization of the Tumor Using Molecular Imaging and Fluorescent Markers Bevacizumab-IRDye-800CW,WITHDRAWN,application has been withdrawn,PHASE2,INTERVENTIONAL,0,Breast Cancer,Bevacizumab-IRDye800CW,DRUG,Determination of the sensitivity and specificity of bevacizumab- IRDye800CW,2021-06,2023-03,Technical University of Munich,OTHER
NCT01096810,Study of TBL 12 Sea Cucumber Extract for Patients With Untreated Asymptomatic Myeloma,A Phase II Trial of TBL 12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma,TERMINATED,The research is permanently closed to enrollment.,PHASE2,INTERVENTIONAL,20,Multiple Myeloma,TBL 12,DRUG,"Time to Progression, Response Rate",2008-09,2014-03,"Jagannath, Sundar, M.D.",INDIV
NCT02145910,Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases,Phase I Study of Vemurafenib Combined With Whole Brain Radiation Therapy (WBRT) or Radiosurgery (SRS) for Melanoma Patients With BRAF Mutation Presented With Brain Metastases,WITHDRAWN,Study was never opened to accrual. There is no clinical benefit to patients.,PHASE1,INTERVENTIONAL,0,"Recurrent Melanoma, Stage IV Melanoma, Tumors Metastatic to Brain",Vemurafenib,"DRUG, RADIATION, RADIATION",Maximum tolerated dose (MTD) of vemurafenib,,,Sidney Kimmel Cancer Center at Thomas Jefferson University,OTHER
NCT02515513,The Role of Muscle Cachexia in Pancreatic Cancer,The Role of Muscle Cachexia in Pancreatic Cancer,WITHDRAWN,Original PI left the institution. No subjects enrolled,NA,INTERVENTIONAL,0,Pancreas Cancer,,PROCEDURE,"Ultrastructural abnormalities in muscle tissue samples between the groups, Myofiber atrophy in muscle tissue samples between the groups, Identify gene networks within the skeletal muscle between the groups",2016-03,2023-06-23,University of Florida,OTHER
NCT03540160,Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch),An Open-Label Long-Term Safety Study of Serlopitant for the Treatment of Pruritus,TERMINATED,No longer pursuing development of serlopitant,PHASE3,INTERVENTIONAL,558,"Pruritus, Prurigo Nodularis, Atopic Dermatitis, Psoriasis",5 mg Serlopitant Tablets,DRUG,Number of Subjects With Treatment-emergent Adverse Events,2018-03-15,2020-06-17,Vyne Therapeutics Inc.,INDUSTRY
NCT03804424,64Cu-LLP2A for Imaging Multiple Myeloma,Early Phase I Evaluation of 64Cu-LLP2A for Imaging Multiple Myeloma,TERMINATED,"Drug formulation changed, opening new trial",EARLY_PHASE1,INTERVENTIONAL,10,Multiple Myeloma,64Cu-LLP2A,"DRUG, DEVICE, PROCEDURE, PROCEDURE, PROCEDURE, PROCEDURE, PROCEDURE, DEVICE","Feasibility of imaging MM patients with 64Cu-LLP2A-PET/MR as measured by average organ activity concentration of 64Cu-LLP2A, Feasibility of imaging MM patients with 64Cu-LLP2A-PET/MR as measured by the number of participants who experience an adverse event related to 64Cu-LLP2A, Feasibility of imaging MM patients with 64Cu-LLP2A-PET/MR as measured by the optimal image time after injection of 64Cu-LLP2A, Feasibility of imaging MM patients with 64Cu-LLP2A-PET/MR as measured by image quality of 64Cu-LLP2A-PET/MR images, Feasibility of imaging MM patients with 64Cu-LLP2A-PET/MR as measured by lesion detection of 64Cu-LLP2A-PET/MR images",2018-11-20,2021-10-01,Washington University School of Medicine,OTHER
NCT03352882,Impact of Transjugular Intrahepatic Portosystemic Shunts on Liver Stiffness,Impact of Transjugular Intrahepatic Portosystemic Shunts on Liver Stiffness,TERMINATED,Lack of enrollment,NA,INTERVENTIONAL,1,"Portal Hypertension, Liver Fibroses",,DIAGNOSTIC_TEST,Decrease in Liver Stiffness,2016-08,2019-04-03,University of Pennsylvania,OTHER
NCT01561482,Study of Metformin With Simvastatin for Men With Prostate Carcinoma,Open-Label Study Of Metformin In Combination With Simvastatin For Men With Prostate Carcinoma And A Rising Serum Prostate-Specific Antigen Level After Radical Prostatectomy And/Or Radiation Therapy,WITHDRAWN,Study closed due to slow/low enrollment; no subjects were enrolled.,PHASE2,INTERVENTIONAL,0,Prostate Carcinoma,"Metformin, Simvastatin","DRUG, DRUG","Efficacy, as measured by an improvement in PSA doubling time (PSADT) between baseline and 6 months, of the combination of metformin plus simvastatin in patients with recurrent prostate cancer following definitive treatment.",2012-01,2014-07,Nicholas Mitsiades,OTHER
NCT01264835,Assessment of a Slotted Anoscope That Facilitates Hemorrhoidectomy,,TERMINATED,Slow Enrollment,NA,INTERVENTIONAL,2,Excisional Hemorrhoidectomy,,DEVICE,Procedure Duration (Surgery Time),2010-12,2011-06,Ethicon Endo-Surgery,INDUSTRY
NCT04028635,Treating the Fear of Gaining Weight in Anorexia Nervosa,Treating the Fear of Gaining Weight. A Randomized Controlled Clinical Trial for Patients With Anorexia Nervosa,TERMINATED,"The study was terminated with a total of 35 patients finally enrolled, due to the Sars-Cov-2 (COVID-19) global pandemic breakout and the confinement measures considered.",NA,INTERVENTIONAL,35,Anorexia Nervosa,,"BEHAVIORAL, BEHAVIORAL","Change in Body Mass Index, Change in Eating Disorders Inventory-3 (EDI-3) drive for thinness (EDI-DT) scale, Change in Eating Disorders Inventory-3 (EDI-3) body dissatisfaction (EDI-BD) scale, Change in Silhouette Test for Adolescents (TSA) body distortion scores, Change in Silhouette Test for Adolescents (TSA) body dissatisfaction scores, Figural Drawing Scale for Body Image Assessment (BIAS-BD) body distortion scores, Figural Drawing Scale for Body Image Assessment (BIAS-BD) body dissatisfaction scores, Change in Physical Appearance State Anxiety Scale (PASTAS), Change in Body Appreciation Scale (BAS)",2019-02-25,2020-07-30,University of Barcelona,OTHER
NCT01259076,Effect of Weight Loss on Breast Density Using Digital Mammography and MRI in Women Who Are At Increased Risk For Breast Cancer,Effect of Weight Loss on Breast Density Using Both Digital Mammography and Breast MRI,TERMINATED,Study was closed early due to slow accrual.,,OBSERVATIONAL,43,"Healthy, no Evidence of Disease",,"PROCEDURE, PROCEDURE, PROCEDURE",Change in BMI and breast density,2011-02,2014-07,Northwestern University,OTHER
NCT03473340,Studying the Treatment Effect of Pirfenidone in Chronic Lung Allograft Dysfunction (STOP-CLAD),"A Phase Two Randomized, Double-blinded, Placebo-controlled Study Combining Physiological, Radiographic, and Biological Biomarkers to Study the Anti-fibrotic Effect of Pirfenidone in CLAD Post Lung-transplantation",TERMINATED,"Slow and delayed recruitment due in part to COVID, led to a decision to end funding and terminate the trial.",PHASE2,INTERVENTIONAL,24,"Disorder Related to Lung Transplantation, Chronic Lung Allograft Dysfunction","Pirfenidone Capsule, Placebo Capsule","DRUG, DRUG",Change in Percent of Functional Small Airways Disease (fSAD) as Measured by Parametric Response Mapping,2018-04-27,2021-08-20,University of Michigan,OTHER
NCT00206089,Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events,"The ""EXTEND"" Study: A Randomized, Double-blind, Parallel-group, Phase III b, Multi-centre Study Evaluating Extended Prophylactic Treatment With Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events in Patients Undergoing Elective Hip Replacement or Hip Fracture Surgery.",TERMINATED,Melagatran/ximelagatran was withdrawn from the market and clinical development in February 2006 in the interest of patient safety.,PHASE3,INTERVENTIONAL,3300,Thromboembolism,EXANTA,DRUG,Non-inferiority for the prevention of VTE or VTE related death,2005-09,2006-08,AstraZeneca,INDUSTRY
NCT05180318,Prophylactic Effects of Esketamine in Surgical Patients,Effects of Esketamine Pre-administration on Blood Lymphocyte Subsets and Inflammatory Factors in Early Postoperative Period:,WITHDRAWN,No Participants Enrolled,PHASE4,INTERVENTIONAL,0,Surgical Injury,"Esketamine Hydrochloride 28 Mg in 0.2 mL NASAL SOLUTION [Spravato], 0.9% saline","DRUG, DRUG","Recovery percentage of peripheral blood lymphocyte subsets, Deterioration percentage of peripheral blood pro-inflammatory cytokines",2024-10-01,2024-12-31,"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",OTHER
NCT04945590,The VIDA After COVID Study,Virtual Intervention and Direct Assessment (VIDA) of Social Determinants of Health in Southern Minnesota Latino Communities After Coronavirus Disease 2019 (COVID-19): a Pilot Study. the VIDA After COVID Study.,WITHDRAWN,Lack of enrollment,NA,INTERVENTIONAL,0,Covid19,,BEHAVIORAL,Social Determinants of Health (SDOH) Assessment Completed,2024-12,2025-12,Mayo Clinic,OTHER
NCT00084890,Docetaxel and Carboplatin in Treating Patients With Recurrent Stage IVB Squamous Cell Carcinoma (Cancer) of the Cervix,Weekly Docetaxel and Carboplatin in Patients With Recurrent Squamous Carcinoma of the Cervix: A Phase I/II Study,TERMINATED,slow accrual,PHASE1,INTERVENTIONAL,15,Cervical Cancer,"carboplatin, docetaxel","DRUG, DRUG",Maximum tolerated dose of docetaxel,2003-11,2010-04,Wake Forest University Health Sciences,OTHER
NCT00545597,A Phase III Trial of Lorenzo's Oil in Adrenomyeloneuropathy,A Phase III Trial of Lorenzo's Oil in Adrenomyeloneuropathy,TERMINATED,Upon recommendation of DSMB,PHASE3,INTERVENTIONAL,240,"Adrenomyeloneuropathy, Adrenoleukodystrophy",Lorenzo's oil,DRUG,Clinical Progression of the disorder,2005-03,2007-10,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),NIH
NCT03777410,Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma,Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma,TERMINATED,Insufficient pace of enrollment due to changes in MM SOC practices,,OBSERVATIONAL,33,Multiple Myeloma in Relapse,,,Best Response 4 months,2019-02-11,2024-06-30,Travera Inc,INDUSTRY
NCT03044210,Metabolic Study of Cockayne Syndrome,Metabolic Study of Cockayne Syndrome,TERMINATED,pas assez de patients,NA,INTERVENTIONAL,25,Cockayne Syndrome,,OTHER,Rest energetic cost measured by indirect calorimetry compared to calculated Black equation,2017-04-04,2024-08-01,"University Hospital, Strasbourg, France",OTHER
NCT01179113,Esmolol Infusion During Laminectomy: Effect on Quality of Recovery,Esmolol Infusion for Maintaining Hemodynamic Stability During Single or Double Level Lumbar Laminectomy: Effect on Quality of Recovery.,TERMINATED,The preliminary result didn't show any benefit.,PHASE4,INTERVENTIONAL,33,Laminectomy,"Esmolol, Saline","DRUG, DRUG",Post-operative Pain Using Verbal Rating Scale (VRS),2011-06,2015-05,Cedars-Sinai Medical Center,OTHER
NCT00697060,A Safety and Efficacy Trial of Amplimexon Plus Taxotere in Metastatic Non-Small Cell Lung Cancer,"A Multicenter, Phase II Trial of the Safety and Efficacy of Amplimexon® (Imexon for Injection) in Combination With Taxotere® (Docetaxel) for Previously Treated Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)",WITHDRAWN,Study cancelled prior to start due to change in company priorities.,PHASE2,INTERVENTIONAL,0,"Carcinoma, Non-Small-Cell Lung",Imexon + docetaxel,DRUG,Overall response rates (CR + PR) in subjects with measurable disease will be determined by RECIST methodology.,2010-08,2012-08,AmpliMed Corporation,INDUSTRY
NCT03127813,PAIR Study-PAP And IOP Relationship: Study 1,The PAIR Study. Positive Airway Pressure and Intraocular Relationship: IOP Response to a Short-term Application of CPAP,TERMINATED,After recruiting just over 50% of target an interim review conclude a larger sample size was highly unlikely to alter the study outcomes,NA,INTERVENTIONAL,46,"Obstructive Sleep Apnoea, Primary Open Angle Glaucoma",,OTHER,Intraocular pressure (IOP),2017-02-15,2018-01-05,Papworth Hospital NHS Foundation Trust,OTHER_GOV
NCT03410082,Patient's Satisfaction of Bispectral Index-guided Monitored Anesthesia Care,A Prospective Randomized Controlled Trial on the Patient's Satisfaction of Bispectral Index-guided Monitored Anesthesia Care,TERMINATED,extremely slow enrollment,NA,INTERVENTIONAL,31,"Bispectral Index, Monitored Anesthesia Care",,"DEVICE, DIAGNOSTIC_TEST",Iowa Satisfaction with Anesthesia Scale(ISAS),2017-08-15,2019-03-30,Seoul National University Hospital,OTHER
NCT05529082,The Attitudes and Beliefs of Hispanic/Latino Individuals Toward Prescription Opioids and Non-Medical Opioid Use,The Attitudes and Beliefs of Hispanic/Latino Individuals Toward Prescription Opioids and Non-Medical Opioid Use,WITHDRAWN,Withdrawn,,OBSERVATIONAL,0,Opioids,,"OTHER, OTHER",Opioid Attitudes and Beliefs Survey,2023-03-23,2024-07-30,M.D. Anderson Cancer Center,OTHER
NCT04731259,Study to Evaluate the Safety of ATR-04,"A Phase 1b/2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of ATR-04 to Reduce the Severity of Epidermal Growth Factor Inhibitor Associated Papulopustular Rash",WITHDRAWN,Business reasons.,"PHASE1, PHASE2",INTERVENTIONAL,0,"Epidermal Growth Factor, Papulopustular Rosacea",ATR-04,"DRUG, OTHER","Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), incidence of abnormal laboratory values, abnormal physical exams and abnormal vital signs.",2024-01,2026-01,Azitra Inc.,INDUSTRY
NCT01333059,Cycling of Sedative Infusions in Critically Ill Pediatric Patients,"A Randomized, Double-blind, Controlled Trial of Cycling Continuous Sedative Infusions in Critically Ill Pediatric Patients Requiring Mechanical Ventilation",TERMINATED,Unable to adequately enroll over a reasonable enrollment period.,NA,INTERVENTIONAL,25,Respiratory Failure,"Midazolam, Normal saline, Fentanyl","DRUG, DRUG, DRUG",Duration of Mechanical Ventilation Days,2010-09,2013-01,"Javier Gelvez, MD",OTHER
NCT03091998,Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support,A Phase I Trial to Determine Safety and Efficacy of Chronic Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support,WITHDRAWN,No funding available,PHASE1,INTERVENTIONAL,0,"Heart Failure, Left Ventricular Assist Device, Natriuretic Peptide",CD-NP,"DRUG, OTHER",Hypotension,2017-09-30,2020-05-01,Mayo Clinic,OTHER
NCT03379363,Retrospective Chart Review Study of Pediatric Patients Treated With Korlym for Cushing Syndrome,Retrospective Chart Review Study of Pediatric Patients Treated With Korlym for Cushing Syndrome,TERMINATED,Insufficient number of patients,,OBSERVATIONAL,2,"Hypercortisolism, Cushing Syndrome",,,Drug utilization patterns as assessed by chart review,2017-09-18,2018-02-12,Corcept Therapeutics,INDUSTRY
NCT05108363,Effect of Obstructive Sleep Apnea on Glucose Control and Cognitive Function,Effect of Obstructive Sleep Apnea on Glucose Control and Cognitive Function - a Substudy of 'Continuous Glucose Monitoring as an Adjunct to Lifestyle Modification in Individuals With Impaired Glucose Tolerance: a Randomised Controlled Trial',WITHDRAWN,no funding,NA,INTERVENTIONAL,0,Cognitive Change,,BEHAVIORAL,Change of Montreal Cognitive Assessment (MoCA) score,2021-11-01,2023-11-30,Chinese University of Hong Kong,OTHER
NCT04807387,Newly Designed Vaginal Stent to Improve Patient Comfort and Healing Following Vaginal Surgery or Vaginal Radiation,Newly-designed Vaginal Stent to Improve Tissue Healing for Girls and Women With Congenital and Reproductive Anomalies,TERMINATED,"After enrolling 6 healthy participants the study is being put on halted due to funding and personnel gap. All participants have been informed, per study IRB, of study status.",NA,INTERVENTIONAL,6,Vaginal Stricture,,"DEVICE, DEVICE, DEVICE",Number of Participants Reporting Vaginal Stent as Comfortable.,2022-05-05,2023-01-18,Baylor College of Medicine,OTHER
NCT01622621,Stereotactic Body Radiotherapy (SBRT) Versus Sublobar Resection for High-Risk Patients Non-Small Lung Cancer,Randomized Phase II Trial of Stereotactic Body Radiotherapy (SBRT) Versus Sublobar Resection for High-Risk Patients With Early Stage Non-Small Lung Cancer (NSCLC),TERMINATED,Unable to enroll to the randomized arm.,PHASE2,INTERVENTIONAL,20,Lung Neoplasms,,"PROCEDURE, RADIATION",Number of patients alive at 2 years (Overall Survival [OS]),2012-05,2017-04-25,Mayo Clinic,OTHER
NCT00756106,MRI Scans in Evaluating the Effects of Radiation Therapy and Chemotherapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Glioma,Quantitative Assessment of the Early and Late Effects of Radiation and Chemotherapy on Glioblastoma Using Multiple MRI Techniques,TERMINATED,Funding ended,NA,INTERVENTIONAL,15,Brain and Central Nervous System Tumors,temozolomide,"DRUG, OTHER, RADIATION","Relative Cerebral Blood Volume as Measured by Perfusion-weighted MRI Before, During, and After Chemoradiotherapy, Relative Cerebral Blood Flow as Measured by Perfusion-weighted MRI Before, During, and After Chemoradiotherapy, Vessel Diameter as Measured by Perfusion-weighted MRI Before, During, and After Chemoradiotherapy, Mean Transit Time as Measured by Perfusion-weighted MRI Before, During, and After Chemoradiotherapy, Permeability-surface Area Product Before, During, and After Chemoradiotherapy, Apparent Diffusion Coefficient Before, During, and After Chemoradiotherapy, Tensor Fractional Anisotropy Before, During, and After Chemoradiotherapy, Relative Regional Concentrations of Choline, N-acetyl-asparate, and Myoinositol as Measured by Magnetic Resonance Spectroscopy Before, During, and After Chemoradiotherapy to Interrogate Cell Membrane Turnover, Neuronal Integrity, and Glial Reactions, Affects of a Short Period of 100% Oxygen Inhalation on Imaging of Tumor and Surrounding Tissue Regions of Interest, Specifically Cerebral Blood Volume Changes in Each Area as Compared to Room Air",2008-07,2012-02,Massachusetts General Hospital,OTHER
NCT03471104,The Diabetes Patient-Reported Outcome Measures Trial,The Use of Patient-Reported Outcome Measures (PROMs) to Promote Quality of Clinical Diabetes Consultations,WITHDRAWN,We have piloted the trial and concluded not to proceed to a fullscale trial.,NA,INTERVENTIONAL,0,"Diabetes Mellitus, Type 1",,OTHER,Change in Diabetes Distress Scale (DDS),2018-01-15,2023-12-31,Haukeland University Hospital,OTHER
NCT05732233,RITUAL Ultivision AI CADe Randomized Controlled Trial,Randomized Clinical Trial of the Ultivision AI Artificial Intelligence System for Colorectal Cancer Screening or Surveillance in Colonoscopy,TERMINATED,Business decision to discontinue the study. Discontinuation is not related to any patient safety or performance issues.,NA,INTERVENTIONAL,137,"Colon Adenoma, Polyp of Colon, Adenoma Colon",,DEVICE,"Adenoma per Colonoscopy (APC), Adenoma Per Extraction (APE).",2023-07-21,2024-02-23,"Satisfai Health, Inc.",INDUSTRY
NCT04322747,Hearing Changes After Surgery,Hearing Changes After Skull Base and Mastoid Surgery,WITHDRAWN,COVID protocols caused extreme delays.,,OBSERVATIONAL,0,Hearing Loss,,DIAGNOSTIC_TEST,"Number of Participants with a Difference of 5 dB or more between Pre- and Post-surgery DPOAE Measurements at any Frequency, Number of Participants with No change between Pre- and Post-surgery DPOAE Measurements",2021-09-01,2022-02-28,"Gateway Biotechnology, Inc.",INDUSTRY
NCT03026049,Stent Versus Conservative Treatment in Patients With Deep Venous Obstruction,A Randomized Controlled Trial Comparing Venous Stenting With Conservative Treatment in Patients With Deep Venous Obstruction,TERMINATED,it was not possible to recruit the required amount of participants within a reseanable timefram.,NA,INTERVENTIONAL,65,"Deep-Venous Thrombosis, Deep Venous Stenting, Randomized Clinical Trial",,DEVICE,Quality of Life score,2017-03-09,2021-10-07,Maastricht University Medical Center,OTHER
NCT01488149,Intrapartum Epidural Fentanyl and Breast-feeding in the Immediate Postpartum Period: a Prospective Cohort Study,Intrapartum Epidural Fentanyl and Breast-feeding in the Immediate Postpartum Period: a Prospective Cohort Study,WITHDRAWN,Study never started,,OBSERVATIONAL,0,"Maternal Anaesthesia and Analgesia Affecting Fetus or Newborn, Breast Feeding, Fentanyl, Bupivacaine, Nalbuphine",,,Neonatal deficiency in latching on to the breast and/or audibly swallowing during feeding,2012-02,2012-06,University Hospitals Cleveland Medical Center,OTHER
NCT06901349,"A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes","A Phase 2b Double-Blind, Randomized, Placebo-Controlled Study of Bimagrumab and Tirzepatide, Alone or in Combination, to Investigate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes",WITHDRAWN,Study terminated for strategic business reasons,PHASE2,INTERVENTIONAL,0,"Obesity, Overweight","Bimagrumab, Tirzepatide, Bimagrumab Placebo, Tirzepatide Placebo","DRUG, DRUG, DRUG, DRUG",Percent Change from Baseline in Body Weight,2025-05-23,2025-06-10,Eli Lilly and Company,INDUSTRY
